

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

BY

(51) International Patent Classification <sup>6</sup> : C12N 1/21, 5/10, 15/11, 15/12, 15/63, A61K 38/16, 38/17, C07K 14/00, 14/435, 16/00, G01N 33/50		A1	(11) International Publication Number: WO 00/06698 (43) International Publication Date: 10 February 2000 (10.02.00)
(21) International Application Number: PCT/US99/17130 (22) International Filing Date: 29 July 1999 (29.07.99) (30) Priority Data: 60/094,657      30 July 1998 (30.07.98)      US 60/095,486      5 August 1998 (05.08.98)      US 60/095,455      6 August 1998 (06.08.98)      US 60/095,454      6 August 1998 (06.08.98)      US 60/096,319      12 August 1998 (12.08.98)      US (71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): KOMATSOULIS, George, A. [US/US]; 9518 Garwood Street, Silver Spring, MD 20901 (US). ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Ol- ney, MD 20832 (US). DUAN, Roxanne [US/US]; 5515 Northfield Road, Bethesda, MD 20817 (US). MOORE, Paul, A. [GB/US]; 19005 Leatherbark Drive, Germantown, MD 20874 (US). SHI, Yanggu [CN/US]; Apartment 102,		437 West Side Drive, Gaithersburg, MD 20878 (US). LAFLEUR, David [US/US]; 3142 Quesada Street, N.W., Washington, DC 20015 (US). WEI, Ying-Fei [CN/US]; 242 Gravatt Drive, Berkeley, CA 94705 (US). NI, Jian [CN/US]; 5502 Manorfield Road, Rockville, MD 20853 (US). FLORENCE, Kimberly, A. [US/US]; 12805 Atlantic Avenue, Rockville, MD 20851 (US). YOUNG, Paul, E. [US/US]; 122 Beckwith Street, Gaithersburg, MD 20878 (US). BREWER, Laurie, A. [US/US]; Apartment 115, 410 Van Dyke Street, St. Paul, MN 55119-4321 (US). SOPPET, Daniel, R. [US/US]; 15050 Stillfield Place, Centreville, VA 22020 (US). ENDRESS, Gregory, A. [US/US]; 9729 Clagett Farm Drive, Potomac, MD 20854 (US). EBNER, Reinhard [DE/US]; 9906 Shelburne Terrace #316, Gaithersburg, MD 20878 (US). OLSEN, Henrik, S. [DK/US]; 182 Kendrick Place #24, Gaithersburg, MD 20878 (US). MUCENSKI, Michael [US/US]; 3265 Mandale Drive, Cincinnati, OH 45239 (US). (74) Agents: HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, MI, MR, NE, SN, TD, TG). Published With international search report. With an indication in relation to deposited biological material furnished under Rule 13bis separately from the description.	
(54) Title: 98 HUMAN SECRETED PROTEINS			
(57) Abstract			
The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## 98 Human Secreted Proteins

### *Field of the Invention*

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and  
5 their production.

### *Background of the Invention*

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or  
10 organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic  
15 reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

20 Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in  
25 secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly, proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins  
30 include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of

the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent medical disorders by using secreted proteins or the genes that encode them.

5

### *Summary of the Invention*

The present invention relates to novel polynucleotides and the encoded polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and  
10 polynucleotides. Also provided are diagnostic methods for detecting disorders related to the polypeptides, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying binding partners of the polypeptides.

15

### *Detailed Description*

#### Definitions

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original  
20 environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide.

25 In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing  
30 to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.



In specific embodiments, the polynucleotides of the invention are less than 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, or 7.5 kb in length. In a further embodiment, polynucleotides of the invention comprise at least 15 contiguous nucleotides of the coding sequence, but do not comprise all or a portion of any intron.

5 In another embodiment, the nucleic acid comprising the coding sequence does not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene in the genome).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone

10 deposited with the ATCC. For example, the polynucleotide can contain the nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a

15 molecule having the translated amino acid sequence generated from the polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID

20 NO:X was deposited with the American Type Culture Collection ("ATCC"). As shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of

25 microorganisms for purposes of patent procedure.

A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an

30 overnight incubation at 42° C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's

solution, 10% dextran sulfate, and 20 µg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions.

5 Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M  
10  $\text{NaH}_2\text{PO}_4$ ; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 µg/ml salmon sperm blocking DNA; followed by washes at 50°C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the  
15 inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above,  
20 due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid  
25 molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of  
30 single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA

that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA  
5 backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids  
10 joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more  
15 detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of  
20 modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a  
25 heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation,  
30 iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

(See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth  
5 Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting  
10 activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the  
15 present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to the polypeptide of the present invention.)

## 20 Polynucleotides and Polypeptides of the Invention

### FEATURES OF PROTEIN ENCODED BY GENE NO: 1

The translation product of this gene is a human glycoprotein-associated amino acid transporter (See, e.g., Genbank Accession No. emb|CAA10198.1| (AJ130718);  
25 all references available through this accession are hereby incorporated by reference herein). Amino acid transport across cellular membranes is mediated by multiple transporters with overlapping specificities. The transport system L, which mediates Na<sup>+</sup>-independent exchange of large neutral amino acids, consists of a novel amino acid permease-related protein (LAT1 or AmAT-L-1c) which for surface expression  
30 and function requires formation of disulfide-linked heterodimers with the glycosylated heavy chain of the h4F2/CD98 surface antigen. h4F2hc also associates with other mammalian light chains, e.g. y+LAT1 from mouse and human which are

approximately 48% identical with LAT1 and thus belong to the same family of glycoprotein-associated amino acid transporters.

The novel heterodimers form exchangers which mediate the cellular efflux of cationic amino acids and the Na<sup>+</sup>-dependent uptake of large neutral amino acids.

5 These transport characteristics and kinetic and pharmacological fingerprints identify them as y<sup>+</sup>L-type transport systems. mRNA encoding y<sup>+</sup>LAT1 is detectable in most adult tissues and expressed at high levels in kidney cortex and intestine. This indicates that the y<sup>+</sup>LAT1-4F2hc heterodimer, besides participating in amino acid uptake/secretion in many cell types, is the basolateral amino acid exchanger involved  
10 in transepithelial reabsorption of cationic amino acids; hence, its defect might be the cause of the human genetic disease lysinuric protein intolerance.

The gene encoding the disclosed cDNA is believed to reside on chromosome 14. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 14.

15 Preferred polypeptides comprise the following amino acid sequence:  
LALYSALFSYSGWDTLN (SEQ ID NO: 237), VTEEIKNPERNLPL (SEQ ID NO: 238), IGISMPIVT (SEQ ID NO: 239), IYILTNVAYYTVL (SEQ ID NO: 240), SDA  
VAVTFADQ (SEQ ID NO: 241), VALSCFGGLNASI (SEQ ID NO: 242), SRLFFV  
GSREGHLPD (SEQ ID NO: 243), SFSYWFFVGLS (SEQ ID NO: 244), VGQLYLR  
20 WKEP (SEQ ID NO: 245), RPRPLKLSVFFPIVFC (SEQ ID NO: 246), DTINSLIGI  
(SEQ ID NO: 247), LLAAACICLLTFINCA YVKWGT LVQDIFTYAKVLALIAVI  
VAGIVRLGQGASTHFENSFEGSSFAVGDI ALALYSALFSYSGWDTLN YVTEEI  
KNPERNLPLSIGISMPIVTIYILTNVAYYTVLDMRDILASDAVAVTFADQIFGIF  
NWIPLSVALSCFGGLNASIVAASRLFFVGSREGHLPDAICMIHVERFTPVPSSL  
25 FNGIMALIYLCVEDIFQLINY SFSYWFFVGLSIVGQLYLRWKEPDRPRPLKLS  
VFFPIVFLCTIFLVAVPLYSDTINSLIGIAIALSGLPFYFLIIRVPEHKRPLYLRRI  
VGSATRYLQVLCMSVAAEMDLEDGGEMP KQRDPKSN (SEQ ID NO: 249)  
and/or ATALPPKIVGSATRYLQVLCMSVAAEMDLEDGGEMP KQRDPKSN  
(SEQ ID NO: 248). Polynucleotides encoding these polypeptides are also provided.

30 Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of THP-1 monocyte cells to calcium. Thus, it is likely that the product of this gene is involved in a signal

transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both THP-1 monocytes, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating monocytes.

5           This gene is expressed primarily in endothelial cells and brain, and, to a lesser extent, in a wide variety of human tissues.

          Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
10   not limited to, disorders of the neural or gastrointestinal systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circulation system or central nervous system, expression of this gene at significantly higher or  
15   lower levels is routinely detected in certain tissues or cell types (e.g., neural, gastrointestinal, cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not  
20   having the disorder.

          Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 124 as residues: Glu-102 to Asn-110, Arg-256 to Leu-266, Pro-316 to Trp-328, Pro-331 to Arg-336, Met-350 to Gly-358.

Polynucleotides encoding said polypeptides are also provided.

25           The tissue distribution in brain combined with its homology to a amino acid transporter and biological activity of increasing ion flux in monocytes indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the  
30   "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,

Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1550 of SEQ ID NO:11, b is an integer of 15 to 1564, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

## **FEATURES OF PROTEIN ENCODED BY GENE NO: 2**

The gene encoding the disclosed cDNA is believed to reside on the X chromosome. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for the X chromosome.

Preferred polypeptides of the invention comprise the following amino acid sequence:

AARGSGVRDPLEEAVCPFSDLQLHAGRTTALFKAVRQGHLSLQRLLLSFVCL  
CPAPRGGAYRGRQASLSCGGLHPVRASRLCLPKQAWAMAGAPPVSLPPCS  
LISDCCASNQRDSVG (SEQ ID NO: 250). Polynucleotides encoding these  
polypeptides are also provided.

5           This gene is expressed primarily in cord blood cells, and, to a lesser extent, in  
frontal lobe of the brain.

          Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
10   not limited to, developmental, reproductive, hematopoietic or neural disorders.  
Similarly, polypeptides and antibodies directed to these polypeptides are useful in  
providing immunological probes for differential identification of the tissue(s) or cell  
type(s). For a number of disorders of the above tissues or cells, particularly of the  
immune and central nervous systems, expression of this gene at significantly higher or  
15   lower levels is routinely detected in certain tissues or cell types (e.g., immune,  
developmental, or cancerous and wounded tissues) or bodily fluids (e.g., lymph,  
amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue  
or cell sample taken from an individual having such a disorder, relative to the  
standard gene expression level, i.e., the expression level in healthy tissue or bodily  
20   fluid from an individual not having the disorder.

          Preferred polypeptides of the present invention comprise immunogenic  
epitopes shown in SEQ ID NO: 125 as residues: His-56 to Gln-65, Leu-80 to Ile-85.  
Polynucleotides encoding said polypeptides are also provided.

          The tissue distribution in cord blood cells indicates polynucleotides and  
25   polypeptides corresponding to this gene are useful for the treatment and diagnosis of  
hematopoietic related disorders such as anemia, pancytopenia, leukopenia,  
thrombocytopenia or leukemia since stromal cells are important in the production of  
cells of hematopoietic lineages. Representative uses are described in the "Immune  
Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19,  
30   20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo  
culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or  
chemotherapy of neoplasia.



The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the

5 differentiation and/or proliferation of various cell types. Alternatively, polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly,

10 embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their

15 interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

20 related to SEQ ID NO:12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

25 formula of a-b, where a is any integer between 1 to 1743 of SEQ ID NO:12, b is an integer of 15 to 1757, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

### **FEATURES OF PROTEIN ENCODED BY GENE NO: 3**

30 This gene is expressed primarily in human T cell lymphomas.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, T cell lymphoma, immunodeficiencies, in addition to other immune system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
5 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample  
10 taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 126 as residues: Met-1 to Phe-10. Polynucleotides  
15 encoding said polypeptides are also provided.

The tissue distribution in human T cell lymphomas indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14,  
20 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting  
25 immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory  
30 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity

disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that  
5 recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify  
10 agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
15 related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
20 formula of a-b, where a is any integer between 1 to 1359 of SEQ ID NO:13, b is an integer of 15 to 1373, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 4**

25 The protein product of this clone shares sequence homology with the C-terminus of a human N-acetylglucosamine-phosphate mutase (See, e.g., Genbank Accession No. gb|AAC72409.1| (AF102265); all references available through this accession are hereby incorporated by reference herein.) Hofmann, et al. (Eur. J. Biochem. 221:741-747 (1994)) studied the N-acetylglucosamine-phosphate mutase of  
30 *Saccharomyces cerevisiae* and showed it to be essential for viability. A *S. cerevisiae* agm1 deletion mutant progressed through only approximately five cell cycles to form a 'string' of undivided cells with an abnormal cell morphology resembling

glucosamine auxotrophic mutants. Expression of the AGM1 gene on a multi-copy plasmid led to a significantly increased N-acetylglucosamine-phosphate mutase activity. Unlike over-expression of the *S. cerevisiae* AGM1 gene in a phosphoglucomutase (pgm1 delta/pgm2 delta) double deletion mutant which could  
 5 restore phosphoglucomutase activity, over-expression of the PGM2 gene encoding the major isoenzyme of phosphoglucomutase did not increase N-acetylglucosamine-phosphate-mutase activity and did not restore growth of agm1 deletion mutant cells. These observations indicate that the different hexosephosphate mutases of *S. cerevisiae* have partially overlapping substrate specificities but, nevertheless, distinct  
 10 physiological functions. The human N-acetylglucosamine-phosphate-mutase is expected to share at least some biological activities with the Agm1 protein.

Preferred polypeptide fragments of the invention comprise the following amino acid sequences: LSKAFLDSPNRL LAVEMNTDHLRLTVPNGIGALKLRXM EHYFSQGLSVQLFNDGSKGKLNHL CGADFKSHQKPPQGMEIKSNERCCSFD  
 15 GDADRIVYYYHDADGHFHLIDGDKIATLISSFLKELLVEIGESLNIGVVQTAYA NGSSTRYLEEV MKVPVYCTKTGVKHLHHKAQEFDIGVYFEANGHG TALFST AVEMKIKQSAEQLEDKKRKA AKMLENIIDLFNQAAGDAISDMLVIEAILALK GLTVQQWDALYTDLPNRQLKVQVADRRVISTTXAERQAVTPPGLQEAINDL VKKYKLSRAFVRPSGTEDVVRVYAEADSQESADHLAHEVSLAVFQLAGGIGE  
 20 RPQPGF (SEQ ID NO: 251), LSKAFLDSPNRL LAVEMNTDHLRLTV (SEQ ID NO: 252), PNGIGALKLRXMEHYFSQGLSVQLFNDG (SEQ ID NO: 253), SKGKLNHL CGADFKSHQKPPQGMEIKS (SEQ ID NO: 254), NERCCSFDGDADRIV YYYHDADGHFHLI (SEQ ID NO: 255), DGDKIATLISSFLKELLVEIGESLNIGV (SEQ ID NO: 256), VQTAYANGSSTRYLEEV MKVPVYCTKTG (SEQ ID NO: 257), VKHLHHKAQEFDIGVYFEANGHG TALFS (SEQ ID NO: 258), TAVEMK IKQSAEQLEDKKRKA AKMLENI (SEQ ID NO: 259), IDLFNQAAGDAISDMLVIEAILALKGLT (SEQ ID NO: 260), VQQWDALYTDLPNRQLKVQVADRR VIST (SEQ ID NO: 261), TXAERQAVTPPGLQEAINDLVKKYKLSR (SEQ ID NO: 262), AFVRPSGTEDVVRVYAEADSQESA (SEQ ID NO: 263), and/or DH  
 30 LAHEVSLAVFQLAGGIGERPQPGF (SEQ ID NO: 264). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 6. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 6.

5 This gene is expressed primarily in fetal brain, and, to a lesser extent, in a wide variety of human tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental disorders, particularly of the central nervous system.

10 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central and peripheral nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, or

15 cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 127 as residues: Asn-36 to Lys-42, Lys-53 to Gln-60, Ile-64 to Ala-77, Ala-128 to Tyr-135, Lys-184 to Ala-199, Leu-245 to Leu-250. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution of N-acetylglucosamine-phosphate mutase in fetal

25 brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to

30 the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital

malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition,  
5 elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity,  
10 to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
15 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
20 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3726 of SEQ ID NO:14, b is an integer of 15 to 3740, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a + 14.

## 25 **FEATURES OF PROTEIN ENCODED BY GENE NO: 5**

This gene is expressed primarily in human stomach and stomach tumor cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
30 not limited to, disorders of the gastrointestinal system, particularly cancer or ulcers of stomach tissue. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the

tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., gastrointestinal, or cancerous and wounded tissues) or bodily fluids (e.g., bile, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in tumors of the stomach indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis, treatment and intervention of these tumors, in addition to other tumors where expression has been indicated. Additionally, the protein product of this gene may play a role in the normal function of the stomach and/or digestive system. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1182 of SEQ ID NO:15, b is an integer of 15 to 1196, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

## **FEATURES OF PROTEIN ENCODED BY GENE NO: 6**

Preferred polypeptides of the invention comprise the following amino acid sequences:

FEIALPRESNITVLIKLGTPDLLAKPCYIVISKRHITMLSIKSGERIVFTFSCQSPE  
NHFVIEIQKNIDCMSGPCPFGEVQLQPSTSLPTLNRTFIWDVKAHKSIGLELQ  
FSIPRLRQIGPGESCPDGVTHSISGRIDATVVRIGTFCSNGTVSRIKM (SEQ ID  
NO: 266), and/or GTRAAPGLGAWGRRSPPSFSPRRPGVMAGLNCVSIAL  
5 LGVLLLGAARLPRGAFAFEIALPRESNITVLIKLGTPDLLAKPCYIVISKRHITM  
LSIKSGERIVFTFSCQSPENHFVIEIQKNIDCMSGPCPFGEVQLQPSTSLPTLN  
RTFIWDVKAHKSIGLELQFSIPRLRQIGPGESCPDGVTHSISGRIDATVVRIGTF  
CSNGTVSRIKMQEGVKMALHLPWFHPRNVSGFSIANRSSIKRLCIIESVFEGE  
ATLMSANYPEGFPEDELMTWQFVVPAPHLRASVSFLNFNLSNCERKEERVEYY  
10 IPGSTTNPEVFKLEDKQPGNMAGNFNLSLQGCDDAQSPGILRLQFQVLVQH  
PQNESNKIYVVDLSNERAMSLTIEPRPVKQSRKFVPGCFVCLESRTCSSNLT  
SGSKHKISFLCDDLTRLWMNVEKP (SEQ ID NO: 265). Polynucleotides encoding  
these polypeptides are also provided.

15 This gene is expressed primarily in placenta, and to a lesser extent in, prostate  
and ovary.

Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
not limited to, male and female infertility, and associated disorders of the  
20 reproductive system. Similarly, polypeptides and antibodies directed to these  
polypeptides are useful in providing immunological probes for differential  
identification of the tissue(s) or cell type(s). For a number of disorders of the above  
tissues or cells, particularly of the reproductive system, expression of this gene at  
significantly higher or lower levels is routinely detected in certain tissues or cell types  
25 (e.g., reproductive, or cancerous and wounded tissues) or bodily fluids (e.g., lymph,  
amniotic fluid, seminal fluid, serum, plasma, urine, synovial fluid and spinal fluid) or  
another tissue or cell sample taken from an individual having such a disorder, relative  
to the standard gene expression level, i.e., the expression level in healthy tissue or  
bodily fluid from an individual not having the disorder.

30 The tissue distribution of this gene in the prostate, placenta and ovary  
indicates that polynucleotides and polypeptides corresponding to this gene are useful  
for treatment, prevention, and/or diagnosis of male or female infertility, endocrine



disorders, fetal deficiencies, ovarian failure, amenorrhea, ovarian cancer, benign prostate hyperplasia and prostate cancer. Similarly, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within placental tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2195 of SEQ ID NO:16, b is an integer of 15 to 2209, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 7**

The translation product of this gene shares homology with the human and rat HNK-1 sulfotransferase protein (See, e.g., Genbank Accession Nos. gblAAB88123.11 (AF022729) and gil2921306|gblAAC04707.11 (AF033827); all references available through these accessions are hereby incorporated herein by reference.) Ong E, et al. (J Biol Chem. 273(9):5190-5 (1998)) have characterized the human HNK-1 sulfotransferase, and show that it is involved in the synthesis of the HNK-1

carbohydrate epitope which is expressed on various adhesion molecules in the nervous system and on immune cells (e.g., natural killer cells) and is suggested to play a role in cell-cell and cell-substratum interactions. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with HNK-1 sulfotransferase proteins. Such activities are known in the art, some of which are described elsewhere herein, or in, for example, Bakker, et al., J Biol Chem. 272:29942-6 (1997), incorporated herein by reference. Based on sequence similarity between sulfotransferases, a consensus sequence for the active site was developed (Ong, et al., supra). The consensus pattern is as follows:

xxRPDzzzz, where x represents hydrophobic amino acid residues and z represents any amino acid residue. Therefore,

Preferred polypeptides of the invention comprise the following amino acid sequences: FVRDPFVRL (SEQ ID NO: 267), FLFVRDPFVRLIS (SEQ ID NO: 268), FLFVRDPFVRLISAF (SEQ ID NO: 269), and/or YLHTSFSPHTGPPLPTPG PDRDRELTADSDVDEFLDKFLSAGVKQSDLPRKETEQPPAPGSMEENVRGY DWSPRDARRSPDQGRQQAERRSVLRGFCANSSLAFTKERAFDDIPNSELSHL IVDDRHGAICYVPKVACTNWKRMIVLSGSLHARGAPYRDPLRPREHVH NASAHLTFNKFWRRYGKLSRHLMKVKLKKYTKFLFVRDPFVRLISAFRSK FELENEEFYRKFAVPMRLYANHTSLPASAREAFRAGLKVSFANFIQYLLDPH TEKLAPFNEHWRQVYRLCHPCQIDYDFVGKLETLEDAAQLLQLLQVDRQ LRFPPSYRNRTASSWEEDWFAKIPLAWRQQLYKLYEADFVLFGYPKPENLL RD (SEQ ID NO: 270). Polynucleotides encoding these polypeptides are also provided.

Further preferred are the sulfotransferase active site polypeptides listed above, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of the sequence referenced in Table I for this gene. The additional contiguous amino acid residues is N-terminal or C-terminal to the sulfotransferase active site polypeptides. Alternatively, the additional contiguous amino acid residues is both N-terminal and C-terminal to the sulfotransferase active site polypeptides, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The above preferred polypeptide domains are characteristic of a signature specific to sulfotransferase proteins. The nucleotides sequence of this gene was found to be

homologous to the human hypoxanthine guanine phosphoribosyl transferase 2 cDNA which is known to be involved in the purine salvage pathway resulting in the maintenance of homeostatic levels of uric acid (See Genbank Accession No.T30127).

The gene encoding the disclosed cDNA is believed to reside on chromosome

5 7. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 7.

This gene is expressed to a very high level in HL-60 myelogenous leukemia cell lines, and to a lesser extent, in most cell types of the immune system.

Therefore, polynucleotides and polypeptides of the invention are useful as  
10 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, myelopoiesis, and metabolic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For  
15 a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, metabolic, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an  
20 individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 130 as residues: Ser-39 to Gly-46, Leu-49 to Ala-62,  
25 Lys-79 to Ala-93, Gly-95 to Asp-105, Ser-107 to Val-127, Gly-193 to Leu-200, Lys-218 to Ser-227, Lys-234 to Thr-239, Pro-366 to Asp-379, Pro-406 to Asp-414. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in HL-60 myelogenous leukemia cell lines and homology to HNK-1 sulfotransferase proteins indicates that polynucleotides and  
30 polypeptides corresponding to this gene are useful for the diagnosis, prevention and/or treatment of a variety of immune system disorders, including but not limited to, those involving the HNK-1 carbohydrate epitope, (e.g. HNK-1 as an auto-antigen

in peripheral demyelinating neuropathy). Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, expression of this gene product in tonsils indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the homology to a conserved purine metabolism protein may suggest that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, prevention, and/or treatment of various metabolic disorders such as Tay-Sach's Disease, phenylketonuria, galactosemia, porphyrias, Hurler's syndrome, and various urogenital disorders related to metabolic conditions, particularly Lesch-Nyhan syndrome. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1760 of SEQ ID NO:17, b is an integer of 15 to 1774, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 8

When tested against Jurkat T-cell lines, supernatants removed from cells containing this gene activated the gamma activating sequence (GAS) promoter element. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway, a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. Thus, it is likely that this gene activates T-cells through the Jak-STAT signal transduction pathway.

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: KLVRLQVPVRNSRVDPRVRSKIGSRRWMLQLI MQLGSVLLTRCPFWGCFSQLMLYAERAEARRKPDIPVPYLYFDMGAAVLCA SFMSFGVKRRWFALGAALQLAISTYAA YIGGYVHYGDWLKVRMYSRTVAII GGFLVLASGAGELYRRKPRSRSLQSTGQVFLGIYLCVAYSLQHSKEDRLA YLNHLPGGELMIQLFFVLYGILALAFSLGYVTLAAQILAVLLPPVMLLIDG NVAYWHNTRRVEFWNQMKLLGESVGIFGTAVILATDG (SEQ ID NO: 271).

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MQLGSVLLTRCPFWGCFSQLMLYAERAEARRKPDIPVP YLYFDMGAAVLCASFMSFGVKRRWFALGAALQLAISTYAA YIGGYVHYGD

WLKVRMYSRTVAIIGGFLVLASGAGELYRRKPRSRSLQSTGQVFLGIYLICVA  
YSLQHSKEDRLAYLNHLPGGELMIQLFFVLYGILAPGLSVRLLRDPRCPDPGC  
TAAPCHAAH (SEQ ID NO: 272). Polynucleotides encoding these polypeptides are also provided.

5           The gene encoding the disclosed cDNA is believed to reside on chromosome 17. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 17.

          This gene is expressed primarily in endometrial tumors, and to a lesser extent, in T-cells, pituitary and to a certain extent in most cell types.

10           Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, female reproductive, immune, or endocrine disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing  
15 immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and/or immune systems expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, reproductive, or cancerous and wounded tissues) or bodily fluids (e.g., amniotic fluid, lymph, serum,  
20 plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

          Preferred polypeptides of the present invention comprise immunogenic  
25 epitopes shown in SEQ ID NO: 131 as residues: Ala-27 to Asp-34, Tyr-116 to Leu-125. Polynucleotides encoding said polypeptides are also provided.

          The tissue distribution predominantly in the endometrium indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of a range of immune and/or reproductive  
30 disorders including endometriosis, endometritis, and endometrioma. Similarly, the tissue distribution in T-cells and the ability of supernatants expressing this gene to stimulate the GAS promoter element in T-cells indicates polynucleotides and

polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the tissue distribution in pituitary indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of the Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g., diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-

hypopituitarism), thyroid (e.g., hyper-, hypothyroidism), parathyroid (e.g., hyper-, hypoparathyroidism), hypothalamus, and testes.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1660 of SEQ ID NO:18, b is an integer of 15 to 1674, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 9

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of the myeloid leukemia cell line AML-193 to calcium. Thus, it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of myeloid leukemia cells, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating myeloid leukemia cells.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: SNEILLSFPQNYIQLNGSLIHGLWNLASLFS NLCLFVLMPPFAFFLESEGFAGLKKGIRARILETLVMLLLLALLILGIVWVAS ALIDNDAASMESLYDLWEFYLPYLYSCISLMGCLLLLCTPVGLSRMFTVMG HLLVKPTILEDLDEQIYIITLEEEALQRRNLGLSSSVVEYNIMELEQELENVKT LKTLERRKKASAWERNLVPAVMVLLLIETSSISVLLVACNILCLLVDETAM PKGTRGPGIGNASLSTFGFVGAALIEILIFYLMVSSVVGIFYSLRFFGNFTPKKD DTTMTKIIGNCVSILVLSSALPVMSTLGITRFDLLGDFGRFNWLGNFYIVLS YNLLFAIVTTLCLVRKFTSAVREELFKALGLHKLHLPNTSRDSETAKPSVNGH



QKAL (SEQ ID NO: 273). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in fetal heart, and to a lesser extent, in colon and the adult pulmonary system.

5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, heart, lung and digestive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological  
10 probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular, pulmonary and digestive systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developmental, cardiovascular, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid,  
15 serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
20 epitopes shown in SEQ ID NO: 132 as residues: Glu-67 to Asn-74, Glu-88 to Asn-93, Lys-95 to Ala-107, Ala-147 to Arg-153, Phe-197 to Thr-205, Pro-292 to His-308. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in fetal heart, colon and pulmonary tissues and the biological activity in increasing the permeability of the plasma membrane of the  
25 myeloid leukemia cell line AML-193 to calcium, likely indicating that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of myeloid leukemia cells, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, prevention, and/or detection of a range of disorders including  
30 a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, myocardial infarction, myocarditis, ischemia, thrombosis, coronary artery disease,

arteriosclerosis, and/or atherosclerosis; pulmonary edema and embolism, bronchitis and/or cystic fibrosis; Crohn's Disease and/or colon cancer. Similarly, the tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2004 of SEQ ID NO:19, b is an integer of 15 to 2018, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 10**

The protein product of this clone shares sequence homology with the human MaxiK channel beta 2 subunit (See, Genbank Accession No. gblAAD23380.1|AF099137\_1 (AF099137); all references available through this accession are hereby incorporated herein by reference), which is believed to be a modulatory subunit of the voltage and Ca<sup>2+</sup> activated K<sup>+</sup> (MaxiK) channel. Additionally, this protein shares homology to the human calcium-activated potassium

channel beta subunit, which, when combined with its corresponding alpha subunit and modulating peptide, are believed to be useful in treating asthma, angina, hypertension, incontinence, migraine, irritable bowel syndrome (IBS). The subsequent heteromultimer that forms upon combining the alpha, beta, and modulator subunits  
5 are also thought to be useful in preventing premature labour, preventing and treating cerebral ischemia, inducing pain modulation and decreasing neurogenic inflammation in a patient (See GeneSeq Accession No. R85306).

Preferred polypeptides comprise the soluble domain which consists of the following amino acid sequence: RSYMQSVWTEESQCTLLNASITETFNCSFSCGP  
10 DCWKLSQYPCLQVYVNLTSSEKLLLYHTEETIKINQKCSYIPKCGKNFEESM  
SLVNVVMENFRKYQHFSCYSDEGNQKSVILTKLYSSNVLFHSLFWPTCMMA  
GGVAIVAMVKLTQYLSLLCERIQRINR (SEQ ID NO: 274). Polynucleotides encoding these polypeptides are also provided. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities  
15 with modulatory subunits of voltage and Ca<sup>2+</sup> activated K<sup>+</sup> channel proteins. Such activities are known in the art, some of which are described in Wallner, et al., PNAS 96:4137-4142 (1999), incorporated herein by reference.

This gene is expressed primarily in adrenal gland tumor, and to a lesser extent, in Hodgkin's lymphoma.

20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endocrine and immune disorders, particularly Hodgkin's Lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in  
25 providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and/or endocrine systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, endocrine, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum,  
30 plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression

level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 133 as residues: Trp-25 to Gln-30, Pro-50 to Gln-57,  
5 Pro-93 to Glu-101, Arg-114 to Cys-121, Ser-123 to Gln-129, Ile-177 to Arg-182. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in adrenal gland tumor and its identification as the modulatory subunit of the voltage and Ca<sup>2+</sup> activated K<sup>+</sup> (MaxiK) channel indicates that polynucleotides and polypeptides corresponding to this gene are useful for the  
10 detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g., diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g., hyper-, hypothyroidism), parathyroid (e.g., hyper-, hypoparathyroidism), hypothalamus, and testes. Alternatively, expression in  
15 proliferative immune tissues combined with its homology to a novel human K channel indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein.  
20 Briefly, the expression of this gene product in Hodgkin's lymphoma indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune  
25 responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory  
30 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity

disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that

5 recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify

10 agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

15 related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

20 formula of a-b, where a is any integer between 1 to 2084 of SEQ ID NO:20, b is an integer of 15 to 2098, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 11**

25 The translation product of this gene shares homology with collagen and collagen like proteins (See, e.g., Genbank Accession Nos. gil2920535|gb|AAC39658.1| (AF018081) and gil2384942|gb|AAB69961.1| (AF022985); all references available through these accession numbers are hereby incorporated by reference herein). Additionally, it has been determined that this gene

30 has homology to the human Kruppel related zinc finger protein (HTF10) which is known to be important as a transcription factor, particularly in development (See Genebank Accession No.L11672).

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: AFAHLQLGPMWKLWRAEEGAAALGGALFLLL  
5 FALGVRQLLKQRRPMGFPPGPPGLPFIGNIYSLAASSELPHVYMRKQSQVYG  
EVQPRRAPGREGRQAGPGWPGPSWLDLWPPLGRLVGTSPCAGCPLRDRFPG  
LEGRS PRRRAPLQGEPRPCR (SEQ ID NO: 275). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in human erythroleukemia cell line (HEL),  
10 serum induced smooth muscle, and to a lesser extent in human 8 week whole embryo.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, leukemia, musculoskeletal, or developmental disorders. Similarly,  
15 polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic system and muscular system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune,  
20 musculoskeletal, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 134 as residues: Leu-30 to Gly-38, Arg-67 to Val-72, Val-76 to Ala-89, Pro-118 to Arg-123, Gly-129 to Ala-136, Leu-138 to Arg-146. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in human erythroleukemia cell line (HEL), and serum  
30 induced smooth muscle, and the shared homology with collagen and collagen like proteins indicates that polynucleotides and polypeptides corresponding to this gene are useful for disorders of hematopoietic or muscular systems, such as leukemia and

muscular dystrophy. Additionally, the shared homology with collagen proteins would suggest that this protein may also be important in the diagnosis or treatment of various autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and  
5 chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid, etc.).

The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents  
10 that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g., for treating human  
15 immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g., for treating  
20 infections, tumours); haemostatic or thrombolytic activity (e.g., for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative disease; for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the corresponding nucleic acid in gene therapy  
25 procedures. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:21 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
5 formula of a-b, where a is any integer between 1 to 1732 of SEQ ID NO:21, b is an integer of 15 to 1746, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 12**

10 A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MRVRIGLTLLLCVLLSLASASSDEEGSQD  
ESLGFQDYFDIR (SEQ ID NO: 276). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome  
15 8. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 8.

This gene is expressed primarily in dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at  
25 significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an  
30 individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 135 as residues: Ser-22 to Ser-41, Glu-43 to Thr-50,



Ser-63 to Leu-68, Ser-71 to Gly-84, Ser-96 to Gly-114. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in dendritic cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis, prevention, and/or treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

The secreted protein can be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation

modulating activity or induction of other cytokines;  
immunostimulating/immunosuppressant activities (e.g., for treating human  
immunodeficiency virus infection, cancer, autoimmune diseases and allergy);  
regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to  
5 chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or  
nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for  
control of fertility); chemotactic and chemokinetic activities (e.g., for treating  
infections, tumours); haemostatic or thrombolytic activity (e.g., for treating  
haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating  
10 septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other  
hyperproliferative disease; for regulation of metabolism, behaviour, and many others.  
Also contemplated is the use of the corresponding nucleic acid in gene therapy  
procedures. Furthermore, the protein may also be used to determine biological  
activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to  
15 identify agents that modulate their interactions, in addition to its use as a nutritional  
supplement. Protein, as well as, antibodies directed against the protein may show  
utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are  
20 related to SEQ ID NO:22 and may have been publicly available prior to conception of  
the present invention. Preferably, such related polynucleotides are specifically  
excluded from the scope of the present invention. To list every related sequence is  
cumbersome. Accordingly, preferably excluded from the present invention are one or  
more polynucleotides comprising a nucleotide sequence described by the general  
25 formula of a-b, where a is any integer between 1 to 2862 of SEQ ID NO:22, b is an  
integer of 15 to 2876, where both a and b correspond to the positions of nucleotide  
residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 13

30 A preferred polypeptide variant of the invention comprises the following  
amino acid sequence: MARGSLRLLRLLVLGLWLALLRSVAGEQAPGTAPC  
SRGSSWSADLDKCMDCSTSCPLPA ALAHPWGRSEPDLRAGAAFWLFGLE

TMPQE REVHHPHRGDRRRGLPSCGADPVTMCPLPAGARPLIIHSSILEPVSAS  
QTRREPSSSNHK GGGGR (SEQ ID NO: 277). Polynucleotides encoding these  
polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome  
5 16. Accordingly, polynucleotides related to this invention are useful as a marker in  
linkage analysis for chromosome 16.

This gene is expressed primarily in tumor growth factor or lipopolysaccharide  
treated bone marrow stroma, epithelioid sarcoma, umbilical vein endothelial cells, and  
to a lesser extent, in other tissues.

10 Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
not limited to, hematopoiesis or immune disorders. Similarly, polypeptides and  
antibodies directed to these polypeptides are useful in providing immunological  
15 probes for differential identification of the tissue(s) or cell type(s). For a number of  
disorders of the above tissues or cells, particularly of the hematopoietic,  
integumentary, or immune systems expression of this gene at significantly higher or  
lower levels is routinely detected in certain tissues or cell types (e.g., hematopoietic,  
immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum,  
20 plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken  
from an individual having such a disorder, relative to the standard gene expression  
level, i.e., the expression level in healthy tissue or bodily fluid from an individual not  
having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
25 epitopes shown in SEQ ID NO: 136 as residues: Pro-35 to Trp-42, Pro-65 to Asp-72,  
Thr-86 to Phe-93, Ile-97 to Glu-103. Polynucleotides encoding said polypeptides are  
also provided.

The tissue distribution in tumor growth factor or lipopolysaccharide treated  
bone marrow stroma, epithelioid sarcoma, and umbilical vein endothelial cells  
30 indicates that polynucleotides and polypeptides corresponding to this gene are useful  
for the diagnosis, prevention, and/or treatment of a variety of immune system  
disorders. Representative uses are described in the "Immune Activity" and "infectious

disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

The secreted protein can be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g., for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for

control of fertility); chemotactic and chemokinetic activities (e.g., for treating infections, tumours); haemostatic or thrombolytic activity (e.g., for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other  
5 hyperproliferative disease; for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
10 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
15 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1038 of SEQ ID NO:23, b is an integer of 15 to 1052, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

## 20 FEATURES OF PROTEIN ENCODED BY GENE NO: 14

The translation product of this gene shares sequence homology with chromaffin granule amine transporter protein which is thought to be important in vesicle membrane amine transport, particularly in the neural and endocrine tissue, and the human vesicular monoamine transporter hVMAT1 which is involved in the  
25 regulation of amine storage in cardiovascular, endocrine, and central nervous system function (See, Genbank Accession Nos. gi1314290 and gb|AAC50472.1; all references available through these accession numbers are hereby incorporated by reference herein). Based on these sequence similarities, The translation product of this gene is expected to share at least some biological activities with amine transporter  
30 proteins. Such activities are known in the art, some of which are described in Erickson, et al., PNAS 93:5166-5171 (1996), and/or Liu, et al., Cell 70:539-551 (1992), which are both incorporated herein by reference.

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GTSFLDPTLSLVLEKFNLPAGYVGLVFLGMAL  
5 SYAISSPLFGLLSDKRPPPLRKWLLVFGNLITAGCYMLLGPVPILHIKSQLWLL  
VLILVVSGLSAGMSIIPTFPEILSCAHENGFEGLSTLGLVSGLFSAMWSIGAF  
MGPTLGGFLYEKIGFEWAAAIQGLWALISGLAMGLFYLLLEYSRRKRKSKSQNIL  
STEEERTTLLPNET (SEQ ID NO: 278). Polynucleotides encoding these  
polypeptides are also provided.

10 The gene encoding the disclosed cDNA is believed to reside on chromosome 6. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 6.

This gene is expressed primarily in colon cancer, osteoclastoma, and T-cell lymphoma, and to a lesser extent in many tumor or proliferative tissues such as  
15 endometrial tumor, chondrosarcoma, induced umbilical vein endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases resulting from disorders in small molecule transport (i.e.,  
20 signalling molecules) in afflicted tissues and organs, particularly of the endocrine and central nervous systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the musculoskeletal, immune, and/or digestive systems  
25 and cancer expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, endocrine, or cancerous and wounded tissues) or bodily fluids (e.g., bile, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression  
30 level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 137 as residues: Ser-114 to Asn-123, Thr-127 to Thr-132. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in colon cancer, osteoclastoma, and T-cell lymphoma  
5 and homology to amine transporter family members indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of disorders or diseases resulted from small molecule transport in afflicted tissues and organs, particularly that of colon, osteoclast or T-cells. The expression in cancer tissues, and shared homology with transporter proteins may also indicate its role in  
10 anti-cancer drug resistance. Additionally, the protein can be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell  
15 proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or  
20 nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumours); haemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other  
25 hyperproliferative disease; or for identifying inhibitors or promoters of the transport of toxic molecules to vesicles, for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.  
30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
5 formula of a-b, where a is any integer between 1 to 1527 of SEQ ID NO:24, b is an integer of 15 to 1541, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 15

10 The translation product of this gene shares sequence homology with the human prolyl 4-hydroxylase alpha (II) subunit which is important in catalyzing the formation of 4-hydroxyproline in collagens which is essential for the folding of newly synthesised collagen polypeptide chains into triple-helical molecules (See Genbank Accession No. gblAAB71339.11; all references available through this accession are  
15 hereby incorporated herein by reference). Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with Prolyl 4-hydroxylase proteins. Such activities are known in the art, some of which are described in Annunen, et al., J. Biol. Chem. 272:17342-17348 (1997) which is incorporated herein by reference.

20 When tested against U937 myeloid and Jurkat T-cell cell lines, supernatants removed from cells containing this gene activated the gamma activating sequence (GAS), a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the  
25 Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. Thus, it is likely that this gene activates myeloid cells and T-cells through the Jak-STAT signal transduction pathway.

In a specific embodiment, polypeptides comprising the amino acid sequence  
30 of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence:



GTREARLRDLTRFYDKVLSLHEDSTTPVANPLLAFTLIKRLQSDWRNVVHSL  
 EASENIRALKDGYEKVEQDLPAFEDLEGAARALMRLQDVYMLNVKGLAR  
 GVFQRTGSAITDLYSPKRLFSLTGDDCFQVGKVA YDMGDYYHAIPWLEEA  
 VSLFRGSYGEWKTEDEASLEDALDHLAFAYFRAGNVSCALSLSREFLLYSPD  
 5 NKRMAENVLKYERLLAESPNHVVAEAVIQRPNIPHLQTRDTYEGLCQTL  
 GSQPTLYQIPSLYCSYETNSNAYLLLQPIRKEVIHLEPYIALYHDFVSDSEAQ  
 KIRELAEPWLQRSVVASGEKQLQVEYRISKSAWLKDTVDLKLVTLNHRIAA  
 LTGLDVRPPYAEYLQVVNYGIGGHHYEPHFDHATSPSSPLYRMKSGNRVATFM  
 IYLSSVEAGGATAFIYANLSVPVVRNAALFWWNLHRSGEGDSDTLHAGCP  
 10 VLVGDKWVANKWIEHYGQEFRRPCSSSPED (SEQ ID NO: 282). Additional,

Preferred polypeptides comprise the following amino acid sequence: GTREA  
 RLRDLTRFYDKVLSLHEDSTTPVANPLLAFTLIKRLQSDWRNVVHSL EASENI  
 RALKDGYEKVEQ DLPAFEDLEGAARAL (SEQ ID NO: 279), ALMRLQD (SEQ  
 ID NO: 280), and/or VEAGGAT (SEQ ID NO: 281). Polynucleotides  
 15 encoding these polypeptides are also provided.

This gene is expressed primarily in lymph node breast cancer, colon  
 carcinoma, and to a lesser extent in osteoblasts and adipocytes.

Therefore, polynucleotides and polypeptides of the invention are useful as  
 reagents for differential identification of the tissue(s) or cell type(s) present in a  
 20 biological sample and for diagnosis of diseases and conditions which include, but are  
 not limited to, disorders of connective and immune tissues, particularly autoimmune  
 disorders. Similarly, polypeptides and antibodies directed to these polypeptides are  
 useful in providing immunological probes for differential identification of the  
 tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,  
 25 particularly of the connective tissues in breast, colon, bone, and fat, expression of this  
 gene at significantly higher or lower levels is routinely detected in certain tissues or  
 cell types (e.g., immune, connective, or cancerous and wounded tissues) or bodily  
 fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another  
 tissue or cell sample taken from an individual having such a disorder, relative to the  
 30 standard gene expression level, i.e., the expression level in healthy tissue or bodily  
 fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 138 as residues: Ser-74 to Ala-84, Gln-156 to Tyr-161, Tyr-184 to Asn-189, Ser-218 to Ile-223, Pro-299 to Ser-308, His-359 to Thr-368, Tyr-390 to Asp-404. Polynucleotides encoding said polypeptides are also provided.

5       The tissue distribution in lymph node breast cancer and colon carcinoma and homology to prolyl 4-hydroxylase alpha (II) subunit indicates that polynucleotides and polypeptides corresponding to this gene are useful for intervention of connective tissue disorders and diseases (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation), as well as, in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as  
10       well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias ie. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid. Alternatively, the tissue distribution within various tissue carcinomas and tumor tissues, and  
15       biological activity reflected by the binding and activation of the GAS promoter element indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders.

Expression in cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic  
20       development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

25       Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is  
30       cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2065 of SEQ ID NO:25, b is an

integer of 15 to 2079, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 16

5 In an additional embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: IQPSHAALLHCRSTFRKTECLDPW  
WVRRQLLG MAGIGGLQKMKAPHTGVLHLGSVWVFLGPFL LGVGYTLTFNPL  
10 SGCMSTVRWLNSNITANRTLSRSVCHVTPLHRSLSPHDGEYLRQMLNSSSR  
AGEAGSWG Y (SEQ ID NO: 283). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 20. Accordingly, polynucleotides related to this invention are useful as a marker in  
15 linkage analysis for chromosome 20.

This gene is expressed primarily in fetal liver, and, to a lesser extent, in a variety of fetal and other tissues and cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, liver disorders and cancers (e.g., hepatoblastoma, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
25 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the liver, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., hepatic, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, bile, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an  
30 individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 139 as residues: Ser-67 to Tyr-75. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in fetal liver indicates that polynucleotides and polypeptides corresponding to this gene are useful for detection and treatment of liver disorders and cancers (e.g., hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various wound-healing models and/or tissue trauma. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1933 of SEQ ID NO:26, b is an integer of 15 to 1947, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 17**

The translation product of this gene shares sequence homology with human laminin B1 which is thought to be an important structural extracellular matrix component involved in cell migration and signalling, particularly in stimulating epithelial cell growth and differentiation (See, Genbank Accession No g1186837).

Preferred polypeptides of the invention comprise the following amino acid sequences: CSSPPGRLPWCWTAPRTLKGKHSGLISTLRLTAPLHLAWKMMLS RKALFVLLNTPVLFHALEGRFLFSKLCHHHTIQRTLTVPKFRSS (SEQ ID NO: 284), RSPTSrvQLLKRQSCPCQRNDLNEEPQHFTHYAIYDFIVKGSCFCNG

5 HADQCIPVHGFRPVKAPGTFHVMVHGKCM (SEQ ID NO: 285), and/or HNTAG SHCQHCAPLYNDRPWEAADGKTGAPNECRTCKCNGHADTCHFDVNVWEAS GNRSGGVCDDCQHNTGQYQCQRCKPGFYRDLRRPFSAPDACKPCSCHPV GSAVLPANSVTFCDPNSGDCPCKPGVAGRRCDRCMVGYWGFGDYGCRP CDCAGSCDPITGDCISSHTDIDWYHEVPDFRPVHNKSEPAWEWEDAQGFSA

10 LHSKGCECKEQLGNKAFKGMKYSYVLKIKILSAHDKGTHVEVNVKIK KVLKSTKLKIFRGKANIISRIMDGQ RMHLSNPQSWFGIPCSRT (SEQ ID NO: 286). Polynucleotides encoding these polypeptides are also provided.

Included in this invention as preferred domains are Laminin-type EGF-like (LE) domain signatures, which were identified using the ProSite analysis tool (Swiss

15 Institute of Bioinformatics). Laminins are the major noncollagenous components of basement membranes that mediate cell adhesion, growth migration, and differentiation. They are composed of distinct but related alpha, beta and gamma chains. The three chains form a cross-shaped molecule that consist of a long arm and three short globular arms. The long arm consists of a coiled coil structure contributed

20 by all three chains and cross-linked by interchain disulfide bonds. Beside different types of globular domains each subunit contains, in its first half, consecutive repeats of about 60 amino acids in length that include eight conserved cysteines. The tertiary structure of this domain is remotely similar in its N-terminal to that of the EGF-like module. It is known as a 'LE' or 'laminin-type EGF-like' domain. The number of

25 copies of the LE domain in the different forms of laminins is highly variable; from 3 up to 22 copies have been found. A schematic representation of the topology of the four disulfide bonds in the LE domain is shown below.

5                   +-----+  
                  +-|-----+           |   +-----+   +-----+  
                  | |                   |   |           |   |                   |  
                  xxCxCxxxxxxxxxxxxCxxxxxxxxCxxCxxxxGxxCxxCxxgaagxxxxxxxxxxxxCxx  
    \*\*\*\*\*  
                  ssssssssssssssssssssssssssssssssssssss

10

'C': conserved cysteine involved in a disulfide bond

'a': conserved aromatic residue

'G': conserved glycine (lower case = less conserved)

15 's': region similar to the EGF-like domain

'\*': position of the pattern

In mouse laminin gamma-1 chain, the seventh LE domain has been shown to be the only one that binds with a high affinity to nidogen. The binding-sites are  
 20 located on the surface within the loops C1-C3 and C5-C6. Long consecutive arrays of LE domains in laminins form rod-like elements of limited flexibility, which determine the spacing in the formation of laminin networks of basement membranes. We derived a signature pattern for the LE domain which covers the C-terminal half of the repeat starting with the fourth conserved cysteine. The consensus pattern is as  
 25 follows: C-x(1,2)-C-x(5)-G-x(2)-C-x(2)-C-x(3,4)-[FYW]-x(3,15)-C [All C's are involved in disulfide bonds]

Preferred polypeptides of the invention comprise the following amino acid sequence: CDDCQHNTGQYCQRCKPGFYRDLRRPFSAPDACKPC (SEQ ID NO: 287) and/or CPCKPGVAGRRCRDMVGWYWGFGDYGCRPCDCAGSC (SEQ  
 30 ID NO: 288). Polynucleotides encoding these polypeptides are also provided.

Further preferred are polypeptides comprising the laminin-type EGF-like domains listed above, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of the sequence encoded by this gene. The additional contiguous amino acid residues is N-terminal or C- terminal to the laminin-type EGF-

like domain. Alternatively, the additional contiguous amino acid residues is both N-terminal and C-terminal to the laminin-type EGF-like domain, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The above preferred polypeptide domain is characteristic of a signature specific to

5 Laminin proteins. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with Laminin proteins. Such activities are known in the art, some of which are described elsewhere herein.

This gene is expressed primarily in osteoblastic tissues and cell types, including osteoblasts, osteoblastomas and osteoclastomas. Expression is also

10 abundant in vascular-pulmonary tissues such as lung, micro-vasculature, pulmonary, endothelial and smooth muscle cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

15 not limited to, cancer and malignancies (particularly of osteoblastic tissues and rhabdomyosarcoma), as well as cardiovascular and respiratory or pulmonary disorders such as asthma, pulmonary edema, pneumonia, atherosclerosis, restenosis, stroke, thrombosis hypertension, inflammation and wound healing. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological

20 probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardio-respiratory system, and skeletal system expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., skeletal, osteoblast, cardio-respiratory, vascular, or cancerous and wounded tissues) or bodily fluids (e.g., lymph,

25 pulmonary surfactant, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic

30 epitopes shown in SEQ ID NO: 140 as residues: Ser-28 to Cys-34, Thr-51 to Thr-58, Tyr-64 to Asn-81, Asp-111 to Lys-116, Asp-145 to Phe-160, Pro-203 to Glu-217. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in osteoblastic tissues and cell types and homology to laminin indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, prevention and diagnosis of cardiovascular and respiratory or pulmonary disorders such as asthma, pulmonary edema, pneumonia, atherosclerosis, restenosis, stroke, angina, thrombosis hypertension, inflammation and wound healing. As a homolog of laminin, this gene product quite possibly has a role in cell adhesion, migration, proliferation, angiogenesis, chondrogenesis, wound healing and oncogenesis. An EST (Int J Cancer 1996 May 16;66(4):571-577) with an identical sequence to part of this contig was shown to be differentially expressed in human primary myoblasts and embryonal rhabdomyosarcoma and therefore might have an important role in the determination or maintenance of the normal phenotype, and thus its loss is possibly involved in the progression of malignancies, particularly of skeletal muscle. Similarly, the homology to a laminin would suggest a role in the detection and treatment of disorders and conditions afflicting connective tissues (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation) in the diagnosis or treatment of various autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma, and dermatomyositis as well as dwarfism, spinal deformation, and specific joint abnormalities as well as chondrodysplasias i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general



formula of a-b, where a is any integer between 1 to 3365 of SEQ ID NO:27, b is an integer of 15 to 3379, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 18

The gene encoding the disclosed cDNA is believed to reside on chromosome 10. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 10.

10 In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: NISSQYCILKSLEMMISGLKLLVLFLKFAPENY CLSTETLQMPNRHLRLSKATCYLMKCLLP SYFE (SEQ ID NO: 289).

Polynucleotides encoding these polypeptides are also provided.

15 This gene is expressed primarily in placenta, brain, and to a lesser extent, in a variety of other tissues and cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, reproductive, behavioral, or nervous system disorders, such as: depression, schizophrenia, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, dementia, paranoia, addictive behavior, epilepsy, transmissible spongiform encephalopathy (TSE), Creutzfeldt-Jakob disease (CJD). Other diseases and conditions related to expression in the placenta might include developmental anomalies and fetal deficiencies, ovarian and endometrial cancers, reproductive disfunction and pre-natal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous and reproductive systems, 25 expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, reproductive, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial 30

fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
5 epitopes shown in SEQ ID NO: 141 as residues: Ala-16 to Leu-22. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions.

10 Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia,  
15 trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, expression in placenta would suggest a  
20 possible role in the treatment and diagnosis of developmental anomalies and fetal deficiencies, ovarian and endometrial cancers, reproductive dysfunction and pre-natal disorders.

Similarly, expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the  
25 regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or  
30 receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may

show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1992 of SEQ ID NO:28, b is an integer of 15 to 2006, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 19**

The translation product of this gene shares sequence homology with the murine transforming protein (See, e.g., Genbank Accession No. gil53529|embl|CAA36859.1; all references available through this accession are hereby incorporated by reference herein).

In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: PIEGTPAGTGPEFPGRPTRPQRMRS LISSHPCQ HLLLLLLLLFLILAILVDVKWYLVLFICISLMTSDVEHLFMCLLAIRISSWR NVY (SEQ ID NO: 290). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in activated and basal T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immunodeficiency, tumor necrosis, infection, lymphomas, auto-immunities, cancer, metastasis, wound healing, inflammation, anemias (leukemia) and other hematopoietic disorders. Similarly, polypeptides and antibodies directed to these

polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types  
5 (e.g., immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 The tissue distribution in activated T-cells and the homology to a murine transforming protein indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere  
15 herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

20 Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,  
25 such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted  
30 factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of

various blood lineages, and in the differentiation and/or proliferation of various cell types.

The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in the specification. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g. for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumours); haemostatic or thrombolytic activity (e.g. for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative disease; for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3056 of SEQ ID NO:29, b is an

integer of 15 to 3070, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 20

5       The translation product of this gene was shown to have homology to the Mus musculus ALG-2 protein, which is known to code for a Ca(2+)-binding protein required for T cell receptor-, Fas-, and glucocorticoid-induced cell death. ALG-2 mediate Ca(2+)-regulated signals along the death pathway and may play a role in the onset of Alzheimer's Disease (See e.g., Genbank Accession No.gil1213520; all  
10    references available through this accession are hereby incorporated by reference herein).

      Preferred polypeptides comprise the following amino acid sequence: NWVPT CLCP SAPCSFHLLSRFKCLFSPQRLTDIFRRYDTDQDGWIQVSYEQYLSMVFS  
15    IV (SEQ ID NO: 291), and/or QRLTDIFRRYDTDQDGWIQVSYEQYLSMVFSIV (SEQ ID NO: 292). Polynucleotides encoding these polypeptides are also provided.

      When tested against K562 cell lines, supernatants removed from cells containing this gene activated the ISRE (interferon-sensitive responsive element). Thus, it is likely that this gene activates immune or leukemia cells through the Jaks-STAT signal transduction pathway. ISRE is a promoter element found upstream in  
20    many genes which are involved in the Jaks-STAT pathway. The Jaks-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

25       A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MFYKLTLLCELSVAGVTQAASQRPLQRLPRHICSQR XPPGRCLLKAXLQTTWXXPDKPI PRLSPPLXSDPKR (SEQ ID NO: 293). Polynucleotides encoding these polypeptides are also provided.

      The gene encoding the disclosed cDNA is believed to reside on chromosome  
30    5. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 5.

This gene is expressed primarily in placenta, and to a lesser extent, in a variety of other tissues and cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental anomalies, fetal deficiencies ovarian and endometrial cancers, reproductive dysfunction and pre-natal disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, developmental, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 143 as residues: Arg-24 to Arg-31, Ile-33 to Gly-41.

Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in placenta indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, prevention and/or diagnosis of developmental anomalies, fetal deficiencies, ovarian and endometrial cancers, reproductive dysfunction and pre-natal disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells combined with the observed ISRE activity, and homology to the apoptosis linked, ALG-2 indicates that this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2213 of SEQ ID NO:30, b is an integer of 15 to 2227, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.



**FEATURES OF PROTEIN ENCODED BY GENE NO: 21**

The translation product of this gene was shown to have homology to the human histo-blood group A transferase (See, e.g., Genbank Accession No. gb|AAD26573.1|AF134413\_1 (AF134413); all references available through this  
 5 accession are hereby incorporated by reference herein) which is known to represent one of the major allogeneic antigens in both erythrocytes and tissues of humans. Its been proposed that the A phenotype is associated with the glycosyltransferase that converts the H substance associated with the O phenotype to A through the addition of alpha1-3-N-acetylgalactosamine or alpha1-3-galactosyl residues to the H antigen  
 10 Fuc-alpha1-2Gal- beta1-R. Therefore, the primary product of the histo-blood group A is its respective glycosyltransferase. Preferred polypeptides of the invention comprise the following amino acid sequence: TSSPVFSFCSMAVREPDHLQ  
 RVSLPRYNVSASLQWLPCRIVLQPWHMCAMWELGQVLFHPVAPREGAAPS  
 PVSTLTWPSSCSHSESTMELELQF (SEQ ID NO: 294), LPCRIV (SEQ ID NO:  
 15 296), SLQWLPCRIVLQPW (SEQ ID NO: 297), and/or MAVREPDHLQRVSLPR (SEQ ID NO: 295). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in 12-week-old human embryo.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
 20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental anomalies, fetal deficiencies, pre-natal disorders, hematopoietic disorders, or cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above  
 25 tissues or cells, particularly of the developing fetus, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., hematopoietic, lymph, developing, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, amniotic fluid, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder,  
 30 relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in 12 week old embryo indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of developmental anomalies, fetal deficiencies, pre-natal disorders and cancer. Similarly, expression within embryonic tissue and other cellular sources marked by

5 proliferating cells indicates that this protein may play a role in the regulation of cellular division. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus, this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Alternatively, the tissue distribution and homology to human blood group A

10 and B glycosyltransferase enzymes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "infectious

15 disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

The gene product may also be involved in lymphopoiesis, therefore, it can be

20 used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to

25 isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly

30 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1274 of SEQ ID NO:31, b is an integer of 15 to 1288, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 22

The translation product of this gene shares sequence homology with CD97 (EMR1), which is thought to be important in both adhesion and signaling processes early after leukocyte activation (See, e.g., Genbank Accession No. gi1784994; all references available through this accession are hereby incorporated by reference herein). EMR1 belongs to a novel family of G-protein receptors that has recently been recognized on the basis of homologous primary amino acid sequences, comprises receptors to hormones of the secretin/vasoactive intestinal peptide/glucagon family, parathyroid hormone and parathyroid hormone-related peptides, growth hormone-releasing factor, corticotropin-releasing factor, and calcitonin. Proteins with seven transmembrane segments (7TM) define a superfamily of receptors (7TMreceptors) sharing the same topology: an extracellular N-terminus, three extramembranous loops on either side of the plasma membrane, and a cytoplasmic C-terminal tail. Upon ligand binding, cytoplasmic portions of the activated receptor interact with heterotrimeric G-coupled proteins to induce various second messengers, which subsequently activate various signal transduction pathways depending upon the specific G-coupled protein associated with the receptor. Preferred polypeptides of the invention comprise the following amino acid sequence: CFKRKPKREHCSCP

ITYQSLGDILNASFFSKRKGMQEVKLNSYVVSGTIGLKEKISLSEPVFLTFRHN  
 QPGDKRTKHICVYWEGSEGGRWSTEGCSHVHSNGSYTKCKCFHLSSFAVLV  
 ALAPKEDPVLTVITQVGLTISLLCLFLAILTFLLCRPIQNTSTSLHLELSLCLFLA  
 HLLFLTGINRTEPEVLCSIIAGLLHFLYLACFTWMLLEGLHLFLTVRNLKVAN  
 YTSTGRFKKRFMYPGYGIPAVIIA VSAIVGPQNYGTFTHCWLKLDKGFIWSF  
 MGPVAVIILINLVFYFQVLWILRSKLSSLNKEVSTIQDTRVMTFKAISQLFILGC  
 SWGLGFFMVEEVGKTIGSIIAYSFTIINTLQGVLLFVVHCLLNQRQVRMEYKKW

FSGMRKGVETESTEMSRSTTQTKTEEVGKSSEIFHKGGTASSSAESTKQPQPQ  
 VHLVSAAWLKMN (SEQ ID NO: 298), and/or FFWKENLRRNGSREDFARRATQ  
 LIQSVELSIWNASFASPGKGQISEFDIVYETKRCNETRENAFLEAGNNTMDINC  
 ADALKGNLRESTAVALSLINLLGIF SEQ ID NO: 299. Polynucleotides

5 encoding these polypeptides are also provided.

Included in this invention as preferred domains are two EGF-like protein domains, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). First, a sequence of about forty amino-acid residues long found in the sequence of epidermal growth factor (EGF) has been shown to be present in a  
 10 large number of membrane-bound and extracellular, mostly animal proteins. Many of these proteins require calcium for their biological function and a calcium-binding site has been found to be located at the N-terminus of some EGF-like domains. Calcium-binding is crucial for numerous protein-protein interactions. We have used the N-terminal part of the EGF domain as a consensus pattern. It includes the negative N-  
 15 terminus and the possible hydroxylation site. The consensus pattern is as follows:[DEQN].[DEQN]{2}C.{3,14}C.{3,7}C.[DN].{4}[FY].C [The four C's are involved in disulfide bonds].

Preferred polypeptides of the invention comprise the following amino acid sequence: DINECETGLAKCKYKAYCRNKVGGYIC (SEQ ID NO: 300).

20 Polynucleotides encoding these polypeptides are also provided. Secondly, post-translational hydroxylation of aspartic acid or asparagine to form erythro-beta-hydroxyaspartic acid or erythro-beta-hydroxyasparagine has been identified in a number of proteins with domains homologous to (EGF). Based on sequence comparisons of the EGF-homology region that contains hydroxylated Asp or Asn, a  
 25 consensus sequence located in the N-terminal of EGF-like domains has been identified that seems to be required by the hydroxylase(s). The consensus sequence is as follows: C.[DN].{4}[FY].C.C.

Preferred polypeptides of the invention comprise the following amino acid sequence: CRNKVGGYICSC (SEQ ID NO: 301). Polynucleotides encoding these  
 30 polypeptides are also provided.

Further preferred are polypeptides comprising the calcium-binding EGF-like domain and aspartic acid and asparagine hydroxylation site listed above, and at least

5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of the sequence referenced in Table I for this gene and the embodiments listed herein. The additional contiguous amino acid residues is N-terminal or C-terminal to one or both of the listed domains. Alternatively, the additional contiguous amino acid residues is  
5 both N-terminal and C-terminal to one or both of the listed domains, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The above preferred polypeptide domains are characteristic of a signature specific to EGF like proteins. Based on the sequence similarity and conserved domains, The translation product of this gene is expected to share at least some biological activities  
10 with EGF-like proteins. Such activities are known in the art, some of which are described elsewhere herein.

This gene is expressed primarily in eosinophils.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
15 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic disorders or anemias and leukemias, immunodeficiencies, infection, lymphomas, auto-immunities and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For  
20 a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an  
25 individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 145 as residues: Ser-22 to Ser-30, Pro-33 to Cys-48,  
30 Asp-50 to Lys-67, Pro-117 to Ser-130. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in eosinophils combined with its homology to a known human seven transmembrane domain protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders, particularly considering the fact that the majority of 7 transmembrane receptors are tightly associated with signal transduction pathways which are integral to the modulation of the cell cycle. As such, the protein product of this gene may play a role in the regulation of cellular division, where loss of regulation may result in proliferating cells and the onset of tumors or cancer. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. In such an event, this gene is useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Similarly, the tissue distribution and homology to CD97 indicates that the protein product of this gene might be a marker for differentiation and activation of eosinophils, and therefore is useful for the diagnosis and treatment of immune disorders including: leukemias, lymphomas, auto-immunities, immunodeficiencies (e.g., AIDS), immuno-suppressive conditions (transplantation) and hematopoietic disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. In addition this gene product is applicable in conditions of general microbial infection, inflammation or cancer. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
 5 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3266 of SEQ ID NO:32, b is an integer of 15 to 3280, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

## 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 23

The translation product of this gene has been found to have homology to the rat neural F box protein NFB42, in addition to a conserved *Caenorhabditis elegans* C14B1.3 protein (See, e.g., Genbank Accession Nos. gil3851648|gb|AAC97505.11 (AF098301) and gil558270; all references available through these accessions are  
 15 hereby incorporated by reference herein). Preferred polypeptides of the invention comprise the following amino acid sequence: ALCPPHILNVTVPAPSCRHVK KVVASPPSTTMIAMDAPHSKAALDSINELPENILLELFTHVPARQLLLNCRL VCSLWRDLIDMTLWKRKCLREGFITKDWDQPVADWKIFYFLRSLHRNLLR NPCAEEDMFAWQIDFNGGDRWKVESLPGAHGTDFFDPKVKKYFVTSYEMCL  
 20 KSQVLVDLVAEGYWEELLDTRPDIVVKDWFAARADCGCTYQLKVQLASA DYFVLASFEPPTTIQQWNNATWTEVSYTFSDYPRGVRYILFQHGGRTQY WAGWYGPRVTNSSIVVSPKMTRNQASSEAQPGQKHGQEEAAQSPYRAVV QIF (SEQ ID NO: 302). Polynucleotides encoding these polypeptides are also provided.

25 The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in immune cells, especially primary dendritic cells, and T cells, and to a lesser extent in a variety of other tissues including breast,  
 30 keratinocytes, epididymus (cauda), lung, multiple sclerosis, endometrial stromal cells, IL4 induced umbilical vein endothelial cells, fetal kidney, fetal dura mater, rejected kidney, and osteoblasts.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and other proliferative disorders, particularly of the immune system or endothelial cells. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 146 as residues: Pro-41 to Cys-47, Phe-52 to Gly-59, Pro-62 to His-70. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product in T-cells indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g., by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,



such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's  
5 Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell  
10 types.

The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. It may also have a very wide range of biological activities although no evidence for any is provided in  
15 the specification. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g., for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to  
20 chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumours); haemostatic or thrombolytic activity (e.g., for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating  
25 septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative disease; for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:33 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
 5 formula of a-b, where a is any integer between 1 to 1283 of SEQ ID NO:33, b is an integer of 15 to 1297, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 24

10 The translation product of this gene shares sequence homology with the human, mouse, and bovine dopamine hydroxylase which is thought to be important in the modification of dopamine, a neurotransmitter (See Genbank Accession Nos. gil30474, gil162965, and/or gil2358082; all references available through these accessions are hereby incorporated by reference herein). Preferred polypeptides of the  
 15 invention comprise the following amino acid sequence: RQRSWNPGT  
 NCYHPNMPDAFLTCETVIFAWAIGGEGFSYPPHVGLSLGTPLDPHYVLLEVH  
 YDNPTYEEGLIDNSGLRLFYTMDIRKYDAGVIEAGLWVSLFHTIPPGMPEF  
 QSEGHCTLECLEEAEAEKPSGIHVFAVLLHAHLAAGRIRLRHFRKGKEMKL  
 LAYDDDFDFNFQEFQYLKEEQTILPGDNLITECRYNTKDRAEMTWGGLSTR  
 20 SEMCLSYLLYYPRINLTRCASIPDIMEQLQFIGVKEIYRPVTTWPFIKSPKQYK  
 NLSFMDAMNKFkwTKKEGLSFNKLVLSPVNVRCskTDNAEWSIPRNDsIT  
 SRYRKTL (SEQ ID NO: 303). Polynucleotides encoding these polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following  
 25 amino acid sequence: MCCWPLLLLWGLLPGTAAGGSGRTYPHRTLLDSEGK  
 YWLGWSQRGSQIAFRLQVRTAGYVGFGFSPTGAMASADIVVGGVAHGR  
 PYLQDYFTNANRELKKDAQQDYHLEYAMENSTHTIIEFTRELHTCDINDKS  
 ITDSTVRVIWAYHHE DAGEAGPKYHDSNRGTKSLRLLNPEKTSVLSTALPYF  
 DLVNQDVPINPKDTTYWCQMFKIPVFQEKHHVIKVEPVIQRGHESLVHHILL  
 30 YQCSNNFNDSVPGIRARIAITPTCPMHSSPV KL (SEQ ID NO: 304).

Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in brain, the pulmonary system, and to a lesser extent in kidney.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological and behavioral disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, endocrine, or cancerous and wounded tissues) or bodily fluids (e.g., sputum, lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 147 as residues: Ser-33 to Trp-38, Gly-40 to Gly-45, Asn-93 to Asp-105, Thr-128 to Thr-137, Glu-150 to Lys-167, Pro-197 to Tyr-203, Cys-242 to Asn-247, Ser-253 to Tyr-258, His-307 to Glu-314, Glu-357 to Gly-362, Trp-373 to Gln-378, Ser-402 to Glu-408. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain and homology to a protein involved in the modification of dopamine indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive

compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Alternatively, the homology to dopamine hydroxylase indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g., diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g., hyper-, hypothyroidism), parathyroid (e.g., hyper-, hypoparathyroidism), hypothalamus, and testes. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:34 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2170 of SEQ ID NO:34, b is an integer of 15 to 2184, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 25**

When tested against Jurkat T-cell lines, supernatants removed from cells containing this gene activated the gamma activating sequence (GAS), a promoter element found upstream of many genes which are involved in the Jak-STAT pathway.

The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells. Thus, it is likely that  
5 this gene activates T-cells through the JakStat signal transduction pathway.

This gene is expressed in a variety of human normal and diseased tissues including breast, infant adrenal gland, skin tumor, colon, pituitary, Wilm's tumor, and to a lesser extent in other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as  
10 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, breast cancer and other proliferative disorders, afflicting endocrine or endothelial tissues. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
15 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system or of breast and/or breast lymph nodes, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, endocrine, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial  
20 fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in breast, infant adrenal gland, skin tumor, colon, pituitary, and Wilm's tumor, and biological activity in activating the GAS promoter  
25 element indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers, particularly Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g., diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g., hyper-,  
30 hypothyroidism), parathyroid (e.g., hyper-, hypoparathyroidism), hypothalamus, and testes. Alternatively, the tissue distribution and biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the

diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells, (i.e., breast, skin and Wilm's tumors) indicates that this protein may play a role in the regulation of cellular division. Additionally, the expression in hematopoietic cells and tissues  
5 indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. In such an event, this gene is useful in the treatment of lymphoproliferative disorders, and in the maintenance and  
10 differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Furthermore, the protein may also be used to determine  
15 biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is  
25 cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 935 of SEQ ID NO:35, b is an integer of 15 to 949, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 26**

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the  
5 following amino acid sequence: TGTFWSPRSQRRGCCGRRAPRPEAMENGAVYS  
PTTEEDPGPARGPRSGLAAYFFMGRLPLLRRVLKGLQLLSLLAFICEEVVSQ  
CTLCGGLYFFFEFVSCSAFLLSLLLIVYCTPFYERVDTTKVKSSDFYITLGTGCV  
FLLASIIFVSTHDRTSAEIAAIVFGFIASFMLLDFFITMLYEKRQESQLRKPENTT  
RAEALTEPLNA (SEQ ID NO: 305). Polynucleotides encoding these polypeptides  
10 are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 3. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 3.

This gene is expressed primarily in dendritic cells, and to a lesser extent in  
15 melanocytes, fetal liver and spleen and several other tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammation, and disorders of the hepatic and immune systems.  
20 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and hematopoietic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., hematopoietic,  
25 hepatic, immune, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 149 as residues: Phe-63 to Ser-75, Thr-97 to Ser-102, Glu-128 to Arg-143. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product in dendritic cells indicates a role in the regulation of the proliferation; survival; differentiation; and/or activation of potentially all hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes that may also suggest a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also used as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, scleroderma and tissues. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Alternatively, the tissue distribution in fetal liver indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of liver disorders and cancers (e.g., hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells). In addition the expression in fetus would suggest a useful role for the protein product in developmental abnormalities, fetal deficiencies, pre-natal disorders and various wound-healing models and/or tissue trauma. Furthermore, the protein may also be used to determine biological activity, raise



antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

- 5 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is  
10 cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3324 of SEQ ID NO:36, b is an integer of 15 to 3338, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

15

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 27**

- In a specific embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the  
20 following amino acid sequence: ASAPRVMRGHLAGFPALSGLASVCLWATFSA QLPGPVAATSWTPAPLGCSAARSGPEKRLGTAAPGSAASLAQAGPGAPCRV LPVDPAPAALNVREPGWLGGFLFDGALLQVLLNFLRKSTDVLMDTREAESLEV E (SEQ ID NO: 306).

- In another embodiment polypeptides of the invention comprise the following  
25 amino acid sequence: NKLHSFPVFLSQLLLDRQLLHAPQTLPTPHCGGSSRPGP SHPPWLLIQLPCVHVALWQMLRDFSDSRITPSTLTTQPAAQTAAPAKDQES DIVGGEGILCDIAFLQEDHPLGVGGASAPSSRRELSRRGVHTQTLPEDGTLHG TPSSSFDCGIKYIISWPLAPGCDLPSLELSLVCKGVSSCMGFAAG (SEQ ID NO: 307). Polynucleotides encoding these polypeptides are also provided.

- 30 This gene is expressed primarily in endothelial cells, lung, and fetal kidney, and to a lesser extent in epididymis, keratinocytes and cerebellum.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cardiovascular diseases involving endothelial cell disturbances such as atherosclerosis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cardiovascular, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 150 as residues: Arg-47 to Leu-54. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in endothelial cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating disorders of endothelial cells such as atherosclerosis, vasculitis, cardiovascular disease, and emphysema. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions and as nutritional supplements. The polypeptide may possess a wide range of undetected biological activities. Typical of these are cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g., for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of haematopoiesis (e.g., for treating anaemia or as adjunct to chemotherapy); stimulation of growth of bone, cartilage, tendons, ligaments and/or nerves (e.g., for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g., for treating infections, tumours); haemostatic or

thrombolytic activity (e.g., for treating haemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g., for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative disease; for regulation of metabolism, behaviour, and many others. Also contemplated is the use of the  
5 corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
10 related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
15 formula of a-b, where a is any integer between 1 to 1549 of SEQ ID NO:37, b is an integer of 15 to 1563, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 28

20 In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: PGRPTRPTKNKVCVCLGMLFWAYPICVFIDSL SCQPCLWSTGATSHFNSPTTSPLFTLFMPICALAPNPFT QLGKLDDR (SEQ ID  
25 NO: 308). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in meningima.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
30 not limited to, tumors or disorders of the central nervous system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For

a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 151 as residues: His-29 to Thr-34. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in meningioma indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception, as well as disorders of the meninges such as meningioma and meningitis. In addition, the gene or gene product may also play a role in the treatment and/or detection of developmental disorders associated with the developing embryo, sexually-linked disorders, or disorders of the cardiovascular system. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
5 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1034 of SEQ ID NO:38, b is an integer of 15 to 1048, where both a and b correspond to the positions of nucleotide  
10 residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 29

The translation product of this gene has been shown to encode a human brain specific mitochondrial carrier (Genbank Accession No. gil3851540|gb|AAD04346.1|  
15 (AF078544); all references available through this accession are hereby incorporated herein by reference) which shares sequence homology with the human body weight disorder associated gene C5 product which is known to be differentially expressed in obese compared to lean mice (See GeneSeq Accession No. R91281). Based on the sequence similarity, the translation product of this gene is expected to share at least  
20 some biological activities with mitochondrial carriers proteins. Such activities are known in the art, some of which are described in Sanchis et al, J. Biol. Chem. 273:34611-34615 (1998), incorporated herein by reference.

Included in this invention as preferred domains are mitochondrial energy transfer protein (METP) domains, which were identified using the ProSite analysis  
25 tool (Swiss Institute of Bioinformatics). Structurally, members of the family of mitochondrial energy transfer proteins consist of three tandem repeats of a domain of approximately one hundred residues. Each of these domains contains two transmembrane regions. As a signature pattern, we selected one of the most conserved regions in the repeated domain, located just after the first transmembrane region. To  
30 detect this widespread family of proteins, a consensus sequence was developed that contains the most conserved regions in the repeated domain. The consensus pattern is as follows: P.[DE].[LIVAT][RK].[LRH][LIVMFY][QMAIGV].

Preferred polypeptides of the invention comprise the following amino acid sequences: PVDLTKTRLQ (SEQ ID NO: 309) and PTDVLKIRMQ (SEQ ID NO: 310). Polynucleotides encoding these polypeptides are also provided.

Further preferred are polypeptides comprising the METP domains of the sequence listed above, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of the sequence referenced in Table I for this gene. The additional contiguous amino acid residues is N-terminal or C-terminal to the METP domain. Alternatively, the additional contiguous amino acid residues is both N-terminal and C-terminal to the METP domain, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. The above preferred polypeptide domain is characteristic of a signature specific to mitochondrial energy transfer proteins.

The gene encoding the disclosed cDNA is believed to reside on chromosome X. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome X.

This gene is expressed primarily in brain, and to a lesser extent, in T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological and behavioral disorders and immune disorders and/or obesity. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive, immune, and nervous systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, neural, or cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 152 as residues: Gln-189 to Gly-195. Polynucleotides encoding said polypeptides are also provided.

5 The tissue distribution in brain and homology to mitochondrial carrier proteins indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to  
10 the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression,  
15 panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation,  
20 neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show  
25 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:39 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
30 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1416 of SEQ ID NO:39, b is an integer of 15 to 1430, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 30

Preferred polypeptides of the invention comprise the following amino acid sequence: MTFGSTISPTSTHASPSLG FCCSWLLEDLEEQLYCSAFEEAALTR  
RICNPTSCWLPLDMELLHRQVLALQTQRVLLGMWLRRAWDTWVSPRRVAP  
GSRCLLTASHPCTEKRRKASAXQRNLGYPLAMLCLLVLTGLSVLIVAIHILEL  
10 LIDEAAMP RGMQGTSLGQVSFSKLG SFGAVIQVVLIFYLMVSSVVG FYSSPLF  
RSLRPRWHD T AMTQIIGNCVCLLV LSSALPVFSRTLGLTRFDLLGDFGRFNWL  
GNFYIVFLYNAAFAGLTTLCLVKTFTA AVRAELIRAFGLDRLPLPVSGFPQAS  
RKTQHQ (SEQ ID NO: 311). Polynucleotides encoding such polypeptides are also provided.

15 This gene is expressed primarily in immune system tissues (e.g. resting T-cells, primary dendritic cells, and neutrophils, apoptotic T-cells) and umbilical vein. This gene is expressed to a lesser extent in the gastrointestinal tissue (e.g. small intestine, colon), brain (e.g. cerebellum, frontal cortex), aorta endothelial cells, skin tumor, embryonic tissue, thymus, and cancers (e.g. cheek, breast, synovial).

20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and immune disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for  
25 differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system and gastrointestinal tract expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, gastrointestinal, cancerous and wounded tissues) or bodily fluids (e.g., amniotic, serum, plasma, urine, synovial fluid and  
30 spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.



Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 153 as residues: Asp-21 to Ser-29. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune cells (e.g. T-cells, dendritic cells, 5 neutrophils) indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the 10 proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene 15 product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and 20 tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits 25 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The tissue distribution in skin tumors and cancerous tissue (e.g. cheek, breast, synovial sarcoma) indicates that polynucleotides and polypeptides corresponding to this gene are useful for the 30 diagnosis and treatment of cancer and other proliferative disorders. Expression in cellular sources such as embryonic tissue marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Additionally, the


expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. In such an event, this gene is useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from  
5 early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or  
10 immunotherapy targets for the above listed tissues. The tissue distribution in cerebellum and frontal cortex indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative  
15 Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction,  
20 aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.  
25 Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional  
30 supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2089 of SEQ ID NO:40, b is an integer of 15 to 2103, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 31**

The polypeptide of this gene has been determined to have a zinc finger (Zinc finger, C2H2 type) domain at about amino acid position 16-50 of the amino acid sequence referenced in Table 1 for this gene. Therefore,

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: LCVCLVYL~~CMYGVCLCVIVCVSGVSLCLYVWGV~~SVC DCVSVFMCVCLCVIFCVYGKPRTEHYHSPHLAKQKAFREMCGRHDVSAAGIF QSYV (SEQ ID NO: 312). Polynucleotides encoding these polypeptides are also provided. 'Zinc finger' domains are nucleic acid-binding protein structures first identified in the *Xenopus* transcription factor TFI~~II~~A. These domains have since been found in numerous nucleic acid-binding proteins. A zinc finger domain is composed of 25 to 30 amino-acid residues. There are two cysteine or histidine residues at both extremities of the domain, which are involved in the tetrahedral coordination of a zinc atom. It has been proposed that such a domain interacts with about five nucleotides. A schematic representation of a zinc finger domain is shown below:



Many classes of zinc fingers are characterized according to the number and positions of the histidine and cysteine residues involved in the zinc atom coordination. In the first class to be characterized, called C2H2, the first pair of zinc coordinating residues are cysteines, while the second pair are histidines. A number of experimental reports have demonstrated the zinc- dependent DNA or RNA binding property of some members of this class. Some of the proteins known to include C2H2-type zinc fingers are listed below. We have indicated, between brackets, the number of zinc finger regions found in each of these proteins; a '+' symbol indicates that only partial sequence data is available and that additional finger domains is present.

This gene is expressed primarily in salivary gland.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, salivary gland related diseases, diseases of the mouth, and other digestive disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., saliva, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 154 as residues: Gly-46 to His-54. Polynucleotides encoding said polypeptides are also provided.

5 The tissue distribution indicates that the protein products of this gene are useful for diagnosis and treatment of salivary gland related diseases (mumps, calculi formation in ducts, sarcoidosis, facial palsy, tumors, Sjogrens Syndrome) and other digestive system disorders. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a  
10 nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
15 related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
20 formula of a-b, where a is any integer between 1 to 2335 of SEQ ID NO:41, b is an integer of 15 to 2349, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 32**

25 This gene is expressed primarily in fetal tissue (e.g. spleen, liver, brain), cancerous tissues (e.g. ovarian, colon, stomach, parathyroid) and to a lesser extent in immune cells and tissue (e.g. B-cells, T-cells, bone marrow), and reproductive organs.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
30 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer, particularly of the colon and ovaries, disorders of the developing fetus, neurodegenerative conditions, and immune system disorders.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is  
5 routinely detected in certain tissues or cell types (e.g., immune, reproductive, neural, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 155 as residues: Lys-35 to Lys-47. Polynucleotides encoding said polypeptides are also provided.

The expression of this gene within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular  
15 division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern  
20 formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of  
25 potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types  
30 of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in

modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The tissue distribution in immune cells (such as T-cells and B-cells) and immune tissues (bone marrow) indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The tissue distribution in parathyroid indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for

the detection, treatment, and/or prevention of Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Additionally, the tissue distribution in brain tissue indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or



more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1545 of SEQ ID NO:42, b is an integer of 15 to 1559, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

5

### FEATURES OF PROTEIN ENCODED BY GENE NO: 33

When tested against U937 Myeloid cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates myeloid cells through the Jak-STAT signal transduction pathway. The gamma  
10 activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and  
15 differentiation of cells.

This gene is expressed primarily in skin tumors.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
20 not limited to, skin disorders, particularly skin cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skin, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell  
25 types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 156 as residues: Pro-38 to Gly-44, Phe-56 to Thr-64. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in skin indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders including congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. 5 keratoses, Bowen's Disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, 10 pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. Moreover, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm). Protein, as well as, antibodies directed against the 15 protein may show utility as a tumor marker and immunotherapy targets for the above listed tumors and tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of 20 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1752 of SEQ ID NO:43, b is an 25 integer of 15 to 1766, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 34**

The translation product of this gene shares sequence homology with mitogen- 30 induced prostate carcinoma (mouse) which is thought to be important in the etiology of cancer. In this respect, this gene is mitogen-induced and/or involved in cell proliferation.

Preferred polypeptides of the invention comprise the following amino acid sequence: GHMPYGWLTEIRAVYPAFDKNNPSNKLVSTSNTVTAAHIKKF  
TFVCMALSLTLCFVMFWTPNVSEKILIDIIGVDFAFaelcVVPLRIFSFFPVPVT  
VRAHLTGWLMTLKKTFVLAPSSVLRIIVLIASLVVLPYLGVBHGATLGVGSLLA  
5 GFVGESTMVAIAACYVYRKQKKK MENESATEGEDSAMTDMPTTEEVTDIVE  
MREENE (SEQ ID NO: 313) and/or QVVFVAILLHSHLECREPLLIPILSLYMGA  
LVRCTTLCLGYYKNIHDIIPDRSGPELGGDATIRKMLSFWWPLALILATQRI SR  
PIVNLFVSRDLGGSSAATEAVAILTATYPV (SEQ ID NO: 314). Polynucleotides  
encoding these polypeptides are also provided.

10 The gene encoding the disclosed cDNA is believed to reside on chromosome  
5. Accordingly, polynucleotides related to this invention are useful as a marker in  
linkage analysis for chromosome 5.

This gene is expressed primarily in early infant and adult brain, retina, fetal  
tissue (e.g., liver, spleen, whole embryo) and to a lesser extent in immune cells (e.g.,  
15 monocytes and T-cells), colon, and parathyroid tumor tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
not limited to, cancers, disorders of the immune system and nervous system.  
20 Similarly, polypeptides and antibodies directed to these polypeptides are useful in  
providing immunological probes for differential identification of the tissue(s) or cell  
type(s). For a number of disorders of the above tissues or cells, particularly of the  
metabolic system (cancers), expression of this gene at significantly higher or lower  
levels is routinely detected in certain tissues or cell types (e.g., immune, neural,  
25 cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial  
fluid and spinal fluid) or another tissue or cell sample taken from an individual having  
such a disorder, relative to the standard gene expression level, i.e., the expression  
level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
30 epitopes shown in SEQ ID NO: 157 as residues: Arg-122 to Ser-139, Met-144 to Glu-  
149. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution and homology to mitogen induced prostate carcinoma (mouse) indicates that polynucleotides and polypeptides corresponding to this gene are useful for the study and treatment of cancers, including but not limited to the colon, parathyroid, and adrenal glands. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The tissue distribution in immune cells (T-cells, monocytes) indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or

activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

5           Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, 10 such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that 15 influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are 20 useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, 25 Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, 30 and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to  
5 identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
10 related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
15 formula of a-b, where a is any integer between 1 to 2558 of SEQ ID NO:44, b is an integer of 15 to 2572, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 35**

20 This gene is expressed primarily in adult pulmonary tissue, umbilical vein, prostate, and fetal tissue (e.g., heart).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
25 not limited to, diseases of the pulmonary system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the pulmonary system, expression of this gene at significantly higher or lower levels is routinely detected in  
30 certain tissues or cell types (e.g., pulmonary, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the

standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 158 as residues: Arg-45 to Gly-51, Glu-75 to Asn-81.

5 Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in pulmonary tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the detection and treatment of disorders associated with developing lungs, particularly in premature infants where the lungs are the last tissues to develop. Additionally, the tissue distribution indicates  
10 that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and intervention of lung tumors, since the gene is involved in the regulation of cell division, particularly since it is expressed in fetal tissue. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may  
15 show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

20 Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have  
25 applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue  
30 differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in

proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 512 of SEQ ID NO:45, b is an integer of 15 to 526, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 36**

This gene is expressed primarily in adipose tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, fat metabolism. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the metabolic system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,



the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 159 as residues: Pro-96 to Ser-106. Polynucleotides  
5 encoding said polypeptides are also provided.

The tissue distribution in adipose tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of obesity and other metabolic and endocrine conditions or disorders. Furthermore, the protein product of this gene may show utility in ameliorating conditions which occur  
10 secondary to aberrant fatty-acid metabolism (e.g. aberrant myelin sheath development), either directly or indirectly. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
15 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
20 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1018 of SEQ ID NO:46, b is an integer of 15 to 1032, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

## 25 **FEATURES OF PROTEIN ENCODED BY GENE NO: 37**

This gene is expressed primarily in adult brain tissue, testes, placenta, kidney, infant and fetal tissue (e.g., liver, spleen, lung) and to a lesser extent in immune cells (e.g., T-cells and neutrophils) and in cancerous tissues (e.g., ovarian tumor, Hodgekins lymphoma, pancreas, T-cell).

30 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, CNS disorders, disorders of the testicles, cancer, particularly ovarian, pancreatic, T-cell, and Hodgekin's lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain, CNS, and testes expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, urogenital, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders"

and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The tissue distribution indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,

such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's

5 Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Additionally, the

10 tissue distribution in testes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to

15 identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play

20 related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement.

25 Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:47 and may have been publicly available prior to conception of

30 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or

more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2666 of SEQ ID NO:47, b is an integer of 15 to 2680, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 38

When tested against fibroblast cell lines, supernatants removed from cells containing this gene activated the EGR1 assay. Thus, it is likely that this gene activates fibroblast cells through a signal transduction pathway. Early growth response 1 (EGR1) is a promoter associated with certain genes that induces various tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation.

This gene is expressed primarily in endometrial stromal cells, endometrial tumors, keratinocytes, fetal tissue (e.g. liver, spleen) and to a lesser extent in endothelial cells and immune cells (e.g., T-cells).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, endometrial carcinoma and immune cells disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in the endometrium indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating female infertility. The protein product is likely involved in preparation of the endometrium of implantation and could be administered either topically or orally. Alternatively, this gene could be

transfected in gene-replacement treatments into the cells of the endometrium and the protein products could be produced. Similarly, these treatments could be performed during artificial insemination for the purpose of increasing the likelihood of implantation and development of a healthy embryo. In both cases this gene or its gene product could be administered at later stages of pregnancy to promote healthy development of the endometrium. Additionally, polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of endometrial carcinoma. The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of cancer and other proliferative disorders. Expression within embryonic tissue and other cellular sources marked by proliferating cells indicates that this protein may play a role in the regulation of cellular division. Additionally, the expression in hematopoietic cells and tissues indicates that this protein may play a role in the proliferation, differentiation, and/or survival of hematopoietic cell lineages. In such an event, this gene is useful in the treatment of lymphoproliferative disorders, and in the maintenance and differentiation of various hematopoietic lineages from early hematopoietic stem and committed progenitor cells. Similarly, embryonic development also involves decisions involving cell differentiation and/or apoptosis in pattern formation. Thus this protein may also be involved in apoptosis or tissue differentiation and could again be useful in cancer therapy. The tissue distribution in immune cells such as helper T-cells indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such

as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The tissue distribution in keratinocytes indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", "infectious disease", and "Regeneration" sections below, in Example 11, 19, and 20, and elsewhere herein. Briefly, the protein is useful in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's Disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm). Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders (i.e., arthritis, trauma, tendonitis, chondromalacia and inflammation, etc.), autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and

chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents  
5 that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
10 related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
15 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1716 of SEQ ID NO:48, b is an integer of 15 to 1730, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 39**

20 This gene is expressed primarily in LNCAP cells (prostate cell line) and retina derived N2b5HR cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
25 not limited to, prostate cancer and eye disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male urogenital and reproductive system expression of this gene at significantly higher or lower levels is  
30 routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative



to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 162 as residues: Asn-50 to Ser-57. Polynucleotides  
5 encoding said polypeptides are also provided.

The expression in prostate may indicate the gene or its products can be used in the disorders of the prostate, including inflammatory disorders, such as chronic prostatitis, granulomatous prostatitis and malacoplakia, prostatic hyperplasia and prostate neoplastic disorders, including adenocarcinoma, transitional cell carcinomas,  
10 ductal carcinomas, squamous cell carcinomas, or as hormones or factors with systemic or reproductive functions. The tissue distribution in retina indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and/or detection of eye disorders including blindness, color blindness, impaired vision, short and long sightedness, retinitis pigmentosa, retinitis proliferans,  
15 and retinoblastoma, retinochoroiditis, retinopathy and retinoschisis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or  
20 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
25 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1261 of SEQ ID NO:49, b is an integer of 15 to 1275, where both a and b correspond to the positions of nucleotide  
30 residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 40**

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the  
5 following amino acid sequence: RCCCRGCSCRARLCPPARSTAVAPECRGAHPSR  
AMRPGTALQAVLLAVLLVGLRAATGRLLSGQPVCRRGTQRPCYKVIYFHD  
TSRRLNFEEAKEACRRGWRPASQHRVLKMNRN (SEQ ID NO: 315).

Polynucleotides encoding these polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following  
10 amino acid sequence: MRPGTALQAVLLAVLLVGLRAATGRLLSGQPVCRRG  
TQRPCYKVIYFHDTSRRLNFEEAKEACRRGWRPASQHRVLKMNRN (SEQ ID  
NO: 316). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in smooth muscle and human thyroid and to a lesser extent in amniotic cells and human endometrial stromal cells-treated with  
15 progesterone.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, thyroid disorders. Similarly, polypeptides and antibodies directed to  
20 these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endocrine system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine,  
25 synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
30 epitopes shown in SEQ ID NO: 163 as residues: Ser-75 to Leu-81. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of endocrine disorders of the thyroid.

Many polynucleotide sequences, such as EST sequences, are publicly  
5 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:50 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
10 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1748 of SEQ ID NO:50, b is an integer of 15 to 1762, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

#### 15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 41**

This gene is expressed primarily in human testes tumor and bone marrow.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
20 not limited to, disorders of the testicles including but not limited to testicular cancer and immune system disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the male reproductive system and immune system  
25 expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or  
30 bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 164 as residues: His-31 to Gly-41. Polynucleotides encoding said polypeptides are also provided.

5 The tissue distribution in testes, particularly testicular tumors, indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. The tissue distribution in bone marrow indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

25 Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatou's Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity

disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits

5 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their

10 interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

15 related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

20 formula of a-b, where a is any integer between 1 to 2045 of SEQ ID NO:51, b is an integer of 15 to 2059, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 42**

25 The translation product of this gene shares sequence homology with protocadherins, which are related to cadherin, and possess cell adhesive ability. Cadherins are glycosylated integral membrane proteins that are involved in cell-cell adhesion.

This gene is expressed primarily in brain (infant, adult frontal lobe, manic

30 depression tissue) and to a lesser extent in epididymus, healing groin wounds, ovary, adipocytes, and fetal tissue (e.g., kidney and retina).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurodegenerative disorders, impaired male and female fertility,  
5 developmental disorders, fibrosis, and manic depression. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the nervous system and reproductive system expression of this gene at significantly higher or lower levels is  
10 routinely detected in certain tissues or cell types (e.g., neural, reproductive, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

15 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 165 as residues: Val-35 to Lys-41, Ser-68 to Gln-73, Glu-88 to Glu-93, Arg-156 to Gly-163, Ala-199 to Gly-206, Asp-216 to Ser-226, Thr-249 to Asn-254, Asp-339 to Pro-345, Ile-370 to Gly-379, Pro-429 to Glu-434, Arg-461 to Pro-466, Ala-475 to Thr-482, Pro-585 to Gly-593, Glu-631 to Gln-639, Pro-  
20 674 to Pro-682, Gln-715 to Gly-720, Ser-736 to Arg-742. Polynucleotides encoding said polypeptides are also provided.

BLAST analysis reveals high homology to protocadherin sequences. These sequences are related to cadherin, and possess cell adhesive ability. Such proteins may have regulatory functions in the cell, as well as the cell-cell adhesive properties.  
25 Antibodies produced against these sequences are useful for modulating the binding activity of these protocadherins, and can be used therapeutically. The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses  
30 are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease,

Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive  
5 disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation,  
10 neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The tissue distribution in epididymus indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment  
15 of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues  
20 of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Moreover, the expression within fetal tissue (e.g., kidney and retina) and other cellular sources marked by proliferating cells indicates this  
25 protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including blindness, cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions  
30 involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent

of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3268 of SEQ ID NO:52, b is an integer of 15 to 3282, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

### **FEATURES OF PROTEIN ENCODED BY GENE NO: 43**

Preferred polypeptides of the invention comprise the following amino acid sequence:



IRHEQQGEEDDEHARPLAESLLLAIADLLFCPDFTVQSHRRSTVDSAEDVHSL  
 DSCEYTWEAGVGFAHSPQPNYIHDNMNRMELLKLLLTCFSEAMYLPPAPESGS  
 TNPWVQFFCSTENRHALPLFTSLLNTVCA YDPVGYGIPYNHLLFSDYREPLVE  
 EAAQVLIVTLDHDSASSASPTVDGTTTGTAMDDADPPGPENLFVNYLSRIHRE  
 5 EDFQFILKGIARLLSNPLLQTYLPNSTKKDPVPPGAASSLLEALRLQQEIPLLRA  
 EEQRRPRHPCPHPLLQRCPPGRSV (SEQ ID NO: 317). Polynucleotides encoding  
 such polypeptides are also provided.

This gene is expressed primarily in brain, breast, breast cancer tissue and to a  
 lesser extent in epididymus, amniotic cells, and embryo tissue.

10 Therefore, polynucleotides and polypeptides of the invention are useful as  
 reagents for differential identification of the tissue(s) or cell type(s) present in a  
 biological sample and for diagnosis of diseases and conditions which include, but are  
 not limited to, neurodegenerative disorders, impaired CNS function, male sterility,  
 and breast cancer. Similarly, polypeptides and antibodies directed to these  
 15 polypeptides are useful in providing immunological probes for differential  
 identification of the tissue(s) or cell type(s). For a number of disorders of the above  
 tissues or cells, particularly of the nervous and reproductive systems, expression of  
 this gene at significantly higher or lower levels is routinely detected in certain tissues  
 or cell types (e.g., neural, male reproductive, cancerous and wounded tissues) or  
 20 bodily fluids (e.g., amniotic, serum, plasma, urine, synovial fluid and spinal fluid) or  
 another tissue or cell sample taken from an individual having such a disorder, relative  
 to the standard gene expression level, i.e., the expression level in healthy tissue or  
 bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
 25 epitopes shown in SEQ ID NO: 166 as residues: Pro-22 to Pro-31, Ser-38 to His-43,  
 Asp-74 to Leu-79, Asp-113 to Glu-121, Leu-157 to Val-166, Ala-189 to Arg-196,  
 Gln-206 to Arg-211. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain, particularly in the cerebellum, indicates  
 polynucleotides and polypeptides corresponding to this gene are useful for the  
 30 detection, treatment, and/or prevention of neurodegenerative disease states, behavioral  
 disorders, or inflammatory conditions. Representative uses are described in the  
 "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11,

15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal  
5 cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in  
10 normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The tissue distribution in epididymus indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of  
15 conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment  
20 and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few  
25 possible target indications. The expression in the breast tissue may indicate its uses in the diagnosis and/or treatment of breast neoplasia and breast cancers, such as fibroadenoma, papillary carcinoma, ductal carcinoma, Paget's Disease, medullary carcinoma, mucinous carcinoma, tubular carcinoma, secretory carcinoma and apocrine carcinoma, as well as juvenile hypertrophy and gynecomastia, mastitis and  
30 abscess, duct ectasia, fat necrosis and fibrocystic diseases. Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may

show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions  
5 involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of  
10 potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types  
15 of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new  
20 insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or  
25 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
30 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1846 of SEQ ID NO:53, b is an integer of 15 to 1860, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 44

Contact of cells with supernatant expressing the product of this gene increases the permeability of monocytes to calcium. Thus, it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product of this gene binds a receptor on the surface of the monocyte cell. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating monocyte cells.

This gene is expressed primarily in CD34 positive cells derived from human cord blood.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic disorders; immune dysfunction; defects in hematopoietic stem and progenitor cells; susceptibility to chemotherapy and irradiation. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 167 as residues: Ala-38 to Leu-59, Ala-63 to Thr-71, Lys-82 to Leu-91, Glu-97 to Ser-107, Gln-143 to Ala-149, Ile-153 to Leu-158, Ser-169 to Arg-182. Polynucleotides encoding said polypeptides are also provided.

Elevated expression of this gene product in CD34 positive hematopoietic cells indicates that it is expressed by early stem and progenitor cells of the hematopoietic lineages. Therefore, this may represent a soluble factor that is able to control the survival, proliferation, differentiation, or activation of all hematopoietic lineages, including stem and progenitor cells. Thus, it could be quite useful, for example, in ex vivo expansion of stem cell numbers for hematopoietic disorders or for cancer patients. Alternately, it may represent a factor that influences the hematopoietic microenvironment by affecting stromal cells that release other factors required for hematopoietic development. Additionally, the tissue distribution in CD34 positive cells also indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of hematopoietic related disorders such as anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the uses include bone marrow cell ex-vivo culture, bone marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 756 of SEQ ID NO:54, b is an integer of 15 to 770, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 45**

This gene is expressed primarily in breast and 12-week old human embryos and to a lesser extent in stomach cancer and liver.

5 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, breast cancer; stomach cancer; embryonic defects; hepatic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in  
10 providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive and endocrine systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal  
15 fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution indicates that the protein products of this gene are useful for the diagnosis and/or treatment of a variety of disorders. Elevated expression  
20 of this gene product in stomach cancer indicates it is useful as a marker or therapeutic target for stomach cancer. Alternately, expression in breast tissue is influenced by the presence or absence of breast cancer tissue, and may thus also serve as a diagnostic marker for this cancer as well. Expression in the developing embryo may correlate with the normal development of human embryos, and expression in the liver is  
25 involved in the regulation of normal liver function and/or liver regeneration.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
30 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1079 of SEQ ID NO:55, b is an integer of 15 to 1093, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 46

This gene is expressed primarily in human hypothalamus derived from a patient with schizophrenia.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
10 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, schizophrenia; neurological disorders; impaired nervous system function. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,  
15 particularly of the nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression  
20 level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 169 as residues: Glu-34 to Trp-39. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain, particularly in the hypothalamus, indicates  
25 polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the  
30 detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal

cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated  
 5 expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity,  
 10 to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
 15 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
 20 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 618 of SEQ ID NO:56, b is an integer of 15 to 632, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

## 25 **FEATURES OF PROTEIN ENCODED BY GENE NO: 47**

The translation product of this gene shares sequence homology with human lecithin-cholesterol acyltransferase (LCAT), which catalyses the transfer of fatty acid from the sn-2 position of lecithin to the free hydroxyl group of cholesterol. Preferred polypeptides of the invention comprise the following amino acid sequence: RLVYN  
 30 KTSRATQFPDGVDRVPGFGKTSLEFLDPSKSSVGSYFHTMVESLVGWGYT  
 RGEDVRGAPYDWRRAPNENGPYFLALREMIEEMYQLYGGPVVLVAHSMGN  
 MYTLYFLQRQPQAWKDKYIRAFVSLGAPWGGVAKTLRVLASGDNNRIPVIG



PLKIREQQRSAVSTSWLLPYNYSPEKVFVQTPTINYTLRDYRKFFQDIGFE  
DGWLMRQDTEGLVEATMPPGVQLHCLYGTGVPTPDSFYYESFPDRDPKICFG  
DGDGTVNLKSALQCQAWQSRQEHQVLLQELPGSEHIEMLANATTLAYLKRV  
LLGP (SEQ ID NO: 318). Polynucleotides encoding such polypeptides are also

5 provided.

This gene is expressed primarily in osteoblasts & dendritic cells and to a lesser extent in muscle and other hematopoietic cell lineages.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
10 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, hematopoietic disorders; immune dysfunction; osteoporosis; osteopetrosis; muscle degeneration. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
15 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the skeletal and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e.,  
20 the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 170 as residues: Cys-65 to Ser-71. Polynucleotides encoding said polypeptides are also provided.

25 The tissue distribution and homology to lecithin-cholesterol acyltransferase (LCAT) indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of a variety of disorders. For example, arteriosclerosis is a pathological condition of mammals characterised by the accumulation of cholesterol in the arteries, which leads to heart disease, strokes, heart  
30 attacks and peripheral vascular disease. The enzyme could be used in a novel method of treating arteriosclerosis, which involves increasing the level of LCAT activity, which then causes a decrease in the accumulation of cholesterol. The method and the

products can be used for the prophylaxis and treatment of atherosclerosis, and associated heart disease, myocardial infarction, stroke and peripheral vascular disease, as well as individuals suffering from Fish Eye Syndrome (caused by LCAT deficiency) or Classic LCAT Deficiency Syndrome. Alternately, elevated expression  
5 of this gene product in osteoblasts and hematopoietic cell lineages indicates that it may play additional roles in bone turnover, regulation of immune system function, and muscular function.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
10 related to SEQ ID NO:57 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
15 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2673 of SEQ ID NO:57, b is an integer of 15 to 2687, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 48**

20 When tested against HELA epithelial cell lines, supernatants removed from cells containing this gene activated the GAS assay. Thus, it is likely that this gene activates epithelial cells through the Jak-STAT signal transduction pathway. The gamma activating sequence (GAS) is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a  
25 large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in adult brain, infant brain, fibroblasts,  
30 embryonic and fetal tissue (e.g., spleen, liver), placenta and to a lesser extent in endocrine organs, cancerous colon and breast.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, dementia, epilepsy, schizophrenia, and developmental abnormalities.

5 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the neural system, endocrine system, and during development, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types  
10 (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

15 The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly,  
20 the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive  
25 compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation,  
30 neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. In addition, the expression of this gene product in synovium (synovial sarcoma) would suggest a role in the detection and treatment of disorders and

conditions afflicting the skeletal system, in particular osteoporosis, bone cancer, connective tissue disorders (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation). The protein is also useful in the diagnosis or treatment of various autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, and

5 dermatomyositis), dwarfism, spinal deformation, joint abnormalities, and chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid, etc.). The tissue distribution in endocrine tissues indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or

10 prevention of various endocrine disorders and cancers. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the

15 pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism) , hypothalamus, and testes. Additionally, the expression within fetal tissue, cancerous colon and breast, and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular

20 division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern

25 formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of

30 potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the

polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of

5 degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue

10 markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly

15 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or

20 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 605 of SEQ ID NO:58, b is an integer of 15 to 619, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a + 14.

## 25 **FEATURES OF PROTEIN ENCODED BY GENE NO: 49**

Preferred polypeptides of the invention comprise the following amino acid sequence or a subfragment thereof: MNKEDKVWNDCKGVNKLTNLEEQYIILIFQ NGLDPPANMVFESIINEIGIKNNISNFFAKIPFEEANGRLVACTRITYEESIKGSC GQKENKIKTVSFESKIQLRSKQEFQFFDEEEETGENHTIFIGPVEKLIVYPPPPA

30 KGGISVTNEDLHCLNEGEFLNDVIIDFYLYLVLEKLKKEDADRIHIFSSFFYK RLNQRERRNHETTNLISIQQKRHGRVKTWTRHVDIFEKDFIFVPLNEAAHWFL AVVCFPGLEKPKYEPNPHYHENA VIQKCSTVEDSCISSASEMESCSQNSSAK

PVIKKMLNKKHCIAVIDSNPGQEESDPYKRNICSVKYSVKKINHTASENEEF  
NKGESTSQKS (SEQ ID NO: 319). Polynucleotides encoding such polypeptides are  
also provided.

5 This gene is expressed primarily in fetal tissue, stomach, brain, endometrial  
cells, and bone and to a lesser extent in prostate, retina, adipocytes, smooth muscle,  
and tumors of the endometrium, ovaries, and parathyroid.

Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
10 not limited to, disorders of the endocrine system, ulcers, stomach cancer, epilepsy,  
schizophrenia, dementia, bone growth, developmental disorders and resorption.  
Similarly, polypeptides and antibodies directed to these polypeptides are useful in  
providing immunological probes for differential identification of the tissue(s) or cell  
type(s). For a number of disorders of the above tissues or cells, particularly of the  
15 digestive system and neural systems expression of this gene at significantly higher or  
lower levels is routinely detected in certain tissues or cell types (e.g., neural,  
endocrine system, cancerous and wounded tissues) or bodily fluids (e.g., serum,  
plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken  
from an individual having such a disorder, relative to the standard gene expression  
20 level, i.e., the expression level in healthy tissue or bodily fluid from an individual not  
having the disorder.

The tissue distribution in brain indicates polynucleotides and polypeptides  
corresponding to this gene are useful for the detection, treatment, and/or prevention of  
neurodegenerative disease states, behavioral disorders, or inflammatory conditions.  
25 Representative uses are described in the "Regeneration" and "Hyperproliferative  
Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly,  
the uses include, but are not limited to the detection, treatment, and/or prevention of  
Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome,  
meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia,  
30 trauma, congenital malformations, spinal cord injuries, ischemia and infarction,  
aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive  
compulsive disorder, depression, panic disorder, learning disabilities, ALS,

psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Expression of this gene product in stomach tissue indicates involvement in digestion, processing, and elimination of food, as well as a potential role for this gene as a diagnostic marker or causative agent in the development of stomach cancer, and cancer in general. The expression within embryonic, fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. The tissue distribution in parathyroid tumor indicates polynucleotides and polypeptides corresponding to this

gene are useful for the detection, treatment, and/or prevention of various endocrine disorders and cancers. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for

5 the detection, treatment, and/or prevention of Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. The tissue distribution in testes indicates that polynucleotides and

10 polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male

15 contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to

20 identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

25 related to SEQ ID NO:59 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

30 formula of a-b, where a is any integer between 1 to 1364 of SEQ ID NO:59, b is an integer of 15 to 1378, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:59, and where b is greater than or equal to a + 14.



**FEATURES OF PROTEIN ENCODED BY GENE NO: 50**

The translation product of this gene shares good protein homology with Xenopus NaDC-2 gene and a rabbit renal sodium/dicarboxylate cotransporter. The translation product of this gene also shares good homology with a rat placental protein which is a sodium-coupled high affinity dicarboxylate transporter. Therefore, it is likely that the translated product encoded by this gene shares similar biological activity.

This gene is expressed primarily in the placenta and colon adenocarcinoma. Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental abnormalities as well as failure to thrive anomalies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the female reproductive system and colon, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., amniotic, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 173 as residues: Lys-166 to Gly-181. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in human placenta and the shared homology of this translation product to a rat placental protein indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of disorders of the placenta. Specific expression within the placenta indicates that this gene product may play a role in the proper establishment and maintenance of placental function. Alternately, this gene product is produced by the placenta and then transported to the embryo, where it may play a crucial role in the development and/or

survival of the developing embryo or fetus. Expression of this gene product in a vascular-rich tissue such as the placenta also indicates that this gene product is produced more generally in endothelial cells or within the circulation. In such instances, it may play more generalized roles in vascular function, such as in  
5 angiogenesis. It may also be produced in the vasculature and have effects on other cells within the circulation, such as hematopoietic cells. It may serve to promote the proliferation, survival, activation, and/or differentiation of hematopoietic cells, as well as other cells throughout the body. The tissue distribution in colon tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the  
10 diagnosis and/or treatment of disorders involving the colon. Expression of this gene product in colon tissue indicates involvement in digestion, processing, and elimination of food, as well as a potential role for this gene as a diagnostic marker or causative agent in the development of colon cancer, and cancer in general.

Many polynucleotide sequences, such as EST sequences, are publicly  
15 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:60 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
20 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1112 of SEQ ID NO:60, b is an integer of 15 to 1126, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:60, and where b is greater than or equal to a + 14.

## 25 **FEATURES OF PROTEIN ENCODED BY GENE NO: 51**

This gene is expressed primarily in the spinal cord.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
30 not limited to, paralysis, neurologic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of

the above tissues or cells, particularly of the nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken  
5 from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in spinal cord indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or  
10 prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,  
15 Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including  
20 disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or  
25 survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:61 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
5 formula of a-b, where a is any integer between 1 to 2064 of SEQ ID NO:61, b is an integer of 15 to 2078, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:61, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 52**

10 This gene is expressed primarily in keratinocytes, brain, fetal tissues, pericardium, stomach, and cancerous tissues (e.g., stomach, adrenals, parathyroid, germ cell, colon, breast).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
15 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skin disorders, neurodegenerative and developmental disorders, heart disease, and cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above  
20 tissues or cells, particularly of the cardiovascular and gastrointestinal systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the  
25 standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain indicates polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions.  
30 Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of

Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive  
5 compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation,  
10 neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. The tissue distribution in keratinocytes indicates polynucleotides and polypeptides corresponding to this gene are useful for the treatment, diagnosis, and/or prevention of various skin disorders. Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", "infectious disease", and  
15 "Regeneration" sections below, in Example 11, 19, and 20, and elsewhere herein. Briefly, the protein is useful in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's Disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's Disease, mycosis  
20 fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may  
25 predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm). Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders (i.e., arthritis, trauma, tendonitis, chondromalacia and  
30 inflammation, etc.), autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita,

5 familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). The expression within fetal tissue (e.g., spleen and liver) and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

10       Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Additionally, the tissue distribution in the pericardium of the heart indicates that the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the

protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
5 related to SEQ ID NO:62 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
10 formula of a-b, where a is any integer between 1 to 748 of SEQ ID NO:62, b is an integer of 15 to 762, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:62, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 53**

15 This gene is expressed primarily in the brain and in cartilage and to a lesser extent in the retina, activated T-cells, pineal gland, the lungs, and in synovial sarcoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neurological diseases, such as epilepsy and dementia, osteoarthritis, retinopathies, hematopoietic diseases, emphysema, and lung cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For  
25 a number of disorders of the above tissues or cells, particularly of the neurologic system, cartilage and musculature, vision, the hematopoietic system, and the pulmonary system expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, immune, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal  
30 fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 176 as residues: Arg-34 to Cys-44. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain indicates polynucleotides and polypeptides  
5 corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of  
10 Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS,  
15 psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or  
20 survival. The tissue distribution in T-cells indicates polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product  
25 indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

30 Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such



as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The expression of this gene product in synovium would suggest a role in the detection and treatment of disorders and conditions afflicting the skeletal system, in particular osteoporosis, bone cancer, connective tissue disorders (e.g. arthritis, trauma, tendonitis, chondromalacia and inflammation). The protein is also useful in the diagnosis or treatment of various autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, and dermatomyositis), dwarfism, spinal deformation, joint abnormalities, and chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid, etc.). Additionally, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have

applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:63 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1080 of SEQ ID NO:63, b is an integer of 15 to 1094, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:63, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 54

This gene is expressed primarily in umbilical vein endothelial cells induced by IL-4.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are

not limited to, angiogenesis, inflammatory disorders, hematopoietic disease.

Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the  
5 angiogenic and hematopoietic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy  
10 tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in endothelial cells indicates polynucleotides and polypeptides corresponding to this gene are useful in the detection, treatment, and/or prevention of vascular conditions, which include, but are not limited to, microvascular disease, vascular leak syndrome, aneurysm, stroke, atherosclerosis, arteriosclerosis, or  
15 embolism. For example, this gene product may represent a soluble factor produced by smooth muscle that regulates the innervation of organs or regulates the survival of neighboring neurons. Likewise, it is involved in controlling the digestive process, and such actions as peristalsis. Similarly, it is involved in controlling the vasculature in areas where smooth muscle surrounds the endothelium of blood vessels. Furthermore,  
20 the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues. The secreted protein can also be  
25 used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere  
30 herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human

immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility);  
5 chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the  
10 corresponding nucleic acid in gene therapy procedures.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:64 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
15 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1347 of SEQ ID NO:64, b is an integer of 15 to 1361, where both a and b correspond to the positions of nucleotide  
20 residues shown in SEQ ID NO:64, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 55**

This gene is expressed primarily in both normal and cancerous pancreas.

Therefore, polynucleotides and polypeptides of the invention are useful as  
25 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diabetes, gastrointestinal disorders, and pancreatic cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For  
30 a number of disorders of the above tissues or cells, particularly of the digestive and blood systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded

tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5           The tissue distribution in pancreas indicates that the protein products of this gene are useful as a therapeutic and/or diagnostic agent for pancreatic disorders and disorders of the endocrine and exocrine system, including but not limited to diabetes, blood disorders, pancreatic cancer, gastrointestinal diseases, hormonal imbalance, autoimmune disorders, cystic fibrosis, pancreatitis, and gallstones. Furthermore, the  
10       protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

15           Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:65 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is  
20       cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 933 of SEQ ID NO:65, b is an integer of 15 to 947, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:65, and where b is greater than or equal to a + 14.

25

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 56**

          The translation product of this gene shares sequence homology with oxidoreductase. Preferred polypeptides of the invention comprise the following amino acid sequence: MSPLSAARAALRVYAVGAAVILAQLLRRCRGGFLEPVXPPRP  
30    DRVAIVTGGTDGIGYSTANTWRDLGMHVIIAGNNSKAKQVVSKIKEETLND  
KVEFLYCDLASMTSIRQFVQKFKMKKIPLHVLINNAGVMMVPQRKTRDGFEE  
HFGLNYLGHFLLTNLLDNLKESGSPGHSARVVTVSSATHYVAELNMDDLQS

SACYSPHAAAYAQSKLALVLFTYHLQRLAAEGSHVTANVVDPGVVNTDXYK  
HVFWATRLAKKLLGWLLFKTPDEGAWTSIYAAVTPELEGVGGRYLYNEKET  
KSLHVTYNQKLQQQLWSKSCMTGVLDVTL (SEQ ID NO: 320). The mature  
form of this protein begins at residue 32. Thus, polypeptides comprising residues 2-  
5 330 and 32-330 of the sequence shown above are also provided. Polynucleotides  
encoding such polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following  
amino acid sequence: MSPLSAARAALRVYAVGAAVILAQLLRRCRGGFLEP  
VXPPRPDRVAIVTGGTDGIG YSTANIWRDLACMLS (SEQ ID NO: 321).  
10 Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in breast cancer cells, osteoclastoma, wilm's  
tumor, thymus stromal cells, and T cell helper I.

Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
15 biological sample and for diagnosis of diseases and conditions which include, but are  
not limited to, cancer, e.g., breast cancer, osteoclastoma, and wilm's tumor. Similarly,  
polypeptides and antibodies directed to these polypeptides are useful in providing  
immunological probes for differential identification of the tissue(s) or cell type(s). For  
a number of disorders of the above tissues or cells, particularly of the immune system,  
20 expression of this gene at significantly higher or lower levels is routinely detected in  
certain tissues or cell types (e.g., reproductive, kidney, immune, hematopoietic, and  
cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, breast milk,  
urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an  
individual having such a disorder, relative to the standard gene expression level, i.e.,  
25 the expression level in healthy tissue or bodily fluid from an individual not having the  
disorder.

The tissue distribution in breast cancer tissue, combined with the homology to  
oxidoreductase indicates that polynucleotides and polypeptides corresponding to this  
gene are useful for diagnosis and treatment of cancer, particularly, breast cancer,  
30 osteoclastoma, and wilm's tumor. This protein may play a role in the regulation of  
cellular division, and may show utility in the diagnosis, treatment, and/or prevention  
of developmental diseases and disorders, including cancer, and other proliferative

conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

5           Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

25           Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:66 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1362 of SEQ ID NO:66, b is an

integer of 15 to 1376, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:66, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 57**

5           This gene is expressed primarily in monocytes, T cell helper II and B cell lymphoma.

          Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
10   not limited to, immune and hematopoietic diseases and/or disorders, particularly B-cell lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or  
15   lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not  
20   having the disorder.

          Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 180 as residues: Asp-30 to Val-40. Polynucleotides encoding said polypeptides are also provided.

          The tissue distribution in monocytes, T cell helper, and B cell lymphoma cells  
25   indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of B cell lymphoma. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or  
30   activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or



other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:67 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2420 of SEQ ID NO:67, b is an integer of 15 to 2434, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:67, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 58**

This gene is expressed primarily in human lung cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, pulmonary diseases and/or disorders, particularly cancers of the lung. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., pulmonary, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, pulmonary lavage, pulmonary surfactant, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 181 as residues: Phe-39 to Asp-45. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in lung cancer tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system disorders such as ARDS, cystic fibrosis, and cancer, particularly lung cancer. This protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of

potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, 5 detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in 10 proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, 15 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:68 and may have been publicly available prior to conception of 20 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1072 of SEQ ID NO:68, b is an 25 integer of 15 to 1086, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:68, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 59**

This gene is expressed primarily in larynx carcinoma and early stage human 30 lung.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a

biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental, gastrointestinal, and pulmonary diseases and/or disorders, particularly larynx carcinoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for

5 differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developmental, gastrointestinal, pulmonary, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, amniotic fluid, pulmonary lavage,

10 sputum, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic

15 epitopes shown in SEQ ID NO: 182 as residues: His-42 to Lys-49. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in larynx carcinoma and early stage human lung indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating immune system disorders such as cancer, particularly larynx carcinoma.

20 This protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell

25 differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of

30 potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the

polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of

5 degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue

10 markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly

15 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:69 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or

20 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1248 of SEQ ID NO:69, b is an integer of 15 to 1262, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:69, and where b is greater than or equal to a + 14.

## 25 **FEATURES OF PROTEIN ENCODED BY GENE NO: 60**

Preferred polypeptides of the invention comprise the following amino acid sequence: MEVTTEDTSRTDVSEPATSGGAADGVTSIAPTAVASSTTAASITTA ASSMTVASSAPTTAASSTTVASIAPTTTASSMTAASSTPMTLALPAPTSTXTGR TPSTTATGHPSLSTALAQVPKSSALPRTATLATLATRAQTVATTANTSSPMST

30 RPSPSKHMPSDTAASPVPMPXPQAQGPISQVSVDQPVVNTTXKSTXMPSTNTT XEPLTQAVVDKTLVVLLGVTLFITVLVLFALQAYESYKKKDYTQVDYLI

NGMYADSEM (SEQ ID NO: 322). Polynucleotides encoding these polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the  
5 following amino acid sequence: ARCPELPGLRCRPRPRAGPQAPSYCPRATRPPG  
ACCARMRLLEWRVYLRLLTCATKDGMARECPTTWLSPPAKPDFAQRHVS  
KPTALQGGRWSRLGASP (SEQ ID NO: 323). Polynucleotides encoding these polypeptides are also provided.

10 This gene is expressed primarily in adipocytes, osteoblasts, cerebellum, hypothalamus and Hodgkin's lymphoma.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
15 not limited to, metabolic, skeletal, neural, and immune diseases and/or disorders, particularly Hodgkin's lymphoma. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at  
20 significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., metabolic, skeletal, neural, immune, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily  
25 fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 183 as residues: Pro-33 to Gln-40, Gly-51 to Arg-56. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in Hodgkin's lymphoma cells indicates that  
30 polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system disorders such as cancer, particularly Hodgkin's lymphoma. The secreted protein can also be used to determine biological activity, to

raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity" sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy); regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:70 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1628 of SEQ ID NO:70, b is an integer of 15 to 1642, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:70, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 61**

The translation product of this gene shares sequence homology with polypeptide in the cystatin family. Cystatin polypeptides are cysteine protease inhibitors. For an analysis of the composition of several members of the cystatin family see Gene (1987) 61(3):329-338, incorporated herein by reference. The cystatin activity of polypeptides encoded by this gene is measured by several assays known in the art including assays described in coowned, copending US Patent Application Serial No. 08/744,138, incorporated herein by reference. Preferred polypeptides of the invention comprise the following amino acid sequence: LPATVEFAVHTFNQQSKD  
5 YYAYRLGHILNSWKEQVESKTVFSMELLGRTRCGKFEDDIDNCHFQESTEL  
10 NNTFTCFFTISTRPWMTQFSLNKC (SEQ ID NO: 324). Fragments of such polypeptides having cystatin activity (cysteine protease inhibitory activity are particularly preferred). Polynucleotides encoding such polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: LLWARGLGRAKSAVPTVST MLGLPWKGGLS  
15 WALLLLLLGSQILLIYAWHFHEQRDCDEHNVMARYLPATVEFAVHTFNQQS  
KDYYAYRLGHILNSWKEQVESKTVFSMELLGRTRCGKFEDDIDNCHFQE  
20 STELNNTFTCFFTISTRPWMTQFSLNK TCLEGFH (SEQ ID NO: 325). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in testes and epididymus. For a review of a cystatin showing testes- specific expression see Mol. Endocrinol. (1992 Oct.) 6(10):1653-1664, incorporated herein by reference.

25 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, They should therefore serve a protective function to regulate the activities of such endogenous proteinases, which otherwise may cause uncontrolled  
30 proteolysis and tissue damage. Cysteine proteinase activity can normally not be measured in body fluids, but can be detected extracellularly in conditions like endotoxin-induced sepsis, metastasizing cancer, and at local inflammatory processes



in rheumatoid arthritis , purulent bronchiectasis and periodontitis. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune,

5 expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, testicular, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, seminal fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in

10 healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 184 as residues: Phe-31 to Asp-38, Asn-59 to Tyr-65, Ser-76 to Glu-82, Thr-96 to Cys-108, Gln-111 to Asn-118. Polynucleotides encoding said polypeptides are also provided.

15 The tissue distribution in testes and epididymus, combined with the homology to cystatins indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or

20 impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene

25 product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues

30 rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent

of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may  
5 also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of  
10 degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue  
15 markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Cysteine proteinase inhibitors of the cystatin superfamily are ubiquitous in the  
20 body and are generally tight-binding inhibitors of papain-like cysteine proteinases, such as cathepsins B, H, L, S, and K. They should therefore serve a protective function to regulate the activities of such endogenous proteinases, which otherwise may cause uncontrolled proteolysis and tissue damage. Cysteine proteinase activity can normally not be measured in body fluids, but can be detected extracellularly in  
25 conditions like endotoxin-induced sepsis, metastasizing cancer, and at local inflammatory processes in rheumatoid arthritis, purulent bronchiectasis and periodontitis, which indicates that a tight cystatin regulation is a necessity in the normal state. A deficiency state in which the levels of the intracellular cystatin, cystatin B, are lowered due to mutations has recently been shown to segregate with a  
30 form of progressive myoclonus epilepsy, which points to additional specialized functions of cystatins. Moreover, results showing that chicken cystatin inhibits polio virus replication, human cystatin C inhibits corona- and herpes simplex virus

replication, and human cystatin A inhibits rhabdovirus-induced apoptosis in cell cultures indicates that cystatins play additional roles in the human defense system. The cystatins constitute a superfamily of evolutionarily related proteins, all composed of at least one 100-120 residue domain with conserved sequence motifs.

5           The previously well characterized single-domain human members of this superfamily could be grouped in two protein families. The Family 1 members, cystatins (or stefins) A and B, contain approximately 100 amino acid residues, lack disulfide bridges, and are not synthesized as preproteins with signal peptides. The Family 2 cystatins (cystatins C, D, S, SN, and SA) are secreted proteins of approx.  
10   120 amino acid residues (Mr 13,000-14,000) and have two characteristic intrachain disulfide bonds. Recently, we identified an additional human cystatin superfamily member by EST1 sequencing in epithelial cell derived cDNA libraries which we named cystatin E. The same cystatin was independently discovered by differential display experiments as a mRNA species down-regulated in breast tumor tissue, but  
15   present in the surrounding epithelium and reported under the name cystatin M. Cystatin E/M is an atypical, secreted low-Mr cystatin in that it is a glycoprotein and just shows 30-35% sequence identity in alignments with the human Family 2 cystatins, which shows that additional cystatin families are yet to be identified. The cystatin E/M gene has been localized to chromosome 2, whereas all human Family 2  
20   cystatin genes are clustered on the short arm of chromosome 20, which further stresses that cystatin E/M is just distantly related to the other secreted human low-Mr cystatins. It is believed therefore, that polypeptides encoded by this gene are useful in diagnosing and treating disease consistent with the aforementioned conditions in which cystatins are implicated.

25           Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:71 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is  
30   cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 907 of SEQ ID NO:71, b is an

integer of 15 to 921, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:71, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 62

- 5       The translation product of this gene shares sequence homology with Neutrophil Gelatinase-Associated Lipocalin which is thought to be important in immune regulation (See Genbank and Geneseq Accession Nos. emb|CAA58127.1, and US5627034, respectively; all references and information available through these accessions are hereby incorporated herein by reference; for example, Biochem. 10   Biophys. Res. Commun. 202 (3), 1468-1475 (1994), and FEBS Lett. 314 (3), 386-388 (1992)).

- In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the 15   following amino acid sequence: LEQKLELHRGGGRSRTSGSPGLQEFGTREERGE GEQRTGREFSGNGGRAVEAARMRLLCGLWLWLSLLKVLQAQTPTPLPLPP PMQSFQGNQFQGEWFVLGLAGNSFRPEHRALLNAFTATFELSDDGRFEVWN AMTRGQHCDTWSYVLIPAAQPGQFTVDHGVGRSWLLPPGTLDQFICLGRAQ GLSDDNIVFPDVTGXALDL XSLPWVAAPA (SEQ ID NO: 326). Polynucleotides 20   encoding these polypeptides are also provided.

This gene is expressed primarily in epididymus and osteoclastoma.

- Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are 25   not limited to, reproductive and skeletal diseases and/or disorders, particularly cancers such as osteoclastoma testicular cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene 30   at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, testicular, skeletal, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, seminal fluid, urine, synovial fluid and spinal fluid)

or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
5 epitopes shown in SEQ ID NO: 185 as residues: Met-82 to Thr-90. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in epididymus and homology to neutrophil gelatinase-associated lipocalin indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of skin diseases and immune system  
10 disorders such as cancer, particularly osteoclastoma. The secreted protein can also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, and as nutritional supplements. It may also have a very wide range of biological activities. Representative uses are described in the "Chemotaxis" and "Binding Activity"  
15 sections below, in Examples 11, 12, 13, 14, 15, 16, 18, 19, and 20, and elsewhere herein. Briefly, the protein may possess the following activities: cytokine, cell proliferation/differentiation modulating activity or induction of other cytokines; immunostimulating/immunosuppressant activities (e.g. for treating human immunodeficiency virus infection, cancer, autoimmune diseases and allergy);  
20 regulation of hematopoiesis (e.g. for treating anemia or as adjunct to chemotherapy); stimulation or growth of bone, cartilage, tendons, ligaments and/or nerves (e.g. for treating wounds, stimulation of follicle stimulating hormone (for control of fertility); chemotactic and chemokinetic activities (e.g. for treating infections, tumors); hemostatic or thrombolytic activity (e.g. for treating hemophilia, cardiac infarction  
25 etc.); anti-inflammatory activity (e.g. for treating septic shock, Crohn's Disease); as antimicrobials; for treating psoriasis or other hyperproliferative diseases; for regulation of metabolism, and behavior. Also contemplated is the use of the corresponding nucleic acid in gene therapy procedures. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or  
30 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:72 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
5 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 892 of SEQ ID NO:72, b is an integer of 15 to 906, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:72, and where b is greater than or equal to a + 14.

## 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 63

The translation product of this gene was shown to have homology to colipase which plays an essential role in the intestinal fat digestion by anchoring lipase on lipid/water interfaces in the presence of bile salts (See Genbank Accession No. gblAAA03513.1; all references and information available through this accession are  
15 hereby incorporated by reference herein).

This gene is expressed primarily in epididymus.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
20 not limited to, reproductive diseases and/or disorders, particularly epididymus-related diseases. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or  
25 lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, metabolic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, seminal fluid, bile, chyme, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from  
30 an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 186 as residues: Ile-40 to Cys-49, Arg-52 to Cys-57,

Ser-94 to Trp-99, Gly-105 to Gly-111. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in epididymus indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune system diseases and disorders of the epididymus. Polynucleotides and polypeptides corresponding to this gene are useful for the treatment and diagnosis of conditions concerning proper testicular function (e.g. endocrine function, sperm maturation), as well as cancer. Therefore, this gene product is useful in the treatment of male infertility and/or impotence. This gene product is also useful in assays designed to identify binding agents, as such agents (antagonists) are useful as male contraceptive agents. Similarly, the protein is believed to be useful in the treatment and/or diagnosis of testicular cancer. The testes are also a site of active gene expression of transcripts that is expressed, particularly at low levels, in other tissues of the body. Therefore, this gene product is expressed in other specific tissues or organs where it may play related functional roles in other processes, such as hematopoiesis, inflammation, bone formation, and kidney function, to name a few possible target indications. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:73 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 666 of SEQ ID NO:73, b is an integer of 15 to 680, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:73, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 64**

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: MCVCKERGREKEGGVTPTMTSNFPFCTLILGI  
AQAQACPGCPGDWPGLGSGVGEGLHHIRTCRTPIPCSPAPAAACLGSGH  
ARLPCVLRLLWPVPANLSSPFRLEALHCSFWSSPLLPAFLAFFGFRDLLTDFL  
LAACLLTFQKTPLELPMVHVLLVATPCYQMLDNLPLPSAAAN WC (SEQ ID  
NO: 327). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in melanocytes and placenta and to a lesser extent in bone marrow and many cells of the immune system, including B-cells, dendritic cells, and T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, skin cancer and disorders of the reproductive and immune systems. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., reproductive tissue, hematopoietic tissue, melanocytes and cells and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in melanocytes indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the skin, the reproductive system, and the immune system, particularly cancers. Representative uses are described in the "Biological Activity",



"Hyperproliferative Disorders", "infectious disease", and "Regeneration" sections below, in Example 11, 19, and 20, and elsewhere herein. Briefly, the protein is useful in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's Disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis), atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm). Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders (i.e., arthritis, trauma, tendonitis, chondromalacia and inflammation, etc.), autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:74 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 1619 of SEQ ID NO:74, b is an integer of 15 to 1633, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:74, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 65

Preferred polypeptides of the invention comprise the following amino acid sequence: YLWGRPRLRMAGTSPSAPWGKREKLGHKLPVALQGYHPWIL  
LECTVFWARVVLACFSLYLIRGPNCINRQPEPTYQKACNLDCSSDFGQER  
APAWELLGPESEQRLREYTAQGLQSLASSHRWRQFKTEGKMRGGASPLPWL  
10 CFW LCSYKGSDNSLKPVVPGPTLCPQSLVSPSVHPSTRSASLGRHRAEAA  
(SEQ ID NO: 328). Polynucleotides encoding these polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the  
15 following amino acid sequence: MPGILAGIPVKDLCLSLQGFRLLLCVCPGWL  
SGWMGGQKGSPRIVDIG (SEQ ID NO: 329). Polynucleotides encoding these polypeptides are also provided. This gene maps to chromosome 15, accordingly, polynucleotides of the invention is used in linkage analysis as a marker for chromosome 15.

20 This gene is expressed primarily in brain and breast and to a lesser extent in the liver, pancreas, and T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
25 not limited to, disorders affecting the brain and CNS, the reproductive system, or the immune system. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, the reproductive system, and the immune  
30 system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., brain and other tissue of the nervous system, mammary tissue, endocrine tissue, hepatic tissue, reproductive tissue, cells

and tissue of the immune system, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 188 as residues: Met-37 to Ser-43. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in brain cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the central nervous system, the reproductive system, and the immune system, including cancers. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:75 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
5 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1008 of SEQ ID NO:75, b is an integer of 15 to 1022, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:75, and where b is greater than or equal to a + 14.

## 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 66

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: AKGEERKEAFSLKMOVLSSEPISFGLMYLYLGV  
15 FFHLIYPGALSITTLGKHSHPFFTAEQNSTVWMEHTLFHQSPVASHLVCFQSF  
AFSE (SEQ ID NO: 330). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in the brain and the immune system, in particular T-cells.

20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting the brain, such as Alzheimer's or disorders affecting the immune system, such as AIDS. Similarly, polypeptides and antibodies directed to  
25 these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the brain and CNS and the immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., brain and other tissue of the nervous system, cells and  
30 tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in brain cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment  
5 of disorders affecting the brain and CNS or disorders affecting the immune system. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome,  
10 meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep  
15 patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity,  
20 to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
25 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:76 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
30 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1170 of SEQ ID NO:76, b is an

integer of 15 to 1184, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:76, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 67**

- 5           The translation product of this gene shares sequence homology with penaeidin-2 which is thought to be a members of a new family of antimicrobial peptides from the hemolymph of shrimps *Penaeus vannamei*. The molecules display antimicrobial activity against fungi and bacteria with a predominant activity against Gram-positive bacteria.
- 10           In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GPAHPASPPLMTLSLQLAELVHFVCAFAQSQWT GVYPMMPLKPTPLCFA CVPCR (SEQ ID NO: 331). Polynucleotides
- 15           encoding these polypeptides are also provided.
- This gene is expressed primarily in spleen.
- Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are
- 20           not limited to, immune and hematopoietic diseases and/or disorders, particularly disorders affecting the spleen, including bacterial and fungal infections. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the hematopoietic
- 25           and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., immune, hematopoietic, and cells and tissue of the immune system, cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard
- 30           gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in spleen and homology to the penaeidin family of antibiotics indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the spleen, especially fungal and bacterial infections. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:77 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
5 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 298 of SEQ ID NO:77, b is an integer of 15 to 312, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:77, and where b is greater than or equal to a + 14.

#### 10 **FEATURES OF PROTEIN ENCODED BY GENE NO: 68**

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of THP-1 cells to calcium. Thus it is likely that the product of this gene is involved in a signal  
transduction pathway that is initiated when the product binds a receptor on the surface  
15 of the plasma membrane of both monocytes, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating immune and hematopoietic cells and tissue cell types. Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium and sodium, as well as alter pH and membrane  
20 potential. Alterations in small molecule concentration can be measured to identify supernatants which bind to receptors of a particular cell.

Moreover, when tested in TF-1 cell lines, the protein product of this gene has been shown to alter the steady-state messenger RNA levels of the following genes: c-fos, c-jun, egr-1, b561, bcl-2, CD40, cyclin D2, GADPH, ICER, MAD3, p21, STAT3,  
25 ID3, and STAT-1. When tested in U937 cell lines, the protein product of this gene has been shown to alter the steady-state messenger RNA levels of the following genes: egr2, MKP1, ATF3, B562, cyclin D, cyclin D2, GATA3, MAD3, p21, TGF, DHFR, and JAK3. Based upon these results, it is anticipated that polynucleotides and polypeptides corresponding to this gene are useful as agonists or antagonists of the  
30 above referenced genes. Such activity is useful in therapeutic and/or diagnostic applications as referenced and more specifically discussed elsewhere herein.



In specific embodiments, polypeptides of the invention comprise the sequence: MLLEVYGDSISVTVAIPL (SEQ ID NO: 332), MHSPCQSKAADGLGKSETE (SEQ ID NO: 333), and/or MLKSLGLSTN (SEQ ID NO: 334). Polynucleotides encoding these polypeptides are also provided.

5 In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: AQRLAEECFYMLLEVYGDSISVTVAIPLMHSP  
CQSKAADGLGKSETEMLKSLGLSTNMSPFHLGLKVFLTWALTLAQICLY  
10 FFEVQPLGLLALNFFCTATAGLKELCMHPPSLAFTPEFHTSLSPLAIPSCGTS  
VSLSNSHTIPLSLYLPFPSKSRMPDTLHLLVHSLPLVHSQVLPVKDVTIEWPLC  
QRCLGSTCH Q (SEQ ID NO: 335). Polynucleotides encoding these polypeptides are also provided.

The polypeptide of this gene has been determined to have a transmembrane  
15 domain at about amino acid position 11 - 27 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 28 to 143 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

20 This gene is expressed primarily in neutrophils and T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders and/or diseases affecting the immune system. Similarly,  
25 polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., immune, hematopoietic, cells and tissue  
30 of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene

expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 191 as residues: Pro-97 to Asp-104. Polynucleotides  
5 encoding said polypeptides are also provided.

The tissue distribution in neutrophils and T-cells, combined with the detected calcium flux biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the immune system. Representative uses are described in the "Immune  
10 Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or  
15 other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such  
20 as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic  
25 lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and  
30 in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their

interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:78 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1356 of SEQ ID NO:78, b is an integer of 15 to 1370, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:78, and where b is greater than or equal to a + 14.

#### 15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 69**

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: WIPRAAGIRHEVQVSLFQMFCFSSIFCSH  
20 EHTHLPGTFWLFLFLFLILPPSCPCFLPFLAIETVRWPCWHHPTSFELCY  
PGTSIYYASRGGPXPNSEX (SEQ ID NO: 336). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in neutrophils.

Therefore, polynucleotides and polypeptides of the invention are useful as  
25 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, diseases and/or disorders affecting the immune system, and neutrophils in particular. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the  
30 tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues and cell types (e.g., blood cells,

and cells and tissue of the immune system, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in neutrophils indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting the immune system and neutrophils in particular. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,

antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:79 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 354 of SEQ ID NO:79, b is an integer of 15 to 368, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:79, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 70**

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: XNXKSPLTIGNKSWSTAVAAALELVDPPGCR NSARDSPELVHLGKGRPRKLMTYLFCSSISLLLLKVHSSGHQDIRKAKSKVP RLLIQCPQQRE (SEQ ID NO: 337). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in smooth muscle.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders affecting smooth muscle tissue, particularly vascular conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of smooth muscle tissue expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., muscle, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial

fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
5 epitopes shown in SEQ ID NO: 193 as residues: Ser-18 to Val-31. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution primarily in smooth muscle indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of disorders affecting smooth muscle tissue. Moreover, the  
10 protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate  
15 cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
20 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:80 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
25 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1074 of SEQ ID NO:80, b is an integer of 15 to 1088, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:80, and where b is greater than or equal to a + 14.

### 30 **FEATURES OF PROTEIN ENCODED BY GENE NO: 71**

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by

the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GPEENLSPSTPSQMPTIWVKLCLLQVCHGLFP LLKHWSQPMPLCVTLAPVSYWL (SEQ ID NO: 338). Polynucleotides encoding these polypeptides are also provided.

5           This gene is expressed primarily in fetal heart, smooth muscle, and frontal cortex.

          Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
10   not limited to, muscular, vascular, or neural diseases and/or disorders, particularly defects or injury to cardiac muscle. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the cardiovascular system, expression of this gene at  
15   significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., muscular, vascular, neural, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy  
20   tissue or bodily fluid from an individual not having the disorder.

          The tissue distribution in fetal heart indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating defects to the heart either due to injury or congenital defects. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and  
25   conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Alternatively, polynucleotides and polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory  
30   conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection,

treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:81 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1848 of SEQ ID NO:81, b is an integer of 15 to 1862, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:81, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 72**

The translation product of this gene shares sequence homology with adipose complement related protein which is thought to be important in regulating energy metabolism, insulin levels and fat stores. Moreover, the protein product of this gene has also been shown to have homology to the complement subcomponent C1q A-chain precursor and HP-25 protein (See Genbank and Geneseq Accession Nos. emb|CAA41664.1, dbj|BAA02352.1, and W98013; all references and information



available through this accession are hereby incorporated by reference herein). Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with complement proteins.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: PRVRKEPEAMQWLRVRESPGEATGHRVTMG TAALGPVWAALLLFLLMCEIPMVELTFDRAVASDCQRCCDSEDPLDPAHVSS ASSSGRPHALPEIRPYINITILKGDKGDPGPMGLPGYMGREGPGQEPGPQGSK GDKGEMGSPGAPCQKRFFAFSVGRKTALHSGEDFQTLLFERVFNLDGC FDMATGQFAAPLRGIYFFSLNVHSWNYKETVYHIMHNQKEAVILYAQPS ERSIMQSQSVMLDLAYGDRVWVRLFKRQRENAIYSNDFDTYITFSGHLIKA EDD (SEQ ID NO: 339). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in placenta and, fetal kidney, and umbilical vein and to a lesser extent in fetal heart, fetal liver/spleen, microvascular endothelial cells and cancers of the lung and pharynx.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, vascular, renal, and reproductive diseases and/or disorders, particularly cancers of the lung and pharynx. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the pulmonary and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., vascular, renal, reproductive, immune, hematopoietic, pulmonary, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 195 as residues: Asp-36 to Asp-48, Ser-57 to His-62, Lys-77 to Gly-84, Met-92 to Gly-114, Gln-203 to Ile-209, Lys-231 to Tyr-239.

Polynucleotides encoding said polypeptides are also provided.

5       The tissue distribution in pharynx or lung, combined with the homology to adipose complement related proteins indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating cancers of the pharynx or lung by modifying the metabolic balance in such tissues. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular  
10 disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product  
15 may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional  
20 supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:82 and may have been publicly available prior to conception of  
25 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1604 of SEQ ID NO:82, b is an  
30 integer of 15 to 1618, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:82, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 73**

The translation product of this gene shares sequence homology with a hypothetical 54.7 kD protein (F37A4.1) from *Caenorhabditis elegans* (SwissProt locus YPT1\_CAEEL, accession P41879). The protein product of this gene also has

5 homology to the human NG26 which is thought to contain a human major histocompatibility complex class III and is involved in T-cell maturation (See Genbank Accession No. gblAAD18079.1l (AF129756); all references and information available through this accession are hereby incorporated by reference herein; for example, J. Neurochem. 69 (6), 2516-2528 (1997)). Based on the sequence similarity,

10 the translation product of this gene is expected to share at least some biological activities with nitric oxide synthase proteins.

Preferred polypeptides of the invention comprise the following amino acid sequence: MLYPGSVYLLQKALMPVLLQGQARLVEECNGRRAKLLACDGNE  
IDTMFVDRRGTAEPQGQKLVICCEGNAGFYEVGCVSTPLEAGYSVLGWNHP

15 GFAGSTGVFPQNEANAMDVVVQFAIHR LGFQPQDIIYAWSIGGFTATWAA  
MSYPDVSAMILDASFDDLVLALKVMPDSWRGLVTRTVRQHLNLNNAEQLC  
RYQGPVLLIRRTKDEIITTTVPEDIMSNRGNL LLLKLLQHRYPVMAEEGLRV  
VRQWLEASSQLEEASIYSRWEVEEDWCLSVLRSYQAEHGPD F PWSVGEDMS  
ADGRRQLALFLARKHLHNFEATHCTPLPAQNFQMPWHL (SEQ ID NO: 340).

20 Polynucleotides encoding such polypeptides are also provided.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: VCPKWCRFLTMLGHCCYFWQVWPASEALAA

25 GPTPSTGSSSPSWKQHIGTSLQKTRGSLPTTTLTSGAGQSTSTGKNPAAGR  
SLEGALPAGVWPCFAQSPCTGGQQTTP SSTGLRSCLVRSPATWW RTP (SEQ ID  
NO: 341). Polynucleotides encoding these polypeptides are also provided.

Preferred polypeptides of the invention comprise the following amino acid sequence: WIPRAAGIRHEIYREXDSERAPASVPETPTAVTAPHSSSWDTYYQ

30 PRALEKHADSILALASVFW SISYSSPFAFFYL YRKG YLSLSKVVPFSHYAG  
TLLLLLAGVACXRGIGRW TN PQYRQFITILEATHRNQSS ENKRQLANYNFD  
FRSWPVDFHWEPPSSRKESRGGPSRRGVALLRPEPLHRGTADTLLNRVKKL

PCQITSYLVAHTLGRRMLYPGSVYLLQKALMPVLLQGQARLVEECNGRRAK  
LLACDGNEIDTMFVDRRGTAEPQGQKLVICCEGNAGFYEVGCVSTPLEAGYS  
VLGWNHPGFAGSTGVFPQNEANAMDVVVQFAIHR LGFQPQDIITYAWSI  
GGFTATWAAMSYPDVSAMILDASFDDL VPLALKVMPDSWRGLVTRTVRQ  
5 HLNLNNAEQLCRYQGPVLLIRRTKDEIITTTVPEDIMSNRGNDLLLKLLQHRY  
PRVMAEEGLRVVRQWLEASSQLEEASIYSRWEVEEDWCLSVLRSYQAEHGP  
DFPWSVGEDMSADGRRQLALFLARKHLHNFEATHCT PLPAQNFQMPWHL

(SEQ ID NO: 342). Polynucleotides encoding these polypeptides are also provided. A preferred polypeptide variant of the invention comprises the following amino acid

10 sequence: HERAXGPSRGHGELLSCVLGPRLYKIYRERDSERAPASVPETPTA  
VTAPHSSSWDTYYQP RALEKHADSILALASVFWSISYYSSPFAFFLYRKG  
LSLSKVVPFSHYAGTLLLLLAGV ACSEALAAGPTPSTGSSSPSWKQHIGTSLQ  
KTRGSLPTTTLTSGAGQSTSTGKNPAAGRSLEGALPAGVWPCFAQSPCTGG  
QQTPSSTGL RSCLVRSPATWW RTP (SEQ ID NO: 343). Polynucleotides

15 encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 6. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 6.

20 This gene is expressed primarily in cerebellum, pituitary, fetal liver, and primary dendritic cells and to a lesser extent in a wide range of tissues and developmental stages (i.e. fetal and adult tissue, etc.).

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
25 not limited to, neural, developmental, and immune diseases and/or disorders, particularly those involving self recognition and T- and B-cell maturation, and cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the  
30 neural or hormonal system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, developmental, immune, hepatic, and cancerous and wounded tissues) or bodily fluids (e.g., serum,

plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

5 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 196 as residues: Thr-23 to Lys-34, Leu-41 to Ser-47, Ala-57 to Ala-68, Pro-89 to Gly-101, Pro-110 to Pro-117. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in developmental and immune cells, combined with the  
10 homology to the human major histocompatibility complex class III region, indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of cancer and other proliferative disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the  
15 expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

20 Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities,  
25 such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that  
30 influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and

in the differentiation and/or proliferation of various cell types. Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to  
5 isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
10 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:83 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
15 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2020 of SEQ ID NO:83, b is an integer of 15 to 2034, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:83, and where b is greater than or equal to a + 14.

## 20 FEATURES OF PROTEIN ENCODED BY GENE NO: 74

The translation product of this gene shares sequence homology with the br-1 protein from the snail nervous system (EMBL HPBR1GENE) which codes for nitric oxide synthetase and which is thought to be important in mediating a variety of cellular responses, including vasodilation. Preferred polypeptides of the invention  
25 comprise the following amino acid sequence: MFKRHQRLKKDSTQAEEDLSEQ  
EQNQLNVLKKHGYVVGRVGRFTFLYSEEQKDNIPFEFDADSLAFDMENDPVM  
GTHKSTKQVELTAQDVKDAHWFYDTPGITKENCILNLLTEKEVNIVLPTQSIV  
PRTFVLKPGMVLFLGAIGRIDFLQGNQSAWFTVVASNILPVHITSLDRADALY  
QKHAGHTLLQIPMGGKERMAGFPPLVAEDIMLKEGLGASEAVADIKFSSAG  
30 WWSVTPNFKDRLHLRGYTPEGTVLTVRPPLPYIVNIKGQRIKKSVAAYKTKKP  
PSLMYNVRKKKGKINV (SEQ ID NO: 344). Polynucleotides encoding such polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MLPARLPFRLLSLFLRGSAPTAARHGLREPLLERRCAA ASSFQHSSSLGRELPYDPVDTEGFGEGGDMQERFLFPEYILDPEPQPTREKQL QELQQQQEEEEERQRQQRREERRQQNLRARSREHPVVGHDPALPPSGVNCS  
5 GCGAXLHCQDAGVPGYLPREKFLRTAEADGGLARTVCQRCWLLSHHRRALR LQVSREQYLELVSAALRXPGPSLVLYMVDLLDLPDALLPDLPALVGPKQLIV LGNKVDLLPQDAPGYRQLRERLWEDCARAGLLLAPGTKGHSAPSRTSHR TGRIRIRRTGPAQWSGTCG (SEQ ID NO: 345). Polynucleotides encoding these polypeptides are also provided.

10 When tested against U937 cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid cells through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is  
15 a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

This gene is expressed primarily in early stage human brain, smooth muscle,  
20 and endometrial tumor and to a lesser extent in a variety of tissues representing many organs and developmental states.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
25 not limited to, cardiovascular, vascular, and neural diseases and/or disorders, particularly congestive heart disease and neurological disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the circulatory and  
30 neural systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cardiovascular, vascular, neural, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma,

urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

- 5 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 197 as residues: Phe-42 to Leu-48, Pro-53 to Asp-58, Pro-81 to Glu-123, Asp-256 to Trp-269, Gly-282 to Ser-306, Arg-333 to Gly-339, Arg-403 to Gln-425, Ser-446 to Asn-452, His-475 to Gln-480, Gly-592 to Met-597, Pro-635 to His-642, Lys-667 to Lys-672, Lys-678 to Ser-684. Polynucleotides  
10 encoding said polypeptides are also provided.

- The tissue distribution in smooth muscle and vascular tissues, combined with the homology to nitric oxide synthetase indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of congestive heart failure and neurological degenerative disorders. polynucleotides and  
15 polypeptides corresponding to this gene are useful for the detection, treatment, and/or prevention of neurodegenerative disease states, behavioral disorders, or inflammatory conditions. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection,  
20 treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder,  
25 learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

- Potentially, this gene product is involved in synapse formation,  
30 neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to



microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis.

Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents  
 5 that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
 10 related to SEQ ID NO:84 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
 15 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2226 of SEQ ID NO:84, b is an integer of 15 to 2240, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:84, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 75**

20 The translation product of this gene shares sequence homology with the human KE04p, in addition to an unidentified *C.elegans* gene.

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 9 - 25 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 1 to 8  
 25 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type II membrane proteins.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by  
 30 the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: PSFRRERVETGGGGPVTHGTEGPFLPLPGGTRM NMTQARVLVA VVGLVAVLLYASIHKIEEGLAVYYRGGALLTSPSPGPYH

IMLPFITFRSVQTTLQTDEVKNVPCGTSGGVMYIDRIE VVNMLAPYAVFDIV  
 RNYTADYDKTLIFNKHHELNQFCSAHTLQEVYIELFDQIDENLKQALQKDL  
 NLMAPGLTIQAVRVTKPKIPEAIRNFELMEAEKTKLLIAAQKQKVVEKEA  
 ETERKKAVIEAEKIAQVAKIRFQQKVMETEKRISEIEDAAFLAREKAKA  
 5 DAEYYAAHKYATSNKHKLTPEYLELKKYQAIASNSKIYFGSNIPNMFVDSSC  
 ALKYS DIRTGRESSLPSKEALEPSGENVIQNKESTG (SEQ ID NO: 346).

Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome  
 10. Accordingly, polynucleotides related to this invention are useful as a marker in  
 10 linkage analysis for chromosome 10.

This gene is expressed primarily in fetal tissue, including 8 week whole  
 embryo, fetal liver spleen, nine week old early stage human, fetal heart, fetal liver,  
 fetal lung, and placenta and to a lesser extent in a variety of cancers, and other normal  
 tissues.

15 Therefore, polynucleotides and polypeptides of the invention are useful as  
 reagents for differential identification of the tissue(s) or cell type(s) present in a  
 biological sample and for diagnosis of diseases and conditions which include, but are  
 not limited to, cancer and diseases of fetal development. Similarly, polypeptides and  
 antibodies directed to these polypeptides are useful in providing immunological  
 20 probes for differential identification of the tissue(s) or cell type(s). For a number of  
 disorders of the above tissues or cells, particularly of the fetal tissues, especially the  
 liver, expression of this gene at significantly higher or lower levels is routinely  
 detected in certain tissues or cell types (e.g., developmental, hepatic, immune,  
 hematopoietic, pulmonary, cardiovascular, and cancerous and wounded tissues) or  
 25 bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another  
 tissue or cell sample taken from an individual having such a disorder, relative to the  
 standard gene expression level, i.e., the expression level in healthy tissue or bodily  
 fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
 30 epitopes shown in SEQ ID NO: 198 as residues: Leu-68 to Lys-74, Tyr-109 to Lys-  
 115, Gln-200 to Val-205, Lys-207 to Lys-214, Glu-237 to Ile-244, Ala-271 to Thr-

279, Ser-317 to Ser-329, Gln-342 to Gly-348. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution of this gene (primarily fetal tissue and cancerous tissue, both of which are undergoing rapid growth) indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of cancer and disorders of fetal development. Moreover, the expression within fetal tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as,

antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
5 related to SEQ ID NO:85 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
10 formula of a-b, where a is any integer between 1 to 1474 of SEQ ID NO:85, b is an integer of 15 to 1488, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:85, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 76

15 When tested against U937 and Jurkat cell lines, supernatants removed from cells containing this gene activated the GAS (gamma activating sequence) promoter element. Thus, it is likely that this gene activates myeloid and T-cells, and to a lesser extent in other immune cells and tissue cell types, through the JAK-STAT signal transduction pathway. GAS is a promoter element found upstream of many genes  
20 which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the GAS element, can be used to indicate proteins involved in the proliferation and differentiation of cells.

25 In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: WSTGNASWEKKDNFILSADFEMMGLGNRR  
SMKSPPLVLAALVACIIVLGFNYWIIASSRSVDLQTRIMELEGRVRRRAAERG  
30 AVELKKNEFQGELEKQREQLDKIQSSHNFQLESVNKLYQDEKAVLVNNITTG  
ERLIRVLQDQLKTLQRNYGRLQQDVLQFQKNQTNLERKFSYDLSQCINQMKE  
VKEQCEERIEEVTKKGNEAVASRDLSNNNDQRQQLQALSEPQPRLQAAGL

PHTEVPQGKGNVLGNSKSQTPAPSSEVVLD SKRQVEKEETNEIQVVNEE  
 PQRDRLPQEPGREQVVEDRPVGGRGFGGAGELGQTPQVQAALXVSQENPE  
 MEGPERDQLVIPDGQEEEQEAAGEGRNQKLRGEDDYNMDENEAESETDKQ  
 AALAGNDRNIDVFNVE DQKRDTINLLDQREKRNHTL (SEQ ID NO: 347).

5 Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 9. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 9.

This gene is expressed primarily in human endometrial tumor and other  
 10 tumors and to a lesser extent in a variety of other healthy adult and fetal tissues

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental diseases and/or disorders, particularly cancer and other  
 15 proliferative disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the endometrial tissue, cervix and uterus, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues  
 20 or cell types (e.g., developmental, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 199 as residues: Asn-6 to Lys-12, Leu-65 to Phe-70, Glu-73 to His-88, Gln-123 to Gln-135, Gln-142 to Leu-156, Arg-173 to Gly-181, Asp-189 to Gln-199, Ser-204 to Arg-209, Glu-219 to Gly-225, Gly-229 to Pro-238, Ser-246 to Asn-256, Glu-263 to Arg-276. Polynucleotides encoding said polypeptides  
 30 are also provided.

The tissue distribution in endometrial tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of

endometrial, cervical and uterine cancer. Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:86 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 3160 of SEQ ID NO:86, b is an integer of 15 to 3174, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:86, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 77**

The translation product of this gene shares sequence homology with protein disulfide isomerase from *Acanthamoeba castellanii* (See Genbank Locus ACADISPROA accession L28174, genpep locus 456013) which is thought to be important in converting proteins into their native conformations. The protein product of this gene was also shown to have homology to a phospholipase C homologue

derived from a mast cell cDNA library (See Geneseq Accession No. R99411). All references and information available through these accessions are hereby incorporated by reference herein - for example, Gene 150 (1), 175-179 (1994).

Included in this invention as preferred domains are endoplasmic reticulum targeting sequence domain and the thioredoxin family active site domain, which were identified using the ProSite analysis tool (Swiss Institute of Bioinformatics). Proteins that permanently reside in the lumen of the endoplasmic reticulum (ER) seem to be distinguished from newly synthesized secretory proteins by the presence of the C-terminal sequence Lys-Asp-Glu-Leu (KDEL) [1,2]. While KDEL is the preferred signal in many species, variants of that signal are used by different species. This situation is described in the following table.

Signal	Species-----
KDEL	Vertebrates, Drosophila, Caenorhabditis elegans, plants
HDEL	Saccharomyces cerevisiae, Kluyveromyces lactis, plants
DDEL	Kluyveromyces lactis
ADEL	Schizosaccharomyces pombe (fission yeast)
SDEL	Plasmodium falciparum

The signal is usually very strictly conserved in major ER proteins but some minor ER proteins have divergent sequences (probably because efficient retention of these proteins is not crucial to the cell). Proteins bearing the KDEL-type signal are not simply held in the ER, but are selectively retrieved from a post-ER compartment by a receptor and returned to their normal location. The consensus pattern is as follows: [KRHQSA]-[DENQ]-E-L>. Thioredoxins are small proteins of approximately one hundred amino- acid residues which participate in various redox reactions via the reversible oxidation of an active center disulfide bond. They exist in either a reduced form or an oxidized form where the two cysteine residues are linked in an intramolecular disulfide bond. Thioredoxin is present in prokaryotes and eukaryotes and the sequence around the redox-active disulfide bond is well conserved. Bacteriophage T4 also encodes for a thioredoxin but its primary structure is not homologous to bacterial, plant and vertebrate thioredoxins. A number of eukaryotic

proteins contain domains evolutionary related to thioredoxin, all of them seem to be protein disulphide isomerases (PDI). PDI (EC 5.3.4.1) is an endoplasmic reticulum enzyme that catalyzes the rearrangement of disulfide bonds in various proteins. The various forms of PDI which are currently known are: - PDI major isozyme; a  
5 multifunctional protein that also function as the beta subunit of prolyl 4-hydroxylase (EC 1.14.11.2), as a component of oligosaccharyl transferase (EC 2.4.1.119), as thyroxine deiodinase (EC 3.8. 1.4), as glutathione-insulin transhydrogenase (EC 1.8.4.2) and as a thyroid hormone-binding protein - ERp60 (ER-60; 58 Kd microsomal protein). ERp60 was originally thought to be a phosphoinositide-specific  
10 phospholipase C isozyme and later to be a protease. - ERp72. - P5. All PDI contains two or three (ERp72) copies of the thioredoxin domain. The concensus pattern is as follows: [LIVMF]-[LIVMSTA]-x-[LIVMFYC]-[FYWSTHE]-x(2)-[FYWGTN]-C-[GATPLVE]-[PHYWSTA]-C-x(6)-[LIVMFYWT]. The two C's form the redox-active bond.

15 Preferred polypeptides of the invention comprise the following amino acid sequence: SLHRFVLSQAKDEL (SEQ ID NO: 348), FIKFFAPWCGHCKALAPTW (SEQ ID NO: 349), and/or FIKFYAPWCGHCKTLAPTW (SEQ ID NO: 350). Polynucleotides encoding these polypeptides are also provided.

Further preferred are polypeptides comprising the endoplasmic reticulum  
20 targeting sequence domain and thioredoxin family active site domain of the sequence referenced in Table for this gene, and at least 5, 10, 15, 20, 25, 30, 50, or 75 additional contiguous amino acid residues of this referenced sequence. The additional contiguous amino acid residues is N-terminal or C- terminal to the endoplasmic reticulum targeting sequence domain and thioredoxin family active site domain.  
25 Alternatively, the additional contiguous amino acid residues is both N-terminal and C-terminal to the endoplasmic reticulum targeting sequence domain and thioredoxin family active site domain, wherein the total N- and C-terminal contiguous amino acid residues equal the specified number. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with  
30 thioredoxin proteins. Such activities are known in the art, some of which are described elsewhere herein.



In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: RRGRGVPGPRGRRRLWSAACGHCQRLQPTWN  
5 DLGDKYNSMEXAKVYVAKVDCTAHS DVC SAQGV RGYPTLKL FKPGQEAV  
KYQGPRDFQTLN WMLQTLNEEPVTP EPEVEPPSAPELKQGLYELSASN FELH  
VAQGDHFIKFFAPWCGHCKALAPTWEQLALGLEHSETVKIGKVDCTQHY  
ELCSGNQVRGYPTLLWFRD GKKVDQYK GKRDLES LREYVESQLQRTETGA  
TETVTPSEAPVLAAEPEADKGTVLALTENN FDDTIAEGITFIKFYAPWCGHC  
10 KTLAPTWEELSKKEFPGLAGVKIAEVDCTAERNICKYSVRGYPTLLLFRGGK  
KVSEHSGGRDLDS LHRFVLSQAKDEL (SEQ ID NO: 351). Polynucleotides  
encoding these polypeptides are also provided.

This gene is expressed primarily in human chondrosarcoma and endothelial cells and to a lesser extent in a wide range of normal and diseased adult and fetal  
15 tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, chondrosarcoma and other cancers and proliferative disorders.  
20 Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., vascular, skeletal,  
25 developmental, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.  
30 The tissue distribution in chondrosarcoma, combined with the homology to protein disulfide isomerase and phospholipase C indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of

chondrosarcoma and other cancers and proliferative disorders, and possibly as a reagent for in vitro production of proteins. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation  
5 and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of  
10 potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types  
15 of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new  
20 insight into the regulation of cellular growth and proliferation. Moreover, the expression in endothelial cells indicates the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis,  
25 and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed  
30 tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:87 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
5 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2766 of SEQ ID NO:87, b is an integer of 15 to 2780, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:87, and where b is greater than or equal to a + 14.

## 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 78

This gene is expressed primarily in thyroid and thymus

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
15 not limited to, thyroid diseases including thyroid cancer and diseases of function including Grave's Disease, hyper- and hypo- thyroidism as well as Diseases of the thymus. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells,  
20 particularly of the endocrine and immune systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., endocrine, immune, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene  
25 expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in thyroid cells and tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of diseases of the thyroid and thymus. Representative uses are  
30 described in the "Biological Activity", "Hyperproliferative Disorders", and "Binding Activity" sections below, in Example 11, 17, 18, 19, 20 and 27, and elsewhere herein. Briefly, the protein can be used for the detection, treatment, and/or prevention of

Addison's Disease, Cushing's Syndrome, and disorders and/or cancers of the pancreas (e.g. diabetes mellitus), adrenal cortex, ovaries, pituitary (e.g., hyper-, hypopituitarism), thyroid (e.g. hyper-, hypothyroidism), parathyroid (e.g. hyper-, hypoparathyroidism), hypothalamus, and testes. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:88 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1047 of SEQ ID NO:88, b is an integer of 15 to 1061, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:88, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 79

The translation product of this gene shares sequence homology with collagen which is thought to be important as a structural material in a variety of human tissues and products including hair, nails, muscle and bone.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MRPQGPAASPQRLRGLLLLLLLQLPAPSSASEIPKGKQK AHSGRGRWWTCIMECAYKGQQECLVETGALGPMAFRVHLGSQVGMDSKEK RGNV (SEQ ID NO: 352). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in smooth muscle and to a lesser extent in 12 week old early stage human, epididymus, healing groin wound, synovial hypoxia,

stromal cells, ulcerative colitis, breast and 8 week old embryo, as well as a variety of other normal and diseased cell types from adult and fetal tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cancer and other proliferative disorders as well as Diseases of smooth muscle. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the muscular system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., vascular, developmental, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 202 as residues: Glu-32 to Glu-46, Pro-63 to Ala-71, Pro-81 to Lys-90, Ser-97 to Trp-111, Lys-130 to Ser-135, Leu-147 to Cys-154, Asp-179 to Asn-186, Ser-219 to Gly-229. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in smooth muscle and homology to collagen indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of diseases of vascular diseases and/or disorders.

Representative uses are described in the "Biological Activity", "Hyperproliferative Disorders", "infectious disease", and "Regeneration" sections below, in Example 11, 19, and 20, and elsewhere herein. Briefly, the protein is useful in detecting, treating, and/or preventing congenital disorders (i.e. nevi, moles, freckles, Mongolian spots, hemangiomas, port-wine syndrome), integumentary tumors (i.e. keratoses, Bowen's Disease, basal cell carcinoma, squamous cell carcinoma, malignant melanoma, Paget's Disease, mycosis fungoides, and Kaposi's sarcoma), injuries and inflammation of the skin (i.e. wounds, rashes, prickly heat disorder, psoriasis, dermatitis),

atherosclerosis, urticaria, eczema, photosensitivity, autoimmune disorders (i.e. lupus erythematosus, vitiligo, dermatomyositis, morphea, scleroderma, pemphigoid, and pemphigus), keloids, striae, erythema, petechiae, purpura, and xanthelasma. In addition, such disorders may predispose increased susceptibility to viral and bacterial  
5 infections of the skin (i.e. cold sores, warts, chickenpox, molluscum contagiosum, herpes zoster, boils, cellulitis, erysipelas, impetigo, tinea, athlete's foot, and ringworm).

Moreover, the protein product of this gene may also be useful for the treatment or diagnosis of various connective tissue disorders (i.e., arthritis, trauma,  
10 tendonitis, chondromalacia and inflammation, etc.), autoimmune disorders (i.e., rheumatoid arthritis, lupus, scleroderma, dermatomyositis, etc.), dwarfism, spinal deformation, joint abnormalities, and chondrodysplasias (i.e. spondyloepiphyseal dysplasia congenita, familial osteoarthritis, Atelosteogenesis type II, metaphyseal chondrodysplasia type Schmid). Moreover, the protein is useful in the detection,  
15 treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or  
20 receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
25 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:89 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
30 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1328 of SEQ ID NO:89, b is an

integer of 15 to 1342, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:89, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 80**

5           This gene is expressed primarily in immune cells and to a lesser extent in a wide variety of human tissues.

          Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
10       not limited to, T cell or B cell leukemia and various immunodeficiencies. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in  
15       certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

20           Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 203 as residues: Gly-3 to Gln-9. Polynucleotides encoding said polypeptides are also provided.

          The tissue distribution in immune cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of  
25       immune system diseases such as immunodeficiencies and T cell and/or B cell leukemia. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell  
30       lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory  
5 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's  
10 Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the  
15 protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:90 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is  
25 cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 756 of SEQ ID NO:90, b is an integer of 15 to 770, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:90, and where b is greater than or equal to a + 14.



**FEATURES OF PROTEIN ENCODED BY GENE NO: 81**

The translation product of this gene shares sequence homology with IgE receptor. See for example, Isolation and Characterization of cDNAs coding for the Beta Subunit of the High-affinity Receptor for Immunoglobulin E, Proc. Natl. Acad. Sci. U S A. (1988 Sep.) 85(17): 6483-6487. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with IgE receptor proteins. Such activities are known in the art, some of which are described elsewhere herein. IgE and its receptors are believed to have evolved as a mechanism to protect mammals against parasites. But other and intrinsically innocuous antigens can subvert this system to provoke an allergic response. For human populations in industrialized countries, allergy and asthma now represent a far greater threat than parasitic infection, and the main impetus for current studies of the IgE system is the hope of understanding and intervening in the aetiology of allergic diseases. The high-affinity receptor for immunoglobulin (Ig) E (Fc epsilon RI) on mast cells and basophils plays a key role in IgE-mediated allergies. Fc epsilon RI is composed of one alpha, one beta, and two gamma chains, which are all required for cell surface expression of Fc epsilon RI, but only the alpha chain is involved in the binding to IgE. Fc epsilon RI-IgE interaction is highly species specific, and rodent Fc epsilon RI does not bind human IgE. New homolog can be used to develop anti-allergic agents. FcR deliver signals when they are aggregated at the cell surface. The aggregation of FcR having immunoreceptor tyrosine-based activation motifs (ITAMs) activates sequentially src family tyrosine kinases and syk family tyrosine kinases that connect transduced signals to common activation pathways shared with other receptors. FcR with ITAMs elicit cell activation, endocytosis, and phagocytosis. The nature of responses depends primarily on the cell type. The aggregation of FcR without ITAM does not trigger cell activation. Most of these FcR internalize their ligands, which can be endocytosed, phagocytosed, or transcytosed. The fate of internalized receptor-ligand complexes depends on defined sequences in the intracytoplasmic domain of the receptors. The coaggregation of different FcR results in positive or negative cooperation. Some FcR without ITAM use FcR with ITAM as signal transduction subunits. The coaggregation of antigen receptors or of FcR having ITAMs with FcR having immunoreceptor tyrosine-based inhibition motifs (ITIMs)

negatively regulates cell activation. FcR therefore appear as the subunits of multichain receptors whose constitution is not predetermined and which deliver adaptative messages as a function of the environment.

The polypeptide of this gene has been determined to have four transmembrane domains at about amino acid position 51 - 67, 89 - 105, 119 - 135, and 190 - 206 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIa membrane proteins.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: ETRVKTSLELLRTQLEPTGTVGNTIMTSQPVPN ETIIVLPSNVINFSQAEKPEPTNQGQDSLKKHLHAEIKVIGTIQILCGMMVLSL GILASASFSNFTQVTSTLLNSAYPFIGPFFFFIISGSLSIATEKRLTKLLVHSSLV GSILSALSALVGFIILSVKQATLNPASLQCELDKNNIPTRSYVSYFYHDSLYTT DCYTAKASLAGXLSLMLICTLLEFCLAVLTAVLRWKQAYSDFPGSVLFLPH SYIGNSGMSSKMTHDCGYEELLTS (SEQ ID NO: 353). Polynucleotides encoding these polypeptides are also provided.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MMVLSLGIILASASFSNFTQVTSTLLNSAYPFIGPFFFFI ISGSLSIATEKRLTKLLVHSSLVGSILSALSALVGFIILSVKQATLNPASLQC ELDKNNIPTRSYVSYFYHDSLYTTDCYTAKASLAGXLSLMLICTLLEFCL AVLTAVLRWKQAYSDFPGSVLFLPHSYIGNSGMSSKMTHDCGYEELLTS (SEQ ID NO: 354). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in immune system tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune system diseases and/or disorders such as cancer. Similarly,

polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in  
5 certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

10 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 204 as residues: Gln-23 to Lys-39, Glu-150 to Thr-158. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in immune cells and tissues combined with the homology to IgE receptor indicates that polynucleotides and polypeptides  
15 corresponding to this gene are useful for diagnosis and treatment of immune system disorders. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell  
20 lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for  
25 immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity  
30 disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that

influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. The gene product may also be involved in lymphopoiesis, therefore, it can be used in immune disorders such as infection, inflammation, allergy, immunodeficiency etc. In addition, this gene product may have commercial utility in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:91 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1556 of SEQ ID NO:91, b is an integer of 15 to 1570, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:91, and where b is greater than or equal to a + 14.

## 25 FEATURES OF PROTEIN ENCODED BY GENE NO: 82

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GASCEGGGAAARAALGVHRSQKALLVFRRTL  
30 SNLLYMPLLRGLLWLQVLCAGPLHTEAVVLLVPSDDGRAFLLRSLHPEAH  
VPPAADRGASLQCVLHQAAPKSRPRSPAAGAALLHXPRRTGDEPCREFHGN  
GFPGPTQLTPGECGLPAPSSLLQHASAPVRTGSEGQVVGCPRARGETGEGLSL

AFLSSLMFTSRNGLVGC GASCEGGGAAARAALGVHRSQKALLVFRRTLNL  
LYMPLLRLGLLWLQVLCAGPLHTEAVVLLVPSDDGRAFLLSRLLHPEAHVPP  
AAD RGASLQCVLHQAAPKSRPRSPAAGAALLHXPRRTGDEPCREFHGNGFP  
GPTQLTPGECGLPAPSSLLQHASAPVRTGSEGQVVGCPRARGETGEGLSLA  
5 FLSSLMFTSRNGLVGC (SEQ ID NO: 355). Polynucleotides encoding these  
polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome  
7. Accordingly, polynucleotides related to this invention are useful as a marker in  
linkage analysis for chromosome 7.

10 This gene is expressed primarily in activated T cells, and to a lesser extent in a  
wide variety of human tissues.

Therefore, polynucleotides and polypeptides of the invention are useful as  
reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
15 not limited to, immune and hematopoietic diseases and/or disorders, particularly  
immunodeficiencies. Similarly, polypeptides and antibodies directed to these  
polypeptides are useful in providing immunological probes for differential  
identification of the tissue(s) or cell type(s). For a number of disorders of the above  
tissues or cells, particularly of the immune system, expression of this gene at  
20 significantly higher or lower levels is routinely detected in certain tissues or cell types  
(e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids  
(e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell  
sample taken from an individual having such a disorder, relative to the standard gene  
expression level, i.e., the expression level in healthy tissue or bodily fluid from an  
25 individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
epitopes shown in SEQ ID NO: 205 as residues: Pro-67 to Ser-73. Polynucleotides  
encoding said polypeptides are also provided.

The tissue distribution in activated T cells indicates that polynucleotides and  
30 polypeptides corresponding to this gene are useful for diagnosis and treatment of  
immunodeficiencies. Representative uses are described in the "Immune Activity" and  
"infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and

elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:92 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 2936 of SEQ ID NO:92, b is an integer of 15 to 2950, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:92, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 83

The translation product of this gene was shown to have homology to the human transmembrane protein (See Genbank Accession No. gblAAC51364.11 (AF000959); all references and information available through this accession are hereby incorporated by reference herein; for example, Genomics 42 (2), 245-251  
10 (1997)) which is thought to be implicated in velo-cardio-facial syndrome.

A preferred polypeptide fragment of the invention comprises the following amino acid sequence: MGSAALEILGLVLCLVGWGGILACGLPMWQVTAFLD  
HNIVTAQTTWKGLWMSCVVQSTGTCSAKCTTRCWL (SEQ ID NO: 356).

Polynucleotides encoding these polypeptides are also provided.

15 The gene encoding the disclosed cDNA is believed to reside on chromosome 22. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 22.

This gene is expressed primarily in dementia brain tissue, and to a lesser extent in a wide variety of human tissues.

20 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural diseases and/or disorders, particularly dementia. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing  
25 immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or  
30 another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 206 as residues: Ser-201 to Tyr-217. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in dementia brain tissue, combined with the homology  
5 to the transmembrane protein indicates that polynucleotides and polypeptides  
corresponding to this gene are useful for diagnosis and treatment of dementia, and  
potentially for velo-cardio-facial syndrome. Representative uses are described in the  
"Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11,  
15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the  
10 detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease,  
Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating  
diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal  
cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia,  
mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder,  
15 learning disabilities, ALS, psychoses, autism, and altered behaviors, including  
disorders in feeding, sleep patterns, balance, and perception. In addition, elevated  
expression of this gene product in regions of the brain indicates it plays a role in  
normal neural function.

Potentially, this gene product is involved in synapse formation,  
20 neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or  
survival. Furthermore, the protein may also be used to determine biological activity,  
to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to  
identify agents that modulate their interactions, in addition to its use as a nutritional  
supplement. Protein, as well as, antibodies directed against the protein may show  
25 utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are  
related to SEQ ID NO:93 and may have been publicly available prior to conception of  
the present invention. Preferably, such related polynucleotides are specifically  
30 excluded from the scope of the present invention. To list every related sequence is  
cumbersome. Accordingly, preferably excluded from the present invention are one or  
more polynucleotides comprising a nucleotide sequence described by the general



formula of a-b, where a is any integer between 1 to 1708 of SEQ ID NO:93, b is an integer of 15 to 1722, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:93, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 84

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: LKRAPPGPALAKGLLQPSSTFQALETNIGDQVR  
10 RHSTAVVIREMTSYILISFVLLIGVGCIEKDQSCPVFGGRKRLHLLFVGGQLRQ  
VRMLRGELSCACYRPHVQALQLGGCTCF (SEQ ID NO: 357). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in the adult pulmonary system.

Therefore, polynucleotides and polypeptides of the invention are useful as  
15 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, cystic fibrosis, bronchitis and any pulmonary disorders in general. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell  
20 type(s). For a number of disorders of the above tissues or cells, particularly of the pulmonary system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., pulmonary, cardiovascular, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, pulmonary surfactant, pulmonary lavage/sputum, synovial fluid and spinal fluid) or  
25 another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution of this gene only in the pulmonary system indicates that it plays a key role in the functioning of the pulmonary system. This would suggest  
30 that misregulation of the expression of this protein product in the adult could lead to lymphoma or sarcoma formation, particularly in the lung and the protein product could be used either in the treatment and/or detection of these disease states. The gene

or gene product may also useful in the treatment and/or detection of pulmonary defects such as pulmonary edema and embolism, bronchitis and cystic fibrosis.

Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents  
5 that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
10 related to SEQ ID NO:94 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
15 formula of a-b, where a is any integer between 1 to 621 of SEQ ID NO:94, b is an integer of 15 to 635, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:94, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 85

20 The translation product of this gene was found to be homologous to CAM proteins. Based on the sequence similarity, the translation product of this gene is expected to share at least some biological activities with CAM proteins. Such activities are known in the art, some of which are described elsewhere herein.

A preferred polypeptide variant of the invention comprises the following  
25 amino acid sequence: MLCPWRTANLGLLLILTIFLVAEAEGAAQPNNSLM  
LQTSKENHALASSSLCMDEKQITQNYSKVLAEVNTSWPVKMATNAVLC  
CPPIALRNLIITWEILRGQPSCTKAYKKETNETKETNCTDERITWVSRPDQ  
NSDLQIRTVAITHDGYRCIMVTPDGNFHRGYHLQVLVTPEVTLFQNRNRTA  
VCKAVAGKPAAHISWIPEGDCATKQEYWSNGTVTVKSTCHWEVHNVSTV  
30 NCHVSHLTGNKSLYIELLPVPGAKKSSKLYIPYIILTIILTIVGXIWLLKVNG  
CXKYKLNKPESTPVVEEDEMOPYAFYTEKNNPLXXTTNKVKASEALQSEV

DTDHLTL (SEQ ID NO:208). Polynucleotides encoding these polypeptides are also provided.

5 The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 271 - 287 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 288 to 348 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ia membrane proteins.

This gene is expressed primarily in dendritic cells.

10 Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immunodeficiency, tumor necrosis, infection, lymphomas, auto-immunities, cancer, metastasis, wound healing, inflammation, anemias  
15 (leukemia) and other hematopoietic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell  
20 types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 208 as residues: Asp-53 to Tyr-61, Pro-105 to Ile-128, Arg-133 to Leu-140, Gln-182 to Ala-188, Pro-205 to Asn-218, Gly-259 to Ala-264, Asn-290 to Ser-302, Glu-307 to Tyr-314, Tyr-317 to Lys-332. Polynucleotides encoding said polypeptides are also provided.

30 The tissue distribution in dendritic cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of immune disorders including: leukemias, lymphomas, auto-immunities,

immunodeficiencies (e.g. AIDS), immuno-suppressive conditions (transplantation) and hematopoietic disorders. In addition this gene product is applicable in conditions of general microbial infection, inflammation or cancer. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in  
5 Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the  
10 treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory  
15 bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's  
20 Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the  
25 protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:95 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general  
5 formula of a-b, where a is any integer between 1 to 3784 of SEQ ID NO:95, b is an integer of 15 to 3798, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:95, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 86

10 In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: VIKLICPAAFPVYFQDMARGCVCSLCASVCIFLS  
SLFPLLPSVHSVNIISCLLLSKCFEGLELMCEHL YQLSQLHVLHHIFSÝLLCTP  
15 (SEQ ID NO: 358). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in embryonic tissue and to a lesser extent in in a variety of other tissues and cell types.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, developmental anomalies, fetal deficiencies, cancer and neoplastic states. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the  
25 developing fetus, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., developmental, differentiating, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, amniotic fluid, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression  
30 level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in embryonic tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and treatment of developmental anomalies, fetal deficiencies and pre-natal disorders, as well as abnormal cell proliferation and/or differentiation, neoplastic states and cancer.

- 5 Moreover, the expression within embryonic tissue and other cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders"
- 10 and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

- Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent
- 15 of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the
- 20 polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in
- 25 modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their
- 30 interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:96 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
5 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2669 of SEQ ID NO:96, b is an integer of 15 to 2683, where both a and b correspond to the positions of nucleotide  
10 residues shown in SEQ ID NO:96, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 87**

The translation product of this gene shares sequence homology with inter-alpha-trypsin inhibitor which is thought to be important in inhibition of trypsin and  
15 other serine proteases (See Genbank Accession No. pirlS30350|S30350; all references and information available through this accession are hereby incorporated herein by reference; for example, Eur. J. Biochem. 179 (1), 147-154 (1989), J. Biol. Chem. 264 (27), 15975-15981 (1989), and J. Biol. Chem. 266 (2), 747-751 (1991)).

Contact of cells with supernatant expressing the product of this gene has been  
20 shown to increase the permeability of the plasma membrane of THP-1 cells to calcium. Thus it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both monocytes, in addition to other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are  
25 not limited to, activating monocytes, and to a lesser extent, other immune and/or hematopoietic cells. Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium and sodium, as well as alter pH and membrane potential. Alterations in small molecule concentration can be measured to identify supernatants which bind to receptors of a particular cell.

30 In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the

following amino acid sequence: YXIPGSTHASGRQRGSGRGEDDSGPPSTVINQ  
NETFANIIFKPTVVQQARIAQNGILGDFIIRYDVNREQSIGDIQVLNGYFVHYF  
APKDLPLPKNVVFVLDSSASMGVTKLRQTKDALFTILHDLRPQDRFSIIGFS  
NRIKVWKDHLISVTPDSIRDGKVYIHHMSPTGGTDINGVLQRAIRLLNKYVAH  
5 SGIGDRSVSLIVFLTDG KPTVGETHTLKILNNTREAARGQVCIFTIGIGNDVD  
FRLLEKLSLENCGLTRRVHEEEDAGSQLIGFYDEIRTPLLSDIRIDYPPSSVVQ  
ATKTLFPNYFNGSEIIIAGKLVDKLDHLHVEVTASNSKKFILKTDVPVRPQK  
AGKDVGTGSPRPGDGEGDXNHIERLWSYLTTKELLSSWLQSDDEPEKERLRQ  
RAQALAVSYRFLTPFTSMKLRGPVPRMDGLEEAHGMSAAMGPEPVVQSVR  
10 GAGTQPGPLLKKPYQPRIKISKTSVDGDPHFVVDFFPLSRLTVCFNIDGQPGDIL  
RLVSDHRDSGVTVNGELIGAPAPPNGHKKQRTYLRITILINKPERSYLEITPS  
RVILDGGDRLVLPCNQSVVVGSGWGLEVSVSANANVTVTIQGSI AFVILHLYK  
KPAPFQRHHLGFYIANSEGLSSNCHGLLGQFLNQDARLTEDPAGPSQNLTHP  
LLLQVGEGPEAVLTVKGHQVPVWVKQRKIYN GEEQXDCWFARNMPPN  
15 (SEQ ID NO: 359). Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in placenta and adipose tissue and to a lesser extent in several other organs and tissues including cancer.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a  
20 biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of developing organs and metabolic diseases, in addition to vascular diseases and conditions. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
25 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the developing systems and metabolic systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., reproductive, vascular, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or  
30 another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.



Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 210 as residues: Lys-5 to Lys-10, Asn-33 to Lys-39, Asp-48 to Lys-54, Pro-62 to Asp-67, Asn-116 to Arg-123, His-157 to Ala-162, Val-242 to Lys-249, Val-251 to Asp-264. Polynucleotides encoding said polypeptides are  
5 also provided.

The tissue distribution in placenta, combined with the homology to inter-alpha-trypsin inhibitor and the detected calcium flux biological activity indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of developing and metabolic systems. This protein may  
10 play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation  
15 and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of  
20 potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types  
25 of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new  
30 insight into the regulation of cellular growth and proliferation. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease,

vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Polynucleotides and polypeptides of the invention are also useful for the treatment, detection, and/or prevention of inflammation, tumor invasion and metastasis, wound healing, liver disease, 5 disseminated intravascular coagulation, alzheimer's Disease, ophthalmic disease, apoptosis, tissue remodeling, intrauterine growth retardation, preeclampsia, angiogenesis, cell migration, fetal development, trophoblast implantation, ovulation, pemphigus and psoriasis, and antiviral therapy. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate 10 cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly 15 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:97 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or 20 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2167 of SEQ ID NO:97, b is an integer of 15 to 2181, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:97, and where b is greater than or equal to a + 14.

## 25 **FEATURES OF PROTEIN ENCODED BY GENE NO: 88**

The translation product of this gene was shown to have homology to the human colon carcinoma antigen NY-CO-7 (See Genbank and Geneseq Accession Nos. gblAAC18038.11 (AF039689) and WO9904265; all references available through this accession are hereby incorporated herein by reference; for example, Int. J. Cancer 30 76 (5), 652-658 (1998)).

This gene is expressed primarily in breast and breast cancer and to a lesser extent in several other organs and tissues including cancers.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, disorders of reproductive organs and the gastrointestinal system, including cancers. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the reproductive systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., gastrointestinal, reproductive, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, breast milk, chyme, bile, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 211 as residues: Gly-22 to Gly-28, Leu-71 to Phe-77, Asn-101 to Val-108, Pro-122 to Ser-127, Arg-149 to Pro-154, Gly-191 to Phe-196, Pro-199 to Thr-211. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in breast and breast cancer tissue, combined with the homology to a colon cancer antigen indicates that polynucleotides and polypeptides corresponding to this gene are useful for treatment and diagnosis of disorders of the reproductive systems and cancers. This protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of

potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, 5 detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in 10 proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, 15 antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:98 and may have been publicly available prior to conception of 20 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1943 of SEQ ID NO:98, b is an 25 integer of 15 to 1957, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:98, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 89**

The translation product of this gene shares sequence homology with the amino 30 acid and protein sequence of a *Xenopus* transmembrane protein of unknown function. The very 5'-end of the contig is identical to the mRNA for the human LGN mosaic protein. Based on the sequence similarity, the translation product of this gene is

expected to share at least some biological activities with LGN mosaic proteins. Such activities are known in the art, some of which are described elsewhere herein.

Preferred polypeptides of the invention comprise the following amino acid sequence:

PRVRPPTKALAVTFTTFVTEPLKHIGKGTGEFIKALMKEIPALLHLPVLIIMAL  
5 AILSFCYGAGKSVHVL RHIGGPEREPPQALRPDRRRQEEIDYRPDGGAGDAD  
FHYRGQMGPTEQGPYAKTYEGRREILRERDVDLRFQTGNKSPEVLRAFDVPD  
AEAREHPTVVPSHKSPVLDTKPKETGGILGEGTPKESSTESSQSAKPVSGQDTS  
GNTEGSPA AEKAQLKSEAAGSPDQGSTYSPARGVAGPRGQDPVSSPCG (SEQ  
ID NO:339). Polynucleotides encoding such polypeptides are also provided.

10 The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in small intestine and adipocytes and to a lesser extent in various other normal and transformed cell types, mostly of endocrine  
15 origin.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, conditions of growth and metabolism. Similarly, polypeptides and  
20 antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the digestive and endocrine systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., metabolic, gastrointestinal, and  
25 cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, bile, chyme, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

30 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 212 as residues: Pro-40 to Gly-68, Gly-79 to Arg-93, Phe-106 to Glu-114, Pro-122 to His-129, Thr-143 to Gly-149, Gly-155 to Ala-168,

Val-171 to Gly-182, Ala-195 to Pro-207, Pro-214 to Val-220. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in small intestine indicates that polynucleotides and polypeptides corresponding to this gene are useful for study and treatment of disorders of growth and metabolism as well as endocrine abnormalities. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:99 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1098 of SEQ ID NO:99, b is an integer of 15 to 1112, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:99, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 90**

The translation product of this gene shares sequence homology with IgE receptor beta chain which is thought to be important in immune function.

This gene is expressed primarily in kidney medulla tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and renal diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and renal systems,

expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, renal, urogenital, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such  
5 a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in kidney renal medulla tissue, combined with the homology to the IgE receptor beta chain indicates that polynucleotides and polypeptides corresponding to this gene are useful for the treatment of immune and  
10 renal disorders. The protein product of this gene could be used in the treatment and/or detection of kidney diseases including renal failure, nephritis, renal tubular acidosis, proteinuria, pyuria, edema, pyelonephritis, hydronephritis, nephrotic syndrome, crush syndrome, glomerulonephritis, hematuria, renal colic and kidney stones, in addition to Wilm's Tumor Disease, and congenital kidney abnormalities such as horseshoe  
15 kidney, polycystic kidney, and Falconi's syndrome. Alternatively, this gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene  
20 product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and  
25 tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits  
30 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the

protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or  
 5 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:100 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
 10 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 873 of SEQ ID NO:100, b is an integer of 15 to 887, where both a and b correspond to the positions of nucleotide  
 15 residues shown in SEQ ID NO:100, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 91

The translation product of this gene shares sequence homology with Diff 40 gene product (See Genbank Accession No. gb|AAC51134.1; all references and  
 20 information available through this reference are hereby incorporated herein).

Preferred polypeptides of the invention comprise the following amino acid sequence: PRVRSIKVTELKGLANHVVVGSVSCETKDLFAALPQVVAVDIN  
 DLGTIKLSLEVTWSPFDKDDQPSAASSVNKASTVTKRFSTYSQSPDTPS  
 LREQAFYNMLRRQEELNGTAWSLSSSESSDDSSSPQLSGTARHSPAPRPLV  
 25 QQPEPLPIQVAFRRPETPSSGPLDEEGAVAPVLANGHAPYSRTLHISEASVNA  
 ALAEASVEAVGPKSLSWGSPPTHAPTHGKHPSVPVPPALDPGHSATSS  
 LGTTGSVPTSTDPAPSAHLDSVHKSTDSGPSELPGPTHHTTGSTYSAITTTHS  
 APSPLTHHTTGSTHKPIISTLTGPTLNIIGPVQTTTSPHTMPSPSSHNSPQ  
 YVDFCSSLVDNIFVHYVIGIFFHTLYSSKTL (SEQ ID NO:360), and/or PRVRS  
 30 IKVTELKGLANHVVVGSVSCETKDLFAALPQVVAVDINDLGTIKLSLEVTWSP  
 FDKDDQPSAASSVNKASTVTKRFSTYSQSPDTPSLREQAFYNMLRRQEEL  
 NGTAWSLSSSESSDDSSSPQLSGTARHSPAP RPLVQQPEPLPIQVAFRRPET



PSSGPLDEEGAVAPVLANGHAPYSRTLSEASVNAALAEASVEAVGPKSL  
SWGSPPTHPAPTHGKHPSVPPALDPGHSATSSTLGTGTVPTSTD (SEQ ID  
NO: 361). Polynucleotides encoding these polypeptides are also provided.

Polypeptides of the invention do not consist of the primary amino acid sequence  
5 shown as Geneseq Accession No.W69430, which is hereby incorporated herein by  
reference.

This gene is expressed primarily in liver and to a lesser extent in gall bladder  
tissue.

Therefore, polynucleotides and polypeptides of the invention are useful as  
10 reagents for differential identification of the tissue(s) or cell type(s) present in a  
biological sample and for diagnosis of diseases and conditions which include, but are  
not limited to, metabolic and endocrine diseases and/or disorders, particularly hepatic  
and gall bladder disorders. Similarly, polypeptides and antibodies directed to these  
polypeptides are useful in providing immunological probes for differential  
15 identification of the tissue(s) or cell type(s). For a number of disorders of the above  
tissues or cells, particularly of the metabolic and endocrine systems, expression of this  
gene at significantly higher or lower levels is routinely detected in certain tissues or  
cell types (e.g., hepatic, metabolic, gall bladder, gastrointestinal, and cancerous and  
wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, bile, synovial  
20 fluid and spinal fluid) or another tissue or cell sample taken from an individual having  
such a disorder, relative to the standard gene expression level, i.e., the expression  
level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic  
epitopes shown in SEQ ID NO: 214 as residues: Val-9 to Cys-14, Pro-42 to Thr-47,  
25 Thr-56 to Ala-64, Asp-88 to His-98, Cys-128 to Ser-136, Arg-153 to Trp-161.  
Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in liver and gall bladder, combined with the homology  
to the diff 40 gene product indicates that polynucleotides and polypeptides  
corresponding to this gene are useful for the study and treatment of endocrine and  
30 metabolic disorders. polynucleotides and polypeptides corresponding to this gene are  
useful for the detection and treatment of liver disorders and cancers. Representative  
uses are described in the "Hyperproliferative Disorders", "infectious disease", and

"Binding Activity" sections below, in Example 11, and 27, and elsewhere herein.

Briefly, the protein can be used for the detection, treatment, and/or prevention of hepatoblastoma, jaundice, hepatitis, liver metabolic diseases and conditions that are attributable to the differentiation of hepatocyte progenitor cells. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:101 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1234 of SEQ ID NO:101, b is an integer of 15 to 1248, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:101, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 92

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 3 - 19 of the amino acid sequence referenced in Table 1 for this gene. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type II membrane proteins.

This gene is expressed primarily in fetal brain and to a lesser extent in pancreas tumor, melanocyte and infant brain.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, neural diseases and/or disorders, particularly neurodevelopmental disorders. Similarly, polypeptides and antibodies directed to these polypeptides are

useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the central nervous system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., neural, developmental, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

The tissue distribution in fetal brain tissue indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of developmental disorders of the central nervous system. Representative uses are described in the "Regeneration" and "Hyperproliferative Disorders" sections below, in Example 11, 15, and 18, and elsewhere herein. Briefly, the uses include, but are not limited to the detection, treatment, and/or prevention of Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, meningitis, encephalitis, demyelinating diseases, peripheral neuropathies, neoplasia, trauma, congenital malformations, spinal cord injuries, ischemia and infarction, aneurysms, hemorrhages, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, depression, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, elevated expression of this gene product in regions of the brain indicates it plays a role in normal neural function.

Potentially, this gene product is involved in synapse formation, neurotransmission, learning, cognition, homeostasis, or neuronal differentiation or survival. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:102 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or  
 5 more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1827 of SEQ ID NO:102, b is an integer of 15 to 1841, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:102, and where b is greater than or equal to a + 14.

## 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 93

The translation product of this gene shares sequence homology with a probable membrane protein YGL054c -yeast (*Saccharomyces cerevisiae*). Moreover,

The translation product of this gene also have homology to the human and mouse cornichon protein which is known to be necessary for both anterior-posterior  
 15 and dorsal-ventral pattern formation in conjunction with the EGF receptor signaling process (See Genbank Accession Nos. gb|AAC98388.1| (AF104398), and sp|P52159; all references and information available through these accessions are hereby incorporated herein by reference; for example, Cell 81 (6), 967-978 (1995)).

The polypeptide of this gene has been determined to have two transmembrane  
 20 domains at about amino acid position 57 - 73, and 121 - 137 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 1 - 14 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type IIIa membrane proteins.

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: YGCEKTTEGGRRRRRRMEAVVFVFSLLDCCAL  
 IFLSVYFIITLSDLECDYINARSCSKLNKWWIPELIGHTIVTVLLMSLHWF  
 30 IFLLNLPVATWNIYRYIMVPSGNMGVFDPTIEHNRGQLKSHMKEAMIKLGFH  
 LLCFFMYLYSMILALIND (SEQ ID NO:362). Polynucleotides encoding these polypeptides are also provided.

The gene encoding the disclosed cDNA is believed to reside on chromosome 1. Accordingly, polynucleotides related to this invention are useful as a marker in linkage analysis for chromosome 1.

This gene is expressed primarily in activated T-cells and to a lesser extent in endometrial tumor, T cell helper II cells, microvascular endothelial cells, Raji cells treated with cyclohexamide and umbilical vein endothelial cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune, hematopoietic, and vascular diseases and/or disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, vascular, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, amniotic fluid, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 216 as residues: Ser-39 to Asn-45, Asn-103 to Ser-109. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution in activated T-cells indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of immune disorders involving activated T-cells. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or

other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Moreover, the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:103 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 671 of SEQ ID NO:103, b is an integer of 15 to 685, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:103, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 94

In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: ARAPAPSLPPLPSPAPALAPAHSLGLLLGRMS  
10 GSSLPSALALSLLLVSGLLPGPAAQNVRVQSGQDQ (SEQ ID NO: 363).

Polynucleotides encoding these polypeptides are also provided.

This gene is expressed primarily in dendritic cells and to a lesser extent in healing abdomen wound, and pancreas islet cell tumor cells.

Therefore, polynucleotides and polypeptides of the invention are useful as  
15 reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune and hematopoietic diseases and/or disorders, particularly wound healing disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential  
20 identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or  
25 cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 217 as residues: Gln-34 to Lys-40. Polynucleotides  
30 encoding said polypeptides are also provided.

The tissue distribution in dendritic cells and early healing wound indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating

wounds to enhance the healing process. Representative uses are described in the "Immune Activity" and "infectious disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression of this gene product indicates a role in regulating the proliferation; survival; differentiation; and/or  
5 activation of hematopoietic cell lineages, including blood stem cells. This gene product is involved in the regulation of cytokine production, antigen presentation, or other processes suggesting a usefulness in the treatment of cancer (e.g. by boosting immune responses).

Since the gene is expressed in cells of lymphoid origin, the natural gene  
10 product is involved in immune functions. Therefore it is also useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous Disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and  
15 tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lens tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's Disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits  
20 hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their  
25 interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
30 related to SEQ ID NO:104 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is



cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1154 of SEQ ID NO:104, b is an integer of 15 to 1168, where both a and b correspond to the positions of nucleotide  
5 residues shown in SEQ ID NO:104, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 95**

Contact of cells with supernatant expressing the product of this gene has been shown to increase the permeability of the plasma membrane of aortic smooth muscle  
10 cells to calcium. Thus it is likely that the product of this gene is involved in a signal transduction pathway that is initiated when the product binds a receptor on the surface of the plasma membrane of both smooth muscle cells, and in other cell-lines or tissue cell types. Thus, polynucleotides and polypeptides have uses which include, but are not limited to, activating smooth muscle cells. Binding of a ligand to a receptor is  
15 known to alter intracellular levels of small molecules, such as calcium, potassium and sodium, as well as alter pH and membrane potential. Alterations in small molecule concentration can be measured to identify supernatants which bind to receptors of a particular cell.

This gene is expressed primarily in pancreatic carcinoma, gall bladder and  
20 primary dendritic cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, metabolic and immune diseases and/or disorders, particularly cancers,  
25 such as pancreatic carcinoma and gall bladder tumor. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain  
30 tissues or cell types (e.g., metabolic, immune, hematopoietic, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such

a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 218 as residues: Lys-34 to Ile-41. Polynucleotides  
5 encoding said polypeptides are also provided.

The tissue distribution in pancreatic carcinoma and gall bladder indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosing and treating cancer, such as pancreatic carcinoma and gall bladder tumors. Representative uses are described here and elsewhere herein. Alternatively, the  
10 detected calcium flux biological activity indicates the protein is useful in the detection, treatment, and/or prevention of a variety of vascular disorders and conditions, which include, but are not limited to microvascular disease, vascular leak syndrome, aneurysm, stroke, embolism, thrombosis, coronary artery disease, arteriosclerosis, and/or atherosclerosis. Furthermore, the protein may also be used to  
15 determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:105 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is  
25 cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1161 of SEQ ID NO:105, b is an integer of 15 to 1175, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:105, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 96**

The polypeptide of this gene has been determined to have a transmembrane domain at about amino acid position 10 - 26 of the amino acid sequence referenced in Table 1 for this gene. Moreover, a cytoplasmic tail encompassing amino acids 27 to 48 of this protein has also been determined. Based upon these characteristics, it is believed that the protein product of this gene shares structural features to type Ib membrane proteins.

This gene is expressed primarily in osteosarcoma, wilm's tumor, ovarian cancer and in T-cells.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, inflammatory diseases and cancers, such as osteosarcoma, wilm's tumor and ovarian cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., skeletal, renal, reproductive, immune, and cancerous and wounded tissues) or bodily fluids (e.g., lymph, serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 219 as residues: Ser-30 to Pro-35. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for diagnosis and treatment of inflammatory conditions and cancer, such as osteosarcoma, wilm's tumor and ovarian cancer. Moreover, the expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of developmental diseases

and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern formation.

5           Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of potential roles in proliferation and differentiation, this gene product may have  
10 applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types of degenerative conditions. Thus this protein may modulate apoptosis or tissue  
15 differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new insight into the regulation of cellular growth and proliferation. Furthermore, the  
20 protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

25           Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:106 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence is  
30 cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1007 of SEQ ID NO:106, b is an

integer of 15 to 1021, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:106, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 97

5           In another embodiment, polypeptides comprising the amino acid sequence of the open reading frame upstream of the predicted signal peptide are contemplated by the present invention. Specifically, polypeptides of the invention comprise the following amino acid sequence: GTSKDCVLYAFLDPGMAVPLFLYIFTLLPLLPLFLLSLCFSPLTVKRSSSSSESKSSL (SEQ ID NO: 364). Polynucleotides encoding  
10 these polypeptides are also provided.

          This gene is expressed primarily in ovarian cancer.

          Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are  
15 not limited to, ovarian cancer. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune system, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types  
20 (e.g., reproductive, ovarian, and cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial amniotic fluid, fluid or spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

25           Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 220 as residues: Thr-28 to Ser-40. Polynucleotides encoding said polypeptides are also provided.

          The tissue distribution in ovarian tissues indicates that polynucleotides and polypeptides corresponding to this gene are useful for treating and diagnosing cancer,  
30 e.g., ovarian cancer. Moreover, the expression within cellular sources marked by proliferating cells indicates this protein may play a role in the regulation of cellular division, and may show utility in the diagnosis, treatment, and/or prevention of

developmental diseases and disorders, including cancer, and other proliferative conditions. Representative uses are described in the "Hyperproliferative Disorders" and "Regeneration" sections below and elsewhere herein. Briefly, developmental tissues rely on decisions involving cell differentiation and/or apoptosis in pattern  
5 formation.

Dysregulation of apoptosis can result in inappropriate suppression of cell death, as occurs in the development of some cancers, or in failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders, such as spinal muscular atrophy (SMA). Because of  
10 potential roles in proliferation and differentiation, this gene product may have applications in the adult for tissue regeneration and the treatment of cancers. It may also act as a morphogen to control cell and tissue type specification. Therefore, the polynucleotides and polypeptides of the present invention are useful in treating, detecting, and/or preventing said disorders and conditions, in addition to other types  
15 of degenerative conditions. Thus this protein may modulate apoptosis or tissue differentiation and is useful in the detection, treatment, and/or prevention of degenerative or proliferative conditions and diseases. The protein is useful in modulating the immune response to aberrant polypeptides, as may exist in proliferating and cancerous cells and tissues. The protein can also be used to gain new  
20 insight into the regulation of cellular growth and proliferation. Furthermore, the protein may also be used to determine biological activity, to raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or  
25 immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:107 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
30 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general

formula of a-b, where a is any integer between 1 to 816 of SEQ ID NO:107, b is an integer of 15 to 830, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:107, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 98

This gene is expressed primarily in macrophages and breast cancer tissue and to a lesser extent in osteoblasts and smooth muscle.

Therefore, polynucleotides and polypeptides of the invention are useful as reagents for differential identification of the tissue(s) or cell type(s) present in a biological sample and for diagnosis of diseases and conditions which include, but are not limited to, immune system dysfunction; inflammation; breast cancer; cancer; osteoporosis; osteopetrosis; peristaltic disorders. Similarly, polypeptides and antibodies directed to these polypeptides are useful in providing immunological probes for differential identification of the tissue(s) or cell type(s). For a number of disorders of the above tissues or cells, particularly of the immune and skeletal systems, expression of this gene at significantly higher or lower levels is routinely detected in certain tissues or cell types (e.g., cancerous and wounded tissues) or bodily fluids (e.g., serum, plasma, urine, synovial fluid and spinal fluid) or another tissue or cell sample taken from an individual having such a disorder, relative to the standard gene expression level, i.e., the expression level in healthy tissue or bodily fluid from an individual not having the disorder.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 221 as residues: Glu-16 to Ala-40. Polynucleotides encoding said polypeptides are also provided.

The tissue distribution indicates that polynucleotides and polypeptides corresponding to this gene are useful for the diagnosis and/or treatment of a variety of disorders. Expression in macrophages and other hematopoietic cell types indicates that this gene product is involved in the regulation of hematopoietic cell survival, proliferation, differentiation, or activation. It is involved in the control of such processes as immune surveillance, antigen presentation, T cell activation, cytokine release, and inflammation. Expression in breast cancer tissue may possibly correlate with the diagnosis and differentiation of cancerous tissue from normal breast tissue.

Expression in osteoblasts and osteoclasts may implicate this gene product in the process of bone turnover, and target it as a likely candidate for the treatment of osteoporosis and/or osteopetrosis. Finally, expression in smooth muscle may indicate an involvement in the normal function of numerous internal organs and in the  
5 function of the digestive system.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:108 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
10 excluded from the scope of the present invention. To list every related sequence is cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1287 of SEQ ID NO:108, b is an integer of 15 to 1301, where both a and b correspond to the positions of nucleotide  
15 residues shown in SEQ ID NO:108, and where b is greater than or equal to a + 14.



Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HDPTK41	209965 06/11/98	pCMV/Sport 3.0	11	1564	1	1564	39	39	124	1	26	27	369
2	HFXGT26	209965 06/11/98	Lambda ZAP II	12	1757	1	1757	13	13	125	1	22	23	85
3	HLTGX30	209965 06/11/98	Uni-ZAP XR	13	1373	1	1373	13	13	126	1	41	42	43
4	HLTHG37	209965 06/11/98	Uni-ZAP XR	14	3740	1908	3740	50	50	127	1	1	2	319
4	HLTHG37	209965 06/11/98	Uni-ZAP XR	109	1932	98	1932	313	313	222	1	35	36	42
5	HNTMZ90	209965 06/11/98	pSport1	15	1196	1	1196	282	282	128	1	21	22	45

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Secreted Portion	Last AA of ORF	
6	HPIBX03	209965 06/11/98	Uni-ZAP XR	16	2209	1	2178	81	81	129	1	29	30	709
7	H6EDY30	209965 06/11/98	Uni-ZAP XR	17	1774	1	1774	321	321	130	1	29	30	414
8	HAMGR28	209965 06/11/98	pCMVSPORT 3.0	18	1674	47	1674	98	98	131	1	18	19	242
8	HAMGR28	209965 06/11/98	pCMVSPORT 3.0	110	1534	1	1534	40	40	223	1	18	19	203
9	HAPNZ94	209965 06/11/98	Uni-ZAP XR	19	2018	255	2018	287	287	132	1	36	37	312
10	HATCP77	209965 06/11/98	Uni-ZAP XR	20	2098	1	2098	37	37	133	1	21	22	182

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
11	HDABR72	209965 06/11/98	pSport1	21	1746	1	1746	28	134	1	29	30	146
12	HDPKB18	209965 06/11/98	pCMVSPORT 3.0	22	2876	1	2876	98	135	1	21	22	122
12	HDPKB18	209965 06/11/98	pCMVSPORT 3.0	111	2871	1	2871	87	224	1	21	22	42
13	HEQCC55	209965 06/11/98	pCMVSPORT 3.0	23	1052	30	1052	62	136	1	27	28	112
13	HEQCC55	209965 06/11/98	pCMVSPORT 3.0	112	1037	1	1037	57	225	1	27	28	155
14	HETDE26	209965 06/11/98	Uni-ZAP XR	24	1541	1	1541	205	137	1	29	30	139

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
15	HOEDH84	209965 06/11/98	Uni-ZAP XR	25	2079	1	2079	256	256	138	1	20	21	404
16	HPIBT55	209965 06/11/98	Uni-ZAP XR	26	1947	129	1947	253	253	139	1	30	31	95
17	HSLCS05	209965 06/11/98	Uni-ZAP XR	27	3379	1	3354	168	168	140	1	23	24	239
18	HDPDD03	209965 06/11/98	pCMV Sport 3.0	28	2006	1	2006	233	233	141	1	21	22	53
19	HDPDI66	209965 06/11/98	pCMV Sport 3.0	29	3070	1	3070	93	93	142	1	45	46	66
20	HDTDQ23	209965 06/11/98	pCMV Sport 2.0	30	2227	1	2206	148	148	143	1	20	21	108

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
20	HDTDQ23	209965 06/11/98	pCMVSPORT 2.0	113	2214	1	2206	148	226	1	20	21	73
21	HE2PY40	209965 06/11/98	Uni-ZAP XR	31	1288	1	1288	147	144	1	22	23	83
22	HEONM66	209965 06/11/98	pSPORT1	32	3280	1	3280	89	145	1	24	25	166
22	HEONM66	209965 06/11/98	pSPORT1	114	3300	1	3300	98	227	1	20	21	166
23	HKAEG43	209965 06/11/98	pCMVSPORT 2.0	33	1297	1	1297	32	146	1	29	30	70
23	HKAEG43	209965 06/11/98	pCMVSPORT 2.0	115	1286	1	1286	21	228	1	29	30	70

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
24	HLHDP65	209965 06/11/98	Uni-ZAP XR	34	2184	1	2184	19	19	147	1	19	20	412
24	HLHDP65	209965 06/11/98	Uni-ZAP XR	116	2189	1	2189	26	26	229	1	21	22	272
25	HLMDO03	209965 06/11/98	Uni-ZAP XR	35	949	1	949	72	72	148	1	45	46	84
26	HMAGK93	209965 06/11/98	Uni-ZAP XR	36	3338	162	1884	164	164	149	1	30	31	153
27	HMEAL02	209965 06/11/98	Lambda ZAP II	37	1563	1	1563	237	237	150	1	33	34	129
28	HMKCH52	209965 06/11/98	pSport1	38	1048	1	1048	53	53	151	1	17	18	61

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
29	HCEFB69	209965 06/11/98	Uni-ZAP XR	39	1430	1	1430	188	152	1	24	25	224
30	HNFEC43	203027 06/26/98	Uni-ZAP XR	40	2103	209	2058	488	153	1	15	16	68
31	HSPMG77	203027 06/26/98	pSport1	41	2349	1	2349	130	154	1	46	47	83
32	HSQAC69	203027 06/26/98	Uni-ZAP XR	42	1559	1	1559	146	155	1	21	22	60
33	HSTB186	203027 06/26/98	Uni-ZAP XR	43	1766	1	1766	120	156	1	24	25	83
34	HLDQR62	203027 06/26/98	pCMV Sport 3.0	44	2572	427	2572	520	157	1	18	19	161

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	5' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
35	HUVDJ43	203027 06/26/98	Uni-ZAP XR	45	526	69	526	89	158	1	31	32	146
36	HADCP14	203027 06/26/98	pSport1	46	1032	1	1032	35	159	1	20	21	142
37	HBXCF95	203027 06/26/98	ZAP Express	47	2680	1	2680	118	160	1	22	23	50
38	HEQBU15	203027 06/26/98	pCMVSPORT 3.0	48	1730	1	1730	56	161	1	26	27	64
39	HL1BD22	203027 06/26/98	Uni-ZAP XR	49	1275	1	1275	53	162	1	39	40	58
40	HOEEU24	203027 06/26/98	Uni-ZAP XR	50	1762	1	1762	113	163	1	21	22	374



Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
40	HOEEU24	203027 06/26/98	Uni-ZAP XR	117	1763	1	1763	113	113	230	1	21	22	81
41	HTTBR96	203027 06/26/98	Uni-ZAP XR	51	2059	1	2059	96	96	164	1	26	27	63
42	HWHQS55	203027 06/26/98	pCMVSPORT 3.0	52	3282	1	3282	169	169	165	1	26	27	742
43	HCEEK50	203027 06/26/98	Uni-ZAP XR	53	1860	1	1860	233	233	166	1	17	18	213
44	HCWBU94	203027 06/26/98	ZAP Express	54	770	1	770	109	109	167	1	26	27	212
45	HE2NR62	203027 06/26/98	Uni-ZAP XR	55	1093	1	1093	145	145	168	1	38	39	74

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
46	HHS GH19	203027 06/26/98	Uni-ZAP XR	56	632	1	632	291	169	1	15	16	47
47	HDP GT01	203027 06/26/98	pCMV Sport 3.0	57	2687	138	2687	8	170	1	28	29	87
48	HOB AF11	203027 06/26/98	pBluescript	58	619	153	579	166	171	1	30	31	41
49	HOH CA35	203027 06/26/98	pCMV Sport 2.0	59	1378	1	1378	153	172	1	15	16	47
50	HPM GP24	203027 06/26/98	Uni-ZAP XR	60	1126	1	1126	215	173	1	33	34	232
51	HSD IE16	203027 06/26/98	Uni-ZAP XR	61	2078	1	2078	182	174	1	29	30	44

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	5' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
52	HSOBK48	203027 06/26/98	Uni-ZAP XR	62	762	1	762	433	175	1	16	17	84
53	HTADH39	203027 06/26/98	Uni-ZAP XR	63	1094	1	1094	173	176	1	24	25	65
54	HUSGT36	203027 06/26/98	pSport1	64	1361	1	1361	112	177	1	16	17	54
55	HVAAE95	203027 06/26/98	pSport1	65	947	1	947	325	178	1	14	15	82
56	HHEAH25	203071 07/27/98	pCMVSPORT 3.0	66	1376	1	1376	43	179	1	31	32	330
56	HHEAH25	203071 07/27/98	pCMVSPORT 3.0	118	1375	1	1375	43	231	1	31	32	71

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	5' NT of Clone Seq.	5' NT of Clone Seq.	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
57	HBIIY92	203071 07/27/98	Uni-ZAP XR	67	2434	487	2366	548	548	180	1	29	30	40
58	HCLCW50	203071 07/27/98	Lambda ZAP II	68	1086	1	1086	255	255	181	1	17	18	51
59	HDRMF68	203071 07/27/98	pSport1	69	1262	1	1262	309	309	182	1	22	23	54
60	HOUGG12	203071 07/27/98	Uni-ZAP XR	70	1642	35	1642	116	116	183	1	22	23	61
61	HEEAQ11	203071 07/27/98	Uni-ZAP XR	71	921	1	921	213	213	184	1	28	29	147
62	HEEAZ65	203071 07/27/98	Uni-ZAP XR	72	906	1	906	182	182	185	1	19	20	160

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	Signal Pep	AA ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
63	HEGAN94	203071 07/27/98	Uni-ZAP XR	73	680	1	680	133	133	186	1	23	24	121
64	HFXBL33	203071 07/27/98	Lambda ZAP II	74	1633	1	1633	152	152	187	1	24	25	162
65	HLIBD68	203071 07/27/98	pCMVSPORT 1	75	1022	1	1022	186	186	188	1	35	36	50
66	HLTCO33	203071 07/27/98	Uni-ZAP XR	76	1184	1	1184	80	80	189	1	18	19	64
67	HL YAC95	203071 07/27/98	pSport1	77	312	1	312	92	92	190	1	16	17	46
68	HNFGF20	203071 07/27/98	Uni-ZAP XR	78	1370	38	1370	206	206	191	1	45	46	143

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
69	HNHKS18	203071 07/27/98	Uni-ZAP XR	79	368	1	368	125	125	192	1	36	37	81
70	HSLJW78	203071 07/27/98	Uni-ZAP XR	80	1088	1	1088	159	159	193	1	20	21	44
71	HHFHD01	203071 07/27/98	Uni-ZAP XR	81	1862	1	1862	177	177	194	1	16	17	41
72	HLWAE11	203071 07/27/98	pCMVSPORT 3.0	82	1618	1	1618	85	85	195	1	27	28	259
73	HICYBN55	203071 07/27/98	pBluescript SK-	83	2034	1	1984	341	341	196	1	19	20	117
73	HICYBN55	203071 07/27/98	pBluescript SK-	119	1022	78	1022		3	232	1	1	2	225

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
74	HEONX38	203071 07/27/98	pSport1	84	2240	5	2240	23	23	197	1	23	24	698
74	HEONX38	203071 07/27/98	pSport1	120	2311	1	2311	24	24	233	1	23	24	314
75	HLDQU79	203071 07/27/98	pCMVSPORT 3.0	85	1488	1	1488	99	99	198	1	23	24	348
76	HSYBK21	203071 07/27/98	pCMVSPORT 3.0	86	3174	1	1466	119	119	199	1	29	30	401
77	HELCB12	203071 07/27/98	Uni-ZAP XR	87	2780	2110	2738	120	120	200	1	30	31	324
78	HTHDS25	203071 07/27/98	Uni-ZAP XR	88	1061	1	1061	70	70	201	1	15	16	90

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
79	HFIHO70	203071 07/27/98	pSport1	89	1342	1	1271	141	141	202	1	30	31	243
79	HFIHO70	203071 07/27/98	pSport1	121	1286	1	1279	131	131	234	1	30	31	93
80	HPMEI86	203071 07/27/98	Uni-ZAP XR	90	770	40	770	50	50	203	1	30	31	75
81	HSOBV29	203071 07/27/98	Uni-ZAP XR	91	1570	207	1570	244	244	204	1	24	25	248
82	HWABY10	203071 07/27/98	pCMVSPORT 3.0	92	2950	78	2914	263	263	205	1	22	23	168
83	HACCI17	203071 07/27/98	Uni-ZAP XR	93	1722	336	1714	461	461	206	1	24	25	218



Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
83	HACCI17	203071 07/27/98	Uni-ZAP XR	122	1380	12	1380	135	135	235	1	24	25	72
84	HAPQT22	203070 07/27/98	Uni-ZAP XR	94	635	1	635	132	132	207	1	17	18	72
85	HDPBO81	203070 07/27/98	pCMVSPORT 3.0	95	3798	1	3798	265	265	208	1	26	27	348
85	HDPBO81	203070 07/27/98	pCMVSPORT 3.0	123	3793	1	3793	255	255	236	1	26	27	348
86	HDPGI49	203070 07/27/98	pCMVSPORT 3.0	96	2683	1	2640	266	266	209	1	29	30	72
87	HDTBV77	203070 07/27/98	pCMVSPORT 2.0	97	2181	1	2181	326	326	210	1	22	23	608

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
88	HFIUE82	203070 07/27/98	pSport1	98	1957	1	1957	24	24	211	1	23	24	251
89	HHEND31	203070 07/27/98	pCMVSPORT 3.0	99	1112	1	1112	109	109	212	1	25	26	225
90	HKMND01	203069 07/27/98	pBluescript	100	887	1	887	23	23	213	1	26	27	50
91	HLDBI84	203069 07/27/98	pCMVSPORT 3.0	101	1248	1	1248	50	50	214	1	35	36	171
92	HLTEK17	203069 07/27/98	Uni-ZAP XR	102	1841	1	1841	112	112	215	1	13	14	47
93	HEBEJ18	203069 07/27/98	Uni-ZAP XR	103	685	7	649	51	51	216	1	15	16	139

Gene No.	cDNA Clone ID	ATCC Deposit Nr and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
94	HMEAI48	203069 07/27/98	Lambda ZAP II	104	1168	1	1168	95	95	217	1	29	30	40
95	HNHGN91	203069 07/27/98	Uni-ZAP XR	105	1175	161	1175	184	184	218	1	24	25	51
96	HODAE92	203069 07/27/98	Uni-ZAP XR	106	1021	1	1021	123	123	219	1	29	30	48
97	HODDF13	203069 07/27/98	Uni-ZAP XR	107	830	1	830	46	46	220	1	27	28	41
98	HCDCF30	203027 06/26/98	Uni-ZAP XR	108	1301	102	1301	151	151	221	1	14	15	40

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X and the translated SEQ ID NO:Y are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization

probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID  
5 NO:Y may be used to generate antibodies which bind specifically to the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or  
10 deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

15 Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC,  
20 as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods. The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a  
25 suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed  
30 herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate sources of genomic material.

Also provided in the present invention are species homologs. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for the desired homologue.

5        The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

10       The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification , such as multiple histidine residues, or an additional sequence for stability during  
15 recombinant production.

      The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified by the one-step method described in Smith and Johnson, Gene 67:31-40  
20 (1988). Polypeptides of the invention also can be purified from natural or recombinant sources using antibodies of the invention raised against the secreted protein in methods which are well known in the art.

### Signal Sequences

25        Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, Virus Res. 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, Nucleic Acids Res. 14:4683-4690 (1986) uses the  
30 information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of

these methods is in the range of 75-80%. (von Heinje, supra.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

#### **Polynucleotide and Polypeptide Variants**

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

By a polynucleotide having a nucleotide sequence at least, for example, 95%

"identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent identity is corrected by calculating the number of bases of the query sequence



that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid.

These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

- 5       As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequences shown in Table 1 or to the amino acid sequence encoded by deposited DNA clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. (1990) 6:237-245). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity.
- 10       Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.
- 15       If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and
- 20
- 25
- 30

C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

5           For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is  
10           subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no  
15           residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual  
20           corrections are to be made for the purposes of the present invention.

          The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced  
25           by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as E.  
30           coli).

          Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an

organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level.

Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

5        Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988  
10        (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

15        Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over  
20        the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500 nucleotide sequences examined, produced a protein that significantly differed in  
25        activity from wild-type.

      Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted  
30        form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic

activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, 5 inversions, repeats, and substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

10 The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these 15 positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. 20 For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used. (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are 25 surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions 30 involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of

the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention  
5 include (i) substitutions with one or more of the non-conserved amino acid residues, where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for  
10 example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino acids, such as an IgG Fc fusion region peptide, or leader or secretory sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of  
15 charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev.  
20 Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid  
25 substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1  
30 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is

1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

### **Polynucleotide and Polypeptide Fragments**

5           In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence contained in the deposited clone or shown in SEQ ID NO:X. The short nucleotide fragments are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length. A fragment "at least 20 nt  
10 in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in the deposited clone or the nucleotide sequence shown in SEQ ID NO:X. These nucleotide fragments are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

15           Moreover, representative examples of polynucleotide fragments of the invention, include, for example, fragments having a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-  
20 1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X or the cDNA contained in the deposited clone. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini.  
25 Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein.

          In the present invention, a "polypeptide fragment" refers to a short amino acid sequence contained in SEQ ID NO:Y or encoded by the cDNA contained in the  
30 deposited clone. Protein fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the

invention, include, for example, fragments from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges, larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form. Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotide fragments encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotide fragments encoding these domains are also contemplated.

Other preferred fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

### Epitopes & Antibodies



In the present invention, "epitopes" refer to polypeptide fragments having antigenic or immunogenic activity in an animal, especially in a human. A preferred embodiment of the present invention relates to a polypeptide fragment comprising an epitope, as well as the polynucleotide encoding this fragment. A region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." In contrast, an "immunogenic epitope" is defined as a part of a protein that elicits an antibody response. (See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983).)

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985) further described in U.S. Patent No. 4,631,211.)

In the present invention, antigenic epitopes preferably contain a sequence of at least seven, more preferably at least nine, and most preferably between about 15 to about 30 amino acids. Antigenic epitopes are useful to raise antibodies, including monoclonal antibodies, that specifically bind the epitope. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe, J. G. et al., Science 219:660-666 (1983).)

Similarly, immunogenic epitopes can be used to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F. J. et al., J. Gen. Virol. 66:2347-2354 (1985).) A preferred immunogenic epitope includes the secreted protein. The immunogenic epitopes may be presented together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting.)

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')<sub>2</sub> fragments) which are capable of specifically binding to protein. Fab and F(ab')<sub>2</sub> fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding than an intact antibody. (Wahl et al., J. Nucl. Med. 24:316-325 (1983).) Thus, these

fragments are preferred, as well as the products of a FAB or other immunoglobulin expression library. Moreover, antibodies of the present invention include chimeric, single chain, and humanized antibodies.

## 5 **Fusion Proteins**

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second  
10 protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous  
15 functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the  
20 polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-  
30 polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).) Fusion proteins having disulfide-linked dimeric structures (due to the

IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion  
5 proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified,  
10 would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol.  
15 Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue,  
20 Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767  
25 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

### **Vectors, Host Cells, and Protein Production**

30 The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral

vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

5 The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

10 The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding  
15 portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin  
20 resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as  
25 CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and  
30 ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1

and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods  
5 are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

10 A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most  
15 preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical  
20 synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also  
25 include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some  
30 proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding  
5 sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences  
10 via homologous recombination (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their  
15 entireties).

#### **Uses of the Polynucleotides**

Each of the polynucleotides identified herein can be used in numerous ways as  
20 reagents. The following description should be considered exemplary and utilizes known techniques.

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat  
25 polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted  
30 exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids

containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined. First, visible structural alterations in the chromosomes, such as deletions or

translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Both methods rely on binding of the polynucleotide to DNA or RNA. For these techniques, preferred polynucleotides are usually 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res. 6:3073 (1979); Cooney et al., Science 241:456 (1988); and Dervan et al., Science 251:1360 (1991) ) or to the mRNA itself (antisense - Okano, J. Neurochem. 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.



The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more  
5 restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

10 The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a  
15 unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological  
20 samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with  
25 one or more restriction enzymes, yielding an identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a  
30 particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the

present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as  
5 molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an  
10 immune response.

#### Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

15 A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene  
20 expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99\text{m}}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine, and  
25 biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which  
30 emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as

deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example,  $^{131}\text{I}$ ,  $^{112}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ ), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99\text{m}}\text{Tc}$ . The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder.

Moreover, polypeptides of the present invention can be used to treat disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B), to inhibit the activity of a polypeptide (e.g., an oncogene), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

#### **Biological Activities**

The polynucleotides and polypeptides of the present invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides and polypeptides could be used to treat the associated disease.

#### **Immune Activity**

A polypeptide or polynucleotide of the present invention may be useful in treating deficiencies or disorders of the immune system, by activating or inhibiting the proliferation, differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune deficiencies or disorders may be genetic, somatic, such as cancer or some autoimmune disorders, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotide or polypeptide of the present invention can be used as a marker or detector of a particular immune system disease or disorder.

A polynucleotide or polypeptide of the present invention may be useful in treating or detecting deficiencies or disorders of hematopoietic cells. A

polypeptide or polynucleotide of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem  
5 cells, in an effort to treat those disorders associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein disorders (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion  
10 deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, a polypeptide or polynucleotide of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity  
15 (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotide or polypeptide of the present invention could be used to treat blood coagulation disorders (e.g., afibrinogenemia, factor deficiencies), blood platelet disorders (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotide or polypeptide of the present invention that  
20 can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment of heart attacks (infarction), strokes, or scarring.

A polynucleotide or polypeptide of the present invention may also be useful in treating or detecting autoimmune disorders. Many autoimmune disorders result from  
25 inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing  
30 autoimmune disorders.

Examples of autoimmune disorders that can be treated or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic

anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, 5 Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated by a polypeptide 10 or polynucleotide of the present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotide or polypeptide of the present invention may also be used to treat and/or prevent organ rejection or graft-versus-host disease (GVHD). Organ 15 rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polypeptide or polynucleotide of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of 20 T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polypeptide or polynucleotide of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat inflammatory conditions, both chronic 25 and acute conditions, including inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or 30 IL-1.)

#### Hyperproliferative Disorders

A polypeptide or polynucleotide can be used to treat or detect hyperproliferative disorders, including neoplasms. A polypeptide or polynucleotide of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polypeptide or polynucleotide of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

Examples of hyperproliferative disorders that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but are not limited to neoplasms located in the: abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative disorders can also be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

### **Infectious Disease**

A polypeptide or polynucleotide of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response.

Alternatively, the polypeptide or polynucleotide of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention. Examples of viruses, include, but are not limited to the following DNA and RNA viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza), Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Nocardia), Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia, Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, Enterobacteriaceae (Klebsiella, Salmonella, Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Neisseriaceae (e.g., Acinetobacter, Gonorrhea, Meningococcal), Pasteurellaceae Infections (e.g., Actinobacillus, Haemophilus, Pasteurella), Pseudomonas, Rickettsiaceae,



Chlamydiaceae, Syphilis, and Staphylococcal. These bacterial or fungal families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis, Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Moreover, parasitic agents causing disease or symptoms that can be treated or detected by a polynucleotide or polypeptide of the present invention include, but not limited to, the following families: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas. These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), Malaria, pregnancy complications, and toxoplasmosis. A polypeptide or polynucleotide of the present invention can be used to treat or detect any of these symptoms or diseases.

Preferably, treatment using a polypeptide or polynucleotide of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

### **Regeneration**

A polynucleotide or polypeptide of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotide or polypeptide of the present invention.

**Chemotaxis**

A polynucleotide or polypeptide of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or  
5 endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used  
10 to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

15 It is also contemplated that a polynucleotide or polypeptide of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, a polynucleotide or polypeptide of the present invention could be used as an inhibitor of chemotaxis.

**20 Binding Activity**

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples  
25 of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology  
30 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable

of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell

5 membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

10 The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations,  
15 polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

20 Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

All of these above assays can be used as diagnostic or prognostic markers.

25 The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptide from suitably manipulated cells or tissues.

30 Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a

candidate binding compound with a polypeptide of the invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the invention, (b) assaying a biological activity, and (b)  
5 determining if a biological activity of the polypeptide has been altered.

### **Other Activities**

A polypeptide or polynucleotide of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as  
10 discussed above, hematopoietic lineage.

A polypeptide or polynucleotide of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide or polynucleotide of the present invention may be  
15 used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

A polypeptide or polynucleotide of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, circadian rhythms, depression (including depressive disorders), tendency for violence,  
20 tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

A polypeptide or polynucleotide of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat  
25 content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

### **Other Preferred Embodiments**

Other preferred embodiments of the claimed invention include an isolated  
30 nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3'

5 Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3'

10 Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the

15 nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

20 Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

25 A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

30

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only  
5 A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said  
10 cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the  
15 ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide  
20 sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human  
25 cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological  
30 sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X

wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one  
5 nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid  
10 molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA  
15 molecules.

A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence  
20 selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

25 The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

30 Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a



biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; 5 and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at 10 least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise 15 a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 20 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the 25 amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the 30 Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid  
5 sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

10 Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

15 Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

20 Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

25 Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

30 Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1

and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence  
5 selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

10 Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino  
15 acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising  
20 inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising  
25 culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of  
30 SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is

defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

### Examples

#### Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

25	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited</u>
	<u>Plasmid</u>	
	Lambda Zap	pBluescript (pBS)
	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
30	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0

pCMVSPORT 3.0

pCMVSPORT 3.0

pCR<sup>®</sup>2.1pCR<sup>®</sup>2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR<sup>®</sup>2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional

plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50  
5 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly  
10 isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with  $^{32}\text{P}$ - $\gamma$ -ATP using T4 polynucleotide  
15 kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above.  
20 The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to  
25 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain  
30 reaction is carried out under routine conditions, for instance, in 25  $\mu\text{l}$  of reaction mixture with 0.5  $\mu\text{g}$  of the above cDNA template. A convenient reaction mixture is 1.5-5 mM  $\text{MgCl}_2$ , 0.01% (w/v) gelatin, 20  $\mu\text{M}$  each of dATP, dCTP, dGTP, dTTP, 25



pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., *Nucleic Acids Res.* 21(7):1683-1684 (1993).)

Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of

the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

**Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide**

- 5           A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

**Example 3: Tissue Distribution of Polypeptide**

- 10           Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P<sup>32</sup> using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After  
15           labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

- Multiple Tissue Northern (MTN) blots containing various human tissues (H)  
20           or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and the films developed according to standard procedures.

25

**Example 4: Chromosomal Mapping of the Polynucleotides**

- An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of  
30           conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing

individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

5

#### **Example 5: Bacterial Expression of a Polypeptide**

A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers  
10 used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp<sup>r</sup>), a  
15 bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at  
20 the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan<sup>r</sup>). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and  
25 confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.<sup>600</sup>) of between 0.4 and 0.6. IPTG  
30 (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1

mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80°C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an E. coli origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (lacIq). The

origin of replication (oriC) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

#### **Example 6: Purification of a Polypeptide from an Inclusion Body**

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without  
5 mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive  
10 Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4  
15 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using  
20 a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant  $A_{280}$  monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the  
25 above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 µg of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

**Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System**

In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector  
5 contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak  
10 *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

Many other baculovirus vectors can be used in place of the vector above, such  
15 as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

20 Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP)  
25 to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

The amplified fragment is isolated from a 1% agarose gel using a  
30 commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.).

5       The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by  
10       gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

Five µg of a plasmid containing the polynucleotide is co-transfected with 1.0 µg of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method  
15       described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One µg of BaculoGold™ virus DNA and 5 µg of the plasmid are mixed in a sterile well of a microtiter plate containing 50 µl of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 µl Lipofectin plus 90 µl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the  
20       transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

25       After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell  
30       culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then



resuspended in a microcentrifuge tube containing 200  $\mu$ l of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

- 5 To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and
- 10 cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5  $\mu$ Ci of  $^{35}$ S-methionine and 5  $\mu$ Ci  $^{35}$ S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).
- 15 Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

#### **Example 8: Expression of a Polypeptide in Mammalian Cells**

- The polypeptide of the present invention can be expressed in a mammalian
- 20 cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient
- 25 transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV, HIV and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

- Suitable expression vectors for use in practicing the present invention include,
- 30 for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109),

pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human HeLa, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

- 5           Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

          The transfected gene can also be amplified to express large amounts of the  
10    encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker  
15    is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the  
20    production of proteins.

          Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the  
25    CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

- 30           Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be  
5 modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

10 The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

15 Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five  $\mu$ g of the expression plasmid pC6 is cotransfected with 0.5  $\mu$ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded  
20 in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM,  
25 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1  $\mu$ M, 2  $\mu$ M, 5  $\mu$ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 -  
30 200  $\mu$ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

#### **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see  
5 also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create  
10 chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

15 Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion  
20 can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will  
25 not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

30

Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCACCGTGC  
CCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAA  
CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT  
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG  
5 ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA  
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT  
GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA  
ACCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC  
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG  
10 GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT  
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCT  
CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTG  
GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA  
TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG  
15 GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

**Example 10: Production of an Antibody from a Polypeptide**

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) For example, cells expressing a polypeptide of the present invention is administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of the secreted protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

25 In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., Nature 256:495 (1975); Köhler et al., Eur. J. Immunol. 6:511 (1976); Köhler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell  
30 Hybridomas, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in

any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

5       The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as  
10       described by Wands et al. (Gastroenterology 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

          Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method  
15       makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody  
20       whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies.

          It will be appreciated that Fab and F(ab')<sub>2</sub> and other fragments of the  
25       antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic  
30       chemistry.

          For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced

using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

### **Example 11: Production Of Secreted Protein For High-Throughput Screening**

#### **Assays**

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at  $2 \times 10^5$  cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45

minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37°C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl<sub>2</sub> (anhyd); 0.00130 mg/L CuSO<sub>4</sub>·5H<sub>2</sub>O; 0.050 mg/L of Fe(NO<sub>3</sub>)<sub>3</sub>·9H<sub>2</sub>O; 0.417 mg/L of FeSO<sub>4</sub>·7H<sub>2</sub>O; 311.80 mg/L of KCl; 28.64 mg/L of MgCl<sub>2</sub>; 48.84 mg/L of MgSO<sub>4</sub>; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO<sub>3</sub>; 62.50 mg/L of NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O; 71.02 mg/L of Na<sub>2</sub>HPO<sub>4</sub>; 4320 mg/L of ZnSO<sub>4</sub>·7H<sub>2</sub>O; .002 mg/L of Arachidonic Acid ; 1.022 mg/L of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitic Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml of L-Asparagine-H<sub>2</sub>O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H<sub>2</sub>O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H<sub>2</sub>O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H<sub>2</sub>O; 99.65 mg/ml of L-Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319



mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and 0.680 mg/L of Vitamin B<sub>12</sub>; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of

5 Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for

10 endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37°C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

15 On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the

20 polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

#### 25 **Example 12: Construction of GAS Reporter Construct**

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The

30 binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six

members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at  
5 higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2,  
10 Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two  
15 groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b) Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

20 Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the  
25 proliferation and differentiation of cells. For example, growth factors and cytokines are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

		<u>JAKs</u>			<u>STATS</u>	<u>GAS(elements) or ISRE</u>
	<u>Ligand</u>	<u>tyk2</u>	<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>	
	<u>IFN family</u>					
5	IFN-a/B	+	+	-	-	1,2,3 ISRE
	IFN-g		+	+	-	1 GAS (IRF1>Lys6>IFP)
	Il-10	+	?	?	-	1,3
	<u>gp130 family</u>					
10	IL-6 (Pleiotrophic)	+	+	+	?	1,3 GAS (IRF1>Lys6>IFP)
	Il-11(Pleiotrophic)	?	+	?	?	1,3
	OnM(Pleiotrophic)	?	+	+	?	1,3
	LIF(Pleiotrophic)	?	+	+	?	1,3
	CNTF(Pleiotrophic)	-/+	+	+	?	1,3
15	G-CSF(Pleiotrophic)	?	+	?	?	1,3
	IL-12(Pleiotrophic)	+	-	+	+	1,3
	<u>g-C family</u>					
	IL-2 (lymphocytes)	-	+	-	+	1,3,5 GAS
20	IL-4 (lymph/myeloid)	-	+	-	+	6 GAS (IRF1 = IFP >>Ly6)(IgH)
	IL-7 (lymphocytes)	-	+	-	+	5 GAS
	IL-9 (lymphocytes)	-	+	-	+	5 GAS
	IL-13 (lymphocyte)	-	+	?	?	6 GAS
	IL-15	?	+	?	+	5 GAS
25						
	<u>gp140 family</u>					
	IL-3 (myeloid)	-	-	+	-	5 GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5 GAS
	GM-CSF (myeloid)	-	-	+	-	5 GAS
30						
	<u>Growth hormone family</u>					
	GH	?	-	+	-	5

PRL	?	+/-	+	-	1,3,5	
EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)

Receptor Tyrosine Kinases

5	EGF	?	+	+	-	1,3	GAS (IRF1)
	PDGF	?	+	+	-	1,3	
	CSF-1	?	+	+	-	1,3	GAS (not IRF1)

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

10 5':GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCC  
GAAATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:4)

15 PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

20 5':CTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAA  
TGATTTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCG  
CCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATCTCT  
CCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCC  
TCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCT  
25 AGGCTTTTGCAAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

#### **Example 13: High-Throughput Screening Assay for T-cell Activity.**

The following protocol is used to assess T-cell activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells ( $10^7$  per transfection), and resuspend in OPTI-MEM to a final concentration of  $10^7$  cells/ml. Then add 1ml of  $1 \times 10^7$  cells in OPTI-MEM to T25 flask and incubate at 37°C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Gentamicin, and 1% Pen-Strep. These cells are treated with supernatants containing a polypeptide as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the  
5 assay.

The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophane covers) and  
10 stored at -20°C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4°C and serve as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the  
15 positive control wells.

The above protocol may be used in the generation of both transient, as well as, stable transfected cells, which would be apparent to those of skill in the art.

#### **Example 14: High-Throughput Screening Assay Identifying Myeloid Activity**

20 The following protocol is used to assess myeloid activity by identifying factors, such as growth factors and cytokines, that may proliferate or differentiate myeloid cells. Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell  
25 used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest  $2 \times 10^7$  U937 cells and  
30 wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing



10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM  
5 KCl, 375 uM Na<sub>2</sub>HPO<sub>4</sub>·7H<sub>2</sub>O, 1 mM MgCl<sub>2</sub>, and 675 uM CaCl<sub>2</sub>. Incubate at 37°C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37°C for 36 hr.

The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400  
10 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400 ug/ml G418 for couple of passages.

These cells are tested by harvesting  $1 \times 10^8$  cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described growth medium, with a final density of  $5 \times 10^5$  cells/ml. Plate 200 ul cells per well in  
15 the 96-well plate (or  $1 \times 10^5$  cells/well).

Add 50 ul of the supernatant prepared by the protocol described in Example 11. Incubate at 37°C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold induction is typically observed in the positive control wells. SEAP assay the supernatant  
20 according to the protocol described in Example 17.

#### **Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.**

When cells undergo differentiation and proliferation, a group of genes are activated through many different signal transduction pathways. One of these genes,  
25 EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or  
30 differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor).

The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

The EGR/SEAP reporter construct can be assembled by the following  
5 protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

10 Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1 promoter.

15 To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker)  
20 containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and resuspended with pipetting up and down for more than 15 times.

25 Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

30 To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS

(Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count  
5 the cell number and add more low serum medium to reach final cell density as  $5 \times 10^5$  cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to  $1 \times 10^5$  cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR  
10 can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

#### **Example 16: High-Throughput Screening Assay for T-cell Activity**

15 NF- $\kappa$ B (Nuclear Factor  $\kappa$ B) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF- $\kappa$ B regulates the expression of genes involved in immune cell activation, control of  
20 apoptosis (NF-  $\kappa$ B appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF-  $\kappa$ B is retained in the cytoplasm with I- $\kappa$ B (Inhibitor  $\kappa$ B). However, upon stimulation, I-  $\kappa$ B is phosphorylated and degraded, causing NF-  $\kappa$ B to shuttle to the nucleus, thereby activating transcription of target  
25 genes. Target genes activated by NF-  $\kappa$ B include IL-2, IL-6, GM-CSF, ICAM-1 and class 1 MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF- $\kappa$ B promoter element are used to screen the supernatants produced in Example 11. Activators or inhibitors of NF- $\kappa$ B would be useful in  
30 treating diseases. For example, inhibitors of NF- $\kappa$ B could be used to treat those

diseases related to the acute or chronic activation of NF- $\kappa$ B, such as rheumatoid arthritis.

To construct a vector containing the NF- $\kappa$ B promoter element, a PCR based strategy is employed. The upstream primer contains four tandem copies of the NF- $\kappa$ B binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:  
5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC  
TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:  
5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)  
15 Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC  
ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC  
20 ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA  
CTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTA  
TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA  
GCTT:3' (SEQ ID NO:10)

25 Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF- $\kappa$ B/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF- $\kappa$ B/SV40/SEAP cassette is removed from the above NF- $\kappa$ B/SEAP vector using restriction enzymes  
30 SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly,

the NF- $\kappa$ B/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF- $\kappa$ B/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

#### **Example 17: Assay for SEAP Activity**

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15  $\mu$ l of 2.5x dilution buffer into Optiplates containing 35  $\mu$ l of a supernatant. Seal the plates with a plastic sealer and incubate at 65°C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50  $\mu$ l Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50  $\mu$ l Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

#### **Reaction Buffer Formulation:**

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5

13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

---

**Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability**

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO<sub>2</sub> incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37°C in a CO<sub>2</sub> incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to 2-5x10<sup>6</sup> cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37°C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to 1x10<sup>6</sup> cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular  $\text{Ca}^{++}$  concentration.

#### **Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity**

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.



Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4°C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub> and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4°C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4°C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by  
5 determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

10 The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg<sub>2+</sub> (5mM ATP/50mM MgCl<sub>2</sub>), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the  
15 components gently and preincubate the reaction mix at 30°C for 2 min. Initiate the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction  
20 mixture to a microtiter plate (MTP) module and incubating at 37°C for 20 min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37°C for one hour. Wash the well as  
25 above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of  
30 tyrosine kinase activity.

**Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity**

As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation  
5 (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other  
10 phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G  
15 plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at  
20 4°C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts  
25 filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place  
of A431 extract. Plates are then treated with a commercial polyclonal (rabbit)  
30 antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive

incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

5    **Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA  
10    is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky, D., et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4  
15    polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

20    PCR products is cloned into T-tailed vectors as described in Holton, T.A. and Graham, M.W., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining  
25    alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson, Cg. et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to  
30    the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for

precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson, Cv. et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and  
5 chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

10

**Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide  
15 is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with  
20 specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample  
25 containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature.  
30 The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale).  
5 Interpolate the concentration of the polypeptide in the sample using the standard curve.

**Example 23: Formulating a Polypeptide**

10 The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective  
15 amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1  $\mu\text{g/kg/day}$  to 10  $\text{mg/kg/day}$  of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01  
20  $\text{mg/kg/day}$ , and most preferably for humans between about 0.01 and 1  $\text{mg/kg/day}$  for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1  $\mu\text{g/kg/hour}$  to about 50  $\mu\text{g/kg/hour}$ , either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of  
25 treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal  
30 patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to

modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., *Biopolymers* 22:547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., *J. Biomed. Mater. Res.* 15:167-277 (1981), and R. Langer, *Chem. Tech.* 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. USA* 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci. USA* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's

solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in



the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other  
5 therapeutic compounds.

**Example 24: Method of Treating Decreased Levels of the Polypeptide**

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by  
10 administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

15 For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

20 **Example 25: Method of Treating Increased Levels of the Polypeptide**

Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

25 For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

30

**Example 26: Method of Treatment Using Gene Therapy**

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

#### **Example 27: Method of Treatment Using Gene Therapy - In Vivo**

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata H. et al. (1997) Cardiovasc. Res. 35(3):470-479, Chao J et al. (1997) Pharmacol. Res. 35(6):517-522, Wolff J.A. (1997) Neuromuscul. Disord. 7(5):314-318, Schwartz B. et al. (1996) Gene Ther. 3(5):405-411, Tsurumi Y. et al. (1996) Circulation 94(12):3281-3290 (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The

polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) *Ann. NY Acad. Sci.* 772:126-139 and Abdallah B. et al. (1995) *Biol. Cell* 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely

differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or  
5 RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence  
10 can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or  
15 mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard  
20 recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on  
25 the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

30 After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15  $\mu$ m cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A

- time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice.
- 5 The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

**Example 28: Transgenic Animals.**

- 10 The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are
- 15 used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

- Any technique known in the art may be used to introduce the transgene (*i.e.*, polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear
- 20 microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic
- 25 stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, *e.g.*, Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-
- 30 mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse

transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

#### **Example 29: Knock-Out Animals.**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*, see Smithies et al., Nature 317:230-234 (1985); Thomas & Capecchi, Cell 51:503-512 (1987); Thompson et al., Cell 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in



the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

10 In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g.*, knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (*i.e.*, animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (*e.g.*, lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, *e.g.*, by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, *e.g.*, in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, *e.g.*, genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and

Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.


The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned
--	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>259</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit July 27, 1998	Accession Number 203070
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	


<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on:
Authorized officer  Yvette E. Simms PCT International Division	Authorized officer

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned
---	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>260</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit July 27, 1998	Accession Number 203069
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	


<b>For receiving Office use only</b> <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer  Yvette E. Simms PCT International Division	<b>For International Bureau use only</b> <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer
--	--

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned
---	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A.</b> The indications made below relate to the microorganism referred to in the description on page <u>253</u> , line <u>N/A</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution <u>American Type Culture Collection</u>	
Address of depositary institution (including postal code and country) <u>10801 University Boulevard</u> <u>Manassas, Virginia 20110-2209</u> <u>United States of America</u>	
Date of deposit <u>July 27, 1998</u>	Accession Number <u>203071</u>
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")          	


<b>For receiving Office use only</b> <input checked="" type="checkbox"/> This sheet was received with the international application  Authorized officer  <b>Yvette E. Simms</b> PCT International Division	<b>For International Bureau use only</b> <input type="checkbox"/> This sheet was received by the International Bureau on:  Authorized officer
---	--

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned
---	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<b>A.</b> The indications made below relate to the microorganism referred to in the description on page <u>249</u> . line <u>N/A</u>	
<b>B. IDENTIFICATION OF DEPOSIT</b> Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit June 26, 1998	Accession Number 203027
<b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
<b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)	
<b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<b>For receiving Office use only</b> <input checked="" type="checkbox"/> This sheet was received with the international application Authorized officer  Yvette E. Simms PCT International Division	<b>For International Bureau use only</b> <input type="checkbox"/> This sheet was received by the International Bureau on: Authorized officer
--	--

Applicant's or agent's file reference number	PZ031PCT	International application No.	Unassigned
---	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>243</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country)  10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit  June 11, 1998	Accession Number  209965
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<input checked="" type="checkbox"/> For receiving Office use only This sheet was received with the international application	<input type="checkbox"/> For International Bureau use only This sheet was received by the International Bureau on:
Authorized officer  Yvette E. Simms PCT International Division	Authorized officer

***What Is Claimed Is:***

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X, having biological activity;

(f) a polynucleotide which is a variant of SEQ ID NO:X;

(g) a polynucleotide which is an allelic variant of SEQ ID NO:X;

(h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;

(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.



3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.
5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
9. A recombinant host cell produced by the method of claim 8.
10. The recombinant host cell of claim 9 comprising vector sequences.
11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

- (a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;
  - (c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (f) a full length protein of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;
  - (g) a variant of SEQ ID NO:Y;
  - (h) an allelic variant of SEQ ID NO:Y; or
  - (i) a species homologue of the SEQ ID NO:Y.
12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.
14. A recombinant host cell that expresses the isolated polypeptide of claim 11.
15. A method of making an isolated polypeptide comprising:
- (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and
  - (b) recovering said polypeptide.
16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

- (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

- (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

- (a) contacting the polypeptide of claim 11 with a binding partner; and
- (b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

22. A method of identifying an activity in a biological assay, wherein the method comprises:

- (a) expressing SEQ ID NO:X in a cell;
- (b) isolating the supernatant;
- (c) detecting an activity in a biological assay; and
- (d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc.

<120> 98 Human Secreted Proteins

<130> PZ031.PCT

<140> Unassigned

<141> 1999-07-28

<150> 60/094,657

<151> 1998-07-30

<150> 60/095,486

<151> 1998-08-05

<150> 60/095,455

<151> 1998-08-06

<150> 60/095,454

<151> 1998-08-06

<150> 60/096,319

<151> 1998-08-12

<160> 364

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga	gcccaaattct	tctgacaaaa	ctcacacatg	cccaccgtgc	ccagcacctg	60
aattcgaggg	tgcaccgtca	gtcttcctct	tcccccaaa	acccaaggac	accctcatga	120
tctcccgga	tcctgaggtc	acatgcgtgg	tggtggacgt	aagccacgaa	gaccctgagg	180
tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagccgcggg	240
aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtac	aagtgcgaag	tctccaacaa	agccctccca	accccatcgc	360
agaaaacccat	ctccaaagcc	aaagggcagc	cccgagaacc	acaggtgtac	accctgcccc	420
catcccggga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctggtc	aaaggcttct	480
atccaagcga	catcgccgtg	gagtgaggga	gcaatgggca	gccggagAAC	aactacaaga	540
ccacgcctcc	cgtgctggac	tccgacggct	ccttcttcct	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcac	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaataagtg	cgacggccgc	720
gactctagag	gat					733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp Ser Xaa Trp Ser  
1 5

<210> 3

<211> 86

<212> DNA

<213> Homo sapiens

<400> 3

gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60  
cccgaatat ctgccatctc aattag 86

<210> 4

<211> 27

<212> DNA

<213> Homo sapiens

<400> 4

gcggcaagct ttttgcaaag cctaggc 27

<210> 5

<211> 271

<212> DNA

<213> Homo sapiens

<400> 5

ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60  
aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120  
gcccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat 180  
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240  
ttttggaggc ctaggctttt gcaaaaagct t 271

<210> 6

<211> 32

<212> DNA

<213> Homo sapiens

<400> 6

gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 7

<211> 31

<212> DNA

<213> Homo sapiens

<400> 7

gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 8

<211> 12

<212> DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 8

ggggactttc cc

12

&lt;210&gt; 9

&lt;211&gt; 73

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 9

gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg  
ccatctcaat tag

60

73

&lt;210&gt; 10

&lt;211&gt; 256

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

ctcgagggga ctttcccgga gactttccgg ggactttccg ggactttcca tctgccatct  
caattagtc gcaaccatag tcccgcctt aactccgccc atcccgcccc taactccgcc  
cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga  
ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg  
cttttgcaaa aagctt

60

120

180

240

256

&lt;210&gt; 11

&lt;211&gt; 1564

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 11

gcggacgggtg ggctgtgcaa ccttccctccc tttcttaaatt gcttggggca tttgtctggc  
cttccctttt actgctggct gctgcctgca tctgtctctt aaccttcatt aactgtgcct  
atgtcaaatg gggaaccctg gtacaagata ttttcaccta tgctaaagta ttggcactga  
tcgcggtcat cggtgcaggc attgttagac ttggccaggg agcctctact cattttgaga  
attcctttga ggggtcatca tttgcagtgg gtgacattgc cctggcactg tactcagctc  
tgttctccta ctcaggctgg gacaccctca actatgtcac tgaagagatc aagaatcctg  
agaggaacct gcccctctcc attggcatct ccattgccat tgtcaccatc atctatatct  
tgaccaatgt ggcctattat actgtgctag acatgagaga catcttggcc agtgatgctg  
ttgtgtgac ttttgagat cagatatttg gaattttta ctggataatt ccactgtcag  
ttgcattatc ctgttttggg ggcctcaatg cctccattgt ggctgcttct aggcctttct  
ttgtgggctc aagagaaggc catctccctg atgccatctg catgatccat gttgagcggg  
tcacaccagt gccttctctg ctcttcaatg gtatcatggc attgatctac ttgtgcgtgg  
aagacatctt ccagctcatt aactactaca gcttcagcta ctggttcttt gtggggcttt  
ctattgtggg tcagctttat ctgctgtgga aggagcctga tcgacctcgt cccctcaagc  
tcagcgtttt cttcccgatt gtcttctgac tctgcaccaa cttcctgggtg gctgttccac  
tttacagtga tactatcaac tccctcatcg gcattgccat tgccctctca ggccctgcct  
tttacttct catcatcaga gtgccagaac ataagcgacc gctttacctc cgaagatcgt  
ggggtctgcc acaagggtacc tccaggtcct gtgtatgtca gttgctgcag aaatggattt  
ggaagatgga ggagagatgc ccaagcaacg ggatcccaag tctaactaaa caccatctgg  
aatcctgatg tggaaagcag gggtttctgg tctactggct agagctaagg aagttgaaaa  
ggaaagctca cttctttgga ggcacctgtc cagaagcctg gcctaggcag cttcaacctt  
tgaacttact ttttgaaatg aaaagtaatt tatttgtttt gctacatact gttccagact  
tttaaagggg acaatgaagg tgactgtggg gaggagcatg tcaggtttgg gcttgggtgt  
tttagaagca cctgggtgtg cctacctact cctcttttct tttaaaaggg cccacaatgc

60

120

180

240

300

360

420

480

540

600

660

720

780

840

900

960

1020

1080

1140

1200

1260

1320

1380

1440

tccaattttcc	tgtctccttt	agagagacat	gaaactatca	caggtgctgg	atgacaataa	1500
aagtttatgt	tcctaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaagggcggc	1560
cccg						1564

&lt;210&gt; 12

&lt;211&gt; 1757

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

ggcacgaggt	agatggggtt	ttgggtgtgga	tgtcctttct	gtttgttagt	tgtcctttcta	60
acagacagga	ccctcagctg	caggtctgtt	ggagtaccct	gcaatgtgag	gtgtcagtgt	120
gcccctgctg	gaggggtgct	cccagttagg	ctgctcgcgg	gtcaggggtc	agggaccac	180
ttgaggaggc	agtctgcccg	ttctcagatc	tccagctgca	tgctgggaga	accactgctc	240
tcttcaaagc	tgctcagacag	ggacatttaa	gtctgcagag	gttactgctg	tctttttgtt	300
tgtctgtgcc	ctgccccag	aggtggagcc	tacagaggca	ggcaggcctc	cttgagctgt	360
ggtgggctcc	accagttcg	agcttcccgg	ctgctttgtt	tacctaaagca	agcctgggca	420
atggcggggc	cccctcccc	agtctcgtg	ccgccttgca	gtttgatctc	agactgctgt	480
gctagcaatc	agcgagactc	cgtggggtag	gacctctga	gccagggtgg	ggatataatc	540
ttgtgggtgc	ccatttttta	agcccgctcg	aaaagcgcag	tattcagggtg	ggagtgaacc	600
gattttcccg	attttccagg	tgccgtccgt	catcccttct	tttgattagg	aaagggaact	660
ccctgacccc	ttgcgcttcc	cgagtgaggc	aatgccttgc	gctgctttgg	ctcgtgcatg	720
gtgcgtgcac	ccactgacct	gcgcccactg	tctggcactc	cctagtgaga	tgaacccggt	780
acctcagatg	gaaatgcaga	aatcacccgt	cttctgcgtt	gctcaggctg	ggagctgtag	840
accagagctg	ttcctattcc	gccatcttgg	ctctccccc	accccccgcc	caatcctaag	900
tttatctctt	aacaaagtaa	atactgcaca	cgtattttaca	tgttttaaaa	tattgtttat	960
ggagcactta	ctatgtgttt	tacggtccaa	gtactttata	ttattcactg	actctttata	1020
gcaactctat	aacatattaa	tagattgtct	caatttctact	gatgacaaaa	ctggcagctt	1080
agtaactaat	gagtaacaat	accagcccct	aaaacctagg	gtctttccac	tacagcacac	1140
tctgactgac	attgctcttg	ttcagacaca	gcactcttca	cctagaaaaag	gatggagagc	1200
tagaaaagtg	ttttcttttt	caagttgttc	ccattcatca	atattctatc	aagatatatg	1260
gaagagttaa	tttctaggtc	ttccagaagg	ggctgctgac	acttgggaat	tcaaaataat	1320
tactccagag	ggaaatgtgg	gcatagaaac	tttttaaaaa	ctgaattttc	ccgatctaata	1380
atcggcttcc	acatacagta	tattatttct	taaaaaatcag	ccagaaatgc	acctgcagtt	1440
ttatctactg	gattttcctt	tcccagcccc	attcttcttt	aagtagtttt	ttttcccat	1500
tttataaaaag	aaaagcatac	ctcccaccta	tagcttccct	ccttatggta	tattatctca	1560
ggggataaatt	tgaaatattg	cttgagacac	aattctcatt	aagaaataaa	ctttcaggct	1620
gggtgcagtg	gctcacactt	gtaatcccag	aactttggga	ggccaaggcg	ggggaggatc	1680
cctgaaggcc	aagagttcaa	gaccagcctg	gaatatatac	caagatcccc	tctccacaaa	1740
aaaaaaaaaa	aaaaaaa					1757

&lt;210&gt; 13

&lt;211&gt; 1373

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

gtgaaatgaa	atatgtatac	caaaacacat	aaatttaagt	tttataattt	tctttccttg	60
tggatctgga	aaattttctt	tctgctgttt	ttcattctga	tagttgcttt	ggctttccct	120
attccctgcc	tttccatatt	ttgaaatgtt	ttgggtcaaat	tttttcctgt	tgagtgtgca	180
gtatgttttg	attgttaatt	ttattgacca	tcattctcagt	ggattattta	tttgaaactt	240
ttctgtttcc	tgttctggaa	tgtttctctg	tctggaagcc	atattttaac	tgtatactga	300
tccagcttta	tttatcttaa	gtatttttac	aattatttta	ctgataatat	ataactaggt	360
ataatcactc	tagtcagtga	aatcaaacctg	ataacacaaa	atgatgctgc	tagtaaatat	420
agcctgaaaa	ggatcagagg	aagcactttt	tagtctaagt	agtcagatc	aataaactta	480
gaatgagagt	tttgtattat	ttagccttgt	gatagaagga	aaaagtacag	ttattgaatc	540
tgtatattaa	tttatgcaaa	atacacacat	tatctttcca	ttaacacagt	agtatgacat	600



acagttttat caccactgga ttcattgtatg cttaaaaatga aaatgaaagg aacacacagg	660
aaagtagctt cttatcttcc cagatacaga ctccaagagt gcctctgctg tgtactggag	720
tgagtttgaa gaagttcagg taatcctctc ctaaccagca gcttaactta aagtgcattc	780
tcatttttgt cctaccacta aaagcttgct tattgacctc cttctttcct gtctcctaaa	840
ttgtgactgg ctctcagtta gacttgcacg tgttgctatt tgtagcagca attgcaggat	900
tcatttgctt tttctcttgc agtgtatttc tgaatgtttt ataactctgg gtatgcataa	960
tgtacgtata tgcataatcca tatggtcaag agttttcaga attctttggt tgaataatga	1020
atgtgtgtat tccctacccc ttgttttggc ctgtcttaac atttaagctt tgcttattaa	1080
aatgtatttg ttttaattgct ttctcttttag attgtaagct cttcatgggc agtggtcaga	1140
tattctgtat ttgtaacttc ccgagaatct agtattttat catgtacata atgaacatag	1200
aatagtattg attggaagga cagtgaagta caaaatgaga ttctaaaatg acattttcat	1260
tagggctcac aagtgtataa gaagtatccc tttctatttt ttttgtttaa tacttttaga	1320
gctattacat taaaaaagct attctcatta aaaaaaaaaa aaaaaaaaaa aaa	1373

&lt;210&gt; 14

&lt;211&gt; 3740

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (957)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 14

actctctaag gcttttttgg actcaccaaa caggcttctt gcagtggaga tgaatacaga	60
tcacttaagg ttgactgtgc caaatggcat agggggccctg aagctaaggg aaatggaaca	120
ctacttctca cagggcctgt cagttcagct gtttaatgat ggggtccaagg gcaaactcaa	180
tcattttatgt ggagctgact ttgtgaaaag tcatcagaaa cctccacagg gaatggaaat	240
taagtccaat gaaagatgct gttcttttga tggagatgca gacagaattg tttattacta	300
ccatgatgca gatggccact ttcatctcat agatggagac aagatagcaa cgtaattag	360
cagtttctctt aaagagctcc tgggtggagat tggagaaagt ttgaatattg gtgtgtgaca	420
aactgcatat gcaaatggaa gttcaacacg gtatcttgaa gaagtattga aggtacctgt	480
ctattgcaact aagactgggtg taaaacattt gcaccacaag gctcaagagt ttgacattgg	540
agttttatttt gaagcaaatg ggcatggcac tgcactgttt agtacagctg ttgaaatgaa	600
gataaaacaa tcagcagaac aactggaaga taagaaaaga aaagctgcta agatgcttga	660
aaacattatt gacttgttta accaggcagc tgggtgatgct atttctgaca tgctgggtgat	720
tgaagcaatc ttggctctga agggcttgac tgtacaacag tgggatgctc tctatacaga	780
tcttccaaac agacaactta aagttcaggt tgcagacagg agagttatta gcactaccra	840
tgctgaaaga caagcagtta ccccccagg attacaggag gcaatcaatg acctgggtgaa	900
gaagtacaag ctttctcgag cttttgtccg gccctctggt acagaagatg tcgtccngag	960
tatatgcaga agcagactca caagaaagtg cagatcacct tgcacatgaa gtgagcttgg	1020
cagtatttca gctggctgga ggaattggag aaaggcccca accagggttct tgaagataat	1080
tttcatattc ctgagaaaact ggacttttta caagtcttta caaaactgtc aataataatg	1140
gcagtactaa gagatttata atcataatgt ttacaatgca gcctactgga ttgtctctag	1200
atctgttttt cttaaacact aacagaataa ttcttttata ataggtaagc cttacacttg	1260
ttaaagaaat ttacctctaa tttcagttct actaatgtaa aatactggga ctttaagtata	1320
caattcagtc actaactgta cagttttatg tggggaacaa ttcattgcagg ctactggaaa	1380
attaaatctt attaccaact ccttgtgata tctttgccat caccatcaca tgagcaagat	1440
gatgttttgc agcattcccc attgctgata caaatggaga gggcagagaa gactttatac	1500
aaccagtttt tccattgcag agtcttaaga aagattatta gatgacttac ctatatgact	1560
aatgccatca ggaactcaga ggtatgaata ggggggttgc catccctctt ccatactgag	1620
gtggagatgc tcatgcaata cttttaagga tgcattgtcc agccttcagt tattcttcac	1680
tgctcttggg gaaggatatg gggagaaaaa ctaattataa tacgtttccc agcctctgat	1740
ggagaaggaa caccattctg ataccagaac atggttaata aggaaaagag aaaaatcccc	1800
aaccaatctt aattgaacca agtctgaaac caatggaaaa aaaaaatggg tagtgtatat	1860
tttgcagggt taagacaact caggacaata aaaacaatgg actttacatg tgtatatata	1920
tagctctctt aggcaccata atcagtatga gccacaata tttaaacttg attcaggcca	1980

cattcagaca	tttgccttta	tatacaata	tttaaattaa	atacaatctg	aaatgtgttc	2040
tgttacatac	aaaaaaggaa	aaactatata	acgcagagca	gtgtgtgtgt	tttaaataat	2100
tacattttaca	tgtaagctaa	atggaaccag	caatggtgct	caagttttta	tcatecccttc	2160
cagaaaatct	ttttctacca	tctcttctat	tttttgccctg	gctttgctgg	aacatggttt	2220
gtggtttctcc	agtttcatgt	ccttattagg	gaaggcattt	gagtagagga	taggactccc	2280
tgagtgtcct	ccacatcggc	ttgtgacttt	gctgttgaag	acttgactga	gcacattgaa	2340
gaacggcagg	agctgctcca	tactgcgcac	ggtgcagatg	gtgagcagca	agtgccctgg	2400
ctcccaaccc	aatgtttctcc	ctgagttgtc	ttcctctgga	tttttctgca	gaaaacaaaa	2460
agtgaactgg	tattaatata	acagacaatg	tggtatgtta	gaaaaattaa	aaatatataa	2520
actttggcaa	ttggtcaaga	aatgaatata	aatgcattta	agtttctaac	tcctgacctg	2580
atcaaaaccc	ttggtgcttc	tgagaccttt	tactgccatt	tattagtttt	acatggagca	2640
gtctaacatt	gtagtaatag	ttcccaacta	gaatgcgcag	ataagcttag	ttaacagaaa	2700
tagcttttgaa	caggaataga	gtcaaacata	aaagttttat	gttgtgcttt	gtattttactc	2760
aaaaagctcc	caggtttctg	aaccctcact	actgtaacca	aggactaggt	cacaaaatta	2820
ctacagaaaa	aaggaacaaa	gtgctttata	cattttcataa	tatatccctt	tttattataa	2880
ttagtttaatt	cccttttatc	taaatggcct	aaatttgcca	tgatggtagc	agtgtccaaa	2940
gtgaataatt	actgtcagta	ctgcatcaca	gagaaaggaa	gggatccctc	aggagacact	3000
gctgtctcct	tctgggttgt	gctaaacaac	atagggagga	aagctggacc	tggagtcaaa	3060
ggaattgagt	tagtgtgctg	gctctgccat	acttacggca	cccttgggca	ggatatacaa	3120
aggttcctca	cttataaaaat	gggacagtct	aaaactacct	tttagtagag	aagtcaaatg	3180
agaaggtagt	tgaaaactct	gtcaactaaa	tataaagact	aataatttgg	gtattaagag	3240
gctagtttga	gaagccacct	gaattacaca	aacacagcta	cagacatcat	tctgtctaga	3300
gaaagataag	agagaacagg	ttggttgaac	ttgggcagaa	tcacagatac	aattccacac	3360
taaagaatga	aaataagcaa	tgaactagac	agaaggagaa	aatcatgaag	acttaggaag	3420
cagaattaca	atctgtcata	ttaacaaatg	gagtttgcct	tctaagatca	gatgttgctc	3480
agaaactttc	attgtttacc	taataattta	atatcactag	tttcctagt	gggtcaagcag	3540
atgcaaaatc	cagcttattt	tcttctatgt	gctctcaagc	ttattgctta	ttttaagta	3600
aaatcctgaa	aaaggaaaat	attaggttgg	tgcaaacgta	attgcggttt	ttgcattgtt	3660
gaaatttgcc	gttttatatt	ggagtacatt	cttaataaaa	tgtggttatg	ttatacaaaa	3720
aaaaaaaaaa	aaaactcgag					3740

&lt;210&gt; 15

&lt;211&gt; 1196

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

ccacgcgtcc	ggtgaatctg	gatgatctat	ttatgtcatt	tatctatgtg	tctcttctta	60
tgccagtacc	ccactgtctt	gattattgtg	gctttatggg	gtcttgaaat	taagtattgt	120
taagctttgc	aatcttttcc	aagattgttt	tggtatagg	tcctttcttt	ataaagttta	180
tattaagctt	ctccattttt	ctttaagaaa	aaatctgctg	gaatggcact	gaatttttag	240
gtcgatttgg	gaagaattga	caatattgaa	cctttcaatc	gatggacatg	gtatgtttct	300
gcattttatt	gggcctttta	aaatttatct	cagcaatatt	ttgtagtttt	agtgaagaag	360
tcttgatatat	atcttttggt	aaatgtattc	ctaaatattt	tgtggaaatg	ttactgtaaa	420
tagtacttta	atttcatttt	taagtttatt	gctggtatac	agaaatatgt	tttatttttg	480
taatattgac	ttttatatct	tgtaattctta	tttaaattca	cttagttcag	tagtagttct	540
tatttttatt	ttattgcaag	tgcccttagg	ataccttggt	tacacaatcc	atgtcatata	600
tgaataacca	acagggttac	cttttggttc	ttcttgcttt	gtcgtaatgg	ctaggacctt	660
ccaacctaaa	tggttgaata	gaagcgggtg	gtgagtttat	tactcttgct	ttattctcaa	720
cagcagagga	tagcgtctag	tttttacta	ttaaaatag	ttagctatag	gttttttccg	780
tttcatgttt	ttatcagatt	gaagatccct	tttattccta	ttttgccaag	agtgtcatga	840
atgcatgttg	aatttcacca	agtacttttt	cctgcatctg	ttgagagaat	cttgactttt	900
ctctttttatt	ttgttaatgt	agattcttta	atgttaaact	gatcttgcat	tcctgatata	960
aaccatactt	agtcatgata	tgttatcccc	tttatataat	gctggattcg	gtttgcaaat	1020
attttgtttg	atttttgcat	ctatgctcat	gagacagatt	ggtctgtgat	tttcttttct	1080
tgtaagtctt	gtcaggtgtc	aggccttggg	taattttgac	acattttaca	acatatattt	1140
ttaagataaa	aataaacttc	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaa	1196

<210> 16  
 <211> 2209  
 <212> DNA  
 <213> Homo sapiens

<400> 16  
 gagctgcgcc gggcttgggc gcctggggcc gccgctcccc accgtcgttt tccccaccga 60  
 ggccgaggcg tcccggagtc atggccggcc tgaactgcgg ggtctctatc gactgtctag 120  
 gggttctgct gctgggtgcg gcgcgcctgc cgcgcggggc agaagctttt gagattgctc 180  
 tgccacgaga aagcaacatt acagttctca taaagctggg gaccccgact ctgctggcaa 240  
 aacctgttta catcgtcatt tctaaaagac atataacat gttgtccatc aagtctggag 300  
 aaagaatagt ctttaccttt agctgccaga gtcctgagaa tcactttgtc atagagatcc 360  
 agaaaaatat tgactgtatg tcaggcccat gtccttttgg ggaggttcag cttcagccct 420  
 cgacatcggt gttgcctacc ctcaacagaa ctttcatctg ggatgtcaaa gtcataaga 480  
 gcatcggttt agagctgcag ttttccatcc ctgcctgag gcagatcggt ccgggtgaga 540  
 gctgcccgaga cggagtcact cactccatca gcggccgaat cgatgccacc gtggtcagga 600  
 ttggaacctt ctgcagcaat ggcactgtgt cccggatcaa gatgcawgaa ggagtgaana 660  
 tggccttaca cctcccatgg ttccacccca gaaatgtctc cggcttcagc attgcaaac 720  
 gctcatctat aaaacgtctg tgcacatcg agtctgtgtt tgagggtgaa ggctcagcaa 780  
 ccttgatgtc tgccaactac ccagaaggct tccctgagga tgagctcatg acgtggcagt 840  
 ttgtcgttcc tgcacacctg cggggccagc tctccttcc caacttcaac ctctccaact 900  
 gtragaggaa ggaggagcgg gttgaatact acatcccggg ctccaccacc aaccccgagg 960  
 tgttcaagct ggaggacaag cagcctggga acatggcggg gaacttcaac ctctctctgc 1020  
 aaggctgtga ccaagatgcc caaagtccag ggatcctccg gctgcagttc caagttttgg 1080  
 tccaacatcc acaaaatgaa agcaataaaa tctacgtggg tgacttgagt aatgagcgag 1140  
 ccatgtcact caccatcgag ccacggcccg tcaaacagag ccgcaagttt gtccctggct 1200  
 gtttcgtgtg tctagaatct cggacctgca gtacaaacct caccctgaca tctggctcca 1260  
 aacacaaaat ctcttctctt tgtgatgatc tgacacgtct gtggatgaat gtggaaaaam 1320  
 ccataagyty cacagaccac cggtagctgc aaaggaaatc ctactcacty cagggtgcca 1380  
 gtgacatcct ycamctgcct gtggagctgc atgacttctc ctggaagctg ctggtgcca 1440  
 aggacaggct cagcctggtg ctggtgccag cccagaagct gcagcagcat acacacgaga 1500  
 agcctgcaa caccagcttc agctacctcg tggccagtgc catacccagc caggacctgt 1560  
 acttcggctc cttctgcccg ggaggtctta tcaagcagat ccagggtgaag cagaacatct 1620  
 cggtagacct tcgcaccttt gccccagct tccgacaaga ggcctccagg cagggtctga 1680  
 cgggtgctct tataccttat ttcaaagagg aaggcgtttt cacgggtgacc cctgacacaa 1740  
 aaagcaaggt ctacctgagg acccccact gggaccgggg cctgccatcc ctacacctg 1800  
 tgtcctggaa catcagcgtg ccagagacc aggtggcctg cctgactttc ttaaggagc 1860  
 ggagcggcgt ggtctgccag acagggcgcg cattcatgat catccaggag cagcggacce 1920  
 gggctgagga gatcttcagc ctggacgagg atgtgtctcc caagccaagc ttccaccatc 1980  
 acagcttctg ggtcaacatc tytaaytgma gccccacgag cggcaagcag ctagacctgc 2040  
 tcttctcggg gacacttacc ccaaggactg tggacttgac tgtcatctc atcgagcgg 2100  
 tgggaggtgg agtcttactg ctgtctgccc tggggctcat catttctgtg gtgaaaaaaa 2160  
 aaaaaarama aacaaggggc cccgctgtgg gtatctacaa tggcaacat 2209

<210> 17  
 <211> 1774  
 <212> DNA  
 <213> Homo sapiens

<400> 17  
 taggcacccc aggtttttac actttatggt ccggttcgta tgttgtgtga attgtaaccg 60  
 gataccaatt tcacacaagg aaccagctta tgaccatgat tacgccaagc tcgaaattaa 120  
 cctcactaa agggaacaaa agctggagct ccaccgcggt ggcggccgct ctagaactag 180  
 tggatccccc gggctgcagg aattcggcac gagcggctgc gggcgcgagg tgagggggcg 240  
 gaggttccca gcaggatgcc ccggctctgc aggaagctga agtgagaggc ccggagaggg 300  
 cccagcccg cgggggcagg atgaccaagg cccggctgtt ccggctgtgg ctggtgctgg 360  
 ggtcgggtgt catgatcctg ctgatcatcg tgtactggga cagcgcaggc gccgcgcact 420

tctacttgca	cacgtccttc	tctaggccgc	acacggggcc	gccgctgcc	acgcccgggc	480
cggacagga	cagggagctc	acggccgact	ccgatgtcga	cgagtttctg	gacaagtctc	540
tcagtgtctg	cgtgaagcag	agtgtacctc	ccagaaagga	gacggagcag	ccgcctgcgc	600
cggggagcat	ggaggagaac	gtgagaggct	acgactggtc	cccgcgcgac	gcccggcgca	660
gcccagacca	gggccggcag	cagggcggagc	ggaggagcgt	gctgcggggc	ttctgcgcca	720
actccagcct	ggccttcccc	accaaggagc	gcgcattcga	cgacatcccc	aactcggagc	780
tgagccacct	gatcgtggac	gaccggcacg	gggccatcta	ctgctacgtg	cccaaggtgg	840
cctgcaccaa	ctggaagcgc	gtgatgatcg	tgctgagcgg	aagcctgctg	caccgcggtg	900
cgccctaccg	cgaccgcgtg	cgcatcccgc	gcgagcacgt	gcacaacgcc	agcgcgcacc	960
tgaccttcaa	caagtctctg	cgccgctacg	ggaagctctc	ccgccacctc	atgaaggcca	1020
agctcaagaa	gtacaccaag	ttcctctctg	tgccgcgacc	cttcgtgcgc	ctgatctccg	1080
ccttccgcag	caagtctcag	ctggagaacg	aggagtctta	ccgcaagttc	gccgtgcccc	1140
tgctgcggct	gtacgccaac	cacaccagcc	tgcccgcctc	ggcgcgcgag	gccttccgcg	1200
ctggcctcaa	ggtgtccttc	gccaaactta	tccagtacct	gctggaccgc	cacacggaga	1260
agctggcgcc	cttcaacgag	cactggcggc	aggtgtaccg	cctctgccac	ccgtgccaga	1320
tcgactacga	cttcgtgggg	aagctggaga	ctctggacga	ggacgcgcgc	cagctgctgc	1380
agctactcca	ggtggaccgc	cagctccgct	ttcccccgag	ctaccggaac	aggaccgcca	1440
gcagctggga	ggaggactgg	ttcgccaaga	ttcccctggc	ctggaggcag	cagctgtata	1500
aactctacga	ggccgacttt	gttctctctg	gtaccccaa	gcccgaatac	ctcctccgag	1560
actgaaagct	ttcgcgcttc	ttttctctgc	gtgcctggaa	cctgacgcac	gcgcactcca	1620
gtttttttat	gacctacgat	tttgcaatct	gggcttcttg	ttcactccac	tgctctctac	1680
cattgagtac	tgtatcgata	ttgtttttta	agattaatat	atttcaggta	tttaatacga	1740
aaaaaaaaaa	aaaaaaactc	gagggggggc	ccgg			1774

<210> 18  
 <211> 1674  
 <212> DNA  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (1649)  
 <223> n equals a,t,g, or c  
  
 <220>  
 <221> SITE  
 <222> (1663)  
 <223> n equals a,t,g, or c  
  
 <220>  
 <221> SITE  
 <222> (1665)  
 <223> n equals a,t,g, or c

<400> 18						
caagttggta	cgccctgcagg	taccgggtccg	gaattcccgc	gtcgaccac	gcgtccggtc	60
gaagataggt	tcgagacggg	ggatgttgca	gctgatcatg	cagttgggtt	cggtgctgct	120
cacacgctgc	cccttttggg	gctgcttcag	ccagctcatg	ctgtacgctg	agagggctga	180
ggcacgcgcg	aagcccgaca	tcccagtgcc	ttacctgtat	ttcgacatgg	gggcagccgt	240
gctgtgcgct	agtttctatg	cccttggcgt	gaagcggcgc	tggttcgcgc	tgggggcgcc	300
actccaattg	gccattagca	cctacgcgcg	ctacatcggt	ggctacgtcc	actacgggga	360
ctggctgaag	gtccgtatgt	actcgcgcac	agttgccatc	atcgccggct	ttcttgtgtt	420
ggccagcggg	gctggggagc	tgtaccgccc	gaaacctcgc	agccgcctcc	tgacgtccac	480
cggccaggtg	ttcctgggta	tctacctcat	ctgtgtggcc	tactactgc	agcacagcaa	540
ggaggaccgg	ctggcgatc	tgaaccatct	cccaggaggg	gagctgatga	tccagctgtt	600
cttcgtgctg	tatggcatcc	tgccctggc	ctttctgtca	ggctactacg	tgacctcgc	660
tgccagatc	ctggctgtac	tgctgcccc	tgtcatgctg	ctcattgatg	gcaatgttgc	720
ttactggcac	aacacgcggc	gtgttgagtt	ctggaaccag	atgaagctcc	ttggagagag	780

tgtgggcatc	ttcggaaactg	ctgtcatcct	ggccactgat	ggctgagttt	tatggcaaga	840
ggctgagatg	ggcacagggg	gccactgagg	gtcaccctgc	cttcctcctt	gctggcccag	900
ctgctgttta	tttatgcttt	ttggtctggt	tgtttgatct	tttgcttttt	taaaattggt	960
ttttgcagtt	aagaggcagc	tcattttgtcc	aaattttctgg	gctcagcgct	tgggagggca	1020
ggagccctgg	cactaatgct	gtacaggttt	ttttcctggt	aggagagctg	aggccagctg	1080
cccactgagt	ctcctgtccc	tgagaagggg	gtatggcagg	gctgggatgc	ggctactgag	1140
agtgggagag	tgggagacag	aggaaggaag	atggagattg	gaagtgagca	aatgtgaaaa	1200
attcctcctt	gaacctggca	gatgcagcta	ggctctgcag	tgtctgttgg	agactgtgag	1260
agggagtgtg	tgtgttgaca	catgtggatc	aggcccagga	agggcacagg	ggctgagcac	1320
tacagaagtc	acatgggttc	tcagggtatg	ccaggggcag	aaacagtacc	ggctctctgt	1380
cactcacctt	gagagtagag	cagaccctgt	tctgctctgg	gctgtgaagg	ggtggagcag	1440
gcagtggcca	gctttgccc	tctgctgtc	tctgtttcta	gctccatggt	tggcctggtg	1500
ggggtggagt	tccctcccaa	acaccagacc	acacagtcct	ccaaaaataa	acattttata	1560
tagamaaaaa	aaaaaaaaaa	aagggcgcc	gctctagagg	atccctcgag	gggcccagc	1620
ttacgcgtgc	atgcgacgtc	atagctctnt	ccctatagaa	gtngnaaagg	gttc	1674

&lt;210&gt; 19

&lt;211&gt; 2018

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2010)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2012)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2014)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2016)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 19

cagcaatgaa	atcctgcttt	cttttcctca	gaactactat	attcagtggc	taaatggctc	60
cctgattcat	ggtttgtgga	atcttgcttc	ccttttttcc	aacctttggt	tatttgtatt	120
gatgcccttt	gcctttttct	ttctggaatc	agaaggcttt	gctggcctga	aaaagggaat	180
ccgagcccg	atcttagaga	ctttgggtcat	gcttcttctt	cttgcggtac	tcattcttgg	240
gatagtgtgg	gtagcttcag	cactcattga	caacgatgcc	gcaagcatgg	aatctttata	300
tgatctctgg	gagttctatc	taccctatct	atattcctgt	atatcattga	tgggatgttt	360
gttacttctc	ttgtgtacac	cagttggcct	ttctcgatg	ttcacagtga	tgggtcactt	420
gctagtgaag	ccaacaattc	ttgaagacct	ggatgaacaa	atttatata	ttaccttaga	480
ggaagaagca	ctccagagac	gactaaatgg	gctgtcttca	tcgggtggaat	acaacataat	540
ggagtgtgaa	caagaacttg	aaaatgtaaa	gactcttaag	acaaaattag	agaggcgaaa	600
aaaggcttca	gcatgggaaa	gaaatgttgt	gtatcccgt	ggtatggttc	tccttcttat	660
tgagacatcc	atctcggtcc	tcttggtggc	ttgtaatat	ctttgcctat	tggttgatga	720
aacagcaatg	ccaaaaggaa	caagggggcc	tggaaatagga	aatgcctctc	tttctacgtt	780
tggttttgtg	ggagctgcgc	ttgaaatcat	tttgatttct	tatcttatgg	tgtcctctgt	840
tgtcggcttc	tatagccttc	gatttttttg	aaactttact	cccaagaaag	atgacacaac	900
tatgacaaa	atcattggaa	attgtgtgtc	catcttgggt	ttgagctctg	ctctgcctgt	960

gatgtcgaga	acactgggaa	tcactagatt	tgatctactt	ggcgactttg	gaagggtttaa	1020
ttggctggga	aatttctata	ttgtattatc	ctacaatttg	ctttttgcta	ttgtgacaac	1080
attgtgtctg	gtccgaaaat	tcacctctgc	agttcgagaa	gaacttttca	aggccctagg	1140
gcttcataaa	cttcacttac	caaatacttc	aagggattca	gaaacagcca	agccttctgt	1200
aaatgggcat	cagaaagcac	tgtgagacgc	acagacggcg	tcttctgcca	ccaagagacc	1260
cgagaactcc	agattcacga	cattcctgtc	ccatgtagaa	gcatttccat	tcaaccgtgg	1320
ccccctctca	gaacctagac	ctatcagtgc	catttttttt	tcataatcta	cgaagaactt	1380
ggctatggct	gatctttttt	aaatttaact	ttctgatgga	ccctgtagtt	tccagtttaag	1440
tgcagattcc	ttacagacat	atagaacagc	gcattcttct	gtagacattt	gctcatgttg	1500
gtaaatacaa	tcaccatata	gaaaaaattg	ttttcacctg	atatgaaaat	gttagaaaag	1560
gcaaaactccg	ggacttctaa	agattttact	aaatcccat	atgtacttta	ttcagaatgt	1620
agaagctgac	ttgaaaggca	tccttggtac	taagtgaagc	ttattcagaa	aatgcatttt	1680
tcaaatagcaa	tggcaactgc	ttgtagatat	catttttgca	gtgtatgttg	gagctgtaat	1740
ggttgcaatt	atgtttctta	tttccttaaa	agcaaaaagc	gtagtttctg	atztatgtta	1800
tagaatgata	ctgattagac	tttgagccaa	ggggaaaata	ctaaattctt	ttaaacctgg	1860
agccttagag	agccacagga	atatcttctg	ttgtacagtc	taataagctg	tggtagggaag	1920
tatcatgtaa	tcacagttta	atgacagttt	atgtatatat	ataattcagt	attccctcga	1980
ggggggggccc	ggtacccaat	tcgccaagn	tnancnag			2018

&lt;210&gt; 20

&lt;211&gt; 2098

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 20

ggcacgaggg	accgagctat	tctcctggga	ctggctatga	tgggtgtgctc	catcatgatg	60
tattttctgc	tgggaatcac	actcctgcgc	tcatacatgc	agagcgtgtg	gaccgaagag	120
tctcaatgca	ccttgctgaa	tgcgtccatc	acggaaacat	ttaattgctc	cttcagctgt	180
ggtccagact	gctggaaaact	ttctcagtac	ccctgcctcc	agggtgtacgt	taacctgact	240
tcttccgggg	aaaagctcct	cctctaccac	acagaagaga	caataaaaaat	caatcagaag	300
tgtccttata	tacctaaatg	tggaaaaaat	tttgaagaat	ccatgtccct	ggtgaatggt	360
gtcatggaaa	acttcaggaa	gtatcaacac	ttctcctgct	attctgacct	agaaggaaac	420
cagaagagtg	ttatcctaac	aaaactctac	agttccaacg	tgtgtttcca	ttcactcttc	480
tggccaacct	gtatgatggc	tgggggtgtg	gcaattgttg	ccatggtgaa	acttacacag	540
tacctctccc	tactatgtga	gaggatccaa	cggatcaata	gataaatgca	aaaatggata	600
aaataatttt	tgttaaagct	caaatactgt	tttctttcat	tcttcaccaa	agaaccttaa	660
gtttgtaacg	tgcagtctgt	tatgagttcc	ctaataattt	cttatatgta	gagcaataat	720
gcaaaagctg	ttctatatgc	aaacatgatg	tctttattat	tcaggagaat	aaataactgt	780
tttgtgttgg	ttggtggttt	tcataatctt	atctctgtac	tggaaactagt	actttcttct	840
ctcattccgc	caaaacaggg	ctcagttatt	catttgccaa	gcttcgtgga	ggaatgtagg	900
tgacatcaat	gtgataaagt	ctgtgttctg	agttgtcaga	tctcttgaag	acaatatattt	960
tcacacttta	ttgtttacta	aagctacagc	caaaaatatt	tttttttctt	attctaaact	1020
gagccctata	gcaagtgaag	ggaccagatt	tcctaattaa	aggaagttag	gtacttttct	1080
tgtatttttt	accatatcac	tgtaaagaag	aggggaaacc	cagccagcta	cttttttcca	1140
tcacttttta	ttcataactt	cagatttgta	aaactaattt	ccaaaatata	agctgttttc	1200
attagccagt	tctataatat	cttcctgtga	tttatgtaga	aaatgaacac	acctcttttc	1260
catttaagac	cctgctactg	tgtgaagaga	tgatacttac	aaggagtgtc	attacctgtg	1320
agctgactga	atgtttgtag	gtgctccatt	acaattccag	aaagtctgtg	ttactgatat	1380
ttgtgtggaa	atctttattt	cacttcaatt	taaccttag	atggtaaaaat	taagatgcta	1440
cttgttggtg	aaaattgggtg	gactggtttc	aatgggtaaa	tgtgtgtgtg	caaattaatg	1500
tgttggaata	ttgctctttg	tgaatttgtg	cttaagtcaa	tgaatgtgta	gtatctcctt	1560
ctgacaagca	ttccctattg	ggatttttaa	gctatgtgca	cagaatatta	gtctcttcta	1620
catgttttat	ttttctattt	ataattccct	ttttgttgt	tatattttat	acacagaata	1680
gatctttttt	ctaacacata	tttgaactga	ataacagact	taaagaaagc	ctttgtttcac	1740
attgctattt	atctttgtgt	ttgggggaaa	atacagggga	ttgattttta	ataaaaaaca	1800
ttccatcttt	cattttaatat	caatatcaaa	agaagaagac	aaacatctat	ctttctctac	1860
tatatttaag	tacctttttg	taatgtagta	tcaaagtttt	ttaggtaatg	caaaatttta	1920
caaatcattt	gtggaatgaa	tggtaaaact	aatctgatga	aatggaaaat	tattctgcaa	1980

tattgtaatt catagtttga cttttcataa gcaaataaat ccctaggatg taatcaggac 2040  
ttcaaatgtg taattaaatt tttttaaaaa aaatctaaaa aaaaaaaaaa aaaaaaaa 2098

&lt;210&gt; 21

&lt;211&gt; 1746

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

gcgttcgcgc acctccagct cgggccgatg tggaagcttt ggagagctga agagggcgcg 60  
gcggcgctcg gcggcgcgct ctctctgctg ctcttcgcgc taggggtccg ccagctgctg 120  
aagcagaggg gcccgatggg cttccccccg gggccgcggg ggctgccatt tatcggcaac 180  
atctattccc tggcagcctc atccgagctt ccccatgtct acatgagaaa gcagagccag 240  
gtgtacggag aggtacagcc ccgacgggcc ccgggcaggg agggccgcca ggctggcccc 300  
ggctggccag ggcttctctg gttggactta tggccgcccc tgggcccact agtcgggacc 360  
tctccgtgtg ccggctgccc tttgagggac acccgcttcc cgggtctgga agggagaagt 420  
cctcgacgcc gtgccccctt gcagggggag ccccgcccc tgcggtgacc cactccgggc 480  
cgaggctccg aggcgatcca gtctgattt tcccgctacc gctcgagctc ttgctcctgc 540  
gcctgcgcgc tttggctcgc cagccgcgcc gccacttcag gtccagggtg gacgcatgcc 600  
ctcaggtgcg ggcgtcttgc gagtcggcct cgcagctctg tggaagctgc acgcggcttg 660  
tcggaaaatc aaggcgttct gagttctaga tggtaatag caggttcttc ggtgtctgca 720  
gtcgacgaac gactggtgta ggcgtttgct gtgagaatgg agaatgcagg ggaacgcccc 780  
tgactgagaa gcggggccctg ggaacgatt gtgaacgcgt gaatgaattg atgactaaaa 840  
tccgtgcgg gggtcctaca gcgcagatgg taatgccgtt ctgactggct gggaaacggca 900  
ccttagcaga tacttaaaag gcgccttctg tgtgccactg tcaactgcaa cttggtgact 960  
catttaaaac tcataaccag ccggtgaggt cggtaacttc ctcctcctca ttctgaggag 1020  
gggaaagcag cacggaatg ccctgtgact ggcagcgga aaggcgacca ccgcttgtgt 1080  
gtgggtgtcc cgacgtcccg agggggcagg agtttccacg ggtcctggga cagagctcac 1140  
ctgttttgtt ttgaattaca cttatttata tgcaactaca ggctgacgc tagcggtgaa 1200  
gaaggcagat acagcctttt aaggagttgg cagatgagtg ggagagagaa aactaatctc 1260  
attatcggcc acaggctgtg gtcagtgttt tgaaggaata gtacagggat gtttggcaac 1320  
tgtggtattt caggtttgac cttaaatcct tacttaaac agtttttaca aggattgttc 1380  
taggtgcccg ggcgcggtgc tcacgcctat aatcccagca ctttgggagg ccgaggcggg 1440  
cggatcacga aatcaggaga tcgagaccgt cgtggctaac acggtgaaac cccatctcta 1500  
ctaaaagaat acaaaaaatt ggcggggcgt ggtggcgggc acctgtggtc ccagctattc 1560  
ggagagctgg ggcaggagag tggcgtgaac ccgggaggcg gagctttcag tgagccgaga 1620  
tcgcgccact gcactccagc ctgggcaaca gagccagact ccgtctcaaa aaaaaaaaaa 1680  
aaaaagggcg gccgctctag aggatccaag cttacgtacg cgtgcatgcy acgtcaatag 1740  
ctcttc 1746

&lt;210&gt; 22

&lt;211&gt; 2876

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

ccacgcgtcc ggcggcgagg cggcggtggt ggctgagtc gtggtggcag aggcgaaggc 60  
gacagctcta ggggttggca cgggccccga gaggaggatg cgggtccgga tagggctgac 120  
gctgctgctg tgtgcggtgc tgctgagctt ggctcggcg tcctcgatg aagaaggcag 180  
ccaggatgaa tccttagatt ccaagactac tttgacatca gatgagtcag taaaggacca 240  
tactactgca ggcagagtag ttgctggtca aatatttctt gattcagaag aatctgaatt 300  
agaatcctct attcaagaag aggaagacag cctcaagagc caagaggggg aaagtgtcac 360  
agaagatatc agctttctag agtctccaaa tccagaaaac aaggactatg aagagccaaa 420  
gaaagtacgg aaaccaggta gtctggacat tttccttgct ttttgattta tttaggggac 480  
aactgaaaat ttttaagctaa tgaataaaga ggtgaagaa gactggcttc actgattatt 540  
acccacaaat aatatatgga gtgtagtttg gagagaattt ctagatttta atataccaaa 600  
gttattcact taacagattt gacccaagtt acataagctg aattccatag atgagattgc 660

atztatcttt	ttattaatat	cctgacgttt	ctttttggaa	tcaagtatgt	aaataccttt	720
ctcactgaga	aatttaaaaa	aataatatgt	cagggttagca	tacaaaacag	aaacttagga	780
agaactgtct	aacatgccac	tatggttatt	ttcaggattg	tggtaggatt	attactacaa	840
taacctgtgc	gatcatccta	ggtaatttga	tttaggtgtt	tatccctcag	ctgacgcttg	900
tgtgtacttc	catcctattc	taactttcac	aatcttgaaa	cctctacttt	tcaattttaa	960
acttgacctt	tttcacaata	gtcttctaaa	tattaatcct	tttaaaaaatt	attaatgtat	1020
gcattctacc	atgtcttgtt	gcccttctgt	catttattat	ttcaatgatc	actgccttat	1080
ctgttttatta	ttccattact	aaccactctc	aggaactgat	ccaaattgga	acttttttaa	1140
aaaatagaat	ttttttttac	tacaaatata	ccattctcat	gaatagaaaa	ctatttttaa	1200
aaaattaaaa	gtacatgaat	cccatcaact	agaaataaca	gctgctcaca	tcattggagaa	1260
tattctctca	ggattttttt	aggtgtatca	gtagttttta	gaaaagtaaa	ttgggtcaaa	1320
atgtgtattc	tatgttgcag	cctgcatttt	gcacttaaca	gtttaccatg	aatgtttttc	1380
catgtcattt	agcttatttt	caatttgata	gttaatggct	ataaaaaatt	ttatttghtaa	1440
atataaggta	ccataaacca	aaacgtttat	gttttgctgg	gagatcattt	tagatgtatc	1500
tttgtgccta	tctgtgaaaa	tttctttaga	attctttaaag	taaatttgct	gaattggatg	1560
taaaagttaa	aaagacagta	gatacacatt	gttaaatgtt	tcttcagaaa	agtgtattctg	1620
tttacttcct	ctgaaaatac	ctctttccct	gtacctcacc	caagtgtgta	ttaccatttt	1680
aaaattttta	ctaaatataa	tttaattcat	tcttcatttt	ttaattaggg	attttttttt	1740
ttttttttta	gtttttatat	tttttagagac	atgggtctcac	tctgtcactc	aggctggagt	1800
gcagtggcac	gatcatagtt	cactgcagcc	ttgaactcag	gtgatctccc	tctttggcct	1860
cccaaatgtc	tgggattaca	ggcatgagac	actacatcaa	gcctgggaaa	tttttaaaaa	1920
tgcataaaaag	tagagggtaa	aatgacaccc	cttaccaccc	ctcactcagc	ttcaataaac	1980
atcaacattc	tgtgtgtctt	ttcatcttta	ctaccctaca	cacatttgcc	ctttttttct	2040
ttcctagaat	attttaaggc	aaattccgca	tgtgtcttta	catctctgtg	tctctctcta	2100
gtaagaatgt	tcttttcagc	aaaatcacag	aattagccat	tactccttta	ttaccttaata	2160
cccagactgt	ttaatttttc	tagttgtctt	aagtgtctgt	ttacaattta	ttgttttgaa	2220
ttcatttcta	agctactcag	gaggctgagt	caggagaatt	gcttgaaccc	aagaggcaga	2280
ggttgacagt	agctgagatc	gtgccactgt	actccagcct	gggtgacaaa	gtgagactcc	2340
atgtcaaaaac	aaaacaaaac	aaaacaaaac	aaaacaaaac	aaacaacaca	attgaataat	2400
atccctcagt	tattatttag	agaagagatg	actcaatata	aatgtaatat	gtgatcattt	2460
ggtcacagaa	tgaatttcag	tcattgctta	ggtaagcctg	gtaaaaaaaa	aaaaaaaaacgg	2520
gattccatga	ttagtgtgtt	gaaaaggggg	ttgccaagt	gtaacagaca	gagccgggtg	2580
cagtggctca	cgctgtaat	cccagaactt	tgggaggcca	aggcaggcgg	atcacgaggt	2640
caagagattg	agacaatcct	ggccaacatg	gtgaagccct	gtatcaacta	aaaatacaaa	2700
aacaatttagc	tgggcgtggt	gacatgtgcc	tgtagtccca	gctactcagg	aggctgaggc	2760
aggagaattg	cttgaacctg	ggaggcggag	gctgcagtga	gctgagattg	ctccactgca	2820
ctccagcctg	gccacagagt	gagattccat	ctcaaaaaaa	aaaaaaaaaa	aaaaaa	2876

&lt;210&gt; 23

&lt;211&gt; 1052

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 23

tcgacccacg	cgtecgccca	cgcgtccgcc	cacgcgtccg	ggcggggcga	ggacgtgcac	60
tatggctcgg	ggctcgctgc	gccggttgct	gcggtctctc	gtgctggggc	tctggctggc	120
gttgctgcgc	tccgtggccg	gggagcaagc	gccaggcacc	gccccctgct	cccgcggcag	180
ctcctggagc	gcggacctgg	acaagtgcac	ggactgcagc	acctcctgcc	cccttcgggc	240
tgctttggcc	catccttggg	ggcgctctga	gcctgacctt	cgtgctgggg	ctgctttctg	300
gctttttggt	ctggagacga	tgcgcagag	agagaagtgc	accaccccca	tagaggagac	360
cggcgggag	ggctgcccag	ctgtggcgct	gatccagtga	caatgtgccc	cctgccagcc	420
ggggctcgcc	cactcatcat	tcattcatcc	attctagagc	cagtctctgc	ctcccagacg	480
cggcggggagc	caagctcttc	caaccacaag	gggggtgggg	ggcgtggaat	cacctctgag	540
gcctggggccc	agggttcagg	ggaaccttcc	aaggtgtctg	gttgccctgc	ctctggctcc	600
agaacagaaa	gggagcctca	cgctggctca	cacaaaacag	ctgacactga	ctaaggaaact	660
gcagcatttg	cacaggggag	gggggtgccct	ccttcttaga	ggccctgggg	gccaggctga	720
cttggggggc	agacttgaca	ctaggcccca	ctcactcaga	tgtcctgaaa	ttccaccacg	780
gggggtcacc	tggggggtta	gggacctatt	tttaacacta	gggggctggc	ccactaggag	840



```

ggctggccct aagatacaga ccccccaac tccccaaagc ggggaggaga tattttatattt 900
ggggagagtt tggaggggag ggtggggggg gggaaaaaaa aataaaaaaa aaaattttta 960
atttttaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1020
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 1052

```

<210> 24  
 <211> 1541  
 <212> DNA  
 <213> Homo sapiens

```

<400> 24
ggcagagct tcctcgatcc tactctgtct ctctttgttt tggagaagtt caatttacca 60
gctggatatg tgggactagt attcctgggt atggcactgt cctatgccat ctcttcacca 120
ctatttgggt tcctaagtga taaaaggcca cctctaagga aatggcttct ggtgtttggc 180
aacttaatca cagccgggtg ctacatgctc ttagggcctg tcccaatctt gcatattaaa 240
agtcagctct ggctgctggt gctgatatta gttgtaagtg gcctctctgc tggaaatgagt 300
ataattccaa ctttcccgga aattctcagt tgtgcacatg aaaatgggtt tgaagaggga 360
ttaagtacat tgggacttgt atcaggtctt tttagtcaa tgtggtcaat tgggtgctttt 420
atgggaccaa cgctgggtgg atttctgtat gaaaaattg gttttgaatg ggcagcagct 480
atacaaggtc tatgggctct gataagtga ttagccatgg gcttgtttta tctactggag 540
tattcaagga gaaaaaggtc taaatctcaa aacatcctca gcacagagga ggaacgaact 600
actctcttgc ctaatgaaac ctagtccgat ggatcctgga ttgatacaag gttgagaaat 660
gaatgctcct ggccttaaac atcaccttag gaagggtttt taaaatttta cgcgcaaac 720
tccgtggacc ccgtgccagt gtcttggaa gttcaacgtg tttttggatg atcctgtatt 780
gggctgtact tactgtgata ctgaaaagct gtcctgctga agcagctata tttgaaatat 840
taagtatgaa aggagtaatt aaaaacaagc aaaaacaaac aagacttagt ttttaaatga 900
ccaaacttgt ccttaaagat gttgttatta actcgagtta gttcttattt cctctgttta 960
ttttttatcc taagtacact gattctgtga atgtaccttt tttattacac agggaaagaa 1020
atgaattaat ttgatatgct ctaaatacat aaagggtgctt caaaatatgt agaaacatta 1080
ctatgaaatc agtttttaaa agatatactt tctctttgtc ctgagggtttt tccgtcttgt 1140
tcaaaaggaa gaattcttgc ctgccaatac gaaactctct agcactccct gaccttaagc 1200
ttttctaaaa attctgtttg tgtgaaaagt acaagaataa caatacttac aactccatt 1260
tttgaacct acgttcactt atgatctgga tttataaaca ttacttggtg taacgttttt 1320
catttccctt aatgtctctg tttttggct ctaccatctg ttttgttttt gtttttatct 1380
atatcttggt agatgtatct catccctaga gcaggctcagc ctccctcccc taatgcgaat 1440
gcttgttttg ttagggaagg gcttccctca acttcgtgtg aaattgtgat gttgaagtga 1500
ataaatgtct attgtgtaac aaaaaaaaaa aaaaaaaaaa a 1541

```

<210> 25  
 <211> 2079  
 <212> DNA  
 <213> Homo sapiens

```

<400> 25
ggcagaggg aggcgcggct ggcggacctg actagattct acgacaaggt actttctttg 60
catgaggatt caacaacccc tgtggctaac cctctgcttg catttactct catcaaacgc 120
ctgcagtctg actggaggaa tgtggtacat agtctggagg ccagtggaaa catccgagct 180
ctgaaggatg gctatgagaa ggtggagcaa gaccttcag cctttgagga ccttgaggga 240
gcagcaaggg ccctgatgct gctgcaggac gtgtacatgc tcaatgtgaa aggcctggcc 300
cgagggtgct ttcagagagt cactggctct gccatcactg acctgtacag ccccaaacgg 360
ctcttttctc tcacagggga tgactgcttc caagttggca aggtggccta tgacatgggg 420
gattattacc atgccattcc atggctggag gaggctgtca gtctcttccg aggatcttac 480
ggagagtgga agacagagga tgaggcaagt ctagaagatg ccttggatca cttggccttt 540
gcttatttcc gggcaggaaa tgtttcgtgt gccctcagcc tctctcgga gtttcttctc 600
tacagcccag ataataagag gatggccagg aatgtcttga aatatgaaag gctcttgga 660
gagagcccca accacgtggt agctgaggct gtcacccaga ggcccaatat accccacctg 720
cagaccagag acacctacga ggggctatgt cagaccctgg gttcccagcc cactctctac 780

```

cagatcccta	gcctctactg	ttcctatgag	accaattcca	acgcctacct	gctgctccag	840
cccatccgga	aggaggtcat	ccacctggag	ccctacattg	ctctctacca	tgacttcgtc	900
agtgactcag	aggctcagaa	aattagagaa	cttgacagaa	catggctaca	gaggtcagtg	960
gtggcatcag	gggagaagca	gttacaagtg	gagtaccgca	tcagcaaaaag	tgcttggtctg	1020
aaggacactg	ttgacctaaa	actggtgacc	ctcaaccacc	gcattgctgc	cctcacaggc	1080
cttgatgtcc	ggcctcccta	tgcagagtat	ctgcaggttg	tgaactatgg	catcgaggga	1140
cactatgagc	ctcactttga	ccatgctacg	tcaccaagca	gccccctcta	cagaatgaag	1200
tcaggaaaacc	gagttgcaac	atttatgac	tatctgagct	cgggtggaagc	tggaggagcc	1260
acagccttca	tctatgccaa	cctcagcgtg	cctgtgtgta	ggaatgcagc	actgttttgg	1320
tggaaacctgc	acaggagtgg	tgaaggggac	agtgcacac	ttcatgctgg	ctgtcctgtc	1380
ctggtggggag	ataagtgggt	ggccaacaag	tggatacatg	agtatggaca	ggaattccgc	1440
agaccctgca	gctccagccc	tgaagactga	actgttgcca	gagagaagct	ggtggagtcc	1500
tgtggccttcc	cagagaagcc	aggagccaaa	agctggggta	ggagaggaga	aagcagagca	1560
gcctcctgga	agaagccctt	gtcagctttg	tctgtgcctc	gcaaatacaga	ggcaagggag	1620
aggttggttac	caggggacac	tgagaatgta	catttgatct	gccccagcca	cggaaagtcag	1680
agtaggatgc	acagtacaaa	ggagggggga	gtggaggcct	gagagggaag	tttctggagt	1740
tcagatactc	tctgttggga	acaggacatc	tcaacagtct	caggttcgat	cagtgggtct	1800
tttggcactt	tgaaccttga	ccacagggac	caagaagtgg	caatgaggac	acctgcagga	1860
ggggctagcc	tgactcccag	aactttaaga	ctttctcccc	actgccttct	gctgcagccc	1920
aagcagggag	tgtccccctc	ccagaagcat	atccccagatg	agtgggtacat	tatataagga	1980
ttttttttaa	gttgaaaaca	actttctttt	ctttttgtat	gatgggtttt	taacacagtc	2040
attaaaaatg	tttataaatc	aaaaaaaaaa	aaaaaaaaaa			2079

&lt;210&gt; 26

&lt;211&gt; 1947

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 26

tgtaaacaga	ttggagaatc	tagcaataag	attcaaagct	aatctggagc	ataaaggcac	60
agttcagaga	cagaataaca	gggatcacaa	gcataaatta	aaaggaattt	atttgcttca	120
agttcctaga	tacaaccttc	ccatgctgca	cttctccact	gtcggagcac	gttccgaaaa	180
acagaatgcc	ttgatccctg	gtgggtgcca	aggcagttgt	tagggatggc	aggcattggg	240
gggctccaaa	agatgaaggc	cccacacaca	ggtgtgctgc	atttgggatc	tgtgtgggtg	300
tttcttgagc	cctttcttct	gggagtggg	tacacactaa	cgtttaatcc	gctgtctggg	360
tgcatgtcca	cagtacggtg	gctaaactcg	aacatcactg	caaataaggc	gctgagcagg	420
tccgtctgtc	atgtcacgcc	actgcacagg	tccttgtccc	cacacgacgg	ggagtacttg	480
cgtcagatgt	tattgaatag	ctcgtctcgg	gcaggggaag	cggggagttg	gggatattaa	540
ttgggggttt	taattctatt	atcatgtcag	ctgacattat	gactatataa	tgtagttaga	600
gacaattttt	atcttgctta	tagtaaaggt	tcagcctgcc	aattgtaaat	cattctaatt	660
tggcaggctt	atttttgaca	ttggaaagg	cagaaagcga	tttgccccag	tagtgtaata	720
ggagtatatag	accagaggct	gaaacccaaa	ctatataaaa	aggaattcag	tggagggggc	780
tttgtaatct	ccattaattt	gtgttgctac	ttccaggatc	accaaaaatt	acatgtaatt	840
ttacatgtta	aacacattga	aacataacct	atgtttataa	agcataacgg	gcttcccttc	900
cagaagctct	cctgcttgtc	atgaagtgg	aacaatgaaa	agtcatagca	gatactcagt	960
ttaactctgt	gtagaaccta	gtagtgtttg	agctgttatt	cagatttgaa	ttcagactgt	1020
gtgtgttttg	cttatggaca	ctgcctgtcg	ttctgtcact	gttaaattaa	tgagtctata	1080
aggtttttct	tccagaggcc	ataggtgaca	tcactaaaa	tgcaagataa	attgtaattc	1140
ttgctgctgc	tgcactcccc	aacctctccc	ccaccccccg	tggtgtgctg	ctttctagat	1200
gagcgtgttt	tggagcaggc	ccatctggga	cactctatgc	tttcaccaag	gaagtgcgat	1260
ctgagcagcc	acaatccagc	caaaagagga	tcgtagatat	ttgctctgat	caactagatg	1320
aaaatatagc	agaatggatt	tagcccactg	ctctgtttta	tccaactgag	tctctgacca	1380
gcaattgggtg	cataattatt	acagcaaaaag	ttaagaaatg	aaactgtagc	aattatgtaa	1440
atgaatgtgt	tggcctctta	atacctgtta	ctagtggact	tcctgtgagg	aagttagttt	1500
tttgttttga	tgaatgctt	tcgtttttta	aatcttaatt	ctgctgtcca	catcctccca	1560
aagtgtgctt	acttcatttg	tttaatttaa	atgaactttc	ctccttgat	gtatgagggtg	1620
acttggtggg	tgggggtggg	gggttttgtt	tttggtttt	ttctttctta	gggcatctgt	1680
aggcctcaaa	ggacctttcc	tttaggtcat	attcctcaga	aagtcctcaa	tcttcccttg	1740

tttttgtttg	tttgtttttc	ttaaagaata	ttttcaaagc	ttaaatttgt	atattaat	1800
aggactat	agaagtata	gctgtcgtt	gcggcagcag	tatatctga	aatgtctcat	1860
agatatata	ttttgaata	agatggtgt	gttgaacaaa	aaaaaaaaa	aaaaaaaaac	1920
tcgagggggg	gcccgggtacc	caattcg				1947

<210> 27  
 <211> 3379  
 <212> DNA  
 <213> Homo sapiens

<400> 27

atgatattca	agtcgaattc	ccctcactaa	agggaaaaaa	gctggagctc	caccgcgggtg	60
gcggccgctc	taaacctact	ggatcccccg	ggatgcagga	attcggcacg	aggtctcggc	120
tcctctccgc	acccgcccgg	cccggtgct	cccggtcct	cccggccatg	gggagctgcg	180
cgcggtgct	gctgctctgg	ggctgcacgg	tgggtggcgc	aggactgagt	ggagtagctg	240
gagtgaagtc	ccgctgtgaa	aaagcctgca	accctcggat	gggaaatttg	gctttggggc	300
gaaaactctg	ggcagacacc	acctcgggtc	agaatgctac	cgaactgtac	tgcttctaca	360
gtgagaacac	ggatctgact	tgtcggcagc	ccaaatgtga	caagtgcaat	gctgcctatc	420
ctcacttggc	tcacctgcca	tctgccatgg	cagactcacc	ctccgggtt	cctcgcacat	480
ggtggcagtc	tgccggaggat	gtcacagag	aaaagatcca	gttagacctg	gaagctgaat	540
tctacttcac	tcacctaat	gtgatgttca	agtccccag	gccggctgcc	atggtgctgg	600
accgtcccca	ggactttggg	aaaacatgga	agccttataa	gtactttgcg	actaactgct	660
cgctacatt	tgccctggaa	gatgatgttg	tcaagaaagg	cgctatttgt	acttctaaat	720
actccagtcc	ttttccatgc	actggaagga	aggttatttt	caaagctttg	tcaccaccat	780
acgatacaga	gaacctttac	agtgcctaa	ttcaggagca	gctgaagatc	accaacctcc	840
cgctgcagc	tgctgaaacg	acagtcttgt	ccctgtcaga	gaaatgacct	gaacgaagag	900
cctcaacatt	ttacacacta	tgccatctat	gatttcattg	tcaagggcag	ctgcttctgc	960
aatggccacg	ctgatcaatg	catacctgtt	catggcttca	gacctgtcaa	ggccccagga	1020
acattccaca	tggtccatgg	gaagtgtatg	tgtagtcaca	acacagcagg	cagccactgc	1080
cagcactgtg	ccccgttata	caatgaccgg	ccatgggagg	cagctgatgg	caaaacgggg	1140
gtccccaacg	agtgcagaac	ctgcaagtgt	aatgggcctg	ctgataacctg	tcacttcgac	1200
gttaatgtgt	gggaggcatc	agggaaatcgt	agtgggtggtg	tctgtgatga	ctgtcagcac	1260
aacacagaag	gacagtattg	ccagagggtgc	aagccaggct	tctatcgtga	cctgcggaga	1320
cccttctcag	ctccagatgc	ttgcaaaccg	tgctcctgcc	atccagtagg	atcagctgtc	1380
cttcttgcca	actcagtgc	cttctgcgac	cccagcaatg	gtgactgccc	ttgcaagcct	1440
ggggtggcag	ggcgacgttg	tgacaggtgc	atggtgggat	actggggctt	cggagactat	1500
ggctgtcgac	catgtgactg	tgcaaggagc	tgtagcccta	tcaccggaga	ctgcatcagc	1560
agccacacag	acatagactg	gtatcatgaa	gttctgact	tccgtcccgt	gcacaataag	1620
agcgaaccag	cctgggagtg	ggaggatgcg	caggggtttt	ctgcacttct	acactcagggt	1680
aatgccaat	gtaaggaaca	gacattagga	aatgccaagg	cattctgtgg	aatgaaatat	1740
tcatatgtgc	taaaaataaa	gattttatca	gctcatgata	aaggctactca	tgttgagggtc	1800
aatgtgaaga	ttaaaaagggt	cttaaaatct	accaaactga	agattttccg	agggaaagcg	1860
aacattatat	ccagaatcat	ggacggacag	aggatgcact	tgtccaatcc	tcaatcctgg	1920
tttggaatac	ctttagtagc	gacatgagga	tataagaaca	ggcaaactaa	ttgtgaatat	1980
gaaaagcttt	gtccagcact	ggaaaccttc	tcttggaaga	aaagtcattg	atattttaaa	2040
aagagagtgc	aagtagcatt	aagatggata	gcacataatg	gcacttgggt	atgtccaaaa	2100
cacaaacttt	agagcaagaa	gacctcagac	aggaaactgg	aattttttta	agtgcacaaa	2160
catatagaaa	tggttgaaatg	catgggtctt	tatctaattt	atctcttctg	gacccatggt	2220
taaatacagt	tttatttcat	gaagagaaat	gaaaaccctt	acactgatat	ctgttttcta	2280
tgggactgat	tctgaaatc	ttaactatta	agaatatatt	aatagcagca	tgacatttag	2340
cagtaatcca	ttaagggcag	tacctctaac	aaggacgcct	tccagcttca	gctatgttac	2400
ttacgtttga	tgctacttaa	agtaaatgaat	gacgttttaa	ggaatcccta	accctactat	2460
cagaaaagggt	gtttgttaaa	gagccttctc	ttgtgtgtta	cgcatagaact	ttgggtctgta	2520
ggtgttaaat	ggacctctc	catgtgtata	tagtatctcc	ttgtataaag	cacttttacta	2580
cctaccactt	gtgtgttgaa	cgtttggtag	ctgcttttga	aagaaggaaa	aggggtgtgtg	2640
agaaagccta	ctgaagcagc	agcactgcca	ctacatgtgg	acaaaagtga	acatatataaa	2700
gaagtgtgtg	tatttaactc	tgaatacttg	gagaaactag	gtgaagatgc	aaccagaaag	2760
gagaatatgt	atgcgtgaag	tctcagcttt	gagctggagg	ctagattcca	agatgcagc	2820

catgatgaaa	cttttttaaaa	aactaaacca	gaagagactt	taaaataaga	gaaagaaatc	2880
ataaatgtag	acatatgctt	ggctaaaggg	gaaatggact	ttaaatttta	aagagctcat	2940
ttgcaatgca	cttgtataca	cttcaaaaaat	tattgtagac	acagaatttg	ttatatTTTT	3000
gtgcttagta	tttaaacctg	aacattgaaa	cagttttcct	cettgtcttt	cttaacagta	3060
atagtcatta	tattttacctg	ttttttaaca	caatgtatgt	gatagtcaaa	aaatcacagt	3120
ttttcattat	tattcatctt	ctgtacccac	gcataaccac	tatacatagt	ttcttttgta	3180
cttgaatata	caaaacatga	acacagtgcc	atatgaataa	tttcacatac	agaacctttt	3240
ttctctcgaa	gtcctgtgga	cttgcaataa	tatatatata	ttgctttggt	aatttgTTTT	3300
tatatTTcat	atatgtaata	aaggaaatg	atctgaaaaa	aaaaaaaaaa	aaaaactcga	3360
gggggggccc	gtacccaaa					3379

&lt;210&gt; 28

&lt;211&gt; 2006

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 28

cccacgcgtc	cgcggaacgcg	tgggattttc	tcttaagaaa	aaaaaaggaa	gacgttttaa	60
taggaaaaga	aaaacaagaa	gcagtagcag	ctaggtaatt	taaacgtctt	cctttttttt	120
tcttaagaga	aaatggaaca	tttaggttaa	atgtctttta	attttaccac	ttaacaacac	180
tacatgccca	taaaatata	ccagtcagta	ctgtatttta	aaatcccttg	aaatgatgat	240
atcaggggta	aaattacttg	tattgtttct	gaagtttgct	cctgaaaact	actgtttgag	300
cactgaaacg	ttacaaatgc	ctaataggca	tttgagactg	agcaaggcta	cttgttatct	360
catgaaatgc	ctgttgccga	gttattttga	atagaaatat	tttaaagtat	caaaagcaga	420
tcttagttta	agggagtgtg	gaaaaggaa	tatatTTctc	ttttcctga	ttctgtactc	480
aacaagtctt	gatggaatta	aaatactctg	ctttattctg	gtgagcctgc	tagctaatat	540
aagtattgga	caggtaataa	tttgtcatct	ttaatattag	taaaatgaat	taagatatta	600
taggattaaa	cataatttta	tacggttagt	actttattgg	ccgacctaaa	tttatagcgt	660
gtggaaattg	agaaaaatga	agaaacagga	cagatatatg	atgaattaaa	aatatatata	720
ggtcaatttt	ggtctgaaat	ccctgaggtg	tttttaacct	gctacactaa	tttgtacact	780
aattttattc	tttagtctag	aaatagtaaa	ttgtttgcaa	gtcactaata	atcattagat	840
aaattatttt	cttggccata	gccgataatt	ttgtaatcag	tactaagtgt	atacgtattt	900
ttgccacttt	ttcctcagat	gattaaagta	agtcaacagc	ttatttttagg	aaactggaaa	960
agtaataggg	aaagagattt	cactatttgc	ttcatcagtg	gtaggggggc	ggtgactgca	1020
actgtgttag	cagaaattca	cagagaatgg	ggatttaagg	ttagcagaga	aacttggaaa	1080
gttctgtgtt	aggatcttgc	tggcagaatt	aactttttgc	aaaagtttta	tacacagata	1140
tttgtattaa	atttggagcc	atagtcagaa	gactcagatc	ataattggct	tatttttcta	1200
tttccgtaac	tattgtaatt	tccacttttg	taataatttt	gatttataat	ataaatttat	1260
ttattttatt	ttttaatagt	caaaaatctt	tgctgttgta	gtctgcaacc	tctaaaatga	1320
ttgtgttgct	tttaggattg	atcagaagaa	acactccaaa	aattgagatg	aatgtttggt	1380
gcagccagtt	ataagtaata	tagttaacaa	gcaaaaaaag	tgctgccacc	ttttatgatg	1440
attttctaaa	tggagaaaca	tttggctgca	tccacataga	cctttatggt	ttgttttcag	1500
ttgaaaactt	gcctcctttg	gcaacattcg	taaatgaagc	agaatttttt	ttctcttttt	1560
ttccaaatat	gttagttttg	ttcttgtaag	atgtatcatg	ggtattgggtg	ctgtgtaatg	1620
aacaacgaat	tttaatttagc	atgtggttca	gaatatacaa	tgtaggtttt	ttaaaaagta	1680
tcttgatggg	tcttttctat	ttataatttc	agactttcat	aaagtgtacc	aagaatttca	1740
taaatTTgtt	ttcagtgaac	tgctttttgc	tatggtaggt	cattaaacac	agcacttact	1800
cttaaaaaatg	aaaatttctg	atcatctagg	atattgacac	atttcaattt	gcagtgtctt	1860
tttgactgga	tatatTTaag	ttcctctgaa	tggcattgat	agatggttca	gaagagaaac	1920
tcaatgaaat	aaagagaata	tttattcaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1980
aaagggcggc	cgctctagag	gatccc				2006

&lt;210&gt; 29

&lt;211&gt; 3070

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 29

gttggagcct	tagaccttcg	aagtgcctta	tagaaggtag	gcctgcaggt	accgggtccgg	60
aattcccggg	tcgacccacg	cgtccgcaac	gtatgaggag	tctgatttct	tcacatcctt	120
gtcaacattt	gttgtgtgtg	tttgtgtgtg	tggttttaaat	tttagctatc	ctagtagatg	180
tgaagtggta	tctcgtgctt	tttatttgca	tttctctaata	gactagtgat	gttgaacatc	240
ttttcatgtg	cttggtggcc	attcgtatat	cttcttggag	aaatgtctat	taagtccttt	300
gccaatttc	aaattggcct	gtctttttgt	tgagttataa	ccattgaatt	ttaattgctg	360
taaaacactc	catgagtaca	tgtagcatgc	actcaataac	tattagctaa	tactatagtt	420
gtaattattt	ttgccacatg	tggcctgaat	tggaaaggaaa	ttgcctagtt	tttccaagta	480
ggagtggaga	tgtaacaaaa	cctgtattta	aggccaataa	agatttgact	ctgtcagttg	540
tgatactttg	cttttaattg	atgctcccaa	atcaagaaat	tagaaacgtg	tatacataag	600
aatcagttta	tctttggcag	aaatcagtat	attatcaatg	tttaattaat	tcctaagaat	660
taatggcaat	agtgcctcta	gttttagctg	agatttagat	catctttctt	cattctgccc	720
tgttatgcga	catttgctat	aaatgccaca	atgagaattt	tttgaaacct	gggtcagaga	780
agcctacttt	ttatatttaa	taagtattgt	attgatgtat	tatcattggt	ttatgcttat	840
tgcatcttgg	ttttatgggg	tgttcaaaag	aagatagatg	agaatagggtg	atccaaagta	900
atttagaatt	ttatcctcca	gttgggactg	aaccatcttg	aactgatgaa	tatattctac	960
caggtttata	ggtagatatg	ccgtttcatt	atatcgggtga	tttggagtga	gacagtagct	1020
tttaagcaga	acaacagcca	tatgtaagtc	taaatttggg	tattttcttt	gaataagcaa	1080
tggaaactgt	atgcattcag	gaactggtga	ttcagatata	ttctgaaggc	cctctctccc	1140
ctgtgctccc	acagcttttg	tcctgaactc	tcctgtctcc	ttgcgatgcc	tctgtgctta	1200
tacctatttt	gtgaactctg	cctgcaatgc	cgtcccaagt	cagttggtga	ctcctcaaac	1260
ctcactgaag	tctttcgggg	tggattcaaa	tgctgctttt	agccattaaa	atctgttaca	1320
tctgtttacat	actttcacaa	tagcacttat	cctagtgtag	ttttaaaaaat	gcacttaaaa	1380
atttttaaag	cagtgcctgc	atgcagtaaa	caaaattgga	cagtacagaa	ataaatgggtg	1440
aagacagtct	cccagttttc	ttcccatggt	atagcacttt	ctctttttta	tccttccaaa	1500
gatattttgt	gctgatacaa	gaatttttat	accgtatgaa	gtgcttattc	atcttatctt	1560
ttacttcagg	gtaatttatg	agtaatgaaa	aaattcaagc	attacaaaaa	tgtagagtgt	1620
gtgaagcaaa	aggtcccctt	tactttgatc	cctaactacta	gccctttcca	aataaactg	1680
tcctaattaa	cattcctctc	tccagaagta	acctctgtta	taagccttgt	ctgtgccttc	1740
agattgttct	gcttacactt	atatgcctat	ttaaaagtgt	atatttttgt	attttgtttg	1800
tttgtttgtt	tgagacagag	tttcgctctt	ttgcccagg	ctgaagtgca	atggcactat	1860
ctctgctcac	tacaacctgt	gtctccctgg	ttcaagtgat	tctcctggct	cagcctcctg	1920
agtagctagg	attacaggtg	cacgccacca	tgcccggcta	atttttgtat	ttttagtaga	1980
gatggagttt	caccatgttg	gccaggctgg	tcacgaactc	ctgacctcag	gttatccacc	2040
caccttggcc	tttcaaactg	ctgggattac	aaggcatgag	ccactgtgcc	cggccaagaa	2100
tttttttatc	gataccatag	tgagctctct	gcctcttctg	aacgatgtcc	actttgctta	2160
tgatcaaccc	aagcaggact	cttctctccc	tggacgcctc	tcccctgggc	tggaaatctt	2220
cagttctgcc	agaattggcc	tttcccagat	gctgcaaaact	tccagttgaa	cccctttttc	2280
tgtgtggccc	ctggggctgc	gagacaaaaa	tccatgagtt	ctgtgtaccc	tagacctttg	2340
gaaggtgaga	gcaggggccct	gagaaaaggc	aaaacgcctc	ctctccctga	tgatacccct	2400
acccgcctta	ctctcacca	gaattgtcag	tggcctttca	ccacagtggg	ccttcctgcc	2460
tgagccctgc	actgtcccag	accacacaga	agtctggtca	cctctgggcg	cctgggatgg	2520
tcaccgaaga	gaagcacgct	gtccccgtct	tctcctggct	tctgccagaa	aatcgaacaa	2580
gtgcaattaa	cacactgtta	ctgccgaagc	ctgaaactcc	caggacttgt	ccttgatcct	2640
tccagaaacc	accaggtccg	gcacttgag	ccccccggag	agggacctcc	cagccgagcc	2700
ctcaaagaac	tccatgaaat	caggaactgc	ttgatgaaat	gtatctcctt	gtacctggaa	2760
gatgaagccc	aaacacccac	acctctgtct	cccccagggc	tggggatgtc	tccagcagcc	2820
cggccacgca	gcttcccagg	tgggctcggg	gagggtgggag	cagggaccat	ctctgtcccc	2880
tccacctca	ctccatccac	ctcggagacc	accctcccc	agccagatac	ggaataaaa	2940
tacagacgca	gaaaaaaaaa	aaaaaaaaaa	gggcgccgc	tctagaggat	ccctcgaggg	3000
gccccagctt	acgcgtgcat	gcgacgtcat	agctctctcc	ctatagttag	tcgtattata	3060
aggagcaaaa						3070

&lt;210&gt; 30

&lt;211&gt; 2227

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (289)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 30

cgagcgcgtg	ggcgcaccca	cgcgctccggg	aaaaarggaa	aaaratgccgt	gtaaaaatctc	60
gttctgtgtc	tgaattgccg	taggctcaga	tcttcatttg	aggttctgtg	tctgaattgc	120
cgtaggctca	gatcttcatt	tgaggttatg	ttctataagt	taacgttgat	cttgtgtgag	180
ctttcggtag	ctggagtaac	acaggcggcc	tcacagcgac	ctctccagcg	ccttccaagg	240
cacatctgca	gccagcgtaa	tcctcctggg	agatgcctcc	tcaaggccnt	gctccagacc	300
acgtggggar	ggcctgacar	ccaattccca	ggctgtcccc	acccttgrag	agtgacccta	360
aacgctagac	agatggggaa	tgggaaagaa	aagaaagctg	cagacctcaa	gttaaaattc	420
cctcaaaaaac	gtttttatct	atctgctttt	tctgaaagga	taaaggcttt	ttgaaaatta	480
ttttctaaca	aataacatga	acacttctag	aaaccctaga	aaaacacaaa	gtattcaaaa	540
tagaaagaaa	aattacccat	tactctttta	gccagcatta	tccattgcgg	tgcttttgga	600
gttgggtgag	gccgtagcct	ctgccaagtc	aaggagcccg	gtggtggctg	tggcattect	660
gcagggttgt	ttttttttct	ttgagatgga	gtctcactct	tgtcacccca	gctggaatgt	720
ggtgggtgtaa	acagctcact	gcagccttga	ccctgaggct	caagcgatcc	ttctgccttg	780
gcctcctgag	tagctgggat	cccaggcgag	agtcaccaca	ccctgtccat	gttcctgcag	840
gtcttgatat	gcgaggacgc	tgtgtcttcc	ctgccacatt	ttcttcttct	ttcttgagac	900
agacccttgc	tccatcaccc	aggccagagt	gtggtsgtgc	gaacacggct	cactgcagcc	960
tcgaccctca	ggctcaagcg	atcctcacgc	ctcggaaccc	caaagtgcgt	ggatcacagg	1020
cgagagtcac	catgctggcc	tgaatcttca	gggtatttta	cggttgaagt	gtcacttact	1080
tarccatsec	tgtttcaaga	gtgtaggtgg	tcacctgtc	tctgycgctg	acctggcctg	1140
gacctcggc	tgtgagaggg	aggggtgggc	tgggctggag	gaacctraag	ccctcgtgat	1200
gtcacaagcc	catctggctg	ggcatcccct	gctgtgtcct	gagctgcaca	tgtcccaggt	1260
ggccccca	gcagaggcga	gccactgrag	ggtgragggc	ttccacggac	ggtcttcagg	1320
ggragaagaa	gggcccaggc	ccccaggaga	ctcaggagac	cagagcctgg	ggtcaggggc	1380
tyagcagggg	ctyarcagg	gctggatgtc	cggagccagc	ccgmagccc	tgkgktcttt	1440
gttcttcgca	ctcccaccgt	ccgtgtgaac	agctccagcc	ccacctgcgc	ctccctgtgc	1500
tgggctccat	cagggagccc	agaagacgtg	tgtgcttctg	aaattgggtc	cctacatgcc	1560
tttgtcccag	tgcaccttgc	tccttccatt	tactatcgag	atttaaatgc	ctgttttctc	1620
cccagagggt	gacggatata	ttcagacgtt	acgacacgga	tcaggacggc	tggattcagg	1680
tgtcgtacga	acagtacctg	tccatggtct	tcagtatcgt	atgaccctgg	cctctcgtga	1740
agagcagcac	aacatggaaa	gagccaaaat	gtcacagtcc	ctatctgtga	gggaatggag	1800
cacaggtgca	gttagatgct	gttcttctct	tagattttgt	cacgtgggga	cccagctgta	1860
catatgtgga	taagctgatt	aatggttttg	caactgtaat	agtagctgta	tcgtttctaat	1920
gcagacattg	gatttggtga	ctgtctcatt	gtgccatgag	gtaaaatgtaa	tgtttcaggc	1980
attctgcttg	caaaaaaatc	tatcatgtgc	ttttctagat	gtctctggyt	ctatagtgc	2040
aatgctttta	ttagccaata	ggaattttta	aataacatgg	aacttacaca	aaaggctttt	2100
catgtgcctt	acttttttaa	aaaggagttt	attgtattca	ttggaatatg	tgacgtaagc	2160
aataaaggga	atgttagacg	tgtaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2220
aaaaaaa						2227

&lt;210&gt; 31

&lt;211&gt; 1288

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 31

ccccgggct	gcaggaattc	ggcacgagcc	tgacctcccc	agcctcatct	ctccctcctc	60
tgtctcgc	ctctgtgctc	cagccaacgt	ggcctgtcac	tgtccacct	gccatactgt	120
cctgactcca	ggcctttgcc	tgtgctatgg	ctctgtttgg	gaccactctt	gtctctcccc	180
tgtgtgtct	gctaattccc	actcgtgtca	gtgatccatg	gctgcagaac	acaccactcc	240
atccatggaa	aacaatcaca	atcattgatt	actatctctc	cctgggcttc	ctgggggtgga	300
ctgggctcag	ctgggtgggt	cactttgggg	cctcagcagt	catgggcaga	cagtggctgg	360

ggtcactgca	aagacttccc	tgcattctctg	gcagttgatg	ctggctgtca	tctgagacac	420
ctaccagagg	cctctccctg	gggcctgggc	tcctgcttag	cttggttggg	aggctgcaag	480
accaacatcc	caagaaagat	gagacagaag	ccagatcacc	tttttgggcc	tggcttcaga	540
agtcacccag	catcacttct	gctgcattta	tttcttaaaa	cacaaatata	aaaccccatc	600
tcttgatggg	agggggcctc	atggtttgta	aacatgttct	aaactccact	ctgcccggcc	660
ttggctcaac	gtgtctggta	atgtgtgggc	tgtgaggctc	cccgaacgta	gacctcagac	720
tgcaacgctg	gccgttacag	ggctctggc	acgggcccac	gtcaggccca	tcgccacagt	780
gatggttgtt	ctgtgactgt	ttctgtgggc	ctctgctcca	cactccaggc	tgacgctgtg	840
ccccctccac	tgggaccctc	gggtggcttc	catgcacttg	tgccctaaat	cctgctccta	900
gactaaactt	catctcctgt	gttctcattc	tgcagcatgg	ctgttaggga	acctgacct	960
ctgcagcgcg	tctcgttgcc	aaggtataat	gtcagtgcc	cccttcagtg	gctcccatgt	1020
cacagaattg	tcctgcagcc	ctggcacatg	tgtgccatgt	gggagctggg	gcaggctcctc	1080
tttcattcctg	tggctccgag	ggagggggcc	gtccttccc	cagtctctac	cctgacttgg	1140
ccctcgtcct	gcagccactc	agagagcagc	atggagctgg	agcttcagtt	ttgacaaat	1200
gcgtgtcgcc	ggcttttgtg	tgtgtgtgtg	tgtgacagag	ccagaccctg	tctttaaaaa	1260
aaaaaaaaaa	aaactcgagg	gggggccc				1288

&lt;210&gt; 32

&lt;211&gt; 3280

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 32

gcgtccgggtg	agaggcaagg	acttttctac	tttagggcat	tctgaccacg	tcctgcttca	60
gagagattgt	tcggcggtgc	tcagtgtctat	ggggagcagg	ttcctcctgg	tcctgctctc	120
aggtctcact	gtcttactgg	ctctgccagg	atcagaagcc	aagaattctg	gagcttctctg	180
tcctccatgc	cctaaatatg	ccagctgcc	caacagcacc	cactgtactt	gtgaagatgg	240
ctttcggggc	aggtctggca	ggacatactt	tcattgattcc	tctgagaagt	gtgaagatat	300
taatgaatgt	gaaaccgggc	tggcaaagtg	caagtataaa	gcatattgta	ggaataaagt	360
tggagggttac	atctgtagct	gtttggtaaa	atatacttta	ttcaactttc	tggctgggtat	420
tatagattat	gatcatccgg	attgttatga	gaacaatagt	caagggaaga	cacagtcaaa	480
cgtggatatt	tgggtgagtg	gggtgaagcc	tggatttggg	aaacagctgg	tacgtataac	540
tatgccattt	tcctaccctaa	acattaacat	gtcttccctgt	gatttttagg	gtagggtagt	600
tctatccagg	ggtaattttg	tcctctgtcc	caaggctc	tgtcaatgac	tggggacact	660
tttgggtgtc	ataccttggg	ggtgatgtgt	gtgactggca	tctgggtggat	ggagaccagg	720
gatacagctc	aacatccctac	agtgcctcag	acagcctccc	acaatcaaga	agtgcctagt	780
gccatatgtc	catagagata	gagaaataca	agtgtagggg	gaaagtgcct	cagctggcat	840
tcaaagacct	acatcaagca	cctagattct	caatgccaca	cgcaccttgt	agcaccttaa	900
taaatatcgt	tgccttctgg	gctccccact	ccaacacttg	tgcattatcc	ctatttctta	960
catttcagta	agagtcaatc	taattagctt	aatttttttg	gaaggaaaat	ctgagaagaa	1020
atggaagcag	agaggacttt	gcaagaagg	ctactcaact	aattcaaagc	gtggagtgtga	1080
gcattctggaa	tgcgagtttt	gcttctccag	gaaagggtca	aatttctgaa	tttgatatag	1140
tctatgaaac	caagaggtgc	aatgagacaa	gggagaatgc	ttttctggaa	gctggaaaata	1200
acaccatgga	tatcaactgt	gctgatgctt	taaaaggaaa	cctaagagag	agcactgcag	1260
ttgccctatc	acttatcaat	ctcttgggga	tattctgaat	gcattccttt	ttagtaaacg	1320
aaaagggatg	caggaagtaa	aactgaactc	ttacgttgtg	agcggcacca	tcggtttgaa	1380
ggaaaaaatt	tcctctctctg	aacctgtgtt	cctgactttt	cgccataatc	agcctggtga	1440
caagagaaca	aaacatatct	gtgtctactg	ggaggatcca	gagggaaggc	gctggtccac	1500
ggagggctgc	tctcatgtgc	acagcaacgg	ttcttacacc	aaatgcaagt	gcttccatct	1560
gtccagcttt	gccgtcctcg	tggctcttgc	ccccaaaggag	gacctgtgtc	tgacctgtat	1620
caccaggtg	gggtgacca	tctctctgct	gtgcctcttc	ctggccatcc	tcaccttctc	1680
cctgtgccgg	cccattccaga	acaccagcac	ctccctccat	ctagagctct	ccctctgcct	1740
cttctctggc	cacctctctg	tcctgacggg	catcaacaga	actgagcctg	aggtgctgtg	1800
ctccatcatt	gcagggtctgc	tgcacttctc	ctacctggct	tgcttcacct	ggatgctcct	1860
ggaagggtctg	cacctcttcc	tcaccgtcag	gaacctcaag	gtggccaaact	acaccagcac	1920
gggcagattc	aagaagaggt	tcattgtacc	tgtaggctac	gggatccag	ctgtgattat	1980
tgctgtgtca	gcaatagttg	gacccagaaa	ttatggaaaca	tttactcact	gttgggtcaa	2040
gcttgataaa	ggattcatct	ggagcttcat	ggggccagta	gcagtcatta	tcttgataaa	2100

cctggtgttc	tacttccaag	ttctgtggat	tttgagaagc	aaactttcct	ccctcaataa	2160
agaagtttcc	accattcagg	acaccagagt	catgacattt	aaagccattt	ctcagctatt	2220
tatcctgggc	tgttcttggg	gccttgggtt	ttttatgggt	gaagaagtag	ggaagacgat	2280
tggatcaatc	attgcatact	cattcaccat	catcaacacc	cttcagggag	tgttgctctt	2340
tgtggtacac	tgtctcctta	atcgccaggt	tcgaatggaa	tataaaaagt	ggtttagtgg	2400
gatgcggaaa	ggggtagaaa	ctgaaagcac	tgagatgtct	cgctctacta	cccaaaccaa	2460
aacggaagaa	gtggggaagt	cctcagaaat	ctttcataaa	ggaggcactg	catcatcatc	2520
tgcagagtca	accaagcaac	cgcagccaca	ggttcatctc	gtctctgctg	cttggctaaa	2580
gatgaactga	cctggcaagt	gccatggcaa	tgaccgccga	gttacccttc	ctttccgttt	2640
gtctacagcg	cccctgtggg	cacacataga	ttggacaaat	gccactattt	ctagctttcc	2700
tgtgaaaagt	ctaggctcat	tcacctattt	tggcttttta	tgttcataga	aagaacaaga	2760
catttgggag	aattcttaga	tccagagtcc	agtagtgtgg	cacgtgcaat	gaagtgtcgg	2820
aaggatgcat	tttaaagatg	gcgggcgggg	gaagtggatt	ttcttcttgc	agctactgcc	2880
accttgccag	aaactcacta	actggcatct	ggattcagct	catagttccc	tttctggcct	2940
ctctgctgta	ttttatgtct	ccaaagatct	tacattaaca	ctccacattc	acataattca	3000
acaattttca	tatggatcag	tattaaagag	ggtgttgcac	tttgcaatac	aaaaatgcat	3060
tatcaggtgc	tggagaggat	gtggagaaat	aggaacacct	ttacactgtt	ggtgggactg	3120
taaactagtt	caaccattgt	ggaagtcagt	gtggcgattc	ctcagggatc	taggactagg	3180
aataccattt	gacacagcta	tcccattact	gggtatatac	cccaagggct	ataaatcatg	3240
ctgctataaa	gacacatgca	cacgtaaaaa	aaaaaaaaaa			3280

&lt;210&gt; 33

&lt;211&gt; 1297

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 33

ccacgcgtcc	ggactgcttt	acggacattg	gatgaagccg	aagcatttag	aatggtgcct	60
ggcacacagt	tgggtgcgtga	tatggttaag	ctttgtgtcc	ccaccacat	ctcatcttga	120
atgtgacggg	ttccccggct	ccctcctgcc	gccattgtaa	gaaggtcggt	gcttccccct	180
caccttccac	caccatgatt	gccatggatg	ctccccactc	caaagcagcc	ctggacagca	240
ttaacgagct	gcccagagaac	atcctgctgg	agctgttcac	gcacgtgccc	gcccgccagc	300
tgtgtgctga	ctgccgcctg	gtctgcagcc	tctggcggga	cctcatcgac	ctcatgaccc	360
tctggaaacg	caagtgcctg	cgagagggct	tcatcaccaa	ggactgggac	cagcccgtgg	420
ccgactggaa	aatcttctat	ttcctacgga	gcctgcatag	gaacctcctg	cgcaacccgt	480
gtgctgaaga	ggatatgttt	gcatggcaaa	ttgatttcaa	tgggtggggac	cgctggaagg	540
tggagagcct	ccctggagcc	cacgggacag	attttcctga	ccccaaagtc	aagaagtatt	600
ttgtcacatc	ctacgaaatg	tgcctcaagt	cccagctggg	ggaccttgta	gccgagggct	660
actgggagga	gctactagac	acattccggc	cggacatcgt	ggttaaggac	tggtttgctg	720
ccagagccga	ctgtggctgc	acctaccaac	tcaaagtgca	gctggcctcg	gctgactact	780
tcgtgttggc	ctccttcgag	ccccacctg	tgaccatcca	acagtggaac	aatgccacat	840
ggacagaggt	ctcctacacc	ttctcagact	acccccgggg	tgtccgctac	atcctcttcc	900
agcatggggg	cagggacacc	cagtactggg	caggctggta	tgggccccga	gtcaccaaca	960
gcagcattgt	cgtcagcccc	aagatgacca	ggaaccaggc	ctcctccgag	gctcagcctg	1020
ggcagaagca	tggacaggag	gaggctgcc	aatcgcccta	ccgagctggt	gtccagattt	1080
tctgacagct	gtccatcctg	tgtctgggtc	agccagaggt	tcctccaggc	aggagctgag	1140
catgggggtg	gcagtgaggt	ccctgtacca	gcgactcctg	ccccggttca	accctaccag	1200
cttgtggtaa	cttactgtca	catagctctg	acgttttggg	gtaataaatg	ttttcaggcc	1260
gggcaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaa			1297

&lt;210&gt; 34

&lt;211&gt; 2184

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 34

ggcacgaggg	gcccagaggat	gtgctgctgg	ccgctgctcc	tgctgtgggg	gctgctcccc	60
------------	-------------	------------	------------	------------	------------	----



gggacggcgg	cgggggggctc	gggccgaacc	tatccgcacc	ggaccctcct	ggactcggag	120
ggcaagtact	ggctgggctg	gagccagcgg	ggcagccaga	tcgccttcct	cctccagggtg	180
cgcactgcag	gctacgtggg	cttcggcttc	tcgcccaccg	gggccatggc	gtccgccgac	240
atcgctcggtg	gcgggggtggc	ccacggggcg	ccctacctcc	aggattatit	tacaaatgca	300
aatagagagt	tgaaaaaaga	tgctcagcaa	gattaccatc	tagaatatgc	catggaaaat	360
agcacacaca	caataattga	atttaccaga	gagctgcata	catgtgacat	aaatgacaag	420
agtataacgg	atagcactgt	gagagtgate	tgggcctacc	accatgaaga	tgcaggagaa	480
gctgggtccca	agtaccatga	ctccaatagg	ggcaccaaga	gtttgcgggt	attgaatcct	540
gagaaaaacta	gtgtgctatc	tacagcctta	ccatactttg	atctggtaaa	tcaggacgtc	600
cccattcccaa	acaaagatac	aacatattgg	tgccaaatgt	ttaagattcc	tgtgttccaa	660
gaaaagcatc	atgtaataaa	ggttgagcca	gtgatacaga	gaggccatga	gagtctgggtg	720
caccacatcc	tgctctatca	gtgcagcaac	aactttaacg	acagcggtct	ggagtccggc	780
cacgagtgct	atcaccccaa	catgccgat	gcattcctca	cctgtgaaac	tgtgattttt	840
gcctgggcta	ttgggtggaga	gggcttttct	tatccacctc	atgttggtatt	atcccttggc	900
actccattag	atccgcatta	tgtgtctcta	gaagtccatt	atgataatcc	cacttatgag	960
gaaggcttaa	tagataattc	tggactgagg	ttattttaca	caatggatat	aaggaaatat	1020
gatgctgggg	tgattgaggc	tggcctctgg	gtgagcctct	tccataccat	ccctccaggg	1080
atgctgagt	tccagtctga	gggtcactgc	actttggagt	gcctggaaga	gctctggaag	1140
ccgaaaagcc	aagtggaatt	catgtgtttg	ctgttcttct	ccatgctcac	ctggctggca	1200
gagcatcagg	ctgcgtcatt	ttcgaaaagg	gaaggaaaatg	aaattacttg	cctatgatga	1260
tgattttgac	ttcaatttcc	aggagtttca	gtatctaaag	gaagaacaaa	caatcttacc	1320
aggagataac	ctaattactg	agtgtcgcta	caacacgaaa	gatagagctg	agatgacttg	1380
gggaggacta	agcaccagga	gtgaaatgtg	tctctcatac	cttctttatt	acccaagaat	1440
taatcttact	cgatgtgcaa	gtattccaga	cattatggaa	caacttcagt	tcattggggg	1500
taaggagatc	tacagaccag	tcacgacctg	gcctttcatt	atcaaaagtc	ccaagcaata	1560
taaaaacett	tctttcatgg	atgctatgaa	taagtttaaa	tggactaaaa	aggaagggtc	1620
ctccttcaac	aagctgggtc	tcagcctgcc	agtgaatgtg	agatgttcca	agacagacaa	1680
tgctgagtg	tcgattccaa	ggaatgacag	cattacctcc	agatatagaa	agaccctata	1740
aagccagaac	cctttgggtg	gtggcacgtc	ttcttccctc	ttcccctgcc	acagagattt	1800
ctcccatcca	acttgcttgt	ttgccttctg	ctaactcagc	tgcacgctga	gcaccaagag	1860
cttgatgatca	aaattctgtt	ggacttgaca	atgttttcta	tgatctgaac	ctgtcatttg	1920
aagtacaggt	taaagactgt	gtccactttg	ggcatgaaga	gtgtggagac	ttttcttccc	1980
cattttccct	ccctcctttt	tcctttccat	gttacatgag	agacatcaat	caggttctct	2040
tctctttctt	agaaatatct	gatgttatat	atacatggtc	aataaaataa	aactggcctg	2100
acttaagata	accattttta	aaaattgggc	tgtcatgtgg	gaataaaaaga	attctttctt	2160
tcctaaaaaa	aaaaaaaaaa	aaaaa				2184

&lt;210&gt; 35

&lt;211&gt; 949

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 35

ggcacgagct	cccattgacc	ttattgctca	gagtgcagta	ttagggcaag	gtttcgccac	60
tgccctccctc	catgaatgta	tttctccctc	ctgccctggg	gacatgggga	gtggcccggt	120
tctttcccca	tctagtccca	gaaagatggt	gtttgggttt	ctgttggttg	attttttttt	180
ttttttttt	tttttgacc	aaagtggcaa	ctaggtcagt	gttgggggat	caagctggcc	240
tcgggggtggg	gggcccccc	ctgcctctcc	ctggttccca	cagtgttagc	gtccctgaaa	300
agacaatatt	ctctctaag	caataagggg	tgacggggcg	gggggagtg	ttgctgtctg	360
tggccccag	ctcccttcc	ctgccagggtg	tgggggagac	tcctgttgtg	actgaatgta	420
acccccccac	ccctgccgca	gccaatgcag	gggaaggggg	acactcttcc	tgtctcttct	480
ccccagctaa	agagactttg	gacttagggg	gcccattgagc	ctggagaggc	cttaaccctg	540
tgaggaagta	tagggggagc	cctctccccc	ccccatcccc	ttctgagagt	ggtcaatgtt	600
tacaagcccc	tgagccccc	tgcccaggga	ctcagacccc	gttctgtctc	ttccccggcc	660
ccggtcttcc	tgggccctcg	ctgctctctc	gccctttctg	gggttggggg	gggtgcaggg	720
gtcaccgtgt	tccctgtctg	ccttgtaacc	acagtctccc	cgccccctct	ccaccctgtg	780
tgacttccct	ctcttttacc	tgctcctgta	aatactccct	tctcccaata	aaacttgggtg	840
tgtgttctcc	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	900

aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

949

<210> 36  
 <211> 3338  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (2861)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (3328)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (3330)  
 <223> n equals a,t,g, or c

<400> 36  
 taccgggaca ttctggagtc cgagaagtca acggcgcggt tgctgcggcc gccgcgctcc 60  
 ccggcccag gcatggaga acggagcgggt gtacagcccc actacggagg aggacccggg 120  
 ccccgccaga ggccccgga gcggcctcgc tgccactctt tcatggggc ggctcccatt 180  
 gctccggcgc gttctcaagg gcttcagct gttgctgtct ctgctggcct tcatctgtga 240  
 agaagtgtga tcacaatgta ctttatgtgg aggactttat ttttttgagt ttgtaagctg 300  
 cagtgccttt cttctgagtc tccttatact gattgtgtat tgcactccat tttatgagag 360  
 agttgatacc acaaaagtaa aatcatcgga tttttatatt actttgggaa caggatgtgt 420  
 gttttgttg gcatccatca tttttgtttc cacacatgac aggacttcag ctgagattgc 480  
 tgcaattgtg tttggattta tagcaagttt tatgttccta cttgacttta tcactatgct 540  
 gtatgaaaaa cgacaggagt cccagctgag aaaacctgaa aataccacta gggctgaagc 600  
 cctcactgag ccacttaatg cctaaagact ctggggagca gatgttacct aaggtagtga 660  
 ccctgcattg tggtgccctga gccctggcag aagctcttgt aaaatttgtt aattgtttta 720  
 accacttctt ttggagagca aggggaaggt caagaaggca gttttatcaa tattgtgtca 780  
 gtcaccacaa agtaggccag ataagttaaa aaaaattttt ttttaaataa taattgaaac 840  
 ttatctcaaa tggagatttt gttgggagga ggagaaaaca attgttttta aatcacacag 900  
 ctcaacgggt gataaatgat tctgtcattc tgttacaggt cattctttta ctaggcttag 960  
 cttccaaatt atgctttata gctgtataaa catcgtgatt atattcatct acttagaaat 1020  
 tgttttattt ttaaaattaat ttgcttagct gtttgttttg atgcttagat tatgttctgt 1080  
 taatgggaat ttaacatatt taagaaacca atatttaaaa tgttggctta ggtttttttc 1140  
 cttaacatat attaccaggc tttactgtat ttcactcagc cttaaatgtt ataattttt 1200  
 tggataacgg ttattaattc tttgagacct tcgtatagcc tataaaatgt atgggagatg 1260  
 ttggtatttt atgtgtataa aagcaacaat atcagcaact tcgtgtttat actgcacctt 1320  
 gggtgttgat gtcaagtaaa aaaaagattg ttttgtaaca cataaaaaaa tgggaagaaac 1380  
 tgataaccaca cctaaggacc aaagataaga aagacttttt gcccaagaca gtgaaagtaa 1440  
 ttataaaaaa aagctttgac cacttaccaa gtatctgaag agatgagttc atactatgat 1500  
 tttagaaagt gttcaattcc cctgttgga tatgattatt tttactaaaa ttaatacagc 1560  
 tctgtgggtc tcctcttagt tttctttga agccaatctg ttttttttag gacaccagcc 1620  
 tttggttttt catctgttcg agatgcctct tctctgtctc cttatcagat agaaatggag 1680  
 tcatgtgctg ctgcttcac tagcagaggt tggcctctgg ctctgacact ttttgtcagt 1740  
 tgtctttagg tggctcctgaa tcttgggccc ttttgattgt gaatactgtg tagcaggatc 1800  
 ttgagagtcc ttgttcttac ataggcattg ctctagtgtt tctttggcaa aaaaaaaaaa 1860  
 aaaaaaaaaa aatatccag ggaacctgc ccagactaat actgttggtg gcataagaga 1920  
 atcaagccat tctcaagaga taacttcata accagaattg tctgttggtc agcagctgtc 1980  
 acagataggc agggcacttg ggatatgacc tttctgtcca ggtgattcac agactagacc 2040  
 tttcttatcc tcctcctaga gttttgactt gggactctag tgtaaatgag atgagccctg 2100

gcatcaggtc	cttctgca	ct	ttgggtggaag	tctcccagg	taggtttct	atttgaaaca	2160
gtggaatcat	gtttccagt	g	ataaagttta	atgacctcat	cctttttttt	ttttctcate	2220
tgccatttgt	gtgtcttaga	t	tggtttttaa	ttgcatgaat	gtggctaata	tggttctcag	2280
aaattgggtca	gtatggcccr	a	acatagcttc	tgctctgtct	tactgactca	ataccttttag	2340
gatttgtatc	agagtttggg	t	tactagtgtt	agtgggtggg	tcaccactac	ttaattggga	2400
gataatgaaa	ccaatcatgg	a	atgctgtttt	tattgggcat	gtcatctaag	agaggagaaa	2460
tagctgggtt	ttgggtctaa	t	ttatgaataa	ggactgattc	agaaaacgag	tttatggtag	2520
gtagactaaa	gtttcacatc	a	agactgtacc	attgtgattt	agacctatct	aaaattcaga	2580
gcatatcatc	tggtctacct	c	cagggtcacc	acccatgtat	tggtgttagt	caggattgac	2640
agatacatcc	tcagctggcc	t	gtcatataa	aacatactgt	cattgagctt	aagctccgct	2700
tggtctgagg	tttcacctcc	a	atgtgtttca	ttgggtgcaa	agtggatctc	ttagtgtgtc	2760
acttaattct	ttctttttca	g	aaagatagt	atgttcaact	gtatatttgg	tcactcttag	2820
aaccttcctt	cacattgttt	t	ttatggggac	ccatgaatgg	nttagccttt	cttttctatt	2880
gtagaaggaa	ataaatagga	g	taaaaagac	cattgttagta	aataagttca	aggggaactt	2940
gggaccagaa	accactgtta	t	gtacaaaaa	aatggcgaat	tcaataaact	caaattttaa	3000
ataattttta	aattaacagt	t	atgataaat	tttatatttt	atacaaata	attgcttaga	3060
atggttctca	agaattataa	g	agaaatgaa	ctcacagtac	aaaaatttta	taattactat	3120
acttgtgttt	tggttggtgg	c	tggtgaaatg	tattttttaca	ttgtagccaa	tcattttata	3180
tttgtcaatt	taaatcttat	g	gggtcttttt	ttttttatct	ctcttgatgt	cagattttat	3240
agtcttttta	aataaatcca	t	tttaattaaa	acgttaaaaa	aaaaaaaaa	aaaaaaaaa	3300
gggcggccgc	tcgcgaatct	a	agaactangn	cccacgcy			3338

&lt;210&gt; 37

&lt;211&gt; 1563

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

cggcacgagg	agaaaaggac	tcagaccttc	cagattggct	ccagaaggca	gctgctgtca	60
gtgattttcc	ttacagacca	ttgcagccac	ctaccttgcg	ccatgggtccc	gagacagcat	120
ggcgtcttcc	cccacacgga	cctgcagggtg	gcctcttagg	agctttctcg	ctgaaggagg	180
tcctccctct	tagtcacatc	tgagcagcac	tcacttaggc	ctcggccccg	agggtcatgc	240
ggggggcacct	ggccgggttc	ccggctctgt	ctggctctggc	atctgtctgc	ctttgggcta	300
ccttttccgc	acagctccct	gggcctgtgg	ctgctacaag	ctggactcca	gctccccctg	360
gctgcagtgc	tgctcgcagt	ggtccagaaa	agaggctggg	cacagcggct	cctggctcag	420
cagcatcctt	ggcgcagggt	ggcccaggag	ctccgtgcag	ggtgctgcca	gttgaccag	480
ccccggctgc	actcaatgtc	cgagaaccgg	gctggctggg	gggcctcttt	gacggagctt	540
tactccaagt	cttgctgaat	ttcctgagga	aaagcactga	tgttctcatg	gacacaaggg	600
aggcagaatc	tcttgaagta	gaataaactg	cactcctttc	cagtcttctc	ttctcagctt	660
ctcctggacc	gccagctcct	ccatgcgcct	cagacactcc	caacgcgcga	ctgcgggggt	720
tcctccccgc	ctggcccatc	tcacccccct	tggtctgtga	tacagctccc	ctgtgtgcat	780
gtcgcctgt	ggcagatgct	cagggaacttc	tcagactcca	ggatcactcc	gagtacactg	840
accacacagc	ctgctgcaca	aactgcagcg	ccagctaagg	accaggaatc	tgacattgtc	900
ggaggtgaag	ggatcctttg	tgacatagct	ttcctccagg	aggaccatcc	actgggtgtc	960
gggggagctt	ctgccccaa	tagcaggagg	gagctgtcaa	ggcgtggagt	tcacactcaa	1020
acactcccag	aggacggcac	tctgcatggg	acgccatcca	gctcctttga	ctgtggaatc	1080
aagtacatta	tcagctggcc	cctggctcct	ggctgtgacc	tccttctcgt	tgaactgagc	1140
cttgtgtgta	agggcgtatc	aagttgtatg	ggcttcgccg	ctgggtgacc	ccaaatgcaa	1200
ctccaggaag	catgggttac	caatgactaa	ggttaacgat	cagctgggcy	cgggtgtgac	1260
gcttgtaatc	ccagcacttt	gggaggtcga	ggcgaatgga	tcacgaggtc	aggagttcaa	1320
gaccagcctg	gccaacatgg	tgaaaccccc	atctctacta	aaaatacaaa	aattagccgg	1380
gcgtgggtgg	gggcgcctgt	agtcccagct	actcaagagg	ctgaggcagg	agaatcgctg	1440
gaactcggga	ggcgcagctt	gcagttagct	gagatctcgc	ccgctgcact	ccagcctggg	1500
cggcagagcg	agactccgtc	tcaaaaaaaaa	aaaaaaaaaaa	aaaaaaaaa	cagggggggg	1560
ccc						1563

&lt;210&gt; 38

&lt;211&gt; 1048

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 38

```

cccgggtcga cccacgcgtc cgacaaaaaa caaggatatgt gtgtgccttg ggatgctttt      60
ctgggcttac cccatctgtg tcttcataga ttctctgtcc tgccagccat gtcttttggtc      120
cacaggagcc acttcccact tcaactctcc cacaacctcc ccactgttta ctctcttcat      180
gccctgtgct cttgcccacaa atcccttcac ccaattggga aaactggatg atagataagt      240
agtctcttat ttacatgcat ttctctggaa attaaagttg cttccagct agtatttcct      300
cacgtcggaa gcatgtgtaa aataacacat ggaaactatt tccacctggc acataagaaa      360
aaaagggctt gcctatattg taactgactt ctacactttg catgttttag tctgaccac      420
aatttttttt tttggatagt tgaagtaaaa aacgtgggta caagatgact aaagtttggc      480
ctacaatttc ctgtttggac aacaggaaga attgtgcagt gttttgcaac aggactaatt      540
ctagattctc actgccctta aagataacta gagggaaagg gtcttctctt tcttttcat      600
ttactaaaga tacttacagg ttcttcagaa gaagtgatgg gtcttttagg taatgaaata      660
ggtgttgatg gtgttatggg tgatgatgta actgggtggc gctgtataaa gtcttcac      720
ttaaacatca gaactgagag ttgggttact gatttaaaag aaaatgtgta ttaatctaca      780
gtccactacc ttgactacca ggaacttgct acaactacct catatcctgg cacaggattc      840
aaaaggcaaa atctggaacc taattacgtg tagccaaata ttaagcttcc tcttagatca      900
aacagtacaa taaatattcc ttattaagga aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      960
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa     1020
aaaaaaaaaa aaaaaaaagg gcggccgc

```

&lt;210&gt; 39

&lt;211&gt; 1430

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 39

```

cggcagcagg agcagctgag tcccttccct gtctttcact cttctggcat cgggtggttt      60
acttcttcga ttgaaccctg cttcctcgac cccctggga ggccgccttc ttcaggcgcc      120
tcccttctct ccacgagctc gctctgacag ctgaggaaact ggcaagatcc tgctaccag      180
aggggtgaatg ggtatctttc ccggaataat cctaattttt ctaagggtga agtttgcaac      240
ggcggccctg attgtaagcg gacaccagaa aagtaccact gtaagtcacg agatgtctgg      300
tctgaattgg aaaccctttg tatatggcgg ccttgccctc atcgtggctg agtttgggac      360
tttccctgtg gacctacca aaacacgact tcaggttcaa ggccaaagca ttgatgcccg      420
tttcaaagag ataaaatata gagggatggt ccacgcgctg tttcgcatct gtaaagagga      480
aggtgtattg gctctctatt caggaattgc tctgcgctg ctaagacaag catcatatgg      540
caccattaaa attgggattt accaaagctt gaagcgctta ttcgtagaac gtttagaaga      600
tgaaactctt ttaattaata tgatctgtgg ggtagtgtca ggagtgatat ctccactat      660
agccaatccc accgatgttc taaagattcg aatgcaggct caaggaagct tgttccaagg      720
gagcatgatt ggaagcttta tcgatataata ccaacaagaa ggcaccaggg gtctgtggag      780
ggtaagtact cttttcctgc tattatccta cactctcagt tctacaatt tgcagagaat      840
ttttttttat ataaagacat aaaatcgtga attataatcc aaaaactaag gtaagaaact      900
cctcatctcc cttgaaaggc caaaaactta tcattggcct tttatttctg cataatgttt      960
ggggattata taggtgggga aagtatttac attatttgag atggctgttt cgatcatatt     1020
cacagtgaat gtagttgttc agtgtatttt tttgcaagtt ctgtactaac acgatgatgt     1080
atgtctttgt agtgcttatg ttcaaaagct gttaccggct gtgtgctgtg gctcatgcct     1140
gtagtcccag cactttggga ggccaacgcg ggtggatcac ttgaggtcag aagttcaaga     1200
ccagcctggc caacctgggt aaaccccatc tcaactagaa atacaaaaat tagccaggca     1260
tggtggtgca tggctgtggt cacagctact caggaggctg aggcgggaga attgtttgag     1320
ccctggaggt ggaggttgca gtgagccaag atcatgccac tgcactccag cctgggtgac     1380
ggggcgagac tctgtctcaa aaaaaaaaaa aaaaaaaaaa aaaactcgag

```

&lt;210&gt; 40

&lt;211&gt; 2103

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2101)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2102)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 40

ttcctcgtag	cgagcctagt	ggcgggtggt	tgcattgaaa	cgtgagcgcg	acccgacctt	60
aaagagtggg	gagcaaaggg	aggacagagc	cctttaaaac	gaggcggggtg	gtgcctgccc	120
ctttaagggc	ggggcgctcg	gacgactgta	tctgagcccc	agactgcccc	gagtttctgt	180
cgcaggctgc	gaggaaaggg	ccctaggctg	ggtctgggtg	cttggcgggc	gcggcttcct	240
ccccgctcgt	cctccccggg	cccagaggca	cctcggtctc	agtcattgctg	agcagagtat	300
ggaagcacct	gactacgaat	gctatccgtg	cgagaacagc	tattccacga	gaggatccgc	360
gagtgtatta	tatcaacact	tctgtttgca	acactgtaca	tcctctgccca	catcttcctg	420
acccgcttca	agaagcctgc	tgagttcacc	acagggtgtc	ctgggcccgg	tctmtgagac	480
agtgggtgatg	ttgatgtctc	tcactctgct	ggtgctaggt	atgggtgtggg	tggcatcagc	540
cattgtggac	aagaacaagg	ccaacagaga	gtcactctat	gacttttggg	agtactatct	600
cccctacctc	tactcatgca	tctccttcct	tggggttctg	ctgctcctgg	ctgctggaag	660
acctggagga	gcagctgtac	tgctcagcct	ttgaggaggg	agccctgacc	cgcaggatct	720
gtaatcctac	ttcctgctgg	ctgcctttag	acatggagct	gctacacaga	caggtcctgg	780
ctctgcagac	acagaggggtc	ctgctgggta	tgtggcttcg	tagggcttgg	gatacctggg	840
tttccccaag	gagagtagcc	cctgggttcca	ggtgcttgct	gacagcctcc	catccctgca	900
cagagaagag	gcggaaggct	tcagcctgkc	aacggaacct	gggctacccc	ctggctatgc	960
tgtgcttgct	ggtgctgacg	ggcctgtctg	tgctcattgt	ggccatccac	atcctggagc	1020
tgctcatcga	tgaggctgcc	atgccccgag	gcatgcaggg	tacctcctta	ggccaggtct	1080
ccttctccaa	gctgggctcc	tttgggtgcc	tcattcaggt	tgtactcate	ttttaccta	1140
tggtgtctct	agttgtgggc	ttctatagct	ctccactctt	ccggagcctg	cggcccagat	1200
ggcacgacac	tgccatgacg	cagataattg	ggaactgtgt	ctgtctcctg	gtcctaagct	1260
cagcacttec	tgtcttctct	cgaaccctgg	ggctcactcg	ctttgacctg	ctgggtgact	1320
ttggacgctt	caactggctg	ggcaatttct	acattgtggt	cctctacaac	gcagcctttg	1380
caggccctcac	cacactctgt	ctgggtgaaga	ccttcactgc	agctgtgcgg	gcagagctga	1440
tccgggacct	tgggctggac	agactgcgcg	tgcccgctct	cggtttcccc	caggcatcta	1500
ggaagaccga	gcaccagtga	cctccagctg	gggggtggga	ggaaaaaact	ggacactgcc	1560
atctgctgcc	taggcctgga	gggaagccca	aggctacttg	gacctcagga	cctggaatct	1620
gagaggggtg	gtggcagagg	ggagcagagc	catctgcact	attgcataat	ctgagccaga	1680
gtttgggacc	aggacctcct	gcttttccat	acttaactgt	ggcctcagca	tggggtaggg	1740
ctgggtgact	gggtctagcc	cctgatccca	aatctgttta	cacatcaatc	tgccctactg	1800
ctgttctggg	ccatccccat	agccatgttt	acatgatttg	atgtgcaata	gggtggggta	1860
ggggcagggga	aaggactggg	ccagggcagg	ctcgggagat	agattgtctc	ccttgccctct	1920
ggcccagcag	agcctaagca	ctgtgctatc	ctggaggggc	tttggaccac	ctgaaagacc	1980
aaggggatag	ggaggaggag	gcttcagcca	tcagcaataa	agttgatccc	aggggttgct	2040
ttgttttttt	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2100
nna						2103

&lt;210&gt; 41

&lt;211&gt; 2349

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 41

tcgacccacg	cgtccgtcta	tttctgtgtc	tgtatgtatg	ggatgtgtct	gattgtgtgt	60
------------	------------	------------	------------	------------	------------	----

ctgtggtgta	tttctgtgtc	tgtatgtatg	gggtgtgtgt	gattgtgtgt	gtgtctggtg	120
tatctctgta	tgtatgggg	gtgtctgtgt	gtgattgtgt	gtgtgtctgg	tgtatctctg	180
tgtctgtatg	tatgggggtg	gtctgtgtgt	gattgtgtgt	ctgtgtttat	gtgtgtgtgt	240
ctttgtgtga	ttttttgtgt	atatggcaaa	cccagaacag	aacattatca	ctcacctcac	300
ctggcaaaac	aaaaagcttt	cagagagatg	tgtggccgtc	atgatgtctc	agctgcaggc	360
atttttcaaa	gttatgtttg	atgcagctgg	cacctttctt	ctcggggaca	aatgtgatct	420
ttgatcattg	agttgagaat	gagtttactc	aataatttta	aaatgcctcg	gtgtgagagg	480
atggctgct	agtaaacatt	tgtggcaaat	atgcgttgcc	ttttcctcct	tcaagtgcac	540
ggggcaggct	gcttctctgc	acgtccatct	gtgggtcagt	ctgtcctgcc	acctcccttg	600
ccccagggt	tagtgccctg	tgtggatcac	ggctgcccc	gggatgctgg	ggaaggattc	660
agcccaacaa	atagattcgt	tgacgtctc	tcaacgaatg	tgtgctttta	aaaatgtctt	720
taattttgca	ctccatttca	tacaacagg	gcacatttaa	aacatttatt	tttaaacagc	780
tctgtcttct	cagcactgca	gactatttct	cgctcacttg	acaggcagac	gttgggacta	840
tgttcttttc	ctgccaaag	tccatcagcc	cccgaatgcc	tgacacctga	gtccagactc	900
cttagcgttg	cgttgggacg	taattcccc	ttagcatccc	cagccccctc	tccccctgtg	960
agccagcctg	ggttcttttc	ttttcctttt	cttccctgtt	ttccttcttt	cttttttggg	1020
tttgtaataa	gtaatataca	gtcttgtggt	taagaaatca	aaataataaa	gaagatacgg	1080
cttgaggatt	cttgctctgc	actggtcctt	ccgccaggac	ctggtgcgtc	ccccagagg	1140
gccttgccat	gtgcgagctg	agacacatgt	tcacactttc	ctcctttttt	gtacaaaagg	1200
tagcacatgg	taaatagcgt	ctgcacgctt	ctcccctcgc	tctgtcttcg	ggactactcc	1260
acatccatga	agaagcagca	tccttattct	cttgcacagt	gggcagtggc	tacactgtat	1320
tcactcgtct	ctgctgatgg	gcactattgt	agtgggtgca	ttagtaacct	agtatacatg	1380
cccttcagcg	tgtgtactgg	tgtatggatc	tcacattccc	agaggctgag	tgaagaata	1440
aaggcttttt	gacagtattc	ctcaggtaact	cacacactcg	ctctgtgagc	cacgtgatca	1500
tgggagcggc	tccttcgaga	ggtgtctgat	gggagaggct	gatgtccttg	tctgatgggt	1560
gctccaacct	gagaatgggtg	agctgctctc	ccaatgcaga	ctttcatcac	ttgcatctca	1620
tgcgtgagat	tgaactgctt	ctcatttatg	tttttatctt	tgtttgcccc	tatttttagct	1680
gggttgctaa	tcttttaaatg	ttttctaggc	gcttttcata	aattagggag	tttagctgta	1740
gtgatgtgag	ttgaaagtat	tttttcaa	cgtcattgtc	ttgactttcc	tttttttttt	1800
tcttttgcca	cttaaaatat	gtagttgaat	ctcagtatct	gggggcttct	ggattttgag	1860
tcgtagttga	aaaggtcttc	ctattctgag	gttatcacag	aattcaccca	tttttttctc	1920
aatattttat	ttccatttaa	acttttgacc	cacttggatt	gattttgttg	tatgggtgtca	1980
agtatgggtc	caagtttgct	tttctgacct	ggggatccca	acatcgttca	tcaaaatctc	2040
catgttggtc	gggcgtgggtg	gctcaagcct	gtaatcccag	cactttggga	ggctgagggtc	2100
ggtggatcac	aagggtcagga	gatcgagacc	accctggcta	acacggtgaa	atcctatctc	2160
tactaaaaat	acaacaaatt	agccgggtgt	ggtggcaggc	acctgtagtc	ccagctactc	2220
aggaggctga	ggcaggagaa	tcgcttgaa	ccgggaagcg	gaggttgtag	tgagctgaga	2280
ttgcgccact	gcactccagc	ttgggtgaca	gagcaagact	ctgtctcaca	aaaaaaaaaa	2340
aaaaagggc						2349

&lt;210&gt; 42

&lt;211&gt; 1559

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 42

attcatgcc	aaacatagc	tttcagtgc	tattacatat	ggctttcagc	tctctctact	60
gagggatgta	ggagtttatt	tctgaggtct	gagcctcttt	tcctttactt	cctttactct	120
ttcctaagcc	ttctttataa	aaactatgca	tgttctattg	ttttcctttt	tgattccctt	180
tctttttatta	tccccagtag	gagtgacttg	taattctcat	atgttagaaa	ggcagggtctc	240
ctggttgaa	aaaagatcca	cccaagcaag	tcagcagttt	aataaaat	tgagggggat	300
ctcaaatgtg	ggaaggattg	ttatataaga	caaccaaatg	atgacatgag	acaataaatg	360
ctataggaat	tatggaggaa	taattagcta	tttattttct	tggtagggga	agagatatta	420
ttagtgtag	aagtaattac	taacttctac	attttttatt	gtggaaatca	aaaatatata	480
tatgaaaata	aaatgttata	attgacttca	gtgtcccata	aaccagcttc	caacaattac	540
caaattgtga	ccaatccttt	acacacatgc	acagggtgtc	ctccagtatc	tgtggggcat	600
tggttctagg	accacttatg	gataccaaca	tctatggatg	ctcaagtccc	tgatataaaa	660
tggtggacta	tatgcatata	accctgttac	gtcccgtatt	aaccaaatcc	tccttagatc	720

acttacaaca	cgtaacacaa	tctaaatgcc	acgttaacaa	cgcgcatact	gtattaagcg	780
aataaccccg	ccaaaaatgt	acttctctca	gtccagacgc	cttttttttt	tgtgtgtgga	840
atatcccgagc	ccccagtc	ccttcaaccc	cctggcacat	aggaggctga	ctgcgtgtgt	900
gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgcatac	agacacacat	atctctgaaa	960
tgtaaatatt	ctctctttta	aaaaattatt	atcacagcta	aacaaattac	cagtaattct	1020
cttatcctca	tatacccggt	gttcagattt	tctagattgg	ctcctaattt	ttttacagat	1080
tatttgaatc	tgattcaatt	catgtactgt	aatgtttgat	aacttaagta	ccctttatag	1140
gttcccttta	ccacttcttt	attaaattcc	ttgtaatttg	ttgtactaaa	tggattgtct	1200
tcctagaatt	tcctgtagtc	tgaattatgt	ggtaattggt	cacatgttcc	agtgtcctct	1260
tatttctctgt	gagttggtag	ttagatctag	aagcttgatt	aaattcagat	tttctctctt	1320
tagatcatca	acttttagatc	atcaacttgg	atcattttgtt	tcattttgct	tttgatatgt	1380
tgttttttag	aattacctct	taaaaatttg	atttaatttt	ataatcatgt	aaaatgttta	1440
taaatttcca	aattcagatc	agcaaaacac	aataaaatct	attcagagaa	ggcaaaaaaa	1500
aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	1559

&lt;210&gt; 43

&lt;211&gt; 1766

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 43

cggcagcagg	agcactgaag	tattcactac	atgaagtata	ttttgactg	tggacacaaa	60
ttagaaaaat	tgcaagtagt	ggtatattgt	aattggcatg	cactatatga	gcagagtcaa	120
tgtgtctcct	tgtagaatat	tctctgatga	tactcactat	tatccctct	ctgctaagct	180
ttgttctgtg	tctgaagggc	ataaagcatg	gaaactacat	ttttcagact	ccattaccag	240
aaggatatgg	ttggatttca	gcaatgagtg	ggctttgcat	aaaatttggg	agacgaaaga	300
gaagaaaaac	ctggctgctg	caggttggaa	cactggcaac	aatagatacg	gagtttgcaa	360
gaagctgcta	agcttcctca	ggaaaattat	ttgtttcaat	atttctggca	tatgggatca	420
tcaattattg	ttttcagtgg	ttctggctga	aaattgggtc	aattcttcta	tctgagaatt	480
gttcatttct	gtgcttcagg	aaactaagac	catcactggc	agtttttggt	gagggatcct	540
tgtgcattca	tttttcctta	aaacagcctt	cctaaactttt	actccccag	cctctatggg	600
tgtgtaagtc	tttaattctt	agagttacat	ttctcttact	cagtatatcc	tagtgccggt	660
tctgttttcc	agacccaacc	ctgactgata	tagtctccat	gtgtttcaga	tgggtgggata	720
gtttggatat	ttgtccctgc	ccaaatttca	tgttgaactc	taatccccag	tgctgtaggt	780
ggggcccaat	gggaggtgtt	cggatcatgg	gggcagatcc	ctcacggctt	ggtgctgtct	840
tcgtgatagt	gagttcttgt	aagatctggg	catttttaaag	tgtttggcac	ttgtaccatt	900
tcactgtgtc	ttgtcctctg	ttcaccatg	tgaagtgcct	gctccagctt	cacttttcac	960
catgattgta	aacttctctga	ggcctcccta	gaagccaagc	agatgccatc	accaggggtc	1020
ctgtaaagca	tgcaagaactg	ttagccaatt	atacctcttt	tctttacaaa	ttaaaaacct	1080
cttttcttta	caaaatggaa	agaataaagg	tatttcttta	tagcaatgca	agaacggcct	1140
aatacagatg	gctctgccat	tagtgagaaa	attgagacgc	tttctctaga	tggcaaaaaa	1200
gttgtaaaaa	taaaaggaaa	ttattaatat	accgtctatt	gtgatcattt	actaagttaa	1260
gcatattatt	aagaagacaa	gcataagttt	aacacaattt	ggcaatgaat	aaaattgaag	1320
gagagagagc	atatgttggc	tttgctctgt	gaaactcaaa	tgaatgggtc	acctgttcta	1380
gcagctcatg	aaaaattctg	cattgtttat	tatgtgtcag	gatcaacctt	aaattcagtt	1440
ataaaaaagt	tgatgattac	aaaaaaaaag	gaagcactaa	gtaatatagg	tacagagagg	1500
gaagagtgtc	aatagaatt	ttcaatctgt	gtataaggat	acttaagcat	tttttaagga	1560
aagcagaaag	aagcatgaga	aagtctacaa	tgacatctat	gtcaatataa	caagctggat	1620
atttagagaa	gaaactcttg	attaaatact	ttttatgata	tgaacacaca	catataatat	1680
gacatgactg	tgttcatgga	acataaagaa	attcctctga	caaagagaa	ctggaaaaaa	1740
aaaaaaaaa	actcaggggg	gggccc				1766

&lt;210&gt; 44

&lt;211&gt; 2572

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<220>  
 <221> SITE  
 <222> (2527)  
 <223> n equals a,t,g, or c

<400> 44  
 aattcggcac gagtctggac cttcttagmt tgcttgatat cagggttgttt ttgtagccat 60  
 ttgtcttcac agtcacctgg aatgccggga gcccctgctc atccccgatcc tctccttgta 120  
 catgggcgca cttgtgcgct gcaccaccct gtgcctgggc tactacaaga acattcacga 180  
 catcatccct gacagaagtg gcccggagct ggggggagat gcaacaataa gaaagatgct 240  
 gagcttcttg tggccttttg ctctaattct ggccacacag agaatcagtc ggcttattgt 300  
 caacctcttt gtttcccgga accttgggtg cagttctgca gccacagagg cagtggcgat 360  
 tttagacagcc acataccctg tggtcacatg ccatacggct ggttgacgga aatccgtgct 420  
 gtgtatcctg ctttcgacaa gaataacccc agcaacaaac tggtagcac gagcaacaca 480  
 gtcacggcag cccacatcaa gaagttcacc ttcgtctgca tggctctgtc actcacgctc 540  
 tgtttcgtga tgttttgga acccaacgtg tctgagaaaa tcttgataga catcatcgga 600  
 gtggactttg cctttgcaga actctgtggt gttcctttgc ggaatctctc cttcttccca 660  
 gttccagtc cagtggggc gcattctacc ggggtggctga tgacactgaa gaaaaccttc 720  
 gtccttgccc ccagctctgt gctgcggatc atcgtcctca tcgccagcct cgtgggtccta 780  
 ccctacctgg ggggtgcacgg tgcgaccctg ggcgtgggct ccctcctggc gggctttgtg 840  
 ggagaatcca ccatggtcgc catcgctgct tgcattgtct accggaagca gaaaaagaag 900  
 atggagaatg agtcggccac ggagggggaa gactctgcca tgacagacat gcctccgaca 960  
 gaggagggtg cagacatcgt ggaaatgaga gaggagaatg aataaggcac gggacgccat 1020  
 gggcactgca gggacagtca gtcaggatga cacttcggca tcatctcttc cctctcccat 1080  
 cgtattttgt tccctttttt ttgttttgtt ttggtaatga aagaggcctt gatttaaagg 1140  
 ttctgtgtca attctctagc atactgggta tgctcacact gacgggggga cctagtgaat 1200  
 ggtctttact gttgctatgt aaaaacaaac gaaacaactg acttcatacc cctgcctcac 1260  
 gaaaacccaa aagacacagc tgcctcacgg ttgacgttgt gtctcctcc cctggacaat 1320  
 ctctctcttg aaccaaagga ctgcagctgt gccatcgctc ctcggtcacc ctgcacagca 1380  
 ggccacagac tctcctgtcc cccttcctcg ctcttaagaa tcaacagggt aaaaactcggc 1440  
 ttcttttgat ttgcttccca gtcacatggc cgtacaaaaga gatggagccc cgggtggcctc 1500  
 ttaaatttcc cttccgccac ggagttcgaa accatctact ccacacatgc aggaggcggg 1560  
 tggcacgctg cagcccgagg tccccgttca cactgaggaa cggagacctg tgaccacagc 1620  
 aggtgacag atggacagaa tctcccgtag aaagggtttg tttgaaatgc cccgggggca 1680  
 gcaaaactgac atgggtgaat gatagcattt cactctgcgt tctcctagat ctgagcaagc 1740  
 tgtcagttct caccctccac gtgtatatac atgagctaac ttttttaaatt tgtcacaaaa 1800  
 ggcacatctc agattccaga ccctgccgca tgacttttcc tgaaggcttg cttttccctc 1860  
 gcctttcttg aaggctcgat tagagcgagt cacatggagc atcctaactt tgcattttag 1920  
 tttttacagt gaactgaagc tttaagtctc atccagcatt ctaatgccag gttgctgtag 1980  
 ggtaactttt gaagtagata tattacctgg ttctgctatc cttagtcata actctcggt 2040  
 acaggtaatt gagaatgtac tacggtaact ccctcccaca ccatacgata aagcaagaca 2100  
 ttttataacg ataccagag cactatgtgg tctcctctga aataacgcat tcgaaatcca 2160  
 tgcagtgcag tatatttttc taagtttttg aaagcagggt ttttctctta aaaaaattat 2220  
 agacacgggt cactaaattg atttagtcag aattcctaga ctgaaagaac ctaaacaaaa 2280  
 aaatatttta aagatataaa tatatgctgt atatgttatg taattttatt taggctataa 2340  
 tacatttctt attttcgcat tttaataaaa atgtctctaa tacaatacgg tgattgcttg 2400  
 tgtgctcaac atacctgcag ttgaaacgta ttgtatcaat gaacattgta ccttattggc 2460  
 agcagtttta taaagtccgt catttgcat tgaatgtaag gctcagtaaa tgacagaact 2520  
 atttttncat tatgggtaac tgggggaata aatgggggtc ctgggagtag gg 2572

<210> 45  
 <211> 526  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (66)



<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (106)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (484)

<223> n equals a,t,g, or c

<400> 45

ctctgacagc	ttcctctttg	gccaagccct	gcctctgtac	agcctcgagt	ggacagccag	60
aggtcnagac	tgagagcccag	agcccaagat	ggagccccag	ctgggncctg	aggetgcccgc	120
cctccgccct	ggctgggctgg	ccctgctgct	gtgggtctca	gccctgagct	gttctttctc	180
cttgccagct	tcttcccttt	cttctctggg	gccccaaatc	agaaccagct	acaattttgg	240
aaggactttc	ctcggctctg	ataaatgcaa	tgccctgcac	gggacatcta	tttgcaagaa	300
gttcttttaa	gaagaaataa	gatctgacaa	ctggctggct	tcccaccttg	ggactgcctc	360
ccgattccct	ttgstttctt	atccttgcaa	attactccar	atgattycca	aaatctggsg	420
sccttggtga	ratcttttaa	ctggctcagca	awtwtcaaac	gaaatctcca	aacaggaaat	480
cttntgcctc	ctgcatccac	ccccaaagaa	cttgacacatt	gacgtt		526

<210> 46

<211> 1032

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (974)

<223> n equals a,t,g, or c

<400> 46

gtaaaattgt	caaacattta	tttttaaaaa	taaaatgtgg	tgggcggtta	tggtggaggt	60
tattgggtcc	tggtgtctgc	cactgagcat	tgctgaatgt	tgcatgact	tgtaggacttc	120
tcagagctgc	gagcatgcgg	gtgctctttg	tgagagattg	ctctgtgcct	gtaggaaggt	180
gggtgtgtgg	gtgtcattgc	agcaacattg	gtggaacaga	tggtgtgccc	cccatgctgt	240
catcaggggt	cattgcacag	gagcctcata	cacactacag	aaaatatgct	cttgtaaccc	300
caagttcatg	gggaggcatc	cacacagatg	gcagcagatc	aggaaatgct	ctcagccagt	360
cctcaggggc	agtagggcag	ccttcatctg	ggtgcgcttg	gcagccctga	actttatctc	420
ttcttttctg	tgtatttctt	taatatctta	ttcagcattt	tagtttcttt	agttggatga	480
gttgttcagt	gtctttgtac	tgtacagttc	tcctgtgctg	ttggaatgga	cgatcatgggc	540
tatgttactc	ttttgaaata	caaatttctc	tttagaagtt	ttggaaaatc	tgtagagga	600
ggagttctga	gaatatgaga	agacttcttg	ccacatagtt	gtgcctgccc	gatgtatttt	660
tccaaaaaaa	ttgaagggtga	acctgttgga	agctcagttc	tgagtttaat	tgactacttt	720
gcagagacac	aacactctct	ttsttagcatg	tcccttgga	gaaaataggc	tggtgcttgg	780
gtggtgatca	gaactggcag	ttattctagg	cctaaaacag	tttggaata	aaataagaaa	840
aagggggccac	atgtggtggc	tcagtcttta	atccccacac	tttgagaggc	tgaggcaggg	900
ggattgcgtg	aagccagcct	gggcaacata	aaatttaaaa	attagccaga	catggtggca	960
tgtgcctgtg	ggtnacgaa	cctgggtggc	taagaccgaa	ggatcacttg	agcccaggaa	1020
gtcaaggctg	ta					1032

<210> 47

<211> 2680

<212> DNA

<213> Homo sapiens

<400> 47

ggcacgagtc	ttacagcaag	tacttaacaa	acttagat	ccataatcag	atttatctca	60
aaccgcaaaa	aaaagctgat	tttattatgt	taaactgata	ggagattttt	atgagagatg	120
aaagtaagcg	attttaactt	tttaattttt	ttaatttttg	ctctgtttct	cacacttgag	180
gcttttctga	aattcaccaa	aagagttttg	gcagttgtgg	ggaatttacc	agaaccccc	240
attattaaaa	caattgggtt	cttatattaa	aatcatcaga	caggttttgt	gtacacagac	300
atztatgtta	agccactgga	tagaactaaa	ctgtgtgtag	gaacctgttt	tctctaagaa	360
aggactcctt	tgagtctctg	aggatatgtg	cttaaagggt	ttctgtgtca	agctatttta	420
tgaaataaaa	ttttacaaac	aatgaagctt	cattttcaca	cgttgtattt	gtttaatgca	480
gacttggcct	atacagagtt	ttgaaattaa	gggttttttc	cgtaaaacta	gcttaggagt	540
ttaatgagtc	actgtgtctc	tcacctctgt	aggatgagca	cagagatcac	atztatgaa	600
cagggtgtgg	tggtttctgc	tggtcacgtc	tcctctgcct	ctcctctggc	tcagcagtta	660
cttttctca	gtcatggggg	ctgcattcag	ctgcgatgcc	agcattaggg	ccaagctctc	720
ccgttctctg	gacgttttat	tacacgtact	ctttatcagt	agtagctgcc	attccctgag	780
tggttcttcc	accgtgcact	gagaagggtc	gaggatttcc	gaacatcaac	ctcctctaac	840
cctctgtatg	ggaattagat	ttttatcatc	ctgactgttg	gggttttcta	gagctcaggc	900
aacttgcccc	tggggcggat	ggagcctgcc	tggggggagt	gtgaatgagg	cttctgttgt	960
ctgtggcttg	gctctctgtg	gttggaact	tcagaagcag	tagattccag	gtgcaacatt	1020
tggtgccccg	acaagtgtga	aaacctgacc	ttggggaggg	ccttccactgg	cagccagtgt	1080
ccaccctga	gcccgtgtgag	cacagacgtt	agagccaggg	ccggcgggct	cagaggttgg	1140
agccggggac	cagtggtgtc	agaggtcgga	gccggggacc	agtgggctca	gaggtcggag	1200
ccatgtccct	gccgtgaagc	tctgagggtt	ggtggtgaca	tcggggcgat	tgtggcatcg	1260
cgattgtggt	gtcttggtg	cctttggccg	gcgtgccac	tgccctgggt	tcagacgta	1320
ggcaccacat	ggtcctgtgt	tgctcactt	acggctccac	ttctggcttt	ttctacttg	1380
ctacccttg	agataaactt	ctatttcatt	ttcatattcg	tttatatgtg	ggttttcttc	1440
caggtctgat	gttaagccta	taatatgtca	atgtgatgtt	ttgaagttaa	ggtgtaatag	1500
agccagtga	ccaagggttc	acaccccagt	gaaatacaaa	tattcagaat	tgagccactg	1560
tggtgccata	ctgattatgt	aatgtgtgat	taacaagtat	aatgtgtcac	tttcaacatc	1620
agtttcatgc	caaagtgtga	ttttattaga	ttatttgga	gttccatttg	ggcccaaagg	1680
ctcgtgtcta	cataataata	acttatgatt	tttctttttg	tctttgtttt	attttttgtt	1740
ttgtgtttt	tgctttctag	accatgccag	agtaatctca	gcttttctta	gttactggat	1800
cacactatc	cttcttgaga	agagcagtga	ctaaattgga	atatctcttt	aagaacagct	1860
cctctttaac	aaaaaaactt	aaaagacaaa	tgtgagatgg	gcttagagtt	agttctctgg	1920
gaacttgaaa	gacatttatg	ccatattatt	tattcacgtg	tttgttctctg	gtgggcaaga	1980
tgccatctga	ggcttcagat	gagaaattgg	ggtaaaatgg	aaatttttca	cttatttgca	2040
attatatata	tcttgaatta	ctacataaaa	cttgattctg	tttctctact	tattgtaaaa	2100
attgaaaatg	gacattctgt	taagttaa	gtatagtttg	aagctcatat	atttttatga	2160
agttttgaat	cacctgtgat	ctgaaagtct	ctgcttttaag	aatgctttct	gggtattaaa	2220
atgttctagt	ttagtagt	tgaatatagt	tgagtttttt	ttctctctctc	tactttgtga	2280
atcatatcag	gtacctgttt	ttctgttttc	gattttcttt	tctgtgatag	aagcagtcgt	2340
cagttcttgg	tattactaag	tgtaaaaagc	atcagtcagg	ccgggtgcgg	tggtcacgc	2400
ctgtaatcct	ggcactttgg	gagaccgagg	caggcggatc	acaacgtcag	gagatcgaga	2460
gcatcctggc	taacacggtg	aaacccatc	tctattaaaa	atacaaaaaa	ttagccgggc	2520
gtggtggcgg	gcgcctgtag	tcccagctac	tctggaggct	gaggcaagag	aatggcatga	2580
acctgggagg	cagagcttgc	agttagctga	gatcgaccca	ctgcactgca	gcctgggcga	2640
cagagcgaga	ctccagctca	aaataaaaaa	aaaaaaaaaa			2680

&lt;210&gt; 48

&lt;211&gt; 1730

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 48

cccacgcgtc	cgggggcctg	tggcggagtc	caagaggaac	tagggcgcct	tcgggatggt	60
gtggagcgct	gctcctgccc	cctgttgcc	cctcgggggtc	ctggggctgg	tccaggtgtt	120
ggggggccaa	gccgtggg	cctggacggc	ttcagcggtg	ttgggggcag	ctcaggctca	180
gccctgcagg	ccctgcaagg	agagctctct	gaggttattc	tcagcttcag	ctccctcaat	240

gactcactga atgagctcca gaccactgtg gagggccagg ggcctgatct ggctgacctg	300
ggggcaacca aggaccgtat cttttctgag attaacaggc tgcagcagga ggccacagag	360
catgctacag agagtgaaga ggccttccga ggcctagagg agggacaagc acaggccggc	420
cagtgcacca gcttagaggg gcgattgggc cgtcttgagg gtgtctgtga acggttggac	480
actgtggctg ggggactgca gggcctgcgc gagggccttt ccagacacgt ggctgggctc	540
tgggctgggc tccgggaaac caacaccacc agccagatgc aggcagccct gctggagaag	600
ctggtcgggg gacaggcggg cctgggcagg cggctgggtg cccttaacag ctccctgcag	660
ctcctggagg accgtctgca ccagctcagc ctgaaggacc tcaactgggc tgcaggagag	720
gctgggcccc cagggcctcc tgggctgcag ggacccccag gccctgctgg acctccagga	780
tcaccaggca aggacgggca agagggcccc atcggggcac caggctctca aggtgaacag	840
ggagtggagg gggcaccagc agcccctgtg ccccaagtgg cattttcagc tgcctctgag	900
ttgccccggt ctgaaccagg cacggttccc ttgcacagag tcctgctcaa tgatggaggc	960
tattatgac cagagacagg cgtgttcaca gtgcacctg gctggacgct acttgctgag	1020
cgcggtgctg actgggcacc ggcacgagaa agtggaggcc gtgctgtggc cgctccaacc	1080
agggcgtggc cggcgtagac tccgggtggc tacgagcctg agggcctgga gaataagcg	1140
gtggccgaga gccagcccag cccgggcacc ctgggcgtct tcagcctcat cctgccgctg	1200
caggccgggg acacgggtctg cgtcgacctg gtcatggggc agctggcgca ctcgaggag	1260
ccgctcacca tcttcagcgg ggccctgctc tatggggacc cagagcttga acacgcgtag	1320
actgggggtc cgcccagcgt gtctacgtcg gctgaagaga cagcgggggc ggcgggctcc	1380
tgggggtctc cctgagacgg ggcacctagc cctgggcgag cgccgcaccc gggcccgcag	1440
cggcaccgcg cccagagcgg cctctcccca cgcccggggc ggcgggctc agggaggctc	1500
ggggccgccc atgcagactt ttggcctggc gcgatcccc aagaacccct ccagggccgg	1560
cctgcgagg agccgatcct cgcacctcc gctccctcca ctggccctcc aggtcgattc	1620
cctgggctcc aggtctcccc gcgcgggcgc cgcccaccgc catactaaac gatcgaggaa	1680
taaagacact tggtttttct aaaaaaaaaa aaaaaaaaaa aaggggccgg	1730

&lt;210&gt; 49

&lt;211&gt; 1275

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 49

ggcagagacc agctcctctt ccaagatgtc ctccctaaac tttgccagtg aaatggagaa	60
gtactgtttg gggaataata tgctttcaag gttttgctta tttttgataa tgctcctgca	120
catccttctt tttttggtta tcttcattca acgtcacact gttgtctctc tctccaagca	180
ccaccctctt ttctcaacta atggatcaaa gagttatagc agcttttaag gcctgattac	240
tacctgagga ggacctttgc ctaggctatt gctgcaata agaaagatcc tttttaaaca	300
cactgggtgca attctggaag gattacaaca tctatggcag catcaacaac cttgggttaag	360
ttgggggtga agtcaccaag gagtgtgtaa atgctatctg ggaagagata ttgaagacat	420
ttgtccatga cttcaaaaca ttgctaagga tgaggatgtt gcaaaaaaaaa aatattcaca	480
aggcttttagt tgaatggca aacaacttta agctggatgt ggaggaggat gatattgagg	540
aggtcacaga tgtggtcact gaggaattga ctaatgacga gttactggaa ccagaacaga	600
aatgcatagc aagaggaaag gaaactacag gagaaaaaaaa gaaaagcccc caaggatatt	660
cacagtgatg ggtttaggca gaagcttttg cagacctcaa caaactcctt aaaacgtttg	720
aaaatgttga ctccaacatg aaatgatttt cattagtaga gaggaatgtt catcgtgcat	780
tatctattta caagcaaata tatgatgaat aaaagaaaca aaccaaaaca accaccatga	840
acacatttct gaaaagagtg acatctcaag aagagcctca ggcaggtcct tcaggaggta	900
tcccagaaga agaaggcatt gttatcacag gacatgacag ctccctgggt gttattgccc	960
ttaaaggcct tccagtagga taagggtggt agatggaagg tgccgatttt tatgatcctg	1020
accctacata ggtctaggct aatgggtaat ggtgtgtttg tgtcttagtt tttaaagaaa	1080
aatgtaaaaa gtaaaaaata aaaataacat taatataggt aaaagtttat agaataagga	1140
tataaggaga gaaaaaaatt atcttctctt gtatttgtgt ttcaagctgt gttactacaa	1200
aagaataaaa aagttaagag aaattgtttt taaagtaaaa tagttacaat aatctaaaaa	1260
aaaaaaaaaa aaaaaa	1275

&lt;210&gt; 50

&lt;211&gt; 1762

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (447)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 50

ggtggcctag	agatgctgct	gccgcgggtg	cagttgtgcg	gcacgcctct	gcccggccagc	60
ccgctccacc	gccgtagcgc	ccgagtgtcg	gggggcgcac	ccgagtcggg	ccatgaggcc	120
gggaaccgcg	ctacaggccg	tgctgctggc	cgtgctgctg	gtggggctgc	gggcccgcac	180
gggtcgcctg	ctgagtgggc	agccagtctg	ccggggaggg	acacagaggc	cttggtataa	240
agtcatttac	ttccatgata	cttctcgaag	actgaacttt	gaggaagcca	aagaagcctg	300
caggagggat	ggaggccagc	tagtcagcat	cgagtctgaa	gatgaacaga	aactgataga	360
aaakttcatt	gaaaacctct	tgccatctga	tggtgacttc	tggattgggc	tcaggaggcg	420
tgaggagaaa	caaagcaata	gcacagnctg	ccaggacctt	tatgcttggg	ctgatggcag	480
catatcacaa	tttaggaact	ggtatgtgga	tgagccgtcc	tgccggcagcg	aggtctgcgt	540
ggtcatgtac	catcagccat	cggcaccgcg	tggcatcgga	ggccccctaca	tggtccagtg	600
gaatgatgac	cgggtgcaaca	tgaagaacaa	tttcatttgc	aaatattctg	atgagaaacc	660
agcagttcct	tctagagaag	ctgaagggtg	ggaaacagag	ctgacaacac	ctgtacttcc	720
agaagaaaca	caggaagaag	atgccaaaaa	aacattttaa	gaaagtagag	aagctgcctt	780
gaatctggcc	tacatcctaa	tccccagcat	tcccctcttc	ctcctccttg	tggtcaccac	840
agttgtatgt	tgggttttgg	tctgtagaaa	aagaaaacgg	gagcagccag	accctagcac	900
aaagaagcaa	cacaccatct	ggccctctcc	tcaccaggga	aacagccccg	acctagaggt	960
ctacaatgtc	ataagaaaac	aaagcgaagc	tgacttagct	gagacccggc	cagacctgaa	1020
gaatatttca	ttccgagtgt	gttcggggaga	agccactccc	gatgacatgt	cttgtgacta	1080
tgacaacatg	gctgtgaacc	catcagaaag	tgggttttgg	actctggtga	gcgtggagag	1140
tggattttgt	accaatgaca	tttatgagtt	ctcccagac	caaatgggga	ggagtaagga	1200
gtctggatgg	gtggaaaatg	aaatatatgg	ttattaggac	atataaaaaa	ctgaaactga	1260
caacaatgga	aaagaaatga	taagcaaaat	cctcttattt	tctataagga	aaatacacag	1320
aaggtctatg	aacaagctta	gatcagggtc	tgtggatgag	catgtggtcc	ccacgacctc	1380
ctgttggacc	cccacgtttt	ggctgtatcc	tttatcccag	ccagtcaccc	agctcgacct	1440
tatgagaagg	taccttgccc	aggtctggca	catagtagag	tctcaataaa	tgtcacttgg	1500
ttggttgtat	ctaaacttta	agggacagag	ctttacctgg	cagtgataaa	gatgggctgt	1560
ggagcttgga	aaaccacctc	tgttttcctt	gctctataca	gcagcacata	ttatcatata	1620
gacagaaaat	ccagaatctt	ttcaaagccc	acatatggta	gcacaggytg	gcctgtgcat	1680
cggcaattct	catatctgtt	ttttcaaaag	aataaaatca	aataaagagc	aggaaaaaaa	1740
aaaaaaaaaa	aaaaaactcg	ag				1762

&lt;210&gt; 51

&lt;211&gt; 2059

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 51

cggcacgagg	tttgggtctaa	gagtgagcag	aactgtgttg	agatgggagc	acatttggtt	60
gtgttcaaca	cagaagcaga	gcagtggaag	gaggcatgca	tccccagctg	ataccttcgg	120
ttattgctgt	agttttcatc	ttacttctcg	gtgtctgttt	tattgcaagt	tgtttggtga	180
ctcatcacaa	cttttcacgc	tgtaagagag	gcacaggagt	gcacaagtta	gagcaccatg	240
caaagctcaa	atgcatcaaa	gagaaatcag	aactgaaaag	ttgctgaagg	gagcacctgg	300
aactgttgtc	ctattgactg	gagaaccttc	cagttccaac	tgctattttc	ctccttactg	360
acaacaagac	gtgggctgag	agttgaaagg	aactgttcag	ggatgggggc	ccatctgatg	420
accatcagca	cgggaagctga	gcagaacttt	attattcagt	ttctggatag	acggctttcc	480
tatttccttg	gacttagaga	tgagaatgcc	aaaggtcagt	ggcgttgggt	gggaccagac	540
gccatttaac	ccacgccaga	gtattctggc	ataagaatga	acccgacaac	tytcagggag	600
aaaactgtgt	tgttctggtc	ttataaccaa	gataaatggg	cctggaatga	tgttccttgt	660
aactttgaag	caagtaggat	ttgtaaaata	cctggaacaa	cattgaacta	gaaactcaga	720

aagtggctct	tgtgatggaa	agagaaaaga	aaaaccaatt	agaataaggg	agaatgtacg	780
tgcgtcattg	gaacacagaa	aacatgctgg	ttcatcacagc	gttttttagtc	ataatgggtct	840
tttttatttt	gtttgattca	ttcgagacaa	catgtgtgta	tgtgtgtgtg	tgtgtgtgta	900
gataatgtgg	tttttgtatg	gtgtttgatg	gaaggaataa	tctttctttg	ctttcttagt	960
agtatttcaa	ggtgtttact	tttcaattgg	tgtgcactga	atgcatgtat	ggaagaatag	1020
cgtgaataat	gcaatctctt	tgtcattttt	ttccctttct	cagactctta	gctcttaaaa	1080
ttcaaaagat	gggatattct	aactggtagt	ggtgcatcat	ttttaaccca	aatattgcaa	1140
gcactttaaa	gatttgaaac	cacattttta	ttgtttgatg	tttcattttc	agacttttta	1200
atgtcagtca	ttacaattac	attgcatgag	gaaaattttt	ccagaacaac	agtggtgaat	1260
agttctgaat	tatgctgttc	tacagatgga	aaaaagtcca	aatgccttta	aaaatttact	1320
tcttactcca	cccaacacgt	ttttgcaaag	caagaagtct	ttgtaagaca	ccttaaacaa	1380
agtccttcaa	ttctacagca	gaggaaataa	aatccccag	aagccaaagg	gctcaccttc	1440
acattgttag	ttcatgacag	acccaggtgt	gcttcattag	agataacata	cattcccttt	1500
ggatcacag	gaagttactg	gggattactc	gacctcatta	cttagctaac	gactggataa	1560
aatttcttaa	ttgtttgaag	taacattgta	ttcgtgtttg	cattattaat	ttgaatagaa	1620
aataatcaca	ttttcaaccc	atttatacaa	attgttaatg	tttctttaga	gctgtataac	1680
tatagtttga	actagcaagg	aagttattgt	tttgacaacc	agaaattatg	cttttctggt	1740
gcatgaaaca	ctaattgcaa	agggcagtc	catccaactt	taataaaata	tggtggtctt	1800
tcttaaaatt	ttcaatttgc	taatttttcc	tggaacctta	actttcctac	tactactttt	1860
aaaagcagta	tttattttgt	aaattagcta	ctgatttttt	gggtttgaaa	tactggtgtt	1920
tgattgtgtg	gtggtgtgtg	tggtgatgga	tgcgtgtagc	tgtgttaaaa	gctgatactt	1980
ttagctgaaa	tggtgctaaa	taaatttgac	tgtgtttgac	atattcacta	aaaaaaaaaa	2040
aaaaaaacta	gagggggggg					2059

&lt;210&gt; 52

&lt;211&gt; 3282

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 52

cccacgcgtc	cgacttaaaa	gagaagcttt	agctgccaaa	gattgggaaa	gggaaaggac	60
aaaaaagacc	cctgggctac	acggcgtagg	tgcagggttt	cctactgctg	ttctttttatg	120
ctgggagctg	tggctgtaac	caactaggaa	ataacgtatg	cagcagctat	ggctgtcaga	180
gagttgtgct	tcccaagaca	aaggcaagtc	ctgtttcttt	ttcttttttg	gggagtgtcc	240
ttggcagggt	ctgggttttg	acgttattcg	gtgactgagg	aaacagagaa	aggatccttt	300
gtggctcaatc	tggcaaagga	tctgggacta	gcagaggggg	agctggctgc	aaggggaacc	360
aggggtgggtt	ccgatgataa	caaacaatac	ctgctcctgg	attcacatac	cggaattttg	420
ctcacaaatg	agaaactgga	ccgagagaag	ctgtgtggcc	ctaaagagcc	ctgtatgctg	480
tattttccaaa	ttttaatgga	tgatcccttt	cagattttacc	gggctgagct	gagagtcagg	540
gatataaatg	atcacgcgcc	agtattttcag	gacaaagaaa	cagtcttaaa	aatatcagaa	600
aatacagctg	aagggaacgc	atttagacta	gaaagagcac	aggatccaga	tggaggactt	660
aacggtatcc	aaaactacac	gatcagcccc	aactcttttt	tccatattaa	tattagtggc	720
ggtgatgaag	gcatgatata	tccagagcta	gtgttgagca	aagcactgga	tcgggaggag	780
cagggaagagc	tcagcttaac	cctcacagcg	ctggatgggtg	ggtctccatc	caggtctggg	840
acctctactg	tacgcacgtg	tgtcttggac	gtcaatgaca	atgccccaca	gtttgccag	900
gctctgtatg	agaccagcgc	tccagaaaac	agccccattg	ggttccttat	tgtaaggta	960
tgggcagaag	atgtagactc	tggagtcaac	gcggaagtat	cctattcatt	ttttgatgcc	1020
tcagaaaata	ttcgaacaac	ctttcaaate	aatccttttt	ctggggaaaat	ctttctcaga	1080
gaattgcttg	attatgagtt	agtaaatctt	tacaaaataa	atatacaggc	aatggacggg	1140
ggaggccttt	ctgcaagatg	tagggtttta	tggtgaagtat	tggacaccaa	tgacaatccc	1200
cctgaactga	tcgtatcatc	attttccaac	tctgttgctg	agaattctcc	tgagacgcgc	1260
ctggctgttt	ttaagattaa	tgacagagac	tctggagaaa	atggaaagat	ggtttgctac	1320
attcaagaga	atctgccatt	cctactaaaa	cctctctgtg	agaattttta	catcctaatt	1380
acagaaggcg	cgctggacag	agagatcaga	gccaggtaca	acatcactat	caccgctcact	1440
gacttggggg	caccagggct	gaaaaccgag	cacaacataa	ccgtgctggt	ctccgacgtc	1500
aataacaacg	ccccgcctt	cacccaaacc	tcctacacc	tgttcgtccg	cgagaacaac	1560
agccccgccc	tgcacatcgg	cagcgtcagc	gccacagaca	gagactcggg	caccaacgcc	1620
caggtcacct	actcgtctgt	gccgccccaa	gaccgcgacc	tgccccctgc	ctccctggtc	1680

tccatcaacg	cggacaacgg	ccacctgttc	gccctcaggt	cgctggacta	cgaggccctg	1740
caggctttcg	agttccgct	gggcccaca	gaccgaggct	ccccgcgct	gaacagcgag	1800
gcgctgggtg	cgcgtgctgg	tgctggacgc	caacgacaac	tcgcccttcg	tgctgtaccc	1860
gctgcagaac	ggctccgcgc	cctgcaccga	gctggtgccc	cgggcgggcg	agccgggcta	1920
cctggtgacc	aaggtggtgg	cggtggacgg	cgactcgggc	cagaacgcct	ggctgtcgta	1980
ccagctgctc	aaggccacgg	agccccgggt	gttcggtgtg	tgggcgcaca	atggggaggt	2040
gcgcaccgcc	aggctgctga	gcgagcgcg	cgagcccaag	cacaggctgg	tggtgcttgt	2100
caaggacaat	ggcgagcctc	ctcgctcggc	caccgccacg	ctgcacgtgc	tcctggtgga	2160
cggctttctc	cagccctacc	tgccctctcc	ggaggcgggc	cgggccagg	cccaggccga	2220
cttgctcacc	gtctacctgg	tggtggcggt	ggcctcggtg	tcttcgctct	tcctcctctc	2280
ggtgctcctg	ttcgtggcgg	tgccgctgtg	caggaggagc	agggcgccct	cggtgggtcg	2340
ctgctcgggt	cccaggggtc	cttttccagg	gcctctggtg	gacgtgaggg	gcgctgagac	2400
cctgtcccag	agctaccagt	atgaggtgtg	tctgacggga	ggccccggga	ccagtgaagt	2460
caagtctctg	aaaccagtta	tttcggatat	tcaggcacag	ggccctggga	ggaaggggtga	2520
agaaaattcc	acctccgaa	atagcttttg	atttaattt	cagtaaagtc	tgtttttagt	2580
ttcatatact	tttgggtgtg	tacatagcca	tgtttctatt	agtttacttt	taaatctcaa	2640
atttaagtta	ttatgcaact	tcaagcatta	ttttcaagta	gtataccctt	gtggttttac	2700
aatgtttcat	catttttttg	cattaataac	aactgggttt	aatttaatga	gtattttttt	2760
ctaaatgata	gtgttaaggt	tttaattctt	tccaactgcc	caaggaaata	attactatta	2820
tatctcatta	cagaaatctg	aggttttgat	tcatttcaga	gcttgcatct	catgattcta	2880
atcacttctg	tctatagtgt	acttgctcta	tttaaggagg	catatctaca	tttccaaact	2940
cattctaaca	ttctatata	tcgtgtttga	aaaccatgtc	atttatttct	acatcatgta	3000
tttaaaaaga	aatatttctc	tactactatg	ctcatgacaa	aatgaaacaa	agcatattgt	3060
gagcaatact	gaacatcaat	aataccctta	gtttatatac	ttattatttt	atctttaagc	3120
atgctacttt	tacttgccca	atattttctt	atgttaactt	ttgctgatgt	ataaaacaga	3180
ctatgcctta	taattgaaat	aaaattataa	tctgcctgaa	aatgaataaa	aataaaacat	3240
tttgaaattt	gtgaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aa		3282

&lt;210&gt; 53

&lt;211&gt; 1860

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 53

aattcggcac	gagcagcagg	gagaagagga	tgatgagcat	gccaggcccc	tggccgagtc	60
cctgctcctg	gccattgctg	acctgctctt	ctgcccgagc	ttcacggttc	agagccaccg	120
gaggagcact	gtggactcgg	cagaggacgt	ccactccctg	gacagctgtg	aatacatctg	180
ggaggctggg	gtgggcttcg	ctcactcccc	ccagcctaac	tacatccacg	atatgaaccg	240
gatggagctg	ctgaaactgc	tgctgacatg	cttctccgag	gccatgtacc	tgcccccagc	300
tccggaaagt	ggcagcacca	acccatgggt	tcagttcttt	tgttccacgg	agaacagaca	360
tgccctgccc	ctcttcacct	ccctcctcaa	caccgtgtgt	gcctatgacc	ctgtgggcta	420
cgggatacccc	tacaaccacc	tgctcttctc	tgactaccgg	gaacccctgg	tggaggaggc	480
tgcccagggtg	ctcattgtca	ctttggacca	cgacagtgcc	agcagtgcc	gccccactgt	540
ggacgggcacc	accactggca	ccgccatgga	tgatgccgat	cctccaggcc	ctgagaacct	600
gtttgtgaac	tacctgtccc	gcattccatg	tgaggaggac	ttccagttca	tcctcaaggg	660
tatagcccgg	ctgctgtcca	acccctctgt	ccagacctac	ctgcctaact	ccaccaagaa	720
agatccagtt	ccaccaggag	ctgctagtgc	tcttctggaa	gctctgcgac	ttcaacaaga	780
aattcctctt	cttcgtgctg	aagagcagcg	acgtcctaga	catecttgte	cccacccctt	840
tcttcctcaa	cgatgcccg	gccgatcagt	gtaagaccag	ggtgggggtg	ggatgctggg	900
ggctttcctg	gcggcgagggt	ggagggtggg	ctatctgccc	tgactcccag	gagctcagcc	960
tggcactctg	acctcctagg	agggaggcct	ccaaaatggg	cactgcctgg	gccccctcct	1020
ccccctccca	cccagtgtag	ccctccacag	ccacctggcg	cagctcgggt	gggctgatg	1080
cacattggtg	tcttcatctt	gctgcttctg	agcggggagc	ggaacttcgg	ggtgcggctg	1140
aacaaacctt	actcaatccg	cgtgcccatt	gacatcccag	tcttcacagg	gacccacgcc	1200
gacctgctca	ttgtggtggt	ccacaagatc	atcaccagcg	ggcaccagcg	gttgacagccc	1260
ctcttcgact	gcctgctcac	catcgtgggc	aacggttagg	gcccggagct	tgactcccc	1320
gcgctcacca	ccaggtggtg	tcagccacag	gccaaacctg	cacttgctcc	aggtttcaag	1380
ccccccagc	ccacagaaag	aacgcaagct	tgtgtaccct	tcatagtagc	cacattaaaa	1440

aaaaagggtg	acaacaattg	aataatatgt	tttatctatc	atcatctcaa	catgtagcca	1500
atatgaaaat	tactaatgag	atattttaata	ttcccttctc	acactcagtc	ttgtcgccca	1560
ggctggagtg	cagtggcacc	atctcagctc	actgcaacct	ccgccccttg	ggttcaagca	1620
attctcatgc	ctcagcctcc	tgagtaggtg	ggattacagg	cggtgtgccac	cacacctggc	1680
taatttttgt	atcttttagta	gagacggggt	tttgccatgt	tgtccaggct	ggtctcgaac	1740
tcctgacctc	agatgatatg	cccacctcag	cctcccaaag	tgctgggatt	acaggcatga	1800
gccactgcat	ctggcctttt	taaaaaaaaa	aaaaaaaaaa	actcgagggg	gggcccggta	1860

<210> 54  
 <211> 770  
 <212> DNA  
 <213> Homo sapiens

<400> 54	
aattcggcac	gagccgaggg gccaatccat acatccgtcg tgtggactcg ccctgacatc 60
ccctcaacgc	ttagactcgg cattcttttc attgcctgat gccgtttcat gccttctttg 120
cgtttctctg	ctctggccct cctgctggcc atccttcccg cacttcccaa cgcccatgcc 180
gcgcggggga	ttggcggcct gatcggcggc ggctcccagg cctcagccaa ggaagagccc 240
cagagcaacg	cgcaaccag cgccgatgag cgcaacaac gactgctcag ccaggccgag 300
gaaacccggc	agcgcctgac cgatctcaag gccgaactcg ccggcgcacc caaggagatc 360
agcgaggccc	agcgtacgct ctccaaactg gtgagcgagg acaacagcga tctgcccagag 420
cgctctctca	agctttcggg gccggtactg gagcaacgcc tggcggcccg cgtggacgag 480
ctcgccctct	ggcaacaagc gtcagcgcg gccaacagca tgctcatcag cgcgcagacc 540
cggcccagag	gcgccaggg cgatatcagc aagaaccagt tgcgcatcga cgagatcaac 600
ggcctgctga	aaagcggtcg ggagaacaac aagccgctga cggacgaacg tcgcgcgctg 660
ctcgagagta	cttctagagc ggccgcgggc ccacgcattt tccaccggg tgggggtacca 720
ggtaagtgtg	cccaattcgc cctatagtga gtcgtattac aattcactgg 770

<210> 55  
 <211> 1093  
 <212> DNA  
 <213> Homo sapiens

<400> 55	
cagattcggc	acgaggtttt ttttaagatt ttttttttaa aaattatltt tgtggacttg 60
ggtatcaatg	atggcaccta cttttgggaa tctgtagctg tgctttgaga attgccatcg 120
gtcatgtgtt	gcaccgttct ctgtatgttt acgtcctttg gactggcttc tcccaggatt 180
cttttctgtt	tttggttttt tgatttgggc tttatltttt tctgtgtact gtactatatt 240
gtaaaaggga	tttttagcaga gacttttagtc tttggggcaa gaggagaaca ggaatgctgg 300
gctgtttact	ttaggtggag aacctatctt cagacctttg gactatlttc tttcaactgc 360
agtgtataga	aaaaccaaac tacgacctca gagcagagta ttaatgaaa gcacaaaaaa 420
aggaactaag	ttcagcgagg ggtgggggga ggggggagat ttttcttttg aaaaataatg 480
actcttagga	catttggttt tcagttcaag tgctcttcag cactgtcttg tctcccaata 540
taccaaccca	ctggcacatt tttctctgt tttctctctc cgattttgct ctgtctcttc 600
agttaagtgt	ttccttccct tgtgcccccc gctggtagcc ctctgcttcc ctctctcttt 660
ccctttggca	gctgcaatac acagtgttat tttggggaaa taaatctagc aaagcctcgc 720
cttccatgcc	gagcgtcctc ttggctctga gagggaaggg tctgtccttg ggatgctctc 780
tggtcttttt	tccccctaag tctttctctt tcccatcata ccttccctg cccaccttgt 840
tttctgttct	cctttttatta ggaattccca agtgaatttt attaatgtgg gagtgggaaca 900
gatgctaaaa	gctatccagg attttgtttc tgtttgtttt aaattttgtg gttccttccc 960
tttctctccc	ctcccatcgc taagacgttc tgtgtaacct ccattaaatt tggtaaaaaa 1020
ccactcgcca	gagctgtggg gtcagaaaaa taaaatatat tgtttcttam aaaaaaaaaa 1080
aaaaaaaaact	cga 1093

<210> 56  
 <211> 632

<212> DNA  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (29)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (46)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (94)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (162)  
 <223> n equals a,t,g, or c

<400> 56  
 cgcaattaat gtgagttagc tcaactcatna ggcaccccag gctttncact ttatgctttc 60  
 cggctcgtat gttgtgtgga attgtgacgg atancaattt cacacaggaa acagctatgc 120  
 catgattacg ccaagctcga aattaaccct cactaaaggg ancaaaagct ggagctccac 180  
 cgcggtggcg gccgctctag aactagtggg tccccgggc tgcaggaatt cggcacgaga 240  
 ctatgtatat atgtttaata tctgtctttt gaaatgcaga aatagttaa atgtttcttt 300  
 gtctattttt cttttttttt aatgctaccc agggaaatat tttcatatca tttttaagtg 360  
 gcctgcctca atgtatattt atttcttttg aaacaaaaag gttctggaaa ctgtttttct 420  
 gtagctttta atgaataggt gagcaaaatc tatatgggat gtaatttttt tgttcagttc 480  
 cttaaaaaat actttgtttt ggtacatttg gttgtgcttg tggggaaaat aaaaacgcag 540  
 agatccttat atatttatgt taaagtaata ttttattatc tacataaaac agaaatgcac 600  
 aataaaaaaa aaaaaaaaaa gctcgagggg gg 632

<210> 57  
 <211> 2687  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1614)  
 <223> n equals a,t,g, or c

<400> 57  
 gtacaccatg ggcctccacc tccgccccta ccgtgtgggg ctgctcccgg atggcctcct 60  
 gttcctcttg ctgctgctaa tgctgctcgc ggaccacgag ctcccggccg gacgtcaccc 120  
 cccagtgggtg ctggtccctg gtgatttggg taaccaactg gaagccaagc tggacaagcc 180  
 gacagtgggtg cactacctct gctccaagaa gaccgaaagc tacttcacaa tctggctgaa 240  
 cctggaactg ctgctgcctg tgcacatttg actgctggat tgacaatatc aggcctggttt 300  
 acaacaaaac atccagggcc acccagtttc ctgatgggtg ggatgtacgt gtccctggct 360  
 ttgggaagac cttctcactg gagttcctgg accccagcaa aagcagcgtg ggttcctatt 420  
 tccacaccat ggtggagagc cttgtgggct ggggctacac acggggtgag gatgtccgag 480  
 gggctcccta tgactggcgc cgagcccaaa atgaaaacgg gccctacttc ctggccctcc 540  
 gcgagatgat cgaggagatg taccagctgt atggggggcc cgtgggtgctg gttgcccaca 600  
 gtatgggcaa catgtacacg ctctactttc tgcagcggca gccgcaggcc tggaargaca 660



agtatatccg	ggccttcgtg	tcactgggtg	cgccttgggg	gggcgtggcc	aagaccctgc	720
gcgtcctggc	ttcaggagac	aacaaccgga	tcccagtcac	cgggcccctg	aagatccggg	780
agcagcagcg	gtcagctgtc	tccaccagct	ggctgctgcc	ctacaactac	acatggtcac	840
ctgagaaggt	gttcgtgcag	acaccacaaa	tcaactacac	actgcgggac	taccgcaagt	900
tcttccagga	catcggtttt	gaagattggc	ggctcatgct	gcaggacaca	gaagggtgg	960
tggaaagccac	gatgccacct	ggcgtgcagc	tgcactgcct	ctatgggtact	ggcgtcccca	1020
caccagactc	cttctactat	gagagcttcc	ctgaccgtga	ccctaaaatc	tgctttgggtg	1080
acggcgatgg	tactgtgaac	ttgaagagt	ccctgcagt	ccaggcctgg	cagagccgcc	1140
aggagcacca	agtgttgctg	caggagctgc	caggcagcga	gcacatcgag	atgctggcca	1200
acgccaccac	cctggcctat	ctgaaacgtg	tgtccttgg	gccctgactc	ctgtgccaca	1260
ggactcctgt	ggctcggccg	tggacctgct	gttggcctct	ggggctgtca	tggcccacgc	1320
gttttgcaaa	gtttgtgact	caccattcaa	ggccccgagt	cttggactgt	gaagcatctg	1380
ccatggggaa	gtgctgtttg	ttatcctttc	tctgtggcag	tgaagaagga	agaaatgaga	1440
gtctagactc	aaggagacac	ggatggcaag	aatgctgctg	atgggtggaac	tgctgtracc	1500
ttaggactgg	ctccacaggg	tggactggct	gggccctgg	ccagtcctc	gcctggggcc	1560
atgtgtcccc	cctattctctg	tgggcttttc	atacttgctc	actggggcct	ggcncsgcag	1620
ccttcctatg	agggatgtta	ctgggctgtg	gtcctgtacc	cagaggtccc	agggatcggc	1680
tcctggcccc	tcgggtgacc	cttcccacac	accagccaca	gataggcctg	ccactgggtca	1740
tgggtagcta	gagctgctgg	cttcctctgt	gcttagctgg	tggccagcct	gactggcttc	1800
ctgggcgagc	ctagtagctc	ctgcaggcag	gggcagtttg	ttgcgttctt	cgtgggtccc	1860
aggcctggg	acatctcact	ccactcctac	ctcccttacc	accaggagca	ttcaagctct	1920
ggattgggca	gcagatgtgc	ccccagtcct	gcagctgtgt	tccaggggcc	ctgatttcc	1980
cggatgtgct	attggcccca	ggactgaagc	tgcctccctt	cacctgggga	ctgtgggtcc	2040
aaggatgaga	gcaggggttg	gagccatggc	cttctgggaa	cctatggaga	aagggaatcc	2100
aaggaagcag	ccaaggctgc	tcgcagcttc	cctgagctgc	acctcttgct	aacccaccca	2160
tcacactgcc	accctggcct	agggtctcac	tagtaccagg	tgggtcagca	cagggtgag	2220
gatggggctc	ctatccaccc	tggccagcac	ccagcttagt	gctgggacta	gccagaaac	2280
ttgaatggga	ccctgagaga	gccaggggtc	ccctgaggcc	cccctagggg	ctttctgtct	2340
gccccagggt	gtcccatgga	tctccctgtg	gcagcaggca	tggagagtca	gggctgcctt	2400
catggcagta	ggctctaagt	gggtgactgg	ccacaggccg	agaaaagggt	acagcctcta	2460
ggtgggggtc	ccaaagacgc	cttcasgctg	gactgagctg	ctctcccaca	gggtttctgt	2520
gcagctggat	tttctctgtt	gcatacatgc	ctggcatctg	tctccccttg	ttcctgagtg	2580
gccccacatg	gggctctgag	caggctgtat	ctggattctg	gcaataaaaag	tactctggat	2640
gctgtaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaag	ggcgggcc		2687

&lt;210&gt; 58

&lt;211&gt; 619

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (526)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (619)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 58

tcacagctt	tcacctggat	tatcgtgaca	gcctcctact	gcttctctat	catgtggcca	60
gagctatctt	cctaaaaatgc	attgcatagt	tgatcaagtc	actctctggc	ctaaaaacctt	120
ccttggctcc	ctgctgccct	caggataaag	tctggacccc	tcagcatggc	ttgtgagact	180
catggtgtcc	ttgtccctgc	tcacctctct	ggtctcatca	cttgccctct	tgcattctgg	240
gtcccagcct	cctgtatcca	gagatgcagt	ggctctccat	tgccactctg	attcctcctt	300
tcttttggtc	acagagaaaag	ggtactttct	ctgtcaaate	tcaacttaga	cttgacttcc	360
tccaaggagc	tttggctata	ctctctctct	ccgaccccca	ccctggcata	ctacacagat	420

cactctgggc	tcacttgcct	gcctaattggt	catctcccca	gtagactgta	agctccttga	480
gggcaaggat	tgtgttgga	tttttgatt	aacagtgcct	ggcttngtgc	ctggcaccta	540
gaaagcactc	aataaatggt	tgtttaatga	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	600
aaaaaaaaa	aaaaaaaaa					619

<210> 59  
 <211> 1378  
 <212> DNA  
 <213> Homo sapiens

<400> 59	
tcgacttctg	ggatgtagat tctcctttat tgaattcttc attttcactc gcagtatgat 60
ttattttttt	cacactgtat tttaactgc atattgttct ttataacga gggtcacttt 120
cttctgccc	aggattggaa tcaattacag ctatgcaatg tttttgttt agcatcttct 180
taattacagg	cttggcagaa gagttttgtg aacaactctc catttcactg gctgaagaag 240
aaatacaact	gtcctctaca gttgaacatt tctgtatgac agcattttca tggtaatgag 300
gattaggttc	atactttggt ttttccaaac cggggaaaca aacaacagcc aaaaaccagt 360
gtgcagcttc	attaaggggt acaaaaataa aatccttctc aaaaatatct acgtgccggg 420
tccatgtttt	tactctccca tgccgttttt gctgtattga cagattagtt gtttcatgat 480
ttctcctctc	tctctgatta aggcgtttat agaaaaaga actgaatata tgaattcggg 540
cagcgtcttc	cttcttcagt ttttcaagca ccaagtattt caaataaaag tctataataa 600
catcatttaa	aaattctcct tcatttagac agtgcaggtc ctcatggta acagagatgc 660
ctcccttagc	tggagtggtt ggatatacta tcaacttttc tactgggcca atgaagatgg 720
tgtggttttc	tccagtttct tcttcttcat caaaaaactg aaattcttgt ttgcttctaa 780
gttgattttt	agattcaaat gatacagttt taattttgtt ttctttttgc ccacaacttc 840
ctttgatgct	ctcttcatag gttctgtac aggcaacaag tctgccatta gcttcttcaa 900
aggggaatttt	cgcaaaaaaa ttggagatgt tattctttat accaatttca ttaatgatac 960
tttcaaatc	catatttgcg ggaggatcaa ggccattttg aaaaattaaa attatatatt 1020
gttcttctaa	atttgttaat ttatttactc ctttacaatc attccaaact ttatcctcct 1080
tattcatttg	cagttggatg ctcagctttt gataaactgc tgggaattgct tgaagaaaca 1140
ctacaggtaa	ttttcggaca ttacaccatt cacatttagt tagatcagag gtatttaata 1200
taatctctac	aggatcatgg tctggttcgt ctactgtat cttgataaaa tctaaacaaa 1260
aaattacagg	ctctattaac agccggaaga gtgttcttac tgcgtcacgc ggccgcgaat 1320
tcccgggtcg	acgagctcac tagtcggcgg ccgctctaga ggatccctcg aggggccc 1378

<210> 60  
 <211> 1126  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (21)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (35)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (49)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE

&lt;222&gt; (99)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1012)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 60

tccggcttcg	taatgtggtg	ngaaattgta	acggnataac	aatttcacnc	aggaaccagc	60
tatgcccattg	attacgcaa	gttcgaaatt	aaccttcant	aaaggaccaa	aagtgaagtt	120
ccaccgcggt	gccggcccgc	tctagaaact	agtggatccc	ccgggctgca	ggaattcggc	180
acgagccggc	ccgtaccgcc	aggcgatcgc	gctgatggcg	gcgctggcag	cagcggccaa	240
gaaggtgtgg	agcgcgcggc	ggctgctggt	gctgctgttc	acgccgctcg	cgctgctgcc	300
ggtggtcttc	gccctcccgc	ccaaggaagg	ccgctgcttg	tttgtcatcc	tgctcatggc	360
ggtgtactgg	tgacaggagg	ccctgccgct	ctcagtgaag	gcgctgctgc	ccatcgctcc	420
gttccccctc	atgggcatct	tgccctccaa	caaggtctgc	ccccagtact	tcctcgacac	480
caacttcctc	ttcctcagtg	ggctgatcat	ggccagcgcc	attgaggagt	ggaacctgca	540
ccggcgaatc	gccctcaaga	tcctgatgct	tggtggagtc	cagccggcca	ggctcatcct	600
ggggatgatg	gtgaccacct	cgttcttgct	catgtggctg	agcaacaccg	cctccactgc	660
catgatgctt	cccattgcca	atgccatcct	gaaaagtctc	tttggccaga	aggaggttcg	720
aaaggacccc	agccaggaga	gtgaagagaa	cacaggaata	gaaccaata	cttccctctc	780
tgaggaaagg	ctgaaacttc	aagctcccct	tgtgataaga	cttgggtcaga	taactgagtc	840
tggtcaatgg	aatatgagtg	gaaatgatgt	gtgcaacttc	cgggttctgt	ccttcctgcc	900
gggtggaatg	tgaatatgat	ggcacctggg	acccaaagac	aggagccaca	tcttgagaga	960
tagatggcag	atctgccccct	gtggctttgg	atcatttacc	tcagtgaaca	cnacaagcat	1020
tatccatgaa	accataggtt	ttgtgtgcta	gttctagtgt	ttaaaatatg	aattaaatta	1080
aatacgtatc	tgttaaaact	taaaaaaaaa	aaaaaaaaaa	ctcgag		1126

&lt;210&gt; 61

&lt;211&gt; 2078

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (337)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (492)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 61

gattatcttc	aatagattgt	caataaatta	tcaaattatg	gaaatatacct	ttagattcct	60
gtgataatgc	tttgtgcatg	ttttctatta	tttagaaaat	gaaaacagca	gtcatttgac	120
cagccatggt	atgacaccag	ataatattct	gcaaggatct	tccaaacagg	gagaaactgc	180
aatgggaaca	atctttggat	atctacattg	tgtcaaattg	tatgtgcttt	atttcatttt	240
catacttata	acagctgtat	atcacagttt	ttattatcca	cattatagag	gcaaggcact	300
gatatcagga	acttgagtaa	ttggcttaca	cagcaantgt	agttgaaata	gaagccagga	360
ctgtctgatt	ccaagacag	tgctcttgta	ctgcaggtaa	gcctgggtgt	gctgggkttc	420
cctagcactg	agtattgcag	aaatacggag	atttatttac	tcagggtgaat	gatgaagcag	480
aatctttatt	tngcttttta	aattatkgat	gggkckkgag	ttaagctagt	tcaccaatga	540
gtctcaaagg	gtgaagaact	ggcctgtgta	gttttaaaac	aaagcagcag	ttttcttcat	600
ttgtagatat	tatatattaat	ttaccttgca	tttccaatag	cattaaatat	tagaagcgta	660
taagcttttt	ctttttatgc	ctaggggata	tggcttaaca	ctgagaaaaca	cttgagaaac	720
actgccacat	tctaagggaac	aaccaataat	aagaaaaatt	atttcatata	aaaggatgca	780

```

gcttgcatat aaaatgctga attcaactga agttcattat gctgccttta tgtgagctca      840
gggggtgacct tcatgctctg gactcttaaa ggatccagtg tcggatacag ctctgccatt      900
ggagcaatgt gttccataac taggggtgcc taagtatatc ccttcttctg ktatctatag      960
tttttcttta aagggtgtgct tttaaaca tgatgttatt tcatatacmt atatatatat      1020
atgcacacat acatatacmt catgcatgka tcatatatgt gtgtgtatgt atgtatctat      1080
cttcaatctt tcaggaaagt ttgtaaaawa tagccctaag tagaattatg gggaaacagt      1140
tgcagaactg ctgaaattgg ctgagatgaa aaggaaagag caaaaatcta ggttattcac      1200
aggaagttag tccagctgtg ttttgcgagg catgaaccag gctgaatcag agcaagaaca      1260
ggttgcaate ttaggtcaca tggcaattaa attccagcta tagaatattg aagacatgta      1320
agtgttaaat ttaaggatta ttcaatgcag tgaataaatt tatatcattc ccaaaagtat      1380
gcacatcaga taatgagtta actgcatgta acttgaaaac cttaaattat taactgaaag      1440
gattttgtgc atagaaagat gtcttagtca atgtaaaaat gccagtgatt tgtgtagcat      1500
gtcctttgct aaaagtcatt atataaactg aagtcactta tctttgtttc caatgtgata      1560
atattccaca tttaacaggt gataattatt gaaaatatta gtttgcctca ctaatattgt      1620
gtccgagata ttctagttaa aaccaagtaa ctaatactgt aaaagaagta ttctttttat      1680
gaagccagca ttatcctgat actagaactg ggaagagaca cacacaaaaa gaaaacttca      1740
ggccaatatc gctgatgaac atcaatgtga aaatcttcaa taaaatactg gcaaaccgaa      1800
tccagcagca tgaggcgggt ggatcacaa gtcaggagat cgagaccatc ctggctaaca      1860
tggtgaaacc ccatctctac taaaaataca aaaaattagc cgggcatggt gatgggcacc      1920
tgtagtccca gctactgggg aggctgaggg aggagaatgg cgtgaacctg ggaggcggaa      1980
cttacagtga gccgagattg caccactgca ctccagcctg ggtgacagag caagactctg      2040
tctcaaaaaa aaaaaaaaaa aaaaaaaaaa aactcgta      2078

```

```

<210> 62
<211> 762
<212> DNA
<213> Homo sapiens

<220>
<221> SITE
<222> (10)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (12)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (42)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (219)
<223> n equals a,t,g, or c

<220>
<221> SITE
<222> (747)
<223> n equals a,t,g, or c

```

```

<400> 62
cgagtcagtn ancagaaaag cggaagagcg cccaatcgca anccgcctct ccccgcgcggt      60
tgcccgatcc attaatgcag ctggcacgac aggtttcccg actgaaaagc ggccagttag      120
cgcaacgcaa ttaatgtgag ttagctcact cattaggcac cccaggcttt acactttatg      180
cttccggctc gtatgttgtg tggaaattgt agcggatanc aatttcacac aggaaacagc      240

```

tatgaccatg attacgcca	gctcgaaatt aaccctcact	aaagggamca aaagctggag	300
ctccaccgcg gtggcgccg	ctctagaact agtggatccc	ccgggctgca ggaattcggc	360
acgagcacia atgcctatac	aaaacttttt tccatgtcct	caatactttg taccagatta	420
tttatatttc tcatggtttg	gtttcttttt cttgtcttca	ttttcttgaa ggtaaaagg	480
gattttttcc ccccttttct	gatctgtaac ttgttttgta	tttggatgat tacaggcgtg	540
agccaccgcc tccagccaca	aatacttttt agtcgccata	agcataatca agaaatcatt	600
ttgcaaatgg taagcttttc	atgttggtga ttctttccca	tgattagaga ggtaaaaagt	660
gsccctgggat gcataaagat	gtcgtagacm tmtgcaatct	gccacattat ttctttaaaa	720
aaaaaaaaa	aaaactcgag ggggggnacg	gaacccaggg cg	762

&lt;210&gt; 63

&lt;211&gt; 1094

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 63

tcggcacgag gtcaatcaag	tgaatatca tgtaaactgt	ccagcagctt tgaaagtaga	60
gaatgaacaa ggcccccttc	ccacccaccc tgtggaaagc	ccgtctgggt tggtgtctc	120
ctggacacg tcttgccggt	cacctttggc catctcccgg	tgctgtgttc agatgtgggt	180
cctgttttcc tgccccctcc	ctcctctgtg cctgcctgcc	tctgtgtgtc cgggccagt	240
ccttggtggc cagtggagtg	gacaccagct ggcactgctg	gggaggggct ggcattgccg	300
ctgccactgc agggcttggg	cggctgacat gggacgaggc	ttgcacagct gccagctcct	360
gtctcgctga ctttttttat	acagttttgt ctgggccacc	gccttcagtg ccacgggccc	420
cttgccgttc aggctgctcc	tcatagatga acaaggccct	gccccgtgtc cttacccttt	480
agagctgttt aaattcaaat	gaactgaaac tgaatatgaa	aaatccaggc cctcagccgc	540
ccaggccatg tttcaagtgc	tccatggcca catgtggctg	gtggacagtg cagctctaga	600
acattccatc accacagagg	gttctgtctg acagtggcct	tgggggctgt tttgagggtc	660
cgctgtcag tctcctggca	tcaaagtcac tctgccattg	tcaagttaca gttattttcc	720
ttttacctcc aagccactat	gtgcgtatgc tgctatgtgt	ctgtatttcc cgctaaactt	780
cctgtcacgg aggggaagg	gccacagggc cagctcctgg	aggggggttg gatgtctggg	840
tggggggaag ggtgccacag	gccagctcc cggagggggg	ttggatgtct ggggtggggc	900
caggggcgcca cagtccagc	tcccgagggg gggttgatg	tctgggcggg gctttcttca	960
tgttccatgt atgataacgg	tgactggggg gtttacagag	agaggcatac aaatagtgtt	1020
ggagtgttgt tttcgcta	ataaatgttt gaatagctaa	aaaaaaaaaa aaaaaactcg	1080
agggggggcc cgggt			1094

&lt;210&gt; 64

&lt;211&gt; 1361

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 64

cccgggtcga cccacgcgtc	cgaatttctt tagtgtattt	tatgtacttt tgtattaatt	60
acattgggta gactgttcca	taaatgttga atagatccta	tttgttgggt aatgctattg	120
ttgtgtatcc tgctgatttt	ctgtgtagtt ggtctatcag	ttgttgggag aagagtgttg	180
aagtctacaa ctataattgt	gtatttgtct attactcctt	tcagtctctt cagtccatt	240
tcacatattt tccagctctt	gattggtgca cattaatgat	tactatgtct tcttggtgaa	300
tagaccattt tataatttta	tgatgtacct ctctgtcac	tttctttgct ctgaagtcta	360
cctgatatta atatagtcac	tctagctttc tttggagtaa	tgttagtgtg atatactttt	420
tttctgcttt ttacttttaa	ccctatctat atcattatat	tattttaagt gagttttttg	480
tagatagcac ttacttgtgt	ctgtcatgtt tttaaatcca	ctgtacaagt acaaatctgt	540
ctttattttt catttttata	cttattttga gacagagtct	cactttgaca ctcagcctag	600
aatgcagtgg tgtgatctcg	gctcactgca acctctgcct	ccgaggggtc agcaatcctt	660
tcacctcagc ctccaagta	gctgggacta caggcatgaa	ccaccatgcc tggctaattt	720
tttttttttt tttttttgta	gagatgggga ttaccatgt	tgctgaggct ggccctgaac	780
ccctgggctc aaacgacctg	cccagctcag cctcccagag	aaatatgatt ttaattagca	840
catttagatc atttactttc	aatggaatta ttgatgtatt	acaattcaag tctgtcattt	900

tatttattgc cttccatttt tccctccggt tttcatttct gtgctttttt tctttgcatg	960
taaacaatggt ttaggattct gttttgatgt atttagagta ttttttagtg tatcggttta	1020
tgtagctttt ctagtggatc ctttaagtat tacattatat atacataact aagaagtata	1080
tcagtgtcat cattttacca gttcaagtaa agtacagaaa tctttgtccc ttttacctgt	1140
cctgcttata atgtaaatgt cttaaagatt tccttgacac acatttagaa ccataatcaca	1200
gtgtgttttt tgcttcagtt gtgaaatata atttagaac tcatgagaat aaaaacccat	1260
tatattttatt tataaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa	1320
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa agggcgggccg c	1361

<210> 65  
 <211> 947  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (67)  
 <223> n equals a,t,g, or c

<400> 65	
ctttctatag ttaaagccgg tacgcctgca ggtaccggtc cggaattccc gggtcgaccc	60
acgcgtncgg tttctgggtt ctaggccctg ctctccttgc cctttgctgc agaagggcag	120
ctgaaggctc accctagaaa ccgggacctg tgggtcttac ccggctcact cctcccttg	180
tccttacaca tacaggaaga caagacctga gtgggtgctgt ctttggtgcc gtcgtgtatg	240
gctctccctg tcttcatttc ttctcactct gtctctaaac ctctctctct ctcccttccc	300
cctcagtact tartctacag acctatgtgc gtgtycctat ccttctgtcc ttttctctct	360
tcagctctcc ctgcctctca cacacaattt tacatgcccc gaggagccaa gtttgggaca	420
tttaccctcc aggcattctgt gtccctctct gaagagaaaa cacacagctt cacacatcca	480
ggcatagggg gcaagctctt ggggcatcag gaccctggag caccaggctc ttcctggaat	540
attagatcca cctggagcac cagggtctctc taagtctcac ctgggggaatt cgggtcccacc	600
tgggtcacca gttcccacct agagcactgt gtccctgcct agagcacaaa gacctgctcc	660
tcccgagact ctctctgact gcagccaggc atagtacct tgcctgtgtt tgctccctgg	720
tccacagatt tgggtggctgg gcagggtcct ggacagtgat gaggtcttgc cgccttaact	780
gtccccccca gtcacttctc ccacaggccc agcaggacgc agtcctgagg atcagggatt	840
ctacagctgc attaaaatca atcctatcca aaaaaaaaaa aaaaagggcg gccgctctag	900
aggatccaag cttacgtacg cgtgcatgcg acatcaagct ctgaaga	947

<210> 66  
 <211> 1376  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (18)  
 <223> n equals a,t,g, or c

<400> 66	
ggcggggcggc gcggaagngg cggckgcgcg gccggggcag ccatgtcgcc attgtctgcg	60
gcgcggggcgg ccctgcgggt ctacgcggta ggcgcgcgcg tgatcctggc gcagctgctg	120
cggcgctgcc gcgggggctt cctggagcca gtttcccc caccacctga ccgtgtcgct	180
atagtgcagg gagggacaga tggcattggc tattctacag cgaagcatct ggcgagactt	240
ggcatgcatg ttatcatagc tggaaataat gacagcaaag ccaaacaagt tgtaagcaaa	300
ataaaagaag aaaccttgaa cgacaaagtg gaatttttat actgtgactt ggcttccatg	360
acttccatcc ggcagtttgt gcagaagttc aagatgaaga agattcctct ccatgtcctg	420
atcaacaatg ctgggggtgat gatggctcct cagaggaaaa ccagagatgg attcgaagaa	480
catttcggcc tgaactacct agggcacttc ctgctgacca accttctctt ggatacgctg	540

aaagagtctg	ggccccctgg	ccacagtgcg	aggggtggta	ccgtctcctc	tgccacccat	600
tacgtcgctg	agctgaacat	ggatgacctt	cagagcagtg	cctgctactc	accccacgca	660
gcctacgccc	agagcaagct	ggcccttgct	ctgttcacct	accacctcca	gcggctgctg	720
gcggctgagg	gaagccacgt	gaccgccaac	gtgggtggacc	ccgggggtgg	caacacggac	780
stctacaagc	acgtgttctg	ggccacccgt	ctggcggaaga	agcttctcgg	ctggttgctt	840
ttcaagaccc	ccgatgaagg	agcgtggact	tccatctacg	cagcagtcac	cccagagctg	900
gaaggagtgt	gtggccgtta	cctatacaac	gagaaagaga	ccaagtccct	ccacgtcacc	960
tacaaccaga	aactgcagca	gcagctgtgg	tctaagagtt	gtgagatgac	tggggtcctt	1020
gatgtgaccc	tgtgatatcc	tgtctcagga	tagctgctgc	ccaagaaac	acattgcacc	1080
tgccaatagc	ttgtgggtct	gtgaagactg	cggtgtttga	gtttctcaca	cccacctsc	1140
cacagggctc	tgtcctctag	ttttgagaca	gctgcctcaa	cctctgcaga	acttcaagaa	1200
gccaaataaa	cattttggag	gataatcacc	ccaagtggtc	ttcaaccata	aactttgtga	1260
ttccaaagtg	cccagttgtc	acaggtgcc	taaataatta	cattttccaa	cataaaaaaa	1320
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaagggc	ggccgc	1376

&lt;210&gt; 67

&lt;211&gt; 2434

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (10)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (12)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (27)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (73)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (75)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (103)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (130)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 67

ctgggggtan	tncaagaacc	ctctgtngga	cttagatgtc	aagctctttc	ctttgggcag	60
cgtgtttcct	ttntncgagt	agtgtgctgt	gtaaactaaa	ttngccggtt	cgctttccat	120

ttcctgacan	ttgagatgga	atgccttgac	cattggtgct	ctgacagaga	agtcattggag	180
tcattgccat	ttcctgggtg	cccttttgga	atgtgatcct	gttagtagag	gttttctagc	240
ttctactaag	atattttctt	ccctaaccat	catacacttg	gcatgtttca	ttccccatctc	300
ctttccctc	accttaaagg	agactacccc	tttgcccat	attgtcaacc	taattttctc	360
tcgtactctc	tctagtgaat	gatgtgctac	caagtatatg	ccaggctgtg	agaggattat	420
actgagtagt	agaaagaagc	taatttgaaa	taaaaattat	ttgtataatt	aagaaagcag	480
attagatgca	catggtcaac	aggaagttag	ctgtatgtct	gctagttaga	ttcaaaacat	540
cataaagatg	atagcatgtc	aataatattag	cctagccatt	atgttagcct	ttgttaggtg	600
ggcagctttt	ctgctttttc	ccttctcttg	tggtgacaac	ggaggaaata	tccaacagaa	660
atacgtctaa	cagggaaatt	gggatcatag	tttatatgca	tctgatttga	aaggagtatt	720
gaggaaggtt	ttcatatatg	atctatcttt	ggattaaaaa	gaacatttat	gaaatcaagc	780
cttctaacac	tagttataat	tgagaagcaa	cagtaactcc	gtggacagca	atcaagctta	840
aaattgtaaa	taaatatggg	gataattcag	ttgttgcaaa	aaaagggcag	aattcagtag	900
aataaagtc	ttttctctta	cagggtattaa	atgaggacag	agaacctcag	gtgttcttat	960
gctagtgtct	gctgagtgc	tactaagaaa	gcaattccaa	atagatgtat	acatctagag	1020
agagtgggtat	tagagattca	gtgtatgtat	ttatttacat	gagaggaaac	tggaatataa	1080
tcccataaat	tattggaata	taatcccata	aattatcacc	ttttatgact	ggaaaatatt	1140
tgccaatgaa	gaaatgggtct	gtaggtat	gtcttaagat	ttttggctgt	tttaataaaaa	1200
tgtaacttta	acggtttctt	atagttgcct	ttataaagt	tattgtctaa	aatatttttg	1260
tatcatgtgc	ctttgaaatt	tgacagctga	tttgggtgtt	ggatttctgc	ccagccattt	1320
atcagtatta	tcattttatt	cagtagctgg	cagggtgtatt	agacaaacga	gacttaggta	1380
aggaatggaa	cctttcctgt	ggtttgactg	cacatcacac	cagaagactc	cagtatccct	1440
cattccagaa	tgaggaaaaa	gtattctaca	aagaacctaa	tcacctctgt	gaaatctatg	1500
ggatggaaac	agtgtggcct	taggagtcaa	atagtctctg	catggtgggg	aggatcatga	1560
tggaatatgt	gaatttctac	ttctagaagt	tgtgaaatag	gtcctgcact	tttgcagaat	1620
gtccttcttt	aaacctggct	tattccacag	ctgtagctga	taacatgacc	tggggcttag	1680
ctgctctagc	cctgggttct	tgagacctc	acactgcctg	gcccctggcc	atccacctaa	1740
ggactgcctg	ctttctggtc	acatgtggac	cttgatacga	ctaagcgggt	acatatgtgg	1800
ttgtgcaaaa	gctttctgtt	taatgcatag	tgttaccgat	ttacatcttg	gttttcagtg	1860
gcactatgtc	taggaggcaa	tatcctttta	aacagtgtct	tggttaagat	agatacttgt	1920
gaatcaaaaga	tagcacagaa	atgaactaag	tatatcccat	ttggaattat	attttgatac	1980
tatttaaaat	ggtttcacct	gttaaagggc	caacagaact	cttgggttta	cttttgtaat	2040
tactgtacag	aaaatttcaa	gagtgtttga	gtgcttgtca	tcagggtgtt	tccttaataa	2100
gtagggatat	gatcatttac	aggaattata	tatgaaaaaa	gtttttgaaa	tgtatttttg	2160
tgatgtgcta	tgttgagggg	aaaccaaata	tttatgat	taaaacattc	gtatgaaaac	2220
attgtacaat	gtaatatgct	caactttctc	aattttttgc	taatttttct	aagatacatt	2280
aaaaatgttt	tatatttttt	tttaagttaa	atggaccag	taagaaaatt	aaaaatacca	2340
gaacataaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2400
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaa			2434

&lt;210&gt; 68

&lt;211&gt; 1086

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (10)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (77)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1056)



<223> n equals a,t,g, or c

<400> 68

ttgaaacacn cttttgagca ttaggtccca gctccaccgc ggtggcggcc gctctagaac	60
tagtggatcc cccgggntgc akkaattcgg caccgagcaac ctgtagtgag ttggctgtca	120
ctcagcagct ctggaaaatt acctgtctgc actgaatttc ctcatcagta aaatggaaat	180
gattatagta ctgaccttgt aggattattc taaaaatcag agaagttcat gcagcttaga	240
acagtgccag gcacatggca aatgctatgg catacttaag catcttcctc tgtggtgcct	300
cgtcatcacc atgtgattgt gccttgcttg tccctgtttc acttttcaga gggagaaaag	360
tggccaactt taagaatcaa aattctgatg ttacttcggg aaatgcatag agccagagag	420
acacaatttg acttagtatg atccacatca tcccctcagg ctgaatagtg gtggcatgca	480
catctatacc aaaatgtttt accttttttg tagaaggaaa atatttgtat cttctattcc	540
atatcttaga tctttataag agcacttaag ttcaacctcc taagaaactg ccaattttgt	600
tgatcatgat agtctgcaca gattttcgta ctatttagtg ktgggagtg cttagggacc	660
atcaacaaca ggscctcctc tttatccatg agactactga ggccttgagg gttatttgct	720
catccatggc ggggtgcacrg ctgagggtta tctggttagt agcccaacta agattagaac	780
ccaggaattt tgatttaatc tcaaatgacc tcttttattt ctgcatccgg gaaggagaag	840
aggaaagtaa acgggaaatt catgttatct atggaaaagt tatcagtttg atgtttatta	900
aatgatttgt ttcaggagat tgtttacaac ttttatcttc ctagacaata attttctgta	960
agagtaaagt catggtcatt aaggtagtca tattaatgta ttcagtaasc tgtgaagaaa	1020
aatatatatc aatgttttcc aataaaatc agtgantacc tgaaaaaaa aaaaaaaaaa	1080
aaaaaa	1086

<210> 69

<211> 1262

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (568)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (639)

<223> n equals a,t,g, or c

<400> 69

cctyctatag gkmaagctgg tackcctgca ggtaccgggc cggaattccc gggtcgaccc	60
acgcgtccgc ttacaacttc tctyttgttt ctgtgtttct tccacacccat tatggcgtat	120
ttactgatct acaaccggtt ttaagttagt tgcctgctta aaattttctc atgaattctc	180
attacatttt caaacaaaat ccaaagtttt taccatgacc ttgtggatat cttcttgacc	240
tcatttacta ctgttatctt ccttattcat tccattccac ccacagtggc cttcttgcaa	300
gtcagagaat gcaacaaata tgcctctgcc ttggggcatt tgcacttctg ttcctttggc	360
ctggtcactt cacctccaca ttctccattt tttatgactt tcttcctata tttggatctc	420
tgttcaaattg tcaccctcctc aaaaggcctt caaaactacc ctatttataa tagcacctgc	480
cactgccatc tccataccca ttttcatttt tccatagcac ttatccctac ttggcattat	540
gttatatat tgtttatttg kttactgnct gtctccccc ctggactgta agctccatga	600
ctgtaagtac atagatgaat tacaaaatga atcaatggng aawtatcctt gmcatatat	660
atttaagtat tttgmctcca ttttaagtaa aaaaaaata ccattttttt cactcttcaa	720
agtgatatag tttaatcttc taaactacat ttttctcatt tcccgattta attaaatcag	780
tgatataaaa aaaagagtga tggggatatg tgaaagaaga ctaaaataga tgccaggaaa	840
tactaaaact gctgaagttt agtggtatat tttttcttta cacacagtat tatttgagtt	900
actaattgtg tcactgaatt acagaataag caaaaacta ggtaaacaga atcacgcttg	960
ggggctatat tttgtgtaaa atttgtgtta tgcaaaaata atattaaata ttttaattct	1020
acagttttgt tatttctttc ttatttttagg aaatgatttg cagctgagtg aatcaggaag	1080
tgacagtgat gactgaagaa atatyttagct ataaataaaa atttatacag catgtataat	1140

ttatttttga ttaacaataa aaatttcctaa gactgagggg aatatgtctt aactttttgat 1200  
gataaaagaa attaaatttg attcagaaat ttcaaaaaaa aaaaaaaaaa aaggggcggcc 1260  
gc 1262

<210> 70  
<211> 1642  
<212> DNA  
<213> Homo sapiens

<400> 70  
ggcgcgctgc ccggarctgc ctgggttgcg ctgccggcca cgtccccgcg ccggggcctca 60  
ggctccttcc tactgtccga gggccaccag gccgcggggg gcctgctgcg cccgggatgcg 120  
tctgttacta gagtggagag tctaccttcg tctcacatgt gccacaaagg atggcatggc 180  
ccgggagtgcc cccaccacgt ggctttcacc ccctgcaaag ccagacttcg cccagcgaca 240  
cagtgtcaag cccacagctc tccaaggagg aagatgggtcc aggctgggag catcycctta 300  
gcagcagcct ctgacccctt ggccaagcag gagggaacca ttagcagcct gaggagctgg 360  
ctggctggga gcctcgggga ccgcccagcc ttgctcccag ctccccaca agatgtggac 420  
agctcttggt ctcatttgga ttttytctt gtccttatct gaaagccatg cggcatccaa 480  
cgatccacgc aactttgtcc ctaacaaaat gtggaaggga ttagtcaaga ggaatgcac 540  
tgtggaaca gttgataata aaacgtctga ggatgtaacc atggcagcag cttctcctgt 600  
cacattgacc aaagggattc ggcagcccam ctcaactcta tggaagtcac aacagaggac 660  
acaagcagga cagatgtgag tgaaccagca acttcaggag gtgcagctga tgggtgtgacc 720  
tccattgctc ccacggctgt ggcctccagt acgactgcgg cctccattac gactgcggcc 780  
tccagtatga ctgtggcctc cagtgtctcc acgactgcag cctccagtac aactgtggcc 840  
tccattgctc ccacgactac agcctccagt atgactgcgg cctccagcac tcccatgaca 900  
cttgcactcc ccgcgcccac gtccacttyc acagggcgga ccccgccac taccgccact 960  
gggcatccat ctctcagcac agcctcgcga caagtgccaa agagcagcgc gttgccaaaga 1020  
acagcaaccc tggccacatt ggccacacgt gctcagactg tagcgaccac agcaaacaca 1080  
agcagcccca tgagcactcg tccaagtcct tccaagcaca tgcccagtga caccgcggca 1140  
agccctgtac cccctatgck tccccaaagca caaggtccca ttagccagggt gtcagtggac 1200  
cagcctgtgg ttaacacaac awataaatcc acamccatgc cctcaaacac aaccmcwgag 1260  
cccctcacc aggcctggt agacaaaact ctcttctggt tgggtgctgtt actcgggggtg 1320  
acccttttca tcacagtctt ggttttgttt gccctgcagg cctatgagag ctacaagaag 1380  
aaggactaca cccaggtgga ctacttaatc aacgggatgt atgcggactc agaaatgtga 1440  
ggggggcggg ggcctggcgg gaggcctggc cccttcctcg tcctttcctt ttgcctttga 1500  
gaccaaacca agtgcctcca aattcttttg gtgcaattga ggagatatgc cagatgctta 1560  
aacacattta attgctgtca gattaattcc atgatacta aagagttgct gcttttttca 1620  
taaaaaaaaa aaaaaaaaaa gg 1642

<210> 71  
<211> 921  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (4)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (9)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (11)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (15)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (20)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (901)

<223> n equals a,t,g, or c

<400> 71

gcgnggggna	naggnaagcn	ccccactatt	gggttcaaaa	gctggagctc	caccgcggtg	60
gcggccgctc	tagaactagt	ggatcccccg	ggctgcagga	attcggcacg	aggtctgagc	120
agataagatt	aagggctggg	tctgtgtctca	attaactcct	gtgggcacgg	gggctgggaa	180
gagcaaagtc	agcgggtgct	acagtcagca	ccatgctggg	cctgccgtgg	aagggaggtc	240
tgctcctggg	gctgctgctg	cttctcttag	gctcccagat	cctgctgata	tatgcctggc	300
atttcacga	gcaaagggac	tgtgatgaac	acaatgtcat	ggctcgttac	ctccctgcca	360
cagtggagtt	tgctgtccac	acattcaacc	aacagagcaa	ggactactat	gcctacagac	420
tggggcacat	cttgaattcc	tgggaaggagc	aggtggagtc	caagactgta	ttctcaatgg	480
agctactgct	ggggagaact	aggtgtggga	aatttgaaga	cgacattgac	aactgccatt	540
tccaagaaag	cacagagctg	aacaataactt	tcacctgctt	cttcaccatc	agcaccaggc	600
cctggatgac	tcagttcagc	ctcctgaaca	agacctgctt	ggagggattc	cactgagtga	660
aaccactca	caggcttgct	catgtgctgc	tcccacattc	cgtggacatc	agcactactc	720
tyctgaggac	tcttcagtgg	ctgagcagct	ttggacttgt	ttgttatcct	atthtgcatt	780
tgthtgagat	ctcagatcag	tgthtttagaa	aatccacaca	tcttgagcct	aatcatgtag	840
tgtagatcat	taaacatcag	cattttaaga	aaaaaaaaaa	aaaaaaarct	cgaggggggg	900
nccggtaccc	agggcggaag	a				921

<210> 72

<211> 906

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (34)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (833)

<223> n equals a,t,g, or c

<400> 72

ggaaattctc	cctcactaat	tggaaacaaaa	gctngagctc	caccgcggtg	gcggccgctc	60
tagaactagt	ggatcccccg	ggctgcagga	attcggcacg	aggggaagaga	gaggggaggg	120
tgagcagagg	acaggccggg	agthttccgg	gaacggagga	agagcagtgg	aggctgccag	180
gatgaggctg	ctgtgtggcc	tgtggctgtg	gctctccttg	ctgaaagtcc	tgacggccca	240
gaccccaacc	cccctgccac	tcccgcctcc	gatgcagagc	ttccaaggaa	accagttcca	300
gggggaatgg	ttcgtcctgg	gcctggcggg	caacagcttc	aggccggagc	acagggcgct	360
gctgaacgct	ttcaccgcaa	cttttgagct	aagtgatgat	ggccgctttg	aggtgtggaa	420

tcgatgact	cgaggccagc	actgtgacac	atgggtcttat	gtgctgatac	cggcagccca	480
gcctgggag	ttcactgtgg	accacgggtg	gggcaggagc	tggttgctgc	ctcccgggac	540
gctggaccag	ttcatctgcc	tgggcagagc	tcarggcctc	tcggatgaca	acattgtctt	600
cccagatgtg	actggargtg	ccctggacct	carcagcctg	ccctgggtgg	cagccccagc	660
ctgaccactc	agacagccgc	ggcccccaag	gcctgactct	tcttgtggga	gggcgaggct	720
ggtcacccca	ggccagcgtc	tgttgaagga	tgaagcagct	cctgtccggc	ccagccctgc	780
ctcacagctg	tgcgagctct	gccctcctca	gctctcaaac	ctgaataaat	gcnccaagcc	840
cagaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	ctcgaggggg	ggcccgttac	ccaattcgga	900
agattg						906

<210> 73  
 <211> 680  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (7)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (9)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (15)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (16)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (22)  
 <223> n equals a,t,g, or c

<400> 73	
cactcantng	aacannagct
cnagctccac	cgcggtggcg
gccgctctag	aactagtgga
60	
tccccggggc	tgcaggaatt
cggcacgaga	tatttcgctg
gaccctagaa	aagccaccac
120	
gacctgtggg	ccatgatgct
accccaatgg	ctgctgctgc
tggttccttct	cttcttcttt
180	
ctcttctctc	tcaccagggg
ctcactttct	ccaacaaaat
acaacctttt	ggagctcaag
240	
gagtcttgca	tccggaacca
ggactgcgag	actggctgct
gccaacgtgc	tccagacaat
300	
tgcgagtcgc	actgcgcgga
gaaggggtcc	gagggcagtc
tgtgtcaaac	gcaggtgttc
360	
tttggccagt	atagagcgtg
tccctgcctg	cggaacctga
cttgatatata	ttcaaagaat
420	
gagaaatggc	ttagcatcgc
ctatggccgt	tgtcagaaaa
ttggaaggca	gaagtgggt
480	
aagaaaatgt	tcttctagt
ctccctcctt	cttgtgtsct
cctcctycty	cacctgctct
540	
cctccctacc	cagagctctg
tgkctaccct	gttccccaga
gcctccacca	tgagtggagg
600	
gaagtgggga	gtgattgaaa
ttaaagagctt	tttcaatgaa
aaaaaaaaaa	aaaaaaaaaa
660	
aaactcgagg	gggggcccgg
680	

<210> 74  
 <211> 1633  
 <212> DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 74

```

ggcacgagca tcagtaagta ggagctaggg aagagaaagc atgcaaaagg gcaagaatca      60
ggagaattga tatagtagct ggacagaact ctagatgtgt gtgtgtgaga gaaagagagg      120
caggggagaag gagggaggag ttacccccac gatgacctcc aacttccctt tctgcaccct      180
catcctgggg atagcacagg ctccaggcctg ccttggttgc cctggcgatt ggcctggcct      240
gggctcaggg gtggggggagg ggctgcacca cattaggacc tgccgtactc caatcccatg      300
cagtctctct gctcctgctg ctgctgtcct gggctctggt catgccaggc ttcttgtgtg      360
cctgcgtctg tggccgggtc ctgccaacct gtctagtcct ttcaggcttg aggccttgca      420
ttgctctttc tggctctctc ccctccttcc cgctcccatc ctagcctttt ttgggttccg      480
ggatctgctg acagactttc ttcttgcctg ctgcctgctt acatttcaga agaccctctc      540
ggaactgccc atggctgtgg tccacctgct ggtagcaacg ccctgttacc aaatgctaga      600
taatctgcca ctccccctcg cagccgcaa ctggtgctga gctgccacct gttgtctgtt      660
tccacaccct tgtacactgc attctgcctg tctctctgga cagctgcccc gcagctgcag      720
ctgaggccgt cctgccagca cctaccgcag ccccatgggt ggtcctgtcc agttcctggc      780
gctcccagcc tgccctcatc gctgtactta cagagccaca tctggttgaa tacagagctg      840
gggtagcctg gatgggcccc tggcacactc actcccagag aggcggggcat cctctctctg      900
gacctctagg gaaggcaggt gtctggagcc caataataaa acacagtaat gataatcata      960
gctaattgtt actgagaact taggatgtga taggctcaat gatttaccag aattactcta     1020
tactgcataa ctaccctatc aggtaaagta tattaatata ccctttccca catgaagaaa     1080
ctaaggctaa ccaatagaaa tgaacctgtg taatgtccca tgggcataat tcatggagcc     1140
aggattcaga accaggtgct ttacttcagg gctgaagctc ataaccacta gaccaaagcg     1200
ctcctcctcg gacctctggg gaaggcccag caacatcctc tattgcgtcc aatgacttct     1260
ccctggtctg agatccactg actcacaggg gtagggttaa ggtaaggcc agagtctcag     1320
ctaagctttg gatactttct tctggatttg gagaaggctg gaataactga atttctgctc     1380
atcttcagga gcggcctact agagccacac atttcccagc tctccttgtg tgtttccag     1440
acctttcttc catcgtgtcc tctcccttag gctcctggaa agttttcaga gagaatcacc     1500
cagtggtaac attgttaaac aaaacaggaa aatgggactt gtgtgtatat atgattaaat     1560
tattaattga tggatctacc ttcttagctc gtgccgaatt cgatatcaag cttatcgata     1620
cgtcgacct cga                                     1633

```

&lt;210&gt; 75

&lt;211&gt; 1022

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 75

```

ttcccggtgc gaccacgcg tccgcccacg cgtccggctt ggggccagca ccctgtctca      60
aagatggcaa aatgaggcta gttctggatg agctagctgg tgtgggttcc aacctagga      120
acacactgat gctcaaatcc taaggtgcca agctctaggc cctggaggct ggtagaacag      180
gatctatgcc tggaaatcctg gcagggatc ctgtcaagga cttgtgttta agcctgcttc      240
agggcttcag gctgcttctg ctctgtgtct gccaggctg gctgagcggg tggatgggtg      300
gacagaaggg ctaccaagg attgtggaca tagggtaggc cctggtacca cgggtttcag      360
gctgttatca ctcccttgt aggaacatag ccagaagcag atgagccagg gtagagggtc      420
ggccctcctc ctcatcttcc cttcagtctt aaattgtctc cagcgatggg aagaggccag      480
ggactgtaac ccttgtgctg tgtattctct gagcctctgc tctctctcag ggccaagcag      540
ctcccaagcc ggggccctct cttggccaaa atctgaggag cagtctaggt tacaggcttt      600
ttggtaggta ggttctggct gcctgttaat gcagttaggc cccctgatta ggtacagtga      660
gaaacaagct agaacaacc tggcccagaa gactgtgcac tccagcaaga tccagggatg      720
atagccttgc agggccactg ggagtttgtg cccaagcttc tccctcttct ctccccaggg      780
ggcactggga ctggtccctg cctcatcctc tagcctgggc ctccccaga ggtattaaag      840
agaagtatga ttctctgtc ttcagttctt ttcaggggca tctgcccata agtaccagct      900
tcccaagggg ccccagtc cgtggtgaag cctagcactc atgcagctct tagggaacca      960
aaaaccagca ctgaaataaa gctgaatgac tgactgaaaa aaaaaaaaaa aaaggcgccg     1020
cg

```

<210> 76  
 <211> 1184  
 <212> DNA  
 <213> Homo sapiens

<400> 76  
 agcaaaagggt gaagagagaa aggaagcttt ttctctaaaa atgggtgcagc tatcctctga 60  
 accaattttcc ttcggttttaa tgtacctgta tcttgggggtt tttttccact taatttatcc 120  
 tggagctctt tccataacaa cacttggaag gcaactctcat ccttttttca ctgctgaaca 180  
 gaattccact gtgtggatgg aacatactct atttcaccag tcccctgtag ccagtcactt 240  
 ggtttgtttc caatcttttg ctttttcaga gtaataacct tgtatgtcta tcattttgta 300  
 tgcatacagg tttatatgta ggaaaaattc ctagagtagg attgctggac caatggataa 360  
 aagtatattg tggacagaca atgccaaatt gcctttcaga gactgtggcc ctgtgcacc 420  
 catcaggcat gtgtgactac caaagctcct gtcagctgtt ttattttatc tcctttccag 480  
 tctcaggctc aatgcagaac tttgaggtaa gcttttctaa aatgtaggct cctaaacgcc 540  
 acagccagct ctgccacatg aaggagagct caaatgagac agaaacagcc tctgggcagg 600  
 atttctatcc tgcacagata tattttccac attctgggaa accgtgaagc ttccagagcc 660  
 acaattcccc agaaacacat cccctgtctg gtacagccaa gccccagaa aagctgtgct 720  
 tgcctggcac ctcaaagcca agcaccatgg atgccacttg ccatgggtgc ctgcaatttc 780  
 aaataatgag aaataagaaa tttcagcttc tcagtcctc tagccaacat ttcagggtga 840  
 tgacagcctc aggtggcaag cagctactct gccggacagg gcagaagatg gaacacccca 900  
 tccctgggga agatcacgag gtcaggagat caagaccatc ctggctaaca cagtgaacc 960  
 ccgtctctac tgaaaataca aaacattagc tgggtgtggt ggcaggcacc tgtagtccca 1020  
 gctactcagg aggtgagggc aggagaatgg cgtgaacctg ggaggtggag gttgcagtga 1080  
 gccaaagattg cgccactgca ctccagcctg gcaacagagt aagactccat atcaaaaaaa 1140  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 1184

<210> 77  
 <211> 312  
 <212> DNA  
 <213> Homo sapiens

<400> 77  
 aattcccggg tcgacccacg cgctccgtgat gagtggattt gtactcttac ccaggctctg 60  
 agggccagcc caccagcat cccaccctt gatgacgtg tccctacaac tggctgaact 120  
 ggtgcatttt gtgtgtgctt tccagagcca gtggactggt gtgtatccaa tgatgccacc 180  
 tctgaaacct acagaaccac tatgctttgc atgtgtacct tgcagggtct gagggccagg 240  
 ctgtctggtg gctctgctcc tgggtgacag agcaagactc tgtctcaaaa aaaaaaaaaa 300  
 agggcgggccg ct 312

<210> 78  
 <211> 1370  
 <212> DNA  
 <213> Homo sapiens

<400> 78  
 tggttaaaga gtacgacatt ttagtcaggg ctgagcacag cgcctggccg aggagtgctt 60  
 ttatatgtct ttggaagtat atggggactc catttctgtc actgtggcga ttccacttat 120  
 gcattcacca tgccaatcca aggcagctga tggcttagga aagtcagaga ctgagatggt 180  
 aaaatccttg gggctatcta ccaacatgtc tccattccac ctgttagggg taaagggttt 240  
 tctaacctgg gccctgacct tagcacagat ctgcctatat tttttgaag ttcagccact 300  
 tggactatta gccctaaact ttttctgtac tgccactgca gggctgaagg agctttgcat 360  
 gcatccacca agtctggctt tcacacctga atttcacacc tcgctttcac ccttagctat 420  
 tccatctttc tgtggaacat cagtgtcact tagcaatagc catacaatcc cattatcctt 480  
 atacctacct ttcccttcaa agtctcggat gcctgatata ttgcacctgc tagtgcattc 540  
 actcccatta gtacactccc aagtccttcc agtgaaagat gtaacaattg aatggccact 600  
 gtgccaaagg tgccctgggt ctacctgcca ccagtgtagg ggtcctcaca gccaaaccag 660

tggtgtatca tccatttcca aaaccatctc amtgcctgtt ttcttggacc actcctggca	720
tcaactgttt cagggttagag tgactgaaaa tttgggktat aagatattta ttagagatca	780
atatctatta aaaatgtgaa aggaagcagg attktgctga ggaagaagat aacaacaaag	840
ataccacaat gtcagcccat caaagccttt ggccaaccca gcasaaaaat ctggagcagg	900
tgtayctttt tcagagtctc cccagttagg tcaaaatgtg cgcctttaca cccgcacttc	960
cctcaatcac gggcttcagg ctgtcctggg catgacctca gatgaagcgg ctcacacagc	1020
tgaggctaac gttgtcggag ctgacagctg aaagccgttt gctgaccaca ctcccacagc	1080
cgagcagcat gcccttgctt ggaggaggat ttggatgaca cagctctatg tctgccgtat	1140
tttgggggtc acattcctca caccagctc tgctcaaat ggcaacattg acaaaaattc	1200
attccagttg caaaccaatt gtagaatact ataaaaccag agtacaagtc taatagcata	1260
aatctcatcc taagtggaaa agaaagggtc atttattcac acatttttgg ggaaaaaaaa	1320
acaacctttg ctatgtcttt attacaacac ggatactcac aaaaaatagt	1370

&lt;210&gt; 79

&lt;211&gt; 368

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (5)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (13)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (35)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (351)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (367)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 79

aatgnaactc tcnttactaa ttggaaccaa agctngagct ccaccgcggt ggccggccgct	60
ctagaactag tggatccccc gggctgcagg aattcggcac gaggtccagg tgtctttatt	120
tcagatgttc tgtttttcct ctattttctg ctcacatgaa catacacact tgccaggcac	180
attctggctt ttcttatttc tctttctgat ttgcctcct tccgcccct gttttcttcc	240
cttttctctg gctatagaaa ctgtcagggtg gccttgctgg catcatccta cctcttttga	300
actgtgttac ccaggaactt ccatttatta tgctcagagg gggggcccgg nacccaattc	360
ggaagant	368

&lt;210&gt; 80

&lt;211&gt; 1088

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<220>  
 <221> SITE  
 <222> (1)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (4)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (5)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (9)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (11)  
 <223> n equals a,t,g, or c

<400> 80  
 ntttnnaacng naaatctccc cttactattg ggaacaaaag ctggagctcc accgcggtgg 60  
 cggccgctct agaactagt gatcccccgg gctgcaggaa ttcggcacga gattccccag 120  
 aattgggtca tcttgggaaa ggaaggccta ggaagctgat gacctacttg ttttgttcat 180  
 ccatttctct actgcttctt aaagtgcact caagcgggtca ccaggacatc agaaaagcca 240  
 aatccaaggt cccaaggctc ttgatcatcc agtgcccaca acagagggag taagctagac 300  
 ggagaaagctg aagtgaagga ggaaagagag aaggggggtgc ctgttccacc ccttcctag 360  
 cagctgcctc tgtgggctcc ataatcccca tgccctctcc cccacccac cctccggccg 420  
 mcccactctc ctccaccac cccattcatc agtaggaggg cactgtatca gcacagcctt 480  
 tcaaggcctg acagtccctt tctgggtgcc cccacatgt aaccacttaa ccccagcac 540  
 aaagggccag cctgaatggg cttggagccg gtggtctgtg cgraggggga ggcctcaata 600  
 ggatttgggg agctgggtgt ataaaccgct ctgctccagc agccctcaat ggaggagctg 660  
 gagttggggc atgtgccgag gggaggagct cggcagctgc atcccgscct tgaacaatga 720  
 tttattcatt ctctggcac gcacagagaa gacaggctgg ggaaacatgg cccacaaaat 780  
 cgccctcagc ctgagctgat tcccacggca atcattgcag ttcagagtgc cccctccac 840  
 ttgtaatgtt ttgcctcaag cttgcccttc ctcttcctgg taaggaagta gactacatta 900  
 cgggaggcct taagtagcct taaattcagg caagcatcgt tctttgagtt ggttgcacc 960  
 aaactcaatc tcaactcttc aaagctttct ggccaggttt tcctcacaca cccatagaaa 1020  
 cagatgcaga caaaaaaaaaa aaaaaaaaaa actcgagggg gggcccggaa cccaattcgg 1080  
 aagatttg 1088

<210> 81  
 <211> 1862  
 <212> DNA  
 <213> Homo sapiens

<400> 81  
 ggcacgagct ctgcaaagct ccctctgctc cagcacgtcc tgtatttttt caactttgga 60  
 tgtttgcaca agctattatc ttttgcaga atgtcctgcc cctcctatc catctgtgga 120  
 agtcaacctt tctttagggc ccagaggaaa acctatcacc ttctacacct tcccagatgc 180  
 ccaccatttg ggttaaactc tgcctctctc aggtttgcca tggctttttc cctctcttaa 240  
 agcactggtc ccagcctatg ccattgtgtg tcaccttggc tcctgtctcc tactggctgt 300  
 agatcttttg gargggagga actggggaaat tttcatcctg gggctatggg atagtctta 360



ccctaagta	taaaataagc	aagaatcctt	gaattgaaaa	gtccagtg	cttgatagct	420
tccaacagcc	cctaaagatg	gggtagtcca	ctgctcccta	tataggaagg	aagaggttca	480
cagtctcatg	gatttagcag	ccttcgtagc	ctcaggatct	ttcccaatgt	ccccagttct	540
cctgctgggc	cagctgtggg	ctctgagaat	gtcaggttcc	ctgggctagg	ctggcttatg	600
gggccctccc	tcttgacct	gggtccatgt	gaccaagtgg	ccagccagcg	agagagccct	660
gggtgatgag	catctggaag	tcagcttgct	tgtctgcct	aatcacagcc	ctgggctcta	720
ccctcaagta	ccctactcac	atgggtccaag	agggaaaccac	tcttctgtca	ttccctcccc	780
ttctgctcct	catcctaccc	acccagctgt	tctgggcaag	atcctgtggg	catgatggaa	840
tcttcccttt	tctctaccat	ccatcccttt	gatcacctaa	tcctrcarct	gccctccaac	900
caaggtgttc	tttctatacc	aaaaaatctg	atcaggccat	cactcctctg	tttaaaacca	960
ttcaacggct	accactgcc	ctcaggataa	aaactaaaat	tcttaacagg	atttacaat	1020
tcttcacctg	gcccttttga	gataagagga	tttataatct	tttcaaagcc	aacaagcatc	1080
ctgagacaat	cttaattttt	gcagctgtcc	aagctattta	agattgatga	ggtctgcamt	1140
aagttgttaa	atggtgatta	atttatctgg	cctgaatggc	akgtgaattc	caaggggac	1200
atttttctct	accttccttg	ctgcacattg	ggacacagca	aggccaggac	acccttytta	1260
ggtgactgsg	taaccagggt	cattaaggca	gtcagcgag	agaagaagca	gaaaatgggg	1320
aggagtgtg	taaatgaaat	tgccgataat	accaaaggaa	ccccaagaga	ggttcagctc	1380
cccaacaatt	gcagctttgc	tgcaacatgg	cagggtggga	caggggtagg	tttgatctg	1440
ggctgctttg	cmgtggaagt	gggtttacag	ggcagggaga	ggcttaccat	cactgagcat	1500
ctttaattga	ctttgtcatt	ttastgagaa	cttacaatt	gagctattct	tcattgagtt	1560
atattttgaa	gcagggtcaa	tacataatac	agtcctccct	ctagaatttc	tgtttatgt	1620
ccacgtgatg	cagcttggtc	atttctgaat	tccttttaat	gacaaaaaca	tttggaagga	1680
atgtaaagac	tcaaaaaggg	gatggcatgt	aaactatagt	tggacaata	tgtggccatt	1740
taaaagaagt	gttgtccagg	aggtggaggt	tgcagtgagc	tgagattgca	ccactgcact	1800
ctagccctggg	ccatagaatg	agactccttc	tcaaaaaaaa	aaaagaaaaa	aaaaaactcg	1860
ag						1862

&lt;210&gt; 82

&lt;211&gt; 1618

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 82

ccacgcgtcc	gcaaggagcc	agaggccatg	cagtggctca	gggtccgtga	gtcgcctggg	50
gaggccacag	gacacagggg	caccatgggg	acagccgcc	tgggtccgt	ctgggcagcg	120
ctcctgctct	ttctcctgat	gtgtgagatc	cctatggtgg	agctcacctt	tgacagagct	180
gtggccagcg	actgccaaag	gtgctgtgac	tctgaggacc	ccctggatcc	tgcccatgta	240
tcctcagcct	cttctcccg	ccgccccac	gccctgcctg	agatcagacc	ctacattaat	300
atcaccatcc	tgaagggtga	caaaggggac	ccaggcccaa	tgggcctgcc	agggtagatg	360
ggcaggagg	gtccccaagg	ggagccctgg	cctcagggca	gcaagggtga	caagggggag	420
atgggcagcc	ccggcgcccc	gtgccagaag	cgcttcttcg	ccttctcagt	gggcgcgaag	480
acggccctgc	acagcgccga	ggacttccag	acgctgctct	tcgaaagggt	ctttgtgaac	540
cttgatgggt	gctttgacat	ggcgaccggc	cagtttgctg	ctccctgcg	tggcatctac	600
ttcttcagcc	tcaatgtgca	cagctggaat	tacaaggaga	cgtacgtgca	cattatgcat	660
aaccagaaa	aggctgtcat	cctgtacgag	cagccagcg	agcgcagcat	catgcagagc	720
cagagtgtga	tgctggacct	ggcctacggg	gaccgcgtct	gggtgcggct	cttcaagcgc	780
cagcgcgaga	acgccatcta	cagcaacgac	ttcgacacct	acatcacctt	cagcggccac	840
ctcatcaagg	ccgaggacga	ctgaggccct	ctgggccacc	ctcccggtg	gagagctcag	900
ctgatacggc	atcctgcgag	aagacctgcc	ctcctcaactg	ggateccctt	cctgcctcct	960
cccagggtct	tgccaggggc	ttgctcagtc	ccttccacca	aagtcatctg	aacttccgtt	1020
tcccaggggc	tccagctgcc	ctcagacact	gatgtctgtc	cccagggtgct	ctctgcccc	1080
catgccccct	tcaccggccc	agtccccga	ctctccaggc	tttatcaagg	tgctaaggcc	1140
cgggtgggca	gctcctcgtc	tcagagccct	cctccggcct	ggtgctgcct	ttacaaacac	1200
ctgcaggaga	agggccacgg	aagccccagg	cttttagagc	ctcagcaggt	ctggggagct	1260
agagcaaaag	agggaccta	ggccttccgt	ttcttctcc	aggggtgggt	ggcctgggtg	1320
tcccctagcc	ttccaaaccc	aggtggcctg	cccttctccc	cagagggag	cggcctccgc	1380
ccattgggtg	tcatgcagac	tctggggctg	aggtgccccg	gggggtgac	tctgggtgct	1440
acagtcgagg	gagccgtggc	tccatggcca	gatgacggaa	acagggtctg	accaagtggc	1500

aggaagacct gtgctataaa ccaccctgcc tgatcctgcc cctgcctgac cccgccacgc 1560  
cctgccgtcc agcatgatta aagaatgctg tctcctcttg gaaaaaaaaa aaaaaaaa 1618

<210> 83  
<211> 2034  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (14)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (382)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (1999)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (2027)  
<223> n equals a,t,g, or c

<400> 83  
actcactaag ggancaaaagc tggagctcca ccgcggtggc ggccgctcta gaactagtgg 60  
atcccccggt ctgcaggaat tcggcacgag atctaccggg agakggaytc tgaaagggcc 120  
ccggccagcg tccctgagac gccaacggca gtcactgccc cccattccag ctccctgggat 180  
acgtactatc agccccgtgc cctggagaaa catgctgaca gcactcctggc actggcttca 240  
gtattctggg ccactctctta ttactcctct cccttcgcct tcttctactt gtacaggaaa 300  
ggttacttga gtttgtccaa agtgggtgccg ttttctcact atgctgggac attgctgcta 360  
cttctggcag gtgtggcctg cntccgagge attggccgct ggaccaaccc ccagtaccgg 420  
cagttcatca ccactcttga agcaacacat cggaaccagt cttcagaaaa caagaggcag 480  
cttgccaact acaactttga ctcccgagc tggccagtgc acttccactg ggaagaaccc 540  
agcagccgga aggagtctcg agggggccct tcccgcggg gtgtggccct gcttcgccc 600  
gagccccctgc accggggggac agcagacacc ctccctcaacc ggggttaagaa gctgccttgt 660  
cagatcacca gctacctggg ggccgacacc ctaggggcgc ggatgctgta tccaggctct 720  
gtgtacctgc tgcagaaggc cctcatgcct gtgctgctgc agggccaggc ccgactgggtg 780  
gaagagtgtg atgggcgcgc ggcaaagctg ctggcctgtg atggcaatga gattgacacc 840  
atgtttgtgg accggcgggg gacagctgag cccaggggac agaagctggg gatctgctgt 900  
gaggggaatg ctgggtttta tgaggtgggc tgcgtctcca cggccctgga agctggatat 960  
tcagtctctg gctggaatca tccaggcttt gctggaagca cgggggtgac attcccgcag 1020  
aatgaggcta atgccatgga tgtgggtggc cagtttgcca tccaccgcct rggcttccag 1080  
ccccaggaca tcatcatcta cgcctgggtc atcggcggtc tccactgccac gtgggcagcc 1140  
atgtcctacc cagatgttag tgccatgac ctggatgcct cctttgatga cctgggtgcc 1200  
ttggccttga aggtcatgcc agacagctgg aggggcctgg tgaccaggac cgtgaggcag 1260  
catctcaatc taaacaacgc ggagcagctg tgcagatacc agggctcctgt actgctgac 1320  
cggagaacca aggatgagat catcaccacc acggttcctg aggacatcat gtccaaccga 1380  
ggcaatgacc tcctgctgaa gctcctgcag catcggtatc cccgggtgat ggcagaggag 1440  
ggtcttcgag tgggtaggca gtggttggag gctcctcac agctggagga agcctcaatt 1500  
tatagccgat gggaggtgga agaggactgg tgtctgtctg tcctccgctc ctaccaggca 1560  
gaacacgggc ccgacttccc ctggagcgtg ggggaggaca tgagtgcaga tggacggcg 1620  
cagctggctt tgtttctggc tcggaagcat ctgcacaact ttgagggcac tccactgcacc 1680  
ccactcccag ccagaaactt ccagatgccc tggcacctct agggaccaac tgggactcat 1740

tatggaagaa	tggggtgaga	ggagacatga	ggaaagacc	tcttatttgt	gattctctgt	1800
gttcatgttg	ctgtttatag	tttgtggaaa	gtgggggacc	atcccccttc	tcaccactgt	1860
tcctcttgca	cgtttccct	cattcatgtg	gctgtactta	accttctcca	acatacatcc	1920
tgcattacat	gaatggatta	ttcctaataa	ttaataaaaa	ggtatttttt	ctacaaaaaa	1980
aaaaaaaaa	aaactccana	attacttcct	aaaaccggcc	cgcggnccc	atcc	2034

&lt;210&gt; 84

&lt;211&gt; 2240

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 84

tcgaccacgc	gtccgcttcc	tcattgctgcc	cgctcgccta	ccgttcaggc	tgtctgagcct	60
tttcccttct	ggatccgctc	ccacggcagc	gcgccatggc	ctccgggagc	cgctccttga	120
gaggaggtgc	gctgccgcct	cctcccttcca	gcactcatcg	agtctgggac	gcgagcttcc	180
ttatgacccc	gtggacacgg	agggcttttg	agaaggtggt	gacatgcagg	agcgttttct	240
gttcccggag	tacatcctgg	atccggagcc	gcaacccacc	cgcgaaaagc	agctgcagga	300
gctccagcaa	cagcaggagg	aggaggagcg	acagaggcag	cagcggcggg	aggagcggcg	360
acagcaaaaac	ctacggggcca	ggtcccggga	gcacccggtc	gtggggcacc	cggaccggcg	420
attgccgccc	agcggcgctga	actgctcggg	ctgcggggca	gagctgcact	gccaggacgc	480
cggagtggcc	ggctacctgc	cccagagaga	gttccctccg	acggcggagg	cagacggcgg	540
gctggcacgg	accgtgtgcc	agcgtgtctg	gctgctgtcg	caccaccggc	gcgctctacg	600
cctgcaggtg	agccgcgagc	agtacctgga	gctggtgagc	gccgcgttgc	ggcggcccgg	660
cccctccctg	gtgctctaca	tggtggacct	gctggacctg	cccgcgccc	tgctgcccga	720
cttgcgcccg	ctggtggggc	ccaagcagct	gatcgtgctg	ggaaacaaag	tggacctcct	780
gccccaggat	gctcctggct	accggcagag	gctgcgggag	cgactgtggg	aggactgtgc	840
ccgcgcgggg	ctcctgctgg	cccctggcca	ccaaggggcca	cagcgcggcg	tcaaggacga	900
gccacaggac	ggggagaatc	cgaatccgcc	gaactgggtc	cgcacagtgg	tcaggagcgt	960
gcggctgata	agcgccaaga	ccggctatgg	agtggaaagag	ttgatctctg	cccttcagcg	1020
ctcctggcgc	taccgtgggg	acgtctactt	agtgggcggc	accaacgcgg	gcaaattccac	1080
tctctttaac	acgctcctgg	agtcggatta	ctgcactgcc	aagggtcccg	acgccactga	1140
cagagccacc	atctccccct	ggccagggtac	tacattaaac	cttctgaagt	ttcctatttg	1200
caaccacaact	ccttacagaa	tgtttaaaag	gcatcaaaga	cttaaaaaag	attcaactca	1260
agctgaagaa	gatcttagtg	agcaagaaca	aaatcagctt	aatgtcctca	aaaagcatgg	1320
ttatgtcgta	ggaagagttg	gaaggacatt	cttgatttca	gaagaacaga	aggataacat	1380
tcctctttgag	tttgatgctg	attcacttgc	ctttgacatg	gaaaatgacc	ctgttatggg	1440
tacacacaaa	tcacacaaa	aagtagaatt	gactgcacaa	gatgtgaaag	atgccactg	1500
gttttatgac	acccttgga	ttacaaaaga	aaattgtatt	ttaaatcttc	taacagaaaa	1560
agaagttaa	attgttttgc	caacacagtc	cattgtttcca	agaacttttg	tgcttaaac	1620
aggaatggtt	ctgttttttg	gtgctatagg	ccgcatagat	ttcctgcagg	gaaatcagtc	1680
agcttggttt	acagtctgtg	cttccaacat	cctccctgtg	catatcacct	ccttggacag	1740
ggcagacgct	ctgtatcaga	agcatgcagg	tcatacggtta	ctccagattc	caatgggtgg	1800
aaaagaacga	atggcaggat	ttcctcctct	tggtgctgaa	gacattatgt	taaaagaagg	1860
actgggggca	tctgaagcag	tgcccgacat	caagttttcc	tctgcagggt	gggtttcagt	1920
aacaccta	tttaaggaca	gactgcattc	ccgaggctat	acacctgaag	gaacagtttt	1980
gaccgtccgg	ccccctctct	tgccatatat	tggttaacatc	aaaggacagc	gcatcaagaa	2040
aagtgtggcc	tataaaacca	agaagcctcc	ttcccttatg	tacaacgtga	ggaagaagaa	2100
aggaaaagata	aatgtatgag	accgaccttg	ttcactccag	atattaactg	tattgaacac	2160
aacaaaatac	attgaatttg	tattaaacat	ataacgcata	aataaagctc	ccattcttac	2220
ccttaaaaaa	aaaaaaaaaa					2240

&lt;210&gt; 85

&lt;211&gt; 1488

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 85

cgccaagttt	ccggagggag	agggtagaaa	ctggaggggg	tggacctgtc	actcacggga	60
ctgaggggtcc	ttttctccc	ctcccaggag	gaacgagaat	gaatatgact	caagccggg	120
ttctgggtggc	tgcagtgggtg	gggttgggtg	ctgtcctgct	ctacgcctcc	atccacaaga	180
ttgaggagggg	ccatctggct	gtgtactaca	ggggaggagc	tttactaact	agccccagtg	240
gaccaggcta	tcatatcatg	ttgcctttca	ttactacgtt	cagatctgtg	cagacaacac	300
tacaaactga	tgaagttaa	aatgtgcctt	gtggaacaag	tgggtggggc	atgatctata	360
ttgaccgaat	agaagtgggt	aatatgttgg	ctccttatgc	agtgtttgat	atcgtgagga	420
actatactgc	agattatgac	aagaccttaa	tcttcaataa	aatccaccat	gagctgaacc	480
agtctcgcag	tgccacaca	cttcaggaag	tttacctga	attgtttgat	caaatagatg	540
aaaacctgaa	gcaagctctg	cagaaagact	taaacctcat	ggccccaggt	ctcactatac	600
aggctgtgcg	tgttacaaaa	cccaaatcc	cagaagccat	aagaagaaat	tttgagttaa	660
tggaggtga	gaagacaaaa	ctccttatag	ctgcacagaa	acaaaaggtt	gtggaaaaag	720
aagctgagac	agagagga	aaggcagtta	tagaagcaga	gaagattgca	caagtggcaa	780
aaattcgggt	tcagcagaaa	gtgatggaaa	aagaaactga	aaagcgcat	tctgaaatcg	840
aagatgctgc	attcctggcc	cgagagaaa	cgaaagcaga	tgctgaatat	tatgtgcac	900
acaaatatgc	cacctcaaac	aagcacaagt	tgaccccgga	atatctggag	ctcaaaaagt	960
accaggccat	tgcttctaac	agtaagatct	attttggcag	caacatccct	aacatgttcg	1020
tggactcctc	atgtgctttg	aaatatccag	atattaggac	tggagagaaa	agctcactcc	1080
cctctaagga	ggctcttgaa	ccctctggag	agaacgtcat	ccaaaacaaa	gagagcacag	1140
gttgatgcaa	gaggtggaaa	tgttctccat	atcaagatgt	ggcccaagg	gttaagtggg	1200
aacaatcatt	atacggactc	ttcagattta	cagagaactt	acacttcac	tgttccacct	1260
ctcctgcgat	agtctgggt	gtccactga	ttggaggata	gagccagctg	tctgacacac	1320
aaatggctct	ttcagccaca	gtcttatcaa	gtatcctata	tgtattcctt	tctaaactgc	1380
tactcatgaa	tgaggaaa	ctgatgctaa	gatactgcct	gcactggaat	gttaaacact	1440
aaatatataa	caagctgtgt	tttcctaagc	tgaaaaaaaa	aaaaaaaa		1488

&lt;210&gt; 86

&lt;211&gt; 3174

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 86

gcggacgctg	grcscaaaca	ctaaggcctg	agcggtgaca	atcgaggcga	gatgatggtc	60
aacaggggaat	gcctcgtggg	agaaaaaaga	caattttatt	ctcagcgctg	attttgagat	120
gatgggcttg	ggaaacgggc	gtcgcagcat	gaagtcgccc	ccctcgtg	tggccgccct	180
ggctggcctgc	atcatcgctc	tgggcttcaa	ctactggatt	gcgagctccc	ggagcgtgga	240
cctccagaca	cggatcatgg	agctggaagg	cagggtccgc	aggcgggctg	cagagagagg	300
cgccgtggag	ctgaagaaga	acgagttcca	gggagagctg	gagaagcagc	gggagcagct	360
tgacaaaatc	cagtcagcc	acaacttcca	gctggagagc	gtcaacaagc	tgtaccagga	420
cgaaaaggcg	gttttgggtga	ataacatcac	cacaggtgag	aggctcatcc	gagtgtgca	480
agaccagtta	aagaccctgc	agaggaatta	cggcaggctg	cagcaggatg	tcctccagtt	540
tcagaagaac	cagaccaacc	tggagaggaa	gttctctac	gacctgagcc	agtgcacaa	600
tcagatgaag	gaggtgaagg	aacagtgtga	ggagcgaata	gaagaggtca	ccaaaaagg	660
gaatgaagct	gtagcttcca	gagacctgag	tgaaaacaac	gaccagagac	agcagctcca	720
agccctcagt	gagcctcagc	ccaggctgca	ggcagcaggc	ctgccacaca	cagaggtgcc	780
acaagggaag	ggaaacgtgc	ttggtaacag	caagtcccag	acaccagccc	ccagttccga	840
agtgtttttg	gattcaaaga	gacaagttga	gaaagaggaa	accaatgaga	tccaggtggg	900
gaatgaggag	cctcagaggg	acaggctgcc	caggagcgca	ggccgggagc	aggtggtgga	960
agacagacct	gtaggtggaa	gaggcttcgg	gggagccgga	gaactgggcc	agacccaca	1020
ggtgcaggct	gccctgtyag	tgagccagga	aaatccagag	atggaggggc	ctgagcgaga	1080
ccagcttgct	atccccgacg	gacaggagga	ggagcaggaa	gctgccgggg	aagggagaaa	1140
ccagcagaaa	ctgagaggag	aagatgacta	caacatggat	gaaaatgaag	cagaatctga	1200
gacagacaag	caagcagccc	tggcagggaa	tgacagaaac	atagatgttt	ttaatgttga	1260
agatcagaaa	agagacacca	taaatttact	tgatcagcgt	gaaaagcgga	atcatacact	1320
ctgaattgaa	ctggaaatcac	atatttcaca	acagggccga	agagatgact	ataaaatgtt	1380
catgagggac	tgaatactga	aaactgtgaa	atgtactaaa	taaaatgtac	atctgaagat	1440
gattattgtg	aaattttagt	atgcactttg	tgtaggaaaa	aatggaatgg	tcttttaaac	1500
agctttttggg	gggtactttg	gaagtgtcta	ataaggtgtc	acaatttttg	gtagtaggta	1560

tttcgtgaga	agttcaacac	caaaactgga	acatagtctt	ccttcaagtg	ttggcgacag	1620
cggggcttcc	tgattctgga	atataacttt	gtgtaaatta	acagccacct	atagaagagt	1680
ccatctgctg	tgaaggagag	acagagaact	ctgggttccg	tcgtcctgtc	cacgtgctgt	1740
accaagtgtc	gggtgccagcc	tgttacctgt	tctcactgaa	aagtctggct	aatgctcttg	1800
tgtagtcact	tctgattctg	acaatcaatc	aatcaatggc	ctagagcact	gactgttaac	1860
acaaacgtca	ctagcaaagt	agcaacagct	ttaagtctaa	atacaaagct	gttctgtgtg	1920
agaaatTTTT	aaaaggctac	ttgtataata	acccttgtca	tttttaattg	acaaaacgct	1980
attaagtggc	ttagaatttg	aacatttgtg	gtctttattt	actttgcttc	gtgtgtgggc	2040
aaagcaacat	cttccctaaa	tatatattac	caagaaaagc	aagaagcaga	ttaggttttt	2100
gacaaaacaa	acaggccaaa	agggggctga	cctggagcag	agcatgggtg	gaggcaaggc	2160
atgagagggc	aagtttgttg	tggacagatc	tgtgcctact	ttattactgg	agtaaaagaa	2220
aacaaagttc	attgatgtcg	aaggatatat	acagtgttag	aaattaggac	tgtttagaaa	2280
aacagggaata	caatggttgt	ttttatcata	gtgtacacat	ttagcttgtg	gtaaatgact	2340
cacaaaactg	attttaaaat	caagttaatg	tgaattttga	aaattactac	ttaatcctaa	2400
ttcacaataa	caatggcatt	aaggtttgac	ttgagttggt	tcttagtatt	atztatggta	2460
aataggctct	taccacttgc	aaataactgg	ccacatcatt	aatgactgac	ttcccagtaa	2520
ggctctctaa	ggggtaagta	ggaggatcca	caggatttga	gatgctaagg	ccccagagat	2580
cgtttgatcc	aaccctctta	ttttcagagg	ggaaaatggg	gcctagaagt	tacagagcat	2640
ctagctgggtg	cgtgggcacc	cctggcctca	cacagactcc	cgagtagctg	ggactacagg	2700
cacacagtca	ctgaagcagg	ccctgtttgc	aattcacgtt	gccacctcca	acttaaacat	2760
tcttcatatg	tgatgtcctt	agtcactaag	gttaaaacttt	cccaccaga	aaaggcaact	2820
tagataaaat	cttagagtac	tttcatactc	ttctaagtcc	tcttccagcc	tcactttgag	2880
tcctccttgg	ggttgatagg	aattttctct	tgctttctca	ataaagtctc	tattcatctc	2940
atgtttaatt	tgtacgcata	gaattgctga	gaaataaaat	gttctgttca	acttaaaaaa	3000
cttgtcacag	ctctgttttt	ttgcttttcc	ccttcacctt	ctattagatc	cttaagaagt	3060
ccaccctcaa	actgtggact	aaggatggca	gtttgcctta	aaccttctgt	ggaatgagat	3120
gggctgtcag	gacgtcttca	accacagta	ccccgaaagc	tttgtgtcga	ccac	3174

&lt;210&gt; 87

&lt;211&gt; 2780

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2760)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 87

ggcgccggcg	gcggggggtc	ccggggccac	gtggacgccg	acggctctgg	tctgcggcgt	60
gtggacactg	ccagcggctg	cagccgactt	ggaatgacct	gggagacaaa	tacaacagca	120
tggaagakgc	caaagtctat	gtggctaaag	tggactgcac	ggccactcc	gacgtgtgct	180
ccgcccaggg	gggtgcgagga	tacccacact	taaagctttt	caagccaggc	caagaagctg	240
tgaagtacca	gggtcctcgg	gacttccaga	cactggaaaa	ctggatgctg	cagacactga	300
acgaggagcc	agtacacca	gagccggaag	tggaaaccgc	cagtgcctcc	gagctcaagc	360
aagggctgta	tgagctctca	gcaagcaact	ttgagctgca	cgttgccaaa	ggcgaccact	420
ttatcaagtt	cttcgctccg	tgggtgtggtc	actgcaaagc	cctggctcca	acctggggagc	480
agctggctct	gggctttgaa	cattccgaaa	ctgtcaagat	tggcaagggt	gattgtacac	540
agcactatga	actctgctcc	ggaaaccagg	ttcgtggcta	tcccactctt	ctctggttcc	600
gagatgggaa	aaaggtggat	cagtacaagg	gaaagcggga	tttggagtca	ctgagggagt	660
acgtggagtc	gcagctgcag	cgcacagaga	ctggagcgac	ggagaccgtc	acgccctcag	720
aggccccggt	gctggcagct	gagcccagg	ctgacaagg	cactgtgttg	gcactcactg	780
aaaataactt	cgatgacacc	attgcagaag	gaataacctt	catcaagttt	tatgtcccat	840
gggtgtggta	ctgtgaagact	ctggctccta	cttgggagga	actctctaaa	aaggaattcc	900
ctgggtctggc	gggggtcaag	atcgccgaag	tagactgcac	tgctgaacgg	aatatctgca	960
gcaagtattc	ggtacgaggc	tacccacgt	tattgctttt	ccgaggagg	aagaaagtca	1020
gtgagcacag	tggaggcaga	gaccttgact	cgttacaccg	ctttgtcctg	agccaagcga	1080
aagacgaact	ttaggaacac	agttggagg	cacctctcct	gcccagctcc	cgcaccctgc	1140

gttttaggagt	tcagttcccac	agagggccact	gggttcccag	tggtggctgt	tcagaaagca	1200
gaacatacta	agcgtgaggt	atcttctttg	tgtgtgtgtt	ttccaagcca	acacactcta	1260
cagattcttt	attaagttaa	gtttctctaa	gtaaatgtgt	aactcatggt	cactgtgtaa	1320
acattttcag	tggcgatata	tcccccttga	ccttctcttg	atgaaattta	catgggtttcc	1380
tttgagacta	aaatagcggt	gaggggaaatg	aaattgctgg	actatttgtg	gctcctgagt	1440
tgagtgatgt	tggtgaaaga	aagcacatcc	aaagcatagt	ttacctgccc	acgagttctg	1500
gaaaggtggc	cttgtggcag	tattgacggt	cctctgatct	taaggtcaca	gttgactcaa	1560
tactgtgttg	gtccgtagca	tggagcagat	tgaaatgcaa	aaaccacac	ctctggaaga	1620
taccttcacg	gccgtgctg	gagcttctgt	tgtgtgtaat	acttctctca	gtgtgagagg	1680
ttagccgtga	tgaagcagc	gttacttctg	accgtgcctg	agtaagagaa	tgctgatgcc	1740
ataactttat	gtgtcgatac	ttgtcaaata	agttactgtt	caggggatcc	ttctgtttct	1800
cacgggggtga	aacatgtctt	tagttcctca	tgtaaacacg	aagccagagc	ccacatgaac	1860
tggtggatgt	cttccctaga	aagggttaggc	atggaaaatt	ccacgaggct	catttctcagt	1920
atctcattaa	ctcattgaaa	gattccagtt	gtatttgtca	cctggggtga	caagaccaga	1980
caggctttcc	caggcctggg	tatccaggga	ggctctgcag	ccctgctgaa	gggccctaac	2040
tagagtctta	gagtttctga	ttctgtttct	cagtagtccct	tttagaggct	tgctatactt	2100
ggctctgcttc	aaggaggtcg	accttctaat	gtatgaagaa	tgggatgcat	ttgatctcaa	2160
gaccaaagac	agatgtcagt	gggctgctct	ggccctgggtg	tgacaggtcg	tggcagctgt	2220
tgatgccagt	gtcctctaac	tcatgtctgc	cttgtgatta	aacacctcta	tctcccttgg	2280
gaataagcac	atacaggctt	aagctctaag	ataggtgttt	gtccttttac	catcgagcta	2340
cttcccataa	taaccacttt	gcattccaaca	ctcttcaccc	acctcccata	cgcaagggga	2400
tgtggatact	tggtcccaaag	taactggtgg	taggaatctt	agaaacaaga	ccacttatac	2460
tgtctgtctg	aggcagaaga	taacagcagc	atctcgacca	gcctctgcct	taaaggaaat	2520
ctttattaat	cacgtatggt	tcacagataa	ttcttttttt	aaaaaaaccc	aacctcctag	2580
agaagcacaa	ctgtcaagag	tcttgtacac	acaacttcag	ctttgcatca	cgagtcttgt	2640
attccaagaa	aatcaaaagt	gtacaatttg	tttgtttaca	ctatgatact	ttctaataaa	2700
actctttttt	tttaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaggggg	gggggggggn	2760
ggggccccc	cccccccaa					2780

&lt;210&gt; 88

&lt;211&gt; 1061

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens.

&lt;400&gt; 88

aattcggcac	gagagaagga	aatacatcaa	aatgcccaca	ttggttatct	gtagaggata	60
gaatgaaaga	tggtctttatt	ctcttggttg	ctcttattaa	agcaatcaga	tggtgcttct	120
cctgtactca	gagccctggc	tgcttcctgc	ctggcctctc	ctgggggctg	ctgtggaacc	180
agaaaagcct	taaaaggaaa	tgtgggagag	aagggtggat	tcactttcat	gtctttccag	240
ggttgtgacc	cctcaagctc	tggttgccct	tgtgtttctc	tattaccttc	aaacagccag	300
ctcgtcttta	ttcttttttt	agttttgtcg	gggttggctt	gatagatgtt	agtccatcat	360
agccagatgt	gtctagcctt	gtcttttgaa	tgcaagattt	aggatgtggg	tacttagctg	420
ttagtggaca	tcagagtcac	tagtcaggat	gaaagagttc	ttggctttta	ctcccagaaa	480
ttctggtaac	gtcatgtata	gtgacggccg	catgtctaac	aggtggccag	gtaagtcttt	540
tgggggtggc	tgtgaatcac	agtttgggag	acattgactt	ttaggaggat	tgttctgaat	600
tcactagata	atagagatat	aatacagagc	tttgaaagct	ggtgtcttga	tgacagagcc	660
gtggcaatgg	ggaggggtga	ggaggtggct	gttgggcctg	tctcctgggtg	agagttgaaa	720
gggcctgaac	tcaagcagag	gcctcagaac	cgaaagggtg	tggaaggatg	cagcaagagg	780
cgccacacag	gagtactctg	cgccctggca	gggtctgaat	acacgtggga	gtgggtgagag	840
ggagaacttt	aagtccaggt	tttgtgcctc	agtgacttag	tgtggccata	tcattagaaa	900
tgtgttgagg	ccgggcacag	tggctcatgt	ctgtaatccc	agcactttga	gaggctgagg	960
caggaggatg	gcttgaggcc	aggagtttaa	aaccagcctg	gacaacatag	tgagagcctg	1020
tctctacaaa	aaaaaaaaaa	aaaaactcga	ggggggggccc	g		1061

&lt;210&gt; 89

&lt;211&gt; 1342

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 89

ccacgcgtcc	gggcgcgcgg	gtgaaaggcg	cattgatgca	gcctgcggcg	gcctcggagc	60
gcggcggagc	agacgctgac	cacgttcctc	tcctcgggtc	cctccgcctc	cagctccgcg	120
ctgcccggca	gccgggagcc	atgcgacccc	agggcccccg	cgcctccccg	cagcggctcc	180
gcggcctcct	gctgctcctg	ctgctgcagc	tgcccgcgcc	gtcgagcgcc	tctgagatcc	240
ccaaggggaa	gcaaaaaggcg	cagctccggc	agagggaggt	ggtggacctg	tataatggaa	300
tgtgcttaca	agggccagca	ggagtgcctg	gtcgagacgg	gagccctggg	gccaatggca	360
ttccgggtac	acctgggatc	ccaggtcggg	atggattcaa	aggagaaaag	ggggaatgtc	420
tgagggaaaag	ctttgaggag	tcctggacac	ccaactacaa	gcagtgttca	tggagtccat	480
tgaattatgg	catagatctt	gggaaaattg	cggagtgtac	atttacaaag	atgcgttcaa	540
atagtgcctc	aagagttttg	ttcagtggct	cacttcggct	aaaatgcaga	aatgcatgct	600
gtgagcgttg	gtatttcaca	ttcaatggag	ctgaatgttc	aggacctctt	cccattgaag	660
ctataattta	tttggaccaa	ggaagccctg	aaatgaattc	aacaattaat	attcatcgca	720
cttctctctgt	ggaaggactt	tgtgaaggaa	ttggtgctgg	attagtggat	gttgctatct	780
gggttggcac	ttgttcagat	tacccaaaag	gagatgcttc	tactggatgg	aattcagttt	840
ctcgcatcat	tattgaagaa	ctacccaaaat	aaatgcttta	attttcattt	gctacctctt	900
tttttattat	gccttggaa	ggttcactta	aatgacattt	taaataagtt	tatgtataca	960
tctgaatgaa	aagcaaaagct	aaatatgttt	acagaccaaa	gtgtgatttc	acactgtttt	1020
taaaatctagc	attattcatt	ttgcttcaat	caaaagtggg	ttcaatattt	tttttagttg	1080
gttagaatac	tttcttcata	gtcacattct	ctcaacctat	aatttggaat	attgttgttg	1140
tcttttgttt	tttctcttag	tatagcattt	ttaaaaaaat	ataaaagcta	ccaatctttg	1200
tacaatttgt	aaatgttaag	aatttttttt	atatctgtta	aataaaaatt	atttccaaaa	1260
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1320
aaaaaaaaaa	aaaaaaaaaa	aa				1342

&lt;210&gt; 90

&lt;211&gt; 770

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (690)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (762)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 90

ggtagggctg	ggkcgaccyr	cgcgtccggc	tcttcctcag	gcggcggcca	tggcgggaca	60
ggaggatccg	gtgcagcggg	agattcacca	ggactgggct	aaccgggagc	acattgagat	120
aatcaccagc	agcatcaaga	aaatcgcaga	ctttctcaac	tcgttcgata	tgtcttgctg	180
ttcaagactt	gcaacactaa	acgagaaatt	gacagccctt	gaacggagaa	tagagtacat	240
tgaagctcgg	gtgacaaaag	gtgagacact	cacctagaac	agtgccgtgc	tgtgctggg	300
aagttgcttt	acacaacaca	ggccacatgg	gaaaggcccc	agcagccttc	agctccttcc	360
tttctcctta	aagagcaaca	gggcttatcc	ttgtttttct	tttttcaaaa	gtgtggcctt	420
tgggtctctg	catctggggg	gtggtgtggg	atgtgggaag	aagttcagag	gaaccgttgg	480
aaacgacgtt	aggcatttta	ccttttcagt	aacattttat	acatctactt	gtcaatgtat	540
ttgagacatt	cacagccaaa	agcctgggac	tctttgtgaa	ggtcctcctc	amctctatct	600
ttctttctct	ctctctcaaa	ctttccttaa	agtttctcatt	gcctttgcac	tgtctctgtg	660
aacagtcttt	gtctcctccc	cacctttggg	ggaaagtgcg	gggcagtcct	ggtcaagaca	720
ctcatgccct	ggcaatgtgg	cctgcagaga	atgttgttgt	anccaccagt		770

<210> 91  
 <211> 1570  
 <212> DNA  
 <213> Homo sapiens

<400> 91  
 gatgggtttta ctgaagttgc taaaagttta cagaaaagga agtgcaggaa catttcacaa 60  
 atctacaatc tgtgagtatc acatcctgta tagctgtmaa cactggaata aggaagggtc 120  
 gatgactttc agaagatgaa ggtaagtaga aaccgttgat gggactgaga aaccagagtt 180  
 aaaacctctt tggagcttct gaggactcag ctggaaccaa cgggcacagt tggcaacacc 240  
 atcatgacat cacaacctgt tcccaatgag accatcatag tgctcccatc aaatgtcatc 300  
 aacttctccc aagcagagaa acccgaaccc accaaccagg ggcaggatag cctgaagaaa 360  
 catctacacg cagaaatcaa agttattggg actatccaga tcttgtgtgg catgatggta 420  
 ttgagcttgg ggatcatttt ggcattctgt tccttctctc caaattttac ccaagtgact 480  
 tctacactgt tgaactctgc ttaccctatc ataggacctt ttttttttat catctctggc 540  
 tctctatcaa tcgccacaga gaaaaggtrr accaagcttt tgggtgcatag cagcctgggt 600  
 ggaagcattc tgagtgtctt gtctgccctg gtgggtttca ttatcctgtc tgtcaaacag 660  
 gccaccttaa atcctgcctc actgcagtgt gaggttggaca aaaataatat accaacaaga 720  
 agttatgttt cttactttta tcatgattca ctttatacca cggactgcta tacagccaaa 780  
 gccagtctgg ctggawctct ctctctgatg ctgatttgca ctctgtctga attctgccta 840  
 gctgtgtctc ctgctgtgct gcgggtggaa caggcttact ctgacttccc tgggagtgtg 900  
 cttttcctgc ctcacagtta catttgtaat tctggcatgt cctcaaaaat gactcatgac 960  
 tgtggatatt aagaactatt gacttcttaa gaaaaaggg agaaatatta atcagaaagt 1020  
 tgattcttat gataatatgg aaaagttaac cattatagaa aagcaaagct tgagtttctt 1080  
 aaatgtaagc ttttaaagta atgaacatta aaaaaaacca ttatttcaat gtcatttaag 1140  
 atatgtgttc attggggatc tcttgatttg cctgacattg acttcagcaa aagcacgggg 1200  
 ctgtaaatta ccatttacta gattagccaa atagtctgaa tttccagaaa acaaggcaga 1260  
 atgatcattc ccagaaacat ttcccagaaa atgtttccca gaaaactaga cagmatgatc 1320  
 attcaatgga tcacagtga gcaaaggaca caacttttta ttgtaccctt taattgtcaa 1380  
 caggagttaa ctgatttgtt gtggtgtctc gactttttta tacagggtgt agtgttttat 1440  
 cctatgtatt ttaactcatt agtgcataaa ggcaagcccc atataatgaa gtctcagggt 1500  
 atatgaaagt agctggcttc aaaataaaat ttttgagtgc aaaaaaaaaa aaaaataaaa 1560  
 aaaaaaaaaa 1570

<210> 92  
 <211> 2950  
 <212> DNA  
 <213> Homo sapiens

<400> 92  
 cccggctccc gccgctccc agccgggccc cccagcggtc ggccgggacg ctcgccgctg 60  
 cagtctgccc gccgcccccg cgcgggggccc gagtgcgcaa gcgcgcctgc gacccggtc 120  
 ccgggcgcgc tggagaggac gcgaggagcc atgaggcgcc agctgcgaag gtggcggcgc 180  
 tgctgtctcg gctgtctctt gagtgcacag aagccaaaaa gcattgctgg tatttcgaag 240  
 gactctatcc aacctattat atatgccgt cctacgagga ctgctgtggc tccagggtct 300  
 gtgtgccccg cctctccata cagaggctgt ggtacttctg gttccttctg atgatggcg 360  
 tgcttttctg ctgcgagacc ggcttcttca tccggaggcg catgtacccc ccgcccgtga 420  
 tcgaggagcc agccttcaat gtgtcctaca ccaggcagcc cccaaatccc ggcccaggag 480  
 cccagcagcc ggggcccgc tttacacacg acccaggagg accggggatg aacctgtctg 540  
 ggaattccat ggcaatggct ttccaggctc cacccaactc accccagggg agtggtggcct 600  
 gccgcccccc tccagcctac tgcaacacgc ctccgccccg gtacgaacag gtagtgaagg 660  
 ccaagtagtg ggggtgccac gtgcaagagg agagacagga gagggccttt ccctggcctt 720  
 tctgtcttct tctgtgttca cttccaggaa cggctctctg ggctgctaag ggcagttcct 780  
 ctgatattct cacagcaagc acagctctct ttcaggcttt ccatggagta caatatatga 840  
 actcacactt tgtctctctt gttgtctctt tttctgacgc atctgtgtct tcacatggta 900  
 gtgtggtgac agtccccgag ggctgacgtc cttacgggtg cgtgaccaga tctacaggag 960  
 agagactgag aggaagaagg cagtgtctga ggtgcagggt gcatgtagag gggccaggcc 1020  
 gagcatccca ggcaagcatc cttctgcccc ggtattaata ggaagcccca tgccggcg 1080



ctcagccgat	gaagcagcag	ccgactgagc	tgagcccagc	aggatcatctg	ctccagcctg	1140
tcctctcgtc	agccttcctc	ttccagaagc	tggttgagag	acattcagga	gagagcaagc	1200
cccttgatcat	gtttctgtct	ctgttcacat	cctaaagata	gacttctcct	gcaccgccag	1260
gaaagggtag	cacgtgcagc	tctcaccgca	gatggggcct	agaatcaggg	ttgcttgag	1320
gcctgacagt	gatctgacat	ccactaagca	aatttattta	aattcatggg	aatcacttc	1380
ctgccccaaa	ctgagacatt	gcattttgtg	agctcttggt	ctgatttgga	gaaaggactg	1440
ttacecattt	ttttggtgtg	tttatggaag	tgcatgtaga	gcgtcctgcc	ctttgaaatc	1500
agactgggtg	tgtgtcttcc	ctggacatca	ctgcctctcc	agggcattct	caggccgggg	1560
gggtctcttc	cctcaggcag	ctccagtggt	gggttctgaa	gggtgctttc	aaaacggggc	1620
acatctggct	gggaagtcac	atggactctt	ccaggagag	agaccagctg	aggcgtctct	1680
ctctgaggtt	gtgttggtgc	taagcgggtg	tggtgtgggc	tccaaggagg	aggagcttgc	1740
tgggaaaaga	caggagaagt	actgactcaa	ctgcaactgac	catgttgta	taattagaat	1800
aaagaagaag	tggtcggaag	tgacatttcc	tggaataggaa	tcacagctca	ccccaggatc	1860
tcacaggtag	tctcctgagt	agttgacggc	tagcggggag	ctagttccgc	cgcatagtta	1920
tagtggtgat	gtgtgaacgc	tgacctgtcc	tggtgtgtaa	gagctatgca	gcttagctga	1980
ggcgccctaga	ttactagatg	tgctgtatca	cggggaatga	gggtgggggtg	cttatttttt	2040
aatgaactaa	tcagagcctc	ttgagaaatt	gttactcatt	gaactggagc	atcaagacat	2100
ctcatggaag	tggtatcgga	gtgatttggt	gtccatgctt	ttcactctga	ggacatttaa	2160
tcggagaacc	tctcggggaa	ttttgtggga	gacacttggg	aacaaaacag	acaccctggg	2220
aatgcagtgt	caagcacaga	tgctgccacc	agtgtctctg	accaccctgg	tgtgactgct	2280
gactgccagc	gtggtacctc	ccatgctgca	ggcctccatc	taaatgagac	aacaaagcac	2340
aatgttcaact	gtttacaacc	aagacaactg	cgtgggtcca	aacactctc	ttcctccagg	2400
tcatttgttt	tgcattttta	atgtctttat	ttttgtaat	gaaaaagcac	actaagctgc	2460
ccctggaatc	gggtgcagct	gaataggcac	ccaaaagtcc	gtgactaaat	ttcgtttgtc	2520
tttttgatag	caaattatgt	taagagacag	tgatggctag	ggctcaacaa	ttttgtattc	2580
ccatgtttgt	gtgagacaga	gtttgttttc	ccttgaactt	ggtagaatt	gtgctactgt	2640
gaacgctgat	cctgcatatg	gaagtccerc	ttcgggtgaca	tttctgggcc	attcttgttt	2700
ccattgtgtg	gatggtgggt	tggtccact	tcctggagtg	agacagctcc	tggtgtgtag	2760
aattcccggg	gcgtccgtgg	ttcagagtaa	acttgaagca	gatctgtgca	tgcttttctc	2820
ctgcaacaat	tggtcgttt	ctcttttttg	ttctcttttg	ataggatcct	gtttcctatg	2880
tggtcaaaat	aaaaataaat	ttgggcaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2940
aaaaaaaaaa						2950

&lt;210&gt; 93

&lt;211&gt; 1722

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 93

ggcagcagcc	agagcaggct	gctaggcctg	gggccaccac	tgcccctggg	tgctacaccc	60
agtgtgctgg	gtcactggga	acttcttgaa	tggtgtcac	ctgaactggg	cccccaagga	120
tggggtgcgg	gcagtaccgc	aggaagagga	gcagccctg	tgaagattga	gagctgccag	180
aggctctgtg	attggctgcg	gcacgatgac	ccgcgcacgg	attggctgct	tcgggccggg	240
gggcccggcc	cgggggacag	aatccgcccc	cgaaccttca	aagaggggtac	ccccggcgag	300
gagctggcag	accyaggagg	tgcgacagac	ccgcggggca	aacggactgg	ggccaagagc	360
cgggagcgcg	ggcgcaaagg	caccaggggc	cgcccagggc	gcccgcagc	acggccttgg	420
gggttctgcg	ggccttcggg	tgcgctctc	gcctctagcc	atggggtccg	cagcgttgga	480
gacctggg	ctggtgctgt	gcctgggtgg	ctgggggggt	ctgatcctgg	cgtgcgggct	540
gcccattgtg	cagggtgaccg	ccttcttgga	ccacaacatc	gtgacggcgc	agaccacctg	600
gaaggggctg	tggaatgtcg	gcgtggtgca	gagcacsggg	cacatgcagt	gcaaagtgtg	660
cgactcgggtg	ctggctctga	gcaccgaggt	gcaggcggcg	cgggcgctca	ccgtgagcgc	720
cgtgctgctg	gcgttcgttg	cgctcttctg	gacctggg	ggcgcgagc	gcaccacctg	780
cgggccccc	ggcccggcca	argcgctgt	ggccctcacg	ggaggcgtgc	tctacctgtt	840
ttgggggctg	ctggcgctcg	tgccactctg	ctgggtggcc	aacattgtcg	tccgcgagtt	900
ttacgacccg	tctgtgcccc	tgtcgagaa	gtacgagctg	ggcgacgcgc	tgtacatcgg	960
ctgggcggcc	accgcgctgc	tcaggttagg	cggctgcctc	ttgtgctgcg	gcgcctgggt	1020
ctgcaccggc	cgtcccggac	tcagcttccc	cgtgaagtac	tcagcgccgc	ggcgggccac	1080
ggccaccggc	gactacgaca	agaagaacta	cgtctgaggg	cgtggggcac	ggccggggcc	1140

ctcctgccag	ccacgcctgc	gagggcgttg	ataagcctgg	ggagccccgc	atggaccgcg	1200
gcttccgcg	ggtagcgcg	cgcgcaggct	cctcggaacg	tccggctctg	cgccccgacg	1260
cggtcctgg	atccgctcct	gcctgcgccc	gcagctgacc	ttctcctgcc	actagcccgg	1320
ccctgccctt	aacagacgga	atgaagtctt	cttttctgtg	cgcggcgtg	tttccatagg	1380
cagagcgggt	gtcagactga	ggatttctgt	tcccctccaa	gacgctgggg	gtcttggtctg	1440
ctgccttact	tcccagaggc	tcctgctgac	ttcggagggg	cggatgcaga	gcccaggggc	1500
cccaccggaa	gatgtgtaca	gctggctctt	actccatcgg	cagggcccga	gcccaggggac	1560
cagtgaactg	gcctggacct	cccggctctc	ctccagcatc	tccccaggca	aggcttgtgg	1620
gcaccggagc	ttgagagagg	gcgggagtgg	gaaggctaa	aatctgctta	gtaaatgggt	1680
tgaactctca	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aa		1722

&lt;210&gt; 94

&lt;211&gt; 635

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 94

gcctaaagag	agctccccc	ggaccagccc	tggccaagg	attgctgcag	ccctcatcca	60
ccttccaag	actggaaaca	aacattggag	accaagttag	gcgtcactca	acagccgtag	120
taatcaggga	aatgacaagt	tacatactga	tatcctttgt	ttgctgatt	ggagtgtggg	180
gcattgaaaa	agatcagtcg	tgcctcagtg	ttgggggaag	gaagcgtctt	cacctgttgt	240
ttgtgggagg	acagttgagg	caggtgagga	tgctgagagg	tgagctcagc	tgtgcctgtt	300
accgtccaca	tgtgcaagcc	cttcagctcg	gtggtgtgac	ttgtttttga	gatgcagttt	360
cactcttgct	accagggctg	gagtgcatgg	catgatcttg	gctcgtctga	acatccgctt	420
cccgggttca	agcgtattct	ctgtctctac	taaaaataca	aaaattagct	gggtgtgggt	480
gtgcgtgcct	ttaatcccag	ctactcagaa	ggctgagggt	caagaattgc	ttgaacctgg	540
gaggtggagg	ttgccgtggg	ccgagatcac	gccaccgcac	tccagcctag	gcaacagagc	600
tagactgtct	caaaaaaaaa	aaaatgaccc	tcgag			635

&lt;210&gt; 95

&lt;211&gt; 3798

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 95

ccacgcgtcc	ggggcttcat	acaggaaatc	tattgctgtg	tcaagttcca	gagaaaagct	60
tctgttcgtc	caagttacta	accaggctaa	accacataga	cgtgaaggaa	ggggctagaa	120
ggaagggagt	gccccactgt	tgatggggta	agaggatcct	gtactgagaa	gttgaccaga	180
gaggggtctc	ccatgcgcac	agttccttct	gtaccagtgt	ggaggaaaag	tactgagtga	240
agggcagaaa	aagagaaaac	agaaatgtct	tgcccttgga	gaactgctaa	cctagggtcta	300
ctgttgattt	tgactatctt	cttagtgggc	gaagcggagg	gtgctgctca	accaaacaac	360
tcattaatgc	tgcaaaactag	caaggagaat	catgctttag	cttcaagcag	tttatgtatg	420
gatgaaaaac	agattacaca	gaactactcg	aaagtactcg	cagaagttaa	cacttcatgg	480
cctgtaaaga	tggctacaaa	tgctgtgctt	tggtgccctc	ctatcgcat	aagaaatttg	540
atcataataa	catgggaaat	aatcctgaga	ggccagcctt	cctgcacaaa	agcctacaag	600
aaagaaacaa	atgagaccaa	ggaaaccaac	tgtactgatg	agagaataac	ctgggtctcc	660
agacctgatc	agaattcgga	ccttcagatt	cgtaccgtgg	ccatcactca	tgacgggtat	720
tacagatgca	taattgtaac	acctgatggg	aatttccatc	gtggatatca	cctccaagtg	780
ttagttacac	ctgaagtgc	cctgtttcaa	aacaggaaata	gaactgcagt	atgcaaggca	840
gttgacaggga	agccagctgc	gcatactctc	tggatcccag	agggcgattg	tgccactaag	900
caagaatact	ggagcaatgg	cacagtgact	gttaagagta	catgccactg	ggaggtccac	960
aatgtgtcta	ccgtgaaact	ccacgtctcc	catttgactg	gcaacaagag	tctgtacata	1020
gagctacttc	ctgttccagg	tgccaaaaaa	tcagcaaaat	tatatattcc	atatatcatc	1080
cttactatta	ttattttgac	catcgtggga	ttcatttggg	tggtgaaagt	caatggctgc	1140
agaaaaatata	aattgaaata	aacagaatct	actccagttg	ttgaggagga	tgaaatgcag	1200
ccctatgccca	gctacacaga	gaagaacaat	cctctctatg	atactacaaa	caaggtgaag	1260
gcatctgagg	cattacaaag	tgaagtgtgac	acagacctcc	atactttata	agttgttgga	1320

ctctagtagacc	aagaaacaac	aacaaacgag	atacattata	attactgtct	gattttctta	1380
cagttctaga	atgaagactt	atattgaaat	taggttttcc	aaggttctta	gaagacattt	1440
taatggattc	tcattcatac	ccttgataaa	ttggaatttt	tgattcttag	ctgctaccag	1500
ctagttctct	gaagaactga	tgttattaca	aagaaaatac	atgccccatga	ccaaatattc	1560
aaattgtgca	ggacagtaaa	taatgaaaac	caaatcttcc	caagaaataa	ctgaagaagg	1620
agcaagtgtg	aacagtttct	tgtgtatcct	ttcagaatat	tttaatgtac	atatgacatg	1680
tgtatatgcc	tatggatat	gtgtcaattt	atgtgtcccc	ttacatatatac	atgcacatat	1740
ctttgtcaag	gcaccagtgg	gaacaataca	ctgcattact	gttctataca	tatgaaaacc	1800
taataatata	agtcttagag	atcattttat	atcatgacaa	gtagagctac	ctcattcttt	1860
ttaatgggta	tataaaattc	cattgtatag	ttatatcatt	atttaattaa	aaacaaccct	1920
aatgatggat	atthagattc	ttttaagttt	tgtttatattc	ttttaagttt	tgtttggtg	1980
ataaacaata	ccacatagaa	tgtttcttgt	gcatatatct	ctttgttttt	gagtatatct	2040
gtaggataac	tttcttgagt	ggaattgtca	ggcacaagg	tttgtgcatt	ttactattga	2100
tatatatggt	aaattgtgtc	aaatatata	gtcaaattcc	ctccaacatt	gtttaaatgt	2160
gcctttccct	aaatttctat	tttaataact	gtactattcc	tgcttctaca	gttgccactt	2220
tctcttttta	atcaaccaga	ttaaatatga	tgtagagatta	taataagaat	tatactattt	2280
aataaaaaatg	gatttatatt	tttggctatg	tttgaagag	agtgaatgca	cgtgtgagaa	2340
cattagcttc	ttctgaactc	attatatctc	cacagagggtg	ttgatacttg	atgcctaaca	2400
gttttgcaga	tgtgtacat	tggaattgtg	tatttttatg	gtgtacattc	tattgtgata	2460
tatttattga	ataattaatg	tctattgacc	atataagtgg	cgaaaaatgc	accatagagg	2520
acatggggta	tttatttaca	aactatgagc	tacataataa	gcaagtggcc	atgggatggc	2580
atgaccctcc	cctccatatt	tttgtggagc	aaaatattgg	caatgtttat	gtaaatcatt	2640
gttaatatca	tgaattatt	tttaattaaa	aacataagtc	tatttgcctc	atagcagaaa	2700
aaacatgaga	agttttttca	tcatgataga	aattgaaaca	aaatatattc	attcttcaat	2760
cataccatct	gagattttta	agacagctat	tttgtcttat	aagtatattt	ttctccctct	2820
agacatttca	gttactatgg	attttgcct	caaagggacc	tttagtctat	tttggatgta	2880
aagctaactc	aatgacactt	ggcacatgat	attttgatca	agccattttg	acttgacca	2940
aaagcagtg	ccattagggt	tctgcatata	aatattacca	agcaatgttc	acaatagaca	3000
tcattacact	gtccttgaaa	tttattaatt	cttcatccaa	ccctgggtga	gctgaggctc	3060
atagttagg	tcaagactat	ctgtttaaat	attactgaaa	aacaaagtaa	gacagtacta	3120
tgcttacctc	tttaacttgat	aatgtcaaaa	caggcatggt	aaatgacatc	atagaaaaga	3180
cttcaagata	atztatagaa	gttaaattat	attgtacaga	aaataattgt	atgaaaatct	3240
ctactatggg	gctggaacat	ggttgaacat	tagaatgata	taaaaaatta	tatatattct	3300
ccaaatccac	gctagacctg	tcaaattaga	gaatctagag	attagacctg	gcgtgtcagc	3360
aaggtcatcc	aggaagcaga	ggctgagacg	gagttagggtg	tgattactta	catagtcgat	3420
tacattttac	aaataacatt	ttatatgtct	catttactgt	gctttctccc	catcccattt	3480
tgtatctttt	cctttgcttt	gctagatttg	tcaattttct	ctctctttct	gtctctctct	3540
ctttcaatat	ctctaataat	ttgaaagtaa	ttcatcataa	ctaaatatct	attgggggta	3600
tgcttcaact	acaaacttct	gaaaacggct	ttactgagat	ataattgata	tattttaagtg	3660
tacagtttgt	taaattttgc	acatatttaa	aatgtggact	ttggtaaatg	ttgacatagt	3720
tttacatctg	tgaaccatc	agcataatca	agataataaa	cttgtccatc	acccccaaa	3780
aaaaaaaaaa	aaaaaaaaa					3798

&lt;210&gt; 96

&lt;211&gt; 2683

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2640)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2676)

&lt;223&gt; n equals a,t,g, or c

```

<400> 96
acaasgtmac gcctgacagg tmaccggatc cggaattcc cgggtcgacc cacggcgctcc      60
gcatttgcaa taacagaaaa ggaattgcat gtatgaagtt ttcaatcgtg ggctttttctt      120
tggttgggg aggggggtcgg gggatagttt gatttccatt ttctgaaaac gacagacttg      180
gattctgttt gtgtgtgcat attttatcca gccttaagtt ataaagctca tctgtcccgc      240
tgcattccct gtgtattttc aggacatggc tcgtgggtgt gtgtgttcat tgtgtgcgtc      300
tgtatgtatt ttctgtcat cactgttccc tctctccc agtgtgcatt cagttaatat      360
aatcagttgc ttgcttcttt caaagtgcct tgaaggctct gaactcatgt gtgagcatct      420
ttatcaacta tcccaattgc atgttctcca tcacatatcc tcttatttgc tctgtacccc      480
ctgagaatat gtttttagaga tattggaata aagctgtctg ggtaaggagt aggcttagcc      540
gacctatgaa taatacactt tagtctagtt ctttattcta aatctggatt gccagtattg      600
tgtatttaaa ccaagtctgt gaatacctgc tttttttggc cacagagtaa caagttttca      660
tgtaagatct tcataccaaa gtaggaagta aaaatagctt agaaagctct gtcagggtgt      720
ttgtgcagct gacagargta atgttacatc acctaaaaaa gaaagataca cggtcagtta      780
tcctaaaaat aaattgtttg gaaagtacaa tgcaccacat tttttagtaa gtctactatt      840
tgataaacag ttgaaattca agatgtgttt gacccttagt cttttttact ctttggttct      900
gagtatacct attttcttag cgtatctgcc ttgtttatct ttttcttcac cttttaacaa      960
gtatgacata ggaaagtcct ttttttttag aattcatgga tcagtctgat ctactcttat      1020
tcataatgga acatgtaaat atactgaaa ctgtttttca ggagagaaat atgagttgga      1080
gggaaggaaa agtggttcta ctaatgttcc aaaatcctca tcagagaagg tatgatgttc      1140
tcagggtgtg aaaatatttt ttagttgatt gagaatgcag gtttaacaga agagataagg      1200
ggcataatga ctgctggttt tccagactgg attttctac cgcaactatt aatgttctca      1260
gagttgatga ggaccacctt tgtgtatata cttgtagttt taaaccttgc attggttaaca      1320
aaatgatcaa ctttaattcc ggtagaattc aagatggctg tacttcagtt gtatgataaa      1380
attaatgggt ctcatgactt gtgtggcatc taaaaataat gtttttatag catctctctg      1440
ccactaaatt gttgacttga attttgggaa aaaaaaaagt tgggtttgat atgtatatgt      1500
gtgtgtgtat atatgtattt ataaacaagt gtgtttgagt aacaagttag tttcatagtc      1560
ttcccctacg catgtgtatt ccacacacaa atggctgagt tatagtcata aaacaatttg      1620
caataaaaaa aaaacaaaaa cagattgtca gtaaccagg aaacagttaa tgttttttaa      1680
tgaatctggc attatagtga gcaaagtgcg tattaattta ggctaatttc taatactacc      1740
ataatttgtg tctaaatttc tgttggggta gaaattacta aaattgtggg gagttttttc      1800
tgatttttac attgcttttag gaaacatttt tactaattca gctgtcttag gtaaaatgaa      1860
tagttttctt cctgtttttt tatgtgtcat tgttagtggt ctcagaattc tgatcagtaa      1920
ctttgtgtat gatgctgaat tacaaccctg ttgaatgatc cagttgaaaa cgtatccctc      1980
tactttcttc agttgtagaa aagggttaatt tccctcagtg tcccacatta taccaacctc      2040
agagaagaac aggtaatagg gagaaataaa catacgggtg tttcagtggt tttgggtcatg      2100
tgtccacagg agaaactaac cattcagttg tcttaatttt agttcgttct accctgtgag      2160
gagtttggtt ccatcagttg ttgactttcc aaaatgttgc attaaagtaat agttgtcact      2220
ctgttggtct catggtcaat atcaatcaga ctttcatgat ctctactaat tattagtaga      2280
gtcctgtact atgtctgtaa ctactaagtt taaagaaaag cacatagtca cttcatctct      2340
tttttctta gcctacgctc actccccaac ccacccaac attgacatgc tatctgtgga      2400
caaatagcag ttctcagaat ctagtcaagt tgccatcatc ccccttgccct tggccgttca      2460
tagtaggtat gcatatgttt gtttctgtac agtactgtgt gtgtgtgtgt atatatatat      2520
acatctgtat gcacacatct ttgataaaat agctatttga ctagcagggt taaagtggct      2580
tttaattact tcgtgagtggt tattggatac atcttaaaaa aaaaaaatct ggaccagan      2640
ccatgccata cttggttgga ctattttggg gcattnaaaa ttg      2683

```

<210> 97

<211> 2181

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> n equals a,t,g, or c

<400> 97

gtacnggatt	ccccgggtcga	cccacgcrtc	cggcaggcag	agggggcagt	ggcgcgggga	60
agatgattct	gggcctcccc	catctactgt	cattaaccaa	aatgaaacat	ttgccâacat	120
aattttttaa	cctactgtag	tacaacaagc	caggattgcc	cagaatggaa	ttttgggaga	180
ctttatcatt	agatatgacg	tcaatagaga	acagagcatt	ggggacatcc	aggttctaaa	240
tggctatttt	gtgcactact	ttgctcctaa	agaccttcct	cctttaccca	agaatgtggt	300
attcgtgctt	gacagcagtg	cttctatggt	gggaaccaa	ctccggcaga	ccaaggatgc	360
cctcttcaca	attctccatg	acctccgacc	ccaggaccgt	ttcagtatca	ttggattttc	420
caaccggatc	aaagtatgga	aggaccactt	gatatcagtc	actccagaca	gcatcaggga	480
tgggaaagt	tacattcacc	atatgtcacc	cactggaggc	acagacatca	acggggctct	540
gcagagggcc	atcaggctcc	tcaacaagta	cgtggcccac	agtggcattg	gagaccggag	600
cgtgtccctc	atcgtcttcc	tgacggatgg	gaagcccacg	gtcggggaga	cgcacaccct	660
caagatccct	aacaacaccc	gagaggccgc	ccgaggccaa	gtctgcatct	tcaccattgg	720
catcggaac	gacgtggact	tcaggctgct	ggagaaactg	tcgctggaga	actgcggcct	780
cacacggcgc	gtgcacgagg	aggaggacgc	aggctcgag	ctcatcgggt	tctacgatga	840
aatcaggacc	ccgctcctct	ctgacatccg	catcgattat	ccccagct	cagtgggtgca	900
ggccaccaag	accctgttcc	ccaactactt	caacggctcg	gagatcatca	ttgcggggaa	960
gctggtggac	aggaagctgg	atcacctgca	cgtggaggtc	accgccagca	acagtaagaa	1020
attcatcatc	ctgaagacag	atgtgcctgt	gcgccctcag	aaggcaggga	aagatgtcac	1080
aggaagcccc	aggcctggag	gcgatggaga	gggggacmcc	aaccacatcg	agcgtctctg	1140
gagctacctc	accacaaagg	agctgctgag	ctcctggctg	caaagtgcag	atgaaccgga	1200
gaaggagcgg	ctgcggcagc	gggcccaggc	cctggctgtg	agctaccgct	tcctcactcc	1260
cttcacctcc	atgaagctga	gggggccggg	cccacgcag	gacggcctgg	aggaggccca	1320
cggcatgtcg	gctgccatgg	gacccgaacc	ggtggtgcag	agcgtgcgag	gagctggcac	1380
gcagccagga	cctttgctca	agaagccata	ccagccaaga	attaaaatct	ctaaaacatc	1440
agtggatggt	gatccccact	ttgtgtgga	tttccccctg	agcagaactca	ccgtgtgctt	1500
caacattgat	gggcagcccc	gggacatcct	caggctgggtc	tctgatcaca	gggactctgg	1560
tgtcacagtg	aacggagagt	taattggggc	acccgccctc	ccaaatggcc	acaagaaaca	1620
gcgcacttac	ttgcgcacta	tcaccatcct	catcaacaag	ccagagagat	cttatctcga	1680
gatcacaccg	agcagagtca	tcttggtatg	tggggacaga	ctggtgtctc	cctgcaacca	1740
gagtgtggtg	gtggggagct	ggggkctgga	ggtgtccgtg	tctgccaaag	ccaatgtcac	1800
cgtaaccatc	cagggctcca	tagcctttgt	catcctcctc	cacctctaca	aaaagccggc	1860
gcccttccag	cgacaccacc	tgggttttct	cattgccaac	agcgagggcc	tttccagcaa	1920
ctgccacgga	ctgctgggtc	agttcctgaa	tcaggatgcc	agactcacag	aagaccctgc	1980
agggcccagc	cagaacctca	ctcaccctct	gtcctctcag	gtggggagagg	ggcctgaggc	2040
cgtcctaaca	gtgaaaggcc	accaagtccc	agtggctctg	aagcaaagga	agatttacia	2100
cggggaagag	cagwtagayt	gytggtttgc	caggaacatg	ccgccaact	gattgacggg	2160
gagtaacagga	ttacctggca	t				2181

&lt;210&gt; 98

&lt;211&gt; 1957

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 98

acgcgtccgg	aggcggcagg	ctcatggcgc	cggcgtcgcg	gttgctcgcg	ctctggggcg	60
tggcggtctg	ggctctaccc	ggctccgggg	cggagggcga	cggcgggtgg	cgcccgggcg	120
ggccgggggc	cgtggcgag	gaggagcgt	gcacggtgga	gcgtcgggcc	gacctacct	180
acgcggagtt	cgtgcagcag	tacgccttcg	tcaggcccg	catcctgcag	ggactcacgg	240
acaactcgag	gttcggggcc	ctgtgctccc	gcgacaggtt	gctggcttcg	tttggggaca	300
gagtgggtccg	gctgagcacc	gccaacacct	actcctacca	caaagtggac	ttgcccttcc	360
aggagtatgt	ggagcagctg	ctgcaccccc	aggacccac	ctccctgggc	aatgacaccc	420
tgtacttctt	cggggacaac	aacttcaccg	agtgggcctc	tctctttcgg	cactactccc	480
cacccctatt	tggcctgctg	ggaaccgctc	cagcttacag	ctttggaatc	gcaggagctg	540
gctcgggggt	gcccttccac	tggcatggac	ccgggtactc	agaagtgatc	tacggtcgta	600
agcgtgggtt	cctttaccca	cctgagaaga	cgccagagtt	ccaccccaac	aagaccacgc	660
tggcctggct	ccgggacaca	tacccagcct	gcaccgtctg	cacggccctg	gagtgtacca	720
tccgggctgg	tgaggtgctg	acttcccgcg	cgctgggtgc	atgctacgct	caaccttgac	780
accagcgtct	tcactcacc	ttcctcggt	agccaaaaca	gctggcagga	ctgccggtca	840

cacaccagca	cgccccacct	cgctgtcacg	gattttatta	cacagatagt	ggcggcaatg	900
gcctcagccc	agccccacct	cacctgtttt	tccagcccac	aaagggggac	gatcacggcc	960
cagcaaaagc	gatgctgaga	ggggaaacag	tccagagtcc	aacagcagaa	cttgggggaa	1020
gcggtcgggg	tggccaggaa	cataaactat	gtataggggc	cgggggcttc	tgcccagggc	1080
tccccctggac	caggacgcca	ggtagggcag	ggaacctcag	tagtcctcca	cccagccatt	1140
ctcagagatg	aatgcgtcaa	taacctcctt	catagccaag	ttggggatga	gctgttcctg	1200
ggtcaggggg	ctccgggtca	cgggggtcaaa	atgaccacac	cgctgcagtg	acaagaaggg	1260
cagagggcag	tcatggggcc	caggaccatg	ccaactggccc	tgctccccca	gccgcaggcc	1320
tcacctgcag	gtgtctctcg	atgtccttgc	ggtcgttagt	gatgccactg	ggcgtgatgc	1380
acggctcccc	catcagctca	aagctgatct	tgccacacag	gtagtccggg	atgtctcgct	1440
tctgtggcac	aggggcacac	ggtcagaggc	tgaaggggg	cactgcacga	gcacctgcca	1500
gccatcggca	gcaagcgaca	cacactcacc	tccctcttct	catccacctg	agaaaaaagc	1560
tcgtccatgt	ccgccatgta	cttgtcctgt	gaagagttga	gtgctgtgct	tggggggagc	1620
acccccacct	cctcctccat	ggggcacaga	cccaacacaa	ggcgggggatg	ctcccacgcc	1680
acgtgcacac	acacagaccc	acatgtgggt	ggggggcacc	ctcacgtgct	tggcctcaat	1740
gcaggcctgc	tggggcccgga	cgtggctgtc	gtcctcatca	ccctcgtggt	ttcgctggca	1800
ctcttccagc	tccctggggg	ttgaccagga	gccggtcaga	gatggacctg	gccagatgtc	1860
tgaccacacc	ccaatctcag	agctaacatc	cacacttccc	cacatttcct	gcttgccagt	1920
aaagccttcg	ataaacaaaa	aaaaaaaaaa	aaaaaaa			1957

&lt;210&gt; 99

&lt;211&gt; 1112

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 99

ccacgcgtcc	gcccaccaac	aaaggcactt	gcagttacat	tcaccacatt	tgtaacggag	60
ccattgaagc	atattggaac	aggaactggg	gaatttatta	aagcactcat	gaaggaaatt	120
ccagcgtctg	tccatcttcc	agtgtctgata	attatggcat	tagccatcct	gagtttctgc	180
tatgggtgctg	gaaaatcagt	tcatgtgctg	agacatatag	gcggctcctga	gagagaaacct	240
ccccaggcac	ttcggccacg	ggatagaaga	cggcaggagg	aaattgatta	tagacctgat	300
gggtggagcag	gtgatgccga	tttccattat	aggggccaaa	tggggccccc	tgagcaaggc	360
ccttatgccca	aaacgtatga	gggtagaaga	gagattttga	gagagagaga	tgttgacttg	420
agatttcaga	ctggcaacaa	gagccctgaa	gtgtcccggt	catttgatgt	accagacgca	480
gaggcacgag	agcatccccc	ggtggtaccc	agtcataaat	cacctgtttt	ggatacaaaag	540
cccaaggaga	cagggtggaat	cctgggggaa	ggcacaccga	aagaaagcag	tactgaaagc	600
agccagtcgg	ccaagcctgt	ctctggccaa	gacacatcag	ggaatacaga	aggttcaccc	660
gcagcggaaa	aggcccagct	caagtctgaa	gccgcaggca	gcccagacca	aggcagcaca	720
tacagccccg	caagaggtgt	ggctggacca	cgtggacagg	atccggtcag	cagcccctgt	780
ggctagagga	acaccagcac	aaacgacagc	ctcaagtctc	cttcgagctt	tgtaaagtaa	840
tctcacaagc	tgccaaaagaa	cacatcccaa	gcagtaatca	cagatgatga	agcaccttac	900
aggacccctc	caccctcaaa	cgcgcattgtc	cagagaagta	ttaatgcctt	aatagactac	960
tgaagggttaa	ctattttacat	cattctaaaa	atattttaag	ctgtattaca	gtgctataaa	1020
ttctcctttt	aaggaaaaaa	gtaatatagatt	gtttccttac	cgtgtttgaa	aggaaaaaaa	1080
ataaatccat	agtaactaaa	aaaaaaaaaa	aa			1112

&lt;210&gt; 100

&lt;211&gt; 887

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (303)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 100

ggcagcagag	aattataggt	gcatgatggg	gcttttggag	actggcaatg	ttctgttttg	60
ggtctgggta	gtggttactt	gtgtgtattc	actttatgct	aactcattga	actgtacaga	120
tatggactgt	gcccctttct	atatgtgtgt	aatgcttcaa	caaaagtgtc	aatagtgatg	180
catgcacatg	ttaaaatttc	aaactatatt	aaagagtgtg	caattaaaag	gaagttatcc	240
tctcactcta	aagtcctatt	tctctctctc	agtctatcat	tactactagt	ttctagtata	300
tcttttagaa	atgkgctgta	aaagaacaat	gatgtgtatg	tctctacagg	tatatattta	360
ttctttttgt	aattacaaaa	atataaacte	actacatatt	ttattctacc	acatgctttt	420
tttcatgtaa	cagtattgtc	tagacatctt	ttcctattat	tgcgtggaag	ctatcaacct	480
tattctttgt	aatgactcca	taaattatct	tactgtgaaa	acacaccatg	tttaaccagt	540
tctctgttag	tgaacattta	ggatttttcc	agttttttaa	tattacagtg	acataattaa	600
cattaacat	atcttttgac	acatgtcctt	gcacacatgt	ataggtatga	tggactttta	660
caccctttgg	ctagattctt	tagcacataa	cgtaaatatc	ccatagagtc	aaaaccaccc	720
ttaaaacttc	ctcaggaggc	tgggtgtggt	ggctcacgcc	cgtaatccca	gcactttagg	780
aggccgaggt	gggcggatca	cgaggtcagg	agatcgagac	catcctggcc	aacatggtga	840
aaccctgtct	ctactaaaaa	tacaaaaaaa	aaaaaaaaaa	actcgta		887

&lt;210&gt; 101

&lt;211&gt; 1248

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 101

ccacgcgtcc	ggtctattaa	ggtgacagaa	ctgaagggcc	tggccaacca	tgtggttgtg	60
ggcagtgtct	cctgtgagac	caaggacctg	tttgccgccc	tgccccaggt	tgtggctgtg	120
gatatcaatg	accttggtac	catcaagctc	agcctggaag	tcacatggag	ccccttcgac	180
aaggatgacc	agccctcagc	tgtttcttct	gtcaacaagg	cctccacagt	caccaagcgc	240
ttctccacct	atagccagag	cccaccggac	acaccctcac	ttcggaaca	ggctttctat	300
aacatgtctc	gacggcagga	ggagctggag	aatgggacag	catggctcct	gtcatctgaa	360
tcttcagacg	actcatccag	cccacagctc	tcaggcactg	cccgccactc	accagccctt	420
aggccccctg	tgcagcagcc	cgagcccctt	cccattccaag	ttgccttcct	caggcctgag	480
acccccagct	ctgggcccct	ggatgaggag	ggggccgtgg	ccccagtcct	ggcaaatggg	540
catgcacctt	acagtcggac	tctgagccac	atcagtggag	ctagtgtaaa	tgctgccttg	600
gctgaggctt	cagtggaggc	cgttggccca	aaaagcctat	cctggggacc	tagccacctt	660
acacaccag	ctcccaccca	tggaaagcac	cccagtcctg	ttcctctctc	cctggaccct	720
ggccactctg	ccacaagctc	tacctctggt	acaacaggct	ctgtccccac	atctacagac	780
cctgccccat	ctgcacacct	agactcagtt	cataagtcca	cagactcttg	cccttcagaa	840
ctgccaggcc	ccactcacac	cactacaggc	tctacctata	gtgccattac	cactaccac	900
agtgtcccaa	gccccctcac	tcacactact	acaggctcca	cccacaagcc	cataatctct	960
acccttacta	ctacaggccc	tacctcaat	atcataggcc	cagtccagac	taccacaagc	1020
cccaccaca	ctatgccaa	cccttcttcc	cacagcaata	gtccccaata	cgtagatttt	1080
tgctcttctg	tatgtgacaa	catttttcta	cattatgtta	ttggaatttt	ctttcataca	1140
ttatatctct	ctaaaactct	caaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1200
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa		1248

&lt;210&gt; 102

&lt;211&gt; 1841

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 102

ggcagcagct	ggtgcaggag	ctggagcagt	accagttgtt	gccgaagaga	ttggactggg	60
agggcaacga	gcacaacagg	agctacagg	agttgtctt	gtccaataag	catgtggctc	120
ctgatcatct	tttgcaaatc	tgcagcgca	tcggtcctat	gttgataaaa	gaaattccac	180
ccagtatttc	aagagtcact	tctttacttg	gtgcaggaag	gcagtctttg	ctacgtacag	240
caaaaggtac	cttaatttga	agaagtgttc	tgctttgtat	taatagccta	ataattatta	300
taattgtgaa	gtaatgtaag	catgtggaag	aaaggtgata	atgtaactat	aatcatgct	360
gtggactata	aaattctctg	catttagcat	agaacattga	attttattac	ataagtgtt	420

aatgggtcct	tctgcattaa	aaaagttgat	aaagatatag	atgttaagct	aaaaagcttg	480
aattttattct	gagatgttgt	ttgagggtttt	atcaatgtga	gttcttaatt	ttccattttg	540
tagctcactc	ataacttcat	tgaatgtaat	tgtatgtgtc	taataaactc	tttaaatgct	600
agagggtat	catttgatat	ttagcttctg	aaagcccttt	gttataaagg	gaagtgtatt	660
tctaaatttg	gtagcagctt	gaaaacaagc	accacaaatg	taaaattgca	tggttctttt	720
tttactaatt	taattttttt	gccagttat	gtgctagcaa	aatgtttgaa	attgctattc	780
ttttctgtt	agcttgggtat	atatgactta	gactaagtat	atgtatgtga	tataatatat	840
gtgtacatgt	ggctaaactg	ctaattgggca	aagattgttg	gttcttctga	tgctgagtat	900
acatcaagtt	catcccatga	ttatttttta	ttacgagcta	ttgctgatgt	gatgctactc	960
ttagctgcac	caccagtata	aagcttaact	gagaaagaac	acccctccct	cttagttccg	1020
tgccagactg	gtttgttagc	tttagttgtt	tcttagtgct	ctagccatgt	caccctgtgg	1080
cactaatcag	gacactgttt	atattcttcc	tcttctgtgt	ccctattcac	tttgtaatta	1140
ttctatttta	gctggttata	tggtagttaa	ttggtagcct	gttttccctt	gttttcttta	1200
cttgtgtcaa	gctccatgtc	gttggtttgt	gatgagcagt	gatttagaac	tggccagacc	1260
ttagaagagt	cttcagcaag	ctgccctagg	gtaggggcat	attctctgtt	tgttttgtac	1320
tggtacccca	ggaggatgcc	ttgtaactgc	tctttgtcca	tgatagtggg	aatgaatcca	1380
ttcatgtaaa	atgcaatatg	tctgttagtt	tggggcacc	gaggctcagt	agagggttag	1440
tatgatgcct	tccctttctt	ctttgagtta	tgaagaaact	aatttctggc	acagtgtgac	1500
tgcttcaaac	ctatgttctg	ctgctatctc	ctatagagga	gggcagactt	ttttttctta	1560
gtgcatttgc	tggtaggtca	aggagggatg	gactttgaat	tagtgttcag	agtcacagat	1620
cctacgtatg	tgctcttcag	tagaggattt	tctgtgatcc	tacaatgaag	ggaaagctat	1680
ataattttatt	ggtacttcct	aaagatagag	actaaagtca	tggtagtatt	ggccaaatta	1740
attttaaaac	tgaacaagtc	atgaattttc	atataaatca	aagaactttt	tccttataaa	1800
agcttccatt	tttgaaaagt	tgaaaaaaaa	aaaaaaaaa	a		1841

<210> 103  
 <211> 685  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (678)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (679)  
 <223> n equals a,t,g, or c

<400> 103						
actacggctg	cgagaagacg	acagaagggg	ggcggcgacg	gaggaggagg	atggaggcgg	60
tggtgttcgt	cttctctctc	ctcgattgtt	gcgcgctcat	cttctctctg	gtctacttca	120
taattacatt	gtctgattta	gaatgtgatt	acattaatgc	tagatcatgt	tgctcaaaat	180
taaacaagtg	ggtaattcca	gaattgattg	gccataccat	tgctactgta	ttactgctca	240
tgctattgca	ctggttcatc	ttccttctca	acttacctgt	tgccacttgg	aatatatata	300
gatacattat	ggtgccgagt	ggtaacatgg	gagtgtttga	tccaacagaa	atacacaatc	360
gagggcagct	gaagtcacac	atgaaagaag	ccatgatcaa	gcttggtttc	cacttgctct	420
gcttcttcat	gtatctttat	agtatgatct	tagctttgat	aaatgactga	agctggagaa	480
gccgtgggtg	aagtcagcct	acactacagt	gcacagttga	ggagccagag	acttcttaaa	540
tcactccttag	aacctgtacc	atagcagtat	atattttcct	cttggaacaa	aaaactat	600
ttgctgtatt	tttaccatat	aaagtattta	aaaaacatga	aaaaaaaaa	aaaaaaaaa	660
aaaaaaaaa	aaaaaanna	aaaaa				685

<210> 104  
 <211> 1168  
 <212> DNA



&lt;213&gt; Homo sapiens

&lt;400&gt; 104

ggcacgagcc	cccgccccct	cctccctcc	cctccctcc	ccggccccgg	ctctggcccc	60
ggcccatcgc	ctgttggtgc	ttctgctagg	gaggatgtcg	ggttcgtcgc	tgcccagcgc	120
cctggccctc	tcgctgttgc	tggtctctgg	ctccctcctc	ccagggccag	gcgccgctca	180
gaacgtaga	gtacaatctg	gacaggatca	gaagtagaga	atgaagtgtg	aagagaaagg	240
gaaagacaga	agaaaggctg	cagtagtaca	aggagaaaag	caggatgcaa	gaatgaggaa	300
tgaatctttg	tttgaggagc	atccggaaaa	atataagctg	tcagaaagag	taaatagacc	360
agggacctct	aaagtaaatt	cacacatcaa	agttaaaata	atgttggaga	atcacctcct	420
gtgaaaaatt	ggcttagctt	tcagtatgcc	tctttaaaca	aaacattatc	attttataca	480
aatttttaaa	atgttgttca	taatatggag	tttaatttta	agcaccttag	ataatgcatt	540
tgtagcttgc	ttttgtgaaat	ttttatggat	tttttttttc	aaaattccta	attttagttg	600
gtaaggatta	acttcgggaa	gacaggaaaac	ccctccagta	aaattaattg	gttataaatg	660
gttacaatatt	ttaggccttat	atacataaca	aaacttctaa	ctgaatttaa	aagtgatctt	720
gtgtaaaaac	attattctag	tgatattgat	gtctaaattt	aaaagagtga	atacacaagt	780
aaaatatatc	tgctttttta	ggatctattc	agtttaggaa	ggagagtcaa	aatttgtatt	840
taatttcaat	ttattatatt	gtctgaaact	gaaagtaggc	ctaacttttg	tttgcttttg	900
tgtagtaca	aaggcaaca	tttatcaatc	aactcttatt	aatttgagat	tattttgacc	960
tgattgctca	gaacttttgt	ctatctgtat	agaaatgggg	ttttctaaat	atttaaagaa	1020
tttctacgt	atgtaaat	acttgacac	agtaagttag	gggagacatt	taatatcct	1080
cagatacctg	ctgttttctt	gttggtgttc	ttgtttttca	aataaataaa	ctgagtgtta	1140
tctgttcatt	aaaatagaat	gtagtcag				1168

&lt;210&gt; 105

&lt;211&gt; 1175

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (24)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 105

gcatggaaat	atatcctata	catnaagtgc	tgctctgagc	tgtacatwta	gccatattta	60
grattttatt	argcaggatt	caaggccctcc	taaaaatgga	tattcagata	tttaaaaaata	120
cactattaag	gaatgcaatg	taaaatcaca	ctaacatttg	catagcactt	tatagtttac	180
aaaatgcctt	cacataacg	agctcattta	tttctccttc	tcttctttct	attcatctat	240
caaggaatat	cttctataag	ccaggcatca	ggcttgacac	tgaagacaca	aaatgaaaaa	300
gatatacaag	tctctattct	taaagagttc	gtagtttaat	gaagtgaccc	aaaaagtaaa	360
cagttgcaat	ataacatgca	aaggagtgtg	atgaaataca	cctagagtac	tatgaaaatg	420
gcatagaggg	accaagcctg	taatgaagtc	agagaaagta	aaagagggtga	agcckgagct	480
aagttttaaa	ggatgaacaa	aaattgacca	gacaaaggag	ttggagaagt	gggatggtag	540
aggataaaaag	ccttttcta	ttggggaagt	gtgagtcgtc	gatattagat	gatattatta	600
atagattgtg	cacagagtgc	acatggtaga	gagggtgagag	atgaggttagc	actgttaggg	660
cagataggtg	aattctcaca	gtaaccctgt	gwtgtacmtt	atcatcctcc	tctccattat	720
gtagggggaga	acaccaaagc	ccaaagagat	taagtaactt	tccagaattt	tgattttcaaa	780
tcctaagcgt	ttggtagctg	tgtttccctg	catatagtct	gcctcaaaaag	aaaattttaa	840
gttgtagttt	gtattaaatt	taaacaaata	raggcgggtg	gcagtggctc	acgcctgtag	900
tcccagcact	ttggtaggcc	aagggtggcg	gacacctga	ggtcaggatt	tcgagaccag	960
cctggccaat	atggtgaaac	cccatctcta	ctaacataca	aaaattagct	gggcatggtg	1020
gcacatgcct	gtaatcctgg	ctacttggga	agctgaggca	ggagaatctc	ttgaaccag	1080
gaggcgagg	ttgcagttag	ccgagattgt	gccactgcac	tacaacctgg	acaacagagc	1140
aagattccgt	ctcaaaaaaa	aaaaaaaaaa	ctcga			1175

&lt;210&gt; 106

<211> 1021  
<212> DNA  
<213> Homo sapiens

<400> 106  
ggcacgagaa taaaatagat ttaggggtatt cgacacattt aatacataat gaatagtga 60  
tttcttgaat aatataatgc ctaaagtga ctgatatgca aaatatatta atcccttaca 120  
ggatgtgcat ttaccaatca gaacagatgt tggctttact gcttgtatta gttttctgta 180  
ttagtttgct tgtattagtt tgctggggca gccataacaa agtaccacag aaatttatat 240  
tctcacaatt ctgggggcta gaagactgag ataaagatgt ctgcagggtt gggttcttct 300  
aaggactctc ttgttggtt gtagatgggt gttgtctccc tgtgtcttca cctgcacttc 360  
cctctgtaac tgcccgatc ttaattctctt cttataagga cagagtcata ttggattagg 420  
gcctcaccct aatgacctc ttttaactta attacctctt tagagactct gtcttcaaat 480  
acaggcacat tctgaggtag ttttaaggta gaacttcaac atatgcattt ggaactgggg 540  
cataactgag tccatgacac tattggagag ggttctggag ccataacaga tggatgaat 600  
gggccttggt tggattctaa ttttaataaa ccaactatag aaaaacatgt tttaggcaat 660  
cagatttttt gttatgggct aaatathtag aagatgttaa gaaatgttta ttaatttcat 720  
taggtaaaat aatgttggtg tggttatgta gagtatgact tacgtgcaca gaacagaatg 780  
ataagggtgc caggatttgc tttaaaatat tctagatttt tttaaaagggt gagaggaaat 840  
gacacatgta tatctaaatt ttgatggttg ttgaagctgg ctggtaggta cctagtattt 900  
cattatactt tttcttttgt gtgtttggaa atttttataa taagcaggaa aataaaaagt 960  
aagaatatat gtattataga taatttgaaa tatgtagaat catgaaaaaa aaaaaaaaaa 1020  
a 1021

<210> 107  
<211> 830  
<212> DNA  
<213> Homo sapiens

<400> 107  
ggcacgagta aggactgtgt tctttatgca tttcttgatc caggcatggc agttcctctt 60  
ttctgtaca tattcacact cctgccactt ctaccctttc tcttatecct ctgcttttca 120  
cctctgactg taaaaagaag tagcagttcc gaaagcaaga gttccctatg aacacggaag 180  
aagacattgg caacttttga gtacaacaac tatatttaat agagtaattt aagaacatca 240  
gccagtgaat ttataacaag atagtgaag agaaaaggaa gattaattag gggtagttta 300  
ggatgccatt aaatagccta gaattagggg agtagtcgtt gaatagaag gaggccacaa 360  
atttgaggga tataagctaa gaattggtaa gccagaaga aggaaaagggt ttgggcagta 420  
aggataatga ggaacaaaat agagaactca gaagcaatat ctgactgtta tcattggaag 480  
aatttttttg cttgcttgag cttggatatt gaagtggatc aggatacttg agtgactatc 540  
tgatgggctt ttggaactag ctctcaagag gtgaaaatta gctttttttt ctttttcttt 600  
cttttttttt ttttttgagg caaggtctca ctgttggtga ggctgaacct cctgggctca 660  
agcagttgtc ccattgcagc ctctcagat actctgtaag ccaaggcagg gggaatattt 720  
tgtgtcagc agtttgaggc tgtggtgagc taagatcaca ctgctgtgct cacttcagcc 780  
tgggcaacac agtgaaaccc cgtctccatc tgtttaaaaa aaaaaaaaaa 830

<210> 108  
<211> 1301  
<212> DNA  
<213> Homo sapiens

<400> 108  
aagagggtgg ctgccgagtt cttgtttgtc ctgtgctctg agagtgggtga gttatggaga 60  
cccagggtccc agcccacccc acctcagcca ggcttgcaac ctgacctctg ccttgcccct 120  
cagtgtcccg attcatcaag tacacaggct atgggaatgc tgctggcctt ctggctgcca 180  
ggggcctcat ggaggaggc cggcccaggg gccagtactc agaggatgag gacacagaca 240  
cagatgagta caaggaaagg aaagccagca taaacctgt gaccgggagg gtggaggaga 300  
agccgcctaa ccctatggag ggcatgacag aggagcagaa ggagcacgag gccatgaagc 360

tggtgacat	gtttgacaag	ctctccagga	acagagtcac	ccagccaatg	gggatgagtc	420
ccccgggtca	tcttacgtcc	ctgcaggatg	ccatgtgcga	gactatggag	cagcagctct	480
cctcggaccc	tgactcggac	cctgactgag	gatggcagct	cttctgctcc	cccatcagga	540
ctggtgctgc	ttccagagac	ttccttgggg	ttgcaacctg	gggaagccac	atccccactgg	600
atccacaccc	gccccactt	ctccatctta	gaaacccctt	ctcttgactc	cgttctgtt	660
catgatttgc	ctctggtcca	gtttctcatc	tctggaactgc	aacggtcttc	ttgtgctaga	720
actcaggctc	agcctcgaat	tccacagacg	aagtactttc	ttttgtctgc	gccaagagga	780
atgtgttcag	aagctgctgc	ctgagggcag	ggcctacctg	ggcacacaga	agagcatatg	840
ggagggcagg	ggtttgggtg	tgggtgcaca	caaagcaagc	accatctggg	attggcacac	900
tggcagagcc	agtgtgttgg	ggtatgtgct	gcacttccca	gggagaaaac	ctgtcagaac	960
tttccatacy	agtatatcag	aacacaccct	tccaagggtat	gtatgctctg	ttgttcctgt	1020
cctgtcttca	ctgagcgcag	ggctggaggc	ctcttagaca	ttctccttgg	tcctcgttca	1080
gctgccact	gtagtatcca	cagtgcccg	gttctcgtctg	gttttggcaa	ttaaacctcc	1140
ttcctactgg	tttagactac	acttacaaca	aggaaaatgc	ccctcgtgtg	accatagatt	1200
gagatttata	ccacatacca	cacatagcca	cagaaacatc	atcttgaaat	aaagaagagt	1260
tttgacaaa	aaaaaaaaa	aaaaaaaaa	aaaaaactcg	a		1301

&lt;210&gt; 109

&lt;211&gt; 1932

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 109

aatttttttt	tttttttttt	tttttttgaa	aaaaaaaaatg	ggtagtgtat	attttgcagg	60
tttaagacaa	ctcaggacaa	taaaaacaat	ggactttaca	tgtgtatata	tatagctctc	120
ttaggcacca	taatcagtat	gagccaacaa	tatttaaact	tgattcaggc	cacattcaga	180
catttgctct	tatatacaaa	tatttaaatt	aaatacaatc	tgaaatgtgt	tctgttacat	240
acaaaaaagg	aaaaactata	caacgcagag	cagtgtgtgt	gttttaaata	attacattta	300
catgtaagct	aaatggaacc	agcaatgggtg	ctcaagtttt	tatcatccct	tccagaaaat	360
ctttttctac	catctcttct	attttttgcc	tggctttgct	ggaacatggg	ttgtggttct	420
ccagtttcat	gtccttatta	gggaaggcat	ttgagttagag	gataggactc	cctgagtgtc	480
ctccacatcg	gcttgtgact	ttgctgttga	agacttgact	gagcacattg	aagaacggca	540
ggagctgctc	catactgcgc	acggtgcaga	gggtgagcag	caagtgccct	ggctcccaac	600
ccaatgttct	ccctgagttg	tcttctctctg	gatttttctg	cagaaaacaa	aaagtgaact	660
ggtattaata	caacagacaa	tgtggtatgt	tagaaaaatt	aaaaatatat	aaactttggc	720
aattgggtcaa	gaaatgaata	caaatgacat	taagtttcta	actcctgacc	tgatcaaac	780
ccttgggtgct	tctgagacct	tttactgcc	tttattagtt	ttacatggag	cagtctaaca	840
ttgtagtaat	agttcccaac	tagaatgcgc	agataagctt	agttaacaga	aatagctttg	900
aacaggaata	gagtcacaaa	taaaagtttt	atgttgtgct	ttgtatttac	tcaaaaagct	960
cccagggtttc	tgaacctca	ctactgtaac	caaggactag	gtcacaaaat	tactacagaa	1020
aaaaggaaca	aagtgtctta	tacatttcat	aatatatccc	cttttattat	aattagttaa	1080
ttccctttta	tctaaatggc	ctaaatttgc	catgatggta	gcagtgtcca	aagtgaataa	1140
ttactgtcag	tactgcatca	cagagaaaag	aagggatccc	tcaggagaca	ctgctgtctc	1200
cttctgggtt	gtgctaaaca	acatagggag	gaaagctgga	cctggagtca	aaggaattga	1260
gttagtgtgc	tggctctgcc	atacttacgg	cacccttggg	caggatatac	aaaggttccct	1320
cacttataaa	atgggacagt	ctaaaactac	cttttagtag	agaagtcaaa	tgagaaggta	1380
tgtgaaaact	ctgtcaacta	aatataaaga	ctaataattt	gggtattaag	aggctagtgt	1440
gagaagccac	ctgaattaca	caaacacagc	tacagacatc	attctgtcta	gagaaagata	1500
agagagaaca	ggttggttga	acttgggcag	aatcacagat	acaattccac	actaaagaat	1560
gaaaataagc	aatgaactag	acagaaggaa	gaaatcatga	agacttagga	agcagaatta	1620
caatctgtca	tatttaacaaa	tggagtgtgc	cttctaagat	cagatgttgc	tcagaaactt	1680
tcattgttta	cctaataatt	taatatcact	agtttccctag	tgggtcaagc	agatgcaaaa	1740
tccagcttat	tttcttctat	gtgctctcaa	gcttattgct	tatttttaaag	taaaatcctg	1800
aaaaaggaaa	atattaggtt	ggtgcaaagc	taattgoggt	ttttgcattg	ttgaaatttg	1860
ccgttttata	ttggagtaca	ttcttaata	aatgtgggtta	tgttatacaa	aaaaaaaaa	1920
aaaaaactcg	ag					1932

<210> 110  
 <211> 1534  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1212)  
 <223> n equals a,t,g, or c

<400> 110  
 tcgaagatag gtccgagacg gtggatgttg cagctgatca tgcagttggg ttcggtgetg 60  
 ctcacacgct gccccttttg gggctgcttc agccagctca tgctgtacgc tgagagggct 120  
 gaggcacgcc ggaagcccgga catcccagtg ccttacctgt atttcgacat gggggcagcc 180  
 gtgctgtgcg ctagtttcat gtcccttggc gtgaagcggc gctggttcgc gctggggggc 240  
 gcactccaat tggccattag cactacgcc gcctacatcg ggggctacgt ccactacggg 300  
 gactggctga aggtccgtat gtactcgcgc acagttgcca tcatcggcgg ctttcttggtg 360  
 ttggccagcg gtgctgggga gctgtaccgc cggaaacctc gcagccgctc cctgcagtcc 420  
 accggccaggt tgttcctggg tatctacctc atctgtgtgg cctactcact gcagcacagc 480  
 aaggaggacc ggctggcgta tctgaacctat ctcccaggag gggagctgat gatccagctg 540  
 ttcttcgtgc tgtatggcat cctggccctt ggcctttctg tcaggctact acgtgaccct 600  
 cgtgcccag atcctggctg tactgctgcc ccctgtcatg ctgctcattg atggcaatgt 660  
 tgcttactgg cacaacacgc ggcgtgttga gttctggaac cagatgaagc tccttggaga 720  
 gagtgtgggc atcttcgga ctgctgtcat cctggccact gatggctgag ttttatggca 780  
 agaggctgag atgggcacag ggagccactg agggtcaccc tgccttctc cttgctggcc 840  
 cagctgctgt ttatttatgc tttttggtct gtttgtttga tcttttgcct ttttaaaatt 900  
 gttttttgca gtttaagagg agctcatttg tccaaatttc tgggcttcag cgcttgggag 960  
 ggcaggaaacc ctggcactaa tgctgtacaa ggttttttct ctgttaggaa gaacttgagg 1020  
 ccagctgccc actgagtctt ctgtccctga agaaaggag tattgggcag ggcttgggat 1080  
 ccggctactg agagtgggag agtgggagac agaggaaagga agatggagat tgggaagtga 1140  
 caaatgtgaa aaattcctct ttgaacctgg cagatgcagc taaactctgc agtagtggtt 1200  
 ggagactgtg anaggagtg tgtgtgttga cacatgtgga tcaggcccag gaagggcaca 1260  
 ggggctgagc actacagaag tcacatgggt tctcagggtg tgccaggggc agaaacagta 1320  
 ccggctctct gtcactcacc ttgagagtag agcagacctt gttctgctct gggctgtgaa 1380  
 ggggtggagc aggcagtggc cagctttgcc cttcctgctg tctctgtttc tagctccatg 1440  
 gttggcctgg tgggggtgga gttccctccc aaacaccaga ccacacagtc ctccaaaaat 1500  
 aaacatttta tatagacaaa aaaaaaaaaa aaaa 1534

<210> 111  
 <211> 2871  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1234)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1259)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1283)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1284)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1287)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1378)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1912)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1913)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1935)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1947)  
 <223> n equals a,t,g, or c

<400> 111  
 ggcggcgaggc ggcgggtggtg gctgagtcgc tgggtggcaga ggcgaggcg acagctctag 60  
 ggggttggcac cggccccgag aggaggatgc ggggtccggat agggctgacg ctgctgctgt 120  
 gtgcggtgct gctgagcttg gcctcggcgt cctcggatga agaaggcagc caggatgaat 180  
 ccttaggatt ccaagactac tttgacatca gatgagtcag taaaggacca tactactgca 240  
 ggcagagtag ttgctggtca aatattttctt gattcagaag aatctgaatt agaactctct 300  
 attcaagaag aggaagacag cctcaagagc caagaggggg aaagtgtcac agaagatata 360  
 agctttctag agtctccaaa tccagaaaac aaggactatg aagagccaaa gaaagtacgg 420  
 aaaccaggta gtctggacat tttccttgct ttttgattta tttaggggac aactgaaaat 480  
 ttttagctaa tgaataaaga agctgaagaa gactggcttc actgattatt acccaciaat 540  
 aatatatgga gtgtagtttg gagagaattt ctgattttta atataccaaa gttatttact 600  
 taacagattt gacccaagtt acataagctg aattccatag atgagattgc atttatcttt 660  
 ttattaatat cctgacgttt ctttttggaa tcaagtatgt aaataccttt ctactgaga 720  
 aatttaaaaa aataatatgt cagggtagca taaaaaacag aaactcagga agaactgtct 780  
 aacatgccac tatggttatt ttcaggattg tggtaggatt attactacaa taacctgtct 840  
 gatcatccta ggtaatttga tttaggtggt tatccctcca gcttgacgct tgtgtgtact 900  
 tccatcctat tctaactttc acaatcttga aacctctact tttcaattta aaacttgacc 960  
 tttttcacia tagtcttcta aatattaatc ctttttaaaa ttattaatgt atgcattcta 1020  
 ccatgtcttg ttgcccttct gtcattttatt atttcaatga tcaactgcct atctgtttat 1080  
 tattccatta ctaaccactc tcaggaactg atccaaattg gaacttttta aaaaaataga 1140  
 attttttttt actacaaata taccattctc atgaatagaa aactattttt aaaaaattaa 1200  
 aagtacctga atccatcaa ctagaaataa cagntgctca catcatggag aatattctnt 1260  
 caggattttt ttaggtgtat cannagnntt aagaaaagta aattgggtca aaatgtgtat 1320  
 tctatgttgc agcctgcatt ttgcacttaa cagtttacca tgaatgtttt tccatgtnat 1380

ttagcttatt	ttcaatttga	tagttaatgg	ctataaaaaa	ttttatttgt	aaatatatgg	1440
taccataaac	caaaacgttt	atgttttggc	gggagatcat	tttagatgta	tcttttgtgc	1500
tatctgtgaa	aatttcctta	gaattcctta	agtaaatattg	ctgaattgga	tgtaaaagtt	1560
taaaagacag	tagatacaca	ttgttaaatt	gttcttcaga	aaagtgattc	tgtttacttc	1620
ctctgaaaat	acctctttcc	ctgtacctca	cccaagtgtg	tattaccatt	ttaaaatttt	1680
tactaaatat	aatttaattc	attcttcatt	ttttaattag	ggattttttt	tttttttttt	1740
tagtttttat	attttttagag	acatggcttc	actctgtcac	tcaggctgga	gtgcagtggc	1800
acgatcatag	ttcactgcag	ccttgaactc	aggtgatctc	cctctttggc	ctcccaaagt	1860
gctgggatta	caggcatgag	acactacatc	aagcctggga	aatttttaaa	cnngcataaa	1920
aagtagaggg	taaantgccca	ccccttncca	accctcactc	agcttcaata	aacatcaaca	1980
ttctgctggg	cttttcatct	ttactaccct	acacacattt	gccctttttt	tctttcctag	2040
aatattttta	ggcaaattcc	gcattgtgctt	ttacatctct	gtgtctctct	ctagtaagaa	2100
tgctcttttc	agcaaaatca	cagaattagc	cattactcct	ttattacctt	ataccagac	2160
tgtttaattt	ttctagtgtc	ttcaagtgtc	tgtttacaat	ttatttgttt	gaattcattt	2220
ctaagctact	caggaggctg	agtcaggaga	attgcttgaa	ccctagaggc	agaggttgca	2280
gtgagctgag	atcgtgccac	tgtactccag	cctgggtgac	aaagtgagac	tccatgtcat	2340
aacaaaacaa	aacaaaacaa	aacatgacga	aacaaaacaa	acaattgaat	aatatccctc	2400
agttattatt	tagagaagag	atgactcaat	ataaatgtaa	tatgtgatcc	atttggtcac	2460
agaatgaatt	tcagtcattg	cttaggtaag	cctggtaaaa	aaaaaaaaaa	cgggattcca	2520
tgattagtgt	gttgaaaaag	gggtttgccc	aaagtgtaac	agacagagcc	gggtgcagtg	2580
gctcacgcct	gtaatcccag	aactttggga	ggccaaggca	ggcggatcac	gaggtcaaga	2640
gattgagaca	atcctggcca	acatggtgaa	gccctgtatc	aactaaaaat	acaaaaacaa	2700
ttagctgggc	gtggtgacat	gtgcctgtag	tcccagctac	tcaggaggct	gaggcaggag	2760
aattgcttga	acctgggagg	cggaggctgc	agtgagctga	gattgctcca	ctgcactcca	2820
gcctggccac	agagtgggat	tccatctcaa	aaaaaaaaaa	aaaaaaaaaa	a	2871

&lt;210&gt; 112

&lt;211&gt; 1037

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (936)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (946)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (951)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 112

ccggtccgga	attccccggg	cgaccacgc	gtccggcg	gcgcaggacg	tgcactatgg	60
ctcggggctc	gctgcgccg	ttgctgcggc	tcctcgtgct	ggggctctgg	ctggcgttgc	120
tgcgctccgt	ggccggggag	caagcgccag	gcaccgccc	ctgctcccg	ggcagctcct	180
ggagcgcgga	cctggacaag	tgcattgact	cgagcacctc	ctgccccctt	ccggctgctt	240
tggcccatcc	ttggggggcg	tctgagcctg	accttcgtgc	tggggctgct	ttctggcttt	300
ttggtctgga	gacgatgccg	caggagagag	aagttcacca	cccccataga	ggagaccggc	360
ggagagggct	gcccagctgt	ggcgctgac	cagtgaacaat	gtgccccctg	ccagccgggg	420
ctcgcccact	catcattcat	tcattccatt	tagagccagt	ctctgcctcc	cagacggggc	480
gggagccaag	ctcctccaac	cacaaggggg	gtggggggcg	gtgaatcacc	tctgaggcct	540
ggggccagg	ttcaggggaa	ccttccaagg	tgctcggttg	ccctgcctct	ggctccagaa	600
cagaaaggga	gcctcacgct	ggctcacaca	aaacagctga	cactgactaa	ggaactgcag	660

catttgcaca	ggggaagggg	gtgccctcct	tcttagaggg	cctggggggc	aggctgactt	720
ggggggcaga	cttgacacta	ggccccactc	actcagatgt	cctgaaattc	caccacgggg	780
gtcaccctgg	gggggttagg	acctatTTTT	aacactaggg	ggctggccca	ctaggagggc	840
tggccctaag	atacagacc	ccccaactcc	ccaaagcggg	ggggggatat	ttatTTTggg	900
gagagtTTTg	aggggagggg	gattTTTTTT	ttaaangatt	TTTTantTTT	naaaaaaaaa	960
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1020
aaaaaaaaaa	aaaaaaa					1037

<210> 113  
 <211> 2214  
 <212> DNA  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (289)  
 <223> n equals a,t,g, or c

<400> 113

cggacgcgtg	ggctgaccca	cgcgtccggg	aaaaarggaa	aatatgccgt	gtaaaatctc	60
gttctgtgtc	tgaattgccg	taggctcaga	tcttcatttg	aggttctgtg	tctgaattgc	120
cgtaggctca	gatcttcatt	tgaggttatg	ttctataagt	taacgttgat	cttgtgtgag	180
ctttcggtag	ctggagtaac	acaggcggcc	tcacagcgac	ctctccagcg	ccttccaagg	240
cacatctgca	gccagcgtam	tcctcctggg	agatgcctcc	tcaaggccnt	gctccagacc	300
acgtgggrar	ggcctgacaa	gccaatcccc	aggctgtccc	caccttgra	gagtgcacct	360
aaacgctaga	cataggggga	atgggaaaga	aaagaaagct	gcagacctca	agttaaaatt	420
ccctcaaaaa	cgTTTTtatt	tatctgcttt	ttctgaaagg	ataaaggctt	tttgaaaatt	480
atTTTctaac	aaataacatg	aacacttcta	gaaaccctag	aaaaacacaa	agtattcaaa	540
atagaaagaa	aaattaccca	ttactcttta	agccagcatt	atccattgcg	gtgctTTTgg	600
agttgggtga	ggccgtagcc	tctgccaagt	caaggagccc	ggtgggtggc	gtggcattcc	660
tgcaagggtg	TTTTTTTTtc	tttgagatgg	agtctcactc	ttgtcaccac	agctggaatg	720
tggtggtgta	aacagctcac	tgcagccttg	accctgaggg	tcaagcgatc	cttctgcctt	780
ggcctcctga	gtagctggga	tcccaggcga	gagtcaccac	accctgtcca	tgttctgca	840
ggtcttgata	tgcaaggacg	ctgtgtcttc	cctgccacat	tttcttcttc	tttcttgaga	900
cagacccttg	ctccatcacc	caggccagag	tgtggtsgtg	cgaacacggc	tactgcagc	960
ctcgaccctc	aggctcaagc	gatcctcacc	cctcgagccc	ccaaagtgtc	gggatcacag	1020
gcgagagtca	ccatgctggc	ctgaatcttc	aggggtattt	cggttgargt	gycacttact	1080
tarccatsec	tgtttcaaga	gtgtaggtgg	tcaccctgtc	tctgccgctg	acctggcctg	1140
gaccctcggc	tgtgagaggg	aggggtgggc	tgggctggag	gaacctraag	ccctcgtgat	1200
gtcacaagcc	catctggctg	ggcacccttc	gctgtgtcct	gagctgcaca	tgccccaggt	1260
ggccccca	gcagaggcga	gccactgrag	ggtgragggc	ttccacggac	ggtcttcagg	1320
ggragaagaa	gggcccaggc	ccccaggaga	ctcaggagac	cagagcctgg	ggtcaggggc	1380
tmagcagggg	ctyarccagg	gctggatgtc	cggagccagc	cccgmagccc	tgkgtctttt	1440
gttcttcgca	ctcccaccgt	cgtgtgaac	agctccagcc	ccacctgcgc	ctccctgtgc	1500
tgggctccat	cagggagccc	agaagacgtg	tgtgcttctg	aaattgggtc	cctacatgcc	1560
tttgtcccag	tgcaccttgc	tccttccatt	tactatcgag	atttaaatgc	ctgttttctc	1620
cccagagggt	gacggatata	ttcagacgtt	acgacacgga	tcaggacggc	tggattcagg	1680
tgctgtacga	acagtacctg	tccatggctc	tcagtatcgt	atgaccttgg	cctctcgtga	1740
agagcagcac	aacatggaaa	gagccaaaat	gtcacagtcc	ctatctgtga	gggaattggag	1800
cacaggtgca	gttagatgct	gttcttcttc	tagattttgt	cacgtgggga	cccagctgta	1860
catatgtgga	taagctgatt	aatggTTTTg	caactgtaat	agttagctgta	tcgttctaatt	1920
gcagacattg	gattttggtga	ctgtctcatt	gtgccatgag	gtaaatgtaa	tgtttcaggc	1980
attctgcttg	caaaaaaatc	tatcatgtgc	ttttctagat	gtctctggtt	ctatagtgc	2040
aatgctTTTa	ttagccaata	ggaattTTTa	aataacatgg	aacttacaca	aaaggctttt	2100
catgtgcctt	actTTTTttaa	aaaggagttt	attgtattca	ttggaatatg	tgacgtaagc	2160
aataaaggga	atgttagacg	tgtaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaag	2214

<210> 114  
 <211> 3300  
 <212> DNA  
 <213> Homo sapiens

<400> 114

tcgaccacag	cgtccggtga	gaggcaagga	cttttcatct	ttagggcatt	ctgaccacgt	60
cctgcttcag	agagattgtt	cccggcgtct	cagtgcctatg	gggagcaggt	tcctcctggt	120
cctgctctca	ggtctcactg	tcttactggc	tctgccagga	tcagaagcca	agaattcttg	180
agcttcctgt	cctccatgcc	ctaaatatgc	cagctgccac	aacagcacc	actgtacttg	240
tgaagatggc	tttcggggcca	ggtctggcag	gacatacttt	catgattcct	ctgagaagtg	300
tgaagatatt	aatgaatgtg	aaaccgggct	ggcaaatgtc	aagtataaag	catattgtag	360
gaataaagtt	ggagggttaca	tctgtagctg	tttggtaaaa	tatactttat	tcaactttct	420
ggctggtatt	atagattatg	atcatccgga	ttgttatgag	aacaatagtc	aagggacgac	480
acagtcaaac	gtggatattt	gggtgagtg	ggtgaagcct	ggatttggga	aacagctggt	540
acgtataact	atgccatttt	cctacccaaa	cattaacatg	tcttcctgtg	attttttaggg	600
tagggtagtt	ctatccaggg	gtaattttgt	cctctgtccc	aaggctatct	gtcaatgact	660
ggggacactt	ttggttgtca	taccttgggg	gtgatgtgtg	tgactggcat	ctgggtggatg	720
gagaccaggg	atacagctca	acatccctaca	gtgccagga	cagcctcca	caatcaagaa	780
gtgcctagt	ccatagtgtc	atagagatag	agaaatacaa	gtgtaggggg	aaagtgcctc	840
agctggcatt	caagagccta	catcaagcac	ctagattctc	aatgccacac	gcaccttgta	900
gcaccttaat	aaatatcggt	gccttctggg	ctcccactc	caacacttgt	gcatattccc	960
tatttcttac	atttcagtaa	gagtcaatct	aattagctta	atttttttgg	aaggaaaatc	1020
tgagaagaaa	tggaagcaga	gaggactttg	caagaagggc	tactcaacta	attcaaagcg	1080
tggagttgag	catctggaat	gcgagttttg	cttctccagg	aaagggtcaa	atttctgaat	1140
ttgatatagt	ctatgaaacc	aagaggtgca	atgagacaag	ggagaatgct	tttctggaug	1200
ctggaaataa	caccatggat	atcaactgtg	ctgatgcttt	aaaaggaaac	ctaagagaga	1260
gcactgcagt	tgccctatca	cttatcaatc	tcttggggat	attctgaatg	catccttttt	1320
tagtaaacga	aaagggatgc	aggaagtaaa	actgaactct	tacgttgtga	gcggcaccat	1380
cggtttgaa	gaaaaaattt	ccctctctga	acctgtgttc	ctgacttttc	gccataatca	1440
gcctggtgac	aagagaacaa	aacatatctg	tgtctactgg	gagggatcag	agggaggccg	1500
ctggctccac	gagggctgct	ctcatgtgca	cagcaacggg	tcttacacca	aatgcaagt	1560
cttccatctg	tccagctttg	ccgtcctcgt	ggctcttgcc	cccaaggagg	accctgtgct	1620
gaccgtgatc	acccaggtgg	ggctgaccat	ctctctgctg	tgccctctcc	tggccatcct	1680
caccttcctc	ctgtgccggc	ccatccagaa	caccagcacc	tccctccatc	tagagctctc	1740
cctctgcctc	ttcctggccc	acctcctgtt	cctgacgggc	atcaacagaa	ctgagcctga	1800
ggtgctgtgc	tccatcattg	cagggctgct	gcacttcctc	tacctggctt	gcttcacctg	1860
gatgctcctg	gaagggtcgc	acctcttctc	caccgtcagg	aacctcaagg	tggccaacta	1920
caccagcacg	ggcagattca	agaagaggtt	catgtaccct	gtaggctacg	ggatcccagc	1980
tgtgattatt	gctgtgtcag	caatagtggg	accccaagaat	tatggaacat	ttactcactg	2040
ttggctcaag	cttgataaag	gattcatctg	gagcttcatg	gggccagtag	cagtcattat	2100
cttgataaac	ctggtgttct	acttccaagt	tctgtggatt	ttgagaagca	aactttcttc	2160
cctcaataaa	gaagtttcca	ccattcagga	caccagagtc	atgacattta	aagccatttc	2220
tcagctattt	atcctgggct	gttcttgggg	ccttgggttt	tttatggttg	aagaagtagg	2280
gaagacgatt	ggatcaatca	ttgcatactc	attccaccat	atcaacaccc	ttcagggagt	2340
gttgctcttt	gtggtacact	gtctccttaa	tgcgcagggt	cgaatggaat	ataaaaagt	2400
gtttagtggg	atgcggaaag	gggtagaaac	tgaagacact	gagatgtctc	gctctactac	2460
ccaaacaaaa	acggaagaag	tggggaagtc	ctcagaaatc	tttcataaag	gagggcactgc	2520
atcatcatct	gcagagtcaa	ccaagcaacc	gcagccacag	gttcatctcg	tctctgctgc	2580
ttggctaaag	atgaactgac	ctggcaagt	ccatggcaat	gacccggaag	ttacccctcc	2640
tttcggttg	tctacagcgc	cctgtgggtc	acacatagat	tggacaaaatg	ccactatttc	2700
tagctttcct	gtgaaaagtc	taggtcatt	cacctatttt	ggctttttat	gttcatagaa	2760
agaacaagac	atttgggaga	attcttagat	ccagagtcca	gtagtgtggc	acgtgcaatg	2820
aagtgtcgga	aggatgcatt	ttaaagatgg	cgggaggag	aagtggattt	tcttcttgca	2880
gctactgcc	ccttgccaga	aactcactaa	ctggcatctg	gattcagctc	atagttccct	2940
ttctggcctc	tctgctgtat	tttatgtctc	caaagatctt	acattaacac	tccacattca	3000
cataattcaa	caattttcat	atggatcagt	attaaagagg	gtgttgcat	ttgcaatata	3060
aaaatgcatt	atcaggtgct	ggagaggatg	tggagaaata	ggaacacttt	tacactgttg	3120
gtgggactgt	aaactagtct	aaccatcgtg	gaagtcagtg	tggcgatttc	tcagggactct	3180



agaactagaa ataccatttg acacagctat cccattactg ggtatataacc ccaagggtta 3240  
 taaatcatgc tgctataaag acacatgcac acgtaaaaaa aaaaaaaaag ggcggccgct 3300

<210> 115  
 <211> 1286  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1149)  
 <223> n equals a,t,g, or c

<400> 115  
 gactgcttta cggacattgg atgaagccga agcattttaga atgggtgcctg gcacacagtt 60  
 ggtgcgtgat atgggttaagc tttgtgtccc caccacacatc tcatcttgaa tgtgacggtt 120  
 tccccggctc cctcctgccg ccatgtgaag aaggctggtt ctcccccttc acctccacc 180  
 accatgattg ccatggatgc tccccactcc aaagcagccc tggacagcat taacgagctg 240  
 cccgagaaca tctgtctgga gctgttcacg cacgtgcccg cccgccagct gctgctgaac 300  
 tgccgcctgg tctgcagcct ctggcgggga cctcatcgac ctcatgacct tctggaaacy 360  
 caatgcctgc gagagggcct catcaccaag gactgggacc agcccggtggc cgactggaaa 420  
 atcttctatt tcctacggag cctgcatagg aactcctgcg caaccctgtg gctgaagagg 480  
 atatgtttgc atggcaaatt gatttcaatg gtggggaccg ctggaagggtg gagagcctcc 540  
 ctggagccca cgggacagat tttcctgacc ccaaagtcaa gaagtatttt gtcacatcct 600  
 acgaaatgtg cctcaagtcc cagctgggtg acctgttagc cgagggctac tgggaggagc 660  
 tactagacac attccggccg gacatcgtgg ttaaggactg gtttgctgcc agagccgact 720  
 gtggctgcac ctaccaactc aaagtgcagc tggcctcgcc tgactacttc gtgttgccct 780  
 ccttcagacc cccacctgtg accatccaac agtggaaaca tgccacatgg acagaggtct 840  
 cctacacctt ctacagactac ccccggggtg tccgctacat cctcttcag catgggggca 900  
 gggacaccca gtactgggca ggctgggtat ggccccgagt caccaacagc agcattgtcg 960  
 tcagccccaa gatgaccagg aaccaggcct cctccgaggc tcagcctggg cagaagcatg 1020  
 gacaggagga ggctgcccac tcgccctacc gagctgttgt ccagattttc tgacagctgt 1080  
 ccactcctgt tctgggtcag ccagaggttc ctccaggcag gagctgagca tggggtgggc 1140  
 aagtgaaggnc cctgtacca ggcacttctg ccccggttca accctacca gcttggggga 1200  
 acttactgca catagctctg acgttttgtt gtaataaatg ttttcaggcc gggcaaaaaa 1260  
 aaaaaaaaaa aaaaaaaaaa aaaaaa 1286

<210> 116  
 <211> 2189  
 <212> DNA  
 <213> Homo sapiens

<400> 116  
 ggaattcggc acgaggcgcc cgaggatgtg ctgctggccg ctgctcctgc tgtgggggct 60  
 gctccccggg acggcgccgg ggggctcggg ccgaacctat ccgcaccgga ccctcctgga 120  
 ctcgaggggc aagtactggc tgggctggag ccagcggggc agccagatcg ccttcgcct 180  
 ccagggtgcg actgcaggct acgtgggctt cggcttctcg cccaccgggg ccattggcgtc 240  
 cgccgacatc gtcgtgggcg ggggtggcca cgggcggccc tacctccagg attattttac 300  
 aaatgcaaat agagagttga aaaaagatgc tcagcaagat taccatctag aatatgccat 360  
 ggaaaatagc acacacacaa taattgaatt taccagagag ctgcatacat gtgacataaa 420  
 tgacaagagt ataacggata gcaactgtgag agtgatctgg gcctaccacc atgaagatgc 480  
 aggagaagct ggtcccaagt accatgactc caataggggc accaagagtt tgcggttatt 540  
 gaatcctgag aaaactagtg tgctatctac agccttacca tactttgatc tggtaaatca 600  
 ggacgtcccc atcccaaca aagatacaac atattgggtg caaatgttta agattcctgt 660  
 gttccaagaa aagcatcatg taataaagggt tgagccagtg atacagagag gccatgagag 720  
 tctggtgcac cacatcctgc tctatcagtg cagcaacaac tttaacgaca gcgttctctg 780  
 aatccgggca cgaattgcta tcaccccaac atgcccagtg cattcctcac ctgtgaaact 840

gtgatttttg	cctgggctat	tgggtggagag	ggcttttctt	atccacctca	tgttgatta	900
tcccttgga	ctccattaga	tccgcattat	gtgctcctag	aagtcatta	tgataatccc	960
acttatgagg	aaggcttaat	agataattct	ggactgaggt	tattttacac	aatggatata	1020
aggaaatatg	atgctggggt	gattgaggct	ggcctctggg	tgagcctctt	ccataccatc	1080
cctccaggga	tgctgagtt	ccagtctgag	ggctactgca	ctttggagtg	cctggaagag	1140
gctctggaag	ccgaaaagcc	aagtggaatt	catgtgtttg	ctgttcttct	ccatgctcac	1200
ctggctggca	gaggcatcag	gctgcgtcat	tttcgaaaag	ggaaggaaat	gaaattactt	1260
gcctatgatg	atgattttga	cttcaatttc	caggagtttc	agtatctaaa	ggaagaacaa	1320
acaatcttac	caggagataa	cctaattact	gagtgtcgct	acaacacgaa	agatagagct	1380
gagatgactt	ggggaggact	aagcaccagg	agtgaatgt	gtctctcata	ccttctttat	1440
taccaagaa	ttaatcttac	tcgatgtgca	agtattccag	acattatgga	acaacttcag	1500
ttcattgggg	ttaaggagat	ctacagacca	gtcacgacct	ggcctttcat	tatcaaaagt	1560
cccaagcaat	ataaaaaact	ttctttcatg	gatgctatga	ataagttaa	atggactaaa	1620
aaggaaggtc	tctccttcaa	caagctggtc	ctcagcctgc	cagtgaatgt	gagatgttcc	1680
aagacagaca	atgctgagtg	gtcgattcca	aggaatgaca	gcattacctc	cagatataga	1740
aagaccctat	aaagcagAAC	cctttgggtg	gtggcacgtc	ttcttctctc	tccctgcaca	1800
gagatttctc	ccatcaactt	gcttgtttgc	cttctgtctac	tcagctgcac	gctgagcacc	1860
aagagcttgt	gatcaaaatt	ctgttggact	tgacaatgtt	ttctatgac	tgaacctgtc	1920
atttgaagta	caggttaaag	actgtgtcca	ctttgggcat	gaagagtgtg	gagacttttc	1980
ttccccattt	tccctccctc	cttttctctt	tccatgttac	atgagagaca	tcaatcagggt	2040
tctcttctct	ttcttagaaa	tatctgatgt	tatatatata	tggtaataa	aataaaactg	2100
gcctgactta	agataaccat	tttaaaaaat	tgggctgtca	tgtgggaata	aaagaattct	2160
ttctttccta	aaaaaaaaaa	aaaaaaaaaa				2189

&lt;210&gt; 117

&lt;211&gt; 1763

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 117

ggtggcctag	agatgctgct	gccgcggttg	cagttgtcgc	gcacgcctct	gcccgccagc	60
ccgctccacc	gccgtagcgc	ccgagtgtcg	gggggcgcac	ccgagtcggg	ccatgaggcc	120
gggaaccgcg	ctacaggccg	tgctgctggc	cgctgctgctg	gtggggctgc	gggccgcgac	180
gggtcgcttg	ctgagtgggc	agccagtctg	ccggggaggg	acacagaggc	cttgttataa	240
agtcatttac	ttccatgata	cttctcgaag	actgaacttt	gaggaaagcca	aagaagcctg	300
caggagggga	tggaggccag	ctagttagca	tcgagttctg	aagatgaaca	gaaactgata	360
gaaaakttca	ttgaaaacct	cttgccatct	gatggtgayt	tctggawtgg	gctcaggagg	420
cgtgaggaga	aacaaagcaa	tagcacagct	gccaggacct	ttatgcttgg	actgatggca	480
gcatacaca	atttagaac	atggtatgtg	atgagccgtc	ctgcggcagc	gaggtgtcgc	540
tggatcatgta	ccatcagcca	tgggcacccg	ctggcagctg	aggcccttac	atgttccagt	600
ggaatgatga	ccggtgcaac	atgaagaaca	atttcatttg	caaataattct	gatgagaaac	660
cagcagttcc	ttctagagaa	gctgaagggtg	aggaaacaga	gctgacaaca	cctgtacttc	720
cagaagaaac	acaggaagaa	gatgccaata	aaacatttaa	agaaagtaga	gaagctgcct	780
tgaatctggc	ctacatccta	atccccagca	ttccccctct	cctcctcctt	gkggtcacca	840
cagttgtatg	ttgggttttg	atctgtagaa	aaagaaaacg	ggagcagcca	gacctatgca	900
caaagaagca	acacaccatc	tggccctctc	ctcaccaggg	aaacagcccg	gacctagagg	960
tctacaatgt	catwagaaaa	caaagcgaag	ctgacttagc	tgagaccctg	ccagacctga	1020
agaatatttc	attccgagtg	tgttcgggag	aagccactcc	cgatgacatg	tcttgtgact	1080
atgacaacat	ggctgtgaac	ccatcagaaa	gtgggtttgt	gactctgggtg	agcgtggaga	1140
gtggatttgt	gaccaatgac	atttatgagt	tctccccaga	ccaaatgggg	aggagtaagg	1200
agtctggatg	ggtggaaaat	gaaatatatg	gttatttagga	catataaaaa	actgaaactg	1260
acaacaatgg	aaaagaaatg	ataagcaaaa	tctcttattt	ttctataagg	aaaatacaca	1320
gaaggtctat	gaacaagctt	agatcagggtc	ctgtggatga	gcatgtgggtc	cccacgacct	1380
cctgttggac	ccccacgttt	tggctgtatc	ctttatccca	gccagtcac	cagctcgacc	1440
ttatgagaag	gtaccttgcc	caggtctggc	acatagtaga	gtctcaataa	atgtcacttg	1500
gttgggttgta	tctaactttt	aagggacaga	gctttacctg	gcagtgataa	agatgggctg	1560
tggagcttgg	aaaaccacct	ctgttttctt	tgctctatac	agcagcacat	attatcatac	1620
agacagaaaa	tccagaatct	tttcaaagcc	cacatatggg	agcacagggt	ggcctgtgca	1680

tcggcaattc tcatatctgt ttttttcaaa gaataaaatc aaataaagag caggaaaaaa 1740  
 aaaaaaaaaa aaaaaaactc gag 1763

<210> 118  
 <211> 1375  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (18)  
 <223> n equals a,t,g, or c

<400> 118  
 ggcggggcggc gcggaagngg cggckgcgcg gccggggcag ccatgtcgcc attgtctgcg 60  
 gcgcggggcgg ccctgcgggt ctacgcggta ggccgcggcg tgatcctggc gcagctgctg 120  
 cggcgctgcc gsgggggcctt cctggagcca gttytcccc cagcacctga ccgtgtcgct 180  
 atagtgcagg gagggacaga tggcattggc tattctacag cgaacatctg gcgagacttg 240  
 gcatgcatgt tatcatagct ggaaataatg acagcaaacg caaacaagtt gtaagcaaaa 300  
 taaaagaaga aaccttgaac gacaaagtgg aatttttata ctgtgacttg gcttccatga 360  
 cttccatccg gcagtttgtg cagaagttca agatgaagaa gattcctctc catgtcctga 420  
 tcaacaatgc tggggtgatg atgggtccctc agaggaaaac cagagatgga ttcgaagaac 480  
 atttcggcct gaactaccta gggcacttcc tgctgaccaa ccttctcttg gatacgctga 540  
 aagagtcttg gtccccctggc cacagtgcga ggggtggcac cgtctcctct gccacccatt 600  
 acgtcgctga gctgaacatg gatgaccttc agagcagtgc ctgctactca cccacgcag 660  
 cctacgcccga gagcaagctg gcccttgctc tggttacctc ccacctccag cggctgctgg 720  
 cggctgaggg aagccacgtg accgccaacg tgggtggacc cgggggtggc aacacggacs 780  
 tctacaagca cgtgttcttg gccaccctc tggcgaagaa gcttctcggc tgggtgcttt 840  
 tcaagacccc cgatgaagga gcgtggactt ccatctacgc agcagtcacc ccagagctgg 900  
 aaggagttag tggccgttac ctatacaacg agaaagagac caagtccctc caggtcacct 960  
 acaaccagaa actgcagcag cagctgtggt ctaagagttag tgagatgact ggggtccttg 1020  
 atgtgacctt gtgatattct gtctcaggat agctgctgcc ccaagaaaca cattgcacct 1080  
 gccaatagct tgtgggtctg tgaagactgc ggtgtttgag tttctcacac ccacctgccc 1140  
 acagggctct gtcctctagt tttgagacag ctgcctcaac ctctgcagaa cttcaagaag 1200  
 ccaaataaac attttgagg ataatacccc caagtggctc tcaaccataa actttgtgat 1260  
 tccaaagtgc ccagttgtca caggtgccat aaataattac attttccaac ataaaaaaaa 1320  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaggcg gccgc 1375

<210> 119  
 <211> 1022  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (937)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (990)  
 <223> n equals a,t,g, or c

<400> 119  
 ggcacgagag agccrgcggc ccgagccggg gccatggcga actgctgagc tgcgtcctag 60  
 gccccggct ctacaaaatc taccgggaga gggactctga aagggccccc gccagcgctc 120  
 ctgagacgcc aacggcagtc actgcccccc attccagctc ctgggatacg tactatcagc 180

cccgtgccct	ggagaaacat	gctgacagca	tcttggcact	ggcttcagta	ttctgggtcca	240
tctcttatta	ctcctctccc	ttcgccctct	tctacttgta	caggaaaggt	tacttgagtt	300
tgteccaaagt	ggtgccgttt	tctcactatg	ctgggacatt	gctgctactt	ctggcagggtg	360
tggcctgctc	cgaggcattg	gccgctggac	caacccccag	taccggcagt	tcaccacat	420
cttggaagca	acacategga	accagtcttc	agaaaacaag	aggcagcttg	ccaactacaa	480
ctttgacttc	cggagctggc	cagtcgactt	ccactgggaa	gaaccagca	gccggaagga	540
gtctcgaggg	ggcccttccc	gccgggggtg	ggccctgctt	cgcccagagc	ccctgcaccg	600
ggggacagca	gacaccctcc	tcaaccgggt	taagaagctg	ccttgtcaga	tcaccagcta	660
cctggtggcg	cacaccctag	ggcgccggat	gctgtatcca	ggctctgtgt	acctgctgca	720
gaaggccctc	atgcctgtgc	tgctgcaggg	ccaggcccga	ctggtggaag	agtgtaatgg	780
gcgcggggca	aagctgctgg	cctgtgatgg	caatgagatt	gacaccatgt	ttgtggaccg	840
gcggggggaca	gctgagcccc	aggacagaag	ctggtgatct	gctgtgargg	gaatgctggg	900
ttttatgarg	tgggctgctg	ctccamgccc	ctggaanctg	gatattcatc	ckgggtggaa	960
tcacccagct	ttgctggaac	acagggggtn	ccattcccgc	aaaatgaagg	ctaagccat	1020
gg						1022

<210> 120  
 <211> 2311  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (654)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (2293)  
 <223> n equals a,t,g, or c

<400> 120						
tgcacccaag	cgctccgttc	ctcatgctgc	ccgctcgcct	accgttcagg	ctgctgagcc	60
ttttccttcg	tggatccgct	ccacaggcag	cgcgccatgg	cctccgggag	ccgctcctgg	120
agaggaggtg	cgctgccgcc	tcctccttcc	agcactcatc	gagtctggga	cgcgagcttc	180
cttatgaccc	cgtggacacg	gagggctttg	gagaagggtg	tgacatgcag	gagcgttttc	240
tgttcccgga	gtacatcctg	gatccggagc	cgcaaccac	ccgcgaaaag	cagctgcagg	300
agctccagca	acagcaggag	gaggaggagc	gacagaggca	gcagcggcgg	gaggagcggc	360
gacagcaaaa	cctacggggc	aggtcccggg	agcaccgggt	cgtggggcac	ccggaccggg	420
cattgccgcc	cagcggcggtg	aactgctcgg	gctgcggggc	asactgcac	tgccaggacg	480
ccggagtgcc	cggtacctg	ccccgagaga	agttcctccg	cacggcggag	gcagacggcg	540
ggctggcacg	gaccgtgtgc	cagcgtgct	ggctgctgtc	gcaccaccgg	cgcgctctac	600
gcctgcaggt	gagccgcgag	cagtacctgg	agctggtgag	cgccgcgttg	cggngggccc	660
gcccctccct	ggtgctctac	atggtggacc	tgctggacct	gcccagcgc	ctgctgccc	720
acttgccgc	gctgggtggc	cccaagcagc	tgatcgtgct	gggaaaacaa	gtggacctcc	780
tgccccagga	tgctcctggc	taccggcaga	ggctgcggga	gcgactgtgg	gaggactgtg	840
ccgcgcggg	gctcctgctg	gcccctggca	ccaagggcca	cagcgccccg	tcaaggacga	900
gccacaggac	ggggagaatc	cgaatccgcc	gaactggtcc	cgcacagtgg	tcagggacgt	960
gcggctgac	agcgccaaga	ccggctatgg	agtggaaag	ttgatctctg	cccttcagcg	1020
ctcctggcgc	taccgtgggg	acgtctactt	agtgggcgc	accaacgcgc	gcaaatccac	1080
tctctttaac	acgtcctgg	agtcgatta	ctgctactgc	aagggtccg	aggccatcga	1140
cagagccacc	atctccctt	ggccaggtac	tacattaaac	cttctgaagt	ttcctatttg	1200
caacccaact	ccttacagaa	tgtttaaaag	gcataaaaga	cttaaaaaag	attcaactca	1260
agctgaagaa	gatcttagtg	agcaagaaca	aatcagctt	aatgtcctca	aaaagcatgg	1320
ttatgtcgta	ggaagagttg	gaaggacatt	cttgatttca	gaagaacaga	aggataacat	1380
tccttttgag	tttgatgctg	attcacttgc	ctttgacatg	gaaaatgacc	ctgttatggg	1440
tacacacaaa	ttcaccaaac	aagtagaatt	gactgcacaa	gatgtgaaag	atgcccatg	1500
gttttatgac	accctgggaa	ttacaaaaga	aaattgtatt	ttaaatcttc	taacagaaaa	1560

agaagtaa	attgttttgc	caacacagtc	cattgttcca	agaacttttg	tgtctaaacc	1620
aggaatggtt	ctgttttttg	gtgctatagg	ccgcatagat	ttcctgcagg	gaaatcagtc	1680
agcttggttt	acagtcgtgg	cttccaacat	cctccctgtg	catatcacct	ccttgagacag	1740
ggcagacgct	ctgtatcaga	agcatgcagg	tcatacgta	ctccagattc	caatgggtgg	1800
aaaagaacga	atggcrggat	ttcctcctct	tgttgctgaa	gacattatgt	taaaagaagg	1860
actgggggca	tctgaagcag	tggccgacat	caagttttcc	tctgcagggt	gggtttcagt	1920
aacaccta	tttaaggaca	gactgcatct	ccgaggctat	acacctgaag	gaacagtttt	1980
gaccgtccgg	ccccctctct	tgccatata	tgttaacatc	aaaggacagc	gcatcaagaa	2040
aagtgtggcc	tataaaacca	agaagcctcc	ttcccttatg	tacaacgtga	ggaagaagaa	2100
aggaaagata	aatgtatgag	accgaccttg	ttcactccag	atattaactg	tattgaacac	2160
aacaaaatac	attgaatttg	tattaaacat	ataacgcata	aataaagctc	ccattcttac	2220
ccttaaaaaa	aaaaaaaaag	ggcggccgct	ctagaggatc	caagcttacg	tacgcgtgca	2280
tgcgacgtca	tanctcgtct	ataggaactg	g			2311

&lt;210&gt; 121

&lt;211&gt; 1286

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1284)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 121

gggcgcgcgc	gtgaaaggcg	cattgatgca	gcctgcggcg	gcctcggagc	gcggcggagc	60
agacgctgac	caggttcctc	tcctcggctc	cctccgcctc	cagctccgcg	ctgcccggca	120
gccgggagcc	atgcgacccc	agggccccgc	cgctccccgc	cagcggctcc	gcggcctcct	180
gctgctcctg	ctgctgcagc	tgcccgcgcc	gtcgagcgcc	tctgagatcc	ccaaggggaa	240
gcaaaaggcg	cactccggca	gagggagggtg	gtggacctgt	ataatggaat	gtgcttacia	300
gggcccagcag	gagtgccctg	tcgagacggg	agccctgggg	ccaatggcat	tccgggtaca	360
cctgggaccc	caggtcggga	tggattcaaa	ggagaaaagg	gggaatgtct	gagggaaagc	420
tttgaggagt	cctggacacc	caactacaag	cagtgttcac	ggagttcatt	gaattatggc	480
atagatcttg	ggaaaattgc	ggagtgtaca	tttacaaga	tgcgttcaaa	tagtgctcta	540
agagttttgt	tcagtggctc	acttcggcta	aaatgcagaa	atgcatgctg	tcagcgttgg	600
tatttcacat	tcaatggagc	tgaatgttca	ggacctcttc	ccattgaagc	tataatttat	660
ttggaccaag	gaagccctga	aatgaattca	acaattaata	ttcatcgcac	ttcttctgtg	720
gaaggacttt	gtgaagggaat	tgggtgctgga	ttagtggtatg	ttgctatctg	ggttggcact	780
tgttcagatt	acccaaaagg	agatgcttct	actggatgga	attcagtttc	tcgcatcatt	840
attgaagaac	taccaaaata	aatgctttta	ttttcatttg	ctacctcttt	ttttattatg	900
ccttggaatg	gttcaactta	atgacatttt	aaataagttt	atgtatacat	ctgaatgaaa	960
agcaaagcta	aatatgttta	cagaccaaag	tgtgatttca	cactgttttt	aaatctagca	1020
ttattcattt	tgcttcaatc	aaaagtgggt	tcaatatttt	ttttagtgtg	ttagaatact	1080
ttcttcatag	tcacattctc	tcaacctata	atttggaata	ttgttggtgt	cttttgtttt	1140
ttctcttagt	atagcatttt	taaaaaata	taaaagctac	caatctttgt	acaatttgta	1200
aatgttaaga	atttttttta	tatctgttaa	ataaaaatta	tttccaacaa	aaaaaaaaaa	1260
aaaaaaaaaa	aaaaaaaaaa	aaanaa				1286

&lt;210&gt; 122

&lt;211&gt; 1380

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 122

cagacccgcg	gggcaaaccg	actggggcca	agagccggga	gcgcggggcg	aaaggcacca	60
gggcccgcgc	agggcgccgc	gcacacggcc	ttgggggttc	tgccggccctt	cgggtgcgcg	120
tctcgcctct	agccatgggg	tccgcagcgt	tggagatcct	gggcctgggtg	ctgtgcctgg	180

tgggctgggg	gggtctgac	ctggcggtgcg	ggctgccc	gtggcaggtg	accgccttcc	240
tggaccacaa	catcgtgacg	gcgcagacca	cctggaaggg	gctgtggatg	tcgtgctggg	300
tgacagacac	gggcacatgc	agtgcacaa	gtacgactcg	gtgctggctc	tgagcaccga	360
ggtgcaggcg	gcgcggggcg	tcaccgtgag	cgccgtgctg	ctggcgttcg	ttgcgctctt	420
cgtgaccctg	gcggggcgcg	agtgcaccac	ctgcgtggcc	ccggggcccg	ccaaggcgcg	480
tgtggccctc	acgggagggc	tgctctacct	gttttgcggg	ctgctggcgc	tcgtgccact	540
ctgctggttc	gccaacattg	tcgtccgcga	gttttacgac	ccgtctgtgc	ccgtgtcgca	600
gaagtacgag	ctggggcgac	gctgtacatc	ggctggggcg	ccaccgcgct	gctcatggta	660
ggcggctgcc	tcttgctg	cggcgcctgg	gtctgcaccg	gccgtcccga	cctcagcttc	720
cccgtgaagt	actcagcgcc	gcggcgggcc	acggccaccg	gcgactacga	caagaagaac	780
tacgtctgag	ggcgctgggc	acggccgggc	ccctcctgcc	agccacgcct	gcgaggcggt	840
ggataagcct	ggggagcccc	gcatggaccg	cggtctccgc	cgggtagcgc	ggcgcgagg	900
ctcctcgga	cgcccggtc	tgccgcccga	cgcggtcct	ggatccgctc	ctgcctgcgc	960
ccgcagctga	ccttctcctg	ccactagccc	ggccctgccc	ttaacagacg	gaatgaagtt	1020
tccttttctg	tgccggcgcg	tgtttccata	ggcagagcgg	gtgtcagact	gaggatttcg	1080
cttccctcc	aagacgctgg	gggtcttgcc	tgctgcctta	cttcccagag	gctcctgctg	1140
acttcggagg	ggcggtgca	gagcccagg	ccccaccgg	aagatgtgta	cacctgggtc	1200
ttactccatc	ggcaggggcc	gagcccagg	accagtga	tgccctggac	ctcccggtct	1260
cactccagca	tctcccagg	caaggcttgt	gggcaccgga	gcttgagaga	ggcggggagt	1320
gggaaggcta	agaatctgct	tagtaaatgg	tttgaactct	caaaaaaaaa	aaaaaaaaaa	1380

&lt;210&gt; 123

&lt;211&gt; 3793

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1102)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1132)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1199)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1228)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1229)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1231)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (3176)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 123

ggggcttcat	acaggaaatc	tattgctgtg	tcaagttcca	gagaaaagct	tctgttcgtc	60
caagttacta	accaggctaa	accacataga	cgtgaaggaa	ggggctagaa	ggaagggagt	120
gccccactgt	tgatggggta	agaggatcct	gtactgagaa	ggtgaccaga	gaggggtctca	180
ccatgcgcac	agttccttct	gtaccagtgt	ggagggaaaag	tactgagtga	agggcagaaa	240
aagagaaaac	agaaatgctc	tgcccttgga	gaactgctaa	cctagggcta	ctgttgattt	300
tgactatctt	cttagtggcc	gaagcggagg	gtgctgctca	accaaacaac	tcattaatgc	360
tgcaaactag	caaggagaat	catgcttttag	cttcaagcag	tttatgtatg	gatgaaaaac	420
agattacaca	gaactactcg	aaagtactcg	cagaagttaa	cacttcatgg	cctgtaaaga	480
tggctacaaa	tgctgtgctt	tggtggccctc	ctatcgcat	aagaaatttg	atcataataa	540
catgggaaat	aatcctgaga	ggccagcctt	cctgcacaaa	agcctacaag	aaagaaacaa	600
atgagaccaa	ggaaaccaac	tgtactgatg	agagaataac	ctgggtctcc	agacctgatc	660
agaattcggg	ccttcagatt	cgtaccgtgg	ccatcactca	tgacgggtat	tacagatgca	720
taatggtaac	acctgatggg	aatttccatc	gtggatatca	cctccaagtg	ttagttagac	780
ctgaagtga	cctgtttcaa	aacaggaata	gaactgcagt	atgcaaggca	gttcgaggga	840
agccagctgc	gcatatctcc	tggatcccag	agggcgattg	tgccactaag	caagaatact	900
ggagcaatgg	cacagtgact	gttaagagta	catgccactg	ggaggtccac	aatgtgtcta	960
ccgtgaactg	ccagctctcc	catttgactg	gcaacaagag	tctgtacata	gagctacttc	1020
ctgttccagg	tgccaaaaaa	tcatacaaat	tatatattcc	atatacatc	cttactatta	1080
ttattttgac	catcgtggga	tncaatttgg	tggtgaaagt	caatggctgc	anaaaatata	1140
aattgaataa	accagaatct	actccagtig	ttgaggagga	tgaaatgcag	ccctatgcnt	1200
tttacacaga	gaagaacaat	cctctctnng	ntactacaaa	caagggtgaag	gcatctgagg	1260
cattacaaa	tgaagttgac	acagacctcc	atactttata	agttgttgga	ctctagtacc	1320
aagaacaac	atacaacgag	atacattata	attactgtct	gattttctta	cagttctaga	1380
atgaagactt	aatttgaaat	taggttttcc	aaggttctta	gaagacattt	taatggattc	1440
tcattcatac	ccttgataaa	ttggaatttt	tgattcttag	ctgctaccag	ctagtctctc	1500
gaagaactga	tgattattaca	aagaaaatac	atgcccatga	ccaaatattc	aaattgtgca	1560
ggacagtaaa	taatgaaaac	caaatttctc	caagaaataa	ctgaagaagg	agcaagtgtg	1620
aacagtttct	tgtgtatcct	ttcagaatat	tttaattgtac	atatgacatg	tgtatatgcc	1680
tatggtatat	tggtcaattt	atgtgtcccc	ttacatatat	catgcaccct	atctttgtca	1740
aggcaccagt	gggaacaata	cactgcatta	ctgttctata	catatgaaaa	cctaataata	1800
taagtcttag	agatcatttt	atatactgac	aagtagagct	acctcattct	ttttaatggg	1860
tataataaat	tccattgtat	agttatatca	ttatttaatt	aaaaacaacc	ctaattgatg	1920
atatttagat	tcttttaagt	tttgtttatt	tcttttaagt	tttgtttgtg	gtataaacia	1980
taccacatag	aatgtttctt	gtgcataat	ctctttgttt	ttgagtatat	ctgtaggata	2040
actttcttga	gtggaattgt	caggtcaaa	ggttgtgca	ttttactatt	gatataatg	2100
ttaaattgtg	tcaaatatat	atgtcaaat	ccctccaaca	ttgttttaatt	tgccctttcc	2160
ctaaatttct	attttaataa	ctgtactatt	cctgtctcta	cagttgccac	tttctctttt	2220
taatcaacca	gattaaatat	gatgtgagat	tataataaga	attatactat	ttaataaaaa	2280
tggatttata	tttttggtca	tgtttgtaag	agagtgaatg	cacgtgtgag	aacattagct	2340
tcttctgaac	tcattatata	tccacagagg	tggtgatact	tgatgcctaa	cagttttgca	2400
gatgtgctac	attggaattg	tgtattttta	tggtgtacat	tctattgtga	tatattttatt	2460
gaataattaa	tgtctattga	ccatataagt	ggcgaaaaat	gcaccataga	ggacatgggg	2520
tattttattta	caaactatga	gctacataat	aagcaagtgg	ccatgggatg	gcatgaccct	2580
cccctccata	tttttggtga	gcaaaatatt	ggcaatgttt	atgtaaatca	ttgttaatat	2640
catgaaatta	tttttaatta	aaaacataag	tctatttgct	ccatagcaga	aaaaacatga	2700
gaagtttttt	catcatgata	gaaattgaaa	caaaatatat	tcattcttca	atcataccat	2760
ctgagatttt	taagacagct	attttgtctt	ataagtatat	ttttctccct	ctagacattt	2820
cagttactat	ggattttgtc	ctcaaaggga	cytttagtct	aattttggga	tgtaaaagcta	2880
atcttaatga	cacttggcac	atgatatttt	gatcaagcca	ttttgacttg	acaaaaaagc	2940
agtgtccatt	aggtttctgc	atataaatat	taccaagcaa	tgttcacaat	agacatcatt	3000
acactgtcct	tgaaatttat	taattcttca	tccaacctg	gttgagctga	ggctcatagt	3060
taggttcaag	actatctgtt	taaatattac	tgaaaaaaaa	agtaagacag	tactatgctt	3120
acctcttaac	ttgataatgt	caaaccaggc	atgttaaatg	acatcataga	aaaganttca	3180
agataattta	tagaagttta	attatattgt	acagaaaaata	attgtatgaa	aatctctact	3240
atggggctgg	aacatgggtg	aacattagaa	tgatataaaa	aattatatat	attctccaaa	3300

```

tccacgctag acctgtcaaa ttagagaatc tagagattag acctggcgtg tcagcaaggt 3360
catccaggaa gcagaggctg agacggagtt aggtgtgatt acttacatag tcgattacat 3420
tttacaata acattttata tgtctcattt actgtgcttt ctcccatcc cattttgtat 3480
cttttccttt gctttgctag atttgtcaat tttctctctc tttctgtctc tctctcttcc 3540
aatatctcta ataatttgaa agtaattcat cataactaaa tatctattgg ggttatgctt 3600
cacttacaaa cttctgaaaa cggctttact gagatataat tgatatattt aagtgtacag 3660
tttgttaaat ttgtcacata tttaaaatgt ggacttttgg aaatgttgac atagttttac 3720
atctgtgaaa ccatcagcat aatcaagata ataaacttgt ccatcacccc ccaaaaaaaaa 3780
aaaaaaaaaa aaa 3793

```

&lt;210&gt; 124

&lt;211&gt; 370

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (370)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 124

```

Met Leu Gly Ala Phe Val Trp Pro Ser Leu Leu Leu Leu Ala Ala Ala
 1              5              10              15

Cys Ile Cys Leu Leu Thr Phe Ile Asn Cys Ala Tyr Val Lys Trp Gly
      20              25              30

Thr Leu Val Gln Asp Ile Phe Thr Tyr Ala Lys Val Leu Ala Leu Ile
 35              40              45

Ala Val Ile Val Ala Gly Ile Val Arg Leu Gly Gln Gly Ala Ser Thr
 50              55              60

His Phe Glu Asn Ser Phe Glu Gly Ser Ser Phe Ala Val Gly Asp Ile
 65              70              75              80

Ala Leu Ala Leu Tyr Ser Ala Leu Phe Ser Tyr Ser Gly Trp Asp Thr
      85              90              95

Leu Asn Tyr Val Thr Glu Glu Ile Lys Asn Pro Glu Arg Asn Leu Pro
 100              105              110

Leu Ser Ile Gly Ile Ser Met Pro Ile Val Thr Ile Ile Tyr Ile Leu
 115              120              125

Thr Asn Val Ala Tyr Tyr Thr Val Leu Asp Met Arg Asp Ile Leu Ala
 130              135              140

Ser Asp Ala Val Ala Val Thr Phe Ala Asp Gln Ile Phe Gly Ile Phe
 145              150              155              160

Asn Trp Ile Ile Pro Leu Ser Val Ala Leu Ser Cys Phe Gly Gly Leu
      165              170              175

Asn Ala Ser Ile Val Ala Ala Ser Arg Leu Phe Phe Val Gly Ser Arg
      180              185              190

Glu Gly His Leu Pro Asp Ala Ile Cys Met Ile His Val Glu Arg Phe

```



195	200	205
Thr Pro Val Pro Ser Leu Leu Phe Asn Gly Ile Met Ala Leu Ile Tyr 210 215 220		
Leu Cys Val Glu Asp Ile Phe Gln Leu Ile Asn Tyr Tyr Ser Phe Ser 225 230 235 240		
Tyr Trp Phe Phe Val Gly Leu Ser Ile Val Gly Gln Leu Tyr Leu Arg 245 250 255		
Trp Lys Glu Pro Asp Arg Pro Arg Pro Leu Lys Leu Ser Val Phe Phe 260 265 270		
Pro Ile Val Phe Cys Leu Cys Thr Ile Phe Leu Val Ala Val Pro Leu 275 280 285		
Tyr Ser Asp Thr Ile Asn Ser Leu Ile Gly Ile Ala Ile Ala Leu Ser 290 295 300		
Gly Leu Pro Phe Tyr Phe Leu Ile Ile Arg Val Pro Glu His Lys Arg 305 310 315 320		
Pro Leu Tyr Leu Arg Arg Ser Trp Gly Leu Pro Gln Gly Thr Ser Arg 325 330 335		
Ser Cys Val Cys Gln Leu Leu Gln Lys Trp Ile Trp Lys Met Glu Glu 340 345 350		
Arg Cys Pro Ser Asn Gly Ile Pro Ser Leu Thr Lys His His Leu Glu 355 360 365		
Ser Xaa 370		

<210> 125  
 <211> 86  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (86)  
 <223> Xaa equals stop translation

<400> 125  
 Met Gly Phe Trp Cys Gly Cys Pro Phe Cys Leu Leu Val Val Leu Leu  
 1 5 10 15  
 Thr Asp Arg Thr Leu Ser Cys Arg Ser Val Gly Val Pro Cys Asn Val  
 20 25 30  
 Arg Cys Gln Cys Ala Pro Ala Gly Gly Cys Leu Pro Val Arg Leu Leu  
 35 40 45  
 Ala Gly Gln Gly Ser Gly Thr His Leu Arg Arg Gln Ser Ala Arg Ser  
 50 55 60

Gln Ile Ser Ser Cys Met Leu Gly Glu Pro Leu Leu Ser Ser Lys Leu  
 65 70 75 80

Ser Asp Arg Asp Ile Xaa  
 85

<210> 126

<211> 44

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (44)

<223> Xaa equals stop translation

<400> 126

Met Tyr Thr Lys Thr His Lys Phe Lys Phe Tyr Asn Phe Leu Ser Leu  
 1 5 10 15

Trp Ile Trp Lys Ile Phe Phe Leu Leu Phe Phe Ile Leu Ile Val Ala  
 20 25 30

Leu Ala Phe Pro Ile Pro Cys Leu Ser Ile Phe Xaa  
 35 40

<210> 127

<211> 319

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (264)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (303)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 127

Met Asn Thr Asp His Leu Arg Leu Thr Val Pro Asn Gly Ile Gly Ala  
 1 5 10 15

Leu Lys Leu Arg Glu Met Glu His Tyr Phe Ser Gln Gly Leu Ser Val  
 20 25 30

Gln Leu Phe Asn Asp Gly Ser Lys Gly Lys Leu Asn His Leu Cys Gly  
 35 40 45

Ala Asp Phe Val Lys Ser His Gln Lys Pro Pro Gln Gly Met Glu Ile  
 50 55 60

Lys Ser Asn Glu Arg Cys Cys Ser Phe Asp Gly Asp Ala Asp Arg Ile  
 65 70 75 80

Met Asp Met Val Cys Phe Cys Ile Tyr Leu Gly Leu Leu Lys Phe Ile  
1 5 10 15

Ser Ala Ile Phe Cys Ser Phe Ser Glu Glu Val Leu Tyr Ile Ser Phe  
                   20                  25                  30

Val Lys Cys Ile Pro Lys Tyr Phe Val Glu Met Leu Leu Xaa  
                   35                  40                  45

<210> 129

<211> 709

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (189)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (275)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (414)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (438)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (641)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (643)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (696)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (697)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 129

Met Ala Gly Leu Asn Cys Gly Val Ser Ile Ala Leu Leu Gly Val Leu  
   1                  5                  10                  15

Leu Leu Gly Ala Ala Arg Leu Pro Arg Gly Ala Glu Ala Phe Glu Ile  
                   20                  25                  30

Ala Leu Pro Arg Glu Ser Asn Ile Thr Val Leu Ile Lys Leu Gly Thr  
           35                          40                          45  
 Pro Thr Leu Leu Ala Lys Pro Cys Tyr Ile Val Ile Ser Lys Arg His  
           50                          55                          60  
 Ile Thr Met Leu Ser Ile Lys Ser Gly Glu Arg Ile Val Phe Thr Phe  
           65                          70                          75                          80  
 Ser Cys Gln Ser Pro Glu Asn His Phe Val Ile Glu Ile Gln Lys Asn  
                           85                          90                          95  
 Ile Asp Cys Met Ser Gly Pro Cys Pro Phe Gly Glu Val Gln Leu Gln  
                           100                          105                          110  
 Pro Ser Thr Ser Leu Leu Pro Thr Leu Asn Arg Thr Phe Ile Trp Asp  
           115                          120                          125  
 Val Lys Ala His Lys Ser Ile Gly Leu Glu Leu Gln Phe Ser Ile Pro  
           130                          135                          140  
 Arg Leu Arg Gln Ile Gly Pro Gly Glu Ser Cys Pro Asp Gly Val Thr  
           145                          150                          155                          160  
 His Ser Ile Ser Gly Arg Ile Asp Ala Thr Val Val Arg Ile Gly Thr  
                           165                          170                          175  
 Phe Cys Ser Asn Gly Thr Val Ser Arg Ile Lys Met Xaa Glu Gly Val  
                           180                          185                          190  
 Lys Met Ala Leu His Leu Pro Trp Phe His Pro Arg Asn Val Ser Gly  
           195                          200                          205  
 Phe Ser Ile Ala Asn Arg Ser Ser Ile Lys Arg Leu Cys Ile Ile Glu  
           210                          215                          220  
 Ser Val Phe Glu Gly Glu Gly Ser Ala Thr Leu Met Ser Ala Asn Tyr  
           225                          230                          235                          240  
 Pro Glu Gly Phe Pro Glu Asp Glu Leu Met Thr Trp Gln Phe Val Val  
                           245                          250                          255  
 Pro Ala His Leu Arg Ala Ser Val Ser Phe Leu Asn Phe Asn Leu Ser  
           260                          265                          270  
 Asn Cys Xaa Arg Lys Glu Glu Arg Val Glu Tyr Tyr Ile Pro Gly Ser  
           275                          280                          285  
 Thr Thr Asn Pro Glu Val Phe Lys Leu Glu Asp Lys Gln Pro Gly Asn  
           290                          295                          300  
 Met Ala Gly Asn Phe Asn Leu Ser Leu Gln Gly Cys Asp Gln Asp Ala  
           305                          310                          315                          320  
 Gln Ser Pro Gly Ile Leu Arg Leu Gln Phe Gln Val Leu Val Gln His  
                           325                          330                          335  
 Pro Gln Asn Glu Ser Asn Lys Ile Tyr Val Val Asp Leu Ser Asn Glu

340	345	350
Arg Ala Met Ser Leu Thr Ile Glu Pro Arg Pro Val Lys Gln Ser Arg		
355	360	365
Lys Phe Val Pro Gly Cys Phe Val Cys Leu Glu Ser Arg Thr Cys Ser		
370	375	380
Ser Asn Leu Thr Leu Thr Ser Gly Ser Lys His Lys Ile Ser Phe Leu		
385	390	395
Cys Asp Asp Leu Thr Arg Leu Trp Met Asn Val Glu Lys Xaa Ile Ser		
405	410	415
Cys Thr Asp His Arg Tyr Cys Gln Arg Lys Ser Tyr Ser Leu Gln Val		
420	425	430
Pro Ser Asp Ile Leu Xaa Leu Pro Val Glu Leu His Asp Phe Ser Trp		
435	440	445
Lys Leu Leu Val Pro Lys Asp Arg Leu Ser Leu Val Leu Val Pro Ala		
450	455	460
Gln Lys Leu Gln Gln His Thr His Glu Lys Pro Cys Asn Thr Ser Phe		
465	470	475
Ser Tyr Leu Val Ala Ser Ala Ile Pro Ser Gln Asp Leu Tyr Phe Gly		
485	490	495
Ser Phe Cys Pro Gly Gly Ser Ile Lys Gln Ile Gln Val Lys Gln Asn		
500	505	510
Ile Ser Val Thr Leu Arg Thr Phe Ala Pro Ser Phe Arg Gln Glu Ala		
515	520	525
Ser Arg Gln Gly Leu Thr Val Ser Phe Ile Pro Tyr Phe Lys Glu Glu		
530	535	540
Gly Val Phe Thr Val Thr Pro Asp Thr Lys Ser Lys Val Tyr Leu Arg		
545	550	555
Thr Pro Asn Trp Asp Arg Gly Leu Pro Ser Leu Thr Ser Val Ser Trp		
565	570	575
Asn Ile Ser Val Pro Arg Asp Gln Val Ala Cys Leu Thr Phe Phe Lys		
580	585	590
Glu Arg Ser Gly Val Val Cys Gln Thr Gly Arg Ala Phe Met Ile Ile		
595	600	605
Gln Glu Gln Arg Thr Arg Ala Glu Glu Ile Phe Ser Leu Asp Glu Asp		
610	615	620
Val Leu Pro Lys Pro Ser Phe His His His Ser Phe Trp Val Asn Ile		
625	630	635
Xaa Asn Xaa Ser Pro Thr Ser Gly Lys Gln Leu Asp Leu Leu Phe Ser		
645	650	655

Val Thr Leu Thr Pro Arg Thr Val Asp Leu Thr Val Ile Leu Ile Ala  
                   660                  665                  670  
 Ala Val Gly Gly Gly Val Leu Leu Leu Ser Ala Leu Gly Leu Ile Ile  
                   675                  680                  685  
 Cys Cys Val Lys Lys Lys Lys Xaa Xaa Thr Arg Gly Pro Ala Val Gly  
                   690                  695                  700  
 Ile Tyr Asn Gly Asn  
 705

<210> 130  
 <211> 415  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (415)  
 <223> Xaa equals stop translation

<400> 130  
 Met Thr Lys Ala Arg Leu Phe Arg Leu Trp Leu Val Leu Gly Ser Val  
   1                  5                  10                  15  
 Phe Met Ile Leu Leu Ile Ile Val Tyr Trp Asp Ser Ala Gly Ala Ala  
                   20                  25                  30  
 His Phe Tyr Leu His Thr Ser Phe Ser Arg Pro His Thr Gly Pro Pro  
                   35                  40                  45  
 Leu Pro Thr Pro Gly Pro Asp Arg Asp Arg Glu Leu Thr Ala Asp Ser  
                   50                  55                  60  
 Asp Val Asp Glu Phe Leu Asp Lys Phe Leu Ser Ala Gly Val Lys Gln  
   65                  70                  75                  80  
 Ser Asp Leu Pro Arg Lys Glu Thr Glu Gln Pro Pro Ala Pro Gly Ser  
                   85                  90                  95  
 Met Glu Glu Asn Val Arg Gly Tyr Asp Trp Ser Pro Arg Asp Ala Arg  
                   100                  105                  110  
 Arg Ser Pro Asp Gln Gly Arg Gln Gln Ala Glu Arg Arg Ser Val Leu  
                   115                  120                  125  
 Arg Gly Phe Cys Ala Asn Ser Ser Leu Ala Phe Pro Thr Lys Glu Arg  
   130                  135                  140  
 Ala Phe Asp Asp Ile Pro Asn Ser Glu Leu Ser His Leu Ile Val Asp  
  145                  150                  155                  160  
 Asp Arg His Gly Ala Ile Tyr Cys Tyr Val Pro Lys Val Ala Cys Thr  
                   165                  170                  175  
 Asn Trp Lys Arg Val Met Ile Val Leu Ser Gly Ser Leu Leu His Arg  
                   180                  185                  190

Gly Ala Pro Tyr Arg Asp Pro Leu Arg Ile Pro Arg Glu His Val His  
 195 200 205  
 Asn Ala Ser Ala His Leu Thr Phe Asn Lys Phe Trp Arg Arg Tyr Gly  
 210 215 220  
 Lys Leu Ser Arg His Leu Met Lys Val Lys Leu Lys Lys Tyr Thr Lys  
 225 230 235 240  
 Phe Leu Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser Ala Phe Arg  
 245 250 255  
 Ser Lys Phe Glu Leu Glu Asn Glu Glu Phe Tyr Arg Lys Phe Ala Val  
 260 265 270  
 Pro Met Leu Arg Leu Tyr Ala Asn His Thr Ser Leu Pro Ala Ser Ala  
 275 280 285  
 Arg Glu Ala Phe Arg Ala Gly Leu Lys Val Ser Phe Ala Asn Phe Ile  
 290 295 300  
 Gln Tyr Leu Leu Asp Pro His Thr Glu Lys Leu Ala Pro Phe Asn Glu  
 305 310 315 320  
 His Trp Arg Gln Val Tyr Arg Leu Cys His Pro Cys Gln Ile Asp Tyr  
 325 330 335  
 Asp Phe Val Gly Lys Leu Glu Thr Leu Asp Glu Asp Ala Ala Gln Leu  
 340 345 350  
 Leu Gln Leu Leu Gln Val Asp Arg Gln Leu Arg Phe Pro Pro Ser Tyr  
 355 360 365  
 Arg Asn Arg Thr Ala Ser Ser Trp Glu Glu Asp Trp Phe Ala Lys Ile  
 370 375 380  
 Pro Leu Ala Trp Arg Gln Gln Leu Tyr Lys Leu Tyr Glu Ala Asp Phe  
 385 390 395 400  
 Val Leu Phe Gly Tyr Pro Lys Pro Glu Asn Leu Leu Arg Asp Xaa  
 405 410 415

&lt;210&gt; 131

&lt;211&gt; 242

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 131

Met Gln Leu Gly Ser Val Leu Leu Thr Arg Cys Pro Phe Trp Gly Cys  
 1 5 10 15  
 Phe Ser Gln Leu Met Leu Tyr Ala Glu Arg Ala Glu Ala Arg Arg Lys  
 20 25 30  
 Pro Asp Ile Pro Val Pro Tyr Leu Tyr Phe Asp Met Gly Ala Ala Val  
 35 40 45



Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys Arg Arg Trp Phe Ala  
 50 55 60  
 Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr Tyr Ala Ala Tyr Ile  
 65 70 75 80  
 Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys Val Arg Met Tyr Ser  
 85 90 95  
 Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val Leu Ala Ser Gly Ala  
 100 105 110  
 Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg Ser Leu Gln Ser Thr  
 115 120 125  
 Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys Val Ala Tyr Ser Leu  
 130 135 140  
 Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu Asn His Leu Pro Gly  
 145 150 155 160  
 Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu Tyr Gly Ile Leu Ala  
 165 170 175  
 Leu Ala Phe Leu Ser Gly Tyr Tyr Val Thr Leu Ala Ala Gln Ile Leu  
 180 185 190  
 Ala Val Leu Leu Pro Pro Val Met Leu Leu Ile Asp Gly Asn Val Ala  
 195 200 205  
 Tyr Trp His Asn Thr Arg Arg Val Glu Phe Trp Asn Gln Met Lys Leu  
 210 215 220  
 Leu Gly Glu Ser Val Gly Ile Phe Gly Thr Ala Val Ile Leu Ala Thr  
 225 230 235 240

Asp Gly

<210> 132

<211> 313

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (313)

<223> Xaa equals stop translation

<400> 132

Met Glu Ser Leu Tyr Asp Leu Trp Glu Phe Tyr Leu Pro Tyr Leu Tyr  
 1 5 10 15  
 Ser Cys Ile Ser Leu Met Gly Cys Leu Leu Leu Leu Cys Thr Pro  
 20 25 30  
 Val Gly Leu Ser Arg Met Phe Thr Val Met Gly His Leu Leu Val Lys  
 35 40 45

Pro Thr Ile Leu Glu Asp Leu Asp Glu Gln Ile Tyr Ile Ile Thr Leu  
 50 55 60  
 Glu Glu Glu Ala Leu Gln Arg Arg Leu Asn Gly Leu Ser Ser Ser Val  
 65 70 75 80  
 Glu Tyr Asn Ile Met Glu Leu Glu Gln Glu Leu Glu Asn Val Lys Thr  
 85 90 95  
 Leu Lys Thr Lys Leu Glu Arg Arg Lys Lys Ala Ser Ala Trp Glu Arg  
 100 105 110  
 Asn Leu Val Tyr Pro Ala Val Met Val Leu Leu Leu Ile Glu Thr Ser  
 115 120 125  
 Ile Ser Val Leu Leu Val Ala Cys Asn Ile Leu Cys Leu Leu Val Asp  
 130 135 140  
 Glu Thr Ala Met Pro Lys Gly Thr Arg Gly Pro Gly Ile Gly Asn Ala  
 145 150 155 160  
 Ser Leu Ser Thr Phe Gly Phe Val Gly Ala Ala Leu Glu Ile Ile Leu  
 165 170 175  
 Ile Phe Tyr Leu Met Val Ser Ser Val Val Gly Phe Tyr Ser Leu Arg  
 180 185 190  
 Phe Phe Gly Asn Phe Thr Pro Lys Lys Asp Asp Thr Thr Met Thr Lys  
 195 200 205  
 Ile Ile Gly Asn Cys Val Ser Ile Leu Val Leu Ser Ser Ala Leu Pro  
 210 215 220  
 Val Met Ser Arg Thr Leu Gly Ile Thr Arg Phe Asp Leu Leu Gly Asp  
 225 230 235 240  
 Phe Gly Arg Phe Asn Trp Leu Gly Asn Phe Tyr Ile Val Leu Ser Tyr  
 245 250 255  
 Asn Leu Leu Phe Ala Ile Val Thr Thr Leu Cys Leu Val Arg Lys Phe  
 260 265 270  
 Thr Ser Ala Val Arg Glu Glu Leu Phe Lys Ala Leu Gly Leu His Lys  
 275 280 285  
 Leu His Leu Pro Asn Thr Ser Arg Asp Ser Glu Thr Ala Lys Pro Ser  
 290 295 300  
 Val Asn Gly His Gln Lys Ala Leu Xaa  
 305 310

&lt;210&gt; 133

&lt;211&gt; 183

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (183)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 133

Met Met Val Cys Ser Ile Met Met Tyr Phe Leu Leu Gly Ile Thr Leu  
 1 5 10 15

Leu Arg Ser Tyr Met Gln Ser Val Trp Thr Glu Glu Ser Gln Cys Thr  
 20 25 30

Leu Leu Asn Ala Ser Ile Thr Glu Thr Phe Asn Cys Ser Phe Ser Cys  
 35 40 45

Gly Pro Asp Cys Trp Lys Leu Ser Gln Tyr Pro Cys Leu Gln Val Tyr  
 50 55 60

Val Asn Leu Thr Ser Ser Gly Glu Lys Leu Leu Leu Tyr His Thr Glu  
 65 70 75 80

Glu Thr Ile Lys Ile Asn Gln Lys Cys Ser Tyr Ile Pro Lys Cys Gly  
 85 90 95

Lys Asn Phe Glu Glu Ser Met Ser Leu Val Asn Val Val Met Glu Asn  
 100 105 110

Phe Arg Lys Tyr Gln His Phe Ser Cys Tyr Ser Asp Pro Glu Gly Asn  
 115 120 125

Gln Lys Ser Val Ile Leu Thr Lys Leu Tyr Ser Ser Asn Val Leu Phe  
 130 135 140

His Ser Leu Phe Trp Pro Thr Cys Met Met Ala Gly Gly Val Ala Ile  
 145 150 155 160

Val Ala Met Val Lys Leu Thr Gln Tyr Leu Ser Leu Leu Cys Glu Arg  
 165 170 175

Ile Gln Arg Ile Asn Arg Xaa  
 180

&lt;210&gt; 134

&lt;211&gt; 147

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (147)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 134

Met Trp Lys Leu Trp Arg Ala Glu Glu Gly Ala Ala Ala Leu Gly Gly  
 1 5 10 15

Ala Leu Phe Leu Leu Leu Phe Ala Leu Gly Val Arg Gln Leu Leu Lys  
 20 25 30

Gln Arg Arg Pro Met Gly Phe Pro Pro Gly Pro Pro Gly Leu Pro Phe  
           35                          40                          45  
 Ile Gly Asn Ile Tyr Ser Leu Ala Ala Ser Ser Glu Leu Pro His Val  
           50                          55                          60  
 Tyr Met Arg Lys Gln Ser Gln Val Tyr Gly Glu Val Gln Pro Arg Arg  
           65                          70                          75                          80  
 Ala Pro Gly Arg Glu Gly Arg Gln Ala Gly Pro Gly Trp Pro Gly Pro  
                           85                          90                          95  
 Ser Trp Leu Asp Leu Trp Pro Pro Leu Gly Arg Leu Val Gly Thr Ser  
                           100                          105                          110  
 Pro Cys Ala Gly Cys Pro Leu Arg Asp Thr Arg Phe Pro Gly Leu Glu  
           115                          120                          125  
 Gly Arg Ser Pro Arg Arg Arg Ala Pro Leu Gln Gly Glu Pro Arg Pro  
           130                          135                          140  
 Cys Arg Xaa  
 145

<210> 135  
 <211> 122  
 <212> PRT  
 <213> Homo sapiens

<400> 135  
 Met Arg Val Arg Ile Gly Leu Thr Leu Leu Cys Ala Val Leu Leu  
   1                          5                          10                          15  
 Ser Leu Ala Ser Ala Ser Ser Asp Glu Glu Gly Ser Gln Asp Glu Ser  
           20                          25                          30  
 Leu Asp Ser Lys Thr Thr Leu Thr Ser Asp Glu Ser Val Lys Asp His  
           35                          40                          45  
 Thr Thr Ala Gly Arg Val Val Ala Gly Gln Ile Phe Leu Asp Ser Glu  
           50                          55                          60  
 Glu Ser Glu Leu Glu Ser Ser Ile Gln Glu Glu Glu Asp Ser Leu Lys  
           65                          70                          75                          80  
 Ser Gln Glu Gly Glu Ser Val Thr Glu Asp Ile Ser Phe Leu Glu Ser  
                           85                          90                          95  
 Pro Asn Pro Glu Asn Lys Asp Tyr Glu Glu Pro Lys Lys Val Arg Lys  
           100                          105                          110  
 Pro Gly Ser Leu Asp Ile Phe Leu Ala Phe  
           115                          120

<210> 136  
 <211> 112  
 <212> PRT

<213> Homo sapiens

<400> 136

```

Met Ala Arg Gly Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu Gly
 1             5             10             15

Leu Trp Leu Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala Pro Gly
      20             25             30

Thr Ala Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp Leu Asp Lys
      35             40             45

Cys Met Asp Cys Ser Thr Ser Cys Pro Leu Pro Ala Ala Leu Ala His
      50             55             60

Pro Trp Gly Arg Ser Glu Pro Asp Leu Arg Ala Gly Ala Ala Phe Trp
      65             70             75             80

Leu Phe Gly Leu Glu Thr Met Pro Gln Arg Glu Lys Phe Thr Thr Pro
      85             90             95

Ile Glu Glu Thr Gly Gly Glu Gly Cys Pro Ala Val Ala Leu Ile Gln
      100            105            110

```

<210> 137

<211> 140

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (140)

<223> Xaa equals stop translation

<400> 137

```

Met Leu Leu Gly Pro Val Pro Ile Leu His Ile Lys Ser Gln Leu Trp
 1             5             10             15

Leu Leu Val Leu Ile Leu Val Val Ser Gly Leu Ser Ala Gly Met Ser
      20             25             30

Ile Ile Pro Thr Phe Pro Glu Ile Leu Ser Cys Ala His Glu Asn Gly
      35             40             45

Phe Glu Glu Gly Leu Ser Thr Leu Gly Leu Val Ser Gly Leu Phe Ser
      50             55             60

Ala Met Trp Ser Ile Gly Ala Phe Met Gly Pro Thr Leu Gly Gly Phe
      65             70             75             80

Leu Tyr Glu Lys Ile Gly Phe Glu Trp Ala Ala Ala Ile Gln Gly Leu
      85             90             95

Trp Ala Leu Ile Ser Gly Leu Ala Met Gly Leu Phe Tyr Leu Leu Glu
      100            105            110

```

Tyr Ser Arg Arg Lys Arg Ser Lys Ser Gln Asn Ile Leu Ser Thr Glu  
 115 120 125

Glu Glu Arg Thr Thr Leu Leu Pro Asn Glu Thr Xaa  
 130 135 140

<210> 138

<211> 404

<212> PRT

<213> Homo sapiens

<400> 138

Met Arg Leu Gln Asp Val Tyr Met Leu Asn Val Lys Gly Leu Ala Arg  
 1 5 10 15

Gly Val Phe Gln Arg Val Thr Gly Ser Ala Ile Thr Asp Leu Tyr Ser  
 20 25 30

Pro Lys Arg Leu Phe Ser Leu Thr Gly Asp Asp Cys Phe Gln Val Gly  
 35 40 45

Lys Val Ala Tyr Asp Met Gly Asp Tyr Tyr His Ala Ile Pro Trp Leu  
 50 55 60

Glu Glu Ala Val Ser Leu Phe Arg Gly Ser Tyr Gly Glu Trp Lys Thr  
 65 70 75 80

Glu Asp Glu Ala Ser Leu Glu Asp Ala Leu Asp His Leu Ala Phe Ala  
 85 90 95

Tyr Phe Arg Ala Gly Asn Val Ser Cys Ala Leu Ser Leu Ser Arg Glu  
 100 105 110

Phe Leu Leu Tyr Ser Pro Asp Asn Lys Arg Met Ala Arg Asn Val Leu  
 115 120 125

Lys Tyr Glu Arg Leu Leu Ala Glu Ser Pro Asn His Val Val Ala Glu  
 130 135 140

Ala Val Ile Gln Arg Pro Asn Ile Pro His Leu Gln Thr Arg Asp Thr  
 145 150 155 160

Tyr Glu Gly Leu Cys Gln Thr Leu Gly Ser Gln Pro Thr Leu Tyr Gln  
 165 170 175

Ile Pro Ser Leu Tyr Cys Ser Tyr Glu Thr Asn Ser Asn Ala Tyr Leu  
 180 185 190

Leu Leu Gln Pro Ile Arg Lys Glu Val Ile His Leu Glu Pro Tyr Ile  
 195 200 205

Ala Leu Tyr His Asp Phe Val Ser Asp Ser Glu Ala Gln Lys Ile Arg  
 210 215 220

Glu Leu Ala Glu Pro Trp Leu Gln Arg Ser Val Val Ala Ser Gly Glu  
 225 230 235 240

```
<210> 139
<211> 96
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (96)
<223> Xaa equals stop translation
```

```

<400> 139
Met Lys Ala  Pro  His  Thr  Gly  Val  Leu  His  Leu  Gly  Ser  Val  Trp  Val
  1              5              10              15

Phe  Leu  Gly  Pro  Phe  Leu  Leu  Gly  Val  Gly  Tyr  Thr  Leu  Thr  Phe  Asn
          20              25              30

Pro  Leu  Ser  Gly  Cys  Met  Ser  Thr  Val  Arg  Trp  Leu  Asn  Ser  Asn  Ile
          35              40              45

Thr  Ala  Asn  Arg  Thr  Leu  Ser  Arg  Ser  Val  Cys  His  Val  Thr  Pro  Leu
          50              55              60

His  Arg  Ser  Leu  Ser  Pro  His  Asp  Gly  Glu  Tyr  Leu  Arg  Gln  Met  Leu
  65              70              75              80

```

Leu Asn Ser Ser Ser Arg Ala Gly Glu Ala Gly Ser Trp Gly Tyr Xaa  
                                   85                                  90                                  95

<210> 140  
 <211> 240  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (240)  
 <223> Xaa equals stop translation

<400> 140  
 Met Gly Ser Cys Ala Arg Leu Leu Leu Leu Trp Gly Cys Thr Val Val  
   1                                  5                                  10                                  15  
 Ala Ala Gly Leu Ser Gly Val Ala Gly Val Ser Ser Arg Cys Glu Lys  
                                   20                                  25                                  30  
 Ala Cys Asn Pro Arg Met Gly Asn Leu Ala Leu Gly Arg Lys Leu Trp  
                                   35                                  40                                  45  
 Ala Asp Thr Thr Cys Gly Gln Asn Ala Thr Glu Leu Tyr Cys Phe Tyr  
                                   50                                  55                                  60  
 Ser Glu Asn Thr Asp Leu Thr Cys Arg Gln Pro Lys Cys Asp Lys Cys  
   65                                  70                                  75                                  80  
 Asn Ala Ala Tyr Pro His Leu Ala His Leu Pro Ser Ala Met Ala Asp  
                                   85                                  90                                  95  
 Ser Ser Phe Arg Phe Pro Arg Thr Trp Trp Gln Ser Ala Glu Asp Val  
                                   100                                  105                                  110  
 His Arg Glu Lys Ile Gln Leu Asp Leu Glu Ala Glu Phe Tyr Phe Thr  
                                   115                                  120                                  125  
 His Leu Ile Val Met Phe Lys Ser Pro Arg Pro Ala Ala Met Val Leu  
                                   130                                  135                                  140  
 Asp Arg Ser Gln Asp Phe Gly Lys Thr Trp Lys Pro Tyr Lys Tyr Phe  
  145                                  150                                  155                                  160  
 Ala Thr Asn Cys Ser Ala Thr Phe Gly Leu Glu Asp Asp Val Val Lys  
                                   165                                  170                                  175  
 Lys Gly Ala Ile Cys Thr Ser Lys Tyr Ser Ser Pro Phe Pro Cys Thr  
                                   180                                  185                                  190  
 Gly Arg Lys Val Ile Phe Lys Ala Leu Ser Pro Pro Tyr Asp Thr Glu  
                                   195                                  200                                  205  
 Asn Pro Tyr Ser Ala Lys Val Gln Glu Gln Leu Lys Ile Thr Asn Leu



210 215 220  
 Pro Arg Ala Ala Ala Glu Thr Thr Val Leu Ser Leu Ser Glu Lys Xaa  
 225 230 235 240

<210> 141  
 <211> 54  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (54)  
 <223> Xaa equals stop translation

<400> 141  
 Met Met Ile Ser Gly Leu Lys Leu Leu Val Leu Phe Leu Lys Phe Ala  
 1 5 10 15

Pro Glu Asn Tyr Cys Leu Ser Thr Glu Thr Leu Gln Met Pro Asn Arg  
 20 25 30

His Leu Arg Leu Ser Lys Ala Thr Cys Tyr Leu Met Lys Cys Leu Leu  
 35 40 45

Pro Ser Tyr Phe Glu Xaa  
 50

<210> 142  
 <211> 67  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (67)  
 <223> Xaa equals stop translation

<400> 142  
 Met Arg Ser Leu Ile Ser Ser His Pro Cys Gln His Leu Leu Leu Leu  
 1 5 10 15

Leu Leu Leu Leu Phe Leu Ile Leu Ala Ile Leu Val Asp Val Lys Trp  
 20 25 30

Tyr Leu Val Leu Phe Ile Cys Ile Ser Leu Met Thr Ser Asp Val Glu  
 35 40 45

His Leu Phe Met Cys Leu Leu Ala Ile Arg Ile Ser Ser Trp Arg Asn  
 50 55 60

Val Tyr Xaa  
 65

<210> 143  
 <211> 108  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (48)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (55)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (58)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (67)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 143  
 Met Phe Tyr Lys Leu Thr Leu Ile Leu Cys Glu Leu Ser Val Ala Gly  
   1                  5                  10                  15  
 Val Thr Gln Ala Ala Ser Gln Arg Pro Leu Gln Arg Leu Pro Arg His  
           20                  25                  30  
 Ile Cys Ser Gln Arg Asn Pro Pro Gly Arg Cys Leu Leu Lys Ala Xaa  
       35                  40                  45  
 Leu Gln Thr Thr Trp Gly Xaa Pro Asp Xaa Gln Phe Pro Gly Cys Pro  
   50                  55                  60  
 His Pro Xaa Arg Val Thr Leu Asn Ala Arg Gln Met Gly Asn Gly Lys  
   65                  70                  75                  80  
 Glu Lys Lys Ala Ala Asp Leu Lys Leu Lys Phe Pro Gln Lys Arg Phe  
           85                  90                  95  
 Tyr Leu Ser Ala Phe Ser Glu Arg Ile Lys Ala Phe  
       100                  105

<210> 144  
 <211> 84  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (84)  
 <223> Xaa equals stop translation

&lt;400&gt; 144

Met Ala Ser Val Gly Thr Thr Leu Val Ser Pro Leu Leu Cys Leu Leu  
 1 5 10 15

Ile Pro Thr Arg Val Ser Asp Pro Trp Leu Gln Asn Thr Pro Leu His  
 20 25 30

Pro Trp Lys Thr Ile Thr Ile Ile Asp Tyr Tyr Leu Ser Leu Gly Phe  
 35 40 45

Leu Gly Trp Thr Gly Leu Ser Trp Val Val His Phe Gly Ala Ser Ala  
 50 55 60

Val Met Gly Arg Gln Trp Leu Gly Ser Leu Gln Arg Leu Pro Cys Ile  
 65 70 75 80

Ser Gly Ser Xaa

&lt;210&gt; 145

&lt;211&gt; 166

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 145

Met Gly Ser Arg Phe Leu Leu Val Leu Leu Ser Gly Leu Thr Val Leu  
 1 5 10 15

Leu Ala Leu Pro Gly Ser Glu Ala Lys Asn Ser Gly Ala Ser Cys Pro  
 20 25 30

Pro Cys Pro Lys Tyr Ala Ser Cys His Asn Ser Thr His Cys Thr Cys  
 35 40 45

Glu Asp Gly Phe Arg Ala Arg Ser Gly Arg Thr Tyr Phe His Asp Ser  
 50 55 60

Ser Glu Lys Cys Glu Asp Ile Asn Glu Cys Glu Thr Gly Leu Ala Lys  
 65 70 75 80

Cys Lys Tyr Lys Ala Tyr Cys Arg Asn Lys Val Gly Gly Tyr Ile Cys  
 85 90 95

Ser Cys Leu Val Lys Tyr Thr Leu Phe Asn Phe Leu Ala Gly Ile Ile  
 100 105 110

Asp Tyr Asp His Pro Asp Cys Tyr Glu Asn Asn Ser Gln Gly Thr Thr  
 115 120 125

Gln Ser Asn Val Asp Ile Trp Val Ser Gly Val Lys Pro Gly Phe Gly  
 130 135 140

Lys Gln Leu Val Arg Ile Thr Met Pro Phe Ser Tyr Pro Asn Ile Asn  
 145 150 155 160

Met Ser Ser Cys Asp Phe  
 165

<210> 146  
 <211> 70  
 <212> PRT  
 <213> Homo sapiens

<400> 146

Met Lys Pro Lys His Leu Glu Trp Cys Leu Ala His Ser Trp Cys Val  
 1 5 10 15  
 Ile Trp Leu Ser Phe Val Ser Pro Pro Thr Ser His Leu Glu Cys Asp  
 20 25 30  
 Gly Phe Pro Gly Ser Leu Leu Pro Cys Glu Glu Gly Arg Cys Phe  
 35 40 45  
 Pro Phe Thr Phe His His His Asp Cys His Gly Cys Ser Pro Leu Gln  
 50 55 60  
 Ser Ser Pro Gly Gln His  
 65 70

<210> 147  
 <211> 412  
 <212> PRT  
 <213> Homo sapiens

<400> 147

Met Cys Cys Trp Pro Leu Leu Leu Leu Trp Gly Leu Leu Pro Gly Thr  
 1 5 10 15  
 Ala Ala Gly Gly Ser Gly Arg Thr Tyr Pro His Arg Thr Leu Leu Asp  
 20 25 30  
 Ser Glu Gly Lys Tyr Trp Leu Gly Trp Ser Gln Arg Gly Ser Gln Ile  
 35 40 45  
 Ala Phe Arg Leu Gln Val Arg Thr Ala Gly Tyr Val Gly Phe Gly Phe  
 50 55 60  
 Ser Pro Thr Gly Ala Met Ala Ser Ala Asp Ile Val Val Gly Gly Val  
 65 70 75 80  
 Ala His Gly Arg Pro Tyr Leu Gln Asp Tyr Phe Thr Asn Ala Asn Arg  
 85 90 95  
 Glu Leu Lys Lys Asp Ala Gln Gln Asp Tyr His Leu Glu Tyr Ala Met  
 100 105 110  
 Glu Asn Ser Thr His Thr Ile Ile Glu Phe Thr Arg Glu Leu His Thr  
 115 120 125  
 Cys Asp Ile Asn Asp Lys Ser Ile Thr Asp Ser Thr Val Arg Val Ile  
 130 135 140  
 Trp Ala Tyr His His Glu Asp Ala Gly Glu Ala Gly Pro Lys Tyr His  
 145 150 155 160

Asp Ser Asn Arg Gly Thr Lys Ser Leu Arg Leu Leu Asn Pro Glu Lys  
                                 165                                170                                175  
 Thr Ser Val Leu Ser Thr Ala Leu Pro Tyr Phe Asp Leu Val Asn Gln  
                                 180                                185                                190  
 Asp Val Pro Ile Pro Asn Lys Asp Thr Thr Tyr Trp Cys Gln Met Phe  
                                 195                                200                                205  
 Lys Ile Pro Val Phe Gln Glu Lys His His Val Ile Lys Val Glu Pro  
                                 210                                215                                220  
 Val Ile Gln Arg Gly His Glu Ser Leu Val His His Ile Leu Leu Tyr  
                                 225                                230                                235                                240  
 Gln Cys Ser Asn Asn Phe Asn Asp Ser Val Leu Glu Ser Gly His Glu  
                                 245                                250                                255  
 Cys Tyr His Pro Asn Met Pro Asp Ala Phe Leu Thr Cys Glu Thr Val  
                                 260                                265                                270  
 Ile Phe Ala Trp Ala Ile Gly Gly Glu Gly Phe Ser Tyr Pro Pro His  
                                 275                                280                                285  
 Val Gly Leu Ser Leu Gly Thr Pro Leu Asp Pro His Tyr Val Leu Leu  
                                 290                                295                                300  
 Glu Val His Tyr Asp Asn Pro Thr Tyr Glu Glu Gly Leu Ile Asp Asn  
                                 305                                310                                315                                320  
 Ser Gly Leu Arg Leu Phe Tyr Thr Met Asp Ile Arg Lys Tyr Asp Ala  
                                 325                                330                                335  
 Gly Val Ile Glu Ala Gly Leu Trp Val Ser Leu Phe His Thr Ile Pro  
                                 340                                345                                350  
 Pro Gly Met Pro Glu Phe Gln Ser Glu Gly His Cys Thr Leu Glu Cys  
                                 355                                360                                365  
 Leu Glu Glu Leu Trp Lys Pro Lys Ser Gln Val Glu Phe Met Cys Leu  
                                 370                                375                                380  
 Leu Phe Phe Ser Met Leu Thr Trp Leu Ala Glu His Gln Ala Ala Ser  
                                 385                                390                                395                                400  
 Phe Ser Lys Arg Glu Gly Asn Glu Ile Thr Cys Leu  
                                 405                                410

&lt;210&gt; 148

&lt;211&gt; 85

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (85)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 148

Met Asn Val Phe Leu Pro Pro Ala Leu Gly Thr Trp Gly Val Ala Arg  
 1 5 10 15  
 Phe Phe Pro His Leu Val Pro Glu Arg Trp Cys Leu Val Phe Cys Cys  
 20 25 30  
 Trp Ile Phe Phe Phe Phe Phe Phe Cys Thr Lys Val Ala Thr Arg  
 35 40 45  
 Ser Val Leu Gly Asp Gln Ala Gly Leu Gly Val Gly Gly Pro His Leu  
 50 55 60  
 Pro Leu Pro Gly Ser His Ser Val Ser Val Pro Glu Lys Thr Ile Phe  
 65 70 75 80  
 Ser Leu Lys Gln Xaa  
 85

&lt;210&gt; 149

&lt;211&gt; 154

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (154)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 149

Met Gly Arg Leu Pro Leu Leu Arg Arg Val Leu Lys Gly Leu Gln Leu  
 1 5 10 15  
 Leu Leu Ser Leu Leu Ala Phe Ile Cys Glu Glu Val Val Ser Gln Cys  
 20 25 30  
 Thr Leu Cys Gly Gly Leu Tyr Phe Phe Glu Phe Val Ser Cys Ser Ala  
 35 40 45  
 Phe Leu Leu Ser Leu Leu Ile Leu Ile Val Tyr Cys Thr Pro Phe Tyr  
 50 55 60  
 Glu Arg Val Asp Thr Thr Lys Val Lys Ser Ser Asp Phe Tyr Ile Thr  
 65 70 75 80  
 Leu Gly Thr Gly Cys Val Phe Leu Leu Ala Ser Ile Ile Phe Val Ser  
 85 90 95  
 Thr His Asp Arg Thr Ser Ala Glu Ile Ala Ala Ile Val Phe Gly Phe  
 100 105 110  
 Ile Ala Ser Phe Met Phe Leu Leu Asp Phe Ile Thr Met Leu Tyr Glu  
 115 120 125  
 Lys Arg Gln Glu Ser Gln Leu Arg Lys Pro Glu Asn Thr Thr Arg Ala  
 130 135 140  
 Glu Ala Leu Thr Glu Pro Leu Asn Ala Xaa

145

150

&lt;210&gt; 150

&lt;211&gt; 130

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (130)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 150

Met Arg Gly His Leu Ala Gly Phe Pro Ala Leu Ser Gly Leu Ala Ser  
 1 5 10 15

Val Cys Leu Trp Ala Thr Phe Ser Ala Gln Leu Pro Gly Pro Val Ala  
 20 25 30

Ala Thr Ser Trp Thr Pro Ala Pro Leu Gly Cys Ser Ala Ala Arg Ser  
 35 40 45

Gly Pro Glu Lys Arg Leu Gly Thr Ala Ala Pro Gly Ser Ala Ala Ser  
 50 55 60

Leu Ala Gln Ala Gly Pro Gly Ala Pro Cys Arg Val Leu Pro Val Asp  
 65 70 75 80

Pro Ala Pro Ala Ala Leu Asn Val Arg Glu Pro Gly Trp Leu Gly Gly  
 85 90 95

Leu Phe Asp Gly Ala Leu Leu Gln Val Leu Leu Asn Phe Leu Arg Lys  
 100 105 110

Ser Thr Asp Val Leu Met Asp Thr Arg Glu Ala Glu Ser Leu Glu Val  
 115 120 125

Glu Xaa  
 130

&lt;210&gt; 151

&lt;211&gt; 62

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (62)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 151

Met Leu Phe Trp Ala Tyr Pro Ile Cys Val Phe Ile Asp Ser Leu Ser  
 1 5 10 15

Cys Gln Pro Cys Leu Trp Ser Thr Gly Ala Thr Ser His Phe Asn Ser  
 20 25 30

Pro Asn Pro Phe Thr Gln Leu Gly Lys Leu Asp Asp Arg Xaa  
50 55 60

```
<210> 152
<211> 225
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (225)
<223> Xaa equals stop translation
```

<400> 152  
Met Gly Ile Phe Pro Gly Ile Ile Leu Ile Phe Leu Arg Val Lys Phe  
1 5 10 15

Ala Thr Ala Ala Val Ile Val Ser Gly His Gln Lys Ser Thr Thr Val  
20 25 30

Ser His Glu Met Ser Gly Leu Asn Trp Lys Pro Phe Val Tyr Gly Gly  
35 40 45

Leu Ala Ser Ile Val Ala Glu Phe Gly Thr Phe Pro Val Asp Leu Thr  
50 55 60

Lys Thr Arg Leu Gln Val Gln Gly Gln Ser Ile Asp Ala Arg Phe Lys  
65 70 75 80

Glu Ile Lys Tyr Arg Gly Met Phe His Ala Leu Phe Arg Ile Cys Lys  
85 90 95

Glu Glu Gly Val Leu Ala Leu Tyr Ser Gly Ile Ala Pro Ala Leu Leu  
100 105 110

Arg Gln Ala Ser Tyr Gly Thr Ile Lys Ile Gly Ile Tyr Gln Ser Leu  
115 120 125

Lys Arg Leu Phe Val Glu Arg Leu Glu Asp Glu Thr Leu Leu Ile Asn  
130 135 140

Met Ile Cys Gly Val Val Ser Gly Val Ile Ser Ser Thr Ile Ala Asn  
145 150 155 160

Pro Thr Asp Val Leu Lys Ile Arg Met Gln Ala Gln Gly Ser Leu Phe  
165 170 175

Gln Gly Ser Met Ile Gly Ser Phe Ile Asp Ile Tyr Gln Gln Glu Gly  
180 185 190

Thr Arg Gly Leu Trp Arg Val Ser Thr Leu Phe Leu Leu Leu Ser Tyr  
195 200 205

Thr Leu Ser Ser Tyr Asn Leu Gln Arg Ile Phe Phe Tyr Ile Lys Thr  
210 215 220



Xaa  
225

<210> 153  
<211> 69  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (69)  
<223> Xaa equals stop translation

<400> 153  
Met Leu Met Leu Leu Thr Leu Leu Val Leu Gly Met Val Trp Val Ala  
1 5 10 15  
Ser Ala Ile Val Asp Lys Asn Lys Ala Asn Arg Glu Ser Leu Tyr Asp  
20 25 30  
Phe Trp Glu Tyr Tyr Leu Pro Tyr Leu Tyr Ser Cys Ile Ser Phe Leu  
35 40 45  
Gly Val Leu Leu Leu Leu Ala Ala Gly Arg Pro Gly Gly Ala Ala Val  
50 55 60  
Leu Leu Ser Leu Xaa  
65

<210> 154  
<211> 84  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (84)  
<223> Xaa equals stop translation

<400> 154  
Met Tyr Gly Val Cys Leu Cys Val Ile Val Cys Val Ser Gly Val Ser  
1 5 10 15  
Leu Cys Leu Tyr Val Trp Gly Val Ser Val Cys Asp Cys Val Ser Val  
20 25 30  
Phe Met Cys Val Cys Leu Cys Val Ile Phe Cys Val Tyr Gly Lys Pro  
35 40 45  
Arg Thr Glu His Tyr His Ser Pro His Leu Ala Lys Gln Lys Ala Phe  
50 55 60  
Arg Glu Met Cys Gly Arg His Asp Val Ser Ala Ala Gly Ile Phe Gln  
65 70 75 80  
Ser Tyr Val Xaa

<210> 155  
 <211> 61  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (61)  
 <223> Xaa equals stop translation

<400> 155  
 Met His Val Leu Leu Phe Ser Phe Leu Ile Pro Phe Leu Leu Leu Ser  
           1                  5                  10                  15  
 Pro Val Gly Val Thr Cys Asn Ser His Met Leu Glu Arg Gln Val Ser  
                   20                  25                  30  
 Trp Leu Lys Lys Arg Ser Thr Gln Ala Ser Gln Gln Phe Asn Lys Phe  
           35                  40                  45  
 Leu Arg Gly Ile Ser Asn Val Gly Arg Ile Val Ile Xaa  
           50                  55                  60

<210> 156  
 <211> 84  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (84)  
 <223> Xaa equals stop translation

<400> 156  
 Met Cys Leu Leu Val Glu Tyr Ser Leu Met Ile Leu Thr Ile Ile Pro  
           1                  5                  10                  15  
 Ser Leu Leu Ser Phe Val Leu Cys Leu Lys Gly Ile Lys His Gly Asn  
                   20                  25                  30  
 Tyr Ile Phe Gln Thr Pro Leu Pro Glu Gly Tyr Gly Trp Ile Ser Ala  
           35                  40                  45  
 Met Ser Gly Leu Cys Ile Lys Phe Gly Arg Arg Lys Arg Arg Lys Thr  
           50                  55                  60  
 Trp Leu Leu Gln Val Gly Thr Leu Ala Thr Ile Asp Thr Glu Phe Ala  
           65                  70                  75                  80  
 Arg Ser Cys Xaa

<210> 157  
 <211> 162

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (162)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 157

Met	Ala	Leu	Ser	Leu	Thr	Leu	Cys	Phe	Val	Met	Phe	Trp	Thr	Pro	Asn
1				5					10					15	

Val	Ser	Glu	Lys	Ile	Leu	Ile	Asp	Ile	Ile	Gly	Val	Asp	Phe	Ala	Phe
		20					25						30		

Ala	Glu	Leu	Cys	Val	Val	Pro	Leu	Arg	Ile	Phe	Ser	Phe	Phe	Pro	Val
	35						40					45			

Pro	Val	Thr	Val	Arg	Ala	His	Leu	Thr	Gly	Trp	Leu	Met	Thr	Leu	Lys
	50					55					60				

Lys	Thr	Phe	Val	Leu	Ala	Pro	Ser	Ser	Val	Leu	Arg	Ile	Ile	Val	Leu
65				70						75					80

Ile	Ala	Ser	Leu	Val	Val	Leu	Pro	Tyr	Leu	Gly	Val	His	Gly	Ala	Thr
			85						90					95	

Leu	Gly	Val	Gly	Ser	Leu	Leu	Ala	Gly	Phe	Val	Gly	Glu	Ser	Thr	Met
		100						105					110		

Val	Ala	Ile	Ala	Ala	Cys	Tyr	Val	Tyr	Arg	Lys	Gln	Lys	Lys	Lys	Met
	115						120					125			

Glu	Asn	Glu	Ser	Ala	Thr	Glu	Gly	Glu	Asp	Ser	Ala	Met	Thr	Asp	Met
130						135					140				

Pro	Pro	Thr	Glu	Glu	Val	Thr	Asp	Ile	Val	Glu	Met	Arg	Glu	Glu	Asn
145					150					155					160

Glu Xaa

&lt;210&gt; 158

&lt;211&gt; 146

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (96)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (107)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

<221> SITE  
 <222> (111)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (115)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (122)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (132)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <400> 158  
 Met Glu Pro Gln Leu Gly Pro Glu Ala Ala Ala Leu Arg Pro Gly Trp  
   1                  5                  10                  15  
 Leu Ala Leu Leu Leu Trp Val Ser Ala Leu Ser Cys Ser Phe Ser Leu  
                   20                  25                  30  
 Pro Ala Ser Ser Leu Ser Ser Leu Val Pro Gln Val Arg Thr Ser Tyr  
           35                  40                  45  
 Asn Phe Gly Arg Thr Phe Leu Gly Leu Asp Lys Cys Asn Ala Cys Ile  
   50                  55                  60  
 Gly Thr Ser Ile Cys Lys Lys Phe Phe Lys Glu Glu Ile Arg Ser Asp  
   65                  70                  75                  80  
 Asn Trp Leu Ala Ser His Leu Gly Thr Ala Ser Arg Phe Pro Leu Xaa  
                   85                  90                  95  
 Ser Tyr Pro Cys Lys Leu Leu Gln Met Ile Xaa Lys Ile Trp Xaa Pro  
           100                  105                  110  
 Cys Gly Xaa Leu Leu Thr Gly Gln Gln Xaa Ser Asn Glu Ile Ser Lys  
           115                  120                  125  
 Gln Glu Ile Xaa Cys Leu Leu His Pro Pro Pro Lys Asn Leu His Ile  
   130                  135                  140  
 Asp Val  
 145

<210> 159  
 <211> 143  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (143)

<223> Xaa equals stop translation

<400> 159

Met Trp Trp Ala Val Met Gly Gly Val Ile Gly Ser Trp Leu Ser Pro  
1 5 10 15

Leu Ser Ile Ala Glu Cys Cys His Asp Leu Trp Thr Ser Gln Ser Cys  
20 25 30

Glu His Ala Gly Ala Leu Cys Gly Asp Leu Leu Cys Ala Cys Arg Lys  
35 40 45

Val Gly Val Trp Cys Ala Leu Gln Gln His Trp Trp Asn Arg Cys Val  
50 55 60

Cys Pro His Ala Val Ile Arg Val His Cys Thr Gly Ala Ser Tyr Thr  
65 70 75 80

Leu Gln Lys Ile Cys Ser Cys Asn Pro Lys Phe Met Gly Arg His Pro  
85 90 95

His Arg Trp Gln Gln Ile Arg Lys Cys Ser Gln Pro Val Leu Arg Gly  
100 105 110

Ser Arg Ala Ala Phe Ile Trp Val Arg Leu Ala Ala Leu Asn Phe Ile  
115 120 125

Ser Ser Phe Arg Cys Ile Ser Leu Ile Ser Tyr Ser Ala Phe Xaa  
130 135 140

<210> 160

<211> 51

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (51)

<223> Xaa equals stop translation

<400> 160

Met Lys Val Ser Asp Phe Asn Phe Leu Ile Phe Leu Ile Phe Ala Leu  
1 5 10 15

Phe Leu Thr Leu Glu Ala Phe Leu Lys Phe Thr Lys Arg Val Leu Ala  
20 25 30

Val Val Gly Asn Leu Pro Glu Pro Pro Ile Ile Lys Thr Ile Gly Phe  
35 40 45

Leu Tyr Xaa  
50

<210> 161

<211> 65

<212> PRT

<213> Homo sapiens

<220>  
<221> SITE  
<222> (65)  
<223> Xaa equals stop translation

<400> 161  
Met Val Trp Ser Ala Ala Pro Ala Pro Cys Cys Leu Leu Gly Val Leu  
1 5 10 15  
Gly Leu Val Gln Val Leu Gly Ala Gln Ala Val Gly Pro Trp Thr Ala  
20 25 30  
Ser Ala Cys Leu Gly Ala Ala Gln Ala Gln Pro Cys Arg Pro Cys Lys  
35 40 45  
Glu Ser Ser Leu Arg Leu Phe Ser Ala Ser Ala Pro Ser Met Thr His  
50 55 60  
Xaa  
65

<210> 162  
<211> 59  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (59)  
<223> Xaa equals stop translation

<400> 162  
Met Glu Lys Tyr Cys Leu Gly Asn Asn Met Leu Ser Arg Phe Cys Leu  
1 5 10 15  
Phe Leu Ile Met Leu Leu His Ile Leu Leu Phe Leu Val Ile Phe Ile  
20 25 30  
Gln Arg His Thr Val Val Ser Leu Ser Lys His His Pro Phe Val Pro  
35 40 45  
Thr Asn Gly Ser Lys Ser Tyr Ser Ser Phe Xaa  
50 55

<210> 163  
<211> 374  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (84)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE

&lt;222&gt; (112)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 163

Met Arg Pro Gly Thr Ala Leu Gln Ala Val Leu Leu Ala Val Leu Leu  
 1 5 10 15

Val Gly Leu Arg Ala Ala Thr Gly Arg Leu Leu Ser Gly Gln Pro Val  
 20 25 30

Cys Arg Gly Gly Thr Gln Arg Pro Cys Tyr Lys Val Ile Tyr Phe His  
 35 40 45

Asp Thr Ser Arg Arg Leu Asn Phe Glu Glu Ala Lys Glu Ala Cys Arg  
 50 55 60

Arg Asp Gly Gly Gln Leu Val Ser Ile Glu Ser Glu Asp Glu Gln Lys  
 65 70 75 80

Leu Ile Glu Xaa Phe Ile Glu Asn Leu Leu Pro Ser Asp Gly Asp Phe  
 85 90 95

Trp Ile Gly Leu Arg Arg Arg Glu Glu Lys Gln Ser Asn Ser Thr Xaa  
 100 105 110

Cys Gln Asp Leu Tyr Ala Trp Thr Asp Gly Ser Ile Ser Gln Phe Arg  
 115 120 125

Asn Trp Tyr Val Asp Glu Pro Ser Cys Gly Ser Glu Val Cys Val Val  
 130 135 140

Met Tyr His Gln Pro Ser Ala Pro Ala Gly Ile Gly Gly Pro Tyr Met  
 145 150 155 160

Phe Gln Trp Asn Asp Asp Arg Cys Asn Met Lys Asn Asn Phe Ile Cys  
 165 170 175

Lys Tyr Ser Asp Glu Lys Pro Ala Val Pro Ser Arg Glu Ala Glu Gly  
 180 185 190

Glu Glu Thr Glu Leu Thr Thr Pro Val Leu Pro Glu Glu Thr Gln Glu  
 195 200 205

Glu Asp Ala Lys Lys Thr Phe Lys Glu Ser Arg Glu Ala Ala Leu Asn  
 210 215 220

Leu Ala Tyr Ile Leu Ile Pro Ser Ile Pro Leu Leu Leu Leu Val  
 225 230 235 240

Val Thr Thr Val Val Cys Trp Val Trp Ile Cys Arg Lys Arg Lys Arg  
 245 250 255

Glu Gln Pro Asp Pro Ser Thr Lys Lys Gln His Thr Ile Trp Pro Ser  
 260 265 270

Pro His Gln Gly Asn Ser Pro Asp Leu Glu Val Tyr Asn Val Ile Arg  
 275 280 285

Lys Gln Ser Glu Ala Asp Leu Ala Glu Thr Arg Pro Asp Leu Lys Asn

290                      295                      300  
 Ile Ser Phe Arg Val Cys Ser Gly Glu Ala Thr Pro Asp Asp Met Ser  
 305                      310                      315                      320  
 Cys Asp Tyr Asp Asn Met Ala Val Asn Pro Ser Glu Ser Gly Phe Val  
                     325                      330                      335  
 Thr Leu Val Ser Val Glu Ser Gly Phe Val Thr Asn Asp Ile Tyr Glu  
                     340                      345                      350  
 Phe Ser Pro Asp Gln Met Gly Arg Ser Lys Glu Ser Gly Trp Val Glu  
                     355                      360                      365  
 Asn Glu Ile Tyr Gly Tyr  
 370

<210> 164  
 <211> 64  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (64)  
 <223> Xaa equals stop translation

<400> 164  
 Met His Pro Gln Leu Ile Pro Ser Val Ile Ala Val Val Phe Ile Leu  
 1                      5                      10                      15  
 Leu Leu Gly Val Cys Phe Ile Ala Ser Cys Leu Val Thr His His Asn  
                     20                      25                      30  
 Phe Ser Arg Cys Lys Arg Gly Thr Gly Val His Lys Leu Glu His His  
                     35                      40                      45  
 Ala Lys Leu Lys Cys Ile Lys Glu Lys Ser Glu Leu Lys Ser Cys Xaa  
                     50                      55                      60

<210> 165  
 <211> 743  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (743)  
 <223> Xaa equals stop translation

<400> 165  
 Met Ala Val Arg Glu Leu Cys Phe Pro Arg Gln Arg Gln Val Leu Phe  
 1                      5                      10                      15



Leu Phe Leu Phe Trp Gly Val Ser Leu Ala Gly Ser Gly Phe Gly Arg  
                   20                  25                  30  
 Tyr Ser Val Thr Glu Glu Thr Glu Lys Gly Ser Phe Val Val Asn Leu  
                   35                  40                  45  
 Ala Lys Asp Leu Gly Leu Ala Glu Gly Glu Leu Ala Ala Arg Gly Thr  
                   50                  55                  60  
 Arg Val Val Ser Asp Asp Asn Lys Gln Tyr Leu Leu Leu Asp Ser His  
                   65                  70                  75                  80  
 Thr Gly Asn Leu Leu Thr Asn Glu Lys Leu Asp Arg Glu Lys Leu Cys  
                   85                  90                  95  
 Gly Pro Lys Glu Pro Cys Met Leu Tyr Phe Gln Ile Leu Met Asp Asp  
                   100                  105                  110  
 Pro Phe Gln Ile Tyr Arg Ala Glu Leu Arg Val Arg Asp Ile Asn Asp  
                   115                  120                  125  
 His Ala Pro Val Phe Gln Asp Lys Glu Thr Val Leu Lys Ile Ser Glu  
                   130                  135                  140  
 Asn Thr Ala Glu Gly Thr Ala Phe Arg Leu Glu Arg Ala Gln Asp Pro  
                   145                  150                  155                  160  
 Asp Gly Gly Leu Asn Gly Ile Gln Asn Tyr Thr Ile Ser Pro Asn Ser  
                   165                  170                  175  
 Phe Phe His Ile Asn Ile Ser Gly Gly Asp Glu Gly Met Ile Tyr Pro  
                   180                  185                  190  
 Glu Leu Val Leu Asp Lys Ala Leu Asp Arg Glu Glu Gln Gly Glu Leu  
                   195                  200                  205  
 Ser Leu Thr Leu Thr Ala Leu Asp Gly Gly Ser Pro Ser Arg Ser Gly  
                   210                  215                  220  
 Thr Ser Thr Val Arg Ile Val Val Leu Asp Val Asn Asp Asn Ala Pro  
                   225                  230                  235                  240  
 Gln Phe Ala Gln Ala Leu Tyr Glu Thr Gln Ala Pro Glu Asn Ser Pro  
                   245                  250                  255  
 Ile Gly Phe Leu Ile Val Lys Val Trp Ala Glu Asp Val Asp Ser Gly  
                   260                  265                  270  
 Val Asn Ala Glu Val Ser Tyr Ser Phe Phe Asp Ala Ser Glu Asn Ile  
                   275                  280                  285  
 Arg Thr Thr Phe Gln Ile Asn Pro Phe Ser Gly Glu Ile Phe Leu Arg  
                   290                  295                  300  
 Glu Leu Leu Asp Tyr Glu Leu Val Asn Ser Tyr Lys Ile Asn Ile Gln  
                   305                  310                  315                  320  
 Ala Met Asp Gly Gly Gly Leu Ser Ala Arg Cys Arg Val Leu Val Glu  
                   325                  330                  335

Val Leu Asp Thr Asn Asp Asn Pro Pro Glu Leu Ile Val Ser Ser Phe  
 340 345 350  
 Ser Asn Ser Val Ala Glu Asn Ser Pro Glu Thr Pro Leu Ala Val Phe  
 355 360 365  
 Lys Ile Asn Asp Arg Asp Ser Gly Glu Asn Gly Lys Met Val Cys Tyr  
 370 375 380  
 Ile Gln Glu Asn Leu Pro Phe Leu Leu Lys Pro Ser Val Glu Asn Phe  
 385 390 395 400  
 Tyr Ile Leu Ile Thr Glu Gly Ala Leu Asp Arg Glu Ile Arg Ala Glu  
 405 410 415  
 Tyr Asn Ile Thr Ile Thr Val Thr Asp Leu Gly Thr Pro Arg Leu Lys  
 420 425 430  
 Thr Glu His Asn Ile Thr Val Leu Val Ser Asp Val Asn Asn Ala  
 435 440 445  
 Pro Ala Phe Thr Gln Thr Ser Tyr Thr Leu Phe Val Arg Glu Asn Asn  
 450 455 460  
 Ser Pro Ala Leu His Ile Gly Ser Val Ser Ala Thr Asp Arg Asp Ser  
 465 470 475 480  
 Gly Thr Asn Ala Gln Val Thr Tyr Ser Leu Leu Pro Pro Gln Asp Pro  
 485 490 495  
 His Leu Pro Leu Ala Ser Leu Val Ser Ile Asn Ala Asp Asn Gly His  
 500 505 510  
 Leu Phe Ala Leu Arg Ser Leu Asp Tyr Glu Ala Leu Gln Ala Phe Glu  
 515 520 525  
 Phe Arg Val Gly Ala Thr Asp Arg Gly Ser Pro Ala Leu Asn Ser Glu  
 530 535 540  
 Ala Leu Gly Ala Arg Ala Gly Ala Gly Arg Gln Arg Gln Leu Ala Leu  
 545 550 555 560  
 Arg Ala Val Pro Ala Ala Glu Arg Leu Arg Ala Leu His Arg Ala Gly  
 565 570 575  
 Ala Pro Gly Gly Arg Ala Gly Leu Pro Gly Asp Gln Gly Gly Gly Gly  
 580 585 590  
 Gly Arg Arg Leu Gly Pro Glu Arg Leu Ala Val Val Pro Ala Ala Gln  
 595 600 605  
 Gly His Gly Ala Arg Ala Val Arg Cys Val Gly Ala Gln Trp Gly Gly  
 610 615 620  
 Ala His Arg Gln Ala Ala Glu Arg Ala Arg Arg Ser Gln Ala Gln Ala  
 625 630 635 640  
 Gly Gly Ala Cys Gln Gly Gln Trp Arg Ala Ser Ser Leu Gly His Arg

645                      650                      655  
 His Ala Ala Arg Ala Pro Gly Gly Arg Leu Leu Pro Ala Leu Pro Ala  
                          660                      665                      670  
 Ser Pro Gly Gly Gly Pro Gly Pro Gly Pro Gly Arg Leu Ala His Arg  
                          675                      680                      685  
 Leu Pro Gly Gly Gly Val Gly Leu Gly Val Phe Ala Leu Pro Pro Leu  
                          690                      695                      700  
 Gly Ala Pro Val Arg Gly Gly Ala Ala Val Gln Glu Glu Gln Gly Gly  
                          705                      710                      715                      720  
 Leu Gly Gly Ser Leu Leu Gly Ala Arg Gly Ser Phe Ser Arg Ala Ser  
                          725                      730                      735  
 Gly Gly Arg Glu Gly Arg Xaa  
                          740  
  
 <210> 166  
 <211> 214  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (214)  
 <223> Xaa equals stop translation  
  
 <400> 166  
 Met Asn Arg Met Glu Leu Leu Lys Leu Leu Leu Thr Cys Phe Ser Glu  
   1                      5                      10                      15  
 Ala Met Tyr Leu Pro Pro Ala Pro Glu Ser Gly Ser Thr Asn Pro Trp  
                          20                      25                      30  
 Val Gln Phe Phe Cys Ser Thr Glu Asn Arg His Ala Leu Pro Leu Phe  
                          35                      40                      45  
 Thr Ser Leu Leu Asn Thr Val Cys Ala Tyr Asp Pro Val Gly Tyr Gly  
                          50                      55                      60  
 Ile Pro Tyr Asn His Leu Leu Phe Ser Asp Tyr Arg Glu Pro Leu Val  
                          65                      70                      75                      80  
 Glu Glu Ala Ala Gln Val Leu Ile Val Thr Leu Asp His Asp Ser Ala  
                          85                      90                      95  
 Ser Ser Ala Ser Pro Thr Val Asp Gly Thr Thr Thr Gly Thr Ala Met  
                          100                      105                      110  
 Asp Asp Ala Asp Pro Pro Gly Pro Glu Asn Leu Phe Val Asn Tyr Leu  
                          115                      120                      125  
 Ser Arg Ile His Arg Glu Glu Asp Phe Gln Phe Ile Leu Lys Gly Ile  
                          130                      135                      140

120

Ala Arg Leu Leu Ser Asn Pro Leu Leu Gln Thr Tyr Leu Pro Asn Ser  
 145 150 155 160

Thr Lys Lys Asp Pro Val Pro Pro Gly Ala Ala Ser Ser Leu Leu Glu  
 165 170 175

Ala Leu Arg Leu Gln Gln Glu Ile Pro Leu Leu Arg Ala Glu Glu Gln  
 180 185 190

Arg Arg Pro Arg His Pro Cys Pro His Pro Leu Leu Pro Gln Arg Cys  
 195 200 205

Pro Gly Arg Ser Val Xaa  
 210

<210> 167

<211> 213

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (213)

<223> Xaa equals stop translation

<400> 167

Met Pro Ser Leu Arg Phe Leu Ala Leu Ala Leu Leu Ala Ile Leu  
 1 5 10 15

Pro Ala Leu Pro Asn Ala His Ala Ala Pro Gly Ile Gly Gly Leu Ile  
 20 25 30

Gly Gly Gly Ser Gln Ala Ser Ala Lys Glu Glu Pro Gln Ser Asn Ala  
 35 40 45

Gln Pro Ser Ala Asp Glu Arg Lys Gln Arg Leu Leu Ser Gln Ala Glu  
 50 55 60

Glu Thr Arg Gln Arg Leu Thr Asp Leu Lys Ala Glu Leu Ala Gly Ala  
 65 70 75 80

Pro Lys Glu Ile Ser Glu Ala Gln Arg Thr Leu Ser Lys Leu Val Ser  
 85 90 95

Glu Asp Asn Ser Asp Leu Pro Glu Arg Leu Ser Lys Leu Ser Val Pro  
 100 105 110

Val Leu Glu Gln Arg Leu Ala Ala Arg Val Asp Glu Leu Ala Leu Trp  
 115 120 125

Gln Gln Ala Leu Ser Ala Ala Asn Ser Met Leu Ile Ser Ala Gln Thr  
 130 135 140

Arg Pro Glu Arg Ala Gln Ala Asp Ile Ser Lys Asn Gln Leu Arg Ile  
 145 150 155 160

Asp Glu Ile Asn Gly Leu Leu Lys Ser Gly Arg Glu Asn Asn Lys Pro  
 165 170 175

Leu Thr Asp Glu Arg Arg Ala Leu Leu Glu Ser Thr Ser Arg Ala Ala  
                   180                  185                  190

Ala Gly Pro Ser Ile Phe His Pro Gly Gly Val Pro Gly Lys Cys Thr  
                   195                  200                  205

Gln Phe Ala Leu Xaa  
                   210

<210> 168  
 <211> 75  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (75)  
 <223> Xaa equals stop translation

<400> 168  
 Met Phe Thr Ser Phe Gly Leu Ala Ser Pro Arg Ile Leu Phe Cys Phe  
     1                  5                  10                  15

Cys Phe Phe Asp Leu Gly Phe Ile Phe Phe Cys Val Leu Tyr Tyr Ile  
                   20                  25                  30

Val Lys Gly Ile Leu Ala Glu Thr Leu Val Phe Gly Ala Arg Gly Glu  
                   35                  40                  45

Gln Glu Cys Trp Ala Val Tyr Phe Arg Trp Arg Thr His Leu Gln Thr  
     50                  55                  60

Phe Gly Leu Phe Ser Phe Asn Cys Ser Val Xaa  
     65                  70                  75

<210> 169  
 <211> 48  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (48)  
 <223> Xaa equals stop translation

<400> 169  
 Met Phe Leu Cys Leu Phe Phe Phe Phe Asn Ala Thr Gln Gly Asn  
     1                  5                  10                  15

Ile Phe Ile Ser Phe Leu Ser Gly Leu Pro Gln Cys Ile Phe Ile Ser  
                   20                  25                  30

Phe Glu Thr Lys Arg Phe Trp Lys Leu Phe Phe Cys Ser Phe Lys Xaa  
     35                  40                  45

<210> 170  
 <211> 88  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (88)  
 <223> Xaa equals stop translation

<400> 170  
 Met Gly Leu His Leu Arg Pro Tyr Arg Val Gly Leu Leu Pro Asp Gly  
   1                  5                  10                  15  
 Leu Leu Phe Leu Leu Leu Leu Leu Met Leu Leu Ala Asp Pro Ala Leu  
                   20                  25                  30  
 Pro Ala Gly Arg His Pro Pro Val Val Leu Val Pro Gly Asp Leu Gly  
           35                  40                  45  
 Asn Gln Leu Glu Ala Lys Leu Asp Lys Pro Thr Val Val His Tyr Leu  
   50                  55                  60  
 Cys Ser Lys Lys Thr Glu Ser Tyr Phe Thr Ile Trp Leu Asn Leu Glu  
   65                  70                  75                  80  
 Leu Leu Leu Pro Val His His Xaa  
                   85

<210> 171  
 <211> 42  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (42)  
 <223> Xaa equals stop translation

<400> 171  
 Met Ala Cys Glu Thr His Gly Val Leu Val Pro Ala His Leu Ser Gly  
   1                  5                  10                  15  
 Leu Ile Thr Cys Leu Leu Ala Phe Trp Val Pro Ala Ser Cys Ile Gln  
           20                  25                  30  
 Arg Cys Ser Gly Ser Pro Leu Pro Leu Xaa  
   35                  40

<210> 172  
 <211> 48  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (48)  
 <223> Xaa equals stop translation

<400> 172  
 Met Gln Cys Phe Leu Phe Ser Ile Phe Leu Ile Thr Gly Leu Ala Glu  
           1                  5                  10                  15  
 Glu Phe Cys Glu Gln Leu Ser Ile Ser Leu Ala Glu Glu Glu Ile Gln  
                   20                  25                  30  
 Leu Ser Ser Thr Val Glu His Phe Cys Met Thr Ala Phe Ser Trp Xaa  
           35                  40                  45

<210> 173  
 <211> 233  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (233)  
 <223> Xaa equals stop translation

<400> 173  
 Met Ala Ala Leu Ala Ala Ala Lys Lys Val Trp Ser Ala Arg Arg  
           1                  5                  10                  15  
 Leu Leu Val Leu Leu Phe Thr Pro Leu Ala Leu Leu Pro Val Val Phe  
                   20                  25                  30  
 Ala Leu Pro Pro Lys Glu Gly Arg Cys Leu Phe Val Ile Leu Leu Met  
           35                  40                  45  
 Ala Val Tyr Trp Cys Thr Glu Ala Leu Pro Leu Ser Val Thr Ala Leu  
           50                  55                  60  
 Leu Pro Ile Val Leu Phe Pro Phe Met Gly Ile Leu Pro Ser Asn Lys  
           65                  70                  75                  80  
 Val Cys Pro Gln Tyr Phe Leu Asp Thr Asn Phe Leu Phe Leu Ser Gly  
                   85                  90                  95  
 Leu Ile Met Ala Ser Ala Ile Glu Glu Trp Asn Leu His Arg Arg Ile  
           100                  105                  110  
 Ala Leu Lys Ile Leu Met Leu Val Gly Val Gln Pro Ala Arg Leu Ile  
           115                  120                  125  
 Leu Gly Met Met Val Thr Thr Ser Phe Leu Ser Met Trp Leu Ser Asn  
           130                  135                  140  
 Thr Ala Ser Thr Ala Met Met Leu Pro Ile Ala Asn Ala Ile Leu Lys  
           145                  150                  155                  160

Ser Leu Phe Gly Gln Lys Glu Val Arg Lys Asp Pro Ser Gln Glu Ser  
                   165                  170                  175

Glu Glu Asn Thr Gly Ile Glu Pro Asn Thr Phe Leu Ser Glu Glu Arg  
                   180                  185                  190

Leu Lys Leu Gln Ala Pro Leu Val Ile Arg Leu Gly Gln Ile Thr Glu  
                   195                  200                  205

Ser Gly Gln Trp Asn Met Ser Gly Asn Asp Val Cys Asn Phe Arg Val  
                   210                  215                  220

Leu Ser Phe Leu Pro Gly Gly Met Xaa  
                   225                  230

<210> 174  
 <211> 45  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (45)  
 <223> Xaa equals stop translation

<400> 174  
 Met Gly Thr Ile Phe Gly Tyr Leu His Cys Val Lys Cys Tyr Val Leu  
           1                  5                  10                  15

Tyr Phe Ile Phe Ile Leu Ile Thr Ala Val Tyr His Ser Phe Tyr Tyr  
                   20                  25                  30

Pro His Tyr Arg Gly Lys Ala Leu Ile Ser Gly Thr Xaa  
           35                  40                  45

<210> 175  
 <211> 85  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (77)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (85)  
 <223> Xaa equals stop translation

<400> 175  
 Met Val Trp Phe Leu Phe Leu Val Phe Ile Phe Leu Lys Val Lys Gly  
           1                  5                  10                  15

Asp Phe Phe Pro Pro Phe Leu Ile Cys Asn Leu Phe Cys Ile Trp Met  
           20                  25                  30



Ile Thr Gly Val Ser His Arg Leu Gln Pro Gln Ile Leu Phe Ser Arg  
           35                          40                          45  
 His Lys His Asn Gln Glu Ile Ile Leu Gln Met Val Ser Phe Ser Cys  
           50                          55                          60  
 Cys Val Phe Phe Pro Met Ile Arg Glu Val Lys Ser Xaa Leu Gly Cys  
           65                          70                          75                          80  
 Ile Lys Met Ser Xaa  
                           85

<210> 176  
 <211> 66  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (66)  
 <223> Xaa equals stop translation

<400> 176  
 Met Trp Val Leu Leu Ser Cys Pro Leu Pro Pro Leu Cys Leu Pro Ala  
           1                          5                          10                          15  
 Ser Ala Val Pro Gly Gln Cys Leu Gly Gly Gln Trp Ser Gly His Gln  
                           20                          25                          30  
 Leu Arg Leu Arg Gly Arg Gly Trp His Cys Arg Cys His Cys Arg Ala  
           35                          40                          45  
 Trp Ala Ala Asp Met Gly Arg Gly Leu His Ser Cys Gln Leu Leu Ser  
           50                          55                          60  
 Arg Xaa  
           65

<210> 177  
 <211> 55  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (55)  
 <223> Xaa equals stop translation

<400> 177  
 Met Leu Leu Leu Cys Ile Leu Leu Ile Phe Cys Val Val Gly Leu Ser  
           1                          5                          10                          15  
 Val Val Gly Arg Arg Val Leu Lys Ser Thr Thr Ile Ile Val Tyr Leu  
                           20                          25                          30  
 Ser Ile Thr Pro Phe Ser Ser Phe Ser Ser Ile Ser His Ile Phe Gln

35                                      40                                      45  
 Leu Leu Ile Gly Ala His Xaa  
     50                                      55  
  
 <210> 178  
 <211> 83  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (4)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (83)  
 <223> Xaa equals stop translation  
  
 <400> 178  
 Met Cys Val Xaa Leu Ser Phe Cys Pro Phe Leu Ser Ser Ala Leu Pro  
     1                                      5                                      10                                      15  
  
 Ala Ser His Thr Gln Phe Tyr Met Pro Arg Gly Ala Lys Phe Gly Thr  
                     20                                      25                                      30  
  
 Phe Thr Leu Gln Ala Ser Val Ser Pro Leu Glu Glu Lys Thr His Ser  
     35                                      40                                      45  
  
 Phe Thr His Pro Gly Ile Gly Gly Lys Leu Leu Gly His Gln Asp Pro  
     50                                      55                                      60  
  
 Gly Ala Pro Gly Pro Ser Trp Asn Ile Arg Ser Thr Trp Ser Thr Arg  
     65                                      70                                      75                                      80  
  
 Ser Leu Xaa

<210> 179  
 <211> 330  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (38)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (247)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <400> 179  
 Met Ser Pro Leu Ser Ala Ala Arg Ala Ala Leu Arg Val Tyr Ala Val  
     1                                      5                                      10                                      15

Gly Ala Ala Val Ile Leu Ala Gln Leu Leu Arg Arg Cys Arg Gly Gly  
                   20                  25                  30  
 Phe Leu Glu Pro Val Xaa Pro Pro Arg Pro Asp Arg Val Ala Ile Val  
                   35                  40                  45  
 Thr Gly Gly Thr Asp Gly Ile Gly Tyr Ser Thr Ala Lys His Leu Ala  
                   50                  55                  60  
 Arg Leu Gly Met His Val Ile Ile Ala Gly Asn Asn Asp Ser Lys Ala  
                   65                  70                  75                  80  
 Lys Gln Val Val Ser Lys Ile Lys Glu Glu Thr Leu Asn Asp Lys Val  
                   85                  90                  95  
 Glu Phe Leu Tyr Cys Asp Leu Ala Ser Met Thr Ser Ile Arg Gln Phe  
                   100                  105                  110  
 Val Gln Lys Phe Lys Met Lys Lys Ile Pro Leu His Val Leu Ile Asn  
                   115                  120                  125  
 Asn Ala Gly Val Met Met Val Pro Gln Arg Lys Thr Arg Asp Gly Phe  
                   130                  135                  140  
 Glu Glu His Phe Gly Leu Asn Tyr Leu Gly His Phe Leu Leu Thr Asn  
                   145                  150                  155                  160  
 Leu Leu Leu Asp Thr Leu Lys Glu Ser Gly Ser Pro Gly His Ser Ala  
                   165                  170                  175  
 Arg Val Val Thr Val Ser Ser Ala Thr His Tyr Val Ala Glu Leu Asn  
                   180                  185                  190  
 Met Asp Asp Leu Gln Ser Ser Ala Cys Tyr Ser Pro His Ala Ala Tyr  
                   195                  200                  205  
 Ala Gln Ser Lys Leu Ala Leu Val Leu Phe Thr Tyr His Leu Gln Arg  
                   210                  215                  220  
 Leu Leu Ala Ala Glu Gly Ser His Val Thr Ala Asn Val Val Asp Pro  
                   225                  230                  235                  240  
 Gly Val Val Asn Thr Asp Xaa Tyr Lys His Val Phe Trp Ala Thr Arg  
                   245                  250                  255  
 Leu Ala Lys Lys Leu Leu Gly Trp Leu Leu Phe Lys Thr Pro Asp Glu  
                   260                  265                  270  
 Gly Ala Trp Thr Ser Ile Tyr Ala Ala Val Thr Pro Glu Leu Glu Gly  
                   275                  280                  285  
 Val Gly Gly Arg Tyr Leu Tyr Asn Glu Lys Glu Thr Lys Ser Leu His  
                   290                  295                  300  
 Val Thr Tyr Asn Gln Lys Leu Gln Gln Gln Leu Trp Ser Lys Ser Cys  
                   305                  310                  315                  320  
 Glu Met Thr Gly Val Leu Asp Val Thr Leu

325

330

<210> 180  
<211> 41  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (41)  
<223> Xaa equals stop translation

<400> 180  
Met Ile Ala Cys Gln Tyr Ile Ser Leu Ala Ile Met Leu Ala Phe Val  
1 5 10 15  
Arg Trp Ala Ala Phe Leu Leu Phe Pro Phe Leu Cys Gly Asp Asn Gly  
20 25 30  
Gly Asn Ile Gln Gln Lys Tyr Val Xaa  
35 40

<210> 181  
<211> 52  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (52)  
<223> Xaa equals stop translation

<400> 181  
Met Ala Asn Ala Met Ala Tyr Leu Ser Ile Phe Leu Cys Gly Ala Ser  
1 5 10 15  
Ser Ser Pro Cys Asp Cys Ala Leu Leu Val Pro Val Ser Leu Phe Arg  
20 25 30  
Gly Arg Lys Val Ala Asn Phe Lys Asn Gln Asn Ser Asp Val Thr Ser  
35 40 45  
Gly Asn Ala Xaa  
50

<210> 182  
<211> 55  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (55)  
<223> Xaa equals stop translation

<400> 182

Met Gln Gln Ile Cys Ser Cys Leu Gly Ala Phe Ala Leu Leu Phe Phe  
 1 5 10 15  
 Trp Pro Gly His Phe Thr Ser Thr Phe Ser Ile Phe Tyr Asp Phe Leu  
 20 25 30  
 Pro Ile Phe Gly Ser Leu Phe Lys Cys His Pro Ser Lys Arg Pro Ser  
 35 40 45  
 Lys Leu Pro Tyr Leu Lys Xaa  
 50 55

<210> 183  
 <211> 62  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (62)  
 <223> Xaa equals stop translation

<400> 183  
 Met Arg Leu Leu Leu Glu Trp Arg Val Tyr Leu Arg Leu Thr Cys Ala  
 1 5 10 15  
 Thr Lys Asp Gly Met Ala Arg Glu Cys Pro Thr Thr Trp Leu Ser Pro  
 20 25 30  
 Pro Ala Lys Pro Asp Phe Ala Gln Arg His Ser Val Lys Pro Thr Ala  
 35 40 45  
 Leu Gln Gly Gly Arg Trp Ser Arg Leu Gly Ala Ser Pro Xaa  
 50 55 60

<210> 184  
 <211> 148  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> SITE  
 <222> (148)  
 <223> Xaa equals stop translation

<400> 184  
 Met Leu Gly Leu Pro Trp Lys Gly Gly Leu Ser Trp Ala Leu Leu Leu  
 1 5 10 15  
 Leu Leu Leu Gly Ser Gln Ile Leu Leu Ile Tyr Ala Trp His Phe His  
 20 25 30  
 Glu Gln Arg Asp Cys Asp Glu His Asn Val Met Ala Arg Tyr Leu Pro  
 35 40 45  
 Ala Thr Val Glu Phe Ala Val His Thr Phe Asn Gln Gln Ser Lys Asp  
 50 55 60

130

Tyr Tyr Ala Tyr Arg Leu Gly His Ile Leu Asn Ser Trp Lys Glu Gln  
 65 70 75 80  
 Val Glu Ser Lys Thr Val Phe Ser Met Glu Leu Leu Leu Gly Arg Thr  
 85 90 95  
 Arg Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys His Phe Gln Glu  
 100 105 110  
 Ser Thr Glu Leu Asn Asn Thr Phe Thr Cys Phe Phe Thr Ile Ser Thr  
 115 120 125  
 Arg Pro Trp Met Thr Gln Phe Ser Leu Leu Asn Lys Thr Cys Leu Glu  
 130 135 140  
 Gly Phe His Xaa  
 145

<210> 185  
 <211> 161  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (146)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (151)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (161)  
 <223> Xaa equals stop translation

<400> 185  
 Met Arg Leu Leu Cys Gly Leu Trp Leu Trp Leu Ser Leu Leu Lys Val  
 1 5 10 15  
 Leu Gln Ala Gln Thr Pro Thr Pro Leu Pro Leu Pro Pro Pro Met Gln  
 20 25 30  
 Ser Phe Gln Gly Asn Gln Phe Gln Gly Glu Trp Phe Val Leu Gly Leu  
 35 40 45  
 Ala Gly Asn Ser Phe Arg Pro Glu His Arg Ala Leu Leu Asn Ala Phe  
 50 55 60  
 Thr Ala Thr Phe Glu Leu Ser Asp Asp Gly Arg Phe Glu Val Trp Asn  
 65 70 75 80  
 Ala Met Thr Arg Gly Gln His Cys Asp Thr Trp Ser Tyr Val Leu Ile  
 85 90 95

Pro Ala Ala Gln Pro Gly Gln Phe Thr Val Asp His Gly Val Gly Arg  
                   100                  105                  110  
 Ser Trp Leu Leu Pro Pro Gly Thr Leu Asp Gln Phe Ile Cys Leu Gly  
                   115                  120                  125  
 Arg Ala Gln Gly Leu Ser Asp Asp Asn Ile Val Phe Pro Asp Val Thr  
                   130                  135                  140  
 Gly Xaa Ala Leu Asp Leu Xaa Ser Leu Pro Trp Val Ala Ala Pro Ala  
                   145                  150                  155                  160  
 Xaa

<210> 186  
 <211> 122  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (122)  
 <223> Xaa equals stop translation

<400> 186  
 Met Met Leu Pro Gln Trp Leu Leu Leu Leu Phe Leu Leu Phe Phe Phe  
       1                  5                  10                  15  
 Leu Phe Leu Leu Thr Arg Gly Ser Leu Ser Pro Thr Lys Tyr Asn Leu  
                   20                  25                  30  
 Leu Glu Leu Lys Glu Ser Cys Ile Arg Asn Gln Asp Cys Glu Thr Gly  
                   35                  40                  45  
 Cys Cys Gln Arg Ala Pro Asp Asn Cys Glu Ser His Cys Ala Glu Lys  
                   50                  55                  60  
 Gly Ser Glu Gly Ser Leu Cys Gln Thr Gln Val Phe Phe Gly Gln Tyr  
                   65                  70                  75                  80  
 Arg Ala Cys Pro Cys Leu Arg Asn Leu Thr Cys Ile Tyr Ser Lys Asn  
                   85                  90                  95  
 Glu Lys Trp Leu Ser Ile Ala Tyr Gly Arg Cys Gln Lys Ile Gly Arg  
                   100                  105                  110  
 Gln Lys Leu Ala Lys Lys Met Phe Phe Xaa  
                   115                  120

<210> 187  
 <211> 163  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE

&lt;222&gt; (163)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 187

Met Thr Ser Asn Phe Pro Phe Cys Thr Leu Ile Leu Gly Ile Ala Gln  
 1 5 10 15

Ala Gln Ala Cys Pro Gly Cys Pro Gly Asp Trp Pro Gly Leu Gly Ser  
 20 25 30

Gly Val Gly Glu Gly Leu His His Ile Arg Thr Cys Arg Thr Pro Ile  
 35 40 45

Pro Cys Ser Pro Pro Ala Pro Ala Ala Ala Cys Leu Gly Ser Gly His  
 50 55 60

Ala Arg Leu Pro Cys Val Leu Arg Leu Trp Pro Val Pro Ala Asn Leu  
 65 70 75 80

Ser Ser Pro Phe Arg Leu Glu Ala Leu His Cys Ser Phe Trp Ser Ser  
 85 90 95

Pro Leu Leu Pro Ala Pro His Leu Ala Phe Phe Gly Phe Arg Asp Leu  
 100 105 110

Leu Thr Asp Phe Leu Leu Ala Ala Cys Leu Leu Thr Phe Gln Lys Thr  
 115 120 125

Pro Leu Glu Leu Pro Met Ala Val Val His Leu Leu Val Ala Thr Pro  
 130 135 140

Cys Tyr Gln Met Leu Asp Asn Leu Pro Leu Pro Ser Ala Ala Ala Asn  
 145 150 155 160

Trp Cys Xaa

&lt;210&gt; 188

&lt;211&gt; 51

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (51)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 188

Met Pro Gly Ile Leu Ala Gly Ile Pro Val Lys Asp Leu Cys Leu Ser  
 1 5 10 15

Leu Leu Gln Gly Phe Arg Leu Leu Leu Leu Cys Val Cys Pro Gly Trp  
 20 25 30

Leu Ser Gly Trp Met Gly Gly Gln Lys Gly Ser Pro Arg Ile Val Asp  
 35 40 45

Ile Gly Xaa



50

<210> 189  
 <211> 65  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (65)  
 <223> Xaa equals stop translation

<400> 189  
 Met Tyr Leu Tyr Leu Gly Val Phe Phe His Leu Ile Tyr Pro Gly Ala  
   1                  5                  10                  15  
 Leu Ser Ile Thr Thr Leu Gly Lys His Ser His Pro Phe Phe Thr Ala  
                   20                  25                  30  
 Glu Gln Asn Ser Thr Val Trp Met Glu His Thr Leu Phe His Gln Ser  
           35                  40                  45  
 Pro Val Ala Ser His Leu Val Cys Phe Gln Ser Phe Ala Phe Ser Glu  
   50                  55                  60

Xaa  
 65

<210> 190  
 <211> 47  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (47)  
 <223> Xaa equals stop translation

<400> 190  
 Met Thr Leu Ser Leu Gln Leu Ala Glu Leu Val His Phe Val Cys Ala  
   1                  5                  10                  15  
 Phe Gln Ser Gln Trp Thr Gly Val Tyr Pro Met Met Pro Pro Leu Lys  
           20                  25                  30  
 Pro Thr Glu Pro Leu Cys Phe Ala Cys Val Pro Cys Arg Val Xaa  
   35                  40                  45

<210> 191  
 <211> 144  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (144)

<223> Xaa equals stop translation

<400> 191

```

Met Ser Pro Phe His Leu Leu Gly Leu Lys Val Phe Leu Thr Trp Ala
 1           5           10           15

Leu Thr Leu Ala Gln Ile Cys Leu Tyr Phe Phe Glu Val Gln Pro Leu
          20           25           30

Gly Leu Leu Ala Leu Asn Phe Phe Cys Thr Ala Thr Ala Gly Leu Lys
          35           40           45

Glu Leu Cys Met His Pro Pro Ser Leu Ala Phe Thr Pro Glu Phe His
          50           55           60

Thr Ser Leu Ser Pro Leu Ala Ile Pro Ser Phe Cys Gly Thr Ser Val
          65           70           75           80

Ser Leu Ser Asn Ser His Thr Ile Pro Leu Ser Leu Tyr Leu Pro Phe
          85           90           95

Pro Ser Lys Ser Arg Met Pro Asp Thr Leu His Leu Leu Val His Ser
          100          105          110

Leu Pro Leu Val His Ser Gln Val Leu Pro Val Lys Asp Val Thr Ile
          115          120          125

Glu Trp Pro Leu Cys Gln Arg Cys Leu Gly Ser Thr Cys His Gln Xaa
          130          135          140

```

<210> 192

<211> 81

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (76)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (81)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 192

```

Met Phe Cys Phe Ser Ser Ile Phe Cys Ser His Glu His Thr His Leu
 1           5           10           15

Pro Gly Thr Phe Trp Leu Phe Leu Phe Leu Phe Leu Ile Leu Pro Pro
          20           25           30

Ser Cys Pro Cys Phe Leu Pro Phe Ser Leu Ala Ile Glu Thr Val Arg
          35           40           45

```

135

Trp Pro Cys Trp His His Pro Thr Ser Phe Glu Leu Cys Tyr Pro Gly  
 50 55 60

Thr Ser Ile Tyr Tyr Ala Ser Arg Gly Gly Pro Xaa Pro Asn Ser Glu  
 65 70 75 80

Xaa

<210> 193

<211> 45

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (45)

<223> Xaa equals stop translation

<400> 193

Met Thr Tyr Leu Phe Cys Ser Ser Ile Ser Leu Leu Leu Leu Lys Val  
 1 5 10 15

His Ser Ser Gly His Gln Asp Ile Arg Lys Ala Lys Ser Lys Val Pro  
 20 25 30

Arg Leu Leu Ile Ile Gln Cys Pro Gln Gln Arg Glu Xaa  
 35 40 45

<210> 194

<211> 42

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (42)

<223> Xaa equals stop translation

<400> 194

Met Pro Thr Ile Trp Val Lys Leu Cys Leu Leu Gln Val Cys His Gly  
 1 5 10 15

Leu Phe Pro Leu Leu Lys His Trp Ser Gln Pro Met Pro Leu Cys Val  
 20 25 30

Thr Leu Ala Pro Val Ser Tyr Trp Leu Xaa  
 35 40

<210> 195

<211> 260

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

136

&lt;222&gt; (260)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 195

```

Met Gly Thr Ala Ala Leu Gly Pro Val Trp Ala Ala Leu Leu Leu Phe
 1           5           10           15

Leu Leu Met Cys Glu Ile Pro Met Val Glu Leu Thr Phe Asp Arg Ala
      20           25           30

Val Ala Ser Asp Cys Gln Arg Cys Cys Asp Ser Glu Asp Pro Leu Asp
      35           40           45

Pro Ala His Val Ser Ser Ala Ser Ser Ser Gly Arg Pro His Ala Leu
      50           55           60

Pro Glu Ile Arg Pro Tyr Ile Asn Ile Thr Ile Leu Lys Gly Asp Lys
      65           70           75           80

Gly Asp Pro Gly Pro Met Gly Leu Pro Gly Tyr Met Gly Arg Glu Gly
      85           90           95

Pro Gln Gly Glu Pro Gly Pro Gln Gly Ser Lys Gly Asp Lys Gly Glu
      100          105          110

Met Gly Ser Pro Gly Ala Pro Cys Gln Lys Arg Phe Phe Ala Phe Ser
      115          120          125

Val Gly Arg Lys Thr Ala Leu His Ser Gly Glu Asp Phe Gln Thr Leu
      130          135          140

Leu Phe Glu Arg Val Phe Val Asn Leu Asp Gly Cys Phe Asp Met Ala
      145          150          155          160

Thr Gly Gln Phe Ala Ala Pro Leu Arg Gly Ile Tyr Phe Phe Ser Leu
      165          170          175

Asn Val His Ser Trp Asn Tyr Lys Glu Thr Tyr Val His Ile Met His
      180          185          190

Asn Gln Lys Glu Ala Val Ile Leu Tyr Ala Gln Pro Ser Glu Arg Ser
      195          200          205

Ile Met Gln Ser Gln Ser Val Met Leu Asp Leu Ala Tyr Gly Asp Arg
      210          215          220

Val Trp Val Arg Leu Phe Lys Arg Gln Arg Glu Asn Ala Ile Tyr Ser
      225          230          235          240

Asn Asp Phe Asp Thr Tyr Ile Thr Phe Ser Gly His Leu Ile Lys Ala
      245          250          255

Glu Asp Asp Xaa
      260

```

&lt;210&gt; 196

&lt;211&gt; 117

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 196

Met Leu Gly His Cys Cys Tyr Phe Trp Gln Val Trp Pro Ala Ser Glu  
 1 5 10 15

Ala Leu Ala Ala Gly Pro Thr Pro Ser Thr Gly Ser Ser Ser Pro Ser  
 20 25 30

Trp Lys Gln His Ile Gly Thr Ser Leu Gln Lys Thr Arg Gly Ser Leu  
 35 40 45

Pro Thr Thr Thr Leu Thr Ser Gly Ala Gly Gln Ser Thr Ser Thr Gly  
 50 55 60

Lys Asn Pro Ala Ala Gly Arg Ser Leu Glu Gly Ala Leu Pro Ala Gly  
 65 70 75 80

Val Trp Pro Cys Phe Ala Gln Ser Pro Cys Thr Gly Gly Gln Gln Thr  
 85 90 95

Pro Ser Ser Thr Gly Leu Arg Ser Cys Leu Val Arg Ser Pro Ala Thr  
 100 105 110

Trp Trp Arg Thr Pro  
 115

&lt;210&gt; 197

&lt;211&gt; 698

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 197

Met Leu Pro Ala Arg Leu Pro Phe Arg Leu Leu Ser Leu Phe Leu Arg  
 1 5 10 15

Gly Ser Ala Pro Thr Ala Ala Arg His Gly Leu Arg Glu Pro Leu Leu  
 20 25 30

Glu Arg Arg Cys Ala Ala Ala Ser Ser Phe Gln His Ser Ser Ser Leu  
 35 40 45

Gly Arg Glu Leu Pro Tyr Asp Pro Val Asp Thr Glu Gly Phe Gly Glu  
 50 55 60

Gly Gly Asp Met Gln Glu Arg Phe Leu Phe Pro Glu Tyr Ile Leu Asp  
 65 70 75 80

Pro Glu Pro Gln Pro Thr Arg Glu Lys Gln Leu Gln Glu Leu Gln Gln  
 85 90 95

Gln Gln Glu Glu Glu Glu Arg Gln Arg Gln Gln Arg Arg Glu Glu Arg  
 100 105 110

Arg Gln Gln Asn Leu Arg Ala Arg Ser Arg Glu His Pro Val Val Gly  
 115 120 125

His Pro Asp Pro Ala Leu Pro Pro Ser Gly Val Asn Cys Ser Gly Cys

130	135	140
Gly Ala Glu Leu His Cys Gln Asp Ala Gly Val Pro Gly Tyr Leu Pro		
145	150	155 160
Arg Glu Lys Phe Leu Arg Thr Ala Glu Ala Asp Gly Gly Leu Ala Arg		
	165	170 175
Thr Val Cys Gln Arg Cys Trp Leu Leu Ser His His Arg Arg Ala Leu		
	180	185 190
Arg Leu Gln Val Ser Arg Glu Gln Tyr Leu Glu Leu Val Ser Ala Ala		
	195	200 205
Leu Arg Arg Pro Gly Pro Ser Leu Val Leu Tyr Met Val Asp Leu Leu		
	210	215 220
Asp Leu Pro Asp Ala Leu Leu Pro Asp Leu Pro Ala Leu Val Gly Pro		
	225	230 235 240
Lys Gln Leu Ile Val Leu Gly Asn Lys Val Asp Leu Leu Pro Gln Asp		
	245	250 255
Ala Pro Gly Tyr Arg Gln Arg Leu Arg Glu Arg Leu Trp Glu Asp Cys		
	260	265 270
Ala Arg Ala Gly Leu Leu Leu Ala Pro Gly His Gln Gly Pro Gln Arg		
	275	280 285
Pro Val Lys Asp Glu Pro Gln Asp Gly Glu Asn Pro Asn Pro Pro Asn		
	290	295 300
Trp Ser Arg Thr Val Val Arg Asp Val Arg Leu Ile Ser Ala Lys Thr		
	305	310 315 320
Gly Tyr Gly Val Glu Glu Leu Ile Ser Ala Leu Gln Arg Ser Trp Arg		
	325	330 335
Tyr Arg Gly Asp Val Tyr Leu Val Gly Ala Thr Asn Ala Gly Lys Ser		
	340	345 350
Thr Leu Phe Asn Thr Leu Leu Glu Ser Asp Tyr Cys Thr Ala Lys Gly		
	355	360 365
Ser Asp Ala Ile Asp Arg Ala Thr Ile Ser Pro Trp Pro Gly Thr Thr		
	370	375 380
Leu Asn Leu Leu Lys Phe Pro Ile Cys Asn Pro Thr Pro Tyr Arg Met		
	385	390 395 400
Phe Lys Arg His Gln Arg Leu Lys Lys Asp Ser Thr Gln Ala Glu Glu		
	405	410 415
Asp Leu Ser Glu Gln Glu Gln Asn Gln Leu Asn Val Leu Lys Lys His		
	420	425 430
Gly Tyr Val Val Gly Arg Val Gly Arg Thr Phe Leu Tyr Ser Glu Glu		
	435	440 445

Gln Lys Asp Asn Ile Pro Phe Glu Phe Asp Ala Asp Ser Leu Ala Phe  
 450 455 460  
 Asp Met Glu Asn Asp Pro Val Met Gly Thr His Lys Ser Thr Lys Gln  
 465 470 475 480  
 Val Glu Leu Thr Ala Gln Asp Val Lys Asp Ala His Trp Phe Tyr Asp  
 485 490 495  
 Thr Pro Gly Ile Thr Lys Glu Asn Cys Ile Leu Asn Leu Leu Thr Glu  
 500 505 510  
 Lys Glu Val Asn Ile Val Leu Pro Thr Gln Ser Ile Val Pro Arg Thr  
 515 520 525  
 Phe Val Leu Lys Pro Gly Met Val Leu Phe Leu Gly Ala Ile Gly Arg  
 530 535 540  
 Ile Asp Phe Leu Gln Gly Asn Gln Ser Ala Trp Phe Thr Val Val Ala  
 545 550 555 560  
 Ser Asn Ile Leu Pro Val His Ile Thr Ser Leu Asp Arg Ala Asp Ala  
 565 570 575  
 Leu Tyr Gln Lys His Ala Gly His Thr Leu Leu Gln Ile Pro Met Gly  
 580 585 590  
 Gly Lys Glu Arg Met Ala Gly Phe Pro Pro Leu Val Ala Glu Asp Ile  
 595 600 605  
 Met Leu Lys Glu Gly Leu Gly Ala Ser Glu Ala Val Ala Asp Ile Lys  
 610 615 620  
 Phe Ser Ser Ala Gly Trp Val Ser Val Thr Pro Asn Phe Lys Asp Arg  
 625 630 635 640  
 Leu His Leu Arg Gly Tyr Thr Pro Glu Gly Thr Val Leu Thr Val Arg  
 645 650 655  
 Pro Pro Leu Leu Pro Tyr Ile Val Asn Ile Lys Gly Gln Arg Ile Lys  
 660 665 670  
 Lys Ser Val Ala Tyr Lys Thr Lys Lys Pro Pro Ser Leu Met Tyr Asn  
 675 680 685  
 Val Arg Lys Lys Lys Gly Lys Ile Asn Val  
 690 695  
  
 <210> 198  
 <211> 348  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 198  
 Met Asn Met Thr Gln Ala Arg Val Leu Val Ala Ala Val Val Gly Leu  
 1 5 10 15  
 Val Ala Val Leu Leu Tyr Ala Ser Ile His Lys Ile Glu Glu Gly His

140

20	25	30
Leu Ala Val Tyr Tyr Arg Gly Gly Ala Leu Leu Thr Ser Pro Ser Gly		
35	40	45
Pro Gly Tyr His Ile Met Leu Pro Phe Ile Thr Thr Phe Arg Ser Val		
50	55	60
Gln Thr Thr Leu Gln Thr Asp Glu Val Lys Asn Val Pro Cys Gly Thr		
65	70	75
80		
Ser Gly Gly Val Met Ile Tyr Ile Asp Arg Ile Glu Val Val Asn Met		
85	90	95
Leu Ala Pro Tyr Ala Val Phe Asp Ile Val Arg Asn Tyr Thr Ala Asp		
100	105	110
Tyr Asp Lys Thr Leu Ile Phe Asn Lys Ile His His Glu Leu Asn Gln		
115	120	125
Phe Cys Ser Ala His Thr Leu Gln Glu Val Tyr Ile Glu Leu Phe Asp		
130	135	140
Gln Ile Asp Glu Asn Leu Lys Gln Ala Leu Gln Lys Asp Leu Asn Leu		
145	150	155
160		
Met Ala Pro Gly Leu Thr Ile Gln Ala Val Arg Val Thr Lys Pro Lys		
165	170	175
Ile Pro Glu Ala Ile Arg Arg Asn Phe Glu Leu Met Glu Ala Glu Lys		
180	185	190
Thr Lys Leu Leu Ile Ala Ala Gln Lys Gln Lys Val Val Glu Lys Glu		
195	200	205
Ala Glu Thr Glu Arg Lys Lys Ala Val Ile Glu Ala Glu Lys Ile Ala		
210	215	220
Gln Val Ala Lys Ile Arg Phe Gln Gln Lys Val Met Glu Lys Glu Thr		
225	230	235
240		
Glu Lys Arg Ile Ser Glu Ile Glu Asp Ala Ala Phe Leu Ala Arg Glu		
245	250	255
Lys Ala Lys Ala Asp Ala Glu Tyr Tyr Ala Ala His Lys Tyr Ala Thr		
260	265	270
Ser Asn Lys His Lys Leu Thr Pro Glu Tyr Leu Glu Leu Lys Lys Tyr		
275	280	285
Gln Ala Ile Ala Ser Asn Ser Lys Ile Tyr Phe Gly Ser Asn Ile Pro		
290	295	300
Asn Met Phe Val Asp Ser Ser Cys Ala Leu Lys Tyr Ser Asp Ile Arg		
305	310	315
320		
Thr Gly Arg Glu Ser Ser Leu Pro Ser Lys Glu Ala Leu Glu Pro Ser		
325	330	335



Gly Glu Asn Val Ile Gln Asn Lys Glu Ser Thr Gly  
 340 345

<210> 199  
 <211> 401  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (307)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 199  
 Met Met Gly Leu Gly Asn Gly Arg Arg Ser Met Lys Ser Pro Pro Leu  
 1 5 10 15  
 Val Leu Ala Ala Leu Val Ala Cys Ile Ile Val Leu Gly Phe Asn Tyr  
 20 25 30  
 Trp Ile Ala Ser Ser Arg Ser Val Asp Leu Gln Thr Arg Ile Met Glu  
 35 40 45  
 Leu Glu Gly Arg Val Arg Arg Arg Ala Ala Glu Arg Gly Ala Val Glu  
 50 55 60  
 Leu Lys Lys Asn Glu Phe Gln Gly Glu Leu Glu Lys Gln Arg Glu Gln  
 65 70 75 80  
 Leu Asp Lys Ile Gln Ser Ser His Asn Phe Gln Leu Glu Ser Val Asn  
 85 90 95  
 Lys Leu Tyr Gln Asp Glu Lys Ala Val Leu Val Asn Asn Ile Thr Thr  
 100 105 110  
 Gly Glu Arg Leu Ile Arg Val Leu Gln Asp Gln Leu Lys Thr Leu Gln  
 115 120 125  
 Arg Asn Tyr Gly Arg Leu Gln Gln Asp Val Leu Gln Phe Gln Lys Asn  
 130 135 140  
 Gln Thr Asn Leu Glu Arg Lys Phe Ser Tyr Asp Leu Ser Gln Cys Ile  
 145 150 155 160  
 Asn Gln Met Lys Glu Val Lys Glu Gln Cys Glu Glu Arg Ile Glu Glu  
 165 170 175  
 Val Thr Lys Lys Gly Asn Glu Ala Val Ala Ser Arg Asp Leu Ser Glu  
 180 185 190  
 Asn Asn Asp Gln Arg Gln Gln Leu Gln Ala Leu Ser Glu Pro Gln Pro  
 195 200 205  
 Arg Leu Gln Ala Ala Gly Leu Pro His Thr Glu Val Pro Gln Gly Lys  
 210 215 220  
 Gly Asn Val Leu Gly Asn Ser Lys Ser Gln Thr Pro Ala Pro Ser Ser  
 225 230 235 240

Glu Val Val Leu Asp Ser Lys Arg Gln Val Glu Lys Glu Glu Thr Asn  
                   245                                  250                                  255  
 Glu Ile Gln Val Val Asn Glu Glu Pro Gln Arg Asp Arg Leu Pro Gln  
                   260                                  265                                  270  
 Glu Pro Gly Arg Glu Gln Val Val Glu Asp Arg Pro Val Gly Gly Arg  
                   275                                  280                                  285  
 Gly Phe Gly Gly Ala Gly Glu Leu Gly Gln Thr Pro Gln Val Gln Ala  
                   290                                  295                                  300  
 Ala Leu Xaa Val Ser Gln Glu Asn Pro Glu Met Glu Gly Pro Glu Arg  
                   305                                  310                                  315                                  320  
 Asp Gln Leu Val Ile Pro Asp Gly Gln Glu Glu Glu Gln Glu Ala Ala  
                   325                                  330                                  335  
 Gly Glu Gly Arg Asn Gln Gln Lys Leu Arg Gly Glu Asp Asp Tyr Asn  
                   340                                  345                                  350  
 Met Asp Glu Asn Glu Ala Glu Ser Glu Thr Asp Lys Gln Ala Ala Leu  
                   355                                  360                                  365  
 Ala Gly Asn Asp Arg Asn Ile Asp Val Phe Asn Val Glu Asp Gln Lys  
                   370                                  375                                  380  
 Arg Asp Thr Ile Asn Leu Leu Asp Gln Arg Glu Lys Arg Asn His Thr  
                   385                                  390                                  395                                  400  
 Leu

&lt;210&gt; 200

&lt;211&gt; 324

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (3)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 200

Met Glu Xaa Ala Lys Val Tyr Val Ala Lys Val Asp Cys Thr Ala His  
   1                                  5                                  10                                  15

Ser Asp Val Cys Ser Ala Gln Gly Val Arg Gly Tyr Pro Thr Leu Lys  
                   20                                  25                                  30

Leu Phe Lys Pro Gly Gln Glu Ala Val Lys Tyr Gln Gly Pro Arg Asp  
                   35                                  40                                  45

Phe Gln Thr Leu Glu Asn Trp Met Leu Gln Thr Leu Asn Glu Glu Pro  
                   50                                  55                                  60

Val Thr Pro Glu Pro Glu Val Glu Pro Pro Ser Ala Pro Glu Leu Lys

[illegible]

```
<400> 201
Met Ala Leu Phe Ser Cys Leu Leu Leu Leu Lys Gln Ser Asp Gly Ala
  1             5              10             15
```

Ser Pro Val Leu Arg Ala Leu Ala Ala Ser Cys Leu Ala Ser Pro Ala  
                   20                  25                  30  
 Gly Cys Cys Gly Thr Arg Lys Ala Leu Asn Gly Asn Val Gly Glu Lys  
                   35                  40                  45  
 Val Gly Phe Thr Phe Met Ser Phe Gln Gly Cys Asp Pro Ser Ser Pro  
           50                  55                  60  
 Gly Cys Leu Cys Cys Ser Leu Leu Pro Ser Asn Ser Gln Leu Val Phe  
   65                  70                  75                  80  
 Ile Ser Phe Leu Val Leu Ser Gly Leu Ala  
                   85                  90

&lt;210&gt; 202

&lt;211&gt; 243

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 202

Met Arg Pro Gln Gly Pro Ala Ala Ser Pro Gln Arg Leu Arg Gly Leu  
   1                  5                  10                  15  
 Leu Leu Leu Leu Leu Leu Gln Leu Pro Ala Pro Ser Ser Ala Ser Glu  
           20                  25                  30  
 Ile Pro Lys Gly Lys Gln Lys Ala Gln Leu Arg Gln Arg Glu Val Val  
           35                  40                  45  
 Asp Leu Tyr Asn Gly Met Cys Leu Gln Gly Pro Ala Gly Val Pro Gly  
   50                  55                  60  
 Arg Asp Gly Ser Pro Gly Ala Asn Gly Ile Pro Gly Thr Pro Gly Ile  
   65                  70                  75                  80  
 Pro Gly Arg Asp Gly Phe Lys Gly Glu Lys Gly Glu Cys Leu Arg Glu  
           85                  90                  95  
 Ser Phe Glu Glu Ser Trp Thr Pro Asn Tyr Lys Gln Cys Ser Trp Ser  
          100                 105                 110  
 Ser Leu Asn Tyr Gly Ile Asp Leu Gly Lys Ile Ala Glu Cys Thr Phe  
          115                 120                 125  
 Thr Lys Met Arg Ser Asn Ser Ala Leu Arg Val Leu Phe Ser Gly Ser  
          130                 135                 140  
 Leu Arg Leu Lys Cys Arg Asn Ala Cys Cys Glu Arg Trp Tyr Phe Thr  
  145                 150                 155                 160  
 Phe Asn Gly Ala Glu Cys Ser Gly Pro Leu Pro Ile Glu Ala Ile Ile  
          165                 170                 175  
 Tyr Leu Asp Gln Gly Ser Pro Glu Met Asn Ser Thr Ile Asn Ile His  
          180                 185                 190

145

Arg Thr Ser Ser Val Glu Gly Leu Cys Glu Gly Ile Gly Ala Gly Leu  
 195 200 205

Val Asp Val Ala Ile Trp Val Gly Thr Cys Ser Asp Tyr Pro Lys Gly  
 210 215 220

Asp Ala Ser Thr Gly Trp Asn Ser Val Ser Arg Ile Ile Ile Glu Glu  
 225 230 235 240

Leu Pro Lys

<210> 203

<211> 75

<212> PRT

<213> Homo sapiens

<400> 203

Met Ala Gly Gln Glu Asp Pro Val Gln Arg Glu Ile His Gln Asp Trp  
 1 5 10 15

Ala Asn Arg Glu Tyr Ile Glu Ile Ile Thr Ser Ser Ile Lys Lys Ile  
 20 25 30

Ala Asp Phe Leu Asn Ser Phe Asp Met Ser Cys Arg Ser Arg Leu Ala  
 35 40 45

Thr Leu Asn Glu Lys Leu Thr Ala Leu Glu Arg Arg Ile Glu Tyr Ile  
 50 55 60

Glu Ala Arg Val Thr Lys Gly Glu Thr Leu Thr  
 65 70 75

<210> 204

<211> 248

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (185)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 204

Met Thr Ser Gln Pro Val Pro Asn Glu Thr Ile Ile Val Leu Pro Ser  
 1 5 10 15

Asn Val Ile Asn Phe Ser Gln Ala Glu Lys Pro Glu Pro Thr Asn Gln  
 20 25 30

Gly Gln Asp Ser Leu Lys Lys His Leu His Ala Glu Ile Lys Val Ile  
 35 40 45

Gly Thr Ile Gln Ile Leu Cys Gly Met Met Val Leu Ser Leu Gly Ile  
 50 55 60

Ile Leu Ala Ser Ala Ser Phe Ser Pro Asn Phe Thr Gln Val Thr Ser

```
<210> 205
<211> 168
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (83)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 205
Met Pro Leu Leu Arg Gly Leu Leu Trp Leu Gln Val Leu Cys Ala Gly
  1                               5                10              15

Pro Leu His Thr Glu Ala Val Val Leu Leu Val Pro Ser Asp Asp Gly
      20                      25                30

Arg Ala Phe Leu Leu Arg Ser Arg Leu Leu His Pro Glu Ala His Val
    35                          40                  45

Pro Pro Ala Ala Asp Arg Gly Ala Ser Leu Gln Cys Val Leu His Gln
   50                        55                 60
```

147

Ala Ala Pro Lys Ser Arg Pro Arg Ser Pro Ala Ala Gly Ala Ala Leu  
 65 70 75 80

Leu His Xaa Pro Arg Arg Thr Gly Asp Glu Pro Cys Arg Glu Phe His  
 85 90 95

Gly Asn Gly Phe Pro Gly Pro Thr Gln Leu Thr Pro Gly Glu Cys Gly  
 100 105 110

Leu Pro Ala Pro Ser Ser Leu Leu Gln His Ala Ser Ala Pro Val Arg  
 115 120 125

Thr Gly Ser Glu Gly Gln Val Val Gly Cys Pro Arg Ala Arg Gly Glu  
 130 135 140

Thr Gly Glu Gly Leu Ser Leu Ala Phe Leu Ser Ser Leu Met Phe Thr  
 145 150 155 160

Ser Arg Asn Gly Leu Val Gly Cys  
 165

&lt;210&gt; 206

&lt;211&gt; 218

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 206

Met Gly Ser Ala Ala Leu Glu Ile Leu Gly Leu Val Leu Cys Leu Val  
 1 5 10 15

Gly Trp Gly Gly Leu Ile Leu Ala Cys Gly Leu Pro Met Trp Gln Val  
 20 25 30

Thr Ala Phe Leu Asp His Asn Ile Val Thr Ala Gln Thr Thr Trp Lys  
 35 40 45

Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly His Met Gln Cys  
 50 55 60

Lys Val Tyr Asp Ser Val Leu Ala Leu Ser Thr Glu Val Gln Ala Ala  
 65 70 75 80

Arg Ala Leu Thr Val Ser Ala Val Leu Leu Ala Phe Val Ala Leu Phe  
 85 90 95

Val Thr Leu Ala Gly Ala Gln Cys Thr Thr Cys Val Ala Pro Gly Pro  
 100 105 110

Ala Lys Ala Arg Val Ala Leu Thr Gly Gly Val Leu Tyr Leu Phe Cys  
 115 120 125

Gly Leu Leu Ala Leu Val Pro Leu Cys Trp Phe Ala Asn Ile Val Val  
 130 135 140

Arg Glu Phe Tyr Asp Pro Ser Val Pro Val Ser Gln Lys Tyr Glu Leu  
 145 150 155 160

Gly Ala Ala Leu Tyr Ile Gly Trp Ala Ala Thr Ala Leu Leu Met Val

```

<400> 207
Met Thr Ser Tyr Ile Leu Ile Ser Phe Val Leu Leu Ile Gly Val Gly
 1              5              10              15
Cys Ile Glu Lys Asp Gln Ser Cys Pro Val Phe Gly Gly Arg Lys Arg
      20              25              30
Leu His Leu Leu Phe Val Gly Gly Gln Leu Arg Gln Val Arg Met Leu
      35              40              45
Arg Gly Glu Leu Ser Cys Ala Cys Tyr Arg Pro His Val Gln Ala Leu
      50              55              60
Gln Leu Gly Gly Cys Thr Cys Phe Xaa
      65              70

```

```

<400> 208
Met Leu Cys Pro Trp Arg Thr Ala Asn Leu Gly Leu Leu Leu Ile Leu
 1             5             10             15
Thr Ile Phe Leu Val Ala Glu Ala Glu Gly Ala Ala Gln Pro Asn Asn
          20             25             30
Ser Leu Met Leu Gln Thr Ser Lys Glu Asn His Ala Leu Ala Ser Ser
      35             40             45
Ser Leu Cys Met Asp Glu Lys Gln Ile Thr Gln Asn Tyr Ser Lys Val
 50             55             60
Leu Ala Glu Val Asn Thr Ser Trp Pro Val Lys Met Ala Thr Asn Ala
 65             70             75             80

```



Val Leu Cys Cys Pro Pro Ile Ala Leu Arg Asn Leu Ile Ile Ile Thr  
                                   85                                  90                                  95  
 Trp Glu Ile Ile Leu Arg Gly Gln Pro Ser Cys Thr Lys Ala Tyr Lys  
                                   100                                  105                                  110  
 Lys Glu Thr Asn Glu Thr Lys Glu Thr Asn Cys Thr Asp Glu Arg Ile  
                                   115                                  120                                  125  
 Thr Trp Val Ser Arg Pro Asp Gln Asn Ser Asp Leu Gln Ile Arg Thr  
                                   130                                  135                                  140  
 Val Ala Ile Thr His Asp Gly Tyr Tyr Arg Cys Ile Met Val Thr Pro  
                                   145                                  150                                  155                                  160  
 Asp Gly Asn Phe His Arg Gly Tyr His Leu Gln Val Leu Val Thr Pro  
                                   165                                  170                                  175  
 Glu Val Thr Leu Phe Gln Asn Arg Asn Arg Thr Ala Val Cys Lys Ala  
                                   180                                  185                                  190  
 Val Ala Gly Lys Pro Ala Ala His Ile Ser Trp Ile Pro Glu Gly Asp  
                                   195                                  200                                  205  
 Cys Ala Thr Lys Gln Glu Tyr Trp Ser Asn Gly Thr Val Thr Val Lys  
                                   210                                  215                                  220  
 Ser Thr Cys His Trp Glu Val His Asn Val Ser Thr Val Asn Cys His  
                                   225                                  230                                  235                                  240  
 Val Ser His Leu Thr Gly Asn Lys Ser Leu Tyr Ile Glu Leu Leu Pro  
                                   245                                  250                                  255  
 Val Pro Gly Ala Lys Lys Ser Ala Lys Leu Tyr Ile Pro Tyr Ile Ile  
                                   260                                  265                                  270  
 Leu Thr Ile Ile Ile Leu Thr Ile Val Gly Phe Ile Trp Leu Leu Lys  
                                   275                                  280                                  285  
 Val Asn Gly Cys Arg Lys Tyr Lys Leu Asn Lys Thr Glu Ser Thr Pro  
                                   290                                  295                                  300  
 Val Val Glu Glu Asp Glu Met Gln Pro Tyr Ala Ser Tyr Thr Glu Lys  
                                   305                                  310                                  315                                  320  
 Asn Asn Pro Leu Tyr Asp Thr Thr Asn Lys Val Lys Ala Ser Glu Ala  
                                   325                                  330                                  335  
 Leu Gln Ser Glu Val Asp Thr Asp Leu His Thr Leu  
                                   340                                  345

&lt;210&gt; 209

&lt;211&gt; 73

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (73)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 209

Met Ala Arg Gly Cys Val Cys Ser Leu Cys Ala Ser Val Cys Ile Phe  
 1 5 10 15

Leu Ser Ser Leu Phe Pro Leu Leu Pro Ser Val His Ser Val Asn Ile  
 20 25 30

Ile Ser Cys Leu Leu Leu Ser Lys Cys Phe Glu Gly Leu Glu Leu Met  
 35 40 45

Cys Glu His Leu Tyr Gln Leu Ser Gln Leu His Val Leu His His Ile  
 50 55 60

Phe Ser Tyr Leu Leu Cys Thr Pro Xaa  
 65 70

&lt;210&gt; 210

&lt;211&gt; 608

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (265)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (597)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 210

Met Val Gly Thr Lys Leu Arg Gln Thr Lys Asp Ala Leu Phe Thr Ile  
 1 5 10 15

Leu His Asp Leu Arg Pro Gln Asp Arg Phe Ser Ile Ile Gly Phe Ser  
 20 25 30

Asn Arg Ile Lys Val Trp Lys Asp His Leu Ile Ser Val Thr Pro Asp  
 35 40 45

Ser Ile Arg Asp Gly Lys Val Tyr Ile His His Met Ser Pro Thr Gly  
 50 55 60

Gly Thr Asp Ile Asn Gly Val Leu Gln Arg Ala Ile Arg Leu Leu Asn  
 65 70 75 80

Lys Tyr Val Ala His Ser Gly Ile Gly Asp Arg Ser Val Ser Leu Ile  
 85 90 95

Val Phe Leu Thr Asp Gly Lys Pro Thr Val Gly Glu Thr His Thr Leu  
 100 105 110

Lys Ile Leu Asn Asn Thr Arg Glu Ala Ala Arg Gly Gln Val Cys Ile

115	120	125
Phe Thr Ile Gly Ile Gly Asn Asp Val Asp Phe Arg Leu Leu Glu Lys		
130	135	140
Leu Ser Leu Glu Asn Cys Gly Leu Thr Arg Arg Val His Glu Glu Glu		
145	150	155 160
Asp Ala Gly Ser Gln Leu Ile Gly Phe Tyr Asp Glu Ile Arg Thr Pro		
	165	170 175
Leu Leu Ser Asp Ile Arg Ile Asp Tyr Pro Pro Ser Ser Val Val Gln		
	180	185 190
Ala Thr Lys Thr Leu Phe Pro Asn Tyr Phe Asn Gly Ser Glu Ile Ile		
	195	200 205
Ile Ala Gly Lys Leu Val Asp Arg Lys Leu Asp His Leu His Val Glu		
	210	215 220
Val Thr Ala Ser Asn Ser Lys Lys Phe Ile Ile Leu Lys Thr Asp Val		
	225	230 235 240
Pro Val Arg Pro Gln Lys Ala Gly Lys Asp Val Thr Gly Ser Pro Arg		
	245	250 255
Pro Gly Gly Asp Gly Glu Gly Asp Xaa Asn His Ile Glu Arg Leu Trp		
	260	265 270
Ser Tyr Leu Thr Thr Lys Glu Leu Leu Ser Ser Trp Leu Gln Ser Asp		
	275	280 285
Asp Glu Pro Glu Lys Glu Arg Leu Arg Gln Arg Ala Gln Ala Leu Ala		
	290	295 300
Val Ser Tyr Arg Phe Leu Thr Pro Phe Thr Ser Met Lys Leu Arg Gly		
	305	310 315 320
Pro Val Pro Arg Met Asp Gly Leu Glu Glu Ala His Gly Met Ser Ala		
	325	330 335
Ala Met Gly Pro Glu Pro Val Val Gln Ser Val Arg Gly Ala Gly Thr		
	340	345 350
Gln Pro Gly Pro Leu Leu Lys Lys Pro Tyr Gln Pro Arg Ile Lys Ile		
	355	360 365
Ser Lys Thr Ser Val Asp Gly Asp Pro His Phe Val Val Asp Phe Pro		
	370	375 380
Leu Ser Arg Leu Thr Val Cys Phe Asn Ile Asp Gly Gln Pro Gly Asp		
	385	390 395 400
Ile Leu Arg Leu Val Ser Asp His Arg Asp Ser Gly Val Thr Val Asn		
	405	410 415
Gly Glu Leu Ile Gly Ala Pro Ala Pro Pro Asn Gly His Lys Lys Gln		
	420	425 430

Arg	Thr	Tyr	Leu	Arg	Thr	Ile	Thr	Ile	Leu	Ile	Asn	Lys	Pro	Glu	Arg
435						440			445						
Ser	Tyr	Leu	Glu	Ile	Thr	Pro	Ser	Arg	Val	Ile	Leu	Asp	Gly	Gly	Asp
450						455			460						
Arg	Leu	Val	Leu	Pro	Cys	Asn	Gln	Ser	Val	Val	Val	Gly	Ser	Trp	Gly
465			470						475			480			
Leu	Glu	Val	Ser	Val	Ser	Ala	Asn	Ala	Asn	Val	Thr	Val	Thr	Ile	Gln
			485						490			495			
Gly	Ser	Ile	Ala	Phe	Val	Ile	Leu	Ile	His	Leu	Tyr	Lys	Lys	Pro	Ala
			500			505						510			
Pro	Phe	Gln	Arg	His	His	Leu	Gly	Phe	Tyr	Ile	Ala	Asn	Ser	Glu	Gly
515						520						525			
Leu	Ser	Ser	Asn	Cys	His	Gly	Leu	Leu	Gly	Gln	Phe	Leu	Asn	Gln	Asp
530						535						540			
Ala	Arg	Leu	Thr	Glu	Asp	Pro	Ala	Gly	Pro	Ser	Gln	Asn	Leu	Thr	His
545			550						555			560			
Pro	Leu	Leu	Leu	Gln	Val	Gly	Glu	Gly	Pro	Glu	Ala	Val	Leu	Thr	Val
			565						570			575			
Lys	Gly	His	Gln	Val	Pro	Val	Val	Trp	Lys	Gln	Arg	Lys	Ile	Tyr	Asn
			580			585						590			
Gly	Glu	Glu	Gln	Xaa	Asp	Cys	Trp	Phe	Ala	Arg	Asn	Met	Pro	Pro	Asn
595						600						605			

<210> 211

<211> 252

<212> PRT

<213> Homo sapiens

**<220>**

**<221> SITE**

**<222> (252)**

<223> Xaa equals stop translation

<400> 211

Met Ala Pro Ala Ser Arg Leu Leu Ala Leu Trp Ala Leu Ala Ala Val  
1 5 10 15

Ala Leu Pro Gly Ser Gly Ala Glu Gly Asp Gly Gly Trp Arg Pro Gly  
20 25 30

Gly Pro Gly Ala Val Ala Glu Glu Glu Arg Cys Thr Val Glu Arg Arg  
35 40 45

Ala Asp Leu Thr Tyr Ala Glu Phe Val Gln Gln Tyr Ala Phe Val Arg  
50 55 60

Pro Val Ile Leu Gln Gly Leu Thr Asp Asn Ser Arg Phe Arg Ala Leu  
 65 70 75 80  
 Cys Ser Arg Asp Arg Leu Leu Ala Ser Phe Gly Asp Arg Val Val Arg  
 85 90 95  
 Leu Ser Thr Ala Asn Thr Tyr Ser Tyr His Lys Val Asp Leu Pro Phe  
 100 105 110  
 Gln Glu Tyr Val Glu Gln Leu Leu His Pro Gln Asp Pro Thr Ser Leu  
 115 120 125  
 Gly Asn Asp Thr Leu Tyr Phe Phe Gly Asp Asn Asn Phe Thr Glu Trp  
 130 135 140  
 Ala Ser Leu Phe Arg His Tyr Ser Pro Pro Pro Phe Gly Leu Leu Gly  
 145 150 155 160  
 Thr Ala Pro Ala Tyr Ser Phe Gly Ile Ala Gly Ala Gly Ser Gly Val  
 165 170 175  
 Pro Phe His Trp His Gly Pro Gly Tyr Ser Glu Val Ile Tyr Gly Arg  
 180 185 190  
 Lys Arg Trp Phe Leu Tyr Pro Pro Glu Lys Thr Pro Glu Phe His Pro  
 195 200 205  
 Asn Lys Thr Thr Leu Ala Trp Leu Arg Asp Thr Tyr Pro Ala Cys Thr  
 210 215 220  
 Val Cys Thr Ala Leu Glu Cys Thr Ile Arg Ala Gly Glu Val Leu Thr  
 225 230 235 240  
 Ser Arg Pro Leu Val Ala Cys Tyr Ala Gln Pro Xaa  
 245 250

&lt;210&gt; 212

&lt;211&gt; 226

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (226)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 212

Met Lys Glu Ile Pro Ala Leu Leu His Leu Pro Val Leu Ile Ile Met  
 1 5 10 15

Ala Leu Ala Ile Leu Ser Phe Cys Tyr Gly Ala Gly Lys Ser Val His  
 20 25 30

Val Leu Arg His Ile Gly Gly Pro Glu Arg Glu Pro Pro Gln Ala Leu  
 35 40 45

Arg Pro Arg Asp Arg Arg Arg Gln Glu Glu Ile Asp Tyr Arg Pro Asp

```
<210> 213
<211> 51
<212> PRT
<213> Homo sapiens
```

```
<220>
<221> SITE
<222> (51)
<223> Xaa equals stop translation
```

<400> 213

Met Met Gly Leu Leu Glu Thr Gly Asn Val Leu Phe Trp Val Trp Val  
1 5 10 15

Val Val Thr Cys Val Tyr Ser Leu Tyr Ala Asn Ser Leu Asn Cys Thr  
20 25 30

Asp Met Asp Cys Ala Pro Phe Tyr Met Cys Val Met Leu Gln Gln Lys  
35 40 45

Cys Gln Xaa  
50

<210> 214  
 <211> 172  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (172)  
 <223> Xaa equals stop translation

<400> 214  
 Met Trp Leu Trp Ala Val Ser Pro Val Arg Pro Arg Thr Cys Leu Pro  
   1                  5                  10                  15  
 Pro Cys Pro Arg Leu Trp Leu Trp Ile Ser Met Thr Leu Val Pro Ser  
                   20                  25                  30  
 Ser Ser Ala Trp Lys Ser His Gly Ala Pro Ser Thr Arg Met Thr Ser  
           35                  40                  45  
 Pro Gln Leu Leu Leu Leu Ser Thr Arg Pro Pro Gln Ser Pro Ser Ala  
   50                  55                  60  
 Ser Pro Pro Ile Ala Arg Ala His Arg Thr His Pro His Phe Gly Asn  
   65                  70                  75                  80  
 Arg Leu Ser Ile Thr Cys Cys Asp Gly Arg Arg Ser Trp Arg Met Gly  
                   85                  90                  95  
 Gln His Gly Pro Cys His Leu Asn Leu Gln Thr Thr His Pro Ala His  
           100                  105                  110  
 Ser Ser Gln Ala Leu Pro Ala Thr His Gln Pro Leu Gly Pro Trp Cys  
           115                  120                  125  
 Ser Ser Pro Ser Pro Phe Pro Ser Lys Leu Pro Ser Ala Gly Leu Arg  
   130                  135                  140  
 Pro Pro Ala Leu Gly Pro Trp Met Arg Arg Gly Pro Trp Pro Gln Ser  
 145                  150                  155                  160  
 Trp Gln Met Gly Met His Pro Thr Val Gly Leu Xaa  
                   165                  170

<210> 215  
 <211> 48  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (48)  
 <223> Xaa equals stop translation

<400> 215  
 Met Trp Leu Leu Ile Ile Phe Cys Lys Ser Ala Ser Ala Ser Val Leu  
   1                  5                  10                  15

Cys Trp Ile Lys Lys Phe His Pro Val Phe Gln Glu Ser Leu Leu Tyr  
                   20                  25                  30

Leu Val Gln Glu Gly Ser Leu Cys Tyr Val Gln Gln Lys Val Pro Xaa  
           35                  40                  45

<210> 216  
 <211> 139  
 <212> PRT  
 <213> Homo sapiens

<400> 216  
 Met Glu Ala Val Val Phe Val Phe Ser Leu Leu Asp Cys Cys Ala Leu  
   1                  5                  10                  15  
 Ile Phe Leu Ser Val Tyr Phe Ile Ile Thr Leu Ser Asp Leu Glu Cys  
                   20                  25                  30  
 Asp Tyr Ile Asn Ala Arg Ser Cys Cys Ser Lys Leu Asn Lys Trp Val  
           35                  40                  45  
 Ile Pro Glu Leu Ile Gly His Thr Ile Val Thr Val Leu Leu Leu Met  
   50                  55                  60  
 Ser Leu His Trp Phe Ile Phe Leu Leu Asn Leu Pro Val Ala Thr Trp  
   65                  70                  75                  80  
 Asn Ile Tyr Arg Tyr Ile Met Val Pro Ser Gly Asn Met Gly Val Phe  
                   85                  90                  95  
 Asp Pro Thr Glu Ile His Asn Arg Gly Gln Leu Lys Ser His Met Lys  
           100                  105                  110  
 Glu Ala Met Ile Lys Leu Gly Phe His Leu Leu Cys Phe Phe Met Tyr  
           115                  120                  125  
 Leu Tyr Ser Met Ile Leu Ala Leu Ile Asn Asp  
   130                  135

<210> 217  
 <211> 41  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (41)  
 <223> Xaa equals stop translation

<400> 217  
 Met Ser Gly Ser Ser Leu Pro Ser Ala Leu Ala Leu Ser Leu Leu Leu  
   1                  5                  10                  15



Val Ser Gly Ser Leu Leu Pro Gly Pro Gly Ala Ala Gln Asn Val Arg  
20 25 30

Val Gln Ser Gly Gln Asp Gln Lys Xaa  
35 40

<210> 218  
<211> 52  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (52)  
<223> Xaa equals stop translation

<400> 218  
Met Pro Ser His Ile Arg Ala His Leu Phe Leu Leu Leu Phe Phe Leu  
1 5 10 15

Phe Ile Tyr Gln Gly Ile Ser Ser Ile Ser Gln Ala Ser Gly Leu Thr  
20 25 30

Leu Lys Thr Gln Asn Glu Lys Asp Ile Gln Val Ser Ile Leu Lys Glu  
35 40 45

Phe Val Val Xaa  
50

<210> 219  
<211> 49  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (49)  
<223> Xaa equals stop translation

<400> 219  
Met Cys Ile Tyr Gln Ser Glu Gln Met Leu Ala Leu Leu Leu Val Leu  
1 5 10 15

Val Phe Cys Ile Ser Leu Leu Val Leu Val Cys Trp Gly Ser His Asn  
20 25 30

Lys Val Pro Gln Lys Phe Ile Phe Ser Gln Phe Trp Gly Leu Glu Asp  
35 40 45

Xaa

<210> 220  
<211> 42  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (42)  
<223> Xaa equals stop translation

<400> 220  
Met Ala Val Pro Leu Phe Leu Tyr Ile Phe Thr Leu Leu Pro Leu Leu  
1 5 10 15  
Pro Phe Leu Leu Ser Leu Cys Phe Ser Pro Leu Thr Val Lys Arg Ser  
20 25 30  
Ser Ser Ser Glu Ser Lys Ser Ser Leu Xaa  
35 40

<210> 221  
<211> 41  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (41)  
<223> Xaa equals stop translation

<400> 221  
Met Gly Met Leu Leu Ala Phe Trp Leu Pro Gly Ala Ser Trp Gln Glu  
1 5 10 15  
Ala Gly Pro Arg Ala Ser Thr Gln Arg Met Arg Thr Gln Thr Gln Met  
20 25 30  
Ser Thr Arg Lys Pro Lys Pro Ala Xaa  
35 40

<210> 222  
<211> 43  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (43)  
<223> Xaa equals stop translation

<400> 222  
Met Glu Pro Ala Met Val Leu Lys Phe Leu Ser Ser Leu Pro Glu Asn  
1 5 10 15  
Leu Phe Leu Pro Ser Leu Leu Phe Phe Ala Trp Leu Cys Trp Asn Met  
20 25 30  
Val Cys Gly Ser Pro Val Ser Cys Pro Tyr Xaa  
35 40

<210> 223  
 <211> 204  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (204)  
 <223> Xaa equals stop translation  
  
 <400> 223  
 Met Gln Leu Gly Ser Val Leu Leu Thr Arg Cys Pro Phe Trp Gly Cys  
   1                  5                  10                  15  
 Phe Ser Gln Leu Met Leu Tyr Ala Glu Arg Ala Glu Ala Arg Arg Lys  
                   20                  25                  30  
 Pro Asp Ile Pro Val Pro Tyr Leu Tyr Phe Asp Met Gly Ala Ala Val  
                   35                  40                  45  
 Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys Arg Arg Trp Phe Ala  
   50                  55                  60  
 Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr Tyr Ala Ala Tyr Ile  
   65                  70                  75                  80  
 Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys Val Arg Met Tyr Ser  
                   85                  90                  95  
 Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val Leu Ala Ser Gly Ala  
                   100                  105                  110  
 Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg Ser Leu Gln Ser Thr  
                   115                  120                  125  
 Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys Val Ala Tyr Ser Leu  
   130                  135                  140  
 Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu Asn His Leu Pro Gly  
   145                  150                  155                  160  
 Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu Tyr Gly Ile Leu Ala  
                   165                  170                  175  
 Pro Gly Leu Ser Val Arg Leu Leu Arg Asp Pro Arg Cys Pro Asp Pro  
                   180                  185                  190  
 Gly Cys Thr Ala Ala Pro Cys His Ala Ala His Xaa  
                   195                  200  
  
 <210> 224  
 <211> 43  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (43)

<223> Xaa equals stop translation

<400> 224

Met Arg Val Arg Ile Gly Leu Thr Leu Leu Leu Cys Ala Val Leu Leu  
1 5 10 15

Ser Leu Ala Ser Ala Ser Ser Asp Glu Glu Gly Ser Gln Asp Glu Ser  
20 25 30

Leu Gly Phe Gln Asp Tyr Phe Asp Ile Arg Xaa  
35 40

<210> 225

<211> 156

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (156)

<223> Xaa equals stop translation

<400> 225

Met Ala Arg Gly Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu Gly  
1 5 10 15

Leu Trp Leu Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala Pro Gly  
20 25 30

Thr Ala Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp Leu Asp Lys  
35 40 45

Cys Met Asp Cys Ser Thr Ser Cys Pro Leu Pro Ala Ala Leu Ala His  
50 55 60

Pro Trp Gly Arg Ser Glu Pro Asp Leu Arg Ala Gly Ala Ala Phe Trp  
65 70 75 80

Leu Phe Gly Leu Glu Thr Met Pro Gln Glu Arg Glu Val His His Pro  
85 90 95

His Arg Gly Asp Arg Arg Arg Gly Leu Pro Ser Cys Gly Ala Asp Pro  
100 105 110

Val Thr Met Cys Pro Leu Pro Ala Gly Ala Arg Pro Leu Ile Ile His  
115 120 125

Ser Ser Ile Leu Glu Pro Val Ser Ala Ser Gln Thr Arg Arg Glu Pro  
130 135 140

Ser Ser Ser Asn His Lys Gly Gly Gly Gly Arg Xaa  
145 150 155

<210> 226

<211> 74

<212> PRT

<213> Homo sapiens

<220>  
 <221> SITE  
 <222> (38)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (48)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (54)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (55)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (68)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (74)  
 <223> Xaa equals stop translation

<400> 226  
 Met Phe Tyr Lys Leu Thr Leu Ile Leu Cys Glu Leu Ser Val Ala Gly  
   1                  5                  10                  15  
 Val Thr Gln Ala Ala Ser Gln Arg Pro Leu Gln Arg Leu Pro Arg His  
                   20                  25                  30  
 Ile Cys Ser Gln Arg Xaa Pro Pro Gly Arg Cys Leu Leu Lys Ala Xaa  
           35                  40                  45  
 Leu Gln Thr Thr Trp Xaa Xaa Pro Asp Lys Pro Ile Pro Arg Leu Ser  
   50                  55                  60  
 Pro Pro Leu Xaa Ser Asp Pro Lys Arg Xaa  
   65                  70

<210> 227  
 <211> 167  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (167)  
 <223> Xaa equals stop translation

<400> 227

162

Met Gly Ser Arg Phe Leu Leu Val Leu Leu Ser Gly Leu Thr Val Leu  
 1 5 10 15  
 Leu Ala Leu Pro Gly Ser Glu Ala Lys Asn Ser Gly Ala Ser Cys Pro  
 20 25 30  
 Pro Cys Pro Lys Tyr Ala Ser Cys His Asn Ser Thr His Cys Thr Cys  
 35 40 45  
 Glu Asp Gly Phe Arg Ala Arg Ser Gly Arg Thr Tyr Phe His Asp Ser  
 50 55 60  
 Ser Glu Lys Cys Glu Asp Ile Asn Glu Cys Glu Thr Gly Leu Ala Lys  
 65 70 75 80  
 Cys Lys Tyr Lys Ala Tyr Cys Arg Asn Lys Val Gly Gly Tyr Ile Cys  
 85 90 95  
 Ser Cys Leu Val Lys Tyr Thr Leu Phe Asn Phe Leu Ala Gly Ile Ile  
 100 105 110  
 Asp Tyr Asp His Pro Asp Cys Tyr Glu Asn Asn Ser Gln Gly Thr Thr  
 115 120 125  
 Gln Ser Asn Val Asp Ile Trp Val Ser Gly Val Lys Pro Gly Phe Gly  
 130 135 140  
 Lys Gln Leu Val Arg Ile Thr Met Pro Phe Ser Tyr Pro Asn Ile Asn  
 145 150 155 160  
 Met Ser Ser Cys Asp Phe Xaa  
 165

&lt;210&gt; 228

&lt;211&gt; 71

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (71)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 228

Met Lys Pro Lys His Leu Glu Trp Cys Leu Ala His Ser Trp Cys Val  
 1 5 10 15  
 Ile Trp Leu Ser Phe Val Ser Pro Pro Thr Ser His Leu Glu Cys Asp  
 20 25 30  
 Gly Phe Pro Gly Ser Leu Leu Pro Pro Cys Glu Glu Gly Arg Cys Phe  
 35 40 45  
 Pro Phe Thr Phe His His His Asp Cys His Gly Cys Ser Pro Leu Gln  
 50 55 60  
 Ser Ser Pro Gly Gln His Xaa  
 65 70

<210> 229  
 <211> 273  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (273)  
 <223> Xaa equals stop translation

<400> 229

Met Cys Cys Trp Pro Leu Leu Leu Leu Trp Gly Leu Leu Pro Gly Thr  
 1 5 10 15  
 Ala Ala Gly Gly Ser Gly Arg Thr Tyr Pro His Arg Thr Leu Leu Asp  
 20 25 30  
 Ser Glu Gly Lys Tyr Trp Leu Gly Trp Ser Gln Arg Gly Ser Gln Ile  
 35 40 45  
 Ala Phe Arg Leu Gln Val Arg Thr Ala Gly Tyr Val Gly Phe Gly Phe  
 50 55 60  
 Ser Pro Thr Gly Ala Met Ala Ser Ala Asp Ile Val Val Gly Gly Val  
 65 70 75 80  
 Ala His Gly Arg Pro Tyr Leu Gln Asp Tyr Phe Thr Asn Ala Asn Arg  
 85 90 95  
 Glu Leu Lys Lys Asp Ala Gln Gln Asp Tyr His Leu Glu Tyr Ala Met  
 100 105 110  
 Glu Asn Ser Thr His Thr Ile Ile Glu Phe Thr Arg Glu Leu His Thr  
 115 120 125  
 Cys Asp Ile Asn Asp Lys Ser Ile Thr Asp Ser Thr Val Arg Val Ile  
 130 135 140  
 Trp Ala Tyr His His Glu Asp Ala Gly Glu Ala Gly Pro Lys Tyr His  
 145 150 155 160  
 Asp Ser Asn Arg Gly Thr Lys Ser Leu Arg Leu Leu Asn Pro Glu Lys  
 165 170 175  
 Thr Ser Val Leu Ser Thr Ala Leu Pro Tyr Phe Asp Leu Val Asn Gln  
 180 185 190  
 Asp Val Pro Ile Pro Asn Lys Asp Thr Thr Tyr Trp Cys Gln Met Phe  
 195 200 205  
 Lys Ile Pro Val Phe Gln Glu Lys His His Val Ile Lys Val Glu Pro  
 210 215 220  
 Val Ile Gln Arg Gly His Glu Ser Leu Val His His Ile Leu Leu Tyr  
 225 230 235 240  
 Gln Cys Ser Asn Asn Phe Asn Asp Ser Val Pro Gly Ile Arg Ala Arg

164

245 250 255  
 Ile Ala Ile Thr Pro Thr Cys Pro Met His Ser Ser Pro Val Lys Leu  
 260 265 270

Xaa

<210> 230  
 <211> 82  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (82)  
 <223> Xaa equals stop translation

<400> 230  
 Met Arg Pro Gly Thr Ala Leu Gln Ala Val Leu Leu Ala Val Leu Leu  
 1 5 10 15

Val Gly Leu Arg Ala Ala Thr Gly Arg Leu Leu Ser Gly Gln Pro Val  
 20 25 30

Cys Arg Gly Gly Thr Gln Arg Pro Cys Tyr Lys Val Ile Tyr Phe His  
 35 40 45

Asp Thr Ser Arg Arg Leu Asn Phe Glu Glu Ala Lys Glu Ala Cys Arg  
 50 55 60

Arg Gly Trp Arg Pro Ala Ser Gln His Arg Val Leu Lys Met Asn Arg  
 65 70 75 80

Asn Xaa

<210> 231  
 <211> 71  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (38)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 231  
 Met Ser Pro Leu Ser Ala Ala Arg Ala Ala Leu Arg Val Tyr Ala Val  
 1 5 10 15

Gly Ala Ala Val Ile Leu Ala Gln Leu Leu Arg Arg Cys Arg Gly Gly  
 20 25 30

Phe Leu Glu Pro Val Xaa Pro Pro Arg Pro Asp Arg Val Ala Ile Val  
 35 40 45



Thr Gly Gly Thr Asp Gly Ile Gly Tyr Ser Thr Ala Asn Ile Trp Arg  
 50 55 60

Asp Leu Ala Cys Met Leu Ser  
 65 70

<210> 232

<211> 225

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 232

His Glu Arg Ala Xaa Gly Pro Ser Arg Gly His Gly Glu Leu Leu Ser  
 1 5 10 15

Cys Val Leu Gly Pro Arg Leu Tyr Lys Ile Tyr Arg Glu Arg Asp Ser  
 20 25 30

Glu Arg Ala Pro Ala Ser Val Pro Glu Thr Pro Thr Ala Val Thr Ala  
 35 40 45

Pro His Ser Ser Ser Trp Asp Thr Tyr Tyr Gln Pro Arg Ala Leu Glu  
 50 55 60

Lys His Ala Asp Ser Ile Leu Ala Leu Ala Ser Val Phe Trp Ser Ile  
 65 70 75 80

Ser Tyr Tyr Ser Ser Pro Phe Ala Phe Phe Tyr Leu Tyr Arg Lys Gly  
 85 90 95

Tyr Leu Ser Leu Ser Lys Val Val Pro Phe Ser His Tyr Ala Gly Thr  
 100 105 110

Leu Leu Leu Leu Leu Ala Gly Val Ala Cys Ser Glu Ala Leu Ala Ala  
 115 120 125

Gly Pro Thr Pro Ser Thr Gly Ser Ser Ser Pro Ser Trp Lys Gln His  
 130 135 140

Ile Gly Thr Ser Leu Gln Lys Thr Arg Gly Ser Leu Pro Thr Thr Thr  
 145 150 155 160

Leu Thr Ser Gly Ala Gly Gln Ser Thr Ser Thr Gly Lys Asn Pro Ala  
 165 170 175

Ala Gly Arg Ser Leu Glu Gly Ala Leu Pro Ala Gly Val Trp Pro Cys  
 180 185 190

Phe Ala Gln Ser Pro Cys Thr Gly Gly Gln Gln Thr Pro Ser Ser Thr  
 195 200 205

Gly Leu Arg Ser Cys Leu Val Arg Ser Pro Ala Thr Trp Trp Arg Thr  
 210 215 220

Pro  
225

<210> 233  
<211> 314  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (147)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (211)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 233  
Met Leu Pro Ala Arg Leu Pro Phe Arg Leu Leu Ser Leu Phe Leu Arg  
1 5 10 15  
Gly Ser Ala Pro Thr Ala Ala Arg His Gly Leu Arg Glu Pro Leu Leu  
20 25 30  
Glu Arg Arg Cys Ala Ala Ala Ser Ser Phe Gln His Ser Ser Ser Leu  
35 40 45  
Gly Arg Glu Leu Pro Tyr Asp Pro Val Asp Thr Glu Gly Phe Gly Glu  
50 55 60  
Gly Gly Asp Met Gln Glu Arg Phe Leu Phe Pro Glu Tyr Ile Leu Asp  
65 70 75 80  
Pro Glu Pro Gln Pro Thr Arg Glu Lys Gln Leu Gln Glu Leu Gln Gln  
85 90 95  
Gln Gln Glu Glu Glu Glu Arg Gln Arg Gln Gln Arg Arg Glu Glu Arg  
100 105 110  
Arg Gln Gln Asn Leu Arg Ala Arg Ser Arg Glu His Pro Val Val Gly  
115 120 125  
His Pro Asp Pro Ala Leu Pro Pro Ser Gly Val Asn Cys Ser Gly Cys  
130 135 140  
Gly Ala Xaa Leu His Cys Gln Asp Ala Gly Val Pro Gly Tyr Leu Pro  
145 150 155 160  
Arg Glu Lys Phe Leu Arg Thr Ala Glu Ala Asp Gly Gly Leu Ala Arg  
165 170 175  
Thr Val Cys Gln Arg Cys Trp Leu Leu Ser His His Arg Arg Ala Leu  
180 185 190  
Arg Leu Gln Val Ser Arg Glu Gln Tyr Leu Glu Leu Val Ser Ala Ala  
195 200 205

Leu Arg Xaa Pro Gly Pro Ser Leu Val Leu Tyr Met Val Asp Leu Leu  
 210 215 220  
 Asp Leu Pro Asp Ala Leu Leu Pro Asp Leu Pro Ala Leu Val Gly Pro  
 225 230 235 240  
 Lys Gln Leu Ile Val Leu Gly Asn Lys Val Asp Leu Leu Pro Gln Asp  
 245 250 255  
 Ala Pro Gly Tyr Arg Gln Arg Leu Arg Glu Arg Leu Trp Glu Asp Cys  
 260 265 270  
 Ala Arg Ala Gly Leu Leu Leu Ala Pro Gly Thr Lys Gly His Ser Ala  
 275 280 285  
 Pro Ser Arg Thr Ser His Arg Thr Gly Arg Ile Arg Ile Arg Arg Thr  
 290 295 300  
 Gly Pro Ala Gln Trp Ser Gly Thr Cys Gly  
 305 310

<210> 234  
 <211> 93  
 <212> PRT  
 <213> Homo sapiens

<400> 234  
 Met Arg Pro Gln Gly Pro Ala Ala Ser Pro Gln Arg Leu Arg Gly Leu  
 1 5 10 15  
 Leu Leu Leu Leu Leu Leu Gln Leu Pro Ala Pro Ser Ser Ala Ser Glu  
 20 25 30  
 Ile Pro Lys Gly Lys Gln Lys Ala His Ser Gly Arg Gly Arg Trp Trp  
 35 40 45  
 Thr Cys Ile Met Glu Cys Ala Tyr Lys Gly Gln Gln Glu Cys Leu Val  
 50 55 60  
 Glu Thr Gly Ala Leu Gly Pro Met Ala Phe Arg Val His Leu Gly Ser  
 65 70 75 80  
 Gln Val Gly Met Asp Ser Lys Glu Lys Arg Gly Asn Val  
 85 90

<210> 235  
 <211> 73  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (73)  
 <223> Xaa equals stop translation

<400> 235

Met Gly Ser Ala Ala Leu Glu Ile Leu Gly Leu Val Leu Cys Leu Val  
 1 5 10 15  
 Gly Trp Gly Gly Leu Ile Leu Ala Cys Gly Leu Pro Met Trp Gln Val  
 20 25 30  
 Thr Ala Phe Leu Asp His Asn Ile Val Thr Ala Gln Thr Thr Trp Lys  
 35 40 45  
 Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly Thr Cys Ser Ala  
 50 55 60  
 Lys Cys Thr Thr Arg Cys Trp Leu Xaa  
 65 70

<210> 236

<211> 349

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (283)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (293)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (325)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (326)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (349)

<223> Xaa equals stop translation

<400> 236

Met Leu Cys Pro Trp Arg Thr Ala Asn Leu Gly Leu Leu Leu Ile Leu  
 1 5 10 15  
 Thr Ile Phe Leu Val Ala Glu Ala Glu Gly Ala Ala Gln Pro Asn Asn  
 20 25 30  
 Ser Leu Met Leu Gln Thr Ser Lys Glu Asn His Ala Leu Ala Ser Ser  
 35 40 45  
 Ser Leu Cys Met Asp Glu Lys Gln Ile Thr Gln Asn Tyr Ser Lys Val  
 50 55 60

Leu Ala Glu Val Asn Thr Ser Trp Pro Val Lys Met Ala Thr Asn Ala  
 65 70 75 80  
 Val Leu Cys Cys Pro Pro Ile Ala Leu Arg Asn Leu Ile Ile Ile Thr  
 85 90 95  
 Trp Glu Ile Ile Leu Arg Gly Gln Pro Ser Cys Thr Lys Ala Tyr Lys  
 100 105 110  
 Lys Glu Thr Asn Glu Thr Lys Glu Thr Asn Cys Thr Asp Glu Arg Ile  
 115 120 125  
 Thr Trp Val Ser Arg Pro Asp Gln Asn Ser Asp Leu Gln Ile Arg Thr  
 130 135 140  
 Val Ala Ile Thr His Asp Gly Tyr Tyr Arg Cys Ile Met Val Thr Pro  
 145 150 155 160  
 Asp Gly Asn Phe His Arg Gly Tyr His Leu Gln Val Leu Val Thr Pro  
 165 170 175  
 Glu Val Thr Leu Phe Gln Asn Arg Asn Arg Thr Ala Val Cys Lys Ala  
 180 185 190  
 Val Ala Gly Lys Pro Ala Ala His Ile Ser Trp Ile Pro Glu Gly Asp  
 195 200 205  
 Cys Ala Thr Lys Gln Glu Tyr Trp Ser Asn Gly Thr Val Thr Val Lys  
 210 215 220  
 Ser Thr Cys His Trp Glu Val His Asn Val Ser Thr Val Asn Cys His  
 225 230 235 240  
 Val Ser His Leu Thr Gly Asn Lys Ser Leu Tyr Ile Glu Leu Leu Pro  
 245 250 255  
 Val Pro Gly Ala Lys Lys Ser Ser Lys Leu Tyr Ile Pro Tyr Ile Ile  
 260 265 270  
 Leu Thr Ile Ile Ile Leu Thr Ile Val Gly Xaa Ile Trp Leu Leu Lys  
 275 280 285  
 Val Asn Gly Cys Xaa Lys Tyr Lys Leu Asn Lys Pro Glu Ser Thr Pro  
 290 295 300  
 Val Val Glu Glu Asp Glu Met Gln Pro Tyr Ala Phe Tyr Thr Glu Lys  
 305 310 315 320  
 Asn Asn Pro Leu Xaa Xaa Thr Thr Asn Lys Val Lys Ala Ser Glu Ala  
 325 330 335  
 Leu Gln Ser Glu Val Asp Thr Asp Leu His Thr Leu Xaa  
 340 345

&lt;210&gt; 237

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 237

Leu Ala Leu Tyr Ser Ala Leu Phe Ser Tyr Ser Gly Trp Asp Thr Leu  
1 5 10 15

Asn

&lt;210&gt; 238

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 238

Val Thr Glu Glu Ile Lys Asn Pro Glu Arg Asn Leu Pro Leu  
1 5 10

&lt;210&gt; 239

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 239

Ile Gly Ile Ser Met Pro Ile Val Thr  
1 5

&lt;210&gt; 240

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 240

Ile Tyr Ile Leu Thr Asn Val Ala Tyr Thr Val Leu  
1 5 10

&lt;210&gt; 241

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 241

Ser Asp Ala Val Ala Val Thr Phe Ala Asp Gln  
1 5 10

&lt;210&gt; 242

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 242

Val Ala Leu Ser Cys Phe Gly Gly Leu Asn Ala Ser Ile  
1 5 10

<210> 243  
<211> 15  
<212> PRT  
<213> Homo sapiens

<400> 243  
Ser Arg Leu Phe Phe Val Gly Ser Arg Glu Gly His Leu Pro Asp  
1 5 10 15

<210> 244  
<211> 11  
<212> PRT  
<213> Homo sapiens

<400> 244  
Ser Phe Ser Tyr Trp Phe Phe Val Gly Leu Ser  
1 5 10

<210> 245  
<211> 11  
<212> PRT  
<213> Homo sapiens

<400> 245  
Val Gly Gln Leu Tyr Leu Arg Trp Lys Glu Pro  
1 5 10

<210> 246  
<211> 16  
<212> PRT  
<213> Homo sapiens

<400> 246  
Arg Pro Arg Pro Leu Lys Leu Ser Val Phe Phe Pro Ile Val Phe Cys  
1 5 10 15

<210> 247  
<211> 9  
<212> PRT  
<213> Homo sapiens

<400> 247  
Asp Thr Ile Asn Ser Leu Ile Gly Ile  
1 5

<210> 248  
<211> 44  
<212> PRT  
<213> Homo sapiens

<400> 248

Ala Thr Ala Leu Pro Pro Lys Ile Val Gly Ser Ala Thr Arg Tyr Leu  
 1 5 10 15  
 Gln Val Leu Cys Met Ser Val Ala Ala Glu Met Asp Leu Glu Asp Gly  
 20 25 30  
 Gly Glu Met Pro Lys Gln Arg Asp Pro Lys Ser Asn  
 35 40  
  
 <210> 249  
 <211> 352  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 249  
 Leu Leu Ala Ala Ala Cys Ile Cys Leu Leu Thr Phe Ile Asn Cys Ala  
 1 5 10 15  
 Tyr Val Lys Trp Gly Thr Leu Val Gln Asp Ile Phe Thr Tyr Ala Lys  
 20 25 30  
 Val Leu Ala Leu Ile Ala Val Ile Val Ala Gly Ile Val Arg Leu Gly  
 35 40 45  
 Gln Gly Ala Ser Thr His Phe Glu Asn Ser Phe Glu Gly Ser Ser Phe  
 50 55 60  
 Ala Val Gly Asp Ile Ala Leu Ala Leu Tyr Ser Ala Leu Phe Ser Tyr  
 65 70 75 80  
 Ser Gly Trp Asp Thr Leu Asn Tyr Val Thr Glu Glu Ile Lys Asn Pro  
 85 90 95  
 Glu Arg Asn Leu Pro Leu Ser Ile Gly Ile Ser Met Pro Ile Val Thr  
 100 105 110  
 Ile Ile Tyr Ile Leu Thr Asn Val Ala Tyr Tyr Thr Val Leu Asp Met  
 115 120 125  
 Arg Asp Ile Leu Ala Ser Asp Ala Val Ala Val Thr Phe Ala Asp Gln  
 130 135 140  
 Ile Phe Gly Ile Phe Asn Trp Ile Ile Pro Leu Ser Val Ala Leu Ser  
 145 150 155 160  
 Cys Phe Gly Gly Leu Asn Ala Ser Ile Val Ala Ala Ser Arg Leu Phe  
 165 170 175  
 Phe Val Gly Ser Arg Glu Gly His Leu Pro Asp Ala Ile Cys Met Ile  
 180 185 190  
 His Val Glu Arg Phe Thr Pro Val Pro Ser Leu Leu Phe Asn Gly Ile  
 195 200 205  
 Met Ala Leu Ile Tyr Leu Cys Val Glu Asp Ile Phe Gln Leu Ile Asn  
 210 215 220  
 Tyr Tyr Ser Phe Ser Tyr Trp Phe Phe Val Gly Leu Ser Ile Val Gly



225					230						235					240
Gln	Leu	Tyr	Leu	Arg	Trp	Lys	Glu	Pro	Asp	Arg	Pro	Arg	Pro	Leu	Lys	
				245					250					255		
Leu	Ser	Val	Phe	Phe	Pro	Ile	Val	Phe	Cys	Leu	Cys	Thr	Ile	Phe	Leu	
			260					265					270			
Val	Ala	Val	Pro	Leu	Tyr	Ser	Asp	Thr	Ile	Asn	Ser	Leu	Ile	Gly	Ile	
		275					280					285				
Ala	Ile	Ala	Leu	Ser	Gly	Leu	Pro	Phe	Tyr	Phe	Leu	Ile	Ile	Arg	Val	
	290					295					300					
Pro	Glu	His	Lys	Arg	Pro	Leu	Tyr	Leu	Arg	Arg	Ile	Val	Gly	Ser	Ala	
305					310					315					320	
Thr	Arg	Tyr	Leu	Gln	Val	Leu	Cys	Met	Ser	Val	Ala	Ala	Glu	Met	Asp	
				325					330					335		
Leu	Glu	Asp	Gly	Gly	Glu	Met	Pro	Lys	Gln	Arg	Asp	Pro	Lys	Ser	Asn	
			340					345					350			

```
<210> 250
<211> 119
<212> PRT
<213> Homo sapiens
```

```

<400> 250
Ala Ala Arg Gly Ser Gly Val Arg Asp Pro Leu Glu Glu Ala Val Cys
 1              5              10              15
Pro Phe Ser Asp Leu Gln Leu His Ala Gly Arg Thr Thr Ala Leu Phe
          20              25              30
Lys Ala Val Arg Gln Gly His Leu Ser Leu Gln Arg Leu Leu Leu Ser
          35              40              45
Phe Val Cys Leu Cys Pro Ala Pro Arg Gly Gly Ala Tyr Arg Gly Arg
 50              55              60
Gln Ala Ser Leu Ser Cys Gly Gly Leu His Pro Val Arg Ala Ser Arg
 65              70              75              80
Leu Leu Cys Leu Pro Lys Gln Ala Trp Ala Met Ala Gly Ala Pro Pro
          85              90              95
Pro Val Ser Leu Pro Pro Cys Ser Leu Ile Ser Asp Cys Cys Ala Ser
          100              105              110
Asn Gln Arg Asp Ser Val Gly
          115

```

<210> 251

<211> 356  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (37)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (280)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 251  
 Leu Ser Lys Ala Phe Leu Asp Ser Pro Asn Arg Leu Leu Ala Val Glu  
   1                  5                  10                  15  
 Met Asn Thr Asp His Leu Arg Leu Thr Val Pro Asn Gly Ile Gly Ala  
                   20                  25                  30  
 Leu Lys Leu Arg Xaa Met Glu His Tyr Phe Ser Gln Gly Leu Ser Val  
                   35                  40                  45  
 Gln Leu Phe Asn Asp Gly Ser Lys Gly Lys Leu Asn His Leu Cys Gly  
   50                  55                  60  
 Ala Asp Phe Val Lys Ser His Gln Lys Pro Pro Gln Gly Met Glu Ile  
   65                  70                  75                  80  
 Lys Ser Asn Glu Arg Cys Cys Ser Phe Asp Gly Asp Ala Asp Arg Ile  
                   85                  90                  95  
 Val Tyr Tyr Tyr His Asp Ala Asp Gly His Phe His Leu Ile Asp Gly  
                   100                  105                  110  
 Asp Lys Ile Ala Thr Leu Ile Ser Ser Phe Leu Lys Glu Leu Leu Val  
   115                  120                  125  
 Glu Ile Gly Glu Ser Leu Asn Ile Gly Val Val Gln Thr Ala Tyr Ala  
   130                  135                  140  
 Asn Gly Ser Ser Thr Arg Tyr Leu Glu Glu Val Met Lys Val Pro Val  
  145                  150                  155                  160  
 Tyr Cys Thr Lys Thr Gly Val Lys His Leu His His Lys Ala Gln Glu  
                   165                  170                  175  
 Phe Asp Ile Gly Val Tyr Phe Glu Ala Asn Gly His Gly Thr Ala Leu  
   180                  185                  190  
 Phe Ser Thr Ala Val Glu Met Lys Ile Lys Gln Ser Ala Glu Gln Leu  
   195                  200                  205  
 Glu Asp Lys Lys Arg Lys Ala Ala Lys Met Leu Glu Asn Ile Ile Asp  
  210                  215                  220  
 Leu Phe Asn Gln Ala Ala Gly Asp Ala Ile Ser Asp Met Leu Val Ile  
  225                  230                  235                  240

175

Glu Ala Ile Leu Ala Leu Lys Gly Leu Thr Val Gln Gln Trp Asp Ala  
                   245                  250                  255  
 Leu Tyr Thr Asp Leu Pro Asn Arg Gln Leu Lys Val Gln Val Ala Asp  
                   260                  265                  270  
 Arg Arg Val Ile Ser Thr Thr Xaa Ala Glu Arg Gln Ala Val Thr Pro  
                   275                  280                  285  
 Pro Gly Leu Gln Glu Ala Ile Asn Asp Leu Val Lys Lys Tyr Lys Leu  
           290                  295                  300  
 Ser Arg Ala Phe Val Arg Pro Ser Gly Thr Glu Asp Val Val Arg Val  
 305                  310                  315                  320  
 Tyr Ala Glu Ala Asp Ser Gln Glu Ser Ala Asp His Leu Ala His Glu  
                   325                  330                  335  
 Val Ser Leu Ala Val Phe Gln Leu Ala Gly Gly Ile Gly Glu Arg Pro  
           340                  345                  350  
 Gln Pro Gly Phe  
           355

<210> 252  
 <211> 26  
 <212> PRT  
 <213> Homo sapiens

<400> 252  
 Leu Ser Lys Ala Phe Leu Asp Ser Pro Asn Arg Leu Leu Ala Val Glu  
   1                  5                  10                  15  
 Met Asn Thr Asp His Leu Arg Leu Thr Val  
           20                  25

<210> 253  
 <211> 28  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (11)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 253  
 Pro Asn Gly Ile Gly Ala Leu Lys Leu Arg Xaa Met Glu His Tyr Phe  
   1                  5                  10                  15  
 Ser Gln Gly Leu Ser Val Gln Leu Phe Asn Asp Gly  
           20                  25

<210> 254  
 <211> 28

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 254

Ser Lys Gly Lys Leu Asn His Leu Cys Gly Ala Asp Phe Val Lys Ser  
1 5 10 15

His Gln Lys Pro Pro Gln Gly Met Glu Ile Lys Ser  
20 25

&lt;210&gt; 255

&lt;211&gt; 28

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 255

Asn Glu Arg Cys Cys Ser Phe Asp Gly Asp Ala Asp Arg Ile Val Tyr  
1 5 10 15

Tyr Tyr His Asp Ala Asp Gly His Phe His Leu Ile  
20 25

&lt;210&gt; 256

&lt;211&gt; 28

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 256

Asp Gly Asp Lys Ile Ala Thr Leu Ile Ser Ser Phe Leu Lys Glu Leu  
1 5 10 15

Leu Val Glu Ile Gly Glu Ser Leu Asn Ile Gly Val  
20 25

&lt;210&gt; 257

&lt;211&gt; 28

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 257

Val Gln Thr Ala Tyr Ala Asn Gly Ser Ser Thr Arg Tyr Leu Glu Glu  
1 5 10 15

Val Met Lys Val Pro Val Tyr Cys Thr Lys Thr Gly  
20 25

&lt;210&gt; 258

&lt;211&gt; 28

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 258

Val Lys His Leu His His Lys Ala Gln Glu Phe Asp Ile Gly Val Tyr  
1 5 10 15

Phe Glu Ala Asn Gly His Gly Thr Ala Leu Phe Ser  
20 25

<210> 259  
<211> 28  
<212> PRT  
<213> Homo sapiens

<400> 259  
Thr Ala Val Glu Met Lys Ile Lys Gln Ser Ala Glu Gln Leu Glu Asp  
1 5 10 15

Lys Lys Arg Lys Ala Ala Lys Met Leu Glu Asn Ile  
20 25

<210> 260  
<211> 28  
<212> PRT  
<213> Homo sapiens

<400> 260  
Ile Asp Leu Phe Asn Gln Ala Ala Gly Asp Ala Ile Ser Asp Met Leu  
1 5 10 15

Val Ile Glu Ala Ile Leu Ala Leu Lys Gly Leu Thr  
20 25

<210> 261  
<211> 28  
<212> PRT  
<213> Homo sapiens

<400> 261  
Val Gln Gln Trp Asp Ala Leu Tyr Thr Asp Leu Pro Asn Arg Gln Leu  
1 5 10 15

Lys Val Gln Val Ala Asp Arg Arg Val Ile Ser Thr  
20 25

<210> 262  
<211> 28  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (2)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 262  
Thr Xaa Ala Glu Arg Gln Ala Val Thr Pro Pro Gly Leu Gln Glu Ala  
1 5 10 15

Ile Asn Asp Leu Val Lys Lys Tyr Lys Leu Ser Arg  
20 25

<210> 263  
<211> 24  
<212> PRT  
<213> Homo sapiens

<400> 263  
Ala Phe Val Arg Pro Ser Gly Thr Glu Asp Val Val Arg Val Tyr Ala  
1 5 10 15

Glu Ala Asp Ser Gln Glu Ser Ala  
20

<210> 264  
<211> 26  
<212> PRT  
<213> Homo sapiens

<400> 264  
Asp His Leu Ala His Glu Val Ser Leu Ala Val Phe Gln Leu Ala Gly  
1 5 10 15

Gly Ile Gly Glu Arg Pro Gln Pro Gly Phe  
20 25

<210> 265  
<211> 443  
<212> PRT  
<213> Homo sapiens

<400> 265  
Gly Thr Arg Ala Ala Pro Gly Leu Gly Ala Trp Gly Arg Arg Ser Pro  
1 5 10 15

Pro Ser Phe Ser Pro Pro Arg Pro Arg Arg Pro Gly Val Met Ala Gly  
20 25 30

Leu Asn Cys Gly Val Ser Ile Ala Leu Leu Gly Val Leu Leu Leu Gly  
35 40 45

Ala Ala Arg Leu Pro Arg Gly Ala Glu Ala Phe Glu Ile Ala Leu Pro  
50 55 60

Arg Glu Ser Asn Ile Thr Val Leu Ile Lys Leu Gly Thr Pro Thr Leu  
65 70 75 80

Leu Ala Lys Pro Cys Tyr Ile Val Ile Ser Lys Arg His Ile Thr Met  
85 90 95

Leu Ser Ile Lys Ser Gly Glu Arg Ile Val Phe Thr Phe Ser Cys Gln  
100 105 110

Ser Pro Glu Asn His Phe Val Ile Glu Ile Gln Lys Asn Ile Asp Cys  
115 120 125

Met Ser Gly Pro Cys Pro Phe Gly Glu Val Gln Leu Gln Pro Ser Thr

130	135	140
Ser Leu Leu Pro Thr Leu Asn Arg Thr Phe Ile Trp Asp Val Lys Ala		
145	150	155 160
His Lys Ser Ile Gly Leu Glu Leu Gln Phe Ser Ile Pro Arg Leu Arg		
	165	170 175
Gln Ile Gly Pro Gly Glu Ser Cys Pro Asp Gly Val Thr His Ser Ile		
	180	185 190
Ser Gly Arg Ile Asp Ala Thr Val Val Arg Ile Gly Thr Phe Cys Ser		
	195	200 205
Asn Gly Thr Val Ser Arg Ile Lys Met Gln Glu Gly Val Lys Met Ala		
	210	215 220
Leu His Leu Pro Trp Phe His Pro Arg Asn Val Ser Gly Phe Ser Ile		
	225	230 235 240
Ala Asn Arg Ser Ser Ile Lys Arg Leu Cys Ile Ile Glu Ser Val Phe		
	245	250 255
Glu Gly Glu Gly Ser Ala Thr Leu Met Ser Ala Asn Tyr Pro Glu Gly		
	260	265 270
Phe Pro Glu Asp Glu Leu Met Thr Trp Gln Phe Val Val Pro Ala His		
	275	280 285
Leu Arg Ala Ser Val Ser Phe Leu Asn Phe Asn Leu Ser Asn Cys Glu		
	290	295 300
Arg Lys Glu Glu Arg Val Glu Tyr Tyr Ile Pro Gly Ser Thr Thr Asn		
	305	310 315 320
Pro Glu Val Phe Lys Leu Glu Asp Lys Gln Pro Gly Asn Met Ala Gly		
	325	330 335
Asn Phe Asn Leu Ser Leu Gln Gly Cys Asp Gln Asp Ala Gln Ser Pro		
	340	345 350
Gly Ile Leu Arg Leu Gln Phe Gln Val Leu Val Gln His Pro Gln Asn		
	355	360 365
Glu Ser Asn Lys Ile Tyr Val Val Asp Leu Ser Asn Glu Arg Ala Met		
	370	375 380
Ser Leu Thr Ile Glu Pro Arg Pro Val Lys Gln Ser Arg Lys Phe Val		
	385	390 395 400
Pro Gly Cys Phe Val Cys Leu Glu Ser Arg Thr Cys Ser Ser Asn Leu		
	405	410 415
Thr Leu Thr Ser Gly Ser Lys His Lys Ile Ser Phe Leu Cys Asp Asp		
	420	425 430
Leu Thr Arg Leu Trp Met Asn Val Glu Lys Pro		
	435	440

180

<210> 266  
 <211> 159  
 <212> PRT  
 <213> Homo sapiens

<400> 266  
 Phe Glu Ile Ala Leu Pro Arg Glu Ser Asn Ile Thr Val Leu Ile Lys  
   1                  5                  10                  15  
 Leu Gly Thr Pro Thr Leu Leu Ala Lys Pro Cys Tyr Ile Val Ile Ser  
                   20                  25                  30  
 Lys Arg His Ile Thr Met Leu Ser Ile Lys Ser Gly Glu Arg Ile Val  
           35                  40                  45  
 Phe Thr Phe Ser Cys Gln Ser Pro Glu Asn His Phe Val Ile Glu Ile  
   50                  55                  60  
 Gln Lys Asn Ile Asp Cys Met Ser Gly Pro Cys Pro Phe Gly Glu Val  
   65                  70                  75                  80  
 Gln Leu Gln Pro Ser Thr Ser Leu Leu Pro Thr Leu Asn Arg Thr Phe  
                   85                  90                  95  
 Ile Trp Asp Val Lys Ala His Lys Ser Ile Gly Leu Glu Leu Gln Phe  
           100                  105                  110  
 Ser Ile Pro Arg Leu Arg Gln Ile Gly Pro Gly Glu Ser Cys Pro Asp  
           115                  120                  125  
 Gly Val Thr His Ser Ile Ser Gly Arg Ile Asp Ala Thr Val Val Arg  
   130                  135                  140  
 Ile Gly Thr Phe Cys Ser Asn Gly Thr Val Ser Arg Ile Lys Met  
 145                  150                  155

<210> 267  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 267  
 Phe Val Arg Asp Pro Phe Val Arg Leu  
   1                  5

<210> 268  
 <211> 13  
 <212> PRT  
 <213> Homo sapiens

<400> 268  
 Phe Leu Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser  
   1                  5                  10

<210> 269



181

<211> 15  
 <212> PRT  
 <213> Homo sapiens

<400> 269

Phe Leu Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser Ala Phe  
 1 5 10 15

<210> 270  
 <211> 380  
 <212> PRT  
 <213> Homo sapiens

<400> 270

Tyr Leu His Thr Ser Phe Ser Arg Pro His Thr Gly Pro Pro Leu Pro  
 1 5 10 15

Thr Pro Gly Pro Asp Arg Asp Arg Glu Leu Thr Ala Asp Ser Asp Val  
 20 25 30

Asp Glu Phe Leu Asp Lys Phe Leu Ser Ala Gly Val Lys Gln Ser Asp  
 35 40 45

Leu Pro Arg Lys Glu Thr Glu Gln Pro Pro Ala Pro Gly Ser Met Glu  
 50 55 60

Glu Asn Val Arg Gly Tyr Asp Trp Ser Pro Arg Asp Ala Arg Arg Ser  
 65 70 75 80

Pro Asp Gln Gly Arg Gln Gln Ala Glu Arg Arg Ser Val Leu Arg Gly  
 85 90 95

Phe Cys Ala Asn Ser Ser Leu Ala Phe Pro Thr Lys Glu Arg Ala Phe  
 100 105 110

Asp Asp Ile Pro Asn Ser Glu Leu Ser His Leu Ile Val Asp Asp Arg  
 115 120 125

His Gly Ala Ile Tyr Cys Tyr Val Pro Lys Val Ala Cys Thr Asn Trp  
 130 135 140

Lys Arg Val Met Ile Val Leu Ser Gly Ser Leu Leu His Arg Gly Ala  
 145 150 155 160

Pro Tyr Arg Asp Pro Leu Arg Ile Pro Arg Glu His Val His Asn Ala  
 165 170 175

Ser Ala His Leu Thr Phe Asn Lys Phe Trp Arg Arg Tyr Gly Lys Leu  
 180 185 190

Ser Arg His Leu Met Lys Val Lys Leu Lys Lys Tyr Thr Lys Phe Leu  
 195 200 205

Phe Val Arg Asp Pro Phe Val Arg Leu Ile Ser Ala Phe Arg Ser Lys  
 210 215 220

Phe Glu Leu Glu Asn Glu Glu Phe Tyr Arg Lys Phe Ala Val Pro Met  
 225 230 235 240

Leu Arg Leu Tyr Ala Asn His Thr Ser Leu Pro Ala Ser Ala Arg Glu  
                   245                  250                  255  
 Ala Phe Arg Ala Gly Leu Lys Val Ser Phe Ala Asn Phe Ile Gln Tyr  
                   260                  265                  270  
 Leu Leu Asp Pro His Thr Glu Lys Leu Ala Pro Phe Asn Glu His Trp  
                   275                  280                  285  
 Arg Gln Val Tyr Arg Leu Cys His Pro Cys Gln Ile Asp Tyr Asp Phe  
                   290                  295                  300  
 Val Gly Lys Leu Glu Thr Leu Asp Glu Asp Ala Ala Gln Leu Leu Gln  
                   305                  310                  315                  320  
 Leu Leu Gln Val Asp Arg Gln Leu Arg Phe Pro Pro Ser Tyr Arg Asn  
                   325                  330                  335  
 Arg Thr Ala Ser Ser Trp Glu Glu Asp Trp Phe Ala Lys Ile Pro Leu  
                   340                  345                  350  
 Ala Trp Arg Gln Gln Leu Tyr Lys Leu Tyr Glu Ala Asp Phe Val Leu  
                   355                  360                  365  
 Phe Gly Tyr Pro Lys Pro Glu Asn Leu Leu Arg Asp  
                   370                  375                  380  
  
 <210> 271  
 <211> 274  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 271  
 Lys Leu Val Arg Leu Gln Val Pro Val Arg Asn Ser Arg Val Asp Pro  
   1                  5                  10                  15  
 Arg Val Arg Ser Lys Ile Gly Ser Arg Arg Trp Met Leu Gln Leu Ile  
                   20                  25                  30  
 Met Gln Leu Gly Ser Val Leu Leu Thr Arg Cys Pro Phe Trp Gly Cys  
                   35                  40                  45  
 Phe Ser Gln Leu Met Leu Tyr Ala Glu Arg Ala Glu Ala Arg Arg Lys  
                   50                  55                  60  
 Pro Asp Ile Pro Val Pro Tyr Leu Tyr Phe Asp Met Gly Ala Ala Val  
                   65                  70                  75                  80  
 Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys Arg Arg Trp Phe Ala  
                   85                  90                  95  
 Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr Tyr Ala Ala Tyr Ile  
                   100                  105                  110  
 Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys Val Arg Met Tyr Ser  
                   115                  120                  125

Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val Leu Ala Ser Gly Ala  
 130 135 140  
 Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg Ser Leu Gln Ser Thr  
 145 150 155 160  
 Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys Val Ala Tyr Ser Leu  
 165 170 175  
 Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu Asn His Leu Pro Gly  
 180 185 190  
 Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu Tyr Gly Ile Leu Ala  
 195 200 205  
 Leu Ala Phe Leu Ser Gly Tyr Tyr Val Thr Leu Ala Ala Gln Ile Leu  
 210 215 220  
 Ala Val Leu Leu Pro Pro Val Met Leu Leu Ile Asp Gly Asn Val Ala  
 225 230 235 240  
 Tyr Trp His Asn Thr Arg Arg Val Glu Phe Trp Asn Gln Met Lys Leu  
 245 250 255  
 Leu Gly Glu Ser Val Gly Ile Phe Gly Thr Ala Val Ile Leu Ala Thr  
 260 265 270  
 Asp Gly  
 <210> 272  
 <211> 203  
 <212> PRT  
 <213> Homo sapiens  
 <400> 272  
 Met Gln Leu Gly Ser Val Leu Leu Thr Arg Cys Pro Phe Trp Gly Cys  
 1 5 10 15  
 Phe Ser Gln Leu Met Leu Tyr Ala Glu Arg Ala Glu Ala Arg Arg Lys  
 20 25 30  
 Pro Asp Ile Pro Val Pro Tyr Leu Tyr Phe Asp Met Gly Ala Ala Val  
 35 40 45  
 Leu Cys Ala Ser Phe Met Ser Phe Gly Val Lys Arg Arg Trp Phe Ala  
 50 55 60  
 Leu Gly Ala Ala Leu Gln Leu Ala Ile Ser Thr Tyr Ala Ala Tyr Ile  
 65 70 75 80  
 Gly Gly Tyr Val His Tyr Gly Asp Trp Leu Lys Val Arg Met Tyr Ser  
 85 90 95  
 Arg Thr Val Ala Ile Ile Gly Gly Phe Leu Val Leu Ala Ser Gly Ala  
 100 105 110  
 Gly Glu Leu Tyr Arg Arg Lys Pro Arg Ser Arg Ser Leu Gln Ser Thr

184

115                      120                      125  
 Gly Gln Val Phe Leu Gly Ile Tyr Leu Ile Cys Val Ala Tyr Ser Leu  
     130                      135                      140  
 Gln His Ser Lys Glu Asp Arg Leu Ala Tyr Leu Asn His Leu Pro Gly  
     145                      150                      155                      160  
 Gly Glu Leu Met Ile Gln Leu Phe Phe Val Leu Tyr Gly Ile Leu Ala  
                     165                      170                      175  
 Pro Gly Leu Ser Val Arg Leu Leu Arg Asp Pro Arg Cys Pro Asp Pro  
                     180                      185                      190  
 Gly Cys Thr Ala Ala Pro Cys His Ala Ala His  
     195                      200  
  
 <210> 273  
 <211> 407  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 273  
 Ser Asn Glu Ile Leu Leu Ser Phe Pro Gln Asn Tyr Tyr Ile Gln Trp  
     1                      5                      10                      15  
 Leu Asn Gly Ser Leu Ile His Gly Leu Trp Asn Leu Ala Ser Leu Phe  
                     20                      25                      30  
 Ser Asn Leu Cys Leu Phe Val Leu Met Pro Phe Ala Phe Phe Phe Leu  
                     35                      40                      45  
 Glu Ser Glu Gly Phe Ala Gly Leu Lys Lys Gly Ile Arg Ala Arg Ile  
     50                      55                      60  
 Leu Glu Thr Leu Val Met Leu Leu Leu Leu Ala Leu Leu Ile Leu Gly  
     65                      70                      75                      80  
 Ile Val Trp Val Ala Ser Ala Leu Ile Asp Asn Asp Ala Ala Ser Met  
                     85                      90                      95  
 Glu Ser Leu Tyr Asp Leu Trp Glu Phe Tyr Leu Pro Tyr Leu Tyr Ser  
                     100                      105                      110  
 Cys Ile Ser Leu Met Gly Cys Leu Leu Leu Leu Cys Thr Pro Val  
                     115                      120                      125  
 Gly Leu Ser Arg Met Phe Thr Val Met Gly His Leu Leu Val Lys Pro  
     130                      135                      140  
 Thr Ile Leu Glu Asp Leu Asp Glu Gln Ile Tyr Ile Ile Thr Leu Glu  
     145                      150                      155                      160  
 Glu Glu Ala Leu Gln Arg Arg Leu Asn Gly Leu Ser Ser Ser Val Glu  
                     165                      170                      175  
 Tyr Asn Ile Met Glu Leu Glu Gln Glu Leu Glu Asn Val Lys Thr Leu  
                     180                      185                      190

185

Lys Thr Lys Leu Glu Arg Arg Lys Lys Ala Ser Ala Trp Glu Arg Asn  
 195 200 205  
 Leu Val Tyr Pro Ala Val Met Val Leu Leu Leu Ile Glu Thr Ser Ile  
 210 215 220  
 Ser Val Leu Leu Val Ala Cys Asn Ile Leu Cys Leu Leu Val Asp Glu  
 225 230 235 240  
 Thr Ala Met Pro Lys Gly Thr Arg Gly Pro Gly Ile Gly Asn Ala Ser  
 245 250 255  
 Leu Ser Thr Phe Gly Phe Val Gly Ala Ala Leu Glu Ile Ile Leu Ile  
 260 265 270  
 Phe Tyr Leu Met Val Ser Ser Val Val Gly Phe Tyr Ser Leu Arg Phe  
 275 280 285  
 Phe Gly Asn Phe Thr Pro Lys Lys Asp Asp Thr Thr Met Thr Lys Ile  
 290 295 300  
 Ile Gly Asn Cys Val Ser Ile Leu Val Leu Ser Ser Ala Leu Pro Val  
 305 310 315 320  
 Met Ser Arg Thr Leu Gly Ile Thr Arg Phe Asp Leu Leu Gly Asp Phe  
 325 330 335  
 Gly Arg Phe Asn Trp Leu Gly Asn Phe Tyr Ile Val Leu Ser Tyr Asn  
 340 345 350  
 Leu Leu Phe Ala Ile Val Thr Thr Leu Cys Leu Val Arg Lys Phe Thr  
 355 360 365  
 Ser Ala Val Arg Glu Glu Leu Phe Lys Ala Leu Gly Leu His Lys Leu  
 370 375 380  
 His Leu Pro Asn Thr Ser Arg Asp Ser Glu Thr Ala Lys Pro Ser Val  
 385 390 395 400  
 Asn Gly His Gln Lys Ala Leu  
 405

&lt;210&gt; 274

&lt;211&gt; 165

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 274

Arg Ser Tyr Met Gln Ser Val Trp Thr Glu Glu Ser Gln Cys Thr Leu  
 1 5 10 15  
 Leu Asn Ala Ser Ile Thr Glu Thr Phe Asn Cys Ser Phe Ser Cys Gly  
 20 25 30  
 Pro Asp Cys Trp Lys Leu Ser Gln Tyr Pro Cys Leu Gln Val Tyr Val  
 35 40 45

186

Asn Leu Thr Ser Ser Gly Glu Lys Leu Leu Leu Tyr His Thr Glu Glu  
 50 55 60  
 Thr Ile Lys Ile Asn Gln Lys Cys Ser Tyr Ile Pro Lys Cys Gly Lys  
 65 70 75 80  
 Asn Phe Glu Glu Ser Met Ser Leu Val Asn Val Val Met Glu Asn Phe  
 85 90 95  
 Arg Lys Tyr Gln His Phe Ser Cys Tyr Ser Asp Pro Glu Gly Asn Gln  
 100 105 110  
 Lys Ser Val Ile Leu Thr Lys Leu Tyr Ser Ser Asn Val Leu Phe His  
 115 120 125  
 Ser Leu Phe Trp Pro Thr Cys Met Met Ala Gly Gly Val Ala Ile Val  
 130 135 140  
 Ala Met Val Lys Leu Thr Gln Tyr Leu Ser Leu Leu Cys Glu Arg Ile  
 145 150 155 160  
 Gln Arg Ile Asn Arg  
 165

&lt;210&gt; 275

&lt;211&gt; 155

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 275

Ala Phe Ala His Leu Gln Leu Gly Pro Met Trp Lys Leu Trp Arg Ala  
 1 5 10 15  
 Glu Glu Gly Ala Ala Ala Leu Gly Gly Ala Leu Phe Leu Leu Leu Phe  
 20 25 30  
 Ala Leu Gly Val Arg Gln Leu Leu Lys Gln Arg Arg Pro Met Gly Phe  
 35 40 45  
 Pro Pro Gly Pro Pro Gly Leu Pro Phe Ile Gly Asn Ile Tyr Ser Leu  
 50 55 60  
 Ala Ala Ser Ser Glu Leu Pro His Val Tyr Met Arg Lys Gln Ser Gln  
 65 70 75 80  
 Val Tyr Gly Glu Val Gln Pro Arg Arg Ala Pro Gly Arg Glu Gly Arg  
 85 90 95  
 Gln Ala Gly Pro Gly Trp Pro Gly Pro Ser Trp Leu Asp Leu Trp Pro  
 100 105 110  
 Pro Leu Gly Arg Leu Val Gly Thr Ser Pro Cys Ala Gly Cys Pro Leu  
 115 120 125  
 Arg Asp Thr Arg Phe Pro Gly Leu Glu Gly Arg Ser Pro Arg Arg Arg  
 130 135 140  
 Ala Pro Leu Gln Gly Glu Pro Arg Pro Cys Arg

187

145

150

155

&lt;210&gt; 276

&lt;211&gt; 42

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 276

Met Arg Val Arg Ile Gly Leu Thr Leu Leu Leu Cys Ala Val Leu Leu  
 1 5 10 15

Ser Leu Ala Ser Ala Ser Ser Asp Glu Glu Gly Ser Gln Asp Glu Ser  
 20 25 30

Leu Gly Phe Gln Asp Tyr Phe Asp Ile Arg  
 35 40

&lt;210&gt; 277

&lt;211&gt; 155

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 277

Met Ala Arg Gly Ser Leu Arg Arg Leu Leu Arg Leu Leu Val Leu Gly  
 1 5 10 15

Leu Trp Leu Ala Leu Leu Arg Ser Val Ala Gly Glu Gln Ala Pro Gly  
 20 25 30

Thr Ala Pro Cys Ser Arg Gly Ser Ser Trp Ser Ala Asp Leu Asp Lys  
 35 40 45

Cys Met Asp Cys Ser Thr Ser Cys Pro Leu Pro Ala Ala Leu Ala His  
 50 55 60

Pro Trp Gly Arg Ser Glu Pro Asp Leu Arg Ala Gly Ala Ala Phe Trp  
 65 70 75 80

Leu Phe Gly Leu Glu Thr Met Pro Gln Glu Arg Glu Val His His Pro  
 85 90 95

His Arg Gly Asp Arg Arg Arg Gly Leu Pro Ser Cys Gly Ala Asp Pro  
 100 105 110

Val Thr Met Cys Pro Leu Pro Ala Gly Ala Arg Pro Leu Ile Ile His  
 115 120 125

Ser Ser Ile Leu Glu Pro Val Ser Ala Ser Gln Thr Arg Arg Glu Pro  
 130 135 140

Ser Ser Ser Asn His Lys Gly Gly Gly Gly Arg  
 145 150 155

&lt;210&gt; 278

&lt;211&gt; 207

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 278

Gly Thr Ser Phe Leu Asp Pro Thr Leu Ser Leu Phe Val Leu Glu Lys  
1 5 10 15  
Phe Asn Leu Pro Ala Gly Tyr Val Gly Leu Val Phe Leu Gly Met Ala  
20 25 30  
Leu Ser Tyr Ala Ile Ser Ser Pro Leu Phe Gly Leu Leu Ser Asp Lys  
35 40 45  
Arg Pro Pro Leu Arg Lys Trp Leu Leu Val Phe Gly Asn Leu Ile Thr  
50 55 60  
Ala Gly Cys Tyr Met Leu Leu Gly Pro Val Pro Ile Leu His Ile Lys  
65 70 75 80  
Ser Gln Leu Trp Leu Leu Val Leu Ile Leu Val Val Ser Gly Leu Ser  
85 90 95  
Ala Gly Met Ser Ile Ile Pro Thr Phe Pro Glu Ile Leu Ser Cys Ala  
100 105 110  
His Glu Asn Gly Phe Glu Glu Gly Leu Ser Thr Leu Gly Leu Val Ser  
115 120 125  
Gly Leu Phe Ser Ala Met Trp Ser Ile Gly Ala Phe Met Gly Pro Thr  
130 135 140  
Leu Gly Gly Phe Leu Tyr Glu Lys Ile Gly Phe Glu Trp Ala Ala Ala  
145 150 155 160  
Ile Gln Gly Leu Trp Ala Leu Ile Ser Gly Leu Ala Met Gly Leu Phe  
165 170 175  
Tyr Leu Leu Glu Tyr Ser Arg Arg Lys Arg Ser Lys Ser Gln Asn Ile  
180 185 190  
Leu Ser Thr Glu Glu Glu Arg Thr Thr Leu Leu Pro Asn Glu Thr  
195 200 205

&lt;210&gt; 279

&lt;211&gt; 85

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 279

Gly Thr Arg Glu Ala Arg Leu Arg Asp Leu Thr Arg Phe Tyr Asp Lys  
1 5 10 15  
Val Leu Ser Leu His Glu Asp Ser Thr Thr Pro Val Ala Asn Pro Leu  
20 25 30  
Leu Ala Phe Thr Leu Ile Lys Arg Leu Gln Ser Asp Trp Arg Asn Val  
35 40 45  
Val His Ser Leu Glu Ala Ser Glu Asn Ile Arg Ala Leu Lys Asp Gly



50                      55                      60  
 Tyr Glu Lys Val Glu Gln Asp Leu Pro Ala Phe Glu Asp Leu Glu Gly  
 65                      70                      75                      80  
 Ala Ala Arg Ala Leu  
 85  
  
 <210> 280  
 <211> 7  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 280  
 Ala Leu Met Arg Leu Gln Asp  
 1                      5  
  
 <210> 281  
 <211> 7  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 281  
 Val Glu Ala Gly Gly Ala Thr  
 1                      5  
  
 <210> 282  
 <211> 489  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 282  
 Gly Thr Arg Glu Ala Arg Leu Arg Asp Leu Thr Arg Phe Tyr Asp Lys  
 1                      5                      10                      15  
 Val Leu Ser Leu His Glu Asp Ser Thr Thr Pro Val Ala Asn Pro Leu  
 20                      25                      30  
 Leu Ala Phe Thr Leu Ile Lys Arg Leu Gln Ser Asp Trp Arg Asn Val  
 35                      40                      45  
 Val His Ser Leu Glu Ala Ser Glu Asn Ile Arg Ala Leu Lys Asp Gly  
 50                      55                      60  
 Tyr Glu Lys Val Glu Gln Asp Leu Pro Ala Phe Glu Asp Leu Glu Gly  
 65                      70                      75                      80  
 Ala Ala Arg Ala Leu Met Arg Leu Gln Asp Val Tyr Met Leu Asn Val  
 85                      90                      95  
 Lys Gly Leu Ala Arg Gly Val Phe Gln Arg Val Thr Gly Ser Ala Ile  
 100                      105                      110  
 Thr Asp Leu Tyr Ser Pro Lys Arg Leu Phe Ser Leu Thr Gly Asp Asp  
 115                      120                      125

Cys Phe Gln Val Gly Lys Val Ala Tyr Asp Met Gly Asp Tyr Tyr His  
 130 135 140  
 Ala Ile Pro Trp Leu Glu Glu Ala Val Ser Leu Phe Arg Gly Ser Tyr  
 145 150 155 160  
 Gly Glu Trp Lys Thr Glu Asp Glu Ala Ser Leu Glu Asp Ala Leu Asp  
 165 170 175  
 His Leu Ala Phe Ala Tyr Phe Arg Ala Gly Asn Val Ser Cys Ala Leu  
 180 185 190  
 Ser Leu Ser Arg Glu Phe Leu Leu Tyr Ser Pro Asp Asn Lys Arg Met  
 195 200 205  
 Ala Arg Asn Val Leu Lys Tyr Glu Arg Leu Leu Ala Glu Ser Pro Asn  
 210 215 220  
 His Val Val Ala Glu Ala Val Ile Gln Arg Pro Asn Ile Pro His Leu  
 225 230 235 240  
 Gln Thr Arg Asp Thr Tyr Glu Gly Leu Cys Gln Thr Leu Gly Ser Gln  
 245 250 255  
 Pro Thr Leu Tyr Gln Ile Pro Ser Leu Tyr Cys Ser Tyr Glu Thr Asn  
 260 265 270  
 Ser Asn Ala Tyr Leu Leu Leu Gln Pro Ile Arg Lys Glu Val Ile His  
 275 280 285  
 Leu Glu Pro Tyr Ile Ala Leu Tyr His Asp Phe Val Ser Asp Ser Glu  
 290 295 300  
 Ala Gln Lys Ile Arg Glu Leu Ala Glu Pro Trp Leu Gln Arg Ser Val  
 305 310 315 320  
 Val Ala Ser Gly Glu Lys Gln Leu Gln Val Glu Tyr Arg Ile Ser Lys  
 325 330 335  
 Ser Ala Trp Leu Lys Asp Thr Val Asp Leu Lys Leu Val Thr Leu Asn  
 340 345 350  
 His Arg Ile Ala Ala Leu Thr Gly Leu Asp Val Arg Pro Pro Tyr Ala  
 355 360 365  
 Glu Tyr Leu Gln Val Val Asn Tyr Gly Ile Gly Gly His Tyr Glu Pro  
 370 375 380  
 His Phe Asp His Ala Thr Ser Pro Ser Ser Pro Leu Tyr Arg Met Lys  
 385 390 395 400  
 Ser Gly Asn Arg Val Ala Thr Phe Met Ile Tyr Leu Ser Ser Val Glu  
 405 410 415  
 Ala Gly Gly Ala Thr Ala Phe Ile Tyr Ala Asn Leu Ser Val Pro Val  
 420 425 430  
 Val Arg Asn Ala Ala Leu Phe Trp Trp Asn Leu His Arg Ser Gly Glu  
 435 440 445

Gly Asp Ser Asp Thr Leu His Ala Gly Cys Pro Val Leu Val Gly Asp  
 450 455 460

Lys Trp Val Ala Asn Lys Trp Ile His Glu Tyr Gly Gln Glu Phe Arg  
 465 470 475 480

Arg Pro Cys Ser Ser Ser Pro Glu Asp  
 485

<210> 283

<211> 136

<212> PRT

<213> Homo sapiens

<400> 283

Ile Gln Pro Ser His Ala Ala Leu Leu His Cys Arg Ser Thr Phe Arg  
 1 5 10 15

Lys Thr Glu Cys Leu Asp Pro Trp Trp Val Arg Arg Gln Leu Leu Gly  
 20 25 30

Met Ala Gly Ile Gly Gly Leu Gln Lys Met Lys Ala Pro His Thr Gly  
 35 40 45

Val Leu His Leu Gly Ser Val Trp Val Phe Leu Gly Pro Phe Leu Leu  
 50 55 60

Gly Val Gly Tyr Thr Leu Thr Phe Asn Pro Leu Ser Gly Cys Met Ser  
 65 70 75 80

Thr Val Arg Trp Leu Asn Ser Asn Ile Thr Ala Asn Arg Thr Leu Ser  
 85 90 95

Arg Ser Val Cys His Val Thr Pro Leu His Arg Ser Leu Ser Pro His  
 100 105 110

Asp Gly Glu Tyr Leu Arg Gln Met Leu Leu Asn Ser Ser Ser Arg Ala  
 115 120 125

Gly Glu Ala Gly Ser Trp Gly Tyr  
 130 135

<210> 284

<211> 86

<212> PRT

<213> Homo sapiens

<400> 284

Cys Ser Ser Pro Pro Gly Arg Leu Pro Trp Cys Trp Thr Ala Pro Arg  
 1 5 10 15

Thr Leu Gly Lys His Gly Ser Leu Ile Ser Thr Leu Arg Leu Thr Ala  
 20 25 30

Pro Leu His Leu Ala Trp Lys Met Met Leu Ser Arg Lys Ala Leu Phe  
 35 40 45

Val Leu Leu Asn Thr Pro Val Leu Phe His Ala Leu Glu Gly Arg Leu  
 50 55 60  
 Phe Ser Lys Leu Cys His His His Thr Ile Gln Arg Thr Leu Thr Val  
 65 70 75 80  
 Pro Lys Phe Arg Ser Ser  
 85

<210> 285  
 <211> 75  
 <212> PRT  
 <213> Homo sapiens

<400> 285  
 Arg Ser Pro Thr Ser Arg Val Gln Leu Leu Lys Arg Gln Ser Cys Pro  
 1 5 10 15  
 Cys Gln Arg Asn Asp Leu Asn Glu Glu Pro Gln His Phe Thr His Tyr  
 20 25 30  
 Ala Ile Tyr Asp Phe Ile Val Lys Gly Ser Cys Phe Cys Asn Gly His  
 35 40 45  
 Ala Asp Gln Cys Ile Pro Val His Gly Phe Arg Pro Val Lys Ala Pro  
 50 55 60  
 Gly Thr Phe His Met Val His Gly Lys Cys Met  
 65 70 75

<210> 286  
 <211> 296  
 <212> PRT  
 <213> Homo sapiens

<400> 286  
 His Asn Thr Ala Gly Ser His Cys Gln His Cys Ala Pro Leu Tyr Asn  
 1 5 10 15  
 Asp Arg Pro Trp Glu Ala Ala Asp Gly Lys Thr Gly Ala Pro Asn Glu  
 20 25 30  
 Cys Arg Thr Cys Lys Cys Asn Gly His Ala Asp Thr Cys His Phe Asp  
 35 40 45  
 Val Asn Val Trp Glu Ala Ser Gly Asn Arg Ser Gly Gly Val Cys Asp  
 50 55 60  
 Asp Cys Gln His Asn Thr Glu Gly Gln Tyr Cys Gln Arg Cys Lys Pro  
 65 70 75 80  
 Gly Phe Tyr Arg Asp Leu Arg Arg Pro Phe Ser Ala Pro Asp Ala Cys  
 85 90 95  
 Lys Pro Cys Ser Cys His Pro Val Gly Ser Ala Val Leu Pro Ala Asn  
 100 105 110

Ser Val Thr Phe Cys Asp Pro Ser Asn Gly Asp Cys Pro Cys Lys Pro  
 115 120 125  
 Gly Val Ala Gly Arg Arg Cys Asp Arg Cys Met Val Gly Tyr Trp Gly  
 130 135 140  
 Phe Gly Asp Tyr Gly Cys Arg Pro Cys Asp Cys Ala Gly Ser Cys Asp  
 145 150 155 160  
 Pro Ile Thr Gly Asp Cys Ile Ser Ser His Thr Asp Ile Asp Trp Tyr  
 165 170 175  
 His Glu Val Pro Asp Phe Arg Pro Val His Asn Lys Ser Glu Pro Ala  
 180 185 190  
 Trp Glu Trp Glu Asp Ala Gln Gly Phe Ser Ala Leu Leu His Ser Gly  
 195 200 205  
 Lys Cys Glu Cys Lys Glu Gln Thr Leu Gly Asn Ala Lys Ala Phe Cys  
 210 215 220  
 Gly Met Lys Tyr Ser Tyr Val Leu Lys Ile Lys Ile Leu Ser Ala His  
 225 230 235 240  
 Asp Lys Gly Thr His Val Glu Val Asn Val Lys Ile Lys Lys Val Leu  
 245 250 255  
 Lys Ser Thr Lys Leu Lys Ile Phe Arg Gly Lys Ala Asn Ile Ile Ser  
 260 265 270  
 Arg Ile Met Asp Gly Gln Arg Met His Leu Ser Asn Pro Gln Ser Trp  
 275 280 285  
 Phe Gly Ile Pro Cys Ser Arg Thr  
 290 295

&lt;210&gt; 287

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 287

Cys Asp Asp Cys Gln His Asn Thr Glu Gly Gln Tyr Cys Gln Arg Cys  
 1 5 10 15

Lys Pro Gly Phe Tyr Arg Asp Leu Arg Arg Pro Phe Ser Ala Pro Asp  
 20 25 30

Ala Cys Lys Pro Cys  
 35

&lt;210&gt; 288

&lt;211&gt; 36

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 288

Cys Pro Cys Lys Pro Gly Val Ala Gly Arg Arg Cys Asp Arg Cys Met  
 1 5 10 15

Val Gly Tyr Trp Gly Phe Gly Asp Tyr Gly Cys Arg Pro Cys Asp Cys  
 20 25 30

Ala Gly Ser Cys  
 35

&lt;210&gt; 289

&lt;211&gt; 66

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 289

Asn Ile Ser Ser Gln Tyr Cys Ile Leu Lys Ser Leu Glu Met Met Ile  
 1 5 10 15

Ser Gly Leu Lys Leu Leu Val Leu Phe Leu Lys Phe Ala Pro Glu Asn  
 20 25 30

Tyr Cys Leu Ser Thr Glu Thr Leu Gln Met Pro Asn Arg His Leu Arg  
 35 40 45

Leu Ser Lys Ala Thr Cys Tyr Leu Met Lys Cys Leu Leu Pro Ser Tyr  
 50 55 60

Phe Glu  
 65

&lt;210&gt; 290

&lt;211&gt; 88

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 290

Pro Ile Glu Gly Thr Pro Ala Gly Thr Gly Pro Glu Phe Pro Gly Arg  
 1 5 10 15

Pro Thr Arg Pro Gln Arg Met Arg Ser Leu Ile Ser Ser His Pro Cys  
 20 25 30

Gln His Leu Leu Leu Leu Leu Leu Leu Phe Leu Ile Leu Ala Ile  
 35 40 45

Leu Val Asp Val Lys Trp Tyr Leu Val Leu Phe Ile Cys Ile Ser Leu  
 50 55 60

Met Thr Ser Asp Val Glu His Leu Phe Met Cys Leu Leu Ala Ile Arg  
 65 70 75 80

Ile Ser Ser Trp Arg Asn Val Tyr  
 85

&lt;210&gt; 291

<211> 60  
<212> PRT  
<213> Homo sapiens

<400> 291  
Asn Trp Val Pro Thr Cys Leu Cys Pro Ser Ala Pro Cys Ser Phe His  
1 5 10 15  
Leu Leu Ser Arg Phe Lys Cys Leu Phe Ser Pro Gln Arg Leu Thr Asp  
20 25 30  
Ile Phe Arg Arg Tyr Asp Thr Asp Gln Asp Gly Trp Ile Gln Val Ser  
35 40 45  
Tyr Glu Gln Tyr Leu Ser Met Val Phe Ser Ile Val  
50 55 60

<210> 292  
<211> 33  
<212> PRT  
<213> Homo sapiens

<400> 292  
Gln Arg Leu Thr Asp Ile Phe Arg Arg Tyr Asp Thr Asp Gln Asp Gly  
1 5 10 15  
Trp Ile Gln Val Ser Tyr Glu Gln Tyr Leu Ser Met Val Phe Ser Ile  
20 25 30  
Val

<210> 293  
<211> 73  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (38)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (48)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (54)  
<223> Xaa equals any of the naturally occurring L-amino acids

<220>  
<221> SITE  
<222> (55)  
<223> Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (68)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 293

Met Phe Tyr Lys Leu Thr Leu Ile Leu Cys Glu Leu Ser Val Ala Gly  
 1 5 10 15

Val Thr Gln Ala Ala Ser Gln Arg Pro Leu Gln Arg Leu Pro Arg His  
 20 25 30

Ile Cys Ser Gln Arg Xaa Pro Pro Gly Arg Cys Leu Leu Lys Ala Xaa  
 35 40 45

Leu Gln Thr Thr Trp Xaa Xaa Pro Asp Lys Pro Ile Pro Arg Leu Ser  
 50 55 60

Pro Pro Leu Xaa Ser Asp Pro Lys Arg  
 65 70

&lt;210&gt; 294

&lt;211&gt; 95

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 294

Thr Ser Ser Pro Val Phe Ser Phe Cys Ser Met Ala Val Arg Glu Pro  
 1 5 10 15

Asp His Leu Gln Arg Val Ser Leu Pro Arg Tyr Asn Val Ser Ala Ser  
 20 25 30

Leu Gln Trp Leu Pro Cys His Arg Ile Val Leu Gln Pro Trp His Met  
 35 40 45

Cys Ala Met Trp Glu Leu Gly Gln Val Leu Phe His Pro Val Ala Pro  
 50 55 60

Arg Glu Gly Ala Ala Pro Ser Pro Val Ser Thr Leu Thr Trp Pro Ser  
 65 70 75 80

Ser Cys Ser His Ser Glu Ser Thr Met Glu Leu Glu Leu Gln Phe  
 85 90 95

&lt;210&gt; 295

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 295

Met Ala Val Arg Glu Pro Asp His Leu Gln Arg Val Ser Leu Pro Arg  
 1 5 10 15



<210> 296  
 <211> 7  
 <212> PRT  
 <213> Homo sapiens

<400> 296  
 Leu Pro Cys His Arg Ile Val  
 1 5

<210> 297  
 <211> 15  
 <212> PRT  
 <213> Homo sapiens

<400> 297  
 Ser Leu Gln Trp Leu Pro Cys His Arg Ile Val Leu Gln Pro Trp  
 1 5 10 15

<210> 298  
 <211> 454  
 <212> PRT  
 <213> Homo sapiens

<400> 298  
 Cys Phe Lys Arg Lys Pro Lys Arg Glu His Cys Ser Cys Pro Ile Thr  
 1 5 10 15  
 Tyr Gln Ser Leu Gly Asp Ile Leu Asn Ala Ser Phe Phe Ser Lys Arg  
 20 25 30  
 Lys Gly Met Gln Glu Val Lys Leu Asn Ser Tyr Val Val Ser Gly Thr  
 35 40 45  
 Ile Gly Leu Lys Glu Lys Ile Ser Leu Ser Glu Pro Val Phe Leu Thr  
 50 55 60  
 Phe Arg His Asn Gln Pro Gly Asp Lys Arg Thr Lys His Ile Cys Val  
 65 70 75 80  
 Tyr Trp Glu Gly Ser Glu Gly Gly Arg Trp Ser Thr Glu Gly Cys Ser  
 85 90 95  
 His Val His Ser Asn Gly Ser Tyr Thr Lys Cys Lys Cys Phe His Leu  
 100 105 110  
 Ser Ser Phe Ala Val Leu Val Ala Leu Ala Pro Lys Glu Asp Pro Val  
 115 120 125  
 Leu Thr Val Ile Thr Gln Val Gly Leu Thr Ile Ser Leu Leu Cys Leu  
 130 135 140  
 Phe Leu Ala Ile Leu Thr Phe Leu Leu Cys Arg Pro Ile Gln Asn Thr  
 145 150 155 160  
 Ser Thr Ser Leu His Leu Glu Leu Ser Leu Cys Leu Phe Leu Ala His  
 165 170 175

Leu Leu Phe Leu Thr Gly Ile Asn Arg Thr Glu Pro Glu Val Leu Cys  
 180 185 190  
 Ser Ile Ile Ala Gly Leu Leu His Phe Leu Tyr Leu Ala Cys Phe Thr  
 195 200 205  
 Trp Met Leu Leu Glu Gly Leu His Leu Phe Leu Thr Val Arg Asn Leu  
 210 215 220  
 Lys Val Ala Asn Tyr Thr Ser Thr Gly Arg Phe Lys Lys Arg Phe Met  
 225 230 235 240  
 Tyr Pro Val Gly Tyr Gly Ile Pro Ala Val Ile Ile Ala Val Ser Ala  
 245 250 255  
 Ile Val Gly Pro Gln Asn Tyr Gly Thr Phe Thr His Cys Trp Leu Lys  
 260 265 270  
 Leu Asp Lys Gly Phe Ile Trp Ser Phe Met Gly Pro Val Ala Val Ile  
 275 280 285  
 Ile Leu Ile Asn Leu Val Phe Tyr Phe Gln Val Leu Trp Ile Leu Arg  
 290 295 300  
 Ser Lys Leu Ser Ser Leu Asn Lys Glu Val Ser Thr Ile Gln Asp Thr  
 305 310 315 320  
 Arg Val Met Thr Phe Lys Ala Ile Ser Gln Leu Phe Ile Leu Gly Cys  
 325 330 335  
 Ser Trp Gly Leu Gly Phe Phe Met Val Glu Glu Val Gly Lys Thr Ile  
 340 345 350  
 Gly Ser Ile Ile Ala Tyr Ser Phe Thr Ile Ile Asn Thr Leu Gln Gly  
 355 360 365  
 Val Leu Leu Phe Val Val His Cys Leu Leu Asn Arg Gln Val Arg Met  
 370 375 380  
 Glu Tyr Lys Lys Trp Phe Ser Gly Met Arg Lys Gly Val Glu Thr Glu  
 385 390 395 400  
 Ser Thr Glu Met Ser Arg Ser Thr Thr Gln Thr Lys Thr Glu Glu Val  
 405 410 415  
 Gly Lys Ser Ser Glu Ile Phe His Lys Gly Gly Thr Ala Ser Ser Ser  
 420 425 430  
 Ala Glu Ser Thr Lys Gln Pro Gln Pro Gln Val His Leu Val Ser Ala  
 435 440 445  
 Ala Trp Leu Lys Met Asn  
 450

&lt;210&gt; 299

&lt;211&gt; 101

&lt;212&gt; PRT

<213> Homo sapiens

<400> 299

```

Phe Phe Trp Lys Glu Asn Leu Arg Arg Asn Gly Ser Arg Glu Asp Phe
 1           5           10           15

Ala Arg Arg Ala Thr Gln Leu Ile Gln Ser Val Glu Leu Ser Ile Trp
      20           25           30

Asn Ala Ser Phe Ala Ser Pro Gly Lys Gly Gln Ile Ser Glu Phe Asp
      35           40           45

Ile Val Tyr Glu Thr Lys Arg Cys Asn Glu Thr Arg Glu Asn Ala Phe
      50           55           60

Leu Glu Ala Gly Asn Asn Thr Met Asp Ile Asn Cys Ala Asp Ala Leu
      65           70           75           80

Lys Gly Asn Leu Arg Glu Ser Thr Ala Val Ala Leu Ser Leu Ile Asn
      85           90           95

Leu Leu Gly Ile Phe
      100

```

<210> 300

<211> 27

<212> PRT

<213> Homo sapiens

<400> 300

```

Asp Ile Asn Glu Cys Glu Thr Gly Leu Ala Lys Cys Lys Tyr Lys Ala
 1           5           10           15

Tyr Cys Arg Asn Lys Val Gly Gly Tyr Ile Cys
      20           25

```

<210> 301

<211> 12

<212> PRT

<213> Homo sapiens

<400> 301

```

Cys Arg Asn Lys Val Gly Gly Tyr Ile Cys Ser Cys
 1           5           10

```

<210> 302

<211> 331

<212> PRT

<213> Homo sapiens

<400> 302

```

Ala Leu Cys Pro His Pro His Leu Ile Leu Asn Val Thr Val Ser Pro
 1           5           10           15

Ala Pro Ser Cys Arg His Val Lys Lys Val Val Ala Ser Pro Ser Pro
      20           25           30

```

Ser Thr Thr Met Ile Ala Met Asp Ala Pro His Ser Lys Ala Ala Leu  
 35 40 45  
 Asp Ser Ile Asn Glu Leu Pro Glu Asn Ile Leu Leu Glu Leu Phe Thr  
 50 55 60  
 His Val Pro Ala Arg Gln Leu Leu Leu Asn Cys Arg Leu Val Cys Ser  
 65 70 75 80  
 Leu Trp Arg Asp Leu Ile Asp Leu Met Thr Leu Trp Lys Arg Lys Cys  
 85 90 95  
 Leu Arg Glu Gly Phe Ile Thr Lys Asp Trp Asp Gln Pro Val Ala Asp  
 100 105 110  
 Trp Lys Ile Phe Tyr Phe Leu Arg Ser Leu His Arg Asn Leu Leu Arg  
 115 120 125  
 Asn Pro Cys Ala Glu Glu Asp Met Phe Ala Trp Gln Ile Asp Phe Asn  
 130 135 140  
 Gly Gly Asp Arg Trp Lys Val Glu Ser Leu Pro Gly Ala His Gly Thr  
 145 150 155 160  
 Asp Phe Pro Asp Pro Lys Val Lys Lys Tyr Phe Val Thr Ser Tyr Glu  
 165 170 175  
 Met Cys Leu Lys Ser Gln Leu Val Asp Leu Val Ala Glu Gly Tyr Trp  
 180 185 190  
 Glu Glu Leu Asp Thr Phe Arg Pro Asp Ile Val Val Lys Asp Trp  
 195 200 205  
 Phe Ala Ala Arg Ala Asp Cys Gly Cys Thr Tyr Gln Leu Lys Val Gln  
 210 215 220  
 Leu Ala Ser Ala Asp Tyr Phe Val Leu Ala Ser Phe Glu Pro Pro Pro  
 225 230 235 240  
 Val Thr Ile Gln Gln Trp Asn Asn Ala Thr Trp Thr Glu Val Ser Tyr  
 245 250 255  
 Thr Phe Ser Asp Tyr Pro Arg Gly Val Arg Tyr Ile Leu Phe Gln His  
 260 265 270  
 Gly Gly Arg Asp Thr Gln Tyr Trp Ala Gly Trp Tyr Gly Pro Arg Val  
 275 280 285  
 Thr Asn Ser Ser Ile Val Val Ser Pro Lys Met Thr Arg Asn Gln Ala  
 290 295 300  
 Ser Ser Glu Ala Gln Pro Gly Gln Lys His Gly Gln Glu Glu Ala Ala  
 305 310 315 320  
 Gln Ser Pro Tyr Arg Ala Val Val Gln Ile Phe  
 325 330

201

&lt;210&gt; 303

&lt;211&gt; 328

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 303

Arg Gln Arg Ser Trp Asn Pro Gly Thr Asn Cys Tyr His Pro Asn Met  
 1 5 10 15

Pro Asp Ala Phe Leu Thr Cys Glu Thr Val Ile Phe Ala Trp Ala Ile  
 20 25 30

Gly Gly Glu Gly Phe Ser Tyr Pro Pro His Val Gly Leu Ser Leu Gly  
 35 40 45

Thr Pro Leu Asp Pro His Tyr Val Leu Leu Glu Val His Tyr Asp Asn  
 50 55 60

Pro Thr Tyr Glu Glu Gly Leu Ile Asp Asn Ser Gly Leu Arg Leu Phe  
 65 70 75 80

Tyr Thr Met Asp Ile Arg Lys Tyr Asp Ala Gly Val Ile Glu Ala Gly  
 85 90 95

Leu Trp Val Ser Leu Phe His Thr Ile Pro Pro Gly Met Pro Glu Phe  
 100 105 110

Gln Ser Glu Gly His Cys Thr Leu Glu Cys Leu Glu Glu Ala Leu Glu  
 115 120 125

Ala Glu Lys Pro Ser Gly Ile His Val Phe Ala Val Leu Leu His Ala  
 130 135 140

His Leu Ala Gly Arg Gly Ile Arg Leu Arg His Phe Arg Lys Gly Lys  
 145 150 155 160

Glu Met Lys Leu Leu Ala Tyr Asp Asp Asp Phe Asp Phe Asn Phe Gln  
 165 170 175

Glu Phe Gln Tyr Leu Lys Glu Glu Gln Thr Ile Leu Pro Gly Asp Asn  
 180 185 190

Leu Ile Thr Glu Cys Arg Tyr Asn Thr Lys Asp Arg Ala Glu Met Thr  
 195 200 205

Trp Gly Gly Leu Ser Thr Arg Ser Glu Met Cys Leu Ser Tyr Leu Leu  
 210 215 220

Tyr Tyr Pro Arg Ile Asn Leu Thr Arg Cys Ala Ser Ile Pro Asp Ile  
 225 230 235 240

Met Glu Gln Leu Gln Phe Ile Gly Val Lys Glu Ile Tyr Arg Pro Val  
 245 250 255

Thr Thr Trp Pro Phe Ile Ile Lys Ser Pro Lys Gln Tyr Lys Asn Leu  
 260 265 270

Ser Phe Met Asp Ala Met Asn Lys Phe Lys Trp Thr Lys Lys Glu Gly  
 275 280 285

Leu Ser Phe Asn Lys Leu Val Leu Ser Leu Pro Val Asn Val Arg Cys  
 290 295 300

Ser Lys Thr Asp Asn Ala Glu Trp Ser Ile Pro Arg Asn Asp Ser Ile  
 305 310 315 320

Thr Ser Arg Tyr Arg Lys Thr Leu  
 325

<210> 304

<211> 272

<212> PRT

<213> Homo sapiens

<400> 304

Met Cys Cys Trp Pro Leu Leu Leu Leu Trp Gly Leu Leu Pro Gly Thr  
 1 5 10 15

Ala Ala Gly Gly Ser Gly Arg Thr Tyr Pro His Arg Thr Leu Leu Asp  
 20 25 30

Ser Glu Gly Lys Tyr Trp Leu Gly Trp Ser Gln Arg Gly Ser Gln Ile  
 35 40 45

Ala Phe Arg Leu Gln Val Arg Thr Ala Gly Tyr Val Gly Phe Gly Phe  
 50 55 60

Ser Pro Thr Gly Ala Met Ala Ser Ala Asp Ile Val Val Gly Gly Val  
 65 70 75 80

Ala His Gly Arg Pro Tyr Leu Gln Asp Tyr Phe Thr Asn Ala Asn Arg  
 85 90 95

Glu Leu Lys Lys Asp Ala Gln Gln Asp Tyr His Leu Glu Tyr Ala Met  
 100 105 110

Glu Asn Ser Thr His Thr Ile Ile Glu Phe Thr Arg Glu Leu His Thr  
 115 120 125

Cys Asp Ile Asn Asp Lys Ser Ile Thr Asp Ser Thr Val Arg Val Ile  
 130 135 140

Trp Ala Tyr His His Glu Asp Ala Gly Glu Ala Gly Pro Lys Tyr His  
 145 150 155 160

Asp Ser Asn Arg Gly Thr Lys Ser Leu Arg Leu Leu Asn Pro Glu Lys  
 165 170 175

Thr Ser Val Leu Ser Thr Ala Leu Pro Tyr Phe Asp Leu Val Asn Gln  
 180 185 190

Asp Val Pro Ile Pro Asn Lys Asp Thr Thr Tyr Trp Cys Gln Met Phe  
 195 200 205

Lys Ile Pro Val Phe Gln Glu Lys His His Val Ile Lys Val Glu Pro  
 210 215 220

Val Ile Gln Arg Gly His Glu Ser Leu Val His His Ile Leu Leu Tyr  
 225 230 235 240

Gln Cys Ser Asn Asn Phe Asn Asp Ser Val Pro Gly Ile Arg Ala Arg  
 245 250 255

Ile Ala Ile Thr Pro Thr Cys Pro Met His Ser Ser Pro Val Lys Leu  
 260 265 270

<210> 305

<211> 207

<212> PRT

<213> Homo sapiens

<400> 305

Thr Gly Thr Phe Trp Ser Pro Arg Ser Gln Arg Arg Gly Cys Cys Gly  
 1 5 10 15

Arg Arg Ala Pro Arg Pro Glu Ala Met Glu Asn Gly Ala Val Tyr Ser  
 20 25 30

Pro Thr Thr Glu Glu Asp Pro Gly Pro Ala Arg Gly Pro Arg Ser Gly  
 35 40 45

Leu Ala Ala Tyr Phe Phe Met Gly Arg Leu Pro Leu Leu Arg Arg Val  
 50 55 60

Leu Lys Gly Leu Gln Leu Leu Ser Leu Leu Ala Phe Ile Cys Glu  
 65 70 75 80

Glu Val Val Ser Gln Cys Thr Leu Cys Gly Gly Leu Tyr Phe Phe Glu  
 85 90 95

Phe Val Ser Cys Ser Ala Phe Leu Leu Ser Leu Leu Ile Leu Ile Val  
 100 105 110

Tyr Cys Thr Pro Phe Tyr Glu Arg Val Asp Thr Thr Lys Val Lys Ser  
 115 120 125

Ser Asp Phe Tyr Ile Thr Leu Gly Thr Gly Cys Val Phe Leu Leu Ala  
 130 135 140

Ser Ile Ile Phe Val Ser Thr His Asp Arg Thr Ser Ala Glu Ile Ala  
 145 150 155 160

Ala Ile Val Phe Gly Phe Ile Ala Ser Phe Met Phe Leu Leu Asp Phe  
 165 170 175

Ile Thr Met Leu Tyr Glu Lys Arg Gln Glu Ser Gln Leu Arg Lys Pro  
 180 185 190

Glu Asn Thr Thr Arg Ala Glu Ala Leu Thr Glu Pro Leu Asn Ala  
 195 200 205

<210> 306  
<211> 135  
<212> PRT  
<213> Homo sapiens

<400> 306  
Ala Ser Ala Pro Arg Val Met Arg Gly His Leu Ala Gly Phe Pro Ala  
1 5 10 15  
Leu Ser Gly Leu Ala Ser Val Cys Leu Trp Ala Thr Phe Ser Ala Gln  
20 25 30  
Leu Pro Gly Pro Val Ala Ala Thr Ser Trp Thr Pro Ala Pro Leu Gly  
35 40 45  
Cys Ser Ala Ala Arg Ser Gly Pro Glu Lys Arg Leu Gly Thr Ala Ala  
50 55 60  
Pro Gly Ser Ala Ala Ser Leu Ala Gln Ala Gly Pro Gly Ala Pro Cys  
65 70 75 80  
Arg Val Leu Pro Val Asp Pro Ala Pro Ala Ala Leu Asn Val Arg Glu  
85 90 95  
Pro Gly Trp Leu Gly Gly Leu Phe Asp Gly Ala Leu Leu Gln Val Leu  
100 105 110  
Leu Asn Phe Leu Arg Lys Ser Thr Asp Val Leu Met Asp Thr Arg Glu  
115 120 125  
Ala Glu Ser Leu Glu Val Glu  
130 135

<210> 307  
<211> 188  
<212> PRT  
<213> Homo sapiens

<400> 307  
Asn Lys Leu His Ser Phe Pro Val Phe Leu Ser Gln Leu Leu Leu Asp  
1 5 10 15  
Arg Gln Leu Leu His Ala Pro Gln Thr Leu Pro Thr Pro His Cys Gly  
20 25 30  
Gly Ser Ser Arg Pro Gly Pro Ser His Pro Pro Trp Leu Leu Ile Gln  
35 40 45  
Leu Pro Cys Val His Val Ala Leu Trp Gln Met Leu Arg Asp Phe Ser  
50 55 60  
Asp Ser Arg Ile Thr Pro Ser Thr Leu Thr Thr Gln Pro Ala Ala Gln  
65 70 75 80  
Thr Ala Ala Pro Ala Lys Asp Gln Glu Ser Asp Ile Val Gly Gly Glu  
85 90 95  
Gly Ile Leu Cys Asp Ile Ala Phe Leu Gln Glu Asp His Pro Leu Gly



100                      105                      110  
 Val Gly Gly Ala Ser Ala Pro Ser Ser Arg Arg Glu Leu Ser Arg Arg  
           115                      120                      125  
 Gly Val His Thr Gln Thr Leu Pro Glu Asp Gly Thr Leu His Gly Thr  
           130                      135                      140  
 Pro Ser Ser Ser Phe Asp Cys Gly Ile Lys Tyr Ile Ile Ser Trp Pro  
 145                      150                      155                      160  
 Leu Ala Pro Gly Cys Asp Leu Pro Ser Leu Glu Leu Ser Leu Val Cys  
                           165                      170                      175  
 Lys Gly Val Ser Ser Cys Met Gly Phe Ala Ala Gly  
                           180                      185

<210> 308  
 <211> 78  
 <212> PRT  
 <213> Homo sapiens

<400> 308  
 Pro Gly Arg Pro Thr Arg Pro Thr Lys Asn Lys Val Cys Val Cys Leu  
   1                      5                      10                      15  
 Gly Met Leu Phe Trp Ala Tyr Pro Ile Cys Val Phe Ile Asp Ser Leu  
                           20                      25                      30  
 Ser Cys Gln Pro Cys Leu Trp Ser Thr Gly Ala Thr Ser His Phe Asn  
                           35                      40                      45  
 Ser Pro Thr Thr Ser Pro Leu Phe Thr Leu Phe Met Pro Cys Ala Leu  
                           50                      55                      60  
 Ala Pro Asn Pro Phe Thr Gln Leu Gly Lys Leu Asp Asp Arg  
   65                      70                      75

<210> 309  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 309  
 Pro Val Asp Leu Thr Lys Thr Arg Leu Gln  
   1                      5                      10

<210> 310  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 310  
 Pro Thr Asp Val Leu Lys Ile Arg Met Gln  
   1                      5                      10

<210> 311  
 <211> 313  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (117)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 311  
 Met Thr Phe Gly Ser Thr Ile Ser Pro Thr Ser Thr His Ala Ser Pro  
     1                    5                    10                    15  
 Ser Leu Gly Phe Cys Cys Ser Trp Leu Leu Glu Asp Leu Glu Glu Gln  
             20                    25                    30  
 Leu Tyr Cys Ser Ala Phe Glu Glu Ala Ala Leu Thr Arg Arg Ile Cys  
             35                    40                    45  
 Asn Pro Thr Ser Cys Trp Leu Pro Leu Asp Met Glu Leu Leu His Arg  
     50                    55                    60  
 Gln Val Leu Ala Leu Gln Thr Gln Arg Val Leu Leu Gly Met Trp Leu  
     65                    70                    75                    80  
 Arg Arg Ala Trp Asp Thr Trp Val Ser Pro Arg Arg Val Ala Pro Gly  
             85                    90                    95  
 Ser Arg Cys Leu Leu Thr Ala Ser His Pro Cys Thr Glu Lys Arg Arg  
     100                    105                    110  
 Lys Ala Ser Ala Xaa Gln Arg Asn Leu Gly Tyr Pro Leu Ala Met Leu  
     115                    120                    125  
 Cys Leu Leu Val Leu Thr Gly Leu Ser Val Leu Ile Val Ala Ile His  
     130                    135                    140  
 Ile Leu Glu Leu Leu Ile Asp Glu Ala Ala Met Pro Arg Gly Met Gln  
     145                    150                    155                    160  
 Gly Thr Ser Leu Gly Gln Val Ser Phe Ser Lys Leu Gly Ser Phe Gly  
             165                    170                    175  
 Ala Val Ile Gln Val Val Leu Ile Phe Tyr Leu Met Val Ser Ser Val  
             180                    185                    190  
 Val Gly Phe Tyr Ser Ser Pro Leu Phe Arg Ser Leu Arg Pro Arg Trp  
     195                    200                    205  
 His Asp Thr Ala Met Thr Gln Ile Ile Gly Asn Cys Val Cys Leu Leu  
     210                    215                    220  
 Val Leu Ser Ser Ala Leu Pro Val Phe Ser Arg Thr Leu Gly Leu Thr  
     225                    230                    235                    240  
 Arg Phe Asp Leu Leu Gly Asp Phe Gly Arg Phe Asn Trp Leu Gly Asn  
             245                    250                    255

Phe Tyr Ile Val Phe Leu Tyr Asn Ala Ala Phe Ala Gly Leu Thr Thr  
                   260                                  265                                  270  
 Leu Cys Leu Val Lys Thr Phe Thr Ala Ala Val Arg Ala Glu Leu Ile  
                   275                                  280                                  285  
 Arg Ala Phe Gly Leu Asp Arg Leu Pro Leu Pro Val Ser Gly Phe Pro  
                   290                                  295                                  300  
 Gln Ala Ser Arg Lys Thr Gln His Gln  
 305                                  310

<210> 312  
 <211> 92  
 <212> PRT  
 <213> Homo sapiens

<400> 312  
 Leu Cys Val Cys Leu Val Tyr Leu Cys Met Tyr Gly Val Cys Leu Cys  
   1                                  5                                  10                                  15  
 Val Ile Val Cys Val Ser Gly Val Ser Leu Cys Leu Tyr Val Trp Gly  
                   20                                  25                                  30  
 Val Ser Val Cys Asp Cys Val Ser Val Phe Met Cys Val Cys Leu Cys  
                   35                                  40                                  45  
 Val Ile Phe Cys Val Tyr Gly Lys Pro Arg Thr Glu His Tyr His Ser  
                   50                                  55                                  60  
 Pro His Leu Ala Lys Gln Lys Ala Phe Arg Glu Met Cys Gly Arg His  
                   65                                  70                                  75                                  80  
 Asp Val Ser Ala Ala Gly Ile Phe Gln Ser Tyr Val  
                                   85                                  90

<210> 313  
 <211> 207  
 <212> PRT  
 <213> Homo sapiens

<400> 313  
 Gly His Met Pro Tyr Gly Trp Leu Thr Glu Ile Arg Ala Val Tyr Pro  
   1                                  5                                  10                                  15  
 Ala Phe Asp Lys Asn Asn Pro Ser Asn Lys Leu Val Ser Thr Ser Asn  
                   20                                  25                                  30  
 Thr Val Thr Ala Ala His Ile Lys Lys Phe Thr Phe Val Cys Met Ala  
                   35                                  40                                  45  
 Leu Ser Leu Thr Leu Cys Phe Val Met Phe Trp Thr Pro Asn Val Ser  
                   50                                  55                                  60  
 Glu Lys Ile Leu Ile Asp Ile Ile Gly Val Asp Phe Ala Phe Ala Glu  
                   65                                  70                                  75                                  80

Leu Cys Val Val Pro Leu Arg Ile Phe Ser Phe Phe Pro Val Pro Val  
                                   85                                  90                                  95  
 Thr Val Arg Ala His Leu Thr Gly Trp Leu Met Thr Leu Lys Lys Thr  
                                   100                                  105                                  110  
 Phe Val Leu Ala Pro Ser Ser Val Leu Arg Ile Ile Val Leu Ile Ala  
                                   115                                  120                                  125  
 Ser Leu Val Val Leu Pro Tyr Leu Gly Val His Gly Ala Thr Leu Gly  
                                   130                                  135                                  140  
 Val Gly Ser Leu Leu Ala Gly Phe Val Gly Glu Ser Thr Met Val Ala  
                                   145                                  150                                  155                                  160  
 Ile Ala Ala Cys Tyr Val Tyr Arg Lys Gln Lys Lys Lys Met Glu Asn  
                                   165                                  170                                  175  
 Glu Ser Ala Thr Glu Gly Glu Asp Ser Ala Met Thr Asp Met Pro Pro  
                                   180                                  185                                  190  
 Thr Glu Glu Val Thr Asp Ile Val Glu Met Arg Glu Glu Asn Glu  
                                   195                                  200                                  205

<210> 314  
 <211> 114  
 <212> PRT  
 <213> Homo sapiens

<400> 314  
 Gln Val Val Phe Val Ala Ile Leu Leu His Ser His Leu Glu Cys Arg  
   1                                  5                                  10                                  15  
 Glu Pro Leu Leu Ile Pro Ile Leu Ser Leu Tyr Met Gly Ala Leu Val  
                                   20                                  25                                  30  
 Arg Cys Thr Thr Leu Cys Leu Gly Tyr Tyr Lys Asn Ile His Asp Ile  
                                   35                                  40                                  45  
 Ile Pro Asp Arg Ser Gly Pro Glu Leu Gly Gly Asp Ala Thr Ile Arg  
                                   50                                  55                                  60  
 Lys Met Leu Ser Phe Trp Trp Pro Leu Ala Leu Ile Leu Ala Thr Gln  
                                   65                                  70                                  75                                  80  
 Arg Ile Ser Arg Pro Ile Val Asn Leu Phe Val Ser Arg Asp Leu Gly  
                                   85                                  90                                  95  
 Gly Ser Ser Ala Ala Thr Glu Ala Val Ala Ile Leu Thr Ala Thr Tyr  
                                   100                                  105                                  110  
 Pro Val

<210> 315  
 <211> 115

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 315

Arg Cys Cys Cys Arg Gly Cys Ser Cys Arg Ala Arg Leu Cys Pro Pro  
 1 5 10 15

Ala Arg Ser Thr Ala Val Ala Pro Glu Cys Arg Gly Ala His Pro Ser  
 20 25 30

Arg Ala Met Arg Pro Gly Thr Ala Leu Gln Ala Val Leu Leu Ala Val  
 35 40 45

Leu Leu Val Gly Leu Arg Ala Ala Thr Gly Arg Leu Leu Ser Gly Gln  
 50 55 60

Pro Val Cys Arg Gly Gly Thr Gln Arg Pro Cys Tyr Lys Val Ile Tyr  
 65 70 75 80

Phe His Asp Thr Ser Arg Arg Leu Asn Phe Glu Glu Ala Lys Glu Ala  
 85 90 95

Cys Arg Arg Gly Trp Arg Pro Ala Ser Gln His Arg Val Leu Lys Met  
 100 105 110

Asn Arg Asn  
 115

&lt;210&gt; 316

&lt;211&gt; 81

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 316

Met Arg Pro Gly Thr Ala Leu Gln Ala Val Leu Leu Ala Val Leu Leu  
 1 5 10 15

Val Gly Leu Arg Ala Ala Thr Gly Arg Leu Leu Ser Gly Gln Pro Val  
 20 25 30

Cys Arg Gly Gly Thr Gln Arg Pro Cys Tyr Lys Val Ile Tyr Phe His  
 35 40 45

Asp Thr Ser Arg Arg Leu Asn Phe Glu Glu Ala Lys Glu Ala Cys Arg  
 50 55 60

Arg Gly Trp Arg Pro Ala Ser Gln His Arg Val Leu Lys Met Asn Arg  
 65 70 75 80

Asn

&lt;210&gt; 317

&lt;211&gt; 290

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

<400> 317  
 Ile Arg His Glu Gln Gln Gly Glu Glu Asp Asp Glu His Ala Arg Pro  
 1 5 10 15  
 Leu Ala Glu Ser Leu Leu Leu Ala Ile Ala Asp Leu Leu Phe Cys Pro  
 20 25 30  
 Asp Phe Thr Val Gln Ser His Arg Arg Ser Thr Val Asp Ser Ala Glu  
 35 40 45  
 Asp Val His Ser Leu Asp Ser Cys Glu Tyr Ile Trp Glu Ala Gly Val  
 50 55 60  
 Gly Phe Ala His Ser Pro Gln Pro Asn Tyr Ile His Asp Met Asn Arg  
 65 70 75 80  
 Met Glu Leu Leu Lys Leu Leu Leu Thr Cys Phe Ser Glu Ala Met Tyr  
 85 90 95  
 Leu Pro Pro Ala Pro Glu Ser Gly Ser Thr Asn Pro Trp Val Gln Phe  
 100 105 110  
 Phe Cys Ser Thr Glu Asn Arg His Ala Leu Pro Leu Phe Thr Ser Leu  
 115 120 125  
 Leu Asn Thr Val Cys Ala Tyr Asp Pro Val Gly Tyr Gly Ile Pro Tyr  
 130 135 140  
 Asn His Leu Leu Phe Ser Asp Tyr Arg Glu Pro Leu Val Glu Glu Ala  
 145 150 155 160  
 Ala Gln Val Leu Ile Val Thr Leu Asp His Asp Ser Ala Ser Ser Ala  
 165 170 175  
 Ser Pro Thr Val Asp Gly Thr Thr Thr Gly Thr Ala Met Asp Asp Ala  
 180 185 190  
 Asp Pro Pro Gly Pro Glu Asn Leu Phe Val Asn Tyr Leu Ser Arg Ile  
 195 200 205  
 His Arg Glu Glu Asp Phe Gln Phe Ile Leu Lys Gly Ile Ala Arg Leu  
 210 215 220  
 Leu Ser Asn Pro Leu Leu Gln Thr Tyr Leu Pro Asn Ser Thr Lys Lys  
 225 230 235 240  
 Asp Pro Val Pro Pro Gly Ala Ala Ser Ser Leu Leu Glu Ala Leu Arg  
 245 250 255  
 Leu Gln Gln Glu Ile Pro Leu Leu Arg Ala Glu Glu Gln Arg Arg Pro  
 260 265 270  
 Arg His Pro Cys Pro His Pro Leu Leu Pro Gln Arg Cys Pro Gly Arg  
 275 280 285  
 Ser Val  
 290

&lt;210&gt; 318

&lt;211&gt; 318

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 318

Arg Leu Val Tyr Asn Lys Thr Ser Arg Ala Thr Gln Phe Pro Asp Gly  
 1 5 10 15

Val Asp Val Arg Val Pro Gly Phe Gly Lys Thr Phe Ser Leu Glu Phe  
 20 25 30

Leu Asp Pro Ser Lys Ser Ser Val Gly Ser Tyr Phe His Thr Met Val  
 35 40 45

Glu Ser Leu Val Gly Trp Gly Tyr Thr Arg Gly Glu Asp Val Arg Gly  
 50 55 60

Ala Pro Tyr Asp Trp Arg Arg Ala Pro Asn Glu Asn Gly Pro Tyr Phe  
 65 70 75 80

Leu Ala Leu Arg Glu Met Ile Glu Glu Met Tyr Gln Leu Tyr Gly Gly  
 85 90 95

Pro Val Val Leu Val Ala His Ser Met Gly Asn Met Tyr Thr Leu Tyr  
 100 105 110

Phe Leu Gln Arg Gln Pro Gln Ala Trp Lys Asp Lys Tyr Ile Arg Ala  
 115 120 125

Phe Val Ser Leu Gly Ala Pro Trp Gly Gly Val Ala Lys Thr Leu Arg  
 130 135 140

Val Leu Ala Ser Gly Asp Asn Asn Arg Ile Pro Val Ile Gly Pro Leu  
 145 150 155 160

Lys Ile Arg Glu Gln Gln Arg Ser Ala Val Ser Thr Ser Trp Leu Leu  
 165 170 175

Pro Tyr Asn Tyr Thr Trp Ser Pro Glu Lys Val Phe Val Gln Thr Pro  
 180 185 190

Thr Ile Asn Tyr Thr Leu Arg Asp Tyr Arg Lys Phe Phe Gln Asp Ile  
 195 200 205

Gly Phe Glu Asp Gly Trp Leu Met Arg Gln Asp Thr Glu Gly Leu Val  
 210 215 220

Glu Ala Thr Met Pro Pro Gly Val Gln Leu His Cys Leu Tyr Gly Thr  
 225 230 235 240

Gly Val Pro Thr Pro Asp Ser Phe Tyr Tyr Glu Ser Phe Pro Asp Arg  
 245 250 255

Asp Pro Lys Ile Cys Phe Gly Asp Gly Asp Gly Thr Val Asn Leu Lys  
 260 265 270

Ser Ala Leu Gln Cys Gln Ala Trp Gln Ser Arg Gln Glu His Gln Val  
 275 280 285

Leu Leu Gln Glu Leu Pro Gly Ser Glu His Ile Glu Met Leu Ala Asn  
 290 295 300

Ala Thr Thr Leu Ala Tyr Leu Lys Arg Val Leu Leu Gly Pro  
 305 310 315

<210> 319

<211> 362

<212> PRT

<213> Homo sapiens

<400> 319

Met Asn Lys Glu Asp Lys Val Trp Asn Asp Cys Lys Gly Val Asn Lys  
 1 5 10 15

Leu Thr Asn Leu Glu Glu Gln Tyr Ile Ile Leu Ile Phe Gln Asn Gly  
 20 25 30

Leu Asp Pro Pro Ala Asn Met Val Phe Glu Ser Ile Ile Asn Glu Ile  
 35 40 45

Gly Ile Lys Asn Asn Ile Ser Asn Phe Phe Ala Lys Ile Pro Phe Glu  
 50 55 60

Glu Ala Asn Gly Arg Leu Val Ala Cys Thr Arg Thr Tyr Glu Glu Ser  
 65 70 75 80

Ile Lys Gly Ser Cys Gly Gln Lys Glu Asn Lys Ile Lys Thr Val Ser  
 85 90 95

Phe Glu Ser Lys Ile Gln Leu Arg Ser Lys Gln Glu Phe Gln Phe Phe  
 100 105 110

Asp Glu Glu Glu Glu Thr Gly Glu Asn His Thr Ile Phe Ile Gly Pro  
 115 120 125

Val Glu Lys Leu Ile Val Tyr Pro Pro Pro Pro Ala Lys Gly Gly Ile  
 130 135 140

Ser Val Thr Asn Glu Asp Leu His Cys Leu Asn Glu Gly Glu Phe Leu  
 145 150 155 160

Asn Asp Val Ile Ile Asp Phe Tyr Leu Lys Tyr Leu Val Leu Glu Lys  
 165 170 175

Leu Lys Lys Glu Asp Ala Asp Arg Ile His Ile Phe Ser Ser Phe Phe  
 180 185 190

Tyr Lys Arg Leu Asn Gln Arg Glu Arg Arg Asn His Glu Thr Thr Asn  
 195 200 205

Leu Ser Ile Gln Gln Lys Arg His Gly Arg Val Lys Thr Trp Thr Arg  
 210 215 220

His Val Asp Ile Phe Glu Lys Asp Phe Ile Phe Val Pro Leu Asn Glu  
 225 230 235 240



Lys Gln Val Val Ser Lys Ile Lys Glu Glu Thr Leu Asn Asp Lys Val  
85 90 95

Glu Phe Leu Tyr Cys Asp Leu Ala Ser Met Thr Ser Ile Arg Gln Phe  
 100 105 110  
 Val Gln Lys Phe Lys Met Lys Lys Ile Pro Leu His Val Leu Ile Asn  
 115 120 125  
 Asn Ala Gly Val Met Met Val Pro Gln Arg Lys Thr Arg Asp Gly Phe  
 130 135 140  
 Glu Glu His Phe Gly Leu Asn Tyr Leu Gly His Phe Leu Leu Thr Asn  
 145 150 155 160  
 Leu Leu Leu Asp Thr Leu Lys Glu Ser Gly Ser Pro Gly His Ser Ala  
 165 170 175  
 Arg Val Val Thr Val Ser Ser Ala Thr His Tyr Val Ala Glu Leu Asn  
 180 185 190  
 Met Asp Asp Leu Gln Ser Ser Ala Cys Tyr Ser Pro His Ala Ala Tyr  
 195 200 205  
 Ala Gln Ser Lys Leu Ala Leu Val Leu Phe Thr Tyr His Leu Gln Arg  
 210 215 220  
 Leu Leu Ala Ala Glu Gly Ser His Val Thr Ala Asn Val Val Asp Pro  
 225 230 235 240  
 Gly Val Val Asn Thr Asp Xaa Tyr Lys His Val Phe Trp Ala Thr Arg  
 245 250 255  
 Leu Ala Lys Lys Leu Leu Gly Trp Leu Phe Lys Thr Pro Asp Glu  
 260 265 270  
 Gly Ala Trp Thr Ser Ile Tyr Ala Ala Val Thr Pro Glu Leu Glu Gly  
 275 280 285  
 Val Gly Gly Arg Tyr Leu Tyr Asn Glu Lys Glu Thr Lys Ser Leu His  
 290 295 300  
 Val Thr Tyr Asn Gln Lys Leu Gln Gln Gln Leu Trp Ser Lys Ser Cys  
 305 310 315 320  
 Glu Met Thr Gly Val Leu Asp Val Thr Leu  
 325 330

&lt;210&gt; 321

&lt;211&gt; 71

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (38)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 321

Met Ser Pro Leu Ser Ala Ala Arg Ala Ala Leu Arg Val Tyr Ala Val  
 1 5 10 15

Gly Ala Ala Val Ile Leu Ala Gln Leu Leu Arg Arg Cys Arg Gly Gly  
                   20                  25                  30  
 Phe Leu Glu Pro Val Xaa Pro Pro Arg Pro Asp Arg Val Ala Ile Val  
                   35                  40                  45  
 Thr Gly Gly Thr Asp Gly Ile Gly Tyr Ser Thr Ala Asn Ile Trp Arg  
                   50                  55                  60  
 Asp Leu Ala Cys Met Leu Ser  
                   65                  70

<210> 322  
 <211> 266  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (97)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (174)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (195)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (199)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (206)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 322  
 Met Glu Val Thr Thr Glu Asp Thr Ser Arg Thr Asp Val Ser Glu Pro  
   1                  5                  10                  15  
 Ala Thr Ser Gly Gly Ala Ala Asp Gly Val Thr Ser Ile Ala Pro Thr  
                   20                  25                  30  
 Ala Val Ala Ser Ser Thr Thr Ala Ala Ser Ile Thr Thr Ala Ala Ser  
                   35                  40                  45  
 Ser Met Thr Val Ala Ser Ser Ala Pro Thr Thr Ala Ala Ser Ser Thr  
                   50                  55                  60  
 Thr Val Ala Ser Ile Ala Pro Thr Thr Thr Ala Ser Ser Met Thr Ala  
   65                  70                  75                  80

Ala Ser Ser Thr Pro Met Thr Leu Ala Leu Pro Ala Pro Thr Ser Thr  
85 90 95

Xaa Thr Gly Arg Thr Pro Ser Thr Thr Ala Thr Gly His Pro Ser Leu  
100 105 110

Ser Thr Ala Leu Ala Gln Val Pro Lys Ser Ser Ala Leu Pro Arg Thr  
115 120 125

Ala Thr Leu Ala Thr Leu Ala Thr Arg Ala Gln Thr Val Ala Thr Thr  
130 135 140

Ala Asn Thr Ser Ser Pro Met Ser Thr Arg Pro Ser Pro Ser Lys His  
145 150 155 160

Met Pro Ser Asp Thr Ala Ala Ser Pro Val Pro Pro Met Xaa Pro Gln  
165 170 175

Ala Gln Gly Pro Ile Ser Gln Val Ser Val Asp Gln Pro Val Val Asn  
180 185 190

Thr Thr Xaa Lys Ser Thr Xaa Met Pro Ser Asn Thr Thr Xaa Glu Pro  
195 200 205

Leu Thr Gln Ala Val Val Asp Lys Thr Leu Leu Leu Val Val Leu Leu  
210 215 220

Leu Gly Val Thr Leu Phe Ile Thr Val Leu Val Leu Phe Ala Leu Gln  
225 230 235 240

Ala Tyr Glu Ser Tyr Lys Lys Lys Asp Tyr Thr Gln Val Asp Tyr Leu  
245 250 255

Ile Asn Gly Met Tyr Ala Asp Ser Glu Met  
260 265

&lt;210&gt; 323

&lt;211&gt; 99

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 323

Ala Arg Cys Pro Glu Leu Pro Gly Leu Arg Cys Arg Pro Arg Pro Arg  
1 5 10 15

Ala Gly Pro Gln Ala Pro Ser Tyr Cys Pro Arg Ala Thr Arg Pro Pro  
20 25 30

Gly Ala Cys Cys Ala Arg Met Arg Leu Leu Leu Glu Trp Arg Val Tyr  
35 40 45

Leu Arg Leu Thr Cys Ala Thr Lys Asp Gly Met Ala Arg Glu Cys Pro  
50 55 60

Thr Thr Trp Leu Ser Pro Pro Ala Lys Pro Asp Phe Ala Gln Arg His  
65 70 75 80

```
<210> 324
<211> 96
<212> PRT
<213> Homo sapiens
```

```

<400> 324
Leu Pro Ala Thr Val Glu Phe Ala Val His Thr Phe Asn Gln Gln Ser
 1                               10                      15

Lys Asp Tyr Tyr Ala Tyr Arg Leu Gly His Ile Leu Asn Ser Trp Lys
                20                      25                      30

Glu Gln Val Glu Ser Lys Thr Val Phe Ser Met Glu Leu Leu Leu Gly
        35                      40                      45

Arg Thr Arg Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys His Phe
 50                      55                      60

Gln Glu Ser Thr Glu Leu Asn Asn Thr Phe Thr Cys Phe Phe Thr Ile
65                      70                      75                      80

Ser Thr Arg Pro Trp Met Thr Gln Phe Ser Leu Leu Asn Lys Thr Cys
                85                      90                      95

```

```
<210> 325
<211> 166
<212> PRT
<213> Homo sapiens
```

```

<400> 325
Leu Leu Trp Ala Arg Gly Leu Gly Arg Ala Lys Ser Ala Val Pro Thr
  1                               5                10                15
Val Ser Thr Met Leu Gly Leu Pro Trp Lys Gly Gly Leu Ser Trp Ala
          20                25                30
Leu Leu Leu Leu Leu Leu Gly Ser Gln Ile Leu Leu Ile Tyr Ala Trp
          35                40                45
His Phe His Glu Gln Arg Asp Cys Asp Glu His Asn Val Met Ala Arg
          50                55                60
Tyr Leu Pro Ala Thr Val Glu Phe Ala Val His Thr Phe Asn Gln Gln
  65                70                75                80
Ser Lys Asp Tyr Tyr Ala Tyr Arg Leu Gly His Ile Leu Asn Ser Trp
          85                90                95

```

Lys Glu Gln Val Glu Ser Lys Thr Val Phe Ser Met Glu Leu Leu Leu  
                   100                  105                  110  
 Gly Arg Thr Arg Cys Gly Lys Phe Glu Asp Asp Ile Asp Asn Cys His  
                   115                  120                  125  
 Phe Gln Glu Ser Thr Glu Leu Asn Asn Thr Phe Thr Cys Phe Phe Thr  
                   130                  135                  140  
 Ile Ser Thr Arg Pro Trp Met Thr Gln Phe Ser Leu Leu Asn Lys Thr  
 145                  150                  155                  160  
 Cys Leu Glu Gly Phe His  
                   165  
  
 <210> 326  
 <211> 214  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (200)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <220>  
 <221> SITE  
 <222> (205)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <400> 326  
 Leu Glu Gln Lys Leu Glu Leu His Arg Gly Gly Gly Arg Ser Arg Thr  
   1                  5                  10                  15  
 Ser Gly Ser Pro Gly Leu Gln Glu Phe Gly Thr Arg Glu Glu Arg Gly  
                   20                  25                  30  
 Glu Gly Glu Gln Arg Thr Gly Arg Glu Phe Ser Gly Asn Gly Gly Arg  
                   35                  40                  45  
 Ala Val Glu Ala Ala Arg Met Arg Leu Leu Cys Gly Leu Trp Leu Trp  
                   50                  55                  60  
 Leu Ser Leu Leu Lys Val Leu Gln Ala Gln Thr Pro Thr Pro Leu Pro  
   65                  70                  75                  80  
 Leu Pro Pro Pro Met Gln Ser Phe Gln Gly Asn Gln Phe Gln Gly Glu  
                   85                  90                  95  
 Trp Phe Val Leu Gly Leu Ala Gly Asn Ser Phe Arg Pro Glu His Arg  
                   100                  105                  110  
 Ala Leu Leu Asn Ala Phe Thr Ala Thr Phe Glu Leu Ser Asp Asp Gly  
                   115                  120                  125  
 Arg Phe Glu Val Trp Asn Ala Met Thr Arg Gly Gln His Cys Asp Thr  
   130                  135                  140

Trp Ser Tyr Val Leu Ile Pro Ala Ala Gln Pro Gly Gln Phe Thr Val  
145 150 155 160

Asp His Gly Val Gly Arg Ser Trp Leu Leu Pro Pro Gly Thr Leu Asp  
165 170 175

Gln Phe Ile Cys Leu Gly Arg Ala Gln Gly Leu Ser Asp Asp Asn Ile  
180 185 190

Val Phe Pro Asp Val Thr Gly Xaa Ala Leu Asp Leu Xaa Ser Leu Pro  
195 200 205

Trp Val Ala Ala Pro Ala  
210

<210> 327

<211> 181

<212> PRT

<213> Homo sapiens

<400> 327

Met Cys Val Cys Glu Arg Lys Arg Gly Arg Glu Lys Glu Gly Gly Val  
1 5 10 15

Thr Pro Thr Met Thr Ser Asn Phe Pro Phe Cys Thr Leu Ile Leu Gly  
20 25 30

Ile Ala Gln Ala Gln Ala Cys Pro Gly Cys Pro Gly Asp Trp Pro Gly  
35 40 45

Leu Gly Ser Gly Val Gly Glu Gly Leu His His Ile Arg Thr Cys Arg  
50 55 60

Thr Pro Ile Pro Cys Ser Pro Pro Ala Pro Ala Ala Ala Cys Leu Gly  
65 70 75 80

Ser Gly His Ala Arg Leu Pro Cys Val Leu Arg Leu Trp Pro Val Pro  
85 90 95

Ala Asn Leu Ser Ser Pro Phe Arg Leu Glu Ala Leu His Cys Ser Phe  
100 105 110

Trp Ser Ser Pro Leu Leu Pro Ala Pro His Leu Ala Phe Phe Gly Phe  
115 120 125

Arg Asp Leu Leu Thr Asp Phe Leu Leu Ala Ala Cys Leu Leu Thr Phe  
130 135 140

Gln Lys Thr Pro Leu Glu Leu Pro Met Ala Val Val His Leu Leu Val  
145 150 155 160

Ala Thr Pro Cys Tyr Gln Met Leu Asp Asn Leu Pro Leu Pro Ser Ala  
165 170 175

Ala Ala Asn Trp Cys  
180

220

<210> 328  
 <211> 195  
 <212> PRT  
 <213> Homo sapiens

<400> 328

Tyr Leu Trp Gly Arg Pro Arg Leu Arg Met Arg Ala Gly Thr Ser Pro  
 1 5 10 15  
 Ser Ala Pro Trp Gly Glu Lys Arg Glu Lys Leu Gly His Lys Leu Pro  
 20 25 30  
 Val Ala Leu Gln Gly Tyr His Pro Trp Ile Leu Leu Glu Cys Thr Val  
 35 40 45  
 Phe Trp Ala Arg Val Val Leu Ala Cys Phe Ser Leu Tyr Leu Ile Arg  
 50 55 60  
 Gly Pro Asn Cys Ile Asn Arg Gln Pro Glu Pro Thr Tyr Gln Lys Ala  
 65 70 75 80  
 Cys Asn Leu Asp Cys Ser Ser Asp Phe Gly Gln Glu Arg Ala Pro Ala  
 85 90 95  
 Trp Glu Leu Leu Gly Pro Glu Ser Glu Gln Arg Leu Arg Glu Tyr Thr  
 100 105 110  
 Ala Gln Gly Leu Gln Ser Leu Ala Ser Ser His Arg Trp Arg Gln Phe  
 115 120 125  
 Lys Thr Glu Gly Lys Met Arg Gly Gly Ala Ser Pro Leu Pro Trp Leu  
 130 135 140  
 Ile Cys Phe Trp Leu Cys Ser Tyr Lys Gly Ser Asp Asn Ser Leu Lys  
 145 150 155 160  
 Pro Val Val Pro Gly Pro Thr Leu Cys Pro Gln Ser Leu Val Ser Pro  
 165 170 175  
 Ser Val His Pro Ser Thr Arg Ser Ala Ser Leu Gly Arg His Arg Ala  
 180 185 190  
 Glu Ala Ala  
 195

<210> 329  
 <211> 50  
 <212> PRT  
 <213> Homo sapiens

<400> 329

Met Pro Gly Ile Leu Ala Gly Ile Pro Val Lys Asp Leu Cys Leu Ser  
 1 5 10 15  
 Leu Leu Gln Gly Phe Arg Leu Leu Leu Leu Cys Val Cys Pro Gly Trp  
 20 25 30  
 Leu Ser Gly Trp Met Gly Gly Gln Lys Gly Ser Pro Arg Ile Val Asp



35 40 45

Ile Gly  
50

<210> 330  
<211> 90  
<212> PRT  
<213> Homo sapiens

<400> 330  
Ala Lys Gly Glu Glu Arg Lys Glu Ala Phe Ser Leu Lys Met Val Gln  
1 5 10 15  
Leu Ser Ser Glu Pro Ile Ser Phe Gly Leu Met Tyr Leu Tyr Leu Gly  
20 25 30  
Val Phe Phe His Leu Ile Tyr Pro Gly Ala Leu Ser Ile Thr Thr Leu  
35 40 45  
Gly Lys His Ser His Pro Phe Phe Thr Ala Glu Gln Asn Ser Thr Val  
50 55 60  
Trp Met Glu His Thr Leu Phe His Gln Ser Pro Val Ala Ser His Leu  
65 70 75 80  
Val Cys Phe Gln Ser Phe Ala Phe Ser Glu  
85 90

<210> 331  
<211> 56  
<212> PRT  
<213> Homo sapiens

<400> 331  
Gly Pro Ala His Pro Ala Ser Pro Pro Leu Met Thr Leu Ser Leu Gln  
1 5 10 15  
Leu Ala Glu Leu Val His Phe Val Cys Ala Phe Gln Ser Gln Trp Thr  
20 25 30  
Gly Val Tyr Pro Met Met Pro Pro Leu Lys Pro Thr Glu Pro Leu Cys  
35 40 45  
Phe Ala Cys Val Pro Cys Arg Val  
50 55

<210> 332  
<211> 18  
<212> PRT  
<213> Homo sapiens

<400> 332  
Met Leu Leu Glu Val Tyr Gly Asp Ser Ile Ser Val Thr Val Ala Ile  
1 5 10 15

Pro Leu

<210> 333  
 <211> 19  
 <212> PRT  
 <213> Homo sapiens

<400> 333  
 Met His Ser Pro Cys Gln Ser Lys Ala Ala Asp Gly Leu Gly Lys Ser  
 1 5 10 15

Glu Thr Glu

<210> 334  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 334  
 Met Leu Lys Ser Leu Gly Leu Ser Thr Asn  
 1 5 10

<210> 335  
 <211> 200  
 <212> PRT  
 <213> Homo sapiens

<400> 335  
 Ala Gln Arg Leu Ala Glu Glu Cys Phe Tyr Met Leu Leu Glu Val Tyr  
 1 5 10 15  
 Gly Asp Ser Ile Ser Val Thr Val Ala Ile Pro Leu Met His Ser Pro  
 20 25 30  
 Cys Gln Ser Lys Ala Ala Asp Gly Leu Gly Lys Ser Glu Thr Glu Met  
 35 40 45  
 Leu Lys Ser Leu Gly Leu Ser Thr Asn Met Ser Pro Phe His Leu Leu  
 50 55 60  
 Gly Leu Lys Val Phe Leu Thr Trp Ala Leu Thr Leu Ala Gln Ile Cys  
 65 70 75 80  
 Leu Tyr Phe Phe Glu Val Gln Pro Leu Gly Leu Leu Ala Leu Asn Phe  
 85 90 95  
 Phe Cys Thr Ala Thr Ala Gly Leu Lys Glu Leu Cys Met His Pro Pro  
 100 105 110  
 Ser Leu Ala Phe Thr Pro Glu Phe His Thr Ser Leu Ser Pro Leu Ala  
 115 120 125  
 Ile Pro Ser Phe Cys Gly Thr Ser Val Ser Leu Ser Asn Ser His Thr  
 130 135 140

Ile Pro Leu Ser Leu Tyr Leu Pro Phe Pro Ser Lys Ser Arg Met Pro  
 145 150 155 160

Asp Thr Leu His Leu Leu Val His Ser Leu Pro Leu Val His Ser Gln  
 165 170 175

Val Leu Pro Val Lys Asp Val Thr Ile Glu Trp Pro Leu Cys Gln Arg  
 180 185 190

Cys Leu Gly Ser Thr Cys His Gln  
 195 200

<210> 336

<211> 99

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (94)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (99)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 336

Trp Ile Pro Arg Ala Ala Gly Ile Arg His Glu Val Gln Val Ser Leu  
 1 5 10 15

Phe Gln Met Phe Cys Phe Ser Ser Ile Phe Cys Ser His Glu His Thr  
 20 25 30

His Leu Pro Gly Thr Phe Trp Leu Phe Leu Phe Leu Ile Leu  
 35 40 45

Pro Pro Ser Cys Pro Cys Phe Leu Pro Phe Ser Leu Ala Ile Glu Thr  
 50 55 60

Val Arg Trp Pro Cys Trp His His Pro Thr Ser Phe Glu Leu Cys Tyr  
 65 70 75 80

Pro Gly Thr Ser Ile Tyr Tyr Ala Ser Arg Gly Gly Pro Xaa Pro Asn  
 85 90 95

Ser Glu Xaa

<210> 337

<211> 96

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

&lt;222&gt; (1)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (3)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 337

Xaa	Asn	Xaa	Lys	Ser	Pro	Leu	Thr	Ile	Gly	Asn	Lys	Ser	Trp	Ser	Ser
1				5					10					15	

Thr	Ala	Val	Ala	Ala	Ala	Leu	Glu	Leu	Val	Asp	Pro	Pro	Gly	Cys	Arg
			20					25					30		

Asn	Ser	Ala	Arg	Asp	Ser	Pro	Glu	Leu	Val	His	Leu	Gly	Lys	Gly	Arg
		35					40					45			

Pro	Arg	Lys	Leu	Met	Thr	Tyr	Leu	Phe	Cys	Ser	Ser	Ile	Ser	Leu	Leu
	50					55					60				

Leu	Leu	Lys	Val	His	Ser	Ser	Gly	His	Gln	Asp	Ile	Arg	Lys	Ala	Lys
65					70					75					80

Ser	Lys	Val	Pro	Arg	Leu	Leu	Ile	Ile	Gln	Cys	Pro	Gln	Gln	Arg	Glu
				85					90					95	

&lt;210&gt; 338

&lt;211&gt; 54

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 338

Gly	Pro	Glu	Glu	Asn	Leu	Ser	Pro	Ser	Thr	Pro	Ser	Gln	Met	Pro	Thr
1				5					10					15	

Ile	Trp	Val	Lys	Leu	Cys	Leu	Leu	Gln	Val	Cys	His	Gly	Leu	Phe	Pro
			20					25					30		

Leu	Leu	Lys	His	Trp	Ser	Gln	Pro	Met	Pro	Leu	Cys	Val	Thr	Leu	Ala
		35					40					45			

Pro	Val	Ser	Tyr	Trp	Leu
	50				

&lt;210&gt; 339

&lt;211&gt; 287

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 339

Pro	Arg	Val	Arg	Lys	Glu	Pro	Glu	Ala	Met	Gln	Trp	Leu	Arg	Val	Arg
1				5					10					15	

225

Glu Ser Pro Gly Glu Ala Thr Gly His Arg Val Thr Met Gly Thr Ala  
                   20                  25                  30  
 Ala Leu Gly Pro Val Trp Ala Ala Leu Leu Leu Phe Leu Leu Met Cys  
                   35                  40                  45  
 Glu Ile Pro Met Val Glu Leu Thr Phe Asp Arg Ala Val Ala Ser Asp  
                   50                  55                  60  
 Cys Gln Arg Cys Cys Asp Ser Glu Asp Pro Leu Asp Pro Ala His Val  
                   65                  70                  75                  80  
 Ser Ser Ala Ser Ser Ser Gly Arg Pro His Ala Leu Pro Glu Ile Arg  
                   85                  90                  95  
 Pro Tyr Ile Asn Ile Thr Ile Leu Lys Gly Asp Lys Gly Asp Pro Gly  
                   100                  105                  110  
 Pro Met Gly Leu Pro Gly Tyr Met Gly Arg Glu Gly Pro Gln Gly Glu  
                   115                  120                  125  
 Pro Gly Pro Gln Gly Ser Lys Gly Asp Lys Gly Glu Met Gly Ser Pro  
                   130                  135                  140  
 Gly Ala Pro Cys Gln Lys Arg Phe Phe Ala Phe Ser Val Gly Arg Lys  
                   145                  150                  155                  160  
 Thr Ala Leu His Ser Gly Glu Asp Phe Gln Thr Leu Leu Phe Glu Arg  
                   165                  170                  175  
 Val Phe Val Asn Leu Asp Gly Cys Phe Asp Met Ala Thr Gly Gln Phe  
                   180                  185                  190  
 Ala Ala Pro Leu Arg Gly Ile Tyr Phe Phe Ser Leu Asn Val His Ser  
                   195                  200                  205  
 Trp Asn Tyr Lys Glu Thr Tyr Val His Ile Met His Asn Gln Lys Glu  
                   210                  215                  220  
 Ala Val Ile Leu Tyr Ala Gln Pro Ser Glu Arg Ser Ile Met Gln Ser  
                   225                  230                  235                  240  
 Gln Ser Val Met Leu Asp Leu Ala Tyr Gly Asp Arg Val Trp Val Arg  
                   245                  250                  255  
 Leu Phe Lys Arg Gln Arg Glu Asn Ala Ile Tyr Ser Asn Asp Phe Asp  
                   260                  265                  270  
 Thr Tyr Ile Thr Phe Ser Gly His Leu Ile Lys Ala Glu Asp Asp  
                   275                  280                  285  
  
 <210> 340  
 <211> 339  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 340  
 Met Leu Tyr Pro Gly Ser Val Tyr Leu Leu Gln Lys Ala Leu Met Pro

226

1	5	10	15
Val Leu Leu Gln Gly Gln Ala Arg Leu Val Glu Glu Cys Asn Gly Arg	20	25	30
Arg Ala Lys Leu Leu Ala Cys Asp Gly Asn Glu Ile Asp Thr Met Phe	35	40	45
Val Asp Arg Arg Gly Thr Ala Glu Pro Gln Gly Gln Lys Leu Val Ile	50	55	60
Cys Cys Glu Gly Asn Ala Gly Phe Tyr Glu Val Gly Cys Val Ser Thr	65	70	75
Pro Leu Glu Ala Gly Tyr Ser Val Leu Gly Trp Asn His Pro Gly Phe	85	90	95
Ala Gly Ser Thr Gly Val Pro Phe Pro Gln Asn Glu Ala Asn Ala Met	100	105	110
Asp Val Val Val Gln Phe Ala Ile His Arg Leu Gly Phe Gln Pro Gln	115	120	125
Asp Ile Ile Ile Tyr Ala Trp Ser Ile Gly Gly Phe Thr Ala Thr Trp	130	135	140
Ala Ala Met Ser Tyr Pro Asp Val Ser Ala Met Ile Leu Asp Ala Ser	145	150	155
Phe Asp Asp Leu Val Pro Leu Ala Leu Lys Val Met Pro Asp Ser Trp	165	170	175
Arg Gly Leu Val Thr Arg Thr Val Arg Gln His Leu Asn Leu Asn Asn	180	185	190
Ala Glu Gln Leu Cys Arg Tyr Gln Gly Pro Val Leu Leu Ile Arg Arg	195	200	205
Thr Lys Asp Glu Ile Ile Thr Thr Thr Val Pro Glu Asp Ile Met Ser	210	215	220
Asn Arg Gly Asn Asp Leu Leu Leu Lys Leu Leu Gln His Arg Tyr Pro	225	230	235
Arg Val Met Ala Glu Glu Gly Leu Arg Val Val Arg Gln Trp Leu Glu	245	250	255
Ala Ser Ser Gln Leu Glu Glu Ala Ser Ile Tyr Ser Arg Trp Glu Val	260	265	270
Glu Glu Asp Trp Cys Leu Ser Val Leu Arg Ser Tyr Gln Ala Glu His	275	280	285
Gly Pro Asp Phe Pro Trp Ser Val Gly Glu Asp Met Ser Ala Asp Gly	290	295	300
Arg Arg Gln Leu Ala Leu Phe Leu Ala Arg Lys His Leu His Asn Phe	305	310	315
			320

Glu Ala Thr His Cys Thr Pro Leu Pro Ala Gln Asn Phe Gln Met Pro  
                   325                  330                  335

Trp His Leu

<210> 341

<211> 127

<212> PRT

<213> Homo sapiens

<400> 341

Val Cys Pro Lys Trp Cys Arg Phe Leu Thr Met Leu Gly His Cys Cys  
   1                  5                  10                  15

Tyr Phe Trp Gln Val Trp Pro Ala Ser Glu Ala Leu Ala Ala Gly Pro  
                   20                  25                  30

Thr Pro Ser Thr Gly Ser Ser Ser Pro Ser Trp Lys Gln His Ile Gly  
                   35                  40                  45

Thr Ser Leu Gln Lys Thr Arg Gly Ser Leu Pro Thr Thr Thr Leu Thr  
   50                  55                  60

Ser Gly Ala Gly Gln Ser Thr Ser Thr Gly Lys Asn Pro Ala Ala Gly  
   65                  70                  75                  80

Arg Ser Leu Glu Gly Ala Leu Pro Ala Gly Val Trp Pro Cys Phe Ala  
                   85                  90                  95

Gln Ser Pro Cys Thr Gly Gly Gln Gln Thr Pro Ser Ser Thr Gly Leu  
                   100                  105                  110

Arg Ser Cys Leu Val Arg Ser Pro Ala Thr Trp Trp Arg Thr Pro  
                   115                  120                  125

<210> 342

<211> 554

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (16)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (109)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 342

Trp Ile Pro Arg Ala Ala Gly Ile Arg His Glu Ile Tyr Arg Glu Xaa  
   1                  5                  10                  15

Asp Ser Glu Arg Ala Pro Ala Ser Val Pro Glu Thr Pro Thr Ala Val  
                   20                  25                  30

Thr Ala Pro His Ser Ser Ser Trp Asp Thr Tyr Tyr Gln Pro Arg Ala  
 35 40 45  
 Leu Glu Lys His Ala Asp Ser Ile Leu Ala Leu Ala Ser Val Phe Trp  
 50 55 60  
 Ser Ile Ser Tyr Tyr Ser Ser Pro Phe Ala Phe Phe Tyr Leu Tyr Arg  
 65 70 75 80  
 Lys Gly Tyr Leu Ser Leu Ser Lys Val Val Pro Phe Ser His Tyr Ala  
 85 90 95  
 Gly Thr Leu Leu Leu Leu Leu Ala Gly Val Ala Cys Xaa Arg Gly Ile  
 100 105 110  
 Gly Arg Trp Thr Asn Pro Gln Tyr Arg Gln Phe Ile Thr Ile Leu Glu  
 115 120 125  
 Ala Thr His Arg Asn Gln Ser Ser Glu Asn Lys Arg Gln Leu Ala Asn  
 130 135 140  
 Tyr Asn Phe Asp Phe Arg Ser Trp Pro Val Asp Phe His Trp Glu Glu  
 145 150 155 160  
 Pro Ser Ser Arg Lys Glu Ser Arg Gly Gly Pro Ser Arg Arg Gly Val  
 165 170 175  
 Ala Leu Leu Arg Pro Glu Pro Leu His Arg Gly Thr Ala Asp Thr Leu  
 180 185 190  
 Leu Asn Arg Val Lys Lys Leu Pro Cys Gln Ile Thr Ser Tyr Leu Val  
 195 200 205  
 Ala His Thr Leu Gly Arg Arg Met Leu Tyr Pro Gly Ser Val Tyr Leu  
 210 215 220  
 Leu Gln Lys Ala Leu Met Pro Val Leu Leu Gln Gly Gln Ala Arg Leu  
 225 230 235 240  
 Val Glu Glu Cys Asn Gly Arg Arg Ala Lys Leu Leu Ala Cys Asp Gly  
 245 250 255  
 Asn Glu Ile Asp Thr Met Phe Val Asp Arg Arg Gly Thr Ala Glu Pro  
 260 265 270  
 Gln Gly Gln Lys Leu Val Ile Cys Cys Glu Gly Asn Ala Gly Phe Tyr  
 275 280 285  
 Glu Val Gly Cys Val Ser Thr Pro Leu Glu Ala Gly Tyr Ser Val Leu  
 290 295 300  
 Gly Trp Asn His Pro Gly Phe Ala Gly Ser Thr Gly Val Pro Phe Pro  
 305 310 315 320  
 Gln Asn Glu Ala Asn Ala Met Asp Val Val Val Gln Phe Ala Ile His  
 325 330 335  
 Arg Leu Gly Phe Gln Pro Gln Asp Ile Ile Ile Tyr Ala Trp Ser Ile



340                      345                      350  
 Gly Gly Phe Thr Ala Thr Trp Ala Ala Met Ser Tyr Pro Asp Val Ser  
       355                      360                      365  
 Ala Met Ile Leu Asp Ala Ser Phe Asp Asp Leu Val Pro Leu Ala Leu  
       370                      375                      380  
 Lys Val Met Pro Asp Ser Trp Arg Gly Leu Val Thr Arg Thr Val Arg  
       385                      390                      395                      400  
 Gln His Leu Asn Leu Asn Asn Ala Glu Gln Leu Cys Arg Tyr Gln Gly  
                              405                      410                      415  
 Pro Val Leu Leu Ile Arg Arg Thr Lys Asp Glu Ile Ile Thr Thr Thr  
                              420                      425                      430  
 Val Pro Glu Asp Ile Met Ser Asn Arg Gly Asn Asp Leu Leu Leu Lys  
                              435                      440                      445  
 Leu Leu Gln His Arg Tyr Pro Arg Val Met Ala Glu Glu Gly Leu Arg  
       450                      455                      460  
 Val Val Arg Gln Trp Leu Glu Ala Ser Ser Gln Leu Glu Glu Ala Ser  
       465                      470                      475                      480  
 Ile Tyr Ser Arg Trp Glu Val Glu Glu Asp Trp Cys Leu Ser Val Leu  
                              485                      490                      495  
 Arg Ser Tyr Gln Ala Glu His Gly Pro Asp Phe Pro Trp Ser Val Gly  
                              500                      505                      510  
 Glu Asp Met Ser Ala Asp Gly Arg Arg Gln Leu Ala Leu Phe Leu Ala  
                              515                      520                      525  
 Arg Lys His Leu His Asn Phe Glu Ala Thr His Cys Thr Pro Leu Pro  
                              530                      535                      540  
 Ala Gln Asn Phe Gln Met Pro Trp His Leu  
       545                      550

&lt;210&gt; 343

&lt;211&gt; 225

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (5)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 343

His Glu Arg Ala Xaa Gly Pro Ser Arg Gly His Gly Glu Leu Leu Ser  
       1                      5                      10                      15

Cys Val Leu Gly Pro Arg Leu Tyr Lys Ile Tyr Arg Glu Arg Asp Ser  
                              20                      25                      30

Glu Arg Ala Pro Ala Ser Val Pro Glu Thr Pro Thr Ala Val Thr Ala  
           35                          40                          45  
 Pro His Ser Ser Ser Trp Asp Thr Tyr Tyr Gln Pro Arg Ala Leu Glu  
           50                          55                          60  
 Lys His Ala Asp Ser Ile Leu Ala Leu Ala Ser Val Phe Trp Ser Ile  
           65                          70                          75                          80  
 Ser Tyr Tyr Ser Ser Pro Phe Ala Phe Phe Tyr Leu Tyr Arg Lys Gly  
                           85                          90                          95  
 Tyr Leu Ser Leu Ser Lys Val Val Pro Phe Ser His Tyr Ala Gly Thr  
                           100                          105                          110  
 Leu Leu Leu Leu Leu Ala Gly Val Ala Cys Ser Glu Ala Leu Ala Ala  
           115                          120                          125  
 Gly Pro Thr Pro Ser Thr Gly Ser Ser Ser Pro Ser Trp Lys Gln His  
           130                          135                          140  
 Ile Gly Thr Ser Leu Gln Lys Thr Arg Gly Ser Leu Pro Thr Thr Thr  
           145                          150                          155                          160  
 Leu Thr Ser Gly Ala Gly Gln Ser Thr Ser Thr Gly Lys Asn Pro Ala  
                           165                          170                          175  
 Ala Gly Arg Ser Leu Glu Gly Ala Leu Pro Ala Gly Val Trp Pro Cys  
                           180                          185                          190  
 Phe Ala Gln Ser Pro Cys Thr Gly Gly Gln Gln Thr Pro Ser Ser Thr  
           195                          200                          205  
 Gly Leu Arg Ser Cys Leu Val Arg Ser Pro Ala Thr Trp Trp Arg Thr  
           210                          215                          220  
 Pro  
 225

&lt;210&gt; 344

&lt;211&gt; 299

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 344

Met Phe Lys Arg His Gln Arg Leu Lys Lys Asp Ser Thr Gln Ala Glu  
           1                          5                          10                          15  
 Glu Asp Leu Ser Glu Gln Glu Gln Asn Gln Leu Asn Val Leu Lys Lys  
           20                          25                          30  
 His Gly Tyr Val Val Gly Arg Val Gly Arg Thr Phe Leu Tyr Ser Glu  
           35                          40                          45  
 Glu Gln Lys Asp Asn Ile Pro Phe Glu Phe Asp Ala Asp Ser Leu Ala  
           50                          55                          60  
 Phe Asp Met Glu Asn Asp Pro Val Met Gly Thr His Lys Ser Thr Lys

<213> Homo sapiens

<223> Xaa equals any of the naturally occurring L-amino acids

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 345  
 Met Leu Pro Ala Arg Leu Pro Phe Arg Leu Leu Ser Leu Phe Leu Arg  
 1 5 10 15  
 Gly Ser Ala Pro Thr Ala Ala Arg His Gly Leu Arg Glu Pro Leu Leu  
 20 25 30  
 Glu Arg Arg Cys Ala Ala Ala Ser Ser Phe Gln His Ser Ser Ser Leu  
 35 40 45  
 Gly Arg Glu Leu Pro Tyr Asp Pro Val Asp Thr Glu Gly Phe Gly Glu  
 50 55 60  
 Gly Gly Asp Met Gln Glu Arg Phe Leu Phe Pro Glu Tyr Ile Leu Asp  
 65 70 75 80  
 Pro Glu Pro Gln Pro Thr Arg Glu Lys Gln Leu Gln Glu Leu Gln Gln  
 85 90 95  
 Gln Gln Glu Glu Glu Glu Arg Gln Arg Gln Gln Arg Arg Glu Glu Arg  
 100 105 110  
 Arg Gln Gln Asn Leu Arg Ala Arg Ser Arg Glu His Pro Val Val Gly  
 115 120 125  
 His Pro Asp Pro Ala Leu Pro Pro Ser Gly Val Asn Cys Ser Gly Cys  
 130 135 140  
 Gly Ala Xaa Leu His Cys Gln Asp Ala Gly Val Pro Gly Tyr Leu Pro  
 145 150 155 160  
 Arg Glu Lys Phe Leu Arg Thr Ala Glu Ala Asp Gly Gly Leu Ala Arg  
 165 170 175  
 Thr Val Cys Gln Arg Cys Trp Leu Leu Ser His His Arg Arg Ala Leu  
 180 185 190  
 Arg Leu Gln Val Ser Arg Glu Gln Tyr Leu Glu Leu Val Ser Ala Ala  
 195 200 205  
 Leu Arg Xaa Pro Gly Pro Ser Leu Val Leu Tyr Met Val Asp Leu Leu  
 210 215 220  
 Asp Leu Pro Asp Ala Leu Leu Pro Asp Leu Pro Ala Leu Val Gly Pro  
 225 230 235 240  
 Lys Gln Leu Ile Val Leu Gly Asn Lys Val Asp Leu Leu Pro Gln Asp  
 245 250 255  
 Ala Pro Gly Tyr Arg Gln Arg Leu Arg Glu Arg Leu Trp Glu Asp Cys  
 260 265 270  
 Ala Arg Ala Gly Leu Leu Leu Ala Pro Gly Thr Lys Gly His Ser Ala  
 275 280 285  
 Pro Ser Arg Thr Ser His Arg Thr Gly Arg Ile Arg Ile Arg Arg Thr  
 290 295 300

Gly Pro Ala Gln Trp Ser Gly Thr Cys Gly  
305 310

<210> 346

<211> 380

<212> PRT

<213> Homo sapiens

<400> 346

Pro Ser Phe Arg Arg Glu Arg Val Glu Thr Gly Gly Gly Gly Pro Val  
1 5 10 15

Thr His Gly Thr Glu Gly Pro Phe Leu Pro Leu Pro Gly Gly Thr Arg  
20 25 30

Met Asn Met Thr Gln Ala Arg Val Leu Val Ala Ala Val Val Gly Leu  
35 40 45

Val Ala Val Leu Leu Tyr Ala Ser Ile His Lys Ile Glu Glu Gly His  
50 55 60

Leu Ala Val Tyr Tyr Arg Gly Gly Ala Leu Leu Thr Ser Pro Ser Gly  
65 70 75 80

Pro Gly Tyr His Ile Met Leu Pro Phe Ile Thr Thr Phe Arg Ser Val  
85 90 95

Gln Thr Thr Leu Gln Thr Asp Glu Val Lys Asn Val Pro Cys Gly Thr  
100 105 110

Ser Gly Gly Val Met Ile Tyr Ile Asp Arg Ile Glu Val Val Asn Met  
115 120 125

Leu Ala Pro Tyr Ala Val Phe Asp Ile Val Arg Asn Tyr Thr Ala Asp  
130 135 140

Tyr Asp Lys Thr Leu Ile Phe Asn Lys Ile His His Glu Leu Asn Gln  
145 150 155 160

Phe Cys Ser Ala His Thr Leu Gln Glu Val Tyr Ile Glu Leu Phe Asp  
165 170 175

Gln Ile Asp Glu Asn Leu Lys Gln Ala Leu Gln Lys Asp Leu Asn Leu  
180 185 190

Met Ala Pro Gly Leu Thr Ile Gln Ala Val Arg Val Thr Lys Pro Lys  
195 200 205

Ile Pro Glu Ala Ile Arg Arg Asn Phe Glu Leu Met Glu Ala Glu Lys  
210 215 220

Thr Lys Leu Leu Ile Ala Ala Gln Lys Gln Lys Val Val Glu Lys Glu  
225 230 235 240

Ala Glu Thr Glu Arg Lys Lys Ala Val Ile Glu Ala Glu Lys Ile Ala  
245 250 255

Gln Val Ala Lys Ile Arg Phe Gln Gln Lys Val Met Glu Lys Glu Thr

260                      265                      270  
 Glu Lys Arg Ile Ser Glu Ile Glu Asp Ala Ala Phe Leu Ala Arg Glu  
     275                      280                      285  
 Lys Ala Lys Ala Asp Ala Glu Tyr Tyr Ala Ala His Lys Tyr Ala Thr  
     290                      295                      300  
 Ser Asn Lys His Lys Leu Thr Pro Glu Tyr Leu Glu Leu Lys Lys Tyr  
 305                      310                      315                      320  
 Gln Ala Ile Ala Ser Asn Ser Lys Ile Tyr Phe Gly Ser Asn Ile Pro  
                     325                      330                      335  
 Asn Met Phe Val Asp Ser Ser Cys Ala Leu Lys Tyr Ser Asp Ile Arg  
                     340                      345                      350  
 Thr Gly Arg Glu Ser Ser Leu Pro Ser Lys Glu Ala Leu Glu Pro Ser  
                     355                      360                      365  
 Gly Glu Asn Val Ile Gln Asn Lys Glu Ser Thr Gly  
     370                      375                      380  
  
 <210> 347  
 <211> 422  
 <212> PRT  
 <213> Homo sapiens  
  
 <220>  
 <221> SITE  
 <222> (328)  
 <223> Xaa equals any of the naturally occurring L-amino acids  
  
 <400> 347  
 Trp Ser Thr Gly Asn Ala Ser Trp Glu Lys Lys Asp Asn Phe Ile Leu  
     1                      5                      10                      15  
 Ser Ala Asp Phe Glu Met Met Gly Leu Gly Asn Gly Arg Arg Ser Met  
                     20                      25                      30  
 Lys Ser Pro Pro Leu Val Leu Ala Ala Leu Val Ala Cys Ile Ile Val  
                     35                      40                      45  
 Leu Gly Phe Asn Tyr Trp Ile Ala Ser Ser Arg Ser Val Asp Leu Gln  
     50                      55                      60  
 Thr Arg Ile Met Glu Leu Glu Gly Arg Val Arg Arg Ala Ala Glu  
     65                      70                      75                      80  
 Arg Gly Ala Val Glu Leu Lys Lys Asn Glu Phe Gln Gly Glu Leu Glu  
                     85                      90                      95  
 Lys Gln Arg Glu Gln Leu Asp Lys Ile Gln Ser Ser His Asn Phe Gln  
                     100                      105                      110  
 Leu Glu Ser Val Asn Lys Leu Tyr Gln Asp Glu Lys Ala Val Leu Val  
     115                      120                      125

Asn Asn Ile Thr Thr Gly Glu Arg Leu Ile Arg Val Leu Gln Asp Gln  
 130 135 140  
 Leu Lys Thr Leu Gln Arg Asn Tyr Gly Arg Leu Gln Gln Asp Val Leu  
 145 150 155 160  
 Gln Phe Gln Lys Asn Gln Thr Asn Leu Glu Arg Lys Phe Ser Tyr Asp  
 165 170 175  
 Leu Ser Gln Cys Ile Asn Gln Met Lys Glu Val Lys Glu Gln Cys Glu  
 180 185 190  
 Glu Arg Ile Glu Glu Val Thr Lys Lys Gly Asn Glu Ala Val Ala Ser  
 195 200 205  
 Arg Asp Leu Ser Glu Asn Asn Asp Gln Arg Gln Gln Leu Gln Ala Leu  
 210 215 220  
 Ser Glu Pro Gln Pro Arg Leu Gln Ala Ala Gly Leu Pro His Thr Glu  
 225 230 235 240  
 Val Pro Gln Gly Lys Gly Asn Val Leu Gly Asn Ser Lys Ser Gln Thr  
 245 250 255  
 Pro Ala Pro Ser Ser Glu Val Val Leu Asp Ser Lys Arg Gln Val Glu  
 260 265 270  
 Lys Glu Glu Thr Asn Glu Ile Gln Val Val Asn Glu Glu Pro Gln Arg  
 275 280 285  
 Asp Arg Leu Pro Gln Glu Pro Gly Arg Glu Gln Val Val Glu Asp Arg  
 290 295 300  
 Pro Val Gly Gly Arg Gly Phe Gly Gly Ala Gly Glu Leu Gly Gln Thr  
 305 310 315 320  
 Pro Gln Val Gln Ala Ala Leu Xaa Val Ser Gln Glu Asn Pro Glu Met  
 325 330 335  
 Glu Gly Pro Glu Arg Asp Gln Leu Val Ile Pro Asp Gly Gln Glu Glu  
 340 345 350  
 Glu Gln Glu Ala Ala Gly Glu Gly Arg Asn Gln Gln Lys Leu Arg Gly  
 355 360 365  
 Glu Asp Asp Tyr Asn Met Asp Glu Asn Glu Ala Glu Ser Glu Thr Asp  
 370 375 380  
 Lys Gln Ala Ala Leu Ala Gly Asn Asp Arg Asn Ile Asp Val Phe Asn  
 385 390 395 400  
 Val Glu Asp Gln Lys Arg Asp Thr Ile Asn Leu Leu Asp Gln Arg Glu  
 405 410 415  
 Lys Arg Asn His Thr Leu  
 420

&lt;210&gt; 348

<211> 14  
 <212> PRT  
 <213> Homo sapiens

<400> 348  
 Ser Leu His Arg Phe Val Leu Ser Gln Ala Lys Asp Glu Leu  
           1                          5                          10

<210> 349  
 <211> 19  
 <212> PRT  
 <213> Homo sapiens

<400> 349  
 Phe Ile Lys Phe Phe Ala Pro Trp Cys Gly His Cys Lys Ala Leu Ala  
           1                          5                          10                          15

Pro Thr Trp

<210> 350  
 <211> 19  
 <212> PRT  
 <213> Homo sapiens

<400> 350  
 Phe Ile Lys Phe Tyr Ala Pro Trp Cys Gly His Cys Lys Thr Leu Ala  
           1                          5                          10                          15

Pro Thr Trp

<210> 351  
 <211> 363  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (42)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 351  
 Arg Arg Gly Arg Gly Val Pro Gly Pro Arg Gly Arg Arg Arg Leu Trp  
           1                          5                          10                          15

Ser Ala Ala Cys Gly His Cys Gln Arg Leu Gln Pro Thr Trp Asn Asp  
                   20                          25                          30

Leu Gly Asp Lys Tyr Asn Ser Met Glu Xaa Ala Lys Val Tyr Val Ala  
           35                          40                          45

Lys Val Asp Cys Thr Ala His Ser Asp Val Cys Ser Ala Gln Gly Val  
           50                          55                          60

Arg Gly Tyr Pro Thr Leu Lys Leu Phe Lys Pro Gly Gln Glu Ala Val



65		70		75		80
Lys Tyr Gln Gly Pro Arg Asp Phe Gln Thr Leu Glu Asn Trp Met Leu						
	85			90		95
Gln Thr Leu Asn Glu Glu Pro Val Thr Pro Glu Pro Glu Val Glu Pro						
	100		105		110	
Pro Ser Ala Pro Glu Leu Lys Gln Gly Leu Tyr Glu Leu Ser Ala Ser						
	115		120		125	
Asn Phe Glu Leu His Val Ala Gln Gly Asp His Phe Ile Lys Phe Phe						
	130		135		140	
Ala Pro Trp Cys Gly His Cys Lys Ala Leu Ala Pro Thr Trp Glu Gln						
	145		150		155	160
Leu Ala Leu Gly Leu Glu His Ser Glu Thr Val Lys Ile Gly Lys Val						
	165		170		175	
Asp Cys Thr Gln His Tyr Glu Leu Cys Ser Gly Asn Gln Val Arg Gly						
	180		185		190	
Tyr Pro Thr Leu Leu Trp Phe Arg Asp Gly Lys Lys Val Asp Gln Tyr						
	195		200		205	
Lys Gly Lys Arg Asp Leu Glu Ser Leu Arg Glu Tyr Val Glu Ser Gln						
	210		215		220	
Leu Gln Arg Thr Glu Thr Gly Ala Thr Glu Thr Val Thr Pro Ser Glu						
	225		230		235	240
Ala Pro Val Leu Ala Ala Glu Pro Glu Ala Asp Lys Gly Thr Val Leu						
	245		250		255	
Ala Leu Thr Glu Asn Asn Phe Asp Asp Thr Ile Ala Glu Gly Ile Thr						
	260		265		270	
Phe Ile Lys Phe Tyr Ala Pro Trp Cys Gly His Cys Lys Thr Leu Ala						
	275		280		285	
Pro Thr Trp Glu Glu Leu Ser Lys Lys Glu Phe Pro Gly Leu Ala Gly						
	290		295		300	
Val Lys Ile Ala Glu Val Asp Cys Thr Ala Glu Arg Asn Ile Cys Ser						
	305		310		315	320
Lys Tyr Ser Val Arg Gly Tyr Pro Thr Leu Leu Leu Phe Arg Gly Gly						
	325		330		335	
Lys Lys Val Ser Glu His Ser Gly Gly Arg Asp Leu Asp Ser Leu His						
	340		345		350	
Arg Phe Val Leu Ser Gln Ala Lys Asp Glu Leu						
	355		360			

&lt;210&gt; 352

&lt;211&gt; 93

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 352

```

Met Arg Pro Gln Gly Pro Ala Ala Ser Pro Gln Arg Leu Arg Gly Leu
 1             5             10             15

Leu Leu Leu Leu Leu Leu Gln Leu Pro Ala Pro Ser Ser Ala Ser Glu
      20             25             30

Ile Pro Lys Gly Lys Gln Lys Ala His Ser Gly Arg Gly Arg Trp Trp
      35             40             45

Thr Cys Ile Met Glu Cys Ala Tyr Lys Gly Gln Gln Glu Cys Leu Val
      50             55             60

Glu Thr Gly Ala Leu Gly Pro Met Ala Phe Arg Val His Leu Gly Ser
      65             70             75             80

Gln Val Gly Met Asp Ser Lys Glu Lys Arg Gly Asn Val
      85             90

```

&lt;210&gt; 353

&lt;211&gt; 273

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (210)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 353

```

Glu Thr Arg Val Lys Thr Ser Leu Glu Leu Leu Arg Thr Gln Leu Glu
 1             5             10             15

Pro Thr Gly Thr Val Gly Asn Thr Ile Met Thr Ser Gln Pro Val Pro
      20             25             30

Asn Glu Thr Ile Ile Val Leu Pro Ser Asn Val Ile Asn Phe Ser Gln
      35             40             45

Ala Glu Lys Pro Glu Pro Thr Asn Gln Gly Gln Asp Ser Leu Lys Lys
      50             55             60

His Leu His Ala Glu Ile Lys Val Ile Gly Thr Ile Gln Ile Leu Cys
      65             70             75             80

Gly Met Met Val Leu Ser Leu Gly Ile Ile Leu Ala Ser Ala Ser Phe
      85             90             95

Ser Pro Asn Phe Thr Gln Val Thr Ser Thr Leu Leu Asn Ser Ala Tyr
      100             105             110

Pro Phe Ile Gly Pro Phe Phe Phe Ile Ile Ser Gly Ser Leu Ser Ile
      115             120             125

Ala Thr Glu Lys Arg Leu Thr Lys Leu Leu Val His Ser Ser Leu Val

```

130                      135                      140  
 Gly Ser Ile Leu Ser Ala Leu Ser Ala Leu Val Gly Phe Ile Ile Leu  
 145                      150                      155                      160  
 Ser Val Lys Gln Ala Thr Leu Asn Pro Ala Ser Leu Gln Cys Glu Leu  
                     165                      170                      175  
 Asp Lys Asn Asn Ile Pro Thr Arg Ser Tyr Val Ser Tyr Phe Tyr His  
                     180                      185                      190  
 Asp Ser Leu Tyr Thr Thr Asp Cys Tyr Thr Ala Lys Ala Ser Leu Ala  
                     195                      200                      205  
 Gly Xaa Leu Ser Leu Met Leu Ile Cys Thr Leu Leu Glu Phe Cys Leu  
                     210                      215                      220  
 Ala Val Leu Thr Ala Val Leu Arg Trp Lys Gln Ala Tyr Ser Asp Phe  
 225                      230                      235                      240  
 Pro Gly Ser Val Leu Phe Leu Pro His Ser Tyr Ile Gly Asn Ser Gly  
                     245                      250                      255  
 Met Ser Ser Lys Met Thr His Asp Cys Gly Tyr Glu Glu Leu Leu Thr  
                     260                      265                      270  
 Ser

&lt;210&gt; 354

&lt;211&gt; 192

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (129)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 354

Met Met Val Leu Ser Leu Gly Ile Ile Leu Ala Ser Ala Ser Phe Ser  
   1                    5                    10                    15  
 Pro Asn Phe Thr Gln Val Thr Ser Thr Leu Leu Asn Ser Ala Tyr Pro  
                     20                    25                    30  
 Phe Ile Gly Pro Phe Phe Phe Ile Ile Ser Gly Ser Leu Ser Ile Ala  
                     35                    40                    45  
 Thr Glu Lys Arg Leu Thr Lys Leu Leu Val His Ser Ser Leu Val Gly  
                     50                    55                    60  
 Ser Ile Leu Ser Ala Leu Ser Ala Leu Val Gly Phe Ile Ile Leu Ser  
                     65                    70                    75                    80  
 Val Lys Gln Ala Thr Leu Asn Pro Ala Ser Leu Gln Cys Glu Leu Asp  
                     85                    90                    95

Lys Asn Asn Ile Pro Thr Arg Ser Tyr Val Ser Tyr Phe Tyr His Asp  
 100 105 110  
 Ser Leu Tyr Thr Thr Asp Cys Tyr Thr Ala Lys Ala Ser Leu Ala Gly  
 115 120 125  
 Xaa Leu Ser Leu Met Leu Ile Cys Thr Leu Leu Glu Phe Cys Leu Ala  
 130 135 140  
 Val Leu Thr Ala Val Leu Arg Trp Lys Gln Ala Tyr Ser Asp Phe Pro  
 145 150 155 160  
 Gly Ser Val Leu Phe Leu Pro His Ser Tyr Ile Gly Asn Ser Gly Met  
 165 170 175  
 Ser Ser Lys Met Thr His Asp Cys Gly Tyr Glu Glu Leu Leu Thr Ser  
 180 185 190

&lt;210&gt; 355

&lt;211&gt; 204

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (119)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 355

Gly Ala Ser Cys Glu Gly Gly Gly Ala Ala Ala Arg Ala Ala Leu Gly  
 1 5 10 15  
 Val His Arg Ser Gln Lys Ala Leu Leu Val Phe Arg Arg Thr Leu Ser  
 20 25 30  
 Asn Leu Leu Tyr Met Pro Leu Leu Arg Gly Leu Leu Trp Leu Gln Val  
 35 40 45  
 Leu Cys Ala Gly Pro Leu His Thr Glu Ala Val Val Leu Leu Val Pro  
 50 55 60  
 Ser Asp Asp Gly Arg Ala Phe Leu Leu Arg Ser Arg Leu Leu His Pro  
 65 70 75 80  
 Glu Ala His Val Pro Pro Ala Ala Asp Arg Gly Ala Ser Leu Gln Cys  
 85 90 95  
 Val Leu His Gln Ala Ala Pro Lys Ser Arg Pro Arg Ser Pro Ala Ala  
 100 105 110  
 Gly Ala Ala Leu Leu His Xaa Pro Arg Arg Thr Gly Asp Glu Pro Cys  
 115 120 125  
 Arg Glu Phe His Gly Asn Gly Phe Pro Gly Pro Thr Gln Leu Thr Pro  
 130 135 140

Gly Glu Cys Gly Leu Pro Ala Pro Ser Ser Leu Leu Gln His Ala Ser  
 145 150 155 160

Ala Pro Val Arg Thr Gly Ser Glu Gly Gln Val Val Gly Cys Pro Arg  
 165 170 175

Ala Arg Gly Glu Thr Gly Glu Gly Leu Ser Leu Ala Phe Leu Ser Ser  
 180 185 190

Leu Met Phe Thr Ser Arg Asn Gly Leu Val Gly Cys  
 195 200

<210> 356

<211> 72

<212> PRT

<213> Homo sapiens

<400> 356

Met Gly Ser Ala Ala Leu Glu Ile Leu Gly Leu Val Leu Cys Leu Val  
 1 5 10 15

Gly Trp Gly Gly Leu Ile Leu Ala Cys Gly Leu Pro Met Trp Gln Val  
 20 25 30

Thr Ala Phe Leu Asp His Asn Ile Val Thr Ala Gln Thr Thr Trp Lys  
 35 40 45

Gly Leu Trp Met Ser Cys Val Val Gln Ser Thr Gly Thr Cys Ser Ala  
 50 55 60

Lys Cys Thr Thr Arg Cys Trp Leu  
 65 70

<210> 357

<211> 115

<212> PRT

<213> Homo sapiens

<400> 357

Leu Lys Arg Ala Pro Gly Pro Ala Leu Ala Lys Gly Leu Leu Gln  
 1 5 10 15

Pro Ser Ser Thr Phe Gln Ala Leu Glu Thr Asn Ile Gly Asp Gln Val  
 20 25 30

Arg Arg His Ser Thr Ala Val Val Ile Arg Glu Met Thr Ser Tyr Ile  
 35 40 45

Leu Ile Ser Phe Val Leu Leu Ile Gly Val Gly Cys Ile Glu Lys Asp  
 50 55 60

Gln Ser Cys Pro Val Phe Gly Gly Arg Lys Arg Leu His Leu Leu Phe  
 65 70 75 80

Val Gly Gly Gln Leu Arg Gln Val Arg Met Leu Arg Gly Glu Leu Ser  
 85 90 95

Cys Ala Cys Tyr Arg Pro His Val Gln Ala Leu Gln Leu Gly Gly Cys  
                   100                  105                  110

Thr Cys Phe  
           115

<210> 358  
 <211> 88  
 <212> PRT  
 <213> Homo sapiens

<400> 358  
 Val Ile Lys Leu Ile Cys Pro Ala Ala Phe Pro Val Tyr Phe Gln Asp  
       1                  5                  10                  15

Met Ala Arg Gly Cys Val Cys Ser Leu Cys Ala Ser Val Cys Ile Phe  
                   20                  25                  30

Leu Ser Ser Leu Phe Pro Leu Leu Pro Ser Val His Ser Val Asn Ile  
           35                  40                  45

Ile Ser Cys Leu Leu Leu Ser Lys Cys Phe Glu Gly Leu Glu Leu Met  
       50                  55                  60

Cys Glu His Leu Tyr Gln Leu Ser Gln Leu His Val Leu His His Ile  
       65                  70                  75                  80

Phe Ser Tyr Leu Leu Cys Thr Pro  
                   85

<210> 359  
 <211> 716  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (2)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (373)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>  
 <221> SITE  
 <222> (705)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 359  
 Tyr Xaa Ile Pro Gly Ser Thr His Ala Ser Gly Arg Gln Arg Gly Ser  
       1                  5                  10                  15

Gly Arg Gly Glu Asp Asp Ser Gly Pro Pro Pro Ser Thr Val Ile Asn  
           20                  25                  30

Gln Asn Glu Thr Phe Ala Asn Ile Ile Phe Lys Pro Thr Val Val Gln  
                   35                                  40                                  45  
 Gln Ala Arg Ile Ala Gln Asn Gly Ile Leu Gly Asp Phe Ile Ile Arg  
           50                                  55                                  60  
 Tyr Asp Val Asn Arg Glu Gln Ser Ile Gly Asp Ile Gln Val Leu Asn  
   65                                  70                                  75                                  80  
 Gly Tyr Phe Val His Tyr Phe Ala Pro Lys Asp Leu Pro Pro Leu Pro  
                                   85                                  90                                  95  
 Lys Asn Val Val Phe Val Leu Asp Ser Ser Ala Ser Met Val Gly Thr  
                   100                                  105                                  110  
 Lys Leu Arg Gln Thr Lys Asp Ala Leu Phe Thr Ile Leu His Asp Leu  
           115                                  120                                  125  
 Arg Pro Gln Asp Arg Phe Ser Ile Ile Gly Phe Ser Asn Arg Ile Lys  
   130                                  135                                  140  
 Val Trp Lys Asp His Leu Ile Ser Val Thr Pro Asp Ser Ile Arg Asp  
 145                                  150                                  155                                  160  
 Gly Lys Val Tyr Ile His His Met Ser Pro Thr Gly Gly Thr Asp Ile  
                   165                                  170                                  175  
 Asn Gly Val Leu Gln Arg Ala Ile Arg Leu Leu Asn Lys Tyr Val Ala  
           180                                  185                                  190  
 His Ser Gly Ile Gly Asp Arg Ser Val Ser Leu Ile Val Phe Leu Thr  
   195                                  200                                  205  
 Asp Gly Lys Pro Thr Val Gly Glu Thr His Thr Leu Lys Ile Leu Asn  
   210                                  215                                  220  
 Asn Thr Arg Glu Ala Ala Arg Gly Gln Val Cys Ile Phe Thr Ile Gly  
 225                                  230                                  235                                  240  
 Ile Gly Asn Asp Val Asp Phe Arg Leu Leu Glu Lys Leu Ser Leu Glu  
           245                                  250                                  255  
 Asn Cys Gly Leu Thr Arg Arg Val His Glu Glu Glu Asp Ala Gly Ser  
           260                                  265                                  270  
 Gln Leu Ile Gly Phe Tyr Asp Glu Ile Arg Thr Pro Leu Leu Ser Asp  
   275                                  280                                  285  
 Ile Arg Ile Asp Tyr Pro Pro Ser Ser Val Val Gln Ala Thr Lys Thr  
   290                                  295                                  300  
 Leu Phe Pro Asn Tyr Phe Asn Gly Ser Glu Ile Ile Ile Ala Gly Lys  
 305                                  310                                  315                                  320  
 Leu Val Asp Arg Lys Leu Asp His Leu His Val Glu Val Thr Ala Ser  
           325                                  330                                  335  
 Asn Ser Lys Lys Phe Ile Ile Leu Lys Thr Asp Val Pro Val Arg Pro

340	345	350
Gln Lys Ala Gly Lys Asp Val Thr Gly Ser Pro Arg Pro Gly Gly Asp 355 360 365		
Gly Glu Gly Asp Xaa Asn His Ile Glu Arg Leu Trp Ser Tyr Leu Thr 370 375 380		
Thr Lys Glu Leu Leu Ser Ser Trp Leu Gln Ser Asp Asp Glu Pro Glu 385 390 395 400		
Lys Glu Arg Leu Arg Gln Arg Ala Gln Ala Leu Ala Val Ser Tyr Arg 405 410 415		
Phe Leu Thr Pro Phe Thr Ser Met Lys Leu Arg Gly Pro Val Pro Arg 420 425 430		
Met Asp Gly Leu Glu Glu Ala His Gly Met Ser Ala Ala Met Gly Pro 435 440 445		
Glu Pro Val Val Gln Ser Val Arg Gly Ala Gly Thr Gln Pro Gly Pro 450 455 460		
Leu Leu Lys Lys Pro Tyr Gln Pro Arg Ile Lys Ile Ser Lys Thr Ser 465 470 475 480		
Val Asp Gly Asp Pro His Phe Val Val Asp Phe Pro Leu Ser Arg Leu 485 490 495		
Thr Val Cys Phe Asn Ile Asp Gly Gln Pro Gly Asp Ile Leu Arg Leu 500 505 510		
Val Ser Asp His Arg Asp Ser Gly Val Thr Val Asn Gly Glu Leu Ile 515 520 525		
Gly Ala Pro Ala Pro Pro Asn Gly His Lys Lys Gln Arg Thr Tyr Leu 530 535 540		
Arg Thr Ile Thr Ile Leu Ile Asn Lys Pro Glu Arg Ser Tyr Leu Glu 545 550 555 560		
Ile Thr Pro Ser Arg Val Ile Leu Asp Gly Gly Asp Arg Leu Val Leu 565 570 575		
Pro Cys Asn Gln Ser Val Val Val Gly Ser Trp Gly Leu Glu Val Ser 580 585 590		
Val Ser Ala Asn Ala Asn Val Thr Val Thr Ile Gln Gly Ser Ile Ala 595 600 605		
Phe Val Ile Leu Ile His Leu Tyr Lys Lys Pro Ala Pro Phe Gln Arg 610 615 620		
His His Leu Gly Phe Tyr Ile Ala Asn Ser Glu Gly Leu Ser Ser Asn 625 630 635 640		
Cys His Gly Leu Leu Gly Gln Phe Leu Asn Gln Asp Ala Arg Leu Thr 645 650 655		



Glu Asp Pro Ala Gly Pro Ser Gln Asn Leu Thr His Pro Leu Leu Leu  
                   660                                  665                                  670

Gln Val Gly Glu Gly Pro Glu Ala Val Leu Thr Val Lys Gly His Gln  
                   675                                  680                                  685

Val Pro Val Val Trp Lys Gln Arg Lys Ile Tyr Asn Gly Glu Glu Gln  
                   690                                  695                                  700

Xaa Asp Cys Trp Phe Ala Arg Asn Met Pro Pro Asn  
 705                                  710                                  715

<210> 360  
 <211> 387  
 <212> PRT  
 <213> Homo sapiens

<400> 360  
 Pro Arg Val Arg Ser Ile Lys Val Thr Glu Leu Lys Gly Leu Ala Asn  
   1                                  5                                  10                                  15

His Val Val Val Gly Ser Val Ser Cys Glu Thr Lys Asp Leu Phe Ala  
                   20                                  25                                  30

Ala Leu Pro Gln Val Val Ala Val Asp Ile Asn Asp Leu Gly Thr Ile  
                   35                                  40                                  45

Lys Leu Ser Leu Glu Val Thr Trp Ser Pro Phe Asp Lys Asp Asp Gln  
   50                                  55                                  60

Pro Ser Ala Ala Ser Ser Val Asn Lys Ala Ser Thr Val Thr Lys Arg  
   65                                  70                                  75                                  80

Phe Ser Thr Tyr Ser Gln Ser Pro Pro Asp Thr Pro Ser Leu Arg Glu  
                   85                                  90                                  95

Gln Ala Phe Tyr Asn Met Leu Arg Arg Gln Glu Glu Leu Glu Asn Gly  
                   100                                  105                                  110

Thr Ala Trp Ser Leu Ser Ser Glu Ser Ser Asp Asp Ser Ser Ser Pro  
                   115                                  120                                  125

Gln Leu Ser Gly Thr Ala Arg His Ser Pro Ala Pro Arg Pro Leu Val  
                   130                                  135                                  140

Gln Gln Pro Glu Pro Leu Pro Ile Gln Val Ala Phe Arg Arg Pro Glu  
   145                                  150                                  155                                  160

Thr Pro Ser Ser Gly Pro Leu Asp Glu Glu Gly Ala Val Ala Pro Val  
                   165                                  170                                  175

Leu Ala Asn Gly His Ala Pro Tyr Ser Arg Thr Leu Ser His Ile Ser  
                   180                                  185                                  190

Glu Ala Ser Val Asn Ala Ala Leu Ala Glu Ala Ser Val Glu Ala Val  
                   195                                  200                                  205

Gly Pro Lys Ser Leu Ser Trp Gly Pro Ser Pro Pro Thr His Pro Ala

246

210                      215                      220  
 Pro Thr His Gly Lys His Pro Ser Pro Val Pro Pro Ala Leu Asp Pro  
 225                      230                      235                      240  
 Gly His Ser Ala Thr Ser Ser Thr Leu Gly Thr Thr Gly Ser Val Pro  
                     245                      250                      255  
 Thr Ser Thr Asp Pro Ala Pro Ser Ala His Leu Asp Ser Val His Lys  
                     260                      265                      270  
 Ser Thr Asp Ser Gly Pro Ser Glu Leu Pro Gly Pro Thr His Thr Thr  
                     275                      280                      285  
 Thr Gly Ser Thr Tyr Ser Ala Ile Thr Thr Thr His Ser Ala Pro Ser  
                     290                      295                      300  
 Pro Leu Thr His Thr Thr Thr Gly Ser Thr His Lys Pro Ile Ile Ser  
 305                      310                      315                      320  
 Thr Leu Thr Thr Thr Gly Pro Thr Leu Asn Ile Ile Gly Pro Val Gln  
                     325                      330                      335  
 Thr Thr Thr Ser Pro Thr His Thr Met Pro Ser Pro Ser Ser His Ser  
                     340                      345                      350  
 Asn Ser Pro Gln Tyr Val Asp Phe Cys Ser Ser Val Cys Asp Asn Ile  
                     355                      360                      365  
 Phe Val His Tyr Val Ile Gly Ile Phe Phe His Thr Leu Tyr Ser Ser  
                     370                      375                      380  
 Lys Thr Leu  
 385  
  
 <210> 361  
 <211> 260  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 361  
 Pro Arg Val Arg Ser Ile Lys Val Thr Glu Leu Lys Gly Leu Ala Asn  
   1                      5                      10                      15  
 His Val Val Val Gly Ser Val Ser Cys Glu Thr Lys Asp Leu Phe Ala  
                     20                      25                      30  
 Ala Leu Pro Gln Val Val Ala Val Asp Ile Asn Asp Leu Gly Thr Ile  
                     35                      40                      45  
 Lys Leu Ser Leu Glu Val Thr Trp Ser Pro Phe Asp Lys Asp Asp Gln  
                     50                      55                      60  
 Pro Ser Ala Ala Ser Ser Val Asn Lys Ala Ser Thr Val Thr Lys Arg  
   65                      70                      75                      80  
 Phe Ser Thr Tyr Ser Gln Ser Pro Pro Asp Thr Pro Ser Leu Arg Glu  
                     85                      90                      95

Gln Ala Phe Tyr Asn Met Leu Arg Arg Gln Glu Glu Leu Glu Asn Gly  
 100 105 110  
 Thr Ala Trp Ser Leu Ser Ser Glu Ser Ser Asp Asp Ser Ser Ser Pro  
 115 120 125  
 Gln Leu Ser Gly Thr Ala Arg His Ser Pro Ala Pro Arg Pro Leu Val  
 130 135 140  
 Gln Gln Pro Glu Pro Leu Pro Ile Gln Val Ala Phe Arg Arg Pro Glu  
 145 150 155 160  
 Thr Pro Ser Ser Gly Pro Leu Asp Glu Glu Gly Ala Val Ala Pro Val  
 165 170 175  
 Leu Ala Asn Gly His Ala Pro Tyr Ser Arg Thr Leu Ser His Ile Ser  
 180 185 190  
 Glu Ala Ser Val Asn Ala Ala Leu Ala Glu Ala Ser Val Glu Ala Val  
 195 200 205  
 Gly Pro Lys Ser Leu Ser Trp Gly Pro Ser Pro Pro Thr His Pro Ala  
 210 215 220  
 Pro Thr His Gly Lys His Pro Ser Pro Val Pro Pro Ala Leu Asp Pro  
 225 230 235 240  
 Gly His Ser Ala Thr Ser Ser Thr Leu Gly Thr Thr Gly Ser Val Pro  
 245 250 255  
 Thr Ser Thr Asp  
 260

<210> 362  
 <211> 155  
 <212> PRT  
 <213> Homo sapiens

<400> 362  
 Tyr Gly Cys Glu Lys Thr Thr Glu Gly Gly Arg Arg Arg Arg Arg Arg  
 1 5 10 15  
 Met Glu Ala Val Val Phe Val Phe Ser Leu Leu Asp Cys Cys Ala Leu  
 20 25 30  
 Ile Phe Leu Ser Val Tyr Phe Ile Ile Thr Leu Ser Asp Leu Glu Cys  
 35 40 45  
 Asp Tyr Ile Asn Ala Arg Ser Cys Cys Ser Lys Leu Asn Lys Trp Val  
 50 55 60  
 Ile Pro Glu Leu Ile Gly His Thr Ile Val Thr Val Leu Leu Leu Met  
 65 70 75 80  
 Ser Leu His Trp Phe Ile Phe Leu Leu Asn Leu Pro Val Ala Thr Trp  
 85 90 95

Asn Ile Tyr Arg Tyr Ile Met Val Pro Ser Gly Asn Met Gly Val Phe  
 100 105 110  
 Asp Pro Thr Glu Ile His Asn Arg Gly Gln Leu Lys Ser His Met Lys  
 115 120 125  
 Glu Ala Met Ile Lys Leu Gly Phe His Leu Leu Cys Phe Phe Met Tyr  
 130 135 140  
 Leu Tyr Ser Met Ile Leu Ala Leu Ile Asn Asp  
 145 150 155

<210> 363  
 <211> 70  
 <212> PRT  
 <213> Homo sapiens

<400> 363  
 Ala Arg Ala Pro Ala Pro Ser Leu Pro Pro Leu Pro Ser Pro Ala Pro  
 1 5 10 15  
 Ala Leu Ala Pro Ala His Ser Leu Leu Gly Leu Leu Leu Gly Arg Met  
 20 25 30  
 Ser Gly Ser Ser Leu Pro Ser Ala Leu Ala Leu Ser Leu Leu Leu Val  
 35 40 45  
 Ser Gly Ser Leu Leu Pro Gly Pro Gly Ala Ala Gln Asn Val Arg Val  
 50 55 60  
 Gln Ser Gly Gln Asp Gln  
 65 70

<210> 364  
 <211> 56  
 <212> PRT  
 <213> Homo sapiens

<400> 364  
 Gly Thr Ser Lys Asp Cys Val Leu Tyr Ala Phe Leu Asp Pro Gly Met  
 1 5 10 15  
 Ala Val Pro Leu Phe Leu Tyr Ile Phe Thr Leu Leu Pro Leu Leu Pro  
 20 25 30  
 Phe Leu Leu Ser Leu Cys Phe Ser Pro Leu Thr Val Lys Arg Ser Ser  
 35 40 45  
 Ser Ser Glu Ser Lys Ser Ser Leu  
 50 55

Applicant's or agent's file reference number	PZ031PCT	International application	Unassigned
---	----------	---------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

REC'D 18 AUG 1999

A. The indications made below relate to the microorganism referred to in the description on page <u>260</u> , line <u>N/A</u>		WIPO	PCT
B. IDENTIFICATION OF DEPOSIT		Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection			
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America			
Date of deposit July 27, 1998		Accession Number 203069	
C. ADDITIONAL INDICATIONS (leave blank if not applicable)		This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)			
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).			
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)			
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")			

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input checked="" type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer Yvette E. Sims PCT International Division	18 AUGUST 1999 Authorized officer P. Gerschlager

**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PZ031PCT	International application:	Unassigned
---	----------	----------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>243</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country)  10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit  June 11, 1998	Accession Number  209965
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)  Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer  Yves Z. Shamis PCT International Division	Authorized officer



**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PZ031PCT	International application	Unassigned
---	----------	---------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>249</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country)  10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit  June 26, 1998	Accession Number  203027
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)  Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)  The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer  Yves E. Slims PCT International Division	Authorized officer

**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

Applicant's or agent's file reference number	PZ031PCT	International application	Unassigned
---	----------	---------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>253</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country)  10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit  July 27, 1998	Accession Number  203071
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer  Yvonne E. Skinnis PCT International Division	Authorized officer

**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.



Applicant's or agent's file reference number	PZ031PCT	International application.
--	----------	----------------------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>259</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit July 27, 1998	Accession Number 203070
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only
<input checked="" type="checkbox"/> This sheet was received with the international application
Authorized officer Yvette E. Blumms PCT International Division

For International Bureau use only
<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer

**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by an applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/17130

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 23.5; 435/69.1, 320.1, 252.3, 325, 6, 7.1; 530/350, 300, 387.1; 514/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG - Biotech Files

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JACOBS, K. A. et al. A Genetic Selection For Isolating cDNAs Encoding Secreted Proteins. Gene. 1997, Vol. 198, pages 289-296, see entire document.	1-23

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

05 OCTOBER 1999

Date of mailing of the international search report

21 OCT 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ELIZABETH C. KEMMERER

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/17130

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.: 1-23  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
  
Please See Extra Sheet.
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US99/17130

**A. CLASSIFICATION OF SUBJECT MATTER:**

IPC (6):

C12N 1/21, 5/10, 15/11, 15/12, 15/63; A61K 38/16, 38/17; C07K 14/00, 14/435, 16/00; G01N 33/50

**A. CLASSIFICATION OF SUBJECT MATTER:**

US CL :

536/23.1, 23.5; 435/69.1, 320.1, 252.3, 325, 6, 7.1; 530/350, 300, 387.1; 514/2

**BOX I. OBSERVATIONS WHERE CLAIMS WERE FOUND UNSEARCHABLE**

**2. Where no meaningful search could be carried out, specifically:**

All of the claims were unsearchable to the extent that they require reference to sequences from the sequence listing or an ATCC deposit. However, the specific sequence and deposit numbers were replaced in the claims with generic designators X, Y and Z. Therefore, no meaningful search of the sequences or deposits per se can be carried out by this Authority. The subject matter of the claims has been searched only to the extent possible with reference to the balance of the description.